<corpus source="DS">
    <document id="DS.d0" origId="17003041">
        <sentence id="DS.d0.s0" origId="17003041-302" text="Bestrophin-1 enables Ca2+-activated Cl-conductance in epithelia.">
            <entity id="DS.d0.s0.e0" origId="O76090,O88870,Q21973,Q6UY87,Q8WMR7" charOffset="0-12" type="protein" text="Bestrophin-1"/>
            <entity id="DS.d0.s0.e1" origId="312" charOffset="36-38" type="compound" text="Cl"/>
            <pair e1="DS.d0.s0.e1" e2="DS.d0.s0.e0" id="DS.d0.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d0.s1" origId="17003041-304" text="Calcium-dependent Cl (-) currents were activated by ATP in HEK293 cells expressing BEST1.">
            <entity id="DS.d0.s1.e0" origId="312" charOffset="18-20" type="compound" text="Cl"/>
            <entity id="DS.d0.s1.e1" origId="5957" charOffset="52-55" type="compound" text="ATP"/>
            <entity id="DS.d0.s1.e2" origId="O76090,Q6UY87,Q8WMR7" charOffset="83-88" type="protein" text="BEST1"/>
            <pair e1="DS.d0.s1.e1" e2="DS.d0.s1.e2" id="DS.d0.s1.i0" interaction="False"/>
            <pair e1="DS.d0.s1.e0" e2="DS.d0.s1.e2" id="DS.d0.s1.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d1" origId="17321121">
        <sentence id="DS.d1.s0" origId="17321121-703" text="The absorption spectrum of the hydrogenase enzyme showed an absorption peak at 425nm indicating that the enzyme had iron-sulfur clusters.">
            <entity id="DS.d1.s0.e0" origId="P80509,P80510" charOffset="31-42" type="protein" text="hydrogenase"/>
            <entity id="DS.d1.s0.e1" origId="402" charOffset="121-127" type="compound" text="sulfur"/>
            <pair e1="DS.d1.s0.e1" e2="DS.d1.s0.e0" id="DS.d1.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d2" origId="17403602">
        <sentence id="DS.d2.s0" origId="17403602-1067" text="When Vitreoscilla were grown in medium containing 60mM sodium nitrite under both normal and limited aeration conditions, the levels of Vitreoscilla hemoglobin (VHb) were decreased by greater than 90%, while the levels of the terminal respiratory oxidase, cytochrome bo, were increased 350% under normal aeration and 7-23% under limited aeration.">
            <entity id="DS.d2.s0.e0" origId="23668193" charOffset="55-69" type="compound" text="sodium nitrite"/>
            <entity id="DS.d2.s0.e1" origId="P15160,P17724,P73925,Q03459" charOffset="148-158" type="protein" text="hemoglobin"/>
            <pair e1="DS.d2.s0.e0" e2="DS.d2.s0.e1" id="DS.d2.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d3" origId="17590240">
        <sentence id="DS.d3.s0" origId="17590240-1233" text="Epigallocatechin gallate (EGCG) suppresses beta-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3 beta activation.">
            <entity id="DS.d3.s0.e0" origId="65064" charOffset="0-30" type="compound" text="Epigallocatechin gallate (EGCG"/>
            <entity id="DS.d3.s0.e1" origId="P00520,P00522" charOffset="99-102" type="protein" text="Abl"/>
            <entity id="DS.d3.s0.e2" origId="O00213" charOffset="103-107" type="protein" text="FE65"/>
            <entity id="DS.d3.s0.e3" origId="P18266,P49841,Q5YJC2,Q9WV60" charOffset="134-143" type="protein" text="GSK3 beta"/>
            <pair e1="DS.d3.s0.e0" e2="DS.d3.s0.e3" id="DS.d3.s0.i0" interaction="True"/>
            <pair e1="DS.d3.s0.e0" e2="DS.d3.s0.e1" id="DS.d3.s0.i1" interaction="True"/>
            <pair e1="DS.d3.s0.e0" e2="DS.d3.s0.e2" id="DS.d3.s0.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d3.s1" origId="17590240-1234" text="Here, we used a human neuronal cell line MC65 conditional expression of an amyloid precursor protein fragment (APP-C99) to investigate the protection mechanism of epigallocatechin gallate (EGCG), the main constituent of green tea.">
            <entity id="DS.d3.s1.e0" origId="P12023" charOffset="111-118" type="protein" text="APP-C99"/>
            <entity id="DS.d3.s1.e1" origId="65064" charOffset="163-193" type="compound" text="epigallocatechin gallate (EGCG"/>
            <entity id="DS.d3.s1.e2" origId="4630" charOffset="220-229" type="compound" text="green tea"/>
            <pair e1="DS.d3.s1.e2" e2="DS.d3.s1.e0" id="DS.d3.s1.i0" interaction="False"/>
            <pair e1="DS.d3.s1.e1" e2="DS.d3.s1.e0" id="DS.d3.s1.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d4" origId="17616381">
        <sentence id="DS.d4.s0" origId="17616381-938" text="The protease was purified to homogeneity using ammonium sulfate precipitation, and ion exchange chromatography with a fold purification of 1.8 and a recovery of 49%.">
            <entity id="DS.d4.s0.e0" origId="O41798,O89290,O89940,O91080,O93215,P03311,P03353,P03355,P03356,P03362,P03363,P03366,P03367,P03369,P03370,P04023,P04024,P04323,P04584,P04585,P04587,P04588,P04589,P05959,P05960,P05961,P05962,P07570,P0C210,P0C211,P10210,P10265,P10270,P10271,P10272,P10273,P10274,P10394,P10978,P11227,P11365,P12451,P12497,P12498,P12499,P14074,P14078,P15833,P16046,P16423,P16901,P17757,P18042,P18096,P18802,P19028,P19199,P19560,P19561,P20825,P20875,P20876,P20892,P21407,P21414,P24107,P24740,P26808,P26809,P26810,P27502,P28936,P31822,P35956,P35963,P51518,P63119,P63120,P63121,P63122,P63123,P63124,P63125,P63127,P63128,P63129,P63131,P84454,Q09SZ9,Q0R5R2,Q0R5R3,Q1A249,Q1A267,Q4U0X6,Q73368,Q74120,Q75002,Q76634,Q77373,Q79666,Q89928,Q8AII1,Q8I7P9,Q9IDV9,Q9Q720,Q9QBY3,Q9QBZ1,Q9QBZ5,Q9QSR3,Q9WC54,Q9WC63,Q9Y6I0" charOffset="4-12" type="protein" text="protease"/>
            <entity id="DS.d4.s0.e1" origId="223" charOffset="47-55" type="compound" text="ammonium"/>
            <entity id="DS.d4.s0.e2" origId="1117" charOffset="56-63" type="compound" text="sulfate"/>
            <pair e1="DS.d4.s0.e2" e2="DS.d4.s0.e0" id="DS.d4.s0.i0" interaction="False"/>
            <pair e1="DS.d4.s0.e1" e2="DS.d4.s0.e0" id="DS.d4.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d5" origId="17629591">
        <sentence id="DS.d5.s0" origId="17629591-228" text="In addition, we demonstrated that Hsp20, HspB2 and HspB8 induced interleukin-6 production in cultured pericytes and astrocytes, which could be antagonized by dexamethasone, whereas other sHsps and A beta were inactive, suggesting that sHsps may be among the key mediators of the local inflammatory response associated with HCHWA-D and AD lesions.">
            <entity id="DS.d5.s0.e0" origId="O35878,Q16082,Q99PR8" charOffset="41-46" type="protein" text="HspB2"/>
            <entity id="DS.d5.s0.e1" origId="Q5EAC9,Q5RAB0,Q6SJQ8,Q8MJ36,Q9EPX0,Q9JK92,Q9UJY1" charOffset="51-56" type="protein" text="HspB8"/>
            <entity id="DS.d5.s0.e2" origId="P41693" charOffset="65-78" type="protein" text="interleukin-6"/>
            <entity id="DS.d5.s0.e3" origId="5743" charOffset="158-171" type="compound" text="dexamethasone"/>
            <pair e1="DS.d5.s0.e3" e2="DS.d5.s0.e0" id="DS.d5.s0.i0" interaction="False"/>
            <pair e1="DS.d5.s0.e3" e2="DS.d5.s0.e2" id="DS.d5.s0.i1" interaction="True"/>
            <pair e1="DS.d5.s0.e3" e2="DS.d5.s0.e1" id="DS.d5.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d6" origId="17692997">
        <sentence id="DS.d6.s0" origId="17692997-193" text="Furthermore, dithiothreitol was found to be capable of significantly preventing the inhibitory effect of insulin on Abeta oligomer formation.">
            <entity id="DS.d6.s0.e0" origId="19001,439196,446094" charOffset="13-27" type="compound" text="dithiothreitol"/>
            <entity id="DS.d6.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="105-112" type="protein" text="insulin"/>
            <pair e1="DS.d6.s0.e0" e2="DS.d6.s0.e1" id="DS.d6.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d7" origId="17719144">
        <sentence id="DS.d7.s0" origId="17719144-1171" text="The scavenger receptor, class B, type I (SR-BI) is critical in maintaining the homeostasis of cholesterol and alpha-tocopherol.">
            <entity id="DS.d7.s0.e1" origId="O18824,P97943,Q60417,Q61009,Q8SQC1,Q8WTV0" charOffset="41-46" type="protein" text="SR-BI"/>
            <entity id="DS.d7.s0.e2" origId="304,5997,6432564,11025495" charOffset="94-105" type="compound" text="cholesterol"/>
            <entity id="DS.d7.s0.e3" origId="2116,14985" charOffset="110-126" type="compound" text="alpha-tocopherol"/>
            <pair e1="DS.d7.s0.e3" e2="DS.d7.s0.e1" id="DS.d7.s0.i1" interaction="True"/>
            <pair e1="DS.d7.s0.e2" e2="DS.d7.s0.e1" id="DS.d7.s0.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d7.s1" origId="17719144-1172" text="SR-BI binds high-density lipoproteins (HDL) and mediates the selective transfer of cholesteryl esters and alpha-tocopherol from circulating HDL to cells.">
            <entity id="DS.d7.s1.e0" origId="O18824,P97943,Q60417,Q61009,Q8SQC1,Q8WTV0" charOffset="0-5" type="protein" text="SR-BI"/>
            <entity id="DS.d7.s1.e1" origId="P81182" charOffset="12-37" type="protein" text="high-density lipoproteins"/>
            <entity id="DS.d7.s1.e2" origId="2116,14985" charOffset="106-122" type="compound" text="alpha-tocopherol"/>
            <pair e1="DS.d7.s1.e2" e2="DS.d7.s1.e1" id="DS.d7.s1.i0" interaction="False"/>
            <pair e1="DS.d7.s1.e2" e2="DS.d7.s1.e0" id="DS.d7.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d7.s2" origId="17719144-1173" text="Thus, SR-BI influences neural and cognitive processes, a finding that highlights the contribution of cholesterol and alpha-tocopherol homeostasis in proper cognitive function.">
            <entity id="DS.d7.s2.e0" origId="O18824,P97943,Q60417,Q61009,Q8SQC1,Q8WTV0" charOffset="6-11" type="protein" text="SR-BI"/>
            <entity id="DS.d7.s2.e1" origId="304,5997,6432564,11025495" charOffset="101-112" type="compound" text="cholesterol"/>
            <entity id="DS.d7.s2.e2" origId="2116,14985" charOffset="117-133" type="compound" text="alpha-tocopherol"/>
            <pair e1="DS.d7.s2.e1" e2="DS.d7.s2.e0" id="DS.d7.s2.i0" interaction="False"/>
            <pair e1="DS.d7.s2.e2" e2="DS.d7.s2.e0" id="DS.d7.s2.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d8" origId="17768029">
        <sentence id="DS.d8.s0" origId="17768029-984" text="Alloxan is believed to confer its diabetogenic effect by inhibiting pancreatic glucokinase activity, leading to pancreatic beta-cell death.">
            <entity id="DS.d8.s0.e0" origId="5781" charOffset="0-7" type="compound" text="Alloxan"/>
            <entity id="DS.d8.s0.e1" origId="O25731,P0A4E1,P0A4E2,P0A6V8,P0A6V9,P17712,P21908,P35557,P52792,P54495,P58616,P58617,P58618,P58619,P64253,P64254,P82680,Q55855,Q56198,Q59171,Q668N7,Q6D7C4,Q7N6Y0,Q83K86,Q87EG6,Q8FFD4,Q8FV09,Q8P8U7,Q8PKU2,Q8UIV7,Q8YDC6,Q92407,Q92T27,Q93IM5,Q98DM2,Q9A6N3,Q9HZ46,Q9KCZ4,Q9PEG4,Q9ZKB0" charOffset="79-90" type="protein" text="glucokinase"/>
            <pair e1="DS.d8.s0.e0" e2="DS.d8.s0.e1" id="DS.d8.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d9" origId="17882129">
        <sentence id="DS.d9.s0" origId="17882129-602" text="Alpha-tocopherol supplementation prevents the exercise-induced reduction of serum paraoxonase 1/arylesterase activities in healthy individuals.">
            <entity id="DS.d9.s0.e0" origId="2116,14985" charOffset="0-16" type="compound" text="Alpha-tocopherol"/>
            <entity id="DS.d9.s0.e1" origId="P22862" charOffset="96-108" type="protein" text="arylesterase"/>
            <pair e1="DS.d9.s0.e0" e2="DS.d9.s0.e1" id="DS.d9.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d10" origId="17888544">
        <sentence id="DS.d10.s0" origId="17888544-779" text="Although ApoE4 has been repeatedly associated with altered sphingomyelin and cholesterol levels in tissue culture and rodent models, there has not been a direct quantification of sphingomyelin or sterol levels in the brains of patients with different forms of ApoE.">
            <entity id="DS.d10.s0.e0" origId="304,5997,6432564,11025495" charOffset="77-88" type="compound" text="cholesterol"/>
            <entity id="DS.d10.s0.e1" origId="P02649,P02650,P05770,P08226,P10517,P18287,P18649,P18650,P23529,Q03247,Q28502,Q28995,Q7M2U7,Q7M2U8,Q9GJU3,Q9GLC0,Q9GLM6,Q9GLM7,Q9GLM8" charOffset="9-13" type="protein" text="ApoE"/>
            <pair e1="DS.d10.s0.e0" e2="DS.d10.s0.e1" id="DS.d10.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d11" origId="17888546">
        <sentence id="DS.d11.s0" origId="17888546-781" text="ApoE modified the association between cholesterol and cognitive decline, and the association between the ratio of 27-hydroxycholesterol to cholesterol and cognitive functioning.">
            <entity id="DS.d11.s0.e0" origId="P02649,P02650,P05770,P08226,P10517,P18287,P18649,P18650,P23529,Q03247,Q28502,Q28995,Q7M2U7,Q7M2U8,Q9GJU3,Q9GLC0,Q9GLM6,Q9GLM7,Q9GLM8" charOffset="0-4" type="protein" text="ApoE"/>
            <entity id="DS.d11.s0.e1" origId="304,5997,6432564,11025495" charOffset="38-49" type="compound" text="cholesterol"/>
            <entity id="DS.d11.s0.e2" origId="99470,123976,50990021" charOffset="114-135" type="compound" text="27-hydroxycholesterol"/>
            <entity id="DS.d11.s0.e3" origId="304,5997,6432564,11025495" charOffset="124-135" type="compound" text="cholesterol"/>
            <pair e1="DS.d11.s0.e2" e2="DS.d11.s0.e0" id="DS.d11.s0.i0" interaction="True"/>
            <pair e1="DS.d11.s0.e1" e2="DS.d11.s0.e0" id="DS.d11.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d12" origId="17890844">
        <sentence id="DS.d12.s0" origId="17890844-955" text="Here we show that during growth in media containing glucose and in complex medium without glucose RamB activates expression of the aceE gene, encoding the E1p subunit of the pyruvate dehydrogenase complex.">
            <entity id="DS.d12.s0.e0" origId="206,5793,64689,79025" charOffset="52-59" type="compound" text="glucose"/>
            <entity id="DS.d12.s0.e1" origId="206,5793,64689,79025" charOffset="90-97" type="compound" text="glucose"/>
            <entity id="DS.d12.s0.e2" origId="P0AFG8,P0AFG9,P45119,P57301,Q10504,Q59637,Q89AR0,Q8K9T9" charOffset="131-135" type="protein" text="aceE"/>
            <pair e1="DS.d12.s0.e0" e2="DS.d12.s0.e2" id="DS.d12.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d13" origId="17925795">
        <sentence id="DS.d13.s0" origId="17925795-1037" text="The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons.">
            <entity id="DS.d13.s0.e0" origId="28486,3028194" charOffset="21-28" type="compound" text="lithium"/>
            <entity id="DS.d13.s0.e1" origId="3121" charOffset="33-42" type="compound" text="valproate"/>
            <entity id="DS.d13.s0.e2" origId="P25430,P25431,P25432,Q06225" charOffset="83-116" type="protein" text="brain-derived neurotrophic factor"/>
            <pair e1="DS.d13.s0.e0" e2="DS.d13.s0.e2" id="DS.d13.s0.i0" interaction="True"/>
            <pair e1="DS.d13.s0.e1" e2="DS.d13.s0.e2" id="DS.d13.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d13.s1" origId="17925795-1038" text="Treatment of cultured rat cortical neurons with therapeutic concentrations of LiCl or VPA selectively increased the levels of exon IV (formerly rat exon III)-containing BDNF mRNA, and the activity of BDNF promoter IV.">
            <entity id="DS.d13.s1.e0" origId="433294" charOffset="78-82" type="compound" text="LiCl"/>
            <entity id="DS.d13.s1.e1" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="169-173" type="protein" text="BDNF"/>
            <entity id="DS.d13.s1.e2" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="200-204" type="protein" text="BDNF"/>
            <pair e1="DS.d13.s1.e0" e2="DS.d13.s1.e1" id="DS.d13.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d13.s2" origId="17925795-1039" text="We showed that lithium-induced activation of promoter IV was mimicked by pharmacological inhibition of GSK-3 or short interfering RNA (siRNA)-mediated gene silencing of GSK-3alpha or GSK-3beta isoforms.">
            <entity id="DS.d13.s2.e0" origId="28486,3028194" charOffset="15-22" type="compound" text="lithium"/>
            <entity id="DS.d13.s2.e1" origId="P51136,P83101" charOffset="103-108" type="protein" text="GSK-3"/>
            <entity id="DS.d13.s2.e2" origId="P18265,P49840" charOffset="169-179" type="protein" text="GSK-3alpha"/>
            <entity id="DS.d13.s2.e3" origId="P18266,P49841,Q5YJC2,Q9WV60" charOffset="183-192" type="protein" text="GSK-3beta"/>
            <pair e1="DS.d13.s2.e0" e2="DS.d13.s2.e2" id="DS.d13.s2.i0" interaction="True"/>
            <pair e1="DS.d13.s2.e0" e2="DS.d13.s2.e3" id="DS.d13.s2.i1" interaction="True"/>
            <pair e1="DS.d13.s2.e0" e2="DS.d13.s2.e1" id="DS.d13.s2.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d13.s3" origId="17925795-1040" text="Furthermore, treatment with other HDAC inhibitors, sodium butyrate and trichostatin A, or transfection with an HDAC1-specific siRNA also activated BDNF promoter IV.">
            <entity id="DS.d13.s3.e0" origId="264" charOffset="51-66" type="compound" text="sodium butyrate"/>
            <entity id="DS.d13.s3.e1" origId="444732" charOffset="71-85" type="compound" text="trichostatin A"/>
            <entity id="DS.d13.s3.e2" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="147-151" type="protein" text="BDNF"/>
            <pair e1="DS.d13.s3.e0" e2="DS.d13.s3.e2" id="DS.d13.s3.i0" interaction="True"/>
            <pair e1="DS.d13.s3.e1" e2="DS.d13.s3.e2" id="DS.d13.s3.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d13.s4" origId="17925795-1041" text="Our study demonstrates for the first time that GSK-3 and HDAC are respective initial targets for lithium and VPA to activate BDNF promoter IV, and that this BDNF induction involves a novel responsive region in promoter IV of the BDNF gene.">
            <entity id="DS.d13.s4.e0" origId="P51136,P83101" charOffset="47-52" type="protein" text="GSK-3"/>
            <entity id="DS.d13.s4.e1" origId="28486,3028194" charOffset="97-104" type="compound" text="lithium"/>
            <entity id="DS.d13.s4.e2" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="125-129" type="protein" text="BDNF"/>
            <entity id="DS.d13.s4.e3" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="157-161" type="protein" text="BDNF"/>
            <entity id="DS.d13.s4.e4" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="157-161" type="protein" text="BDNF"/>
            <pair e1="DS.d13.s4.e1" e2="DS.d13.s4.e0" id="DS.d13.s4.i0" interaction="True"/>
            <pair e1="DS.d13.s4.e1" e2="DS.d13.s4.e2" id="DS.d13.s4.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d14" origId="17941873">
        <sentence id="DS.d14.s0" origId="17941873-845" text="Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).">
            <entity id="DS.d14.s0.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="21-28" type="protein" text="insulin"/>
            <entity id="DS.d14.s0.e1" origId="4091" charOffset="52-61" type="compound" text="metformin"/>
            <entity id="DS.d14.s0.e2" origId="4829" charOffset="66-78" type="compound" text="pioglitazone"/>
            <entity id="DS.d14.s0.e3" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="162-169" type="protein" text="Insulin"/>
            <pair e1="DS.d14.s0.e2" e2="DS.d14.s0.e0" id="DS.d14.s0.i0" interaction="False"/>
            <pair e1="DS.d14.s0.e1" e2="DS.d14.s0.e0" id="DS.d14.s0.i1" interaction="False"/>
            <pair e1="DS.d14.s0.e2" e2="DS.d14.s0.e3" id="DS.d14.s0.i2" interaction="False"/>
            <pair e1="DS.d14.s0.e1" e2="DS.d14.s0.e3" id="DS.d14.s0.i3" interaction="False"/>
        </sentence>
        <sentence id="DS.d14.s1" origId="17941873-846" text="Efficacy and safety of biphasic insulin aspart (BIAsp 30, 30% short-acting and 70% intermediate-acting insulin aspart) added to an optimized treatment of metformin and pioglitazone (met/pio) were compared with treatment with optimized met/pio in type 2 diabetes patients.">
            <entity id="DS.d14.s1.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="32-39" type="protein" text="insulin"/>
            <entity id="DS.d14.s1.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="103-110" type="protein" text="insulin"/>
            <entity id="DS.d14.s1.e2" origId="4091" charOffset="154-163" type="compound" text="metformin"/>
            <entity id="DS.d14.s1.e3" origId="4829" charOffset="168-180" type="compound" text="pioglitazone"/>
            <pair e1="DS.d14.s1.e3" e2="DS.d14.s1.e0" id="DS.d14.s1.i0" interaction="False"/>
            <pair e1="DS.d14.s1.e2" e2="DS.d14.s1.e0" id="DS.d14.s1.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d15" origId="17943458">
        <sentence id="DS.d15.s0" origId="17943458-544" text="N-acetylaspartic acid (NAA) is converted into aspartate and acetate by aspartoacylase.">
            <entity id="DS.d15.s0.e0" origId="65065" charOffset="0-21" type="compound" text="N-acetylaspartic acid"/>
            <entity id="DS.d15.s0.e1" origId="5960" charOffset="46-55" type="compound" text="aspartate"/>
            <entity id="DS.d15.s0.e2" origId="53627460" charOffset="60-67" type="compound" text="acetate"/>
            <entity id="DS.d15.s0.e3" origId="P45381,P46446,Q60HH2,Q8R3P0,Q9R1T5" charOffset="71-85" type="protein" text="aspartoacylase"/>
            <pair e1="DS.d15.s0.e0" e2="DS.d15.s0.e3" id="DS.d15.s0.i0" interaction="True"/>
            <pair e1="DS.d15.s0.e1" e2="DS.d15.s0.e3" id="DS.d15.s0.i1" interaction="True"/>
            <pair e1="DS.d15.s0.e2" e2="DS.d15.s0.e3" id="DS.d15.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d16" origId="17950491">
        <sentence id="DS.d16.s0" origId="17950491-1121" text="In addition, treatment with rosiglitazone increased interleukin-4 (IL-4) mRNA and reversed the age-related decrease in hippocampal IL-4 concentration.">
            <entity id="DS.d16.s0.e0" origId="77999" charOffset="28-41" type="compound" text="rosiglitazone"/>
            <entity id="DS.d16.s0.e1" origId="O77762,P05112,P07750,P20096,P30367,P30368,P42202,P46652,P47966,P51492,P51744,P55030,P79155,P79339,Q04745,Q2PE74,Q3S4V6,Q58M18,Q60440,Q7YS71,Q865X5,Q865Y0,Q8HYB1,Q9MZR8,Q9XS58" charOffset="67-71" type="protein" text="IL-4"/>
            <entity id="DS.d16.s0.e2" origId="O77762,P05112,P07750,P20096,P30367,P30368,P42202,P46652,P47966,P51492,P51744,P55030,P79155,P79339,Q04745,Q2PE74,Q3S4V6,Q58M18,Q60440,Q7YS71,Q865X5,Q865Y0,Q8HYB1,Q9MZR8,Q9XS58" charOffset="131-135" type="protein" text="IL-4"/>
            <pair e1="DS.d16.s0.e0" e2="DS.d16.s0.e1" id="DS.d16.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d17" origId="17965987">
        <sentence id="DS.d17.s0" origId="17965987-545" text="Serum BDNF levels were increased and plasma levels of HVA and MHPG were decreased according to the recovery from the active phase of the disease.">
            <entity id="DS.d17.s0.e0" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="6-10" type="protein" text="BDNF"/>
            <entity id="DS.d17.s0.e1" origId="1738" charOffset="54-57" type="compound" text="HVA"/>
            <entity id="DS.d17.s0.e2" origId="10805" charOffset="62-66" type="compound" text="MHPG"/>
            <pair e1="DS.d17.s0.e1" e2="DS.d17.s0.e0" id="DS.d17.s0.i0" interaction="False"/>
            <pair e1="DS.d17.s0.e2" e2="DS.d17.s0.e0" id="DS.d17.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d17.s1" origId="17965987-546" text="These results suggest that dysfunctions of catecholaminergic neurons and neurotrophic factors might exist in Sydenham's chorea, and the decreasing catecholamine activities in response to risperidone might be associated with the improvement of the disease.">
            <entity id="DS.d17.s1.e0" origId="P18280,P20181,P20783,P25433,P25434,P25435,Q9TST2" charOffset="73-93" type="protein" text="neurotrophic factors"/>
            <entity id="DS.d17.s1.e1" origId="5073" charOffset="187-198" type="compound" text="risperidone"/>
            <pair e1="DS.d17.s1.e1" e2="DS.d17.s1.e0" id="DS.d17.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d18" origId="17968352">
        <sentence id="DS.d18.s0" origId="17968352-734" text="Based on these validities we identified alterations in the Wolframin gene in the CA1 and amygdala regions, specifically in exposed PTSD-like rats, which were normalized after treatment with citalopram.">
            <entity id="DS.d18.s0.e0" origId="O76024,P56695" charOffset="59-68" type="protein" text="Wolframin"/>
            <entity id="DS.d18.s0.e1" origId="2771,146570" charOffset="190-200" type="compound" text="citalopram"/>
            <pair e1="DS.d18.s0.e1" e2="DS.d18.s0.e0" id="DS.d18.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d19" origId="17968676">
        <sentence id="DS.d19.s0" origId="17968676-958" text="Cyclooxygenase-2 (Cox-2) is a key enzyme in the conversion of arachidonic acid to prostaglandins that has been shown to have a particular importance in the progression of several malignancies including nasopharyngeal carcinoma (NPC).">
            <entity id="DS.d19.s0.e0" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="0-16" type="protein" text="Cyclooxygenase-2"/>
            <entity id="DS.d19.s0.e1" origId="P00411,P24894,P35355,Q05769,Q8HEC3,Q8SEM9" charOffset="18-23" type="protein" text="Cox-2"/>
            <entity id="DS.d19.s0.e2" origId="444899" charOffset="62-78" type="compound" text="arachidonic acid"/>
            <pair e1="DS.d19.s0.e2" e2="DS.d19.s0.e0" id="DS.d19.s0.i0" interaction="True"/>
            <pair e1="DS.d19.s0.e2" e2="DS.d19.s0.e1" id="DS.d19.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d20" origId="17976762">
        <sentence id="DS.d20.s0" origId="17976762-900" text="Other potential treatments discussed for possible use with long-acting insulin overdoses include incision and drainage of the injection site, glucagon, and octreotide.">
            <entity id="DS.d20.s0.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="71-78" type="protein" text="insulin"/>
            <entity id="DS.d20.s0.e2" origId="383414,448601" charOffset="156-166" type="compound" text="octreotide"/>
            <pair e1="DS.d20.s0.e2" e2="DS.d20.s0.e0" id="DS.d20.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d21" origId="18037312">
        <sentence id="DS.d21.s0" origId="18037312-321" text="Cadmium inhalation induced: (1) a transient bronchial inflammation, dominated by neutrophils; (2) a neutrophilia of the blood that persisted for up to 4 weeks; (3) a transient increased bronchial reactivity, and (4) a significant increase in MMP-9 activity in the BALF.">
            <entity id="DS.d21.s0.e0" origId="23973" charOffset="0-7" type="compound" text="Cadmium"/>
            <entity id="DS.d21.s0.e1" origId="O18733,P14780,P41245,P41246,P50282,P52176" charOffset="242-247" type="protein" text="MMP-9"/>
            <pair e1="DS.d21.s0.e0" e2="DS.d21.s0.e1" id="DS.d21.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d22" origId="18042181">
        <sentence id="DS.d22.s0" origId="18042181-811" text="To assess whether follicle-stimulating hormone (FSH) and basic fibroblast growth factor (bFGF) modulate GSH production in Sertoli cells by regulating the expression of GCLC, GCLM and/or GR, we performed in vitro studies using rat Sertoli cells in primary culture.">
            <entity id="DS.d22.s0.e0" origId="P03969,P09038,P12226,P13109,P15655,P20003,P48798,P48799,P48800,Q60487" charOffset="57-87" type="protein" text="basic fibroblast growth factor"/>
            <entity id="DS.d22.s0.e1" origId="124886" charOffset="104-107" type="compound" text="GSH"/>
            <entity id="DS.d22.s0.e2" origId="P48506" charOffset="168-172" type="protein" text="GCLC"/>
            <entity id="DS.d22.s0.e3" origId="P48507,Q2T9Y6" charOffset="174-178" type="protein" text="GCLM"/>
            <pair e1="DS.d22.s0.e1" e2="DS.d22.s0.e3" id="DS.d22.s0.i0" interaction="False"/>
            <pair e1="DS.d22.s0.e1" e2="DS.d22.s0.e0" id="DS.d22.s0.i1" interaction="False"/>
            <pair e1="DS.d22.s0.e1" e2="DS.d22.s0.e2" id="DS.d22.s0.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d22.s1" origId="18042181-812" text="In conclusion, our results show that FSH and bFGF increase GSH levels in Sertoli cells through stimulation of the de novo synthesis and recycling by upregulating GCLM and GR expression respectively.">
            <entity id="DS.d22.s1.e0" origId="124886" charOffset="59-62" type="compound" text="GSH"/>
            <entity id="DS.d22.s1.e1" origId="P48507,Q2T9Y6" charOffset="162-166" type="protein" text="GCLM"/>
            <pair e1="DS.d22.s1.e0" e2="DS.d22.s1.e1" id="DS.d22.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d23" origId="18061671">
        <sentence id="DS.d23.s0" origId="18061671-207" text="Compared to the control, both the stresses individually and in combination led to in reductions in growth, photosynthetic pigments, ascorbic acid, catalase (CAT) activity and yield, whereas a reverse trend was observed for flavonoids, thiols and proline contents, superoxide dismutase (SOD) and peroxidase (POD) activities, and LPO.">
            <entity id="DS.d23.s0.e0" origId="54670067,54690394" charOffset="132-145" type="compound" text="ascorbic acid"/>
            <entity id="DS.d23.s0.e1" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="147-155" type="protein" text="catalase"/>
            <entity id="DS.d23.s0.e2" origId="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7" charOffset="157-160" type="protein" text="CAT"/>
            <entity id="DS.d23.s0.e3" origId="614,8988,145742" charOffset="246-253" type="compound" text="proline"/>
            <entity id="DS.d23.s0.e4" origId="O50258" charOffset="264-284" type="protein" text="superoxide dismutase"/>
            <entity id="DS.d23.s0.e5" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="286-289" type="protein" text="SOD"/>
            <entity id="DS.d23.s0.e6" origId="P15984,P16147,P84714" charOffset="295-305" type="protein" text="peroxidase"/>
            <entity id="DS.d23.s0.e7" origId="P59097,P79076,Q5B2E9,Q5G234,Q6QWR1,Q6UG02,Q75ZP8,Q8J136,Q8J2V8" charOffset="307-310" type="protein" text="POD"/>
            <entity id="DS.d23.s0.e8" origId="P22079,P80025" charOffset="328-331" type="protein" text="LPO"/>
            <pair e1="DS.d23.s0.e0" e2="DS.d23.s0.e6" id="DS.d23.s0.i0" interaction="False"/>
            <pair e1="DS.d23.s0.e3" e2="DS.d23.s0.e6" id="DS.d23.s0.i1" interaction="False"/>
            <pair e1="DS.d23.s0.e3" e2="DS.d23.s0.e2" id="DS.d23.s0.i2" interaction="False"/>
            <pair e1="DS.d23.s0.e0" e2="DS.d23.s0.e1" id="DS.d23.s0.i3" interaction="False"/>
            <pair e1="DS.d23.s0.e3" e2="DS.d23.s0.e5" id="DS.d23.s0.i4" interaction="False"/>
            <pair e1="DS.d23.s0.e0" e2="DS.d23.s0.e7" id="DS.d23.s0.i5" interaction="False"/>
            <pair e1="DS.d23.s0.e0" e2="DS.d23.s0.e2" id="DS.d23.s0.i6" interaction="False"/>
            <pair e1="DS.d23.s0.e0" e2="DS.d23.s0.e5" id="DS.d23.s0.i7" interaction="False"/>
            <pair e1="DS.d23.s0.e3" e2="DS.d23.s0.e8" id="DS.d23.s0.i8" interaction="False"/>
            <pair e1="DS.d23.s0.e3" e2="DS.d23.s0.e4" id="DS.d23.s0.i9" interaction="False"/>
            <pair e1="DS.d23.s0.e3" e2="DS.d23.s0.e7" id="DS.d23.s0.i10" interaction="False"/>
            <pair e1="DS.d23.s0.e3" e2="DS.d23.s0.e1" id="DS.d23.s0.i11" interaction="False"/>
            <pair e1="DS.d23.s0.e0" e2="DS.d23.s0.e8" id="DS.d23.s0.i12" interaction="False"/>
            <pair e1="DS.d23.s0.e0" e2="DS.d23.s0.e4" id="DS.d23.s0.i13" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d24" origId="18068270">
        <sentence id="DS.d24.s0" origId="18068270-465" text="Selenium and aluminum levels were not associated to CSF Abeta42.">
            <entity id="DS.d24.s0.e0" origId="5359268" charOffset="13-21" type="compound" text="aluminum"/>
            <entity id="DS.d24.s0.e1" origId="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481" charOffset="52-55" type="protein" text="CSF"/>
            <pair e1="DS.d24.s0.e0" e2="DS.d24.s0.e1" id="DS.d24.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d24.s1" origId="18068270-466" text="In vitro, the degradation of synthetic Abeta substrate added to CSF was markedly accelerated by low levels (2microM) of exogenous zinc and copper.">
            <entity id="DS.d24.s1.e0" origId="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481" charOffset="64-67" type="protein" text="CSF"/>
            <entity id="DS.d24.s1.e1" origId="23978" charOffset="139-145" type="compound" text="copper"/>
            <pair e1="DS.d24.s1.e1" e2="DS.d24.s1.e0" id="DS.d24.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d25" origId="18068871">
        <sentence id="DS.d25.s0" origId="18068871-859" text="Presenilin-1 mutation impairs cholinergic modulation of synaptic plasticity and suppresses NMDA currents in hippocampus slices.">
            <entity id="DS.d25.s0.e0" origId="O12976,P49768,P49769,P79802,P97887,Q4JIM4,Q5R780,Q6RH31,Q8HXW5,Q9W6T7,Q9XT97" charOffset="0-12" type="protein" text="Presenilin-1"/>
            <entity id="DS.d25.s0.e1" origId="22880" charOffset="91-95" type="compound" text="NMDA"/>
            <pair e1="DS.d25.s0.e1" e2="DS.d25.s0.e0" id="DS.d25.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d25.s1" origId="18068871-860" text="Similarly, mutant PS1 impairs the ability of the cholinesterase inhibitor phenserine to enhance LTP.">
            <entity id="DS.d25.s1.e0" origId="P49768,P79802,Q8HXW5,Q9W6T7" charOffset="18-21" type="protein" text="PS1"/>
            <entity id="DS.d25.s1.e1" origId="192706,9905831,10337156" charOffset="74-84" type="compound" text="phenserine"/>
            <pair e1="DS.d25.s1.e1" e2="DS.d25.s1.e0" id="DS.d25.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d26" origId="18077014">
        <sentence id="DS.d26.s0" origId="18077014-827" text="It was found that the expression of SSAT and ODC were upregulated after reperfusion and the concentrations of spermidine and spermine were significantly decreased, while putrescine concentration was significantly increased.">
            <entity id="DS.d26.s0.e0" origId="P21673,P48026,P49431,Q01612,Q28999,Q3T0Q0,Q8AXL1,Q9JHW6" charOffset="36-40" type="protein" text="SSAT"/>
            <entity id="DS.d26.s0.e1" origId="O22616,P00860,P07805,P08432,P09057,P11926,P14019,P27116,P27117,P27118,P27119,P27121,P40807,P40808,P41931,P43099,P49725,P50134,P78599,Q5RFB7,Q8S3N2,Q92445,Q9BQT8,Q9UQW9" charOffset="45-48" type="protein" text="ODC"/>
            <entity id="DS.d26.s0.e2" origId="1102" charOffset="110-120" type="compound" text="spermidine"/>
            <entity id="DS.d26.s0.e3" origId="1103" charOffset="125-133" type="compound" text="spermine"/>
            <entity id="DS.d26.s0.e4" origId="1045" charOffset="170-180" type="compound" text="putrescine"/>
            <pair e1="DS.d26.s0.e3" e2="DS.d26.s0.e1" id="DS.d26.s0.i0" interaction="True"/>
            <pair e1="DS.d26.s0.e4" e2="DS.d26.s0.e0" id="DS.d26.s0.i1" interaction="True"/>
            <pair e1="DS.d26.s0.e3" e2="DS.d26.s0.e0" id="DS.d26.s0.i2" interaction="True"/>
            <pair e1="DS.d26.s0.e4" e2="DS.d26.s0.e1" id="DS.d26.s0.i3" interaction="True"/>
            <pair e1="DS.d26.s0.e2" e2="DS.d26.s0.e0" id="DS.d26.s0.i4" interaction="True"/>
            <pair e1="DS.d26.s0.e2" e2="DS.d26.s0.e1" id="DS.d26.s0.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d27" origId="18079026">
        <sentence id="DS.d27.s0" origId="18079026-797" text="In the present study, we investigated the effects of quetiapine on memory impairment and pathological changes in an amyloid precursor protein (APP)/presenilin-1 (PS-1) double transgenic mouse model of Alzheimer's disease (AD).">
            <entity id="DS.d27.s0.e0" origId="5002" charOffset="53-63" type="compound" text="quetiapine"/>
            <entity id="DS.d27.s0.e1" origId="O73683,O93279,P05067,P08592,P0A3Z1,P0A3Z2,P0A3Z3,P0A3Z4,P12023,P29216,P47566,P53601,P75313,P79307,Q11207,Q28053,Q28280,Q28748,Q28757,Q29149,Q5IS80,Q60495,Q95241" charOffset="143-146" type="protein" text="APP"/>
            <entity id="DS.d27.s0.e2" origId="O12976,P49768,P49769,P79802,P97887,Q4JIM4,Q5R780,Q6RH31,Q8HXW5,Q9W6T7,Q9XT97" charOffset="148-160" type="protein" text="presenilin-1"/>
            <entity id="DS.d27.s0.e3" origId="P49768,P49769,P79802,P84566,P97887,Q5R780,Q6RH31,Q8HXW5,Q9XT97" charOffset="162-166" type="protein" text="PS-1"/>
            <pair e1="DS.d27.s0.e0" e2="DS.d27.s0.e2" id="DS.d27.s0.i0" interaction="False"/>
            <pair e1="DS.d27.s0.e0" e2="DS.d27.s0.e3" id="DS.d27.s0.i1" interaction="False"/>
            <pair e1="DS.d27.s0.e0" e2="DS.d27.s0.e1" id="DS.d27.s0.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d27.s1" origId="18079026-798" text="Quetiapine also decreased brain Abeta peptides, beta-secretase activity and expression, and the level of C99 (an APP C-terminal fragment following cleavage by beta-secretase) in the transgenic mice.">
            <entity id="DS.d27.s1.e0" origId="5002" charOffset="0-10" type="compound" text="Quetiapine"/>
            <entity id="DS.d27.s1.e1" origId="P05067,P08592,P12023,P53601,P79307,Q5IS80,Q95241" charOffset="105-108" type="protein" text="C99"/>
            <entity id="DS.d27.s1.e2" origId="O73683,O93279,P05067,P08592,P0A3Z1,P0A3Z2,P0A3Z3,P0A3Z4,P12023,P29216,P47566,P53601,P75313,P79307,Q11207,Q28053,Q28280,Q28748,Q28757,Q29149,Q5IS80,Q60495,Q95241" charOffset="113-116" type="protein" text="APP"/>
            <pair e1="DS.d27.s1.e0" e2="DS.d27.s1.e1" id="DS.d27.s1.i0" interaction="True"/>
            <pair e1="DS.d27.s1.e0" e2="DS.d27.s1.e2" id="DS.d27.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d27.s2" origId="18079026-799" text="Furthermore, quetiapine attenuated anxiety-like behavior, up-regulated cerebral Bcl-2 protein, and decreased cerebral nitrotyrosine in the transgenic mice.">
            <entity id="DS.d27.s2.e0" origId="5002" charOffset="13-23" type="compound" text="quetiapine"/>
            <entity id="DS.d27.s2.e1" origId="P10417,P49950" charOffset="80-85" type="protein" text="Bcl-2"/>
            <pair e1="DS.d27.s2.e0" e2="DS.d27.s2.e1" id="DS.d27.s2.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d28" origId="18162361">
        <sentence id="DS.d28.s0" origId="18162361-61" text="Rosuvastatin rapidly phosphorylated Akt and endothelial nitric oxide synthase (eNOS) in human endothelial cells.">
            <entity id="DS.d28.s0.e0" origId="446157" charOffset="0-12" type="compound" text="Rosuvastatin"/>
            <entity id="DS.d28.s0.e1" origId="P31750,Q8INB9" charOffset="36-39" type="protein" text="Akt"/>
            <entity id="DS.d28.s0.e2" origId="O61309,O61608,Q27571,Q9I9M2" charOffset="56-77" type="protein" text="nitric oxide synthase"/>
            <entity id="DS.d28.s0.e3" origId="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600" charOffset="79-83" type="protein" text="eNOS"/>
            <pair e1="DS.d28.s0.e0" e2="DS.d28.s0.e2" id="DS.d28.s0.i0" interaction="True"/>
            <pair e1="DS.d28.s0.e0" e2="DS.d28.s0.e3" id="DS.d28.s0.i1" interaction="True"/>
            <pair e1="DS.d28.s0.e0" e2="DS.d28.s0.e1" id="DS.d28.s0.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d28.s1" origId="18162361-62" text="Our findings indicate that rosuvastatin protects endothelial cells from death with phosphorylation of Akt and eNOS.">
            <entity id="DS.d28.s1.e0" origId="446157" charOffset="27-39" type="compound" text="rosuvastatin"/>
            <entity id="DS.d28.s1.e1" origId="P31750,Q8INB9" charOffset="102-105" type="protein" text="Akt"/>
            <entity id="DS.d28.s1.e2" origId="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600" charOffset="110-114" type="protein" text="eNOS"/>
            <pair e1="DS.d28.s1.e0" e2="DS.d28.s1.e2" id="DS.d28.s1.i0" interaction="True"/>
            <pair e1="DS.d28.s1.e0" e2="DS.d28.s1.e1" id="DS.d28.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d29" origId="18164165">
        <sentence id="DS.d29.s0" origId="18164165-377" text="Superoxide dismutase and glutathione peroxidase antioxidant enzyme activities and malondialdehyde levels were found to be increased; however, beta-carotene, retinol, vitamin C, vitamin E, reduced glutathione, and albumin levels were observed to be significantly decreased.">
            <entity id="DS.d29.s0.e0" origId="O50258" charOffset="0-20" type="protein" text="Superoxide dismutase"/>
            <entity id="DS.d29.s0.e1" origId="O32770,O59858,Q00277,Q9CFV1" charOffset="25-47" type="protein" text="glutathione peroxidase"/>
            <entity id="DS.d29.s0.e2" origId="10964" charOffset="82-97" type="compound" text="malondialdehyde"/>
            <entity id="DS.d29.s0.e3" origId="5280489" charOffset="142-155" type="compound" text="beta-carotene"/>
            <entity id="DS.d29.s0.e4" origId="445354" charOffset="157-164" type="compound" text="retinol"/>
            <entity id="DS.d29.s0.e5" origId="54670067" charOffset="166-175" type="compound" text="vitamin C"/>
            <entity id="DS.d29.s0.e6" origId="2116,14985,1548900,1742129" charOffset="177-186" type="compound" text="vitamin E"/>
            <entity id="DS.d29.s0.e7" origId="124886" charOffset="188-207" type="compound" text="reduced glutathione"/>
            <pair e1="DS.d29.s0.e4" e2="DS.d29.s0.e0" id="DS.d29.s0.i0" interaction="False"/>
            <pair e1="DS.d29.s0.e5" e2="DS.d29.s0.e0" id="DS.d29.s0.i1" interaction="False"/>
            <pair e1="DS.d29.s0.e2" e2="DS.d29.s0.e1" id="DS.d29.s0.i2" interaction="False"/>
            <pair e1="DS.d29.s0.e7" e2="DS.d29.s0.e0" id="DS.d29.s0.i3" interaction="False"/>
            <pair e1="DS.d29.s0.e6" e2="DS.d29.s0.e1" id="DS.d29.s0.i4" interaction="False"/>
            <pair e1="DS.d29.s0.e6" e2="DS.d29.s0.e0" id="DS.d29.s0.i5" interaction="False"/>
            <pair e1="DS.d29.s0.e5" e2="DS.d29.s0.e1" id="DS.d29.s0.i6" interaction="False"/>
            <pair e1="DS.d29.s0.e4" e2="DS.d29.s0.e1" id="DS.d29.s0.i7" interaction="False"/>
            <pair e1="DS.d29.s0.e7" e2="DS.d29.s0.e1" id="DS.d29.s0.i8" interaction="False"/>
            <pair e1="DS.d29.s0.e2" e2="DS.d29.s0.e0" id="DS.d29.s0.i9" interaction="False"/>
            <pair e1="DS.d29.s0.e3" e2="DS.d29.s0.e0" id="DS.d29.s0.i10" interaction="False"/>
            <pair e1="DS.d29.s0.e3" e2="DS.d29.s0.e1" id="DS.d29.s0.i11" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d30" origId="18172601">
        <sentence id="DS.d30.s0" origId="18172601-392" text="Structure-function studies of nitrated SERCA2 in aging heart and skeletal muscle demonstrate stoichiometric nitration of vicinal tyrosines, Tyr (294) and Tyr (295), on the lumenal side of the membrane-spanning helix, M4, which correlates with partial inhibition of Ca(2+)-ATPase activity suggesting a possible regulatory function in down-regulating mitochondrial energy production and the associated generation of reactive oxygen/nitrogen species.">
            <entity id="DS.d30.s0.e0" origId="O46674,O55143,P11507,P11607,P16615,P20647,Q00779,Q03669" charOffset="39-45" type="protein" text="SERCA2"/>
            <entity id="DS.d30.s0.e1" origId="16682741" charOffset="217-219" type="compound" text="M4"/>
            <entity id="DS.d30.s0.e2" origId="977" charOffset="423-429" type="compound" text="oxygen"/>
            <entity id="DS.d30.s0.e3" origId="947,123329" charOffset="430-438" type="compound" text="nitrogen"/>
            <pair e1="DS.d30.s0.e1" e2="DS.d30.s0.e0" id="DS.d30.s0.i0" interaction="False"/>
            <pair e1="DS.d30.s0.e2" e2="DS.d30.s0.e0" id="DS.d30.s0.i1" interaction="False"/>
            <pair e1="DS.d30.s0.e3" e2="DS.d30.s0.e0" id="DS.d30.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d31" origId="18177531">
        <sentence id="DS.d31.s0" origId="18177531-936" text="Carbon monoxide is an endogenous vasodilator gas produced by the enzyme heme oxygenase (HO).">
            <entity id="DS.d31.s0.e0" origId="281" charOffset="0-15" type="compound" text="Carbon monoxide"/>
            <entity id="DS.d31.s0.e1" origId="O19998,O73688,O78497,P51271,P71119" charOffset="72-86" type="protein" text="heme oxygenase"/>
            <pair e1="DS.d31.s0.e0" e2="DS.d31.s0.e1" id="DS.d31.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d32" origId="18179560">
        <sentence id="DS.d32.s0" origId="18179560-930" text="The long pentraxin 3 (PTX3) is a multifunctional soluble pattern recognition receptor, involved in several processes ranging from innate resistance and inflammation to clearance of apoptotic cells and organization of hyaluronic acid-rich extracellular matrices.">
            <entity id="DS.d32.s0.e0" origId="O75364,P26022" charOffset="22-26" type="protein" text="PTX3"/>
            <entity id="DS.d32.s0.e1" origId="24759,453618,3084050,24728612" charOffset="217-232" type="compound" text="hyaluronic acid"/>
            <pair e1="DS.d32.s0.e1" e2="DS.d32.s0.e0" id="DS.d32.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d33" origId="18180755">
        <sentence id="DS.d33.s0" origId="18180755-369" text="The FKBP5 gene product forms part of a complex with the glucocorticoid receptor and can modulate cortisol-binding affinity.">
            <entity id="DS.d33.s0.e0" origId="P0C1J7,Q13451,Q5RF88,Q95L05,Q9XSH5,Q9XSI2,Q9XT11" charOffset="4-9" type="protein" text="FKBP5"/>
            <entity id="DS.d33.s0.e1" origId="O13186,O46567,O73673,P04150,P06536,P06537,P35547,P49115,P49843,P49844,P59667,P79269,P79686,Q5R9P5,Q6XLJ0,Q95267,Q9N1U3" charOffset="56-79" type="protein" text="glucocorticoid receptor"/>
            <entity id="DS.d33.s0.e2" origId="5754" charOffset="97-105" type="compound" text="cortisol"/>
            <pair e1="DS.d33.s0.e2" e2="DS.d33.s0.e0" id="DS.d33.s0.i0" interaction="True"/>
            <pair e1="DS.d33.s0.e2" e2="DS.d33.s0.e1" id="DS.d33.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d34" origId="18190985">
        <sentence id="DS.d34.s0" origId="18190985-361" text="Several studies have shown that epsilon 2 carriers have lower low-density lipoprotein and apo B levels and higher high-density lipoprotein cholesterol and apo A-I levels than epsilon 3 carriers.">
            <entity id="DS.d34.s0.e0" origId="P05463" charOffset="32-39" type="protein" text="epsilon"/>
            <entity id="DS.d34.s0.e1" origId="P81182" charOffset="114-138" type="protein" text="high-density lipoprotein"/>
            <entity id="DS.d34.s0.e2" origId="304,5997,6432564,11025495" charOffset="139-150" type="compound" text="cholesterol"/>
            <entity id="DS.d34.s0.e3" origId="P05463" charOffset="175-182" type="protein" text="epsilon"/>
            <pair e1="DS.d34.s0.e2" e2="DS.d34.s0.e1" id="DS.d34.s0.i0" interaction="True"/>
            <pair e1="DS.d34.s0.e2" e2="DS.d34.s0.e0" id="DS.d34.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d35" origId="18191451">
        <sentence id="DS.d35.s0" origId="18191451-670" text="Toxicity and characterization of cholinesterase-inhibition induced by diisopropyl fluorophosphate in Artemia salina larvae.">
            <entity id="DS.d35.s0.e0" origId="P32749,P32750,P32751,P32752,P32753,P81908" charOffset="33-47" type="protein" text="cholinesterase"/>
            <entity id="DS.d35.s0.e1" origId="5936" charOffset="70-97" type="compound" text="diisopropyl fluorophosphate"/>
            <pair e1="DS.d35.s0.e1" e2="DS.d35.s0.e0" id="DS.d35.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d36" origId="18195714">
        <sentence id="DS.d36.s0" origId="18195714-756" text="Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice.">
            <entity id="DS.d36.s0.e0" origId="11970143" charOffset="0-18" type="compound" text="Lipopolysaccharide"/>
            <entity id="DS.d36.s0.e1" origId="P14902,P28776" charOffset="67-94" type="protein" text="indoleamine 2,3-dioxygenase"/>
            <pair e1="DS.d36.s0.e0" e2="DS.d36.s0.e1" id="DS.d36.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d36.s1" origId="18195714-757" text="We report that peripheral administration of lipopolysaccharide (LPS) activates IDO and culminates in a distinct depressive-like behavioral syndrome, measured by increased duration of immobility in both the forced-swim and tail suspension tests.">
            <entity id="DS.d36.s1.e0" origId="11970143" charOffset="44-62" type="compound" text="lipopolysaccharide"/>
            <entity id="DS.d36.s1.e1" origId="P14902,P28776" charOffset="79-82" type="protein" text="IDO"/>
            <pair e1="DS.d36.s1.e0" e2="DS.d36.s1.e1" id="DS.d36.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d36.s2" origId="18195714-758" text="Administration of L-kynurenine, a metabolite of tryptophan that is generated by IDO, to naive mice dose dependently induces depressive-like behavior.">
            <entity id="DS.d36.s2.e0" origId="846" charOffset="20-30" type="compound" text="kynurenine"/>
            <entity id="DS.d36.s2.e1" origId="1148,6305,9060,5460840" charOffset="48-58" type="compound" text="tryptophan"/>
            <entity id="DS.d36.s2.e2" origId="P14902,P28776" charOffset="80-83" type="protein" text="IDO"/>
            <pair e1="DS.d36.s2.e0" e2="DS.d36.s2.e2" id="DS.d36.s2.i0" interaction="True"/>
            <pair e1="DS.d36.s2.e1" e2="DS.d36.s2.e2" id="DS.d36.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d37" origId="18198986">
        <sentence id="DS.d37.s0" origId="18198986-243" text="Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment.">
            <entity id="DS.d37.s0.e0" origId="O42494,O45035,O76821,P80547,Q17284,Q8MUC1,Q9U5P1" charOffset="16-42" type="protein" text="fatty acid binding protein"/>
            <entity id="DS.d37.s0.e1" origId="3339" charOffset="122-133" type="compound" text="fenofibrate"/>
            <pair e1="DS.d37.s0.e1" e2="DS.d37.s0.e0" id="DS.d37.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d37.s1" origId="18198986-245" text="Serum FABP levels were 2.5-fold higher in T2DM group relative to C and were not affected by fenofibrate treatment (C: 20.6+/-2.1 microg/l, T2DM before F: 55.6+/-5.7 microg/l, T2DM after F: 54.2+/-5.4 microg/l, p 0.0001 for C vs. T2DM before F).">
            <entity id="DS.d37.s1.e0" origId="P80565" charOffset="6-10" type="protein" text="FABP"/>
            <entity id="DS.d37.s1.e1" origId="3339" charOffset="92-103" type="compound" text="fenofibrate"/>
            <pair e1="DS.d37.s1.e1" e2="DS.d37.s1.e0" id="DS.d37.s1.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d37.s2" origId="18198986-246" text="FABP levels positively correlated with BMI, triglyceride levels, blood glucose, glycated hemoglobin, atherogenic index and insulin levels.">
            <entity id="DS.d37.s2.e0" origId="P80565" charOffset="0-4" type="protein" text="FABP"/>
            <entity id="DS.d37.s2.e1" origId="206,5793,64689,79025" charOffset="71-78" type="compound" text="glucose"/>
            <entity id="DS.d37.s2.e2" origId="P15160,P17724,P73925,Q03459" charOffset="89-99" type="protein" text="hemoglobin"/>
            <entity id="DS.d37.s2.e3" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="123-130" type="protein" text="insulin"/>
            <pair e1="DS.d37.s2.e1" e2="DS.d37.s2.e2" id="DS.d37.s2.i0" interaction="False"/>
            <pair e1="DS.d37.s2.e1" e2="DS.d37.s2.e0" id="DS.d37.s2.i1" interaction="True"/>
            <pair e1="DS.d37.s2.e1" e2="DS.d37.s2.e3" id="DS.d37.s2.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d38" origId="18198997">
        <sentence id="DS.d38.s0" origId="18198997-256" text="Butyrate enemas upregulate Muc genes expression but decrease adherent mucus thickness in mice colon.">
            <entity id="DS.d38.s0.e0" origId="264" charOffset="0-8" type="compound" text="Butyrate"/>
            <entity id="DS.d38.s0.e1" origId="P0A9M0" charOffset="27-30" type="protein" text="Muc"/>
            <pair e1="DS.d38.s0.e0" e2="DS.d38.s0.e1" id="DS.d38.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d38.s1" origId="18198997-257" text="We demonstrated that butyrate stimulated the gene expression of both secreted (Muc2) and membrane-linked (Muc1, Muc3, Muc4) mucins.">
            <entity id="DS.d38.s1.e0" origId="264" charOffset="21-29" type="compound" text="butyrate"/>
            <entity id="DS.d38.s1.e1" origId="Q62635" charOffset="79-83" type="protein" text="Muc2"/>
            <entity id="DS.d38.s1.e2" origId="Q02496" charOffset="106-110" type="protein" text="Muc1"/>
            <pair e1="DS.d38.s1.e0" e2="DS.d38.s1.e1" id="DS.d38.s1.i0" interaction="True"/>
            <pair e1="DS.d38.s1.e0" e2="DS.d38.s1.e2" id="DS.d38.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d38.s2" origId="18198997-258" text="Butyrate especially induced a 6-fold increase in Muc2 gene expression in proximal colon.">
            <entity id="DS.d38.s2.e0" origId="264" charOffset="0-8" type="compound" text="Butyrate"/>
            <entity id="DS.d38.s2.e1" origId="Q62635" charOffset="49-53" type="protein" text="Muc2"/>
            <pair e1="DS.d38.s2.e0" e2="DS.d38.s2.e1" id="DS.d38.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d38.s3" origId="18198997-259" text="However, butyrate enemas did not modify the number of epithelial cells containing the protein Muc2, and caused a 2-fold decrease in the thickness of adherent mucus layer.">
            <entity id="DS.d38.s3.e0" origId="264" charOffset="9-17" type="compound" text="butyrate"/>
            <entity id="DS.d38.s3.e1" origId="Q62635" charOffset="94-98" type="protein" text="Muc2"/>
            <pair e1="DS.d38.s3.e0" e2="DS.d38.s3.e1" id="DS.d38.s3.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d39" origId="18204887">
        <sentence id="DS.d39.s0" origId="18204887-141" text="We examined the association of MTHFR C677T and A1298C, and changes in plasma homocysteine in 352 Tunisian patients with angiographically-demonstrated CAD, and 390 age and gender-matched healthy subjects.">
            <entity id="DS.d39.s0.e0" origId="P42898,Q5I598,Q60HE5" charOffset="31-36" type="protein" text="MTHFR"/>
            <entity id="DS.d39.s0.e1" origId="778" charOffset="77-89" type="compound" text="homocysteine"/>
            <pair e1="DS.d39.s0.e1" e2="DS.d39.s0.e0" id="DS.d39.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d40" origId="18205042">
        <sentence id="DS.d40.s0" origId="18205042-213" text="However, we also observed that clotrimazol (1alpha-hydroxylase inhibitor) enhanced 25(OH)D(3)-induced CYP24 expression in breast cancer cells.">
            <entity id="DS.d40.s0.e0" origId="2812" charOffset="31-42" type="compound" text="clotrimazol"/>
            <entity id="DS.d40.s0.e1" origId="Q07973" charOffset="102-107" type="protein" text="CYP24"/>
            <pair e1="DS.d40.s0.e0" e2="DS.d40.s0.e1" id="DS.d40.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d41" origId="18207583">
        <sentence id="DS.d41.s0" origId="18207583-646" text="Expression of senescence-associated beta-galactosidase (SA-beta-Gal) by human skin fibroblasts, effect of advanced glycation end-products and fucose or rhamnose-rich polysaccharides.">
            <entity id="DS.d41.s0.e0" origId="O33815,O52629,O52847,P00722,P00723,P06219,P0C1Y0,P14288,P22498,P23989,P24131,P26257,P30812,P50388,P70753,P77989,P81650,Q1G9Z4,Q47077,Q48727,Q56307,Q59140,Q59750,Q9K9C6" charOffset="36-54" type="protein" text="beta-galactosidase"/>
            <entity id="DS.d41.s0.e1" origId="P10683,P11886,P47212" charOffset="64-67" type="protein" text="Gal"/>
            <entity id="DS.d41.s0.e2" origId="840,17106,19466,94270,439554" charOffset="142-148" type="compound" text="fucose"/>
            <pair e1="DS.d41.s0.e2" e2="DS.d41.s0.e1" id="DS.d41.s0.i0" interaction="False"/>
            <pair e1="DS.d41.s0.e2" e2="DS.d41.s0.e0" id="DS.d41.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d42" origId="18221806">
        <sentence id="DS.d42.s0" origId="18221806-436" text="Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase.">
            <entity id="DS.d42.s0.e0" origId="54454,4677798" charOffset="25-36" type="compound" text="simvastatin"/>
            <entity id="DS.d42.s0.e1" origId="O61309,O61608,Q27571,Q9I9M2" charOffset="159-180" type="protein" text="nitric oxide synthase"/>
            <pair e1="DS.d42.s0.e0" e2="DS.d42.s0.e1" id="DS.d42.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d43" origId="18222028">
        <sentence id="DS.d43.s0" origId="18222028-559" text="It has been shown that the removal efficiency of COD increased with the increasing applied current density and increasing PAC and Na (2)SO(4) dosage and the most effective removal capacity was achieved at the pH 7.">
            <entity id="DS.d43.s0.e0" origId="P14678" charOffset="49-52" type="protein" text="COD"/>
            <entity id="DS.d43.s0.e1" origId="923,373840" charOffset="130-132" type="compound" text="Na"/>
            <pair e1="DS.d43.s0.e1" e2="DS.d43.s0.e0" id="DS.d43.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d44" origId="18222543">
        <sentence id="DS.d44.s0" origId="18222543-918" text="The protective effects of novel synthetic organoselenium compounds (Se I and Se II) against DMBA-induced changes in levels of some (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and glutathione reductase (GR) activities and total glutathione (GSH), malonedialdehyde (MDA)) parameters in rat lung and kidney were investigated.">
            <entity id="DS.d44.s0.e0" origId="6001" charOffset="92-96" type="compound" text="DMBA"/>
            <entity id="DS.d44.s0.e1" origId="O50258" charOffset="132-152" type="protein" text="superoxide dismutase"/>
            <entity id="DS.d44.s0.e2" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="154-157" type="protein" text="SOD"/>
            <entity id="DS.d44.s0.e3" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="160-168" type="protein" text="catalase"/>
            <entity id="DS.d44.s0.e4" origId="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7" charOffset="170-173" type="protein" text="CAT"/>
            <entity id="DS.d44.s0.e5" origId="O32770,O59858,Q00277,Q9CFV1" charOffset="176-198" type="protein" text="glutathione peroxidase"/>
            <entity id="DS.d44.s0.e6" origId="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655" charOffset="210-231" type="protein" text="glutathione reductase"/>
            <entity id="DS.d44.s0.e7" origId="124886" charOffset="176-187" type="compound" text="glutathione"/>
            <entity id="DS.d44.s0.e8" origId="124886" charOffset="271-274" type="compound" text="GSH"/>
            <pair e1="DS.d44.s0.e7" e2="DS.d44.s0.e4" id="DS.d44.s0.i0" interaction="False"/>
            <pair e1="DS.d44.s0.e0" e2="DS.d44.s0.e5" id="DS.d44.s0.i1" interaction="False"/>
            <pair e1="DS.d44.s0.e8" e2="DS.d44.s0.e2" id="DS.d44.s0.i2" interaction="False"/>
            <pair e1="DS.d44.s0.e8" e2="DS.d44.s0.e5" id="DS.d44.s0.i3" interaction="False"/>
            <pair e1="DS.d44.s0.e7" e2="DS.d44.s0.e2" id="DS.d44.s0.i4" interaction="False"/>
            <pair e1="DS.d44.s0.e0" e2="DS.d44.s0.e6" id="DS.d44.s0.i5" interaction="False"/>
            <pair e1="DS.d44.s0.e7" e2="DS.d44.s0.e5" id="DS.d44.s0.i6" interaction="False"/>
            <pair e1="DS.d44.s0.e8" e2="DS.d44.s0.e1" id="DS.d44.s0.i7" interaction="False"/>
            <pair e1="DS.d44.s0.e0" e2="DS.d44.s0.e2" id="DS.d44.s0.i8" interaction="False"/>
            <pair e1="DS.d44.s0.e0" e2="DS.d44.s0.e1" id="DS.d44.s0.i9" interaction="False"/>
            <pair e1="DS.d44.s0.e0" e2="DS.d44.s0.e3" id="DS.d44.s0.i10" interaction="False"/>
            <pair e1="DS.d44.s0.e8" e2="DS.d44.s0.e4" id="DS.d44.s0.i11" interaction="False"/>
            <pair e1="DS.d44.s0.e7" e2="DS.d44.s0.e1" id="DS.d44.s0.i12" interaction="False"/>
            <pair e1="DS.d44.s0.e7" e2="DS.d44.s0.e6" id="DS.d44.s0.i13" interaction="False"/>
            <pair e1="DS.d44.s0.e8" e2="DS.d44.s0.e3" id="DS.d44.s0.i14" interaction="False"/>
            <pair e1="DS.d44.s0.e8" e2="DS.d44.s0.e6" id="DS.d44.s0.i15" interaction="False"/>
            <pair e1="DS.d44.s0.e0" e2="DS.d44.s0.e4" id="DS.d44.s0.i16" interaction="False"/>
            <pair e1="DS.d44.s0.e7" e2="DS.d44.s0.e3" id="DS.d44.s0.i17" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d45" origId="18226951">
        <sentence id="DS.d45.s0" origId="18226951-1110" text="Abnormally high CSF 3-OMD occurs frequently for RLS patients indicating either increased l-dopa synthesis, limitations in l-dopa decarboxylation or increased MAT/COMT activity, or some combination of these.">
            <entity id="DS.d45.s0.e0" origId="6047" charOffset="89-95" type="compound" text="l-dopa"/>
            <entity id="DS.d45.s0.e1" origId="6047" charOffset="122-128" type="compound" text="l-dopa"/>
            <entity id="DS.d45.s0.e2" origId="O50163,O67222,O83772,P0A817,P0A818,P0A819,P0A820,P24752,P43762,P47293,P50307,P54419,P56460,P56878,P57486,P57897,P61945,P61946,P66764,P66765,P66766,P66767,P72871,P77899,P78003,Q1QCH2,Q21NJ5,Q21RM4,Q28UI9,Q2A1N2,Q2FFV6,Q2GBP1,Q2IM98,Q2IZR2,Q2JIN3,Q2JV74,Q2NRD1,Q2NZF1,Q2RK28,Q2RYY4,Q2SLT3,Q2SS11,Q2T267,Q2VYQ2,Q2Y5Z1,Q2YTK1,Q30PN0,Q311V1,Q31CL7,Q31EL0,Q31KC6,Q31WK4,Q32C11,Q38YF8,Q39BZ1,Q39W48,Q3A388,Q3AFS4,Q3AME2,Q3AQC3,Q3AWE6,Q3B531,Q3BXB7,Q3IDQ1,Q3IW86,Q3J7R5,Q3JX94,Q3K1M7,Q3K5E8,Q3MF32,Q3SFY2,Q3YXS9,Q3Z943,Q3ZZN7,Q46H57,Q476V0,Q47JN4,Q47R14,Q486L6,Q48CH3,Q48SU7,Q493F2,Q49YL6,Q4A5F4,Q4FNN1,Q4FTH7,Q4JVH7,Q4K4I7,Q4L7C7,Q4QLC5,Q4UR08,Q4ZM01,Q57K26,Q5E7R2,Q5FAC0,Q5FIN8,Q5FSK6,Q5GW76,Q5HEY9,Q5HNB8,Q5KW02,Q5LJ26,Q5LLL2,Q5LZI0,Q5M434,Q5N1I9,Q5NIC7,Q5NQV7,Q5P2V5,Q5PJJ2,Q5QVM7,Q5SHT8,Q5WDZ8,Q5WV18,Q5X3N0,Q5XBJ6,Q5YTN0,Q5ZTY6,Q60CG7,Q62EZ1,Q632S5,Q63YH5,Q650L4,Q65FV8,Q65UT4,Q661P3,Q666P5,Q67T90,Q6A8H3,Q6AF79,Q6AQ43,Q6D081,Q6F1M6,Q6FAQ6,Q6G8E3,Q6GFR6,Q6HCB4,Q6LMM8,Q6MPK2,Q6MTB6,Q71Z03,Q729A3,Q72I53,Q72SM5,Q72YV6,Q73JR4,Q741G5,Q74KS4,Q7M7Z2,Q7MHK6,Q7MTQ0,Q7N119,Q7NHG0,Q7NZF9,Q7U051,Q7U4S6,Q7URU7,Q7V2Y8,Q7V5A2,Q7VDM7,Q7VFY5,Q7VNG7,Q7VRG5,Q7VUL5,Q7W200,Q7WQX8,Q7WYG5,Q7WYN1,Q816Q8,Q81KI0,Q827Q0,Q82WL2,Q837P9,Q83A78,Q83GE4,Q83HT7,Q84FD3,Q87AY6,Q87LK6,Q88AK7,Q88D60,Q88XB8,Q898W7,Q89HP5,Q8A2T6,Q8CNT5,Q8CXS7,Q8D2N8,Q8DCA3,Q8DK88,Q8DQH0,Q8DT23,Q8E0A3,Q8E5Y0,Q8EIB4,Q8EP05,Q8FT48,Q8G3H4,Q8K715,Q8K9E5,Q8KEG7,Q8NVZ9,Q8P0G6,Q8PCH3,Q8PP75,Q8RCE4,Q8RGE5,Q8Y347,Q8Y6M0,Q8ZHG7,Q92AZ5,Q938W7,Q97F85,Q97RN9,Q98A80,Q98PM0,Q99Z77,Q9CCQ4,Q9CEE0,Q9I5Z0,Q9JVV6,Q9JY09,Q9K5E4,Q9K7Q9,Q9KUP3,Q9L0Y3,Q9PGB0,Q9RL99,Q9RWM6,Q9X1Y8,Q9X4Q2,Q9ZMN5" charOffset="158-161" type="protein" text="MAT"/>
            <entity id="DS.d45.s0.e3" origId="O23760,O81646,O82054,P21964,P28002,P46484,Q06509,Q06528,Q43239,Q43609,Q6ZD89,Q8GU25,Q8LL87,Q8W013,Q99028,Q9FQY8,Q9SWC2" charOffset="162-166" type="protein" text="COMT"/>
            <pair e1="DS.d45.s0.e0" e2="DS.d45.s0.e2" id="DS.d45.s0.i0" interaction="False"/>
            <pair e1="DS.d45.s0.e0" e2="DS.d45.s0.e3" id="DS.d45.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d46" origId="18227836">
        <sentence id="DS.d46.s0" origId="18227836-349" text="To test this hypothesis, we investigated whether disruption of the oxytocin gene (Oxt-/-) made mice more susceptible to the psychosis-related effects of amphetamine (Amp), apomorphine (Apo) and phencyclidine (PCP).">
            <entity id="DS.d46.s0.e0" origId="P01175,P01176,P01177,P01178,P01179,P13389,P32005,P35454,P69043,P69044,P69056,P69057,P69058" charOffset="67-75" type="protein" text="oxytocin"/>
            <entity id="DS.d46.s0.e1" origId="P01179,P35454,Q5QQ53,Q7KVA1" charOffset="82-85" type="protein" text="Oxt"/>
            <entity id="DS.d46.s0.e2" origId="3007,5826,32893" charOffset="153-164" type="compound" text="amphetamine"/>
            <entity id="DS.d46.s0.e3" origId="6083" charOffset="166-169" type="compound" text="Amp"/>
            <entity id="DS.d46.s0.e4" origId="6005" charOffset="172-183" type="compound" text="apomorphine"/>
            <entity id="DS.d46.s0.e5" origId="6468" charOffset="194-207" type="compound" text="phencyclidine"/>
            <pair e1="DS.d46.s0.e4" e2="DS.d46.s0.e1" id="DS.d46.s0.i0" interaction="False"/>
            <pair e1="DS.d46.s0.e3" e2="DS.d46.s0.e0" id="DS.d46.s0.i1" interaction="False"/>
            <pair e1="DS.d46.s0.e4" e2="DS.d46.s0.e0" id="DS.d46.s0.i2" interaction="False"/>
            <pair e1="DS.d46.s0.e2" e2="DS.d46.s0.e0" id="DS.d46.s0.i3" interaction="False"/>
            <pair e1="DS.d46.s0.e2" e2="DS.d46.s0.e1" id="DS.d46.s0.i4" interaction="False"/>
            <pair e1="DS.d46.s0.e5" e2="DS.d46.s0.e1" id="DS.d46.s0.i5" interaction="False"/>
            <pair e1="DS.d46.s0.e5" e2="DS.d46.s0.e0" id="DS.d46.s0.i6" interaction="False"/>
            <pair e1="DS.d46.s0.e3" e2="DS.d46.s0.e1" id="DS.d46.s0.i7" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d47" origId="18227838">
        <sentence id="DS.d47.s0" origId="18227838-352" text="The mood stabilizers lithium and valproate activate the ERK pathway in prefrontal cortex and hippocampus and potentiate ERK pathway-mediated neurite growth, neuronal survival and hippocampal neurogenesis.">
            <entity id="DS.d47.s0.e0" origId="28486,3028194" charOffset="21-28" type="compound" text="lithium"/>
            <entity id="DS.d47.s0.e1" origId="3121" charOffset="33-42" type="compound" text="valproate"/>
            <entity id="DS.d47.s0.e2" origId="P29323" charOffset="56-59" type="protein" text="ERK"/>
            <entity id="DS.d47.s0.e3" origId="P29323" charOffset="120-123" type="protein" text="ERK"/>
            <pair e1="DS.d47.s0.e0" e2="DS.d47.s0.e2" id="DS.d47.s0.i0" interaction="True"/>
            <pair e1="DS.d47.s0.e1" e2="DS.d47.s0.e2" id="DS.d47.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d48" origId="18227970">
        <sentence id="DS.d48.s0" origId="18227970-442" text="In the root soluble fraction, the suicide inhibitor alpha-difluoromethyl-lysine suppressed the activity of lysine decarboxylase and of ornithine decarboxylase to the same extent, but had no effect on arginine decarboxylase activity.">
            <entity id="DS.d48.s0.e0" origId="137670" charOffset="58-72" type="compound" text="difluoromethyl"/>
            <entity id="DS.d48.s0.e1" origId="866,5962" charOffset="73-79" type="compound" text="lysine"/>
            <entity id="DS.d48.s0.e2" origId="P05033" charOffset="107-127" type="protein" text="lysine decarboxylase"/>
            <entity id="DS.d48.s0.e3" origId="O22616,P00860,P07805,P08432,P09057,P11926,P14019,P27116,P27117,P27118,P27119,P27121,P41931,P44317,P49725,P50134,P78599,Q8S3N2,Q92445,Q9UQW9" charOffset="135-158" type="protein" text="ornithine decarboxylase"/>
            <entity id="DS.d48.s0.e4" origId="O81160,O82475,P21885,P22220,P49726,Q39827,Q43075,Q819L4,Q81MS2,Q96412,Q96A70,Q9K9K5,Q9SNN0" charOffset="200-222" type="protein" text="arginine decarboxylase"/>
            <pair e1="DS.d48.s0.e0" e2="DS.d48.s0.e4" id="DS.d48.s0.i0" interaction="False"/>
            <pair e1="DS.d48.s0.e1" e2="DS.d48.s0.e4" id="DS.d48.s0.i1" interaction="False"/>
            <pair e1="DS.d48.s0.e0" e2="DS.d48.s0.e3" id="DS.d48.s0.i2" interaction="True"/>
            <pair e1="DS.d48.s0.e1" e2="DS.d48.s0.e3" id="DS.d48.s0.i3" interaction="True"/>
            <pair e1="DS.d48.s0.e0" e2="DS.d48.s0.e2" id="DS.d48.s0.i4" interaction="True"/>
            <pair e1="DS.d48.s0.e1" e2="DS.d48.s0.e2" id="DS.d48.s0.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d49" origId="18228136">
        <sentence id="DS.d49.s0" origId="18228136-547" text="RT(2) Profiler PCR Array was used to identify differentially expressed genes in Dox and/or 2ME treatment groups, based on significance of results 4 genes were selected: MDR1, Bcl2, P53 and Cyclin D1.">
            <entity id="DS.d49.s0.e0" origId="10903" charOffset="91-94" type="compound" text="2ME"/>
            <entity id="DS.d49.s0.e1" origId="P08183,P13568,P16875,P28873,P53258,Q06034,Q9LJX0,Q9ZR72" charOffset="169-173" type="protein" text="MDR1"/>
            <entity id="DS.d49.s0.e2" origId="P10417,P49950" charOffset="175-179" type="protein" text="Bcl2"/>
            <entity id="DS.d49.s0.e3" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="181-184" type="protein" text="P53"/>
            <entity id="DS.d49.s0.e4" origId="O01377,O16852,P04961,P12004,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P61074,Q00265,Q00268" charOffset="189-195" type="protein" text="Cyclin"/>
            <pair e1="DS.d49.s0.e0" e2="DS.d49.s0.e4" id="DS.d49.s0.i0" interaction="True"/>
            <pair e1="DS.d49.s0.e0" e2="DS.d49.s0.e3" id="DS.d49.s0.i1" interaction="True"/>
            <pair e1="DS.d49.s0.e0" e2="DS.d49.s0.e1" id="DS.d49.s0.i2" interaction="True"/>
            <pair e1="DS.d49.s0.e0" e2="DS.d49.s0.e2" id="DS.d49.s0.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d49.s1" origId="18228136-548" text="The array and western blotting showed that Bcl2 and Cyclin D1 expression were down regulated; P53 expression was not affected while MDR1 was over expressed by combination of 2ME with Dox.">
            <entity id="DS.d49.s1.e0" origId="P10417,P49950" charOffset="43-47" type="protein" text="Bcl2"/>
            <entity id="DS.d49.s1.e1" origId="O01377,O16852,P04961,P12004,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P61074,Q00265,Q00268" charOffset="52-58" type="protein" text="Cyclin"/>
            <entity id="DS.d49.s1.e2" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="94-97" type="protein" text="P53"/>
            <entity id="DS.d49.s1.e3" origId="P08183,P13568,P16875,P28873,P53258,Q06034,Q9LJX0,Q9ZR72" charOffset="132-136" type="protein" text="MDR1"/>
            <entity id="DS.d49.s1.e4" origId="10903" charOffset="174-177" type="compound" text="2ME"/>
            <pair e1="DS.d49.s1.e4" e2="DS.d49.s1.e1" id="DS.d49.s1.i0" interaction="True"/>
            <pair e1="DS.d49.s1.e4" e2="DS.d49.s1.e3" id="DS.d49.s1.i1" interaction="True"/>
            <pair e1="DS.d49.s1.e4" e2="DS.d49.s1.e2" id="DS.d49.s1.i2" interaction="False"/>
            <pair e1="DS.d49.s1.e4" e2="DS.d49.s1.e0" id="DS.d49.s1.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d49.s2" origId="18228136-549" text="In conclusion, 2ME chemosensitizes resistant breast cancer cells to Dox cytotoxicity by down regulating expression of Bcl2 and Cyclin D1, augmenting caspase 3 activity as well as inducing cell cycle block in G(1) and S phases.">
            <entity id="DS.d49.s2.e0" origId="10903" charOffset="15-18" type="compound" text="2ME"/>
            <entity id="DS.d49.s2.e1" origId="P10417,P49950" charOffset="118-122" type="protein" text="Bcl2"/>
            <entity id="DS.d49.s2.e2" origId="O01377,O16852,P04961,P12004,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P61074,Q00265,Q00268" charOffset="127-133" type="protein" text="Cyclin"/>
            <pair e1="DS.d49.s2.e0" e2="DS.d49.s2.e2" id="DS.d49.s2.i0" interaction="True"/>
            <pair e1="DS.d49.s2.e0" e2="DS.d49.s2.e1" id="DS.d49.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d50" origId="18230627">
        <sentence id="DS.d50.s0" origId="18230627-837" text="Randomised trials have demonstrated that the efficacy of anti-tumour necrosis factor (TNF) agents is significantly increased by concomitant methotrexate (MTX) in rheumatoid arthritis (RA).">
            <entity id="DS.d50.s0.e0" origId="O35734,O77510,O77764,P01375,P04924,P13296,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="86-89" type="protein" text="TNF"/>
            <entity id="DS.d50.s0.e1" origId="126941" charOffset="140-152" type="compound" text="methotrexate"/>
            <pair e1="DS.d50.s0.e1" e2="DS.d50.s0.e0" id="DS.d50.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d51" origId="18243311">
        <sentence id="DS.d51.s0" origId="18243311-231" text="Neither apyrase nor ATP altered production of reactive oxygen intermediates (ROI) or reactive nitrogen intermediates (RNI) by bovine monocytes.">
            <entity id="DS.d51.s0.e0" origId="P52914" charOffset="8-15" type="protein" text="apyrase"/>
            <entity id="DS.d51.s0.e1" origId="5957" charOffset="20-23" type="compound" text="ATP"/>
            <entity id="DS.d51.s0.e2" origId="977" charOffset="55-61" type="compound" text="oxygen"/>
            <entity id="DS.d51.s0.e3" origId="947,123329" charOffset="94-102" type="compound" text="nitrogen"/>
            <pair e1="DS.d51.s0.e3" e2="DS.d51.s0.e0" id="DS.d51.s0.i0" interaction="False"/>
            <pair e1="DS.d51.s0.e2" e2="DS.d51.s0.e0" id="DS.d51.s0.i1" interaction="False"/>
            <pair e1="DS.d51.s0.e1" e2="DS.d51.s0.e0" id="DS.d51.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d52" origId="18243368">
        <sentence id="DS.d52.s0" origId="18243368-1130" text="In this systematic review, we have analyzed the results of 52 clinical trials, including 72 intervention groups and 6290 patients, on vitamin D supplementation in order to evaluate the experimental evidence and the effects of age and chronic immobility on responses of parathyroid hormone (PTH).">
            <entity id="DS.d52.s0.e0" origId="5280795" charOffset="134-143" type="compound" text="vitamin D"/>
            <entity id="DS.d52.s0.e1" origId="O27732,O28185,O66677,O74017,O74806,O83975,O84806,O85235,P01268,P01269,P01270,P04089,P0A281,P0A282,P0A7D1,P0A7D2,P0A7D3,P15743,P37470,P38876,P44682,P47329,P47714,P49607,P52212,P56077,P57287,P57820,P59490,P61234,P61235,P61414,P65863,P65864,P65865,P65866,P65867,P65868,P65869,P78034,Q27IM2,Q57NM8,Q59989,Q5F9L4,Q5FFA3,Q5FMA9,Q5FRT7,Q5GTI9,Q5GWR6,Q5HC85,Q5HIH3,Q5HRQ3,Q5HWF9,Q5JDB8,Q5L3U7,Q5LV91,Q5M222,Q5M6L4,Q5N2J4,Q5NGZ6,Q5NL75,Q5P722,Q5P9A6,Q5PCR7,Q5QV03,Q5SHZ2,Q5V1D3,Q5WAD6,Q5WTE7,Q5X1N7,Q5XEM3,Q5YPZ6,Q5ZS66,Q601M5,Q60363,Q60A14,Q62FC1,Q63HI2,Q63XM0,Q64X30,Q65PG8,Q65V47,Q65ZY7,Q66AY1,Q67JD0,Q68WD4,Q6AAC7,Q6ADQ8,Q6AJL9,Q6D557,Q6F240,Q6F8I7,Q6G0F9,Q6G2L1,Q6GBY6,Q6GJG9,Q6HPW6,Q6KHA3,Q6LNA9,Q6MJR3,Q6MS28,Q6N1P9,Q6NI78,Q6YP15,Q6YR64,Q724K0,Q72BR1,Q72IA8,Q72RZ0,Q73FF7,Q73II8,Q73Q01,Q741V9,Q74FE6,Q74LA8,Q7M7U8,Q7MMZ2,Q7MXK9,Q7N5A1,Q7NN75,Q7NQT1,Q7U9I5,Q7UKV0,Q7V342,Q7V4V4,Q7VDT7,Q7VG29,Q7VMI1,Q7VUH3,Q7W179,Q7WNY2,Q81J96,Q81VY9,Q821W6,Q82HE5,Q82TQ6,Q839C0,Q83AP0,Q83FR1,Q83HD8,Q83LE1,Q86Y79,Q877G5,Q87A24,Q87RN9,Q888C8,Q88PX8,Q88Z39,Q899I4,Q89DJ9,Q89YZ2,Q8BW00,Q8CQU9,Q8CXP8,Q8D2K4,Q8DFF4,Q8DJ45,Q8DRQ2,Q8DWN5,Q8E2I1,Q8E7Y8,Q8EHN5,Q8EWQ8,Q8F3Q2,Q8FQV6,Q8G5I6,Q8K8Z7,Q8K9V3,Q8KD05,Q8P327,Q8PC61,Q8PNT8,Q8Q0M4,Q8R757,Q8RIJ5,Q8RLD7,Q8TKX4,Q8TV04,Q8U0N0,Q8UD97,Q8XHJ8,Q8Y2E3,Q8YAD1,Q8YYK4,Q8ZEY4,Q8ZYM4,Q92F62,Q92H41,Q92N67,Q976I0,Q97CB4,Q97E97,Q97TD1,Q980V1,Q98HV6,Q98PE2,Q9A206,Q9AAV9,Q9AEQ5,Q9CD49,Q9CJI1,Q9F8Q3,Q9GL67,Q9HLW6,Q9HVC3,Q9J5H2,Q9JV42,Q9K029,Q9K3T8,Q9KGJ3,Q9KQ21,Q9PA78,Q9PII7,Q9PR67,Q9RRW3,Q9V108,Q9X1W1,Q9XT35,Q9YBD6,Q9Z6V6,Q9ZCV4,Q9ZJC3" charOffset="290-293" type="protein" text="PTH"/>
            <pair e1="DS.d52.s0.e0" e2="DS.d52.s0.e1" id="DS.d52.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d52.s1" origId="18243368-1131" text="The vitamin D supplementation of the chronically immobile patients resulted in a smaller decrease in PTH 0.001).">
            <entity id="DS.d52.s1.e0" origId="5280795" charOffset="4-13" type="compound" text="vitamin D"/>
            <entity id="DS.d52.s1.e1" origId="O27732,O28185,O66677,O74017,O74806,O83975,O84806,O85235,P01268,P01269,P01270,P04089,P0A281,P0A282,P0A7D1,P0A7D2,P0A7D3,P15743,P37470,P38876,P44682,P47329,P47714,P49607,P52212,P56077,P57287,P57820,P59490,P61234,P61235,P61414,P65863,P65864,P65865,P65866,P65867,P65868,P65869,P78034,Q27IM2,Q57NM8,Q59989,Q5F9L4,Q5FFA3,Q5FMA9,Q5FRT7,Q5GTI9,Q5GWR6,Q5HC85,Q5HIH3,Q5HRQ3,Q5HWF9,Q5JDB8,Q5L3U7,Q5LV91,Q5M222,Q5M6L4,Q5N2J4,Q5NGZ6,Q5NL75,Q5P722,Q5P9A6,Q5PCR7,Q5QV03,Q5SHZ2,Q5V1D3,Q5WAD6,Q5WTE7,Q5X1N7,Q5XEM3,Q5YPZ6,Q5ZS66,Q601M5,Q60363,Q60A14,Q62FC1,Q63HI2,Q63XM0,Q64X30,Q65PG8,Q65V47,Q65ZY7,Q66AY1,Q67JD0,Q68WD4,Q6AAC7,Q6ADQ8,Q6AJL9,Q6D557,Q6F240,Q6F8I7,Q6G0F9,Q6G2L1,Q6GBY6,Q6GJG9,Q6HPW6,Q6KHA3,Q6LNA9,Q6MJR3,Q6MS28,Q6N1P9,Q6NI78,Q6YP15,Q6YR64,Q724K0,Q72BR1,Q72IA8,Q72RZ0,Q73FF7,Q73II8,Q73Q01,Q741V9,Q74FE6,Q74LA8,Q7M7U8,Q7MMZ2,Q7MXK9,Q7N5A1,Q7NN75,Q7NQT1,Q7U9I5,Q7UKV0,Q7V342,Q7V4V4,Q7VDT7,Q7VG29,Q7VMI1,Q7VUH3,Q7W179,Q7WNY2,Q81J96,Q81VY9,Q821W6,Q82HE5,Q82TQ6,Q839C0,Q83AP0,Q83FR1,Q83HD8,Q83LE1,Q86Y79,Q877G5,Q87A24,Q87RN9,Q888C8,Q88PX8,Q88Z39,Q899I4,Q89DJ9,Q89YZ2,Q8BW00,Q8CQU9,Q8CXP8,Q8D2K4,Q8DFF4,Q8DJ45,Q8DRQ2,Q8DWN5,Q8E2I1,Q8E7Y8,Q8EHN5,Q8EWQ8,Q8F3Q2,Q8FQV6,Q8G5I6,Q8K8Z7,Q8K9V3,Q8KD05,Q8P327,Q8PC61,Q8PNT8,Q8Q0M4,Q8R757,Q8RIJ5,Q8RLD7,Q8TKX4,Q8TV04,Q8U0N0,Q8UD97,Q8XHJ8,Q8Y2E3,Q8YAD1,Q8YYK4,Q8ZEY4,Q8ZYM4,Q92F62,Q92H41,Q92N67,Q976I0,Q97CB4,Q97E97,Q97TD1,Q980V1,Q98HV6,Q98PE2,Q9A206,Q9AAV9,Q9AEQ5,Q9CD49,Q9CJI1,Q9F8Q3,Q9GL67,Q9HLW6,Q9HVC3,Q9J5H2,Q9JV42,Q9K029,Q9K3T8,Q9KGJ3,Q9KQ21,Q9PA78,Q9PII7,Q9PR67,Q9RRW3,Q9V108,Q9X1W1,Q9XT35,Q9YBD6,Q9Z6V6,Q9ZCV4,Q9ZJC3" charOffset="101-104" type="protein" text="PTH"/>
            <pair e1="DS.d52.s1.e0" e2="DS.d52.s1.e1" id="DS.d52.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d52.s2" origId="18243368-1132" text="Our results also suggest that PTH decreases quite linearly during vitamin D supplementation at any given 25-OHD level.">
            <entity id="DS.d52.s2.e0" origId="O27732,O28185,O66677,O74017,O74806,O83975,O84806,O85235,P01268,P01269,P01270,P04089,P0A281,P0A282,P0A7D1,P0A7D2,P0A7D3,P15743,P37470,P38876,P44682,P47329,P47714,P49607,P52212,P56077,P57287,P57820,P59490,P61234,P61235,P61414,P65863,P65864,P65865,P65866,P65867,P65868,P65869,P78034,Q27IM2,Q57NM8,Q59989,Q5F9L4,Q5FFA3,Q5FMA9,Q5FRT7,Q5GTI9,Q5GWR6,Q5HC85,Q5HIH3,Q5HRQ3,Q5HWF9,Q5JDB8,Q5L3U7,Q5LV91,Q5M222,Q5M6L4,Q5N2J4,Q5NGZ6,Q5NL75,Q5P722,Q5P9A6,Q5PCR7,Q5QV03,Q5SHZ2,Q5V1D3,Q5WAD6,Q5WTE7,Q5X1N7,Q5XEM3,Q5YPZ6,Q5ZS66,Q601M5,Q60363,Q60A14,Q62FC1,Q63HI2,Q63XM0,Q64X30,Q65PG8,Q65V47,Q65ZY7,Q66AY1,Q67JD0,Q68WD4,Q6AAC7,Q6ADQ8,Q6AJL9,Q6D557,Q6F240,Q6F8I7,Q6G0F9,Q6G2L1,Q6GBY6,Q6GJG9,Q6HPW6,Q6KHA3,Q6LNA9,Q6MJR3,Q6MS28,Q6N1P9,Q6NI78,Q6YP15,Q6YR64,Q724K0,Q72BR1,Q72IA8,Q72RZ0,Q73FF7,Q73II8,Q73Q01,Q741V9,Q74FE6,Q74LA8,Q7M7U8,Q7MMZ2,Q7MXK9,Q7N5A1,Q7NN75,Q7NQT1,Q7U9I5,Q7UKV0,Q7V342,Q7V4V4,Q7VDT7,Q7VG29,Q7VMI1,Q7VUH3,Q7W179,Q7WNY2,Q81J96,Q81VY9,Q821W6,Q82HE5,Q82TQ6,Q839C0,Q83AP0,Q83FR1,Q83HD8,Q83LE1,Q86Y79,Q877G5,Q87A24,Q87RN9,Q888C8,Q88PX8,Q88Z39,Q899I4,Q89DJ9,Q89YZ2,Q8BW00,Q8CQU9,Q8CXP8,Q8D2K4,Q8DFF4,Q8DJ45,Q8DRQ2,Q8DWN5,Q8E2I1,Q8E7Y8,Q8EHN5,Q8EWQ8,Q8F3Q2,Q8FQV6,Q8G5I6,Q8K8Z7,Q8K9V3,Q8KD05,Q8P327,Q8PC61,Q8PNT8,Q8Q0M4,Q8R757,Q8RIJ5,Q8RLD7,Q8TKX4,Q8TV04,Q8U0N0,Q8UD97,Q8XHJ8,Q8Y2E3,Q8YAD1,Q8YYK4,Q8ZEY4,Q8ZYM4,Q92F62,Q92H41,Q92N67,Q976I0,Q97CB4,Q97E97,Q97TD1,Q980V1,Q98HV6,Q98PE2,Q9A206,Q9AAV9,Q9AEQ5,Q9CD49,Q9CJI1,Q9F8Q3,Q9GL67,Q9HLW6,Q9HVC3,Q9J5H2,Q9JV42,Q9K029,Q9K3T8,Q9KGJ3,Q9KQ21,Q9PA78,Q9PII7,Q9PR67,Q9RRW3,Q9V108,Q9X1W1,Q9XT35,Q9YBD6,Q9Z6V6,Q9ZCV4,Q9ZJC3" charOffset="30-33" type="protein" text="PTH"/>
            <entity id="DS.d52.s2.e1" origId="5280795" charOffset="66-75" type="compound" text="vitamin D"/>
            <pair e1="DS.d52.s2.e1" e2="DS.d52.s2.e0" id="DS.d52.s2.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d53" origId="18248398">
        <sentence id="DS.d53.s0" origId="18248398-140" text="Leptin did not show any effect in long photoperiod but decreased proliferation by stimulating melatonin in short photoperiod.">
            <entity id="DS.d53.s0.e0" origId="O02750,O93416,Q28603,Q95189,Q95234" charOffset="0-6" type="protein" text="Leptin"/>
            <entity id="DS.d53.s0.e1" origId="896" charOffset="94-103" type="compound" text="melatonin"/>
            <pair e1="DS.d53.s0.e1" e2="DS.d53.s0.e0" id="DS.d53.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d54" origId="18249383">
        <sentence id="DS.d54.s0" origId="18249383-1046" text="To compare the changes in body composition and in leptin levels in postmenopausal women receiving hormone therapy (HT) or tibolone.">
            <entity id="DS.d54.s0.e0" origId="O02750,O93416,Q28603,Q95189,Q95234" charOffset="50-56" type="protein" text="leptin"/>
            <entity id="DS.d54.s0.e1" origId="444008" charOffset="122-130" type="compound" text="tibolone"/>
            <pair e1="DS.d54.s0.e1" e2="DS.d54.s0.e0" id="DS.d54.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d55" origId="18249399">
        <sentence id="DS.d55.s0" origId="18249399-1054" text="Common 677C--&amp;gt;T mutation of the 5,10-methylenetetrahydrofolate reductase gene affects follicular estradiol synthesis.">
            <entity id="DS.d55.s0.e0" origId="O54235,O67422,P0AEZ1,P0AEZ2,P11003,P45208,P57154,P71319,Q89B13,Q8KA62" charOffset="35-75" type="protein" text="5,10-methylenetetrahydrofolate reductase"/>
            <entity id="DS.d55.s0.e1" origId="5757" charOffset="100-109" type="compound" text="estradiol"/>
            <pair e1="DS.d55.s0.e1" e2="DS.d55.s0.e0" id="DS.d55.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d56" origId="18253022">
        <sentence id="DS.d56.s0" origId="18253022-733" text="Surprisingly, a deletion of the pilR gene affected not only insoluble Fe(III) reduction, which requires pili, but also soluble Fe(III) reduction, which, in contrast, does not require pili.">
            <entity id="DS.d56.s0.e0" origId="Q00934" charOffset="32-36" type="protein" text="pilR"/>
            <entity id="DS.d56.s0.e1" origId="29936" charOffset="70-76" type="compound" text="Fe(III"/>
            <entity id="DS.d56.s0.e2" origId="29936" charOffset="127-133" type="compound" text="Fe(III"/>
            <pair e1="DS.d56.s0.e1" e2="DS.d56.s0.e0" id="DS.d56.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d57" origId="18253697">
        <sentence id="DS.d57.s0" origId="18253697-765" text="Furthermore, the suppressive effects of P on cytochrome c release and caspase-9 and caspase-3 activation in serum-deprived MC3T3-E1 cells were also reversed by RU486.">
            <entity id="DS.d57.s0.e0" origId="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3" charOffset="45-57" type="protein" text="cytochrome c"/>
            <entity id="DS.d57.s0.e1" origId="55245" charOffset="160-165" type="compound" text="RU486"/>
            <pair e1="DS.d57.s0.e1" e2="DS.d57.s0.e0" id="DS.d57.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d58" origId="18256928">
        <sentence id="DS.d58.s0" origId="18256928-624" text="Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model.">
            <entity id="DS.d58.s0.e0" origId="4091" charOffset="12-21" type="compound" text="metformin"/>
            <entity id="DS.d58.s0.e1" origId="P54646,Q09136,Q9Y478" charOffset="22-26" type="protein" text="AMPK"/>
            <pair e1="DS.d58.s0.e0" e2="DS.d58.s0.e1" id="DS.d58.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d58.s1" origId="18256928-625" text="However, when ERalpha negative MDA-MB-435 cells were treated with metformin, they demonstrated increased expression of vascular endothelial growth factor (VEGF) in an AMPK dependent manner; while the ERalpha positive MCF-7 cells did not.">
            <entity id="DS.d58.s1.e0" origId="4091" charOffset="66-75" type="compound" text="metformin"/>
            <entity id="DS.d58.s1.e1" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="155-159" type="protein" text="VEGF"/>
            <entity id="DS.d58.s1.e2" origId="P54646,Q09136,Q9Y478" charOffset="167-171" type="protein" text="AMPK"/>
            <pair e1="DS.d58.s1.e0" e2="DS.d58.s1.e2" id="DS.d58.s1.i0" interaction="True"/>
            <pair e1="DS.d58.s1.e0" e2="DS.d58.s1.e1" id="DS.d58.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d58.s2" origId="18256928-626" text="The metformin-treated group showed increased VEGF expression, intratumoral microvascular density and reduced necrosis.">
            <entity id="DS.d58.s2.e0" origId="4091" charOffset="4-13" type="compound" text="metformin"/>
            <entity id="DS.d58.s2.e1" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="45-49" type="protein" text="VEGF"/>
            <pair e1="DS.d58.s2.e0" e2="DS.d58.s2.e1" id="DS.d58.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d58.s3" origId="18256928-627" text="Metformin treatment was sufficient, however, to reduce systemic IGF-1 and the proliferation rate of tumor cells in vascularized regions.">
            <entity id="DS.d58.s3.e0" origId="4091" charOffset="0-9" type="compound" text="Metformin"/>
            <entity id="DS.d58.s3.e1" origId="Q95222" charOffset="64-69" type="protein" text="IGF-1"/>
            <pair e1="DS.d58.s3.e0" e2="DS.d58.s3.e1" id="DS.d58.s3.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d59" origId="18260130">
        <sentence id="DS.d59.s0" origId="18260130-109" text="TNF-alpha, MCP-1, MIP-1alpha, IL-8, IL-6, IL-1beta, VEGF, IL-1ra, and IL-10 were measured from monocyte/macrophage cultures at different stages of activation and differentiation seeded onto polyethylene, polyurethane, expanded polytetrafluoroethylene, polymethyl methacrylate, and a hydrogel copolymer of 2-hydroxyethyl methacrylate, 1-vinyl-2-pyrrolidinone, and polyethylene glycol acrylate in tissue culture polystyrene (TCPS) plates.">
            <entity id="DS.d59.s0.e0" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="0-9" type="protein" text="TNF-alpha"/>
            <entity id="DS.d59.s0.e1" origId="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3" charOffset="11-16" type="protein" text="MCP-1"/>
            <entity id="DS.d59.s0.e2" origId="P10147,P10855,P50229,Q5I1Z0,Q8HYQ3,Q8SQA6" charOffset="18-28" type="protein" text="MIP-1alpha"/>
            <entity id="DS.d59.s0.e3" origId="O62812,P08317,P10145,P19874,P26894,P36925,P41324,P46653,P49113,P67813,P67814,P79255,Q102R3,Q7YRB5,Q9XSX5" charOffset="30-34" type="protein" text="IL-8"/>
            <entity id="DS.d59.s0.e4" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="36-40" type="protein" text="IL-6"/>
            <entity id="DS.d59.s0.e5" origId="P01584,P09428,P10749,P14628,P21621,P26889,P41687,P46648,P48090,P51493,P51745,P79162,P79182,Q28292,Q28386,Q2HZH0,Q2MH07,Q63264,Q6PUD2,Q6R2X3,Q865X8,Q8WNR2,Q9WVG1,Q9XS77" charOffset="42-50" type="protein" text="IL-1beta"/>
            <entity id="DS.d59.s0.e6" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="52-56" type="protein" text="VEGF"/>
            <entity id="DS.d59.s0.e7" origId="O18999,O77482,P18510,P25085,P25086,P26890,Q29056,Q866R8,Q9BEH0,Q9GMZ4" charOffset="58-64" type="protein" text="IL-1ra"/>
            <entity id="DS.d59.s0.e8" origId="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5" charOffset="70-75" type="protein" text="IL-10"/>
            <entity id="DS.d59.s0.e9" origId="12254" charOffset="204-216" type="compound" text="polyurethane"/>
            <entity id="DS.d59.s0.e10" origId="6658" charOffset="252-275" type="compound" text="polymethyl methacrylate"/>
            <entity id="DS.d59.s0.e11" origId="13360" charOffset="305-332" type="compound" text="2-hydroxyethyl methacrylate"/>
            <entity id="DS.d59.s0.e12" origId="6917" charOffset="334-357" type="compound" text="1-vinyl-2-pyrrolidinone"/>
            <entity id="DS.d59.s0.e13" origId="7501" charOffset="410-421" type="compound" text="polystyrene"/>
            <pair e1="DS.d59.s0.e10" e2="DS.d59.s0.e0" id="DS.d59.s0.i0" interaction="False"/>
            <pair e1="DS.d59.s0.e12" e2="DS.d59.s0.e8" id="DS.d59.s0.i1" interaction="False"/>
            <pair e1="DS.d59.s0.e9" e2="DS.d59.s0.e6" id="DS.d59.s0.i2" interaction="False"/>
            <pair e1="DS.d59.s0.e9" e2="DS.d59.s0.e4" id="DS.d59.s0.i3" interaction="False"/>
            <pair e1="DS.d59.s0.e10" e2="DS.d59.s0.e1" id="DS.d59.s0.i4" interaction="False"/>
            <pair e1="DS.d59.s0.e13" e2="DS.d59.s0.e7" id="DS.d59.s0.i5" interaction="False"/>
            <pair e1="DS.d59.s0.e12" e2="DS.d59.s0.e0" id="DS.d59.s0.i6" interaction="False"/>
            <pair e1="DS.d59.s0.e11" e2="DS.d59.s0.e2" id="DS.d59.s0.i7" interaction="False"/>
            <pair e1="DS.d59.s0.e11" e2="DS.d59.s0.e1" id="DS.d59.s0.i8" interaction="False"/>
            <pair e1="DS.d59.s0.e13" e2="DS.d59.s0.e1" id="DS.d59.s0.i9" interaction="False"/>
            <pair e1="DS.d59.s0.e10" e2="DS.d59.s0.e7" id="DS.d59.s0.i10" interaction="False"/>
            <pair e1="DS.d59.s0.e13" e2="DS.d59.s0.e4" id="DS.d59.s0.i11" interaction="False"/>
            <pair e1="DS.d59.s0.e13" e2="DS.d59.s0.e6" id="DS.d59.s0.i12" interaction="False"/>
            <pair e1="DS.d59.s0.e9" e2="DS.d59.s0.e1" id="DS.d59.s0.i13" interaction="False"/>
            <pair e1="DS.d59.s0.e12" e2="DS.d59.s0.e5" id="DS.d59.s0.i14" interaction="False"/>
            <pair e1="DS.d59.s0.e9" e2="DS.d59.s0.e8" id="DS.d59.s0.i15" interaction="False"/>
            <pair e1="DS.d59.s0.e9" e2="DS.d59.s0.e3" id="DS.d59.s0.i16" interaction="False"/>
            <pair e1="DS.d59.s0.e13" e2="DS.d59.s0.e0" id="DS.d59.s0.i17" interaction="False"/>
            <pair e1="DS.d59.s0.e12" e2="DS.d59.s0.e6" id="DS.d59.s0.i18" interaction="False"/>
            <pair e1="DS.d59.s0.e13" e2="DS.d59.s0.e8" id="DS.d59.s0.i19" interaction="False"/>
            <pair e1="DS.d59.s0.e10" e2="DS.d59.s0.e5" id="DS.d59.s0.i20" interaction="False"/>
            <pair e1="DS.d59.s0.e10" e2="DS.d59.s0.e4" id="DS.d59.s0.i21" interaction="False"/>
            <pair e1="DS.d59.s0.e10" e2="DS.d59.s0.e2" id="DS.d59.s0.i22" interaction="False"/>
            <pair e1="DS.d59.s0.e12" e2="DS.d59.s0.e2" id="DS.d59.s0.i23" interaction="False"/>
            <pair e1="DS.d59.s0.e12" e2="DS.d59.s0.e7" id="DS.d59.s0.i24" interaction="False"/>
            <pair e1="DS.d59.s0.e9" e2="DS.d59.s0.e7" id="DS.d59.s0.i25" interaction="False"/>
            <pair e1="DS.d59.s0.e10" e2="DS.d59.s0.e6" id="DS.d59.s0.i26" interaction="False"/>
            <pair e1="DS.d59.s0.e9" e2="DS.d59.s0.e0" id="DS.d59.s0.i27" interaction="False"/>
            <pair e1="DS.d59.s0.e11" e2="DS.d59.s0.e5" id="DS.d59.s0.i28" interaction="False"/>
            <pair e1="DS.d59.s0.e9" e2="DS.d59.s0.e2" id="DS.d59.s0.i29" interaction="False"/>
            <pair e1="DS.d59.s0.e11" e2="DS.d59.s0.e6" id="DS.d59.s0.i30" interaction="False"/>
            <pair e1="DS.d59.s0.e10" e2="DS.d59.s0.e8" id="DS.d59.s0.i31" interaction="False"/>
            <pair e1="DS.d59.s0.e12" e2="DS.d59.s0.e3" id="DS.d59.s0.i32" interaction="False"/>
            <pair e1="DS.d59.s0.e11" e2="DS.d59.s0.e4" id="DS.d59.s0.i33" interaction="False"/>
            <pair e1="DS.d59.s0.e9" e2="DS.d59.s0.e5" id="DS.d59.s0.i34" interaction="False"/>
            <pair e1="DS.d59.s0.e11" e2="DS.d59.s0.e0" id="DS.d59.s0.i35" interaction="False"/>
            <pair e1="DS.d59.s0.e10" e2="DS.d59.s0.e3" id="DS.d59.s0.i36" interaction="False"/>
            <pair e1="DS.d59.s0.e12" e2="DS.d59.s0.e1" id="DS.d59.s0.i37" interaction="False"/>
            <pair e1="DS.d59.s0.e11" e2="DS.d59.s0.e3" id="DS.d59.s0.i38" interaction="False"/>
            <pair e1="DS.d59.s0.e12" e2="DS.d59.s0.e4" id="DS.d59.s0.i39" interaction="False"/>
            <pair e1="DS.d59.s0.e13" e2="DS.d59.s0.e5" id="DS.d59.s0.i40" interaction="False"/>
            <pair e1="DS.d59.s0.e11" e2="DS.d59.s0.e7" id="DS.d59.s0.i41" interaction="False"/>
            <pair e1="DS.d59.s0.e13" e2="DS.d59.s0.e3" id="DS.d59.s0.i42" interaction="False"/>
            <pair e1="DS.d59.s0.e13" e2="DS.d59.s0.e2" id="DS.d59.s0.i43" interaction="False"/>
            <pair e1="DS.d59.s0.e11" e2="DS.d59.s0.e8" id="DS.d59.s0.i44" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d60" origId="18262559">
        <sentence id="DS.d60.s0" origId="18262559-301" text="Systemic administration of hemoglobin vesicle elevates tumor tissue oxygen tension and modifies tumor response to irradiation.">
            <entity id="DS.d60.s0.e0" origId="P15160,P17724,P73925,Q03459" charOffset="27-37" type="protein" text="hemoglobin"/>
            <entity id="DS.d60.s0.e1" origId="977" charOffset="68-74" type="compound" text="oxygen"/>
            <pair e1="DS.d60.s0.e1" e2="DS.d60.s0.e0" id="DS.d60.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d61" origId="18262738">
        <sentence id="DS.d61.s0" origId="18262738-416" text="The participation of protein kinase A (PKA), protein kinase C (PKC) and protein tyrosine kinase (PTK) in capacitation induced by ONOO (-) was evaluated by incubation with specific inhibitors (50 microM H-89, 0.1 microM bisindolylmaleimide I, and 3 microM genistein, respectively).">
            <entity id="DS.d61.s0.e0" origId="Q05608,Q9RI12" charOffset="21-37" type="protein" text="protein kinase A"/>
            <entity id="DS.d61.s0.e1" origId="P13678,Q25378" charOffset="45-61" type="protein" text="protein kinase C"/>
            <entity id="DS.d61.s0.e2" origId="P05130,P13677,P13678,P34722" charOffset="63-66" type="protein" text="PKC"/>
            <entity id="DS.d61.s0.e3" origId="5460609" charOffset="129-133" type="compound" text="ONOO"/>
            <entity id="DS.d61.s0.e4" origId="2396" charOffset="219-240" type="compound" text="bisindolylmaleimide I"/>
            <entity id="DS.d61.s0.e5" origId="5280961" charOffset="255-264" type="compound" text="genistein"/>
            <pair e1="DS.d61.s0.e4" e2="DS.d61.s0.e2" id="DS.d61.s0.i0" interaction="False"/>
            <pair e1="DS.d61.s0.e4" e2="DS.d61.s0.e0" id="DS.d61.s0.i1" interaction="False"/>
            <pair e1="DS.d61.s0.e3" e2="DS.d61.s0.e0" id="DS.d61.s0.i2" interaction="False"/>
            <pair e1="DS.d61.s0.e3" e2="DS.d61.s0.e1" id="DS.d61.s0.i3" interaction="False"/>
            <pair e1="DS.d61.s0.e5" e2="DS.d61.s0.e0" id="DS.d61.s0.i4" interaction="False"/>
            <pair e1="DS.d61.s0.e5" e2="DS.d61.s0.e1" id="DS.d61.s0.i5" interaction="False"/>
            <pair e1="DS.d61.s0.e3" e2="DS.d61.s0.e2" id="DS.d61.s0.i6" interaction="False"/>
            <pair e1="DS.d61.s0.e5" e2="DS.d61.s0.e2" id="DS.d61.s0.i7" interaction="False"/>
            <pair e1="DS.d61.s0.e4" e2="DS.d61.s0.e1" id="DS.d61.s0.i8" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d62" origId="18266054">
        <sentence id="DS.d62.s0" origId="18266054-1214" text="At the time, glutathione reductase activity was significantly inhibited and gamma-glutamyl cysteine increased by ACA exposure.">
            <entity id="DS.d62.s0.e0" origId="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655" charOffset="13-34" type="protein" text="glutathione reductase"/>
            <entity id="DS.d62.s0.e1" origId="594,5862,5360637" charOffset="91-99" type="compound" text="cysteine"/>
            <pair e1="DS.d62.s0.e1" e2="DS.d62.s0.e0" id="DS.d62.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d63" origId="18268501">
        <sentence id="DS.d63.s0" origId="18268501-1260" text="The effect of the polymorphism is non-conservative and results in a glutamine to arginine change (Gln460Arg), which is likely to affect P2RX7 dimerization and protein-protein interactions.">
            <entity id="DS.d63.s0.e0" origId="738,5961" charOffset="68-77" type="compound" text="glutamine"/>
            <entity id="DS.d63.s0.e1" origId="232,4367,6322" charOffset="81-89" type="compound" text="arginine"/>
            <entity id="DS.d63.s0.e2" origId="Q99572" charOffset="136-141" type="protein" text="P2RX7"/>
            <pair e1="DS.d63.s0.e1" e2="DS.d63.s0.e2" id="DS.d63.s0.i0" interaction="True"/>
            <pair e1="DS.d63.s0.e0" e2="DS.d63.s0.e2" id="DS.d63.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d64" origId="18270841">
        <sentence id="DS.d64.s0" origId="18270841-348" text="Increased somatostatin tone and decreased ghrelin concentrations may also contribute to reduced GH levels.">
            <entity id="DS.d64.s0.e0" origId="16129681,16129706" charOffset="10-22" type="compound" text="somatostatin"/>
            <entity id="DS.d64.s0.e1" origId="Q6BEG6,Q6BEG7,Q9BDJ6,Q9BEF8,Q9EQX0,Q9GKY5,Q9QYH7,Q9UBU3" charOffset="42-49" type="protein" text="ghrelin"/>
            <pair e1="DS.d64.s0.e0" e2="DS.d64.s0.e1" id="DS.d64.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d65" origId="18272254">
        <sentence id="DS.d65.s0" origId="18272254-1258" text="Inhibition of LTP by beta-amyloid is prevented by activation of beta2 adrenoceptors and stimulation of the cAMP/PKA signalling pathway.">
            <entity id="DS.d65.s0.e0" origId="O70431,P04274,P07550,P10608,P18762,P54833,Q28044,Q28509,Q28997,Q4KWL2,Q8UUY8,Q9TST5" charOffset="64-83" type="protein" text="beta2 adrenoceptors"/>
            <entity id="DS.d65.s0.e1" origId="6076" charOffset="107-111" type="compound" text="cAMP"/>
            <pair e1="DS.d65.s0.e1" e2="DS.d65.s0.e0" id="DS.d65.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d66" origId="18274872">
        <sentence id="DS.d66.s0" origId="18274872-320" text=") O2 (-) and H2O2 in H. plumaeforme was respectively related to the low activity of SOD and the decreased activity of CAT.">
            <entity id="DS.d66.s0.e0" origId="977,5359597" charOffset="2-4" type="compound" text="O2"/>
            <entity id="DS.d66.s0.e1" origId="784" charOffset="13-17" type="compound" text="H2O2"/>
            <entity id="DS.d66.s0.e2" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="84-87" type="protein" text="SOD"/>
            <entity id="DS.d66.s0.e3" origId="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7" charOffset="118-121" type="protein" text="CAT"/>
            <pair e1="DS.d66.s0.e0" e2="DS.d66.s0.e2" id="DS.d66.s0.i0" interaction="True"/>
            <pair e1="DS.d66.s0.e1" e2="DS.d66.s0.e3" id="DS.d66.s0.i1" interaction="True"/>
            <pair e1="DS.d66.s0.e1" e2="DS.d66.s0.e2" id="DS.d66.s0.i2" interaction="True"/>
            <pair e1="DS.d66.s0.e0" e2="DS.d66.s0.e3" id="DS.d66.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d67" origId="18279956">
        <sentence id="DS.d67.s0" origId="18279956-684" text="A novel oligodeoxynuleotides containing 11 CpG motifs was synthesized and inserted into the VR1020 plasmid containing pig interleukin-6 (IL-6) gene (VPIL6) to construct recombinant plasmid, VPIL6C.">
            <entity id="DS.d67.s0.e0" origId="6804" charOffset="43-46" type="compound" text="CpG"/>
            <entity id="DS.d67.s0.e1" origId="P41693" charOffset="122-135" type="protein" text="interleukin-6"/>
            <entity id="DS.d67.s0.e2" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="137-141" type="protein" text="IL-6"/>
            <pair e1="DS.d67.s0.e0" e2="DS.d67.s0.e1" id="DS.d67.s0.i0" interaction="False"/>
            <pair e1="DS.d67.s0.e0" e2="DS.d67.s0.e2" id="DS.d67.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d68" origId="18280595">
        <sentence id="DS.d68.s0" origId="18280595-101" text="Furthermore, it has also been reported that capsaicin-treated pigs significantly increase mean arterial blood pressure compared with controls and that the decrease in CGRP synthesis and release contributes to the elevated blood pressure.">
            <entity id="DS.d68.s0.e0" origId="1548943" charOffset="44-53" type="compound" text="capsaicin"/>
            <entity id="DS.d68.s0.e1" origId="P10286,P30880,P30881,P31888,P80511" charOffset="167-171" type="protein" text="CGRP"/>
            <pair e1="DS.d68.s0.e0" e2="DS.d68.s0.e1" id="DS.d68.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d69" origId="18283487">
        <sentence id="DS.d69.s0" origId="18283487-569" text="Since then, the efforts of numerous investigators have led to the following conclusions: (a) This enzyme is indeed the molecular machine for the ATP-dependent and-coupled transport of Na (+) and K(+) across the plasma membrane of a living cell in which such a process (sodium pump) is detected.">
            <entity id="DS.d69.s0.e0" origId="5957" charOffset="145-148" type="compound" text="ATP"/>
            <entity id="DS.d69.s0.e1" origId="923,373840" charOffset="184-186" type="compound" text="Na"/>
            <entity id="DS.d69.s0.e2" origId="P13607,P17326,P28774,P35317" charOffset="269-280" type="protein" text="sodium pump"/>
            <pair e1="DS.d69.s0.e0" e2="DS.d69.s0.e2" id="DS.d69.s0.i0" interaction="True"/>
            <pair e1="DS.d69.s0.e1" e2="DS.d69.s0.e2" id="DS.d69.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d70" origId="18286621">
        <sentence id="DS.d70.s0" origId="18286621-29" text="Affinity electrophoresis analysis provided evidence that carboxymethylated dextran polymers grafted with high amounts of benzylamide groups (named DMCB) interact with BMP-2.">
            <entity id="DS.d70.s0.e0" origId="4125253,5460037" charOffset="75-82" type="compound" text="dextran"/>
            <entity id="DS.d70.s0.e1" origId="10391" charOffset="121-132" type="compound" text="benzylamide"/>
            <entity id="DS.d70.s0.e2" origId="O19006,O46564,P12643,P21274,P49001,Q804S2,Q90751" charOffset="167-172" type="protein" text="BMP-2"/>
            <pair e1="DS.d70.s0.e1" e2="DS.d70.s0.e2" id="DS.d70.s0.i0" interaction="True"/>
            <pair e1="DS.d70.s0.e0" e2="DS.d70.s0.e2" id="DS.d70.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d70.s1" origId="18286621-30" text="A screening study provided evidence that the potentiating effects of the dextran derivatives on the BMP-2-induced alkaline phosphatase activity improved with their benzylamide groups content and, therefore, with their affinity for the growth factor.">
            <entity id="DS.d70.s1.e0" origId="4125253,5460037" charOffset="73-80" type="compound" text="dextran"/>
            <entity id="DS.d70.s1.e1" origId="O19006,O46564,P12643,P21274,P49001,Q804S2,Q90751" charOffset="100-105" type="protein" text="BMP-2"/>
            <entity id="DS.d70.s1.e2" origId="O60109,P81800,P83456" charOffset="114-134" type="protein" text="alkaline phosphatase"/>
            <entity id="DS.d70.s1.e3" origId="10391" charOffset="164-175" type="compound" text="benzylamide"/>
            <pair e1="DS.d70.s1.e3" e2="DS.d70.s1.e2" id="DS.d70.s1.i0" interaction="True"/>
            <pair e1="DS.d70.s1.e0" e2="DS.d70.s1.e1" id="DS.d70.s1.i1" interaction="True"/>
            <pair e1="DS.d70.s1.e0" e2="DS.d70.s1.e2" id="DS.d70.s1.i2" interaction="True"/>
            <pair e1="DS.d70.s1.e3" e2="DS.d70.s1.e1" id="DS.d70.s1.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d71" origId="18294936">
        <sentence id="DS.d71.s0" origId="18294936-104" text="Since buprenorphine is metabolized through cytochrome P450 3A4, we genotyped six genetic polymorphisms previously described in poor metabolizers but could not confirm these pharmacogenetic bases in this case.">
            <entity id="DS.d71.s0.e0" origId="40400,644073,5311033,6321408,24838065" charOffset="6-19" type="compound" text="buprenorphine"/>
            <entity id="DS.d71.s0.e1" origId="P08684" charOffset="43-62" type="protein" text="cytochrome P450 3A4"/>
            <pair e1="DS.d71.s0.e0" e2="DS.d71.s0.e1" id="DS.d71.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d72" origId="18295378">
        <sentence id="DS.d72.s0" origId="18295378-334" text="Mitochondrial dysfunction was associated with higher levels of reactive oxygen species, an altered Bcl-xL/Bax ratio and reduction of COX IV activity.">
            <entity id="DS.d72.s0.e0" origId="977" charOffset="72-78" type="compound" text="oxygen"/>
            <entity id="DS.d72.s0.e1" origId="P27297,Q07813,Q63690" charOffset="106-109" type="protein" text="Bax"/>
            <entity id="DS.d72.s0.e2" origId="P11353,P36551,P36552,Q9UTE2,Q9V3D2" charOffset="133-136" type="protein" text="COX"/>
            <pair e1="DS.d72.s0.e0" e2="DS.d72.s0.e2" id="DS.d72.s0.i0" interaction="False"/>
            <pair e1="DS.d72.s0.e0" e2="DS.d72.s0.e1" id="DS.d72.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d73" origId="18298568">
        <sentence id="DS.d73.s0" origId="18298568-1058" text="Peripheral venous levels of testosterone, prolactin, follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), malondialdehyde and glycosylated haemoglobin (HbA(1)c) were obtained in all subjects.">
            <entity id="DS.d73.s0.e0" origId="6013" charOffset="28-40" type="compound" text="testosterone"/>
            <entity id="DS.d73.s0.e1" origId="P10765,P22393,P33089,P33090,P33091,P43001" charOffset="42-51" type="protein" text="prolactin"/>
            <entity id="DS.d73.s0.e2" origId="10964" charOffset="150-165" type="compound" text="malondialdehyde"/>
            <pair e1="DS.d73.s0.e0" e2="DS.d73.s0.e1" id="DS.d73.s0.i0" interaction="False"/>
            <pair e1="DS.d73.s0.e2" e2="DS.d73.s0.e1" id="DS.d73.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d74" origId="18298570">
        <sentence id="DS.d74.s0" origId="18298570-1059" text="Our results showed that catalase abolished the effect of the oxidant, protecting spermatozoa against reactive oxygen species, and improving both sperm motility and chromatin status during incubation.">
            <entity id="DS.d74.s0.e0" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="24-32" type="protein" text="catalase"/>
            <entity id="DS.d74.s0.e1" origId="977" charOffset="110-116" type="compound" text="oxygen"/>
            <pair e1="DS.d74.s0.e1" e2="DS.d74.s0.e0" id="DS.d74.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d75" origId="18298659">
        <sentence id="DS.d75.s0" origId="18298659-1127" text="Intranasal and intravenous administration of live Cpn and Aa, respectively induced an accumulation of activated mast cells in the aortic sinus of apolipoprotein E-deficient mice, however, with varying responses in the systemic levels of lipopolysaccharide (LPS) and TNF-alpha.">
            <entity id="DS.d75.s0.e0" origId="11970143" charOffset="237-255" type="compound" text="lipopolysaccharide"/>
            <entity id="DS.d75.s0.e1" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="266-275" type="protein" text="TNF-alpha"/>
            <pair e1="DS.d75.s0.e0" e2="DS.d75.s0.e1" id="DS.d75.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d76" origId="18304632">
        <sentence id="DS.d76.s0" origId="18304632-1001" text="MnSOD and two additional catalase isozymes were induced by quinclorac or bensulfuron-methyl in S. maltophilia WZ2, but not in E. coli K12.">
            <entity id="DS.d76.s0.e0" origId="P00448,P66828,P66829,Q8Z2V9,Q9RUV2" charOffset="0-5" type="protein" text="MnSOD"/>
            <entity id="DS.d76.s0.e1" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="25-33" type="protein" text="catalase"/>
            <entity id="DS.d76.s0.e2" origId="91739" charOffset="59-69" type="compound" text="quinclorac"/>
            <entity id="DS.d76.s0.e3" origId="54960" charOffset="73-91" type="compound" text="bensulfuron-methyl"/>
            <pair e1="DS.d76.s0.e2" e2="DS.d76.s0.e0" id="DS.d76.s0.i0" interaction="True"/>
            <pair e1="DS.d76.s0.e2" e2="DS.d76.s0.e1" id="DS.d76.s0.i1" interaction="True"/>
            <pair e1="DS.d76.s0.e3" e2="DS.d76.s0.e0" id="DS.d76.s0.i2" interaction="True"/>
            <pair e1="DS.d76.s0.e3" e2="DS.d76.s0.e1" id="DS.d76.s0.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d76.s1" origId="18304632-1002" text="Results indicate that catalase has a much weakly role in the defense against quinclorac or bensulfuron-methyl induced oxidative stress, whereas SOD could be critical.">
            <entity id="DS.d76.s1.e0" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="22-30" type="protein" text="catalase"/>
            <entity id="DS.d76.s1.e1" origId="91739" charOffset="77-87" type="compound" text="quinclorac"/>
            <entity id="DS.d76.s1.e2" origId="54960" charOffset="91-109" type="compound" text="bensulfuron-methyl"/>
            <entity id="DS.d76.s1.e3" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="144-147" type="protein" text="SOD"/>
            <pair e1="DS.d76.s1.e1" e2="DS.d76.s1.e0" id="DS.d76.s1.i0" interaction="True"/>
            <pair e1="DS.d76.s1.e2" e2="DS.d76.s1.e3" id="DS.d76.s1.i1" interaction="True"/>
            <pair e1="DS.d76.s1.e2" e2="DS.d76.s1.e0" id="DS.d76.s1.i2" interaction="True"/>
            <pair e1="DS.d76.s1.e1" e2="DS.d76.s1.e3" id="DS.d76.s1.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d77" origId="18304748">
        <sentence id="DS.d77.s0" origId="18304748-1077" text="Moreover, TARPs (except gamma4) reduce the ion channel block by the synthetic Joro spider toxin analog 1-naphthylacetyl spermine (NASP).">
            <entity id="DS.d77.s0.e0" origId="Q99JR5" charOffset="10-15" type="protein" text="TARPs"/>
            <entity id="DS.d77.s0.e1" origId="119582,5311197" charOffset="78-95" type="compound" text="Joro spider toxin"/>
            <entity id="DS.d77.s0.e2" origId="129695" charOffset="103-128" type="compound" text="1-naphthylacetyl spermine"/>
            <pair e1="DS.d77.s0.e2" e2="DS.d77.s0.e0" id="DS.d77.s0.i0" interaction="True"/>
            <pair e1="DS.d77.s0.e1" e2="DS.d77.s0.e0" id="DS.d77.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d78" origId="18306310">
        <sentence id="DS.d78.s0" origId="18306310-763" text="SMC cultured on P(100/0) films modified by covalently attached fibronectin or fibrin layers proliferated at a rate comparable to that observed on control tissue culture polystyrene.">
            <entity id="DS.d78.s0.e0" origId="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400" charOffset="63-74" type="protein" text="fibronectin"/>
            <entity id="DS.d78.s0.e1" origId="7501" charOffset="169-180" type="compound" text="polystyrene"/>
            <pair e1="DS.d78.s0.e1" e2="DS.d78.s0.e0" id="DS.d78.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d78.s1" origId="18306310-764" text="However, prewetting P(70/30) with a phosphate buffer prior to aminolysis significantly improved cell numbers following immobilization of fibronectin.">
            <entity id="DS.d78.s1.e0" origId="1061,167704,644102" charOffset="36-45" type="compound" text="phosphate"/>
            <entity id="DS.d78.s1.e1" origId="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400" charOffset="137-148" type="protein" text="fibronectin"/>
            <pair e1="DS.d78.s1.e0" e2="DS.d78.s1.e1" id="DS.d78.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d79" origId="18308488">
        <sentence id="DS.d79.s0" origId="18308488-862" text="The dose of ACTH (2.5 microg/kg) was chosen to mimic the cortisol concentrations seen during mixing of unfamiliar sows.">
            <entity id="DS.d79.s0.e0" origId="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5" charOffset="12-16" type="protein" text="ACTH"/>
            <entity id="DS.d79.s0.e1" origId="5754" charOffset="57-65" type="compound" text="cortisol"/>
            <pair e1="DS.d79.s0.e1" e2="DS.d79.s0.e0" id="DS.d79.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d80" origId="18311594">
        <sentence id="DS.d80.s0" origId="18311594-236" text="Our data suggest HumDN1 genotypes are related to total cholesterol levels in Han Chinese MI patients, but deoxyribonuclease I gene polymorphisms are not associated with susceptibility to MI in Han Chinese.">
            <entity id="DS.d80.s0.e0" origId="304,5997,6432564,11025495" charOffset="55-66" type="compound" text="cholesterol"/>
            <entity id="DS.d80.s0.e1" origId="O18998,O42446,P00639,P11936,P11937,P21704,P24855,P49183,Q4AEE3,Q767J3,Q9YGI5" charOffset="106-125" type="protein" text="deoxyribonuclease I"/>
            <pair e1="DS.d80.s0.e0" e2="DS.d80.s0.e1" id="DS.d80.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d81" origId="18314895">
        <sentence id="DS.d81.s0" origId="18314895-1018" text="Specifically, TEG was shown to alter S. mutans gene expression levels of gtfB, a known virulence factor, and yfiV, a putative transcriptional regulator of cell-surface fatty acid genes.">
            <entity id="DS.d81.s0.e0" origId="8172" charOffset="14-17" type="compound" text="TEG"/>
            <entity id="DS.d81.s0.e1" origId="P08987" charOffset="73-77" type="protein" text="gtfB"/>
            <entity id="DS.d81.s0.e2" origId="Q9CJ45" charOffset="126-151" type="protein" text="transcriptional regulator"/>
            <pair e1="DS.d81.s0.e0" e2="DS.d81.s0.e2" id="DS.d81.s0.i0" interaction="True"/>
            <pair e1="DS.d81.s0.e0" e2="DS.d81.s0.e1" id="DS.d81.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d82" origId="18314898">
        <sentence id="DS.d82.s0" origId="18314898-1022" text="Degradation analysis over 8 weeks in the presence of 10 mg/L lysozyme showed a 50% decrease in total weight and an 80% decrease in PLGA molecular weight.">
            <entity id="DS.d82.s0.e0" origId="O64362,O80288,O80292,P00720,P03706,P07540,P09963,P10439,P11187,P13656,P15057,P19385,P19386,P21270,P23472,P23473,P27359,P33486,P37715,P39046,P51771,P62692,P62693,P68920,P68921,P81241,P82174,P82175,P83673,Q27650,Q37875,Q37896,Q48603,Q7SID7,Q9CIT4,Q9T1X2,Q9ZXB7" charOffset="61-69" type="protein" text="lysozyme"/>
            <entity id="DS.d82.s0.e1" origId="36797" charOffset="131-135" type="compound" text="PLGA"/>
            <pair e1="DS.d82.s0.e1" e2="DS.d82.s0.e0" id="DS.d82.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d83" origId="18317936">
        <sentence id="DS.d83.s0" origId="18317936-346" text="Fluo-3 staining used in flow cytometry and video microscopy revealed an oxysterol-induced Ca(2+) influx, varying according to the oxysterol studied, leading to the activation of the MEK/ERK1/2 pathway as demonstrated by Western blot analysis.">
            <entity id="DS.d83.s0.e0" origId="271" charOffset="90-94" type="compound" text="Ca(2"/>
            <entity id="DS.d83.s0.e1" origId="P27361,P28869,P42525,Q07176" charOffset="186-190" type="protein" text="ERK1"/>
            <pair e1="DS.d83.s0.e0" e2="DS.d83.s0.e1" id="DS.d83.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d84" origId="18327670">
        <sentence id="DS.d84.s0" origId="18327670-82" text="To determine if response to endocrine therapy of breast cancer can be predicted by either a metabolic &quot;flare reaction&quot; detected by positron emission tomography (PET) with 2-((18)F)-fluoro-2-deoxyglucose (FDG), induced by an estradiol challenge, or by estrogen-receptor (ER) status, determined by PET with the estrogen analog 16alpha-((18)F)fluoroestradiol-17beta (FES).">
            <entity id="DS.d84.s0.e0" origId="108223" charOffset="188-202" type="compound" text="2-deoxyglucose"/>
            <entity id="DS.d84.s0.e1" origId="5757" charOffset="224-233" type="compound" text="estradiol"/>
            <entity id="DS.d84.s0.e2" origId="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7" charOffset="251-268" type="protein" text="estrogen-receptor"/>
            <pair e1="DS.d84.s0.e0" e2="DS.d84.s0.e2" id="DS.d84.s0.i0" interaction="False"/>
            <pair e1="DS.d84.s0.e1" e2="DS.d84.s0.e2" id="DS.d84.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d85" origId="18328561">
        <sentence id="DS.d85.s0" origId="18328561-582" text="Depletion of GSH levels was accompanied by the induction of glutathione reductase (GR) after 24h exposure with each of the four carbamates to CHO-K1 cells.">
            <entity id="DS.d85.s0.e0" origId="124886" charOffset="13-16" type="compound" text="GSH"/>
            <entity id="DS.d85.s0.e1" origId="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655" charOffset="60-81" type="protein" text="glutathione reductase"/>
            <pair e1="DS.d85.s0.e0" e2="DS.d85.s0.e1" id="DS.d85.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d86" origId="18330498">
        <sentence id="DS.d86.s0" origId="18330498-512" text="Chloroquine and wortmannin inhibited the upregulation induced by insulin stimulation and amino acid deprivation but not that induced by osmotic shock.">
            <entity id="DS.d86.s0.e0" origId="2719" charOffset="0-11" type="compound" text="Chloroquine"/>
            <entity id="DS.d86.s0.e1" origId="312145" charOffset="16-26" type="compound" text="wortmannin"/>
            <entity id="DS.d86.s0.e2" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="65-72" type="protein" text="insulin"/>
            <pair e1="DS.d86.s0.e0" e2="DS.d86.s0.e2" id="DS.d86.s0.i0" interaction="True"/>
            <pair e1="DS.d86.s0.e1" e2="DS.d86.s0.e2" id="DS.d86.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d86.s1" origId="18330498-513" text="Moreover, PD98059 and SP600125 inhibited only amino acid deprivation-induced upregulation and SB202190 inhibited only insulin-induced upregulation.">
            <entity id="DS.d86.s1.e0" origId="4713" charOffset="10-17" type="compound" text="PD98059"/>
            <entity id="DS.d86.s1.e1" origId="8515" charOffset="22-30" type="compound" text="SP600125"/>
            <entity id="DS.d86.s1.e2" origId="5353940" charOffset="94-102" type="compound" text="SB202190"/>
            <entity id="DS.d86.s1.e3" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="118-125" type="protein" text="insulin"/>
            <pair e1="DS.d86.s1.e2" e2="DS.d86.s1.e3" id="DS.d86.s1.i0" interaction="True"/>
            <pair e1="DS.d86.s1.e1" e2="DS.d86.s1.e3" id="DS.d86.s1.i1" interaction="False"/>
            <pair e1="DS.d86.s1.e0" e2="DS.d86.s1.e3" id="DS.d86.s1.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d87" origId="18331557">
        <sentence id="DS.d87.s0" origId="18331557-1201" text="The role of phosphorylated Akt (p-Akt) in oral carcinogenesis induced by nicotine and alkaline environments was investigated.">
            <entity id="DS.d87.s0.e0" origId="P31750,Q8INB9" charOffset="27-30" type="protein" text="Akt"/>
            <entity id="DS.d87.s0.e1" origId="P31750,Q8INB9" charOffset="34-37" type="protein" text="Akt"/>
            <entity id="DS.d87.s0.e2" origId="942,89594,157672" charOffset="73-81" type="compound" text="nicotine"/>
            <pair e1="DS.d87.s0.e2" e2="DS.d87.s0.e0" id="DS.d87.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d88" origId="18336537">
        <sentence id="DS.d88.s0" origId="18336537-456" text="Sera from a population sample of infants with cryptorchidism (n = 43), hypospadias (n = 41) and controls (n = 113) were analyzed for inhibin B, anti-M&#252;llerian hormone (AMH), testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH) and sex hormone binding globulin (SHBG).">
            <entity id="DS.d88.s0.e0" origId="P03971,P03972,P27106,P49000,P79295" charOffset="168-171" type="protein" text="AMH"/>
            <entity id="DS.d88.s0.e1" origId="6013" charOffset="174-186" type="compound" text="testosterone"/>
            <entity id="DS.d88.s0.e2" origId="P04278,P08689,P15196,P97497,Q62588" charOffset="283-287" type="protein" text="SHBG"/>
            <pair e1="DS.d88.s0.e1" e2="DS.d88.s0.e0" id="DS.d88.s0.i0" interaction="False"/>
            <pair e1="DS.d88.s0.e1" e2="DS.d88.s0.e2" id="DS.d88.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d89" origId="18340529">
        <sentence id="DS.d89.s0" origId="18340529-389" text="Myeloperoxidase (MPO) is an endogenous oxidant enzyme that generates reactive oxygen species (ROS).">
            <entity id="DS.d89.s0.e0" origId="P05164,P11247" charOffset="17-20" type="protein" text="MPO"/>
            <entity id="DS.d89.s0.e1" origId="977" charOffset="78-84" type="compound" text="oxygen"/>
            <pair e1="DS.d89.s0.e1" e2="DS.d89.s0.e0" id="DS.d89.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d90" origId="18343629">
        <sentence id="DS.d90.s0" origId="18343629-1064" text="In present study, we investigated the combined effect of emodin and baicalin on pancreatic damage and pancreatitis associated lung injury, as well as tissue TLR4 expression in the setting of AP.">
            <entity id="DS.d90.s0.e0" origId="3220" charOffset="57-63" type="compound" text="emodin"/>
            <entity id="DS.d90.s0.e1" origId="64982" charOffset="68-76" type="compound" text="baicalin"/>
            <entity id="DS.d90.s0.e2" origId="O00206,P58727,Q2V898,Q68Y56,Q8SPE8,Q8SPE9,Q9GL65,Q9MYW3,Q9TSP2,Q9TTN0,Q9WV82" charOffset="157-161" type="protein" text="TLR4"/>
            <pair e1="DS.d90.s0.e0" e2="DS.d90.s0.e2" id="DS.d90.s0.i0" interaction="False"/>
            <pair e1="DS.d90.s0.e1" e2="DS.d90.s0.e2" id="DS.d90.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d90.s1" origId="18343629-1065" text="The results showed that combination of emodin and baicalin significantly reduced serum amylase, tumor necrosis factor-alpha and interleukin-6, attenuated pancreatic and pulmonary damage, also suppressed TLR4 expression in pancreas and lung.">
            <entity id="DS.d90.s1.e0" origId="3220" charOffset="39-45" type="compound" text="emodin"/>
            <entity id="DS.d90.s1.e1" origId="64982" charOffset="50-58" type="compound" text="baicalin"/>
            <entity id="DS.d90.s1.e2" origId="Q8JFG3" charOffset="96-117" type="protein" text="tumor necrosis factor"/>
            <entity id="DS.d90.s1.e3" origId="P41693" charOffset="128-141" type="protein" text="interleukin-6"/>
            <entity id="DS.d90.s1.e4" origId="O00206,P58727,Q2V898,Q68Y56,Q8SPE8,Q8SPE9,Q9GL65,Q9MYW3,Q9TSP2,Q9TTN0,Q9WV82" charOffset="203-207" type="protein" text="TLR4"/>
            <pair e1="DS.d90.s1.e1" e2="DS.d90.s1.e4" id="DS.d90.s1.i0" interaction="True"/>
            <pair e1="DS.d90.s1.e0" e2="DS.d90.s1.e4" id="DS.d90.s1.i1" interaction="True"/>
            <pair e1="DS.d90.s1.e0" e2="DS.d90.s1.e2" id="DS.d90.s1.i2" interaction="True"/>
            <pair e1="DS.d90.s1.e1" e2="DS.d90.s1.e3" id="DS.d90.s1.i3" interaction="True"/>
            <pair e1="DS.d90.s1.e0" e2="DS.d90.s1.e3" id="DS.d90.s1.i4" interaction="True"/>
            <pair e1="DS.d90.s1.e1" e2="DS.d90.s1.e2" id="DS.d90.s1.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d91" origId="18346857">
        <sentence id="DS.d91.s0" origId="18346857-498" text="Results showed that a moderate dose of leptin (250 microg/kg body weight/day) injected during the re-feeding period: (i) promoted the recovery of the regressed ovary as evidenced by an increase in ovary weight and recovery of yellow hierarchical follicles; (ii) elevated the plasma 17beta-estradiol (E(2)) level; (iii) increased the mRNA levels of ovary follicle-stimulating hormone receptor (FSHR), luteinizing hormone receptor (LHR) and estrogen receptor-beta (ER-beta).">
            <entity id="DS.d91.s0.e0" origId="O02750,O93416,Q28603,Q95189,Q95234" charOffset="39-45" type="protein" text="leptin"/>
            <entity id="DS.d91.s0.e1" origId="5757" charOffset="282-298" type="compound" text="17beta-estradiol"/>
            <entity id="DS.d91.s0.e2" origId="P23945,P32212,P35376,P35379,P47799,P49059,P79763,Q5GJ04,Q6R6L8,Q6YNB6,Q7ZTV5,Q8R428,Q95179" charOffset="393-397" type="protein" text="FSHR"/>
            <entity id="DS.d91.s0.e3" origId="O02721,P16235,P16582,P22888,P30730,Q28005,Q28585,Q90674" charOffset="400-428" type="protein" text="luteinizing hormone receptor"/>
            <entity id="DS.d91.s0.e4" origId="P16070,P22888,Q28585" charOffset="430-433" type="protein" text="LHR"/>
            <entity id="DS.d91.s0.e5" origId="O08537,O13012,O93511,P57781,P57782,Q62986,Q92731,Q95171,Q9IAK1,Q9PTU5,Q9PVE2,Q9TTE5,Q9TU15,Q9W6M2,Q9XSB5,Q9XSW2,Q9YH32" charOffset="439-461" type="protein" text="estrogen receptor-beta"/>
            <entity id="DS.d91.s0.e6" origId="O08537,O13012,O93511,P57781,P57782,Q62986,Q92731,Q95171,Q9IAK1,Q9PTU5,Q9PVE2,Q9TTE5,Q9TU15,Q9W6M2,Q9XSB5,Q9XSW2,Q9YH32" charOffset="463-470" type="protein" text="ER-beta"/>
            <pair e1="DS.d91.s0.e1" e2="DS.d91.s0.e4" id="DS.d91.s0.i0" interaction="False"/>
            <pair e1="DS.d91.s0.e1" e2="DS.d91.s0.e5" id="DS.d91.s0.i1" interaction="False"/>
            <pair e1="DS.d91.s0.e1" e2="DS.d91.s0.e3" id="DS.d91.s0.i2" interaction="False"/>
            <pair e1="DS.d91.s0.e1" e2="DS.d91.s0.e6" id="DS.d91.s0.i3" interaction="False"/>
            <pair e1="DS.d91.s0.e1" e2="DS.d91.s0.e2" id="DS.d91.s0.i4" interaction="False"/>
            <pair e1="DS.d91.s0.e1" e2="DS.d91.s0.e0" id="DS.d91.s0.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d92" origId="18357521">
        <sentence id="DS.d92.s0" origId="18357521-771" text="The anti-neoplastic drug taxol binds to beta-tubulin to prevent tumor cell division, promoting cell death.">
            <entity id="DS.d92.s0.e0" origId="4666,36314,441276" charOffset="25-30" type="compound" text="taxol"/>
            <entity id="DS.d92.s0.e1" origId="O04386,O42786,O44388,O59837,P02554,P02556,P02557,P04107,P05219,P05220,P05304,P08562,P10875,P10876,P10878,P11482,P11833,P11857,P12457,P14140,P14643,P16040,P17938,P18699,P18700,P20365,P20802,P21148,P22012,P22852,P24637,P28551,P30668,P32256,P33127,P34108,P35394,P41352,P41385,P41386,P41387,P41388,P41741,P41742,P41799,P53373,P53374,P53375,P53376,P79008,P93176,Q00264,Q04709,Q08115,Q24829,Q27380,Q2U2U3,Q39445,Q3KVN1,Q4HZS8,Q4P235,Q4R9N3,Q4WA70,Q52NY7,Q5UBX3,Q6QDC9,Q7KQL5,Q86ZP5,Q8SS99,Q8WZE0,Q91240,Q92268,Q96TU8,Q9GSR5,Q9HFQ3,Q9LKI8,Q9N2N6,Q9UV72" charOffset="40-52" type="protein" text="beta-tubulin"/>
            <pair e1="DS.d92.s0.e0" e2="DS.d92.s0.e1" id="DS.d92.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d92.s1" origId="18357521-772" text="In the current study, we knocked down Bcl-2 expression using cognate siRNA during low-dose taxol treatment to induce apoptosis in two human glioblastoma U138MG and U251MG cell lines.">
            <entity id="DS.d92.s1.e0" origId="P10417,P49950" charOffset="38-43" type="protein" text="Bcl-2"/>
            <entity id="DS.d92.s1.e1" origId="4666,36314,441276" charOffset="91-96" type="compound" text="taxol"/>
            <pair e1="DS.d92.s1.e1" e2="DS.d92.s1.e0" id="DS.d92.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d92.s2" origId="18357521-773" text="The cells were treated with either 100 nM taxol or 100 nM Bcl-2 siRNA or both for 72 h. Immunofluorescent stainings for calpain and active caspase-3 showed increases in expression and co-localization of these proteases in apoptotic cells.">
            <entity id="DS.d92.s2.e0" origId="4666,36314,441276" charOffset="42-47" type="compound" text="taxol"/>
            <entity id="DS.d92.s2.e1" origId="O41798,O89290,O89940,O91080,O93215,P03311,P03353,P03355,P03356,P03362,P03363,P03366,P03367,P03369,P03370,P04023,P04024,P04323,P04584,P04585,P04587,P04588,P04589,P05959,P05960,P05961,P05962,P07570,P0C210,P0C211,P10210,P10265,P10270,P10271,P10272,P10273,P10274,P10394,P10978,P11227,P11365,P12451,P12497,P12498,P12499,P14074,P14078,P15833,P16046,P16423,P16901,P17757,P18042,P18096,P18802,P19028,P19199,P19560,P19561,P20825,P20875,P20876,P20892,P21407,P21414,P24107,P24740,P26808,P26809,P26810,P27502,P28936,P31822,P35956,P35963,P51518,P63119,P63120,P63121,P63122,P63123,P63124,P63125,P63127,P63128,P63129,P63131,P84454,Q09SZ9,Q0R5R2,Q0R5R3,Q1A249,Q1A267,Q4U0X6,Q73368,Q74120,Q75002,Q76634,Q77373,Q79666,Q89928,Q8AII1,Q8I7P9,Q9IDV9,Q9Q720,Q9QBY3,Q9QBZ1,Q9QBZ5,Q9QSR3,Q9WC54,Q9WC63,Q9Y6I0" charOffset="209-218" type="protein" text="proteases"/>
            <pair e1="DS.d92.s2.e0" e2="DS.d92.s2.e1" id="DS.d92.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d92.s3" origId="18357521-774" text="Our current study demonstrated that Bcl-2 siRNA significantly augmented taxol mediated apoptosis in different human glioblastoma cells through induction of calpain and caspase proteolytic activities.">
            <entity id="DS.d92.s3.e0" origId="4666,36314,441276" charOffset="72-77" type="compound" text="taxol"/>
            <entity id="DS.d92.s3.e1" origId="P27730" charOffset="156-163" type="protein" text="calpain"/>
            <pair e1="DS.d92.s3.e0" e2="DS.d92.s3.e1" id="DS.d92.s3.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d93" origId="18357522">
        <sentence id="DS.d93.s0" origId="18357522-775" text="Based on these findings, altered expression of PLP1 in most areas of the striatum suggests that widespread changes to the myelin structure could be associated with the adaptive changes following chronic cocaine abuse.">
            <entity id="DS.d93.s0.e0" origId="P04116,P23289,P23294,P47789,P47790,P60201,Q04004,Q08868,Q8HXW7" charOffset="47-51" type="protein" text="PLP1"/>
            <entity id="DS.d93.s0.e1" origId="2826,5760,439497,446220,644017,54613779" charOffset="203-210" type="compound" text="cocaine"/>
            <pair e1="DS.d93.s0.e1" e2="DS.d93.s0.e0" id="DS.d93.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d94" origId="18359113">
        <sentence id="DS.d94.s0" origId="18359113-478" text="No correlation was detected between serum leptin level and vitamin D-25(OH)D3, which was under normal range in 60% of the patients.">
            <entity id="DS.d94.s0.e0" origId="O02750,O93416,Q28603,Q95189,Q95234" charOffset="42-48" type="protein" text="leptin"/>
            <entity id="DS.d94.s0.e1" origId="5280795" charOffset="59-68" type="compound" text="vitamin D"/>
            <pair e1="DS.d94.s0.e1" e2="DS.d94.s0.e0" id="DS.d94.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d94.s1" origId="18359113-479" text="The higher leptin levels in women was accompanied by higher serum levels of glucose, albumin, Ca, cholesterol, Na and FT4.">
            <entity id="DS.d94.s1.e0" origId="O02750,O93416,Q28603,Q95189,Q95234" charOffset="11-17" type="protein" text="leptin"/>
            <entity id="DS.d94.s1.e1" origId="206,5793,64689,79025" charOffset="76-83" type="compound" text="glucose"/>
            <entity id="DS.d94.s1.e2" origId="304,5997,6432564,11025495" charOffset="98-109" type="compound" text="cholesterol"/>
            <entity id="DS.d94.s1.e3" origId="923,373840" charOffset="111-113" type="compound" text="Na"/>
            <pair e1="DS.d94.s1.e2" e2="DS.d94.s1.e0" id="DS.d94.s1.i0" interaction="True"/>
            <pair e1="DS.d94.s1.e3" e2="DS.d94.s1.e0" id="DS.d94.s1.i1" interaction="True"/>
            <pair e1="DS.d94.s1.e1" e2="DS.d94.s1.e0" id="DS.d94.s1.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d94.s2" origId="18359113-480" text="Comparison of 50 patients with the lowest leptin levels (mean of 3.4ng/ml) to 50 patients with highest leptin levels (mean of 34ng/ml), did not indicate differences in both 25(OH)D3 and ICTP between these two populations in spite of the highly significant difference in leptin levels.">
            <entity id="DS.d94.s2.e0" origId="O02750,O93416,Q28603,Q95189,Q95234" charOffset="42-48" type="protein" text="leptin"/>
            <entity id="DS.d94.s2.e1" origId="O02750,O93416,Q28603,Q95189,Q95234" charOffset="103-109" type="protein" text="leptin"/>
            <entity id="DS.d94.s2.e2" origId="5283731" charOffset="173-181" type="compound" text="25(OH)D3"/>
            <entity id="DS.d94.s2.e3" origId="O02750,O93416,Q28603,Q95189,Q95234" charOffset="103-109" type="protein" text="leptin"/>
            <pair e1="DS.d94.s2.e2" e2="DS.d94.s2.e0" id="DS.d94.s2.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d95" origId="18363836">
        <sentence id="DS.d95.s0" origId="18363836-902" text="The effects on the early secretory pathway in HEK293 cells were: reduction of the rate of ER-to-Golgi transport of the vesicular stomatitis virus glycoprotein (VSVG), slowed accumulation of a Golgi marker plasmid in pre-Golgi structures after Brefeldin A treatment and inhibition of cargo concentration of the neuronal glutamate transporter excitatory amino-acid carrier 1 (EAAC1) into transpor complexes in HEK293 cells, an effect that could be completely reversed in the presence of an excess of Rab1.">
            <entity id="DS.d95.s0.e0" origId="P08163" charOffset="146-158" type="protein" text="glycoprotein"/>
            <entity id="DS.d95.s0.e1" origId="5287620" charOffset="243-254" type="compound" text="Brefeldin A"/>
            <entity id="DS.d95.s0.e2" origId="P31597,P43005,P51906,P51907,Q95135" charOffset="341-372" type="protein" text="excitatory amino-acid carrier 1"/>
            <entity id="DS.d95.s0.e3" origId="P31597,P43005,Q95135" charOffset="374-379" type="protein" text="EAAC1"/>
            <entity id="DS.d95.s0.e4" origId="P62821,Q4UB16,Q6NYB7,Q9TVU5" charOffset="498-502" type="protein" text="Rab1"/>
            <pair e1="DS.d95.s0.e1" e2="DS.d95.s0.e2" id="DS.d95.s0.i0" interaction="False"/>
            <pair e1="DS.d95.s0.e1" e2="DS.d95.s0.e0" id="DS.d95.s0.i1" interaction="False"/>
            <pair e1="DS.d95.s0.e1" e2="DS.d95.s0.e4" id="DS.d95.s0.i2" interaction="False"/>
            <pair e1="DS.d95.s0.e1" e2="DS.d95.s0.e3" id="DS.d95.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d96" origId="18367388">
        <sentence id="DS.d96.s0" origId="18367388-537" text="Resveratrol did not attenuate GA-induced generation of hydrogen peroxide, but it did block GA-induced phosphorylation of connexin 43 (Cx43), a key modulator of GJIC.">
            <entity id="DS.d96.s0.e0" origId="445154" charOffset="0-11" type="compound" text="Resveratrol"/>
            <entity id="DS.d96.s0.e1" origId="784" charOffset="55-72" type="compound" text="hydrogen peroxide"/>
            <entity id="DS.d96.s0.e2" origId="O57474,P08050,P14154,P16863,P17302,P18246,P23242,Q29101,Q6S9C0" charOffset="121-132" type="protein" text="connexin 43"/>
            <entity id="DS.d96.s0.e3" origId="O57474,P08050,P14154,P16863,P17302,P18246,P23242,Q29101,Q6S9C0" charOffset="134-138" type="protein" text="Cx43"/>
            <pair e1="DS.d96.s0.e1" e2="DS.d96.s0.e3" id="DS.d96.s0.i0" interaction="False"/>
            <pair e1="DS.d96.s0.e0" e2="DS.d96.s0.e3" id="DS.d96.s0.i1" interaction="True"/>
            <pair e1="DS.d96.s0.e1" e2="DS.d96.s0.e2" id="DS.d96.s0.i2" interaction="False"/>
            <pair e1="DS.d96.s0.e0" e2="DS.d96.s0.e2" id="DS.d96.s0.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d96.s1" origId="18367388-538" text="Furthermore, resveratrol down-regulated GA-induced phosphorylation of extracellular signal-regulated kinase (ERK)1/2, one of the critical regulators of Cx43.">
            <entity id="DS.d96.s1.e0" origId="445154" charOffset="13-24" type="compound" text="resveratrol"/>
            <entity id="DS.d96.s1.e1" origId="P29323" charOffset="109-112" type="protein" text="ERK"/>
            <entity id="DS.d96.s1.e2" origId="O57474,P08050,P14154,P16863,P17302,P18246,P23242,Q29101,Q6S9C0" charOffset="152-156" type="protein" text="Cx43"/>
            <pair e1="DS.d96.s1.e0" e2="DS.d96.s1.e1" id="DS.d96.s1.i0" interaction="True"/>
            <pair e1="DS.d96.s1.e0" e2="DS.d96.s1.e2" id="DS.d96.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d97" origId="18368465">
        <sentence id="DS.d97.s0" origId="18368465-1220" text="DFMO accumulated cells in S phase of the cell cycle and reduced cyclin A expression.">
            <entity id="DS.d97.s0.e0" origId="3009" charOffset="0-4" type="compound" text="DFMO"/>
            <entity id="DS.d97.s0.e1" origId="P20248,P30274,P37881,P43449,P51943,Q92161" charOffset="64-72" type="protein" text="cyclin A"/>
            <pair e1="DS.d97.s0.e0" e2="DS.d97.s0.e1" id="DS.d97.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d98" origId="18368485">
        <sentence id="DS.d98.s0" origId="18368485-1240" text="Indeed, treatment of cells with 1 muM all-trans retinoic acid (ATRA) or 1 muM 13-cis retinoic acid (13-CRA) for 7 days induced astrocytic differentiation with upregulation of glial fibrillary acidic protein (GFAP) and down regulation of telomerase activity.">
            <entity id="DS.d98.s0.e0" origId="444795" charOffset="38-61" type="compound" text="all-trans retinoic acid"/>
            <entity id="DS.d98.s0.e1" origId="444795" charOffset="63-67" type="compound" text="ATRA"/>
            <entity id="DS.d98.s0.e2" origId="444795" charOffset="48-61" type="compound" text="retinoic acid"/>
            <entity id="DS.d98.s0.e3" origId="P01538,P01543,P01544,P01545,P08772,P08943,P09617,P09618,P21742,P32032,Q05806,Q42596,Q42597,Q42838,Q8H0Q5,Q8VZK8,Q9C8D6,Q9SBK8" charOffset="192-206" type="protein" text="acidic protein"/>
            <entity id="DS.d98.s0.e4" origId="P03995,P14136,P47819,Q28115" charOffset="208-212" type="protein" text="GFAP"/>
            <pair e1="DS.d98.s0.e0" e2="DS.d98.s0.e3" id="DS.d98.s0.i0" interaction="True"/>
            <pair e1="DS.d98.s0.e2" e2="DS.d98.s0.e4" id="DS.d98.s0.i1" interaction="True"/>
            <pair e1="DS.d98.s0.e0" e2="DS.d98.s0.e4" id="DS.d98.s0.i2" interaction="True"/>
            <pair e1="DS.d98.s0.e1" e2="DS.d98.s0.e3" id="DS.d98.s0.i3" interaction="True"/>
            <pair e1="DS.d98.s0.e2" e2="DS.d98.s0.e3" id="DS.d98.s0.i4" interaction="True"/>
            <pair e1="DS.d98.s0.e1" e2="DS.d98.s0.e4" id="DS.d98.s0.i5" interaction="True"/>
        </sentence>
        <sentence id="DS.d98.s1" origId="18368485-1241" text="Wright staining and ApopTag assay showed, respectively, morphological and biochemical features of apoptosis in glioblastoma cells following exposure to 200 units/ml IFN-gamma for 48 h. Induction of differentiation was associated with decreases in levels of nuclear factor kappa B (NFkappaB), inducible nitric oxide synthase (iNOS), and production of nitric oxide (NO) so as to increase sensitivity to IFN-gamma for apoptosis.">
            <entity id="DS.d98.s1.e0" origId="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9" charOffset="165-174" type="protein" text="IFN-gamma"/>
            <entity id="DS.d98.s1.e1" origId="O61309,O61608,Q27571,Q9I9M2" charOffset="302-323" type="protein" text="nitric oxide synthase"/>
            <entity id="DS.d98.s1.e2" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="325-329" type="protein" text="iNOS"/>
            <entity id="DS.d98.s1.e3" origId="145068" charOffset="302-314" type="compound" text="nitric oxide"/>
            <entity id="DS.d98.s1.e4" origId="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9" charOffset="401-410" type="protein" text="IFN-gamma"/>
            <pair e1="DS.d98.s1.e3" e2="DS.d98.s1.e1" id="DS.d98.s1.i0" interaction="False"/>
            <pair e1="DS.d98.s1.e3" e2="DS.d98.s1.e0" id="DS.d98.s1.i1" interaction="False"/>
            <pair e1="DS.d98.s1.e3" e2="DS.d98.s1.e2" id="DS.d98.s1.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d99" origId="18371961">
        <sentence id="DS.d99.s0" origId="18371961-849" text="Because annexin V binds phosphatidylserine, this study is using this feature to select functional spermatozoa.">
            <entity id="DS.d99.s0.e0" origId="P08758,P14668,P17153,P48036,P70075,P81287,Q4R4H7,Q5R1W0" charOffset="8-17" type="protein" text="annexin V"/>
            <entity id="DS.d99.s0.e1" origId="445141,6323481,44147587" charOffset="24-42" type="compound" text="phosphatidylserine"/>
            <pair e1="DS.d99.s0.e1" e2="DS.d99.s0.e0" id="DS.d99.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d100" origId="18373731">
        <sentence id="DS.d100.s0" origId="18373731-672" text="Cyclo(His-Pro) promotes cytoprotection by activating Nrf2-mediated up-regulation of antioxidant defence.">
            <entity id="DS.d100.s0.e0" origId="65137" charOffset="0-13" type="compound" text="Cyclo(His-Pro"/>
            <entity id="DS.d100.s0.e1" origId="O54968,Q60795" charOffset="53-57" type="protein" text="Nrf2"/>
            <pair e1="DS.d100.s0.e0" e2="DS.d100.s0.e1" id="DS.d100.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d100.s1" origId="18373731-674" text="Here, we addressed this issue and found that cyclo(His-Pro) triggered nuclear accumulation of NF-E2-related factor-2 (Nrf2), a transcription factor that up-regulates antioxidant-/electrophile-responsive element (ARE-EpRE)-related genes, in PC12 cells.">
            <entity id="DS.d100.s1.e0" origId="65137" charOffset="45-58" type="compound" text="cyclo(His-Pro"/>
            <entity id="DS.d100.s1.e1" origId="O54968,Q16236,Q60795" charOffset="94-116" type="protein" text="NF-E2-related factor-2"/>
            <entity id="DS.d100.s1.e2" origId="O54968,Q60795" charOffset="118-122" type="protein" text="Nrf2"/>
            <pair e1="DS.d100.s1.e0" e2="DS.d100.s1.e1" id="DS.d100.s1.i0" interaction="True"/>
            <pair e1="DS.d100.s1.e0" e2="DS.d100.s1.e2" id="DS.d100.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d101" origId="18374997">
        <sentence id="DS.d101.s0" origId="18374997-195" text="In women, Plg levels were higher in individuals with diagnosed ischemic heart disease (IHD) and increased with triglycerides (TG) and glucose level.">
            <entity id="DS.d101.s0.e0" origId="P20918,Q01177" charOffset="10-13" type="protein" text="Plg"/>
            <entity id="DS.d101.s0.e1" origId="206,5793,64689,79025" charOffset="134-141" type="compound" text="glucose"/>
            <pair e1="DS.d101.s0.e1" e2="DS.d101.s0.e0" id="DS.d101.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d102" origId="18375536">
        <sentence id="DS.d102.s0" origId="18375536-500" text="To investigate overnight variations in absolute values and patterns of cytokines including interleukin 6 (IL6) and tumour necrosis factor alpha (TNFalpha) in rheumatoid arthritis (RA), and to relate any changes to those occurring in blood cortisol.">
            <entity id="DS.d102.s0.e0" origId="P41693" charOffset="91-104" type="protein" text="interleukin 6"/>
            <entity id="DS.d102.s0.e1" origId="O35736,P05231,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="106-109" type="protein" text="IL6"/>
            <entity id="DS.d102.s0.e2" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="145-153" type="protein" text="TNFalpha"/>
            <entity id="DS.d102.s0.e3" origId="5754" charOffset="239-247" type="compound" text="cortisol"/>
            <pair e1="DS.d102.s0.e3" e2="DS.d102.s0.e1" id="DS.d102.s0.i0" interaction="False"/>
            <pair e1="DS.d102.s0.e3" e2="DS.d102.s0.e2" id="DS.d102.s0.i1" interaction="False"/>
            <pair e1="DS.d102.s0.e3" e2="DS.d102.s0.e0" id="DS.d102.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d103" origId="18378405">
        <sentence id="DS.d103.s0" origId="18378405-1044" text="Using a cell culture model of synaptic NMDA receptor-dependent synaptic potentiation, we find that this is mediated exclusively by NR2B-containing N-methyl-D-aspartate receptors, as implicated by NR2B-specific antagonists and the use of selective vs. non-selective doses of the NR2A-preferring antagonist NVP-AAM077.">
            <entity id="DS.d103.s0.e0" origId="P35439,Q9R1M7" charOffset="147-177" type="protein" text="N-methyl-D-aspartate receptors"/>
            <entity id="DS.d103.s0.e1" origId="4463" charOffset="305-308" type="compound" text="NVP"/>
            <pair e1="DS.d103.s0.e1" e2="DS.d103.s0.e0" id="DS.d103.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d104" origId="18379782">
        <sentence id="DS.d104.s0" origId="18379782-593" text="Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.">
            <entity id="DS.d104.s0.e0" origId="30623,71384" charOffset="0-11" type="compound" text="Dexrazoxane"/>
            <entity id="DS.d104.s0.e1" origId="P31750,Q8INB9" charOffset="81-84" type="protein" text="Akt"/>
            <pair e1="DS.d104.s0.e0" e2="DS.d104.s0.e1" id="DS.d104.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d105" origId="18380536">
        <sentence id="DS.d105.s0" origId="18380536-252" text="Intracellular oxidative status was assessed by analysis of GSH/GSSG levels and time course of ROS production and glutathione reductase (GR) activity.">
            <entity id="DS.d105.s0.e0" origId="124886" charOffset="59-62" type="compound" text="GSH"/>
            <entity id="DS.d105.s0.e1" origId="65359" charOffset="63-67" type="compound" text="GSSG"/>
            <entity id="DS.d105.s0.e2" origId="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655" charOffset="113-134" type="protein" text="glutathione reductase"/>
            <pair e1="DS.d105.s0.e0" e2="DS.d105.s0.e2" id="DS.d105.s0.i0" interaction="False"/>
            <pair e1="DS.d105.s0.e1" e2="DS.d105.s0.e2" id="DS.d105.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d106" origId="18380539">
        <sentence id="DS.d106.s0" origId="18380539-1099" text="A recently discussed cardiovascular risk factor, asymmetric dimethylarginine (ADMA), is known to act as an endogenous inhibitor of endothelial nitric oxide synthase.">
            <entity id="DS.d106.s0.e0" origId="123831" charOffset="49-76" type="compound" text="asymmetric dimethylarginine"/>
            <entity id="DS.d106.s0.e1" origId="123831" charOffset="78-82" type="compound" text="ADMA"/>
            <entity id="DS.d106.s0.e2" origId="O61309,O61608,Q27571,Q9I9M2" charOffset="143-164" type="protein" text="nitric oxide synthase"/>
            <pair e1="DS.d106.s0.e1" e2="DS.d106.s0.e2" id="DS.d106.s0.i0" interaction="True"/>
            <pair e1="DS.d106.s0.e0" e2="DS.d106.s0.e2" id="DS.d106.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d107" origId="18380542">
        <sentence id="DS.d107.s0" origId="18380542-1100" text="The net exercise-induced increase in 6-keto-PGF (1alpha) concentration, expressed as the difference between the end-exercise minus pre-exercise concentration positively correlated with VO(2max) (r=0.78, p=0.004) as well as with the net VO(2) increase at exhaustion (r=0.81, p=0.003), but not with other respiratory, cardiac, metabolic or inflammatory parameters of the exercise (minute ventilation, heart rate, plasma lactate, IL-6 or TNF-alpha concentrations).">
            <entity id="DS.d107.s0.e0" origId="P49763,Q9XS47" charOffset="44-47" type="protein" text="PGF"/>
            <entity id="DS.d107.s0.e1" origId="612" charOffset="418-425" type="compound" text="lactate"/>
            <entity id="DS.d107.s0.e2" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="427-431" type="protein" text="IL-6"/>
            <entity id="DS.d107.s0.e3" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="435-444" type="protein" text="TNF-alpha"/>
            <pair e1="DS.d107.s0.e1" e2="DS.d107.s0.e3" id="DS.d107.s0.i0" interaction="False"/>
            <pair e1="DS.d107.s0.e1" e2="DS.d107.s0.e2" id="DS.d107.s0.i1" interaction="False"/>
            <pair e1="DS.d107.s0.e1" e2="DS.d107.s0.e0" id="DS.d107.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d108" origId="18380545">
        <sentence id="DS.d108.s0" origId="18380545-1104" text="Adenosine A(3) receptor agonist N(6)-(3-iodobenzyl) adenosine-5 '-N-methyluronamide (IB-MECA) has been tested from the point of view of potentiating the effects of hematopoietic growth factors interleukin-3 (IL-3), stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and granulocyte colony-stimulating factor (G-CSF) on the growth of hematopoietic progenitor cells for granulocytes and macrophages (GM-CFC) in suspension of normal mouse bone marrow cells in vitro.">
            <entity id="DS.d108.s0.e0" origId="123683" charOffset="85-92" type="compound" text="IB-MECA"/>
            <entity id="DS.d108.s0.e1" origId="P01586,P04823,P06740,P08700,P25140,P49875,P51445,Q06435,Q28334,Q28809,Q9BDX4" charOffset="164-192" type="protein" text="hematopoietic growth factors"/>
            <entity id="DS.d108.s0.e2" origId="P01586,P04823,P06740,P08700,P25140,P49875,P51445,Q06435,Q28334,Q28809,Q9BDX4" charOffset="208-212" type="protein" text="IL-3"/>
            <entity id="DS.d108.s0.e3" origId="P20826,P21581,P21583,P79169,P79368,Q06220,Q09108,Q28132,Q29030,Q90314,Q95M19,Q95MD2,Q95N18" charOffset="215-231" type="protein" text="stem cell factor"/>
            <entity id="DS.d108.s0.e4" origId="P20826,P21581,P21583,P79169,P79368,Q06220,Q09108,Q28132,Q29030,Q90314,Q95M19,Q95MD2,Q95N18" charOffset="233-236" type="protein" text="SCF"/>
            <entity id="DS.d108.s0.e5" origId="P48750" charOffset="239-287" type="protein" text="granulocyte-macrophage colony-stimulating factor"/>
            <entity id="DS.d108.s0.e6" origId="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481" charOffset="289-295" type="protein" text="GM-CSF"/>
            <entity id="DS.d108.s0.e7" origId="P35834,Q28746" charOffset="302-339" type="protein" text="granulocyte colony-stimulating factor"/>
            <entity id="DS.d108.s0.e8" origId="O02708,O02837,P09919,P09920,P35833,P35834,Q28746" charOffset="341-346" type="protein" text="G-CSF"/>
            <pair e1="DS.d108.s0.e0" e2="DS.d108.s0.e5" id="DS.d108.s0.i0" interaction="False"/>
            <pair e1="DS.d108.s0.e0" e2="DS.d108.s0.e1" id="DS.d108.s0.i1" interaction="False"/>
            <pair e1="DS.d108.s0.e0" e2="DS.d108.s0.e8" id="DS.d108.s0.i2" interaction="False"/>
            <pair e1="DS.d108.s0.e0" e2="DS.d108.s0.e7" id="DS.d108.s0.i3" interaction="False"/>
            <pair e1="DS.d108.s0.e0" e2="DS.d108.s0.e2" id="DS.d108.s0.i4" interaction="False"/>
            <pair e1="DS.d108.s0.e0" e2="DS.d108.s0.e4" id="DS.d108.s0.i5" interaction="False"/>
            <pair e1="DS.d108.s0.e0" e2="DS.d108.s0.e3" id="DS.d108.s0.i6" interaction="False"/>
            <pair e1="DS.d108.s0.e0" e2="DS.d108.s0.e6" id="DS.d108.s0.i7" interaction="False"/>
        </sentence>
        <sentence id="DS.d108.s1" origId="18380545-1105" text="Significant elevation of numbers of GM-CFC evoked by the combinations of IB-MECA with IL-3, SCF, or GM-CSF as compared with these growth factors alone has been noted.">
            <entity id="DS.d108.s1.e0" origId="123683" charOffset="73-80" type="compound" text="IB-MECA"/>
            <entity id="DS.d108.s1.e1" origId="P01586,P04823,P06740,P08700,P25140,P49875,P51445,Q06435,Q28334,Q28809,Q9BDX4" charOffset="86-90" type="protein" text="IL-3"/>
            <entity id="DS.d108.s1.e2" origId="P20826,P21581,P21583,P79169,P79368,Q06220,Q09108,Q28132,Q29030,Q90314,Q95M19,Q95MD2,Q95N18" charOffset="92-95" type="protein" text="SCF"/>
            <pair e1="DS.d108.s1.e0" e2="DS.d108.s1.e2" id="DS.d108.s1.i0" interaction="False"/>
            <pair e1="DS.d108.s1.e0" e2="DS.d108.s1.e1" id="DS.d108.s1.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d108.s2" origId="18380545-1106" text="Combination of IB-MECA with G-CSF did not induce significantly higher numbers of GM-CFC in comparison with G-CSF alone.">
            <entity id="DS.d108.s2.e0" origId="123683" charOffset="15-22" type="compound" text="IB-MECA"/>
            <entity id="DS.d108.s2.e1" origId="O02708,O02837,P09919,P09920,P35833,P35834,Q28746" charOffset="28-33" type="protein" text="G-CSF"/>
            <entity id="DS.d108.s2.e2" origId="O02708,O02837,P09919,P09920,P35833,P35834,Q28746" charOffset="107-112" type="protein" text="G-CSF"/>
            <pair e1="DS.d108.s2.e0" e2="DS.d108.s2.e1" id="DS.d108.s2.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d108.s3" origId="18380545-1107" text="Joint action of three drugs, namely of IB-MECA+ IL-3+ GM-CSF, produced significantly higher numbers of GM-CFC in comparison with the combinations of IB-MECA+ IL-3, IB-MECA+ GM-CSF, or IL-3+ GM-CSF.">
            <entity id="DS.d108.s3.e0" origId="123683" charOffset="39-46" type="compound" text="IB-MECA"/>
            <entity id="DS.d108.s3.e1" origId="P01586,P04823,P06740,P08700,P25140,P49875,P51445,Q06435,Q28334,Q28809,Q9BDX4" charOffset="48-52" type="protein" text="IL-3"/>
            <entity id="DS.d108.s3.e2" origId="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481" charOffset="54-60" type="protein" text="GM-CSF"/>
            <entity id="DS.d108.s3.e3" origId="123683" charOffset="149-156" type="compound" text="IB-MECA"/>
            <entity id="DS.d108.s3.e4" origId="P01586,P04823,P06740,P08700,P25140,P49875,P51445,Q06435,Q28334,Q28809,Q9BDX4" charOffset="158-162" type="protein" text="IL-3"/>
            <entity id="DS.d108.s3.e5" origId="123683" charOffset="149-156" type="compound" text="IB-MECA"/>
            <entity id="DS.d108.s3.e6" origId="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481" charOffset="173-179" type="protein" text="GM-CSF"/>
            <entity id="DS.d108.s3.e7" origId="P01586,P04823,P06740,P08700,P25140,P49875,P51445,Q06435,Q28334,Q28809,Q9BDX4" charOffset="158-162" type="protein" text="IL-3"/>
            <entity id="DS.d108.s3.e8" origId="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481" charOffset="173-179" type="protein" text="GM-CSF"/>
            <pair e1="DS.d108.s3.e0" e2="DS.d108.s3.e2" id="DS.d108.s3.i0" interaction="False"/>
            <pair e1="DS.d108.s3.e0" e2="DS.d108.s3.e1" id="DS.d108.s3.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d109" origId="18381637">
        <sentence id="DS.d109.s0" origId="18381637-476" text="Rabbit marrow mesenchymal stem cells (MSCs) and gelatin microparticles (MPs) loaded with insulin-like growth factor-1 (IGF-1), transforming growth factor-beta1 (TGF-beta1), or a combination of both growth factors were mixed with OPF, a poly(ethylene glycol)-diacrylate crosslinker and the radical initiators ammonium persulfate and N,N,N',N'-tetramethylethylenediamine, and then crosslinked at 37 degrees C for 8 min to form hydrogel composites.">
            <entity id="DS.d109.s0.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="89-96" type="protein" text="insulin"/>
            <entity id="DS.d109.s0.e1" origId="Q95222" charOffset="119-124" type="protein" text="IGF-1"/>
            <entity id="DS.d109.s0.e2" origId="O19011,O93449,P01137,P04202,P07200,P09531,P09533,P16176,P17246,P18341,P50414,P54831,Q38HS2,Q9PTQ2,Q9Z1Y6" charOffset="161-170" type="protein" text="TGF-beta1"/>
            <entity id="DS.d109.s0.e3" origId="16212859" charOffset="236-268" type="compound" text="poly(ethylene glycol)-diacrylate"/>
            <entity id="DS.d109.s0.e4" origId="8037" charOffset="332-368" type="compound" text="N,N,N',N'-tetramethylethylenediamine"/>
            <pair e1="DS.d109.s0.e4" e2="DS.d109.s0.e2" id="DS.d109.s0.i0" interaction="False"/>
            <pair e1="DS.d109.s0.e4" e2="DS.d109.s0.e1" id="DS.d109.s0.i1" interaction="False"/>
            <pair e1="DS.d109.s0.e3" e2="DS.d109.s0.e2" id="DS.d109.s0.i2" interaction="False"/>
            <pair e1="DS.d109.s0.e4" e2="DS.d109.s0.e0" id="DS.d109.s0.i3" interaction="False"/>
            <pair e1="DS.d109.s0.e3" e2="DS.d109.s0.e1" id="DS.d109.s0.i4" interaction="False"/>
            <pair e1="DS.d109.s0.e3" e2="DS.d109.s0.e0" id="DS.d109.s0.i5" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d110" origId="18381638">
        <sentence id="DS.d110.s0" origId="18381638-477" text="Fibronectin modulates osteoblast behavior on Nitinol.">
            <entity id="DS.d110.s0.e0" origId="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400" charOffset="0-11" type="protein" text="Fibronectin"/>
            <entity id="DS.d110.s0.e1" origId="3081502" charOffset="45-52" type="compound" text="Nitinol"/>
            <pair e1="DS.d110.s0.e1" e2="DS.d110.s0.e0" id="DS.d110.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d111" origId="18384163">
        <sentence id="DS.d111.s0" origId="18384163-783" text="Real-time RT-PCR showed that the expression of osteoblast marker genes such as CBFalpha1 and alkaline phosphatase was increased in hyaluronic acid-based hydrogel, and the expression level was dependent on the molecular weight of hyaluronic acid, RGD peptide, and BMP-2.">
            <entity id="DS.d111.s0.e0" origId="Q08775,Q13950,Q9XSB7,Q9Z2J9" charOffset="79-88" type="protein" text="CBFalpha1"/>
            <entity id="DS.d111.s0.e1" origId="O60109,P81800,P83456" charOffset="93-113" type="protein" text="alkaline phosphatase"/>
            <entity id="DS.d111.s0.e2" origId="24759,453618,3084050,24728612" charOffset="131-146" type="compound" text="hyaluronic acid"/>
            <entity id="DS.d111.s0.e3" origId="24759,453618,3084050,24728612" charOffset="229-244" type="compound" text="hyaluronic acid"/>
            <entity id="DS.d111.s0.e4" origId="104802" charOffset="246-257" type="compound" text="RGD peptide"/>
            <entity id="DS.d111.s0.e5" origId="O19006,O46564,P12643,P21274,P49001,Q804S2,Q90751" charOffset="263-268" type="protein" text="BMP-2"/>
            <pair e1="DS.d111.s0.e4" e2="DS.d111.s0.e1" id="DS.d111.s0.i0" interaction="True"/>
            <pair e1="DS.d111.s0.e4" e2="DS.d111.s0.e5" id="DS.d111.s0.i1" interaction="False"/>
            <pair e1="DS.d111.s0.e2" e2="DS.d111.s0.e1" id="DS.d111.s0.i2" interaction="True"/>
            <pair e1="DS.d111.s0.e4" e2="DS.d111.s0.e0" id="DS.d111.s0.i3" interaction="True"/>
            <pair e1="DS.d111.s0.e2" e2="DS.d111.s0.e5" id="DS.d111.s0.i4" interaction="False"/>
            <pair e1="DS.d111.s0.e2" e2="DS.d111.s0.e0" id="DS.d111.s0.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d112" origId="18386138">
        <sentence id="DS.d112.s0" origId="18386138-732" text="Treatment of H9c2 cell with low concentrations of Dox causes alterations in fibrous structural proteins including the nuclear lamina and sarcomeric cardiac myosin, as well as mitochondrial depolarization and fragmentation, membrane blebbing with cell shape changes, and phosphatidylserine externalization.">
            <entity id="DS.d112.s0.e0" origId="Q04765,Q04766" charOffset="84-103" type="protein" text="structural proteins"/>
            <entity id="DS.d112.s0.e1" origId="445141,6323481,44147587" charOffset="270-288" type="compound" text="phosphatidylserine"/>
            <pair e1="DS.d112.s0.e1" e2="DS.d112.s0.e0" id="DS.d112.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d113" origId="18387753">
        <sentence id="DS.d113.s0" origId="18387753-460" text="We monitored bcr-abl transcript levels by quantitative real time PCR in 50 tunisian patients treated with imatinib for chronic myeloid leukemia in chronic phase for a median of 29 months (3-60) after they started imatinib.">
            <entity id="DS.d113.s0.e0" origId="P28246,P45123" charOffset="13-16" type="protein" text="bcr"/>
            <entity id="DS.d113.s0.e1" origId="P00520,P00522" charOffset="17-20" type="protein" text="abl"/>
            <entity id="DS.d113.s0.e2" origId="5291" charOffset="106-114" type="compound" text="imatinib"/>
            <entity id="DS.d113.s0.e3" origId="5291" charOffset="213-221" type="compound" text="imatinib"/>
            <pair e1="DS.d113.s0.e2" e2="DS.d113.s0.e1" id="DS.d113.s0.i0" interaction="False"/>
            <pair e1="DS.d113.s0.e2" e2="DS.d113.s0.e0" id="DS.d113.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d114" origId="18389169">
        <sentence id="DS.d114.s0" origId="18389169-121" text="The non-covalent interaction of brilliant red (BR) with lysozyme was investigated by the UV spectrometry, circular dichroism (CD) and isothermal titration calorimetry (ITC).">
            <entity id="DS.d114.s0.e0" origId="5483782,6085493" charOffset="32-45" type="compound" text="brilliant red"/>
            <entity id="DS.d114.s0.e1" origId="O64362,O80288,O80292,P00720,P03706,P07540,P09963,P10439,P11187,P13656,P15057,P19385,P19386,P21270,P23472,P23473,P27359,P33486,P37715,P39046,P51771,P62692,P62693,P68920,P68921,P81241,P82174,P82175,P83673,Q27650,Q37875,Q37896,Q48603,Q7SID7,Q9CIT4,Q9T1X2,Q9ZXB7" charOffset="56-64" type="protein" text="lysozyme"/>
            <pair e1="DS.d114.s0.e0" e2="DS.d114.s0.e1" id="DS.d114.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d115" origId="18390571">
        <sentence id="DS.d115.s0" origId="18390571-968" text="Recent studies suggest that crystals of monosodium urate (MSU), deposited in joints of patients with acute gouty arthritis, activate the NACHT domain, leucine-rich repeat and pyrin domain-containing protein (NALP)3 inflammasome.">
            <entity id="DS.d115.s0.e0" origId="1175" charOffset="40-56" type="compound" text="monosodium urate"/>
            <entity id="DS.d115.s0.e1" origId="857,6106,439524" charOffset="151-158" type="compound" text="leucine"/>
            <entity id="DS.d115.s0.e2" origId="O15553,Q9JJ25,Q9JJ26" charOffset="175-180" type="protein" text="pyrin"/>
            <pair e1="DS.d115.s0.e1" e2="DS.d115.s0.e2" id="DS.d115.s0.i0" interaction="False"/>
            <pair e1="DS.d115.s0.e0" e2="DS.d115.s0.e2" id="DS.d115.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d116" origId="18393628">
        <sentence id="DS.d116.s0" origId="18393628-298" text="Nicotine, muscarine, and chlorpyrifos induced the phosphorylation of extracellular signal-regulated kinases 1 and 2.">
            <entity id="DS.d116.s0.e0" origId="942,89594,157672" charOffset="0-8" type="compound" text="Nicotine"/>
            <entity id="DS.d116.s0.e1" origId="9308" charOffset="10-19" type="compound" text="muscarine"/>
            <entity id="DS.d116.s0.e2" origId="2730" charOffset="25-37" type="compound" text="chlorpyrifos"/>
            <entity id="DS.d116.s0.e3" origId="P21708,P27361,P28869,P42525,Q63844" charOffset="69-109" type="protein" text="extracellular signal-regulated kinases 1"/>
            <pair e1="DS.d116.s0.e1" e2="DS.d116.s0.e3" id="DS.d116.s0.i0" interaction="True"/>
            <pair e1="DS.d116.s0.e2" e2="DS.d116.s0.e3" id="DS.d116.s0.i1" interaction="True"/>
            <pair e1="DS.d116.s0.e0" e2="DS.d116.s0.e3" id="DS.d116.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d117" origId="18393672">
        <sentence id="DS.d117.s0" origId="18393672-326" text="Adult bone marrow (BM)-derived insulin-producing cells (IPCs) are capable of regulating blood glucose levels in chemically induced hyperglycemic mice.">
            <entity id="DS.d117.s0.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="31-38" type="protein" text="insulin"/>
            <entity id="DS.d117.s0.e1" origId="206,5793,64689,79025" charOffset="94-101" type="compound" text="glucose"/>
            <pair e1="DS.d117.s0.e1" e2="DS.d117.s0.e0" id="DS.d117.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d117.s1" origId="18393672-328" text="Treatment with benfotiamine activated glucose metabolism in INS-1 cells in high-glucose culture conditions, and appeared to maximize the BM-derived IPCs ability to synthesize insulin.">
            <entity id="DS.d117.s1.e0" origId="3032771" charOffset="15-27" type="compound" text="benfotiamine"/>
            <entity id="DS.d117.s1.e1" origId="206,5793,64689,79025" charOffset="38-45" type="compound" text="glucose"/>
            <entity id="DS.d117.s1.e2" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="175-182" type="protein" text="insulin"/>
            <pair e1="DS.d117.s1.e0" e2="DS.d117.s1.e2" id="DS.d117.s1.i0" interaction="True"/>
            <pair e1="DS.d117.s1.e1" e2="DS.d117.s1.e2" id="DS.d117.s1.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d117.s2" origId="18393672-329" text="Benfotiamine was not shown to induce the glucose receptor Glut-2, however it was shown to activate glucokinase, the enzyme responsible for conversion of glucose to glucose-6-phosphate.">
            <entity id="DS.d117.s2.e0" origId="3032771" charOffset="0-12" type="compound" text="Benfotiamine"/>
            <entity id="DS.d117.s2.e1" origId="P12336,P14246" charOffset="58-64" type="protein" text="Glut-2"/>
            <entity id="DS.d117.s2.e2" origId="O25731,P0A4E1,P0A4E2,P0A6V8,P0A6V9,P17712,P21908,P35557,P52792,P54495,P58616,P58617,P58618,P58619,P64253,P64254,P82680,Q55855,Q56198,Q59171,Q668N7,Q6D7C4,Q7N6Y0,Q83K86,Q87EG6,Q8FFD4,Q8FV09,Q8P8U7,Q8PKU2,Q8UIV7,Q8YDC6,Q92407,Q92T27,Q93IM5,Q98DM2,Q9A6N3,Q9HZ46,Q9KCZ4,Q9PEG4,Q9ZKB0" charOffset="99-110" type="protein" text="glucokinase"/>
            <entity id="DS.d117.s2.e3" origId="5958,439284,439427,439958" charOffset="164-183" type="compound" text="glucose-6-phosphate"/>
            <pair e1="DS.d117.s2.e3" e2="DS.d117.s2.e2" id="DS.d117.s2.i0" interaction="True"/>
            <pair e1="DS.d117.s2.e3" e2="DS.d117.s2.e1" id="DS.d117.s2.i1" interaction="False"/>
            <pair e1="DS.d117.s2.e0" e2="DS.d117.s2.e2" id="DS.d117.s2.i2" interaction="True"/>
            <pair e1="DS.d117.s2.e0" e2="DS.d117.s2.e1" id="DS.d117.s2.i3" interaction="False"/>
        </sentence>
        <sentence id="DS.d117.s3" origId="18393672-330" text="However, in cells where the pentose phosphate pathway was blocked by oxythiamine treatment, there was a clear downregulation of Glut-2, glucokinase, insulin, and GAPDH.">
            <entity id="DS.d117.s3.e0" origId="8682" charOffset="69-80" type="compound" text="oxythiamine"/>
            <entity id="DS.d117.s3.e1" origId="P12336,P14246" charOffset="128-134" type="protein" text="Glut-2"/>
            <entity id="DS.d117.s3.e2" origId="O25731,P0A4E1,P0A4E2,P0A6V8,P0A6V9,P17712,P21908,P35557,P52792,P54495,P58616,P58617,P58618,P58619,P64253,P64254,P82680,Q55855,Q56198,Q59171,Q668N7,Q6D7C4,Q7N6Y0,Q83K86,Q87EG6,Q8FFD4,Q8FV09,Q8P8U7,Q8PKU2,Q8UIV7,Q8YDC6,Q92407,Q92T27,Q93IM5,Q98DM2,Q9A6N3,Q9HZ46,Q9KCZ4,Q9PEG4,Q9ZKB0" charOffset="136-147" type="protein" text="glucokinase"/>
            <entity id="DS.d117.s3.e3" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="149-156" type="protein" text="insulin"/>
            <entity id="DS.d117.s3.e4" origId="O01360,O13507,O27090,O28542,O32755,O34425,O42259,O52631,O57479,O57672,O59494,O59841,O67161,O83816,O96423,P00355,P00356,P00357,P00361,P00362,P04406,P04797,P08439,P09124,P09316,P09317,P0A1P0,P0A1P1,P0C0G6,P0C0G7,P10096,P10097,P10618,P15115,P16858,P17244,P17721,P19089,P19314,P19315,P20287,P20445,P22512,P22513,P23722,P24163,P24164,P24166,P24746,P24748,P24749,P24750,P24751,P24753,P25861,P26518,P26519,P26520,P26521,P26988,P27726,P28844,P29272,P29497,P32637,P32638,P34783,P35143,P39460,P44304,P46406,P46713,P46795,P46796,P47543,P48812,P51009,P51469,P51640,P52694,P52987,P53429,P53430,P54117,P54118,P54226,P55070,P55071,P55971,P56649,P57384,P58839,P61879,P61880,P64178,P64179,P68777,P70685,P75358,P80447,P80534,P83601,P87197,P94915,Q00301,Q00584,Q00640,Q01558,Q01597,Q01651,Q01982,Q05025,Q07234,Q12552,Q1DTF9,Q27652,Q27890,Q28259,Q28554,Q2NEN0,Q3IUT3,Q46450,Q48335,Q4J940,Q4KYY3,Q58546,Q59199,Q59309,Q59800,Q59906,Q5JHB5,Q5R2J2,Q5RAB4,Q5V061,Q5XDW3,Q6BMK0,Q6CCU7,Q6L125,Q6M0E6,Q757I2,Q89AK1,Q8J1H3,Q8K8M9,Q8NK47,Q8PTD3,Q8TFJ2,Q8WZN0,Q8X1X3,Q8ZWK7,Q92211,Q92243,Q92263,Q94469,Q96US8,Q971K2,Q97BJ8,Q9HFX1,Q9HGY7,Q9HJ69,Q9HSS7,Q9N2D5,Q9N655,Q9P8C0,Q9PJN6,Q9UR38,Q9UVC0,Q9UW96,Q9V1P1,Q9Y796,Q9Y8E9,Q9YFS9,Q9Z518,Q9Z7T0,Q9ZKT0" charOffset="162-167" type="protein" text="GAPDH"/>
            <pair e1="DS.d117.s3.e0" e2="DS.d117.s3.e4" id="DS.d117.s3.i0" interaction="True"/>
            <pair e1="DS.d117.s3.e0" e2="DS.d117.s3.e2" id="DS.d117.s3.i1" interaction="True"/>
            <pair e1="DS.d117.s3.e0" e2="DS.d117.s3.e3" id="DS.d117.s3.i2" interaction="True"/>
            <pair e1="DS.d117.s3.e0" e2="DS.d117.s3.e1" id="DS.d117.s3.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d118" origId="18394828">
        <sentence id="DS.d118.s0" origId="18394828-1061" text=") and two oxygen tensions (5 and 20%) were compared for their ability to sustain blastocyst survival and IFNT production from days 8 to 11 post-insemination.">
            <entity id="DS.d118.s0.e0" origId="977" charOffset="10-16" type="compound" text="oxygen"/>
            <entity id="DS.d118.s0.e1" origId="O46633,P28171,P28172,Q95187" charOffset="105-109" type="protein" text="IFNT"/>
            <pair e1="DS.d118.s0.e0" e2="DS.d118.s0.e1" id="DS.d118.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d118.s1" origId="18394828-1062" text="In conclusion, culturing blastocysts of cattle in a 5% oxygen environment with M199 containing serum sustains embryo viability and permits constitutive and inducible IFNT production.">
            <entity id="DS.d118.s1.e0" origId="977" charOffset="55-61" type="compound" text="oxygen"/>
            <entity id="DS.d118.s1.e1" origId="O46633,P28171,P28172,Q95187" charOffset="166-170" type="protein" text="IFNT"/>
            <pair e1="DS.d118.s1.e0" e2="DS.d118.s1.e1" id="DS.d118.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d118.s2" origId="18394828-1063" text="Incubation in 20% oxygen increases IFNT production.">
            <entity id="DS.d118.s2.e0" origId="977" charOffset="18-24" type="compound" text="oxygen"/>
            <entity id="DS.d118.s2.e1" origId="O46633,P28171,P28172,Q95187" charOffset="35-39" type="protein" text="IFNT"/>
            <pair e1="DS.d118.s2.e0" e2="DS.d118.s2.e1" id="DS.d118.s2.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d119" origId="18395421">
        <sentence id="DS.d119.s0" origId="18395421-172" text="Histologic examination investigated deposition of extracellular matrix (ECM) including collagen, elastin, hyaluronic acid (HA), fibronectin, and decorin in the lamina propria of the scarred vocal folds.">
            <entity id="DS.d119.s0.e0" origId="Q13201" charOffset="72-75" type="protein" text="ECM"/>
            <entity id="DS.d119.s0.e1" origId="P11547" charOffset="97-104" type="protein" text="elastin"/>
            <entity id="DS.d119.s0.e2" origId="24759,453618,3084050,24728612" charOffset="106-121" type="compound" text="hyaluronic acid"/>
            <entity id="DS.d119.s0.e3" origId="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400" charOffset="128-139" type="protein" text="fibronectin"/>
            <pair e1="DS.d119.s0.e2" e2="DS.d119.s0.e3" id="DS.d119.s0.i0" interaction="False"/>
            <pair e1="DS.d119.s0.e2" e2="DS.d119.s0.e1" id="DS.d119.s0.i1" interaction="False"/>
            <pair e1="DS.d119.s0.e2" e2="DS.d119.s0.e0" id="DS.d119.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d120" origId="18396353">
        <sentence id="DS.d120.s0" origId="18396353-715" text="A series of novel bis-pyridinium oximes connected by bis-methoxymethyl benzene, 1,4-bis-methoxymethyl (cis)-but-2-ene and 1,4-bis-methoxymethyl but-2-yne linkers were synthesized and their in vitro reactivation efficacy was evaluated against diisopropyl phosphorofluoridate (DFP) inhibited acetylcholinesterase (AChE) and compared with the established antidote 2-PAM and obidoxime.">
            <entity id="DS.d120.s0.e0" origId="10869" charOffset="57-78" type="compound" text="methoxymethyl benzene"/>
            <entity id="DS.d120.s0.e1" origId="5936" charOffset="242-273" type="compound" text="diisopropyl phosphorofluoridate"/>
            <entity id="DS.d120.s0.e2" origId="Q867X2,Q867X3,Q86GC9,Q92081" charOffset="290-310" type="protein" text="acetylcholinesterase"/>
            <entity id="DS.d120.s0.e3" origId="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3" charOffset="312-316" type="protein" text="AChE"/>
            <entity id="DS.d120.s0.e4" origId="107688" charOffset="371-380" type="compound" text="obidoxime"/>
            <pair e1="DS.d120.s0.e0" e2="DS.d120.s0.e2" id="DS.d120.s0.i0" interaction="False"/>
            <pair e1="DS.d120.s0.e0" e2="DS.d120.s0.e3" id="DS.d120.s0.i1" interaction="False"/>
            <pair e1="DS.d120.s0.e1" e2="DS.d120.s0.e3" id="DS.d120.s0.i2" interaction="False"/>
            <pair e1="DS.d120.s0.e4" e2="DS.d120.s0.e2" id="DS.d120.s0.i3" interaction="False"/>
            <pair e1="DS.d120.s0.e4" e2="DS.d120.s0.e3" id="DS.d120.s0.i4" interaction="False"/>
            <pair e1="DS.d120.s0.e1" e2="DS.d120.s0.e2" id="DS.d120.s0.i5" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d121" origId="18396355">
        <sentence id="DS.d121.s0" origId="18396355-716" text="In-vitro regeneration of sarin inhibited electric eel acetylcholinesterase by bis-pyridinium oximes bearing xylene linker.">
            <entity id="DS.d121.s0.e0" origId="7871" charOffset="25-30" type="compound" text="sarin"/>
            <entity id="DS.d121.s0.e1" origId="Q867X2,Q867X3,Q86GC9,Q92081" charOffset="54-74" type="protein" text="acetylcholinesterase"/>
            <entity id="DS.d121.s0.e2" origId="7237" charOffset="108-114" type="compound" text="xylene"/>
            <pair e1="DS.d121.s0.e0" e2="DS.d121.s0.e1" id="DS.d121.s0.i0" interaction="True"/>
            <pair e1="DS.d121.s0.e2" e2="DS.d121.s0.e1" id="DS.d121.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d121.s1" origId="18396355-717" text="A series of bis-pyridinium oximes connected by xylene linker were synthesized and their in-vitro reactivation potential was evaluated against acetylcholinesterase (AChE) inhibited by nerve agent, sarin.">
            <entity id="DS.d121.s1.e0" origId="7237" charOffset="47-53" type="compound" text="xylene"/>
            <entity id="DS.d121.s1.e1" origId="Q867X2,Q867X3,Q86GC9,Q92081" charOffset="142-162" type="protein" text="acetylcholinesterase"/>
            <entity id="DS.d121.s1.e2" origId="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3" charOffset="164-168" type="protein" text="AChE"/>
            <entity id="DS.d121.s1.e3" origId="7871" charOffset="196-201" type="compound" text="sarin"/>
            <pair e1="DS.d121.s1.e0" e2="DS.d121.s1.e1" id="DS.d121.s1.i0" interaction="False"/>
            <pair e1="DS.d121.s1.e3" e2="DS.d121.s1.e1" id="DS.d121.s1.i1" interaction="False"/>
            <pair e1="DS.d121.s1.e0" e2="DS.d121.s1.e2" id="DS.d121.s1.i2" interaction="False"/>
            <pair e1="DS.d121.s1.e3" e2="DS.d121.s1.e2" id="DS.d121.s1.i3" interaction="False"/>
        </sentence>
        <sentence id="DS.d121.s2" origId="18396355-718" text="Among the synthesized compounds, alpha,alpha'xylene-bis-(3,3'-(hydroxyiminomethyl) pyridinium) dibromide (3b) was found to be most potent reactivator for AChE inhibited by sarin.">
            <entity id="DS.d121.s2.e0" origId="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3" charOffset="154-158" type="protein" text="AChE"/>
            <entity id="DS.d121.s2.e1" origId="7871" charOffset="172-177" type="compound" text="sarin"/>
            <pair e1="DS.d121.s2.e1" e2="DS.d121.s2.e0" id="DS.d121.s2.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d122" origId="18396356">
        <sentence id="DS.d122.s0" origId="18396356-720" text="Of the compounds synthesized, compound 2a, which has a primary amide at warhead region of the inhibitor most potently inhibited mu-calpain with an IC(50) value of 2.81+/-1.26 microM, which is ca.">
            <entity id="DS.d122.s0.e0" origId="398803" charOffset="30-41" type="compound" text="compound 2a"/>
            <entity id="DS.d122.s0.e1" origId="P27730" charOffset="131-138" type="protein" text="calpain"/>
            <pair e1="DS.d122.s0.e0" e2="DS.d122.s0.e1" id="DS.d122.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d123" origId="18397836">
        <sentence id="DS.d123.s0" origId="18397836-365" text="Recent studies have focused on possible functional disorders of the enteric nervous system within the abomasal wall, since cattle with abomasal displacement have an increased activity of neuronal nitric oxide synthase, as well as decreased acetylcholine sensitivity.">
            <entity id="DS.d123.s0.e0" origId="O61309,O61608,Q27571,Q9I9M2" charOffset="196-217" type="protein" text="nitric oxide synthase"/>
            <entity id="DS.d123.s0.e1" origId="187" charOffset="240-253" type="compound" text="acetylcholine"/>
            <pair e1="DS.d123.s0.e1" e2="DS.d123.s0.e0" id="DS.d123.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d124" origId="18397960">
        <sentence id="DS.d124.s0" origId="18397960-447" text="Earlier publications have suggested a possible role for the efflux transporter breast cancer resistance protein (BCRP) in acquired resistance to disease-modifying antirheumatic drugs (DMARDs) such as leflunomide and its metabolite A771726 (teriflunomide).">
            <entity id="DS.d124.s0.e0" origId="Q9UNQ0" charOffset="79-111" type="protein" text="breast cancer resistance protein"/>
            <entity id="DS.d124.s0.e1" origId="Q9UNQ0" charOffset="113-117" type="protein" text="BCRP"/>
            <entity id="DS.d124.s0.e2" origId="3899" charOffset="200-211" type="compound" text="leflunomide"/>
            <entity id="DS.d124.s0.e3" origId="54684141" charOffset="231-238" type="compound" text="A771726"/>
            <entity id="DS.d124.s0.e4" origId="54684141" charOffset="240-253" type="compound" text="teriflunomide"/>
            <pair e1="DS.d124.s0.e4" e2="DS.d124.s0.e1" id="DS.d124.s0.i0" interaction="True"/>
            <pair e1="DS.d124.s0.e2" e2="DS.d124.s0.e1" id="DS.d124.s0.i1" interaction="True"/>
            <pair e1="DS.d124.s0.e3" e2="DS.d124.s0.e0" id="DS.d124.s0.i2" interaction="True"/>
            <pair e1="DS.d124.s0.e2" e2="DS.d124.s0.e0" id="DS.d124.s0.i3" interaction="True"/>
            <pair e1="DS.d124.s0.e4" e2="DS.d124.s0.e0" id="DS.d124.s0.i4" interaction="True"/>
            <pair e1="DS.d124.s0.e3" e2="DS.d124.s0.e1" id="DS.d124.s0.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d125" origId="18398609">
        <sentence id="DS.d125.s0" origId="18398609-866" text="Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine.">
            <entity id="DS.d125.s0.e0" origId="P0ABF6,P0ABF7,P19079,P32320,P44325,P47298,P47718,P56389,P75051,Q06549,Q322V3,Q32EM3,Q3IBX5,Q3Z062,Q4QK60,Q57MF5,Q5E4R6,Q5PE68,Q65RG8,Q66C79,Q6D3B4,Q6LRI0,Q7MK48,Q7N6K3,Q7VMJ6,Q87Q52,Q8DA31,Q8EDG1,Q8FFV3,Q8X648,Q8Z5A8,Q8ZG08,Q8ZNM0,Q9CP11,Q9KD53,Q9KSM5,Q9S3M0" charOffset="14-32" type="protein" text="cytidine deaminase"/>
            <entity id="DS.d125.s0.e1" origId="100016,328839,16760709,46783268" charOffset="36-46" type="compound" text="zebularine"/>
            <entity id="DS.d125.s0.e2" origId="451668" charOffset="85-107" type="compound" text="5-aza-2'-deoxycytidine"/>
            <pair e1="DS.d125.s0.e2" e2="DS.d125.s0.e0" id="DS.d125.s0.i0" interaction="False"/>
            <pair e1="DS.d125.s0.e1" e2="DS.d125.s0.e0" id="DS.d125.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d126" origId="18398611">
        <sentence id="DS.d126.s0" origId="18398611-867" text="An individual's response to fludarabine may be influenced by the amount of CD4 (+) and CD8(+) T-lymphocyte suppression.">
            <entity id="DS.d126.s0.e0" origId="657237" charOffset="28-39" type="compound" text="fludarabine"/>
            <entity id="DS.d126.s0.e1" origId="P01730,P05542,P16003,P16004,P33705,P46630,P79184,P79185,Q08336,Q08338,Q08339,Q08340,Q29037,Q9XS78" charOffset="75-78" type="protein" text="CD4"/>
            <pair e1="DS.d126.s0.e0" e2="DS.d126.s0.e1" id="DS.d126.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d127" origId="18398624">
        <sentence id="DS.d127.s0" origId="18398624-876" text="We hypothesise that arginine aspartate acts as a chemical or pharmacological chaperone, and suggest amino acid supplementation as a possible therapy in PDHA1 mutations with mild phenotypes.">
            <entity id="DS.d127.s0.e0" origId="24325" charOffset="20-38" type="compound" text="arginine aspartate"/>
            <entity id="DS.d127.s0.e1" origId="P08559,P29804,P49823,Q5R490,Q8HXW9" charOffset="152-157" type="protein" text="PDHA1"/>
            <pair e1="DS.d127.s0.e0" e2="DS.d127.s0.e1" id="DS.d127.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d128" origId="18400050">
        <sentence id="DS.d128.s0" origId="18400050-469" text="mRNA expressions of matrix metallopeptidase-9, inducible nitric oxide synthase and pro-inflammatory cytokines interleukin-1 beta and tumour necrosis factor-alpha in EAN sciatic nerves were greatly decreased by administration of minocycline as well.">
            <entity id="DS.d128.s0.e0" origId="O61309,O61608,Q27571,Q9I9M2" charOffset="57-78" type="protein" text="nitric oxide synthase"/>
            <entity id="DS.d128.s0.e1" origId="54675783" charOffset="228-239" type="compound" text="minocycline"/>
            <pair e1="DS.d128.s0.e1" e2="DS.d128.s0.e0" id="DS.d128.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d129" origId="18400404">
        <sentence id="DS.d129.s0" origId="18400404-699" text="Then the review evaluates the involvement of KARs activated by the endogenous agonist glutamate in the generation and propagation of epileptiform activity.">
            <entity id="DS.d129.s0.e0" origId="O70503,Q4R5G7,Q53GQ0,Q5E9H7,Q6P7R8" charOffset="45-49" type="protein" text="KARs"/>
            <entity id="DS.d129.s0.e1" origId="611,23327,33032" charOffset="86-95" type="compound" text="glutamate"/>
            <pair e1="DS.d129.s0.e1" e2="DS.d129.s0.e0" id="DS.d129.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d130" origId="18403016">
        <sentence id="DS.d130.s0" origId="18403016-272" text="Glutamate cysteine ligase (GCL), synthesizing gamma-glutamylcysteine from glutamate and cysteine, is the rate-limiting enzyme in glutathione (GSH) biosynthesis.">
            <entity id="DS.d130.s0.e0" origId="O68838,P0A6W9,P0A6X0,P32477,P57485,P58994,P61379,Q09768,Q20117,Q57KV3,Q5E7F8,Q5LYY5,Q5M3J8,Q5PF10,Q65RX0,Q66E64,Q6ANW2,Q6D1T4,Q6LMV1,Q71VZ1,Q72RD4,Q7MHS5,Q7N7A4,Q7W3F2,Q7WES2,Q82ZG8,Q87LS2,Q88AR1,Q88R90,Q88UW5,Q89AD8,Q8D2V5,Q8DC38,Q8DW15,Q8DXM9,Q8E399,Q8EBF9,Q8F4D5,Q8X0X0,Q8X900,Q8XK30,Q8Y3R3,Q8Z4D6,Q8ZBU2,Q926X7,Q97IV1,Q9CM00,Q9HF78,Q9HTY6,Q9KUG5,Q9NFN6,Q9W3K5" charOffset="0-25" type="protein" text="Glutamate cysteine ligase"/>
            <entity id="DS.d130.s0.e1" origId="P28676,Q8NEA9,Q96IK5" charOffset="27-30" type="protein" text="GCL"/>
            <entity id="DS.d130.s0.e2" origId="123938" charOffset="46-68" type="compound" text="gamma-glutamylcysteine"/>
            <entity id="DS.d130.s0.e3" origId="611,23327,33032" charOffset="74-83" type="compound" text="glutamate"/>
            <entity id="DS.d130.s0.e4" origId="594,5862,5360637" charOffset="10-18" type="compound" text="cysteine"/>
            <entity id="DS.d130.s0.e5" origId="124886" charOffset="129-140" type="compound" text="glutathione"/>
            <entity id="DS.d130.s0.e6" origId="124886" charOffset="142-145" type="compound" text="GSH"/>
            <pair e1="DS.d130.s0.e4" e2="DS.d130.s0.e1" id="DS.d130.s0.i0" interaction="True"/>
            <pair e1="DS.d130.s0.e6" e2="DS.d130.s0.e1" id="DS.d130.s0.i1" interaction="True"/>
            <pair e1="DS.d130.s0.e3" e2="DS.d130.s0.e0" id="DS.d130.s0.i2" interaction="True"/>
            <pair e1="DS.d130.s0.e2" e2="DS.d130.s0.e1" id="DS.d130.s0.i3" interaction="True"/>
            <pair e1="DS.d130.s0.e2" e2="DS.d130.s0.e0" id="DS.d130.s0.i4" interaction="True"/>
            <pair e1="DS.d130.s0.e3" e2="DS.d130.s0.e1" id="DS.d130.s0.i5" interaction="True"/>
            <pair e1="DS.d130.s0.e4" e2="DS.d130.s0.e0" id="DS.d130.s0.i6" interaction="True"/>
            <pair e1="DS.d130.s0.e5" e2="DS.d130.s0.e0" id="DS.d130.s0.i7" interaction="True"/>
            <pair e1="DS.d130.s0.e5" e2="DS.d130.s0.e1" id="DS.d130.s0.i8" interaction="True"/>
            <pair e1="DS.d130.s0.e6" e2="DS.d130.s0.e0" id="DS.d130.s0.i9" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d131" origId="18403053">
        <sentence id="DS.d131.s0" origId="18403053-226" text="We observed that lactacystin inhibited the proteasome activities and increased the level and insolubility of different tau species, including phosphorylated tau.">
            <entity id="DS.d131.s0.e0" origId="3870,3034764,6610292" charOffset="17-28" type="compound" text="lactacystin"/>
            <entity id="DS.d131.s0.e1" origId="P10637,P16525,P19332,P58384" charOffset="119-122" type="protein" text="tau"/>
            <entity id="DS.d131.s0.e2" origId="P10637,P16525,P19332,P58384" charOffset="157-160" type="protein" text="tau"/>
            <pair e1="DS.d131.s0.e0" e2="DS.d131.s0.e1" id="DS.d131.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d132" origId="18404246">
        <sentence id="DS.d132.s0" origId="18404246-532" text="Serine and cysteine proteases proved to be suitable tools for the production of amino acids and peptides conjugated to 4-aminoantipyrine, whereas metalloproteases do not seem to be very qualified for accepting this nucleophile.">
            <entity id="DS.d132.s0.e0" origId="O41798,O89290,O89940,O91080,O93215,P03311,P03353,P03355,P03356,P03362,P03363,P03366,P03367,P03369,P03370,P04023,P04024,P04323,P04584,P04585,P04587,P04588,P04589,P05959,P05960,P05961,P05962,P07570,P0C210,P0C211,P10210,P10265,P10270,P10271,P10272,P10273,P10274,P10394,P10978,P11227,P11365,P12451,P12497,P12498,P12499,P14074,P14078,P15833,P16046,P16423,P16901,P17757,P18042,P18096,P18802,P19028,P19199,P19560,P19561,P20825,P20875,P20876,P20892,P21407,P21414,P24107,P24740,P26808,P26809,P26810,P27502,P28936,P31822,P35956,P35963,P51518,P63119,P63120,P63121,P63122,P63123,P63124,P63125,P63127,P63128,P63129,P63131,P84454,Q09SZ9,Q0R5R2,Q0R5R3,Q1A249,Q1A267,Q4U0X6,Q73368,Q74120,Q75002,Q76634,Q77373,Q79666,Q89928,Q8AII1,Q8I7P9,Q9IDV9,Q9Q720,Q9QBY3,Q9QBZ1,Q9QBZ5,Q9QSR3,Q9WC54,Q9WC63,Q9Y6I0" charOffset="20-29" type="protein" text="proteases"/>
            <entity id="DS.d132.s0.e1" origId="2151" charOffset="119-136" type="compound" text="4-aminoantipyrine"/>
            <pair e1="DS.d132.s0.e1" e2="DS.d132.s0.e0" id="DS.d132.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d133" origId="18405417">
        <sentence id="DS.d133.s0" origId="18405417-151" text="Role of serotonin 5-HT1A receptors in the antidepressant-like effect and the antinociceptive effect of venlafaxine in mice.">
            <entity id="DS.d133.s0.e0" origId="P08908,P19327,P28285,Q64264,Q6XXX9,Q6XXY0,Q98998,Q9N296,Q9N297,Q9N298" charOffset="18-24" type="protein" text="5-HT1A"/>
            <entity id="DS.d133.s0.e1" origId="5656" charOffset="103-114" type="compound" text="venlafaxine"/>
            <pair e1="DS.d133.s0.e1" e2="DS.d133.s0.e0" id="DS.d133.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d133.s1" origId="18405417-152" text="The present study was undertaken to evaluate the potential role of 5-HT1A receptors in the antidepressant-like effect and antinociceptive effect of venlafaxine.">
            <entity id="DS.d133.s1.e0" origId="P08908,P19327,P28285,Q64264,Q6XXX9,Q6XXY0,Q98998,Q9N296,Q9N297,Q9N298" charOffset="67-73" type="protein" text="5-HT1A"/>
            <entity id="DS.d133.s1.e1" origId="5656" charOffset="148-159" type="compound" text="venlafaxine"/>
            <pair e1="DS.d133.s1.e1" e2="DS.d133.s1.e0" id="DS.d133.s1.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d133.s2" origId="18405417-154" text="These findings show that 5-HT1A receptors play differing roles in modulating the antidepressant-like and antinociceptive effects of venlafaxine in the models investigated.">
            <entity id="DS.d133.s2.e0" origId="P08908,P19327,P28285,Q64264,Q6XXX9,Q6XXY0,Q98998,Q9N296,Q9N297,Q9N298" charOffset="25-31" type="protein" text="5-HT1A"/>
            <entity id="DS.d133.s2.e1" origId="5656" charOffset="132-143" type="compound" text="venlafaxine"/>
            <pair e1="DS.d133.s2.e1" e2="DS.d133.s2.e0" id="DS.d133.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d133.s3" origId="18405417-155" text="In contrast, the antinociceptive effect of venlafaxine is probably potentiated due to the blockade of somatodendritic 5-HT1A receptors in the same raphe nuclei, facilitating the descending monoaminergic pain control system.">
            <entity id="DS.d133.s3.e0" origId="5656" charOffset="43-54" type="compound" text="venlafaxine"/>
            <entity id="DS.d133.s3.e1" origId="P08908,P19327,P28285,Q64264,Q6XXX9,Q6XXY0,Q98998,Q9N296,Q9N297,Q9N298" charOffset="118-124" type="protein" text="5-HT1A"/>
            <pair e1="DS.d133.s3.e0" e2="DS.d133.s3.e1" id="DS.d133.s3.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d134" origId="18407279">
        <sentence id="DS.d134.s0" origId="18407279-655" text="Moreover, beta-glucuronidase hydrolysis of baicalin sequentially yielded glucuronic acid and baicalein as confirmed by co-TLC with authentic samples.">
            <entity id="DS.d134.s0.e0" origId="P05804" charOffset="10-28" type="protein" text="beta-glucuronidase"/>
            <entity id="DS.d134.s0.e1" origId="64982" charOffset="43-51" type="compound" text="baicalin"/>
            <entity id="DS.d134.s0.e2" origId="5281605" charOffset="93-102" type="compound" text="baicalein"/>
            <pair e1="DS.d134.s0.e2" e2="DS.d134.s0.e0" id="DS.d134.s0.i0" interaction="True"/>
            <pair e1="DS.d134.s0.e1" e2="DS.d134.s0.e0" id="DS.d134.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d135" origId="18407527">
        <sentence id="DS.d135.s0" origId="18407527-68" text="The effect of this diet alone or after 2 weeks of treatment with rosiglitazone or glimepiride on glucose homeostasis, lipid profile, and levels of resistin and leptin was studied.">
            <entity id="DS.d135.s0.e0" origId="77999" charOffset="65-78" type="compound" text="rosiglitazone"/>
            <entity id="DS.d135.s0.e1" origId="3476" charOffset="82-93" type="compound" text="glimepiride"/>
            <entity id="DS.d135.s0.e2" origId="O02750,O93416,Q28603,Q95189,Q95234" charOffset="160-166" type="protein" text="leptin"/>
            <pair e1="DS.d135.s0.e0" e2="DS.d135.s0.e2" id="DS.d135.s0.i0" interaction="False"/>
            <pair e1="DS.d135.s0.e1" e2="DS.d135.s0.e2" id="DS.d135.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d135.s1" origId="18407527-71" text="Rosiglitazone corrected the altered parameters measured, except for liver TGs ; similarly, glimepiride reinstated the inverted parameters but raised insulin level and, consequently, the HOMA index.">
            <entity id="DS.d135.s1.e0" origId="77999" charOffset="0-13" type="compound" text="Rosiglitazone"/>
            <entity id="DS.d135.s1.e1" origId="2724387" charOffset="74-77" type="compound" text="TGs"/>
            <entity id="DS.d135.s1.e2" origId="3476" charOffset="91-102" type="compound" text="glimepiride"/>
            <entity id="DS.d135.s1.e3" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="149-156" type="protein" text="insulin"/>
            <pair e1="DS.d135.s1.e2" e2="DS.d135.s1.e3" id="DS.d135.s1.i0" interaction="True"/>
            <pair e1="DS.d135.s1.e0" e2="DS.d135.s1.e3" id="DS.d135.s1.i1" interaction="False"/>
            <pair e1="DS.d135.s1.e1" e2="DS.d135.s1.e3" id="DS.d135.s1.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d136" origId="18409068">
        <sentence id="DS.d136.s0" origId="18409068-1012" text="AZD0530 inhibited tumor growth in a manner independent of dose and inhibited phosphorylation of FAK and paxillin in a dose-dependent manner in a Calu-6 xenograft model.">
            <entity id="DS.d136.s0.e0" origId="10302451" charOffset="0-7" type="compound" text="AZD0530"/>
            <entity id="DS.d136.s0.e1" origId="Q00944,Q05397" charOffset="96-99" type="protein" text="FAK"/>
            <entity id="DS.d136.s0.e2" origId="P49023,P49024,Q5R7I1,Q66H76,Q8VI36" charOffset="104-112" type="protein" text="paxillin"/>
            <pair e1="DS.d136.s0.e0" e2="DS.d136.s0.e1" id="DS.d136.s0.i0" interaction="True"/>
            <pair e1="DS.d136.s0.e0" e2="DS.d136.s0.e2" id="DS.d136.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d137" origId="18409071">
        <sentence id="DS.d137.s0" origId="18409071-995" text="Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.">
            <entity id="DS.d137.s0.e0" origId="P00533,P13387,P55245" charOffset="21-25" type="protein" text="EGFR"/>
            <entity id="DS.d137.s0.e1" origId="104741" charOffset="120-131" type="compound" text="fulvestrant"/>
            <pair e1="DS.d137.s0.e1" e2="DS.d137.s0.e0" id="DS.d137.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d137.s1" origId="18409071-997" text="Treatment with the EGFR inhibitor gefitinib preferentially inhibited growth and reduced the S phase fraction in the resistant cell lines concomitant with inhibition of Erk and unaltered Akt activation.">
            <entity id="DS.d137.s1.e0" origId="123631" charOffset="34-43" type="compound" text="gefitinib"/>
            <entity id="DS.d137.s1.e1" origId="P31750,Q8INB9" charOffset="186-189" type="protein" text="Akt"/>
            <pair e1="DS.d137.s1.e0" e2="DS.d137.s1.e1" id="DS.d137.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d138" origId="18410309">
        <sentence id="DS.d138.s0" origId="18410309-540" text="Melatonin protects from hepatic reperfusion injury through inhibition of IKK and JNK pathways and modification of cell proliferation.">
            <entity id="DS.d138.s0.e0" origId="896" charOffset="0-9" type="compound" text="Melatonin"/>
            <entity id="DS.d138.s0.e1" origId="P92208,Q966Y3" charOffset="81-84" type="protein" text="JNK"/>
            <pair e1="DS.d138.s0.e0" e2="DS.d138.s0.e1" id="DS.d138.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d138.s1" origId="18410309-541" text="Melatonin significantly improved animal survival and decreased transaminase levels, the indices for necrosis, liver damage, leukocyte infiltration, and iNOS expression.">
            <entity id="DS.d138.s1.e0" origId="896" charOffset="0-9" type="compound" text="Melatonin"/>
            <entity id="DS.d138.s1.e1" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="152-156" type="protein" text="iNOS"/>
            <pair e1="DS.d138.s1.e0" e2="DS.d138.s1.e1" id="DS.d138.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d138.s2" origId="18410309-542" text="At the same time, melatonin reduced the expression of both PCNA 0.05).">
            <entity id="DS.d138.s2.e0" origId="896" charOffset="18-27" type="compound" text="melatonin"/>
            <entity id="DS.d138.s2.e1" origId="O01377,O02115,O10308,O16852,O27367,O29912,O58398,O73947,O82134,O82797,P04961,P11038,P12004,P15873,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P57761,P61074,P61258,Q00265,Q00268,Q03392,Q43124,Q43266,Q57697,Q6B6N4,Q6KZF1,Q6LWJ8,Q74MV1,Q7T6Y0,Q8PX25,Q8TUF7,Q8TWK3,Q979S2,Q9DDF1,Q9DEA3,Q9HJQ0,Q9HN45,Q9M7Q7,Q9MAY3,Q9P9H8,Q9PTP1,Q9UWR9,Q9UYX8,Q9W644" charOffset="59-63" type="protein" text="PCNA"/>
            <pair e1="DS.d138.s2.e0" e2="DS.d138.s2.e1" id="DS.d138.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d138.s3" origId="18410309-543" text="Melatonin is hepatoprotective most likely via mechanisms including inhibition of IKK and JNK pathways and regulation of cell proliferation.">
            <entity id="DS.d138.s3.e0" origId="896" charOffset="0-9" type="compound" text="Melatonin"/>
            <entity id="DS.d138.s3.e1" origId="P92208,Q966Y3" charOffset="89-92" type="protein" text="JNK"/>
            <pair e1="DS.d138.s3.e0" e2="DS.d138.s3.e1" id="DS.d138.s3.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d139" origId="18410522">
        <sentence id="DS.d139.s0" origId="18410522-611" text="Here, we report that the citrus bioflavonoid luteolin reduces amyloid-beta (Abeta) peptide generation in both human 'Swedish' mutant APP transgene-bearing neuron-like cells and primary neurons.">
            <entity id="DS.d139.s0.e0" origId="5280805" charOffset="32-44" type="compound" text="bioflavonoid"/>
            <entity id="DS.d139.s0.e1" origId="5280445" charOffset="45-53" type="compound" text="luteolin"/>
            <entity id="DS.d139.s0.e2" origId="O73683,O93279,P05067,P08592,P0A3Z1,P0A3Z2,P0A3Z3,P0A3Z4,P12023,P29216,P47566,P53601,P75313,P79307,Q11207,Q28053,Q28280,Q28748,Q28757,Q29149,Q5IS80,Q60495,Q95241" charOffset="133-136" type="protein" text="APP"/>
            <pair e1="DS.d139.s0.e1" e2="DS.d139.s0.e2" id="DS.d139.s0.i0" interaction="True"/>
            <pair e1="DS.d139.s0.e0" e2="DS.d139.s0.e2" id="DS.d139.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d139.s1" origId="18410522-612" text="We also find that luteolin induces changes consistent with GSK-3 inhibition that (i) decrease amyloidogenic gamma-secretase APP processing, and (ii) promote presenilin-1 (PS1) carboxyl-terminal fragment (CTF) phosphorylation.">
            <entity id="DS.d139.s1.e0" origId="5280445" charOffset="18-26" type="compound" text="luteolin"/>
            <entity id="DS.d139.s1.e1" origId="P51136,P83101" charOffset="59-64" type="protein" text="GSK-3"/>
            <entity id="DS.d139.s1.e2" origId="O73683,O93279,P05067,P08592,P0A3Z1,P0A3Z2,P0A3Z3,P0A3Z4,P12023,P29216,P47566,P53601,P75313,P79307,Q11207,Q28053,Q28280,Q28748,Q28757,Q29149,Q5IS80,Q60495,Q95241" charOffset="124-127" type="protein" text="APP"/>
            <entity id="DS.d139.s1.e3" origId="O12976,P49768,P49769,P79802,P97887,Q4JIM4,Q5R780,Q6RH31,Q8HXW5,Q9W6T7,Q9XT97" charOffset="157-169" type="protein" text="presenilin-1"/>
            <entity id="DS.d139.s1.e4" origId="P49768,P79802,Q8HXW5,Q9W6T7" charOffset="171-174" type="protein" text="PS1"/>
            <pair e1="DS.d139.s1.e0" e2="DS.d139.s1.e2" id="DS.d139.s1.i0" interaction="True"/>
            <pair e1="DS.d139.s1.e0" e2="DS.d139.s1.e3" id="DS.d139.s1.i1" interaction="True"/>
            <pair e1="DS.d139.s1.e0" e2="DS.d139.s1.e4" id="DS.d139.s1.i2" interaction="True"/>
            <pair e1="DS.d139.s1.e0" e2="DS.d139.s1.e1" id="DS.d139.s1.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d139.s2" origId="18410522-613" text="As validation of these findings in vivo, we find that luteolin, when applied to the Tg2576 mouse model of AD, decreases soluble Abeta levels, reduces GSK-3 activity, and disrupts PS1-APP association.">
            <entity id="DS.d139.s2.e0" origId="5280445" charOffset="54-62" type="compound" text="luteolin"/>
            <entity id="DS.d139.s2.e1" origId="P51136,P83101" charOffset="150-155" type="protein" text="GSK-3"/>
            <entity id="DS.d139.s2.e2" origId="P49768,P79802,Q8HXW5,Q9W6T7" charOffset="179-182" type="protein" text="PS1"/>
            <entity id="DS.d139.s2.e3" origId="O73683,O93279,P05067,P08592,P0A3Z1,P0A3Z2,P0A3Z3,P0A3Z4,P12023,P29216,P47566,P53601,P75313,P79307,Q11207,Q28053,Q28280,Q28748,Q28757,Q29149,Q5IS80,Q60495,Q95241" charOffset="183-186" type="protein" text="APP"/>
            <pair e1="DS.d139.s2.e0" e2="DS.d139.s2.e3" id="DS.d139.s2.i0" interaction="True"/>
            <pair e1="DS.d139.s2.e0" e2="DS.d139.s2.e2" id="DS.d139.s2.i1" interaction="True"/>
            <pair e1="DS.d139.s2.e0" e2="DS.d139.s2.e1" id="DS.d139.s2.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d140" origId="18410527">
        <sentence id="DS.d140.s0" origId="18410527-619" text="Since biliverdin and bilirubin are downstream products of heme degradation by heme oxygenase (HO), it has been suggested that HO-activity protects against curcumin-induced apoptosis.">
            <entity id="DS.d140.s0.e0" origId="5280353,5315455,5353439,6183357" charOffset="6-16" type="compound" text="biliverdin"/>
            <entity id="DS.d140.s0.e1" origId="5280352" charOffset="21-30" type="compound" text="bilirubin"/>
            <entity id="DS.d140.s0.e2" origId="4971" charOffset="58-62" type="compound" text="heme"/>
            <entity id="DS.d140.s0.e3" origId="O19998,O73688,O78497,P51271,P71119" charOffset="78-92" type="protein" text="heme oxygenase"/>
            <pair e1="DS.d140.s0.e1" e2="DS.d140.s0.e3" id="DS.d140.s0.i0" interaction="True"/>
            <pair e1="DS.d140.s0.e2" e2="DS.d140.s0.e3" id="DS.d140.s0.i1" interaction="False"/>
            <pair e1="DS.d140.s0.e0" e2="DS.d140.s0.e3" id="DS.d140.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d141" origId="18410529">
        <sentence id="DS.d141.s0" origId="18410529-629" text="Here, we examine the effect of resistin on glucose uptake in human trophoblast cells and we demonstrate that transplacental glucose transport is mediated by glucose transporter (GLUT)-1.">
            <entity id="DS.d141.s0.e0" origId="206,5793,64689,79025" charOffset="43-50" type="compound" text="glucose"/>
            <entity id="DS.d141.s0.e1" origId="P23586" charOffset="157-176" type="protein" text="glucose transporter"/>
            <pair e1="DS.d141.s0.e0" e2="DS.d141.s0.e1" id="DS.d141.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d141.s1" origId="18410529-630" text="ERK1 and 2 activation stimulated GLUT-1 synthesis and resulted in increase of placental glucose uptake.">
            <entity id="DS.d141.s1.e0" origId="P27361,P28869,P42525,Q07176" charOffset="0-4" type="protein" text="ERK1"/>
            <entity id="DS.d141.s1.e1" origId="P79365" charOffset="33-39" type="protein" text="GLUT-1"/>
            <entity id="DS.d141.s1.e2" origId="206,5793,64689,79025" charOffset="88-95" type="compound" text="glucose"/>
            <pair e1="DS.d141.s1.e2" e2="DS.d141.s1.e1" id="DS.d141.s1.i0" interaction="True"/>
            <pair e1="DS.d141.s1.e2" e2="DS.d141.s1.e0" id="DS.d141.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d141.s2" origId="18410529-631" text="High resistin levels (50-100 ng/ml) seem able to affect glucose-uptake, presumably by decreasing the cell surface glucose transporter.">
            <entity id="DS.d141.s2.e0" origId="206,5793,64689,79025" charOffset="56-63" type="compound" text="glucose"/>
            <entity id="DS.d141.s2.e1" origId="P23586" charOffset="114-133" type="protein" text="glucose transporter"/>
            <pair e1="DS.d141.s2.e0" e2="DS.d141.s2.e1" id="DS.d141.s2.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d142" origId="18410530">
        <sentence id="DS.d142.s0" origId="18410530-134" text="CpG methylation as well as histone H3 methylation of lysines 9 and 27 contribute independently to ARF gene silencing in adenocarcinoma cell lines and can be reversed by 5-aza-2'-deoxycytidine.">
            <entity id="DS.d142.s0.e0" origId="6804" charOffset="0-3" type="compound" text="CpG"/>
            <entity id="DS.d142.s0.e1" origId="O48920,P34727,P34728,P51823,Q94650" charOffset="98-101" type="protein" text="ARF"/>
            <entity id="DS.d142.s0.e2" origId="451668" charOffset="169-191" type="compound" text="5-aza-2'-deoxycytidine"/>
            <pair e1="DS.d142.s0.e0" e2="DS.d142.s0.e1" id="DS.d142.s0.i0" interaction="True"/>
            <pair e1="DS.d142.s0.e2" e2="DS.d142.s0.e1" id="DS.d142.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d143" origId="18410982">
        <sentence id="DS.d143.s0" origId="18410982-929" text="Gly-Pro-, Gly-Pro-Met- and Ala-Ala-Phe-N'-(2-hexyl-1,3-dioxo-2,3-dihydro-1H-benzo(de)isoquinolin-6-yl)-hydrazides are synthesized by guanidinium/uronium type condensing reagent and used as fluorogenic substrates to localize dipeptidyl peptidase IV and tripeptidyl peptidase I activities in mammalian tissue sections.">
            <entity id="DS.d143.s0.e0" origId="79101" charOffset="0-7" type="compound" text="Gly-Pro"/>
            <entity id="DS.d143.s0.e1" origId="79101" charOffset="10-17" type="compound" text="Gly-Pro"/>
            <entity id="DS.d143.s0.e2" origId="3520" charOffset="133-144" type="compound" text="guanidinium"/>
            <entity id="DS.d143.s0.e3" origId="P14740,P22411,P27487,P28843,P81425,Q9N2I7" charOffset="224-247" type="protein" text="dipeptidyl peptidase IV"/>
            <entity id="DS.d143.s0.e4" origId="O14773,O89023,Q5IS74,Q5RFL1,Q60HH1,Q71JP6,Q9EQV6,Q9XSB8" charOffset="252-275" type="protein" text="tripeptidyl peptidase I"/>
            <pair e1="DS.d143.s0.e0" e2="DS.d143.s0.e3" id="DS.d143.s0.i0" interaction="True"/>
            <pair e1="DS.d143.s0.e2" e2="DS.d143.s0.e3" id="DS.d143.s0.i1" interaction="True"/>
            <pair e1="DS.d143.s0.e0" e2="DS.d143.s0.e4" id="DS.d143.s0.i2" interaction="True"/>
            <pair e1="DS.d143.s0.e2" e2="DS.d143.s0.e4" id="DS.d143.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d144" origId="18413191">
        <sentence id="DS.d144.s0" origId="18413191-1010" text="However, increased blood glucose (200 mg/dl) significantly impaired the inhibitory effect of ASA (84% for GPIIb.005; 48% for P-selectin, P=NS).">
            <entity id="DS.d144.s0.e0" origId="206,5793,64689,79025" charOffset="25-32" type="compound" text="glucose"/>
            <entity id="DS.d144.s0.e1" origId="P08514,P53711,Q9QUM0" charOffset="106-111" type="protein" text="GPIIb"/>
            <pair e1="DS.d144.s0.e0" e2="DS.d144.s0.e1" id="DS.d144.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d145" origId="18413206">
        <sentence id="DS.d145.s0" origId="18413206-1026" text="The expressions of MCP-1 mRNA in renal tissues were markedly up-regulated in untreated diabetic rats, and these could be notably reduced by rosiglitazone treatment.">
            <entity id="DS.d145.s0.e0" origId="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3" charOffset="19-24" type="protein" text="MCP-1"/>
            <entity id="DS.d145.s0.e1" origId="77999" charOffset="140-153" type="compound" text="rosiglitazone"/>
            <pair e1="DS.d145.s0.e1" e2="DS.d145.s0.e0" id="DS.d145.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d145.s1" origId="18413206-1027" text="In conclusion, rosiglitazone may have a potential therapeutic target in DN, which may be partly attributed to lowering of the expression of MCP-1 in the local kidney and the urinary excretion of MCP-1.">
            <entity id="DS.d145.s1.e0" origId="77999" charOffset="15-28" type="compound" text="rosiglitazone"/>
            <entity id="DS.d145.s1.e1" origId="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3" charOffset="140-145" type="protein" text="MCP-1"/>
            <entity id="DS.d145.s1.e2" origId="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3" charOffset="195-200" type="protein" text="MCP-1"/>
            <pair e1="DS.d145.s1.e0" e2="DS.d145.s1.e1" id="DS.d145.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d146" origId="18414844">
        <sentence id="DS.d146.s0" origId="18414844-751" text="The homomeric P2X (7) receptor is extraordinary in that in addition to distinctive localization and biological functions it exhibits several hallmark properties, for example, the receptor is potently inhibited by divalent cations such as calcium, magnesium, zinc and copper.">
            <entity id="DS.d146.s0.e0" origId="P13900,P16604" charOffset="14-17" type="protein" text="P2X"/>
            <entity id="DS.d146.s0.e1" origId="5462224" charOffset="247-256" type="compound" text="magnesium"/>
            <entity id="DS.d146.s0.e2" origId="23978" charOffset="267-273" type="compound" text="copper"/>
            <pair e1="DS.d146.s0.e2" e2="DS.d146.s0.e0" id="DS.d146.s0.i0" interaction="True"/>
            <pair e1="DS.d146.s0.e1" e2="DS.d146.s0.e0" id="DS.d146.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d147" origId="18414894">
        <sentence id="DS.d147.s0" origId="18414894-793" text="Replacement doses of hydrocortisone (HC) (10 mg/m2/day) failed to produce a feedback inhibition of adrenocorticotropic hormone (ACTH), and testosterone levels remained high.">
            <entity id="DS.d147.s0.e0" origId="5754" charOffset="21-35" type="compound" text="hydrocortisone"/>
            <entity id="DS.d147.s0.e1" origId="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5" charOffset="99-126" type="protein" text="adrenocorticotropic hormone"/>
            <entity id="DS.d147.s0.e2" origId="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5" charOffset="128-132" type="protein" text="ACTH"/>
            <entity id="DS.d147.s0.e3" origId="6013" charOffset="139-151" type="compound" text="testosterone"/>
            <pair e1="DS.d147.s0.e3" e2="DS.d147.s0.e1" id="DS.d147.s0.i0" interaction="False"/>
            <pair e1="DS.d147.s0.e0" e2="DS.d147.s0.e2" id="DS.d147.s0.i1" interaction="False"/>
            <pair e1="DS.d147.s0.e3" e2="DS.d147.s0.e2" id="DS.d147.s0.i2" interaction="False"/>
            <pair e1="DS.d147.s0.e0" e2="DS.d147.s0.e1" id="DS.d147.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d148" origId="18414974">
        <sentence id="DS.d148.s0" origId="18414974-853" text="Cadmium exposure diminished the activities of enzymatic antioxidants, superoxide dismutase (SOD), catalase (CAT), glutathione-S-transferase (GST), glutathione reductase (GR), glutathione peroxidase (GPx) and glucose-6-phosphate dehydrogenase (G6PD) as well as non-enzymatic antioxidant, reduced glutathione (GSH) and total thiols.">
            <entity id="DS.d148.s0.e0" origId="23973" charOffset="0-7" type="compound" text="Cadmium"/>
            <entity id="DS.d148.s0.e1" origId="O50258" charOffset="70-90" type="protein" text="superoxide dismutase"/>
            <entity id="DS.d148.s0.e2" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="92-95" type="protein" text="SOD"/>
            <entity id="DS.d148.s0.e3" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="98-106" type="protein" text="catalase"/>
            <entity id="DS.d148.s0.e4" origId="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7" charOffset="108-111" type="protein" text="CAT"/>
            <entity id="DS.d148.s0.e5" origId="O04437,O18598,P0A9D2,P0A9D3,P30116,P44521,P46088,P46419,P46423,P46426,P46428,P46437,P48438,P80894,P81065,P82996,P82997,P82998,P82999,P83000,P83001,P83246,Q04522,Q08392,Q08393,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52,Q96324" charOffset="114-139" type="protein" text="glutathione-S-transferase"/>
            <entity id="DS.d148.s0.e6" origId="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52" charOffset="141-144" type="protein" text="GST"/>
            <entity id="DS.d148.s0.e7" origId="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655" charOffset="147-168" type="protein" text="glutathione reductase"/>
            <entity id="DS.d148.s0.e8" origId="O32770,O59858,Q00277,Q9CFV1" charOffset="175-197" type="protein" text="glutathione peroxidase"/>
            <entity id="DS.d148.s0.e9" origId="O00091,O24357,O51581,O54537,O55044,O68282,O83491,O84188,P05370,P0A584,P0A585,P0A586,P0A587,P0AC53,P0AC54,P11410,P11411,P11412,P11413,P12646,P15588,P21907,P29686,P37830,P37986,P41571,P41764,P44311,P48826,P48828,P48848,P48992,P54547,P54996,P56110,P57405,P73411,P77809,P80619,P97324,Q00612,Q23711,Q24625,Q25019,Q25537,Q27464,Q27638,Q29492,Q42919,Q43793,Q43839,Q7YS37,Q89AI7,Q8K9M2,Q8XCJ6,Q9PKK8,Q9X0N9,Q9Z3S2,Q9Z8U6,Q9ZKB2" charOffset="243-247" type="protein" text="G6PD"/>
            <entity id="DS.d148.s0.e10" origId="124886" charOffset="287-306" type="compound" text="reduced glutathione"/>
            <entity id="DS.d148.s0.e11" origId="124886" charOffset="308-311" type="compound" text="GSH"/>
            <pair e1="DS.d148.s0.e11" e2="DS.d148.s0.e6" id="DS.d148.s0.i0" interaction="False"/>
            <pair e1="DS.d148.s0.e10" e2="DS.d148.s0.e6" id="DS.d148.s0.i1" interaction="False"/>
            <pair e1="DS.d148.s0.e0" e2="DS.d148.s0.e3" id="DS.d148.s0.i2" interaction="True"/>
            <pair e1="DS.d148.s0.e11" e2="DS.d148.s0.e1" id="DS.d148.s0.i3" interaction="False"/>
            <pair e1="DS.d148.s0.e10" e2="DS.d148.s0.e5" id="DS.d148.s0.i4" interaction="False"/>
            <pair e1="DS.d148.s0.e10" e2="DS.d148.s0.e4" id="DS.d148.s0.i5" interaction="False"/>
            <pair e1="DS.d148.s0.e10" e2="DS.d148.s0.e3" id="DS.d148.s0.i6" interaction="False"/>
            <pair e1="DS.d148.s0.e10" e2="DS.d148.s0.e2" id="DS.d148.s0.i7" interaction="False"/>
            <pair e1="DS.d148.s0.e11" e2="DS.d148.s0.e4" id="DS.d148.s0.i8" interaction="False"/>
            <pair e1="DS.d148.s0.e0" e2="DS.d148.s0.e6" id="DS.d148.s0.i9" interaction="True"/>
            <pair e1="DS.d148.s0.e11" e2="DS.d148.s0.e7" id="DS.d148.s0.i10" interaction="False"/>
            <pair e1="DS.d148.s0.e0" e2="DS.d148.s0.e9" id="DS.d148.s0.i11" interaction="True"/>
            <pair e1="DS.d148.s0.e11" e2="DS.d148.s0.e2" id="DS.d148.s0.i12" interaction="False"/>
            <pair e1="DS.d148.s0.e0" e2="DS.d148.s0.e2" id="DS.d148.s0.i13" interaction="True"/>
            <pair e1="DS.d148.s0.e11" e2="DS.d148.s0.e8" id="DS.d148.s0.i14" interaction="False"/>
            <pair e1="DS.d148.s0.e10" e2="DS.d148.s0.e9" id="DS.d148.s0.i15" interaction="False"/>
            <pair e1="DS.d148.s0.e10" e2="DS.d148.s0.e1" id="DS.d148.s0.i16" interaction="False"/>
            <pair e1="DS.d148.s0.e0" e2="DS.d148.s0.e1" id="DS.d148.s0.i17" interaction="True"/>
            <pair e1="DS.d148.s0.e10" e2="DS.d148.s0.e8" id="DS.d148.s0.i18" interaction="False"/>
            <pair e1="DS.d148.s0.e0" e2="DS.d148.s0.e7" id="DS.d148.s0.i19" interaction="True"/>
            <pair e1="DS.d148.s0.e0" e2="DS.d148.s0.e8" id="DS.d148.s0.i20" interaction="True"/>
            <pair e1="DS.d148.s0.e11" e2="DS.d148.s0.e5" id="DS.d148.s0.i21" interaction="False"/>
            <pair e1="DS.d148.s0.e0" e2="DS.d148.s0.e5" id="DS.d148.s0.i22" interaction="True"/>
            <pair e1="DS.d148.s0.e10" e2="DS.d148.s0.e7" id="DS.d148.s0.i23" interaction="False"/>
            <pair e1="DS.d148.s0.e0" e2="DS.d148.s0.e4" id="DS.d148.s0.i24" interaction="True"/>
            <pair e1="DS.d148.s0.e11" e2="DS.d148.s0.e3" id="DS.d148.s0.i25" interaction="False"/>
            <pair e1="DS.d148.s0.e11" e2="DS.d148.s0.e9" id="DS.d148.s0.i26" interaction="False"/>
        </sentence>
        <sentence id="DS.d148.s1" origId="18414974-854" text="On the other hand, the levels of oxidized glutathione (GSSG), lipid peroxidation, protein carbonylation, DNA fragmentation, concentration of superoxide radicals and activities of cytochrome P450 enzymes (CYP P450s) have been found to increase due to cadmium intoxication.">
            <entity id="DS.d148.s1.e0" origId="975,65359" charOffset="33-53" type="compound" text="oxidized glutathione"/>
            <entity id="DS.d148.s1.e1" origId="65359" charOffset="55-59" type="compound" text="GSSG"/>
            <entity id="DS.d148.s1.e2" origId="5359597" charOffset="141-151" type="compound" text="superoxide"/>
            <entity id="DS.d148.s1.e3" origId="O08469" charOffset="179-194" type="protein" text="cytochrome P450"/>
            <entity id="DS.d148.s1.e4" origId="P21568,P21569,P24525,P34887,Q26551" charOffset="204-207" type="protein" text="CYP"/>
            <entity id="DS.d148.s1.e5" origId="23973" charOffset="250-257" type="compound" text="cadmium"/>
            <pair e1="DS.d148.s1.e1" e2="DS.d148.s1.e4" id="DS.d148.s1.i0" interaction="False"/>
            <pair e1="DS.d148.s1.e5" e2="DS.d148.s1.e4" id="DS.d148.s1.i1" interaction="True"/>
            <pair e1="DS.d148.s1.e1" e2="DS.d148.s1.e3" id="DS.d148.s1.i2" interaction="False"/>
            <pair e1="DS.d148.s1.e0" e2="DS.d148.s1.e3" id="DS.d148.s1.i3" interaction="False"/>
            <pair e1="DS.d148.s1.e5" e2="DS.d148.s1.e3" id="DS.d148.s1.i4" interaction="True"/>
            <pair e1="DS.d148.s1.e2" e2="DS.d148.s1.e4" id="DS.d148.s1.i5" interaction="False"/>
            <pair e1="DS.d148.s1.e0" e2="DS.d148.s1.e4" id="DS.d148.s1.i6" interaction="False"/>
            <pair e1="DS.d148.s1.e2" e2="DS.d148.s1.e3" id="DS.d148.s1.i7" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d149" origId="18415015">
        <sentence id="DS.d149.s0" origId="18415015-878" text="This paper describes (1) the preparation of the intact oligosaccharides from GM1 (II(3)NeuAcGgOse(4) Cer) and GbOse(4) Cer as examples to show the use of CGase to prepare intact glycan chains from GSLs, and (2) the specificity and detergent requirements of Rhodococcal EGCases for the release of glycan chains from different GSLs.">
            <entity id="DS.d149.s0.e0" origId="P48648" charOffset="77-80" type="protein" text="GM1"/>
            <entity id="DS.d149.s0.e1" origId="871" charOffset="178-184" type="compound" text="glycan"/>
            <entity id="DS.d149.s0.e2" origId="871" charOffset="296-302" type="compound" text="glycan"/>
            <pair e1="DS.d149.s0.e1" e2="DS.d149.s0.e0" id="DS.d149.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d150" origId="18415121">
        <sentence id="DS.d150.s0" origId="18415121-949" text="The discovery of the PLN/HAX-1 interaction therefore unveils an important new link between Ca(2+) homeostasis and cell survival, with significant therapeutic potential.">
            <entity id="DS.d150.s0.e0" origId="P26677,P26678,P61012,P61013,P61015" charOffset="21-24" type="protein" text="PLN"/>
            <entity id="DS.d150.s0.e1" origId="O00165,O35387" charOffset="25-30" type="protein" text="HAX-1"/>
            <entity id="DS.d150.s0.e2" origId="271" charOffset="91-95" type="compound" text="Ca(2"/>
            <pair e1="DS.d150.s0.e2" e2="DS.d150.s0.e1" id="DS.d150.s0.i0" interaction="False"/>
            <pair e1="DS.d150.s0.e2" e2="DS.d150.s0.e0" id="DS.d150.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d151" origId="18418358">
        <sentence id="DS.d151.s0" origId="18418358-391" text="UFP-101 alone evoked effects similar to low N/OFQ doses, suggesting tonic inhibitory control over forelimb movement by endogenous N/OFQ.">
            <entity id="DS.d151.s0.e0" origId="25081457" charOffset="0-7" type="compound" text="UFP-101"/>
            <entity id="DS.d151.s0.e1" origId="Q13519" charOffset="46-49" type="protein" text="OFQ"/>
            <entity id="DS.d151.s0.e2" origId="Q13519" charOffset="132-135" type="protein" text="OFQ"/>
            <pair e1="DS.d151.s0.e0" e2="DS.d151.s0.e1" id="DS.d151.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d152" origId="18418709">
        <sentence id="DS.d152.s0" origId="18418709-605" text="Treating MCF-7 cells with AVE-1642 Qdots, but not unconjugated Qdots alone, downregulated IGF1R levels and rendered cells refractory to IGF-I stimulation.">
            <entity id="DS.d152.s0.e0" origId="16070039" charOffset="26-29" type="compound" text="AVE"/>
            <entity id="DS.d152.s0.e1" origId="P08069,Q05688,Q29000" charOffset="90-95" type="protein" text="IGF1R"/>
            <entity id="DS.d152.s0.e2" origId="P05017,P07455,P08025,P10763,P16545,P17085,P17647,P18254,P33712,P51457,P51458,P51462,Q02815,Q28933,Q68LC0,Q6GUL6,Q6IVA5,Q6JLX1,Q95222" charOffset="136-141" type="protein" text="IGF-I"/>
            <pair e1="DS.d152.s0.e0" e2="DS.d152.s0.e1" id="DS.d152.s0.i0" interaction="True"/>
            <pair e1="DS.d152.s0.e0" e2="DS.d152.s0.e2" id="DS.d152.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d152.s1" origId="18418709-606" text="Our data suggest that AVE-1642 Qdots can be used to detect IGF1R expression and measure changes in cell surface receptor levels.">
            <entity id="DS.d152.s1.e0" origId="16070039" charOffset="22-25" type="compound" text="AVE"/>
            <entity id="DS.d152.s1.e1" origId="P08069,Q05688,Q29000" charOffset="59-64" type="protein" text="IGF1R"/>
            <pair e1="DS.d152.s1.e0" e2="DS.d152.s1.e1" id="DS.d152.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d153" origId="18420260">
        <sentence id="DS.d153.s0" origId="18420260-309" text="Although previous studies indicated reduced levels of sialic acid residues during apoptosis, elevated Sambucus nigra agglutinin (SNA) reactivity might be due to the degradation of high molecular weight glycoproteins (probably including cadherin) that masked the SNA-binding residues of the plasma membrane prior to apoptosis.">
            <entity id="DS.d153.s0.e0" origId="906,444885,445063" charOffset="54-65" type="compound" text="sialic acid"/>
            <entity id="DS.d153.s0.e1" origId="P02872,P05046,P11218,P11219,P30617,P42088,P49329,P82859,P82953" charOffset="117-127" type="protein" text="agglutinin"/>
            <entity id="DS.d153.s0.e2" origId="P08163" charOffset="202-215" type="protein" text="glycoproteins"/>
            <pair e1="DS.d153.s0.e0" e2="DS.d153.s0.e2" id="DS.d153.s0.i0" interaction="False"/>
            <pair e1="DS.d153.s0.e0" e2="DS.d153.s0.e1" id="DS.d153.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d154" origId="18423787">
        <sentence id="DS.d154.s0" origId="18423787-1115" text="We detected a marked decrease in target mRNA, an accumulation of short interfering RNAs (siRNAs), and a decrease in quercetin content relative to kaempferol in leaf tissues, indicating that sequence-specific mRNA degradation of the F3'H gene was induced.">
            <entity id="DS.d154.s0.e0" origId="5280343" charOffset="116-133" type="compound" text="quercetin content"/>
            <entity id="DS.d154.s0.e1" origId="5280863" charOffset="146-156" type="compound" text="kaempferol"/>
            <entity id="DS.d154.s0.e2" origId="Q9SD85" charOffset="232-236" type="protein" text="F3'H"/>
            <pair e1="DS.d154.s0.e1" e2="DS.d154.s0.e2" id="DS.d154.s0.i0" interaction="False"/>
            <pair e1="DS.d154.s0.e0" e2="DS.d154.s0.e2" id="DS.d154.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d155" origId="18423943">
        <sentence id="DS.d155.s0" origId="18423943-93" text="Polyhydroxy phenolic compounds, such as flavonoids, vitamin E, rosmarinic acid and aristolochic acid, are able to inhibit PLA (2) from different sources.">
            <entity id="DS.d155.s0.e0" origId="2116,14985,1548900,1742129" charOffset="52-61" type="compound" text="vitamin E"/>
            <entity id="DS.d155.s0.e1" origId="5281792" charOffset="63-78" type="compound" text="rosmarinic acid"/>
            <entity id="DS.d155.s0.e2" origId="2236" charOffset="83-100" type="compound" text="aristolochic acid"/>
            <entity id="DS.d155.s0.e3" origId="P0C1C0,Q01172,Q6CZT4" charOffset="122-125" type="protein" text="PLA"/>
            <pair e1="DS.d155.s0.e1" e2="DS.d155.s0.e3" id="DS.d155.s0.i0" interaction="True"/>
            <pair e1="DS.d155.s0.e0" e2="DS.d155.s0.e3" id="DS.d155.s0.i1" interaction="True"/>
            <pair e1="DS.d155.s0.e2" e2="DS.d155.s0.e3" id="DS.d155.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d156" origId="18425600">
        <sentence id="DS.d156.s0" origId="18425600-1102" text="Analysis of the protein domain features indicated typical conserved cysteine residues containing a single whey acidic protein (WAP) domain at the C-terminus.">
            <entity id="DS.d156.s0.e0" origId="594,5862,5360637" charOffset="68-76" type="compound" text="cysteine"/>
            <entity id="DS.d156.s0.e1" origId="P09837" charOffset="106-125" type="protein" text="whey acidic protein"/>
            <entity id="DS.d156.s0.e2" origId="O46655,P01173,P01174,P09412,P09837,Q9N0L8" charOffset="127-130" type="protein" text="WAP"/>
            <pair e1="DS.d156.s0.e0" e2="DS.d156.s0.e2" id="DS.d156.s0.i0" interaction="False"/>
            <pair e1="DS.d156.s0.e0" e2="DS.d156.s0.e1" id="DS.d156.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d157" origId="18427801">
        <sentence id="DS.d157.s0" origId="18427801-1197" text="Cross-linked P2X (1/2) heteromers showed strongly reduced or absent function that was selectively recovered upon treatment with DTT.">
            <entity id="DS.d157.s0.e0" origId="P13900,P16604" charOffset="13-16" type="protein" text="P2X"/>
            <entity id="DS.d157.s0.e1" origId="439196,439352,446094" charOffset="128-131" type="compound" text="DTT"/>
            <pair e1="DS.d157.s0.e1" e2="DS.d157.s0.e0" id="DS.d157.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d158" origId="18431601">
        <sentence id="DS.d158.s0" origId="18431601-998" text="Permeabilization of K. marxianus cells in relation to beta-galactosidase activity was carried out using cetyltrimethyl ammonium bromide (CTAB) to avoid the problem of enzyme extraction.">
            <entity id="DS.d158.s0.e0" origId="O33815,O52629,O52847,P00722,P00723,P06219,P0C1Y0,P14288,P22498,P23989,P24131,P26257,P30812,P50388,P70753,P77989,P81650,Q1G9Z4,Q47077,Q48727,Q56307,Q59140,Q59750,Q9K9C6" charOffset="54-72" type="protein" text="beta-galactosidase"/>
            <entity id="DS.d158.s0.e1" origId="25514" charOffset="119-135" type="compound" text="ammonium bromide"/>
            <entity id="DS.d158.s0.e2" origId="2681" charOffset="137-141" type="compound" text="CTAB"/>
            <pair e1="DS.d158.s0.e2" e2="DS.d158.s0.e0" id="DS.d158.s0.i0" interaction="True"/>
            <pair e1="DS.d158.s0.e1" e2="DS.d158.s0.e0" id="DS.d158.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d159" origId="18431759">
        <sentence id="DS.d159.s0" origId="18431759-1114" text="Although the levels of IL-4, IL-13, IL-10, and GRO/KC were affected by polymer implantation, but not dependent on a specific polymer, IL-6 and TNFalpha were significantly greater in those animals implanted with PEU and SR, materials that do not promote fusion.">
            <entity id="DS.d159.s0.e0" origId="O77762,P05112,P07750,P20096,P30367,P30368,P42202,P46652,P47966,P51492,P51744,P55030,P79155,P79339,Q04745,Q2PE74,Q3S4V6,Q58M18,Q60440,Q7YS71,Q865X5,Q865Y0,Q8HYB1,Q9MZR8,Q9XS58" charOffset="23-27" type="protein" text="IL-4"/>
            <entity id="DS.d159.s0.e1" origId="P20109,P35225,P42203,P61126,Q5I6E4,Q864V6,Q865W5,Q865X3,Q95J68,Q9N0W9,Q9XSV9" charOffset="29-34" type="protein" text="IL-13"/>
            <entity id="DS.d159.s0.e2" origId="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5" charOffset="36-41" type="protein" text="IL-10"/>
            <entity id="DS.d159.s0.e3" origId="O46678,O55235,P09340,P09341" charOffset="47-50" type="protein" text="GRO"/>
            <entity id="DS.d159.s0.e4" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="134-138" type="protein" text="IL-6"/>
            <entity id="DS.d159.s0.e5" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="143-151" type="protein" text="TNFalpha"/>
            <entity id="DS.d159.s0.e6" origId="5327147" charOffset="211-214" type="compound" text="PEU"/>
            <pair e1="DS.d159.s0.e6" e2="DS.d159.s0.e3" id="DS.d159.s0.i0" interaction="False"/>
            <pair e1="DS.d159.s0.e6" e2="DS.d159.s0.e0" id="DS.d159.s0.i1" interaction="False"/>
            <pair e1="DS.d159.s0.e6" e2="DS.d159.s0.e1" id="DS.d159.s0.i2" interaction="False"/>
            <pair e1="DS.d159.s0.e6" e2="DS.d159.s0.e5" id="DS.d159.s0.i3" interaction="False"/>
            <pair e1="DS.d159.s0.e6" e2="DS.d159.s0.e2" id="DS.d159.s0.i4" interaction="False"/>
            <pair e1="DS.d159.s0.e6" e2="DS.d159.s0.e4" id="DS.d159.s0.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d160" origId="18431773">
        <sentence id="DS.d160.s0" origId="18431773-1123" text="Incorporation of bromodeoxyuridine into newly synthesized DNA and the concentration of vinculin, beta-actin, osteopontin, and osteocalcin in cells on the scaffolds of all pore sizes were similar to the values obtained on standard tissue culture polystyrene, which indicated good biocompatibility of the scaffolds.">
            <entity id="DS.d160.s0.e0" origId="6035" charOffset="17-34" type="compound" text="bromodeoxyuridine"/>
            <entity id="DS.d160.s0.e1" origId="O46037,P12003,P18206,P19826,P26234,Q04615,Q17162,Q64727" charOffset="87-95" type="protein" text="vinculin"/>
            <entity id="DS.d160.s0.e2" origId="O18840,O42161,O93400,P15475,P29751,P48975,P60706,P60707,P60708,P60709,P60710,P60711,P60712,P60713,P68143,P79818,P83750,P83751,P84336,P84856,Q0PGG4,Q4L0Y2,Q5R1X3,Q711N9,Q71FK5,Q76N69,Q91ZK5,Q9Y702" charOffset="97-107" type="protein" text="beta-actin"/>
            <entity id="DS.d160.s0.e3" origId="P02819,P02821,P02823,P0C225,P0C226,P15504,P28317,P39056,P81455,P83005,P83238,P83473,P83489,P84348,P84349,P84350,P84351,Q7LZI4,Q8HYY9" charOffset="126-137" type="protein" text="osteocalcin"/>
            <entity id="DS.d160.s0.e4" origId="7501" charOffset="245-256" type="compound" text="polystyrene"/>
            <pair e1="DS.d160.s0.e4" e2="DS.d160.s0.e3" id="DS.d160.s0.i0" interaction="False"/>
            <pair e1="DS.d160.s0.e0" e2="DS.d160.s0.e1" id="DS.d160.s0.i1" interaction="False"/>
            <pair e1="DS.d160.s0.e4" e2="DS.d160.s0.e1" id="DS.d160.s0.i2" interaction="False"/>
            <pair e1="DS.d160.s0.e0" e2="DS.d160.s0.e2" id="DS.d160.s0.i3" interaction="False"/>
            <pair e1="DS.d160.s0.e0" e2="DS.d160.s0.e3" id="DS.d160.s0.i4" interaction="False"/>
            <pair e1="DS.d160.s0.e4" e2="DS.d160.s0.e2" id="DS.d160.s0.i5" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d161" origId="18431776">
        <sentence id="DS.d161.s0" origId="18431776-1124" text="To determine the capabilities of previously used microsphere scaffold to deliver growth factors simultaneously, this work investigated a long-term (about three months) release of bovine serum albumin (BSA) from microsphere scaffolds fabricated by using two different polymers, poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV, 8% PHV), poly(lactide-co-glycolide) acid (PLGA, 5050) and a blend of PLGA and PHBV.">
            <entity id="DS.d161.s0.e0" origId="P21847,P83517" charOffset="186-199" type="protein" text="serum albumin"/>
            <entity id="DS.d161.s0.e1" origId="P02769" charOffset="201-204" type="protein" text="BSA"/>
            <entity id="DS.d161.s0.e2" origId="107801" charOffset="277-320" type="compound" text="poly(3-hydroxybutyrate-co-3-hydroxyvalerate"/>
            <entity id="DS.d161.s0.e3" origId="23111554" charOffset="338-363" type="compound" text="poly(lactide-co-glycolide"/>
            <entity id="DS.d161.s0.e4" origId="36797" charOffset="371-375" type="compound" text="PLGA"/>
            <entity id="DS.d161.s0.e5" origId="36797" charOffset="398-402" type="compound" text="PLGA"/>
            <pair e1="DS.d161.s0.e4" e2="DS.d161.s0.e1" id="DS.d161.s0.i0" interaction="False"/>
            <pair e1="DS.d161.s0.e2" e2="DS.d161.s0.e0" id="DS.d161.s0.i1" interaction="False"/>
            <pair e1="DS.d161.s0.e4" e2="DS.d161.s0.e0" id="DS.d161.s0.i2" interaction="False"/>
            <pair e1="DS.d161.s0.e3" e2="DS.d161.s0.e1" id="DS.d161.s0.i3" interaction="False"/>
            <pair e1="DS.d161.s0.e2" e2="DS.d161.s0.e1" id="DS.d161.s0.i4" interaction="False"/>
            <pair e1="DS.d161.s0.e3" e2="DS.d161.s0.e0" id="DS.d161.s0.i5" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d162" origId="18433938">
        <sentence id="DS.d162.s0" origId="18433938-1194" text="Prediction of CCR5 receptor binding affinity of substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas based on the heuristic method, support vector machine and projection pursuit regression.">
            <entity id="DS.d162.s0.e0" origId="O62743,O97878,O97879,O97880,O97881,O97882,O97883,O97962,O97975,P51681,P56439,P56440,P56493,P60574,P61755,P61756,P61757,P61813,P61814,P61815,P68269,P68270,Q1ZY22,Q2HJ17,Q5ECR9,Q6WN98,Q71UI8,Q8HZT9,Q95NC0,Q95NC1,Q95NC2,Q95NC3,Q95NC4,Q95NC5,Q95NC6,Q95NC7,Q95NC8,Q95NC9,Q95ND0,Q95ND1,Q95ND2,Q95NE8,Q9BGN6,Q9TV42,Q9TV43,Q9TV45,Q9TV47,Q9TV48,Q9TV49,Q9XT76" charOffset="14-18" type="protein" text="CCR5"/>
            <entity id="DS.d162.s0.e1" origId="5376415" charOffset="83-94" type="compound" text="piperidinyl"/>
            <pair e1="DS.d162.s0.e1" e2="DS.d162.s0.e0" id="DS.d162.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d162.s1" origId="18433938-1195" text="Quantitative structure-activity relationship (QSAR) models were developed to predict for CCR5 binding affinity of substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas using linear free energy relationship (LFER).">
            <entity id="DS.d162.s1.e0" origId="O62743,O97878,O97879,O97880,O97881,O97882,O97883,O97962,O97975,P51681,P56439,P56440,P56493,P60574,P61755,P61756,P61757,P61813,P61814,P61815,P68269,P68270,Q1ZY22,Q2HJ17,Q5ECR9,Q6WN98,Q71UI8,Q8HZT9,Q95NC0,Q95NC1,Q95NC2,Q95NC3,Q95NC4,Q95NC5,Q95NC6,Q95NC7,Q95NC8,Q95NC9,Q95ND0,Q95ND1,Q95ND2,Q95NE8,Q9BGN6,Q9TV42,Q9TV43,Q9TV45,Q9TV47,Q9TV48,Q9TV49,Q9XT76" charOffset="89-93" type="protein" text="CCR5"/>
            <entity id="DS.d162.s1.e1" origId="5376415" charOffset="149-160" type="compound" text="piperidinyl"/>
            <pair e1="DS.d162.s1.e1" e2="DS.d162.s1.e0" id="DS.d162.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d163" origId="18434046">
        <sentence id="DS.d163.s0" origId="18434046-291" text="It is suggested that GABA acting through the GABA(A) receptor mechanism on the expression of GnRH gene and GnRH-R gene in the hypothalamus may be involved in two processes: the biosynthesis of GnRH and the release of this neurohormone in the hypothalamus.">
            <entity id="DS.d163.s0.e0" origId="119" charOffset="21-25" type="compound" text="GABA"/>
            <entity id="DS.d163.s0.e1" origId="P26714,Q08832,Q9BLY8" charOffset="45-61" type="protein" text="GABA(A) receptor"/>
            <entity id="DS.d163.s0.e2" origId="P27429" charOffset="93-97" type="protein" text="GnRH"/>
            <entity id="DS.d163.s0.e3" origId="O18821,P30968,P30969,P32236,P32237,P49922,Q01776,Q19PY9,Q8CH60,Q8SPZ1,Q9MZI6,Q9TTI8" charOffset="107-113" type="protein" text="GnRH-R"/>
            <entity id="DS.d163.s0.e4" origId="P27429" charOffset="107-111" type="protein" text="GnRH"/>
            <pair e1="DS.d163.s0.e0" e2="DS.d163.s0.e3" id="DS.d163.s0.i0" interaction="True"/>
            <pair e1="DS.d163.s0.e0" e2="DS.d163.s0.e2" id="DS.d163.s0.i1" interaction="True"/>
            <pair e1="DS.d163.s0.e0" e2="DS.d163.s0.e1" id="DS.d163.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d164" origId="18435693">
        <sentence id="DS.d164.s0" origId="18435693-994" text="TT-induced increases in cortisol, adrenocorticotropic hormone and prolactin were reduced only after 3-h REC.">
            <entity id="DS.d164.s0.e0" origId="5754" charOffset="24-32" type="compound" text="cortisol"/>
            <entity id="DS.d164.s0.e1" origId="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5" charOffset="34-61" type="protein" text="adrenocorticotropic hormone"/>
            <entity id="DS.d164.s0.e2" origId="P10765,P22393,P33089,P33090,P33091,P43001" charOffset="66-75" type="protein" text="prolactin"/>
            <entity id="DS.d164.s0.e3" origId="Q9UIJ5" charOffset="104-107" type="protein" text="REC"/>
            <pair e1="DS.d164.s0.e0" e2="DS.d164.s0.e3" id="DS.d164.s0.i0" interaction="False"/>
            <pair e1="DS.d164.s0.e0" e2="DS.d164.s0.e1" id="DS.d164.s0.i1" interaction="False"/>
            <pair e1="DS.d164.s0.e0" e2="DS.d164.s0.e2" id="DS.d164.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d165" origId="18436224">
        <sentence id="DS.d165.s0" origId="18436224-84" text="Quercetin inhibits vascular superoxide production induced by endothelin-1 : Role of NADPH oxidase, uncoupled eNOS and PKC.">
            <entity id="DS.d165.s0.e0" origId="5280343" charOffset="0-9" type="compound" text="Quercetin"/>
            <entity id="DS.d165.s0.e1" origId="5359597" charOffset="28-38" type="compound" text="superoxide"/>
            <entity id="DS.d165.s0.e2" origId="P05305,Q28469" charOffset="61-73" type="protein" text="endothelin-1"/>
            <entity id="DS.d165.s0.e3" origId="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600" charOffset="109-113" type="protein" text="eNOS"/>
            <entity id="DS.d165.s0.e4" origId="P05130,P13677,P13678,P34722" charOffset="118-121" type="protein" text="PKC"/>
            <pair e1="DS.d165.s0.e0" e2="DS.d165.s0.e4" id="DS.d165.s0.i0" interaction="False"/>
            <pair e1="DS.d165.s0.e0" e2="DS.d165.s0.e3" id="DS.d165.s0.i1" interaction="False"/>
            <pair e1="DS.d165.s0.e1" e2="DS.d165.s0.e4" id="DS.d165.s0.i2" interaction="False"/>
            <pair e1="DS.d165.s0.e1" e2="DS.d165.s0.e3" id="DS.d165.s0.i3" interaction="False"/>
            <pair e1="DS.d165.s0.e1" e2="DS.d165.s0.e2" id="DS.d165.s0.i4" interaction="True"/>
            <pair e1="DS.d165.s0.e0" e2="DS.d165.s0.e2" id="DS.d165.s0.i5" interaction="True"/>
        </sentence>
        <sentence id="DS.d165.s3" origId="18436224-87" text="Furthermore, ET-1 increased intracellular O(2*)(-) production in all layers of the vessel, protein expression of NADPH oxidase subunit p47 (phox) without affecting p22 (phox) expression and lucigenin-enhanced chemiluminescence signal stimulated by calcium ionophore A23187.">
            <entity id="DS.d165.s3.e1" origId="O10300,P08567,P26642,P34051,Q12802,Q91375,Q9SZB9,Q9Y240" charOffset="135-138" type="protein" text="p47"/>
            <entity id="DS.d165.s3.e2" origId="O75935,P03304,P11691,P15961,P16342,P17593,P17594,P19751,P23169,P24102,P50629,P50630,P50631,P50632,P50633,P50634,P82796,Q05903,Q66198,Q8V439,Q8V6W7,Q91A29,Q9PYA3" charOffset="164-167" type="protein" text="p22"/>
            <entity id="DS.d165.s3.e3" origId="1959,11957499" charOffset="248-272" type="compound" text="calcium ionophore A23187"/>
            <pair e1="DS.d165.s3.e3" e2="DS.d165.s3.e1" id="DS.d165.s3.i0" interaction="False"/>
            <pair e1="DS.d165.s3.e3" e2="DS.d165.s3.e2" id="DS.d165.s3.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d165.s5" origId="18436224-89" text="Moreover, quercetin but not isorhamnetin, inhibited the increased PKC activity induced by ET-1.">
            <entity id="DS.d165.s5.e0" origId="5280343" charOffset="10-19" type="compound" text="quercetin"/>
            <entity id="DS.d165.s5.e1" origId="5281654" charOffset="28-40" type="compound" text="isorhamnetin"/>
            <entity id="DS.d165.s5.e2" origId="P05130,P13677,P13678,P34722" charOffset="66-69" type="protein" text="PKC"/>
            <pair e1="DS.d165.s5.e1" e2="DS.d165.s5.e2" id="DS.d165.s5.i0" interaction="False"/>
            <pair e1="DS.d165.s5.e0" e2="DS.d165.s5.e2" id="DS.d165.s5.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d165.s6" origId="18436224-90" text="Taken together these results indicate that ET-1-induced NADPH oxidase up-regulation and eNOS uncoupling via PKC leading to endothelial dysfunction and these effects were prevented by quercetin and isorhamnetin.">
            <entity id="DS.d165.s6.e1" origId="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600" charOffset="88-92" type="protein" text="eNOS"/>
            <entity id="DS.d165.s6.e2" origId="P05130,P13677,P13678,P34722" charOffset="108-111" type="protein" text="PKC"/>
            <entity id="DS.d165.s6.e3" origId="5280343" charOffset="183-192" type="compound" text="quercetin"/>
            <entity id="DS.d165.s6.e4" origId="5281654" charOffset="197-209" type="compound" text="isorhamnetin"/>
            <pair e1="DS.d165.s6.e4" e2="DS.d165.s6.e1" id="DS.d165.s6.i1" interaction="True"/>
            <pair e1="DS.d165.s6.e4" e2="DS.d165.s6.e2" id="DS.d165.s6.i2" interaction="True"/>
            <pair e1="DS.d165.s6.e3" e2="DS.d165.s6.e1" id="DS.d165.s6.i3" interaction="True"/>
            <pair e1="DS.d165.s6.e3" e2="DS.d165.s6.e2" id="DS.d165.s6.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d166" origId="18436227">
        <sentence id="DS.d166.s0" origId="18436227-91" text="We hypothesized that variants in PCSK9 that lower LDL cholesterol levels are associated with reduced prevalence and incidence of peripheral artery disease (PAD).">
            <entity id="DS.d166.s0.e0" origId="Q8NBP7" charOffset="33-38" type="protein" text="PCSK9"/>
            <entity id="DS.d166.s0.e1" origId="304,5997,6432564,11025495" charOffset="54-65" type="compound" text="cholesterol"/>
            <pair e1="DS.d166.s0.e1" e2="DS.d166.s0.e0" id="DS.d166.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d167" origId="18436346">
        <sentence id="DS.d167.s0" origId="18436346-156" text="A series of 2-aryl-naphtho(1,2-d) oxazole derivatives have been synthesized and evaluated for PTP-1B inhibitory activity.">
            <entity id="DS.d167.s0.e0" origId="9255" charOffset="34-41" type="compound" text="oxazole"/>
            <entity id="DS.d167.s0.e1" origId="O13016,P18031,P20417,P35821" charOffset="94-100" type="protein" text="PTP-1B"/>
            <pair e1="DS.d167.s0.e0" e2="DS.d167.s0.e1" id="DS.d167.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d168" origId="18436348">
        <sentence id="DS.d168.s0" origId="18436348-931" text="A new series of indanone and aurone derivatives have been synthesized and tested for in vitro AChE inhibitory activity by modified Ellman method.">
            <entity id="DS.d168.s0.e0" origId="6735" charOffset="16-24" type="compound" text="indanone"/>
            <entity id="DS.d168.s0.e1" origId="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3" charOffset="94-98" type="protein" text="AChE"/>
            <pair e1="DS.d168.s0.e0" e2="DS.d168.s0.e1" id="DS.d168.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d169" origId="18436399">
        <sentence id="DS.d169.s0" origId="18436399-180" text="Polyunsaturated fatty acids differentially alter PGF (2alpha) and PGE (2) release from bovine trophoblast and endometrial tissues during short-term culture.">
            <entity id="DS.d169.s0.e0" origId="56842239" charOffset="0-27" type="compound" text="Polyunsaturated fatty acids"/>
            <entity id="DS.d169.s0.e1" origId="P49763,Q9XS47" charOffset="49-52" type="protein" text="PGF"/>
            <entity id="DS.d169.s0.e2" origId="Q29458" charOffset="66-69" type="protein" text="PGE"/>
            <pair e1="DS.d169.s0.e0" e2="DS.d169.s0.e1" id="DS.d169.s0.i0" interaction="True"/>
            <pair e1="DS.d169.s0.e0" e2="DS.d169.s0.e2" id="DS.d169.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d169.s1" origId="18436399-181" text="Two studies tested the hypothesis that eicosapentaenoic (20:5omega3; EPA), docosahexaenoic acids (22:6omega3; DHA) or linoleic acid (C18 :2omega6; LIN) reduced bovine endometrial and trophoblast prostaglandin F(2alpha) (PGF (2alpha)) and prostaglandin E(2) (PGE (2)) release during short-term culture.">
            <entity id="DS.d169.s1.e0" origId="6433873" charOffset="75-96" type="compound" text="docosahexaenoic acids"/>
            <entity id="DS.d169.s1.e1" origId="5280450" charOffset="118-131" type="compound" text="linoleic acid"/>
            <entity id="DS.d169.s1.e2" origId="96" charOffset="147-150" type="compound" text="LIN"/>
            <entity id="DS.d169.s1.e3" origId="P49763,Q9XS47" charOffset="220-223" type="protein" text="PGF"/>
            <entity id="DS.d169.s1.e4" origId="Q29458" charOffset="258-261" type="protein" text="PGE"/>
            <pair e1="DS.d169.s1.e2" e2="DS.d169.s1.e4" id="DS.d169.s1.i0" interaction="True"/>
            <pair e1="DS.d169.s1.e2" e2="DS.d169.s1.e3" id="DS.d169.s1.i1" interaction="True"/>
            <pair e1="DS.d169.s1.e0" e2="DS.d169.s1.e4" id="DS.d169.s1.i2" interaction="True"/>
            <pair e1="DS.d169.s1.e1" e2="DS.d169.s1.e4" id="DS.d169.s1.i3" interaction="True"/>
            <pair e1="DS.d169.s1.e1" e2="DS.d169.s1.e3" id="DS.d169.s1.i4" interaction="True"/>
            <pair e1="DS.d169.s1.e0" e2="DS.d169.s1.e3" id="DS.d169.s1.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d170" origId="18437529">
        <sentence id="DS.d170.s0" origId="18437529-872" text="1-Deoxy-D-xylulose-5-phosphate synthase (DXS) catalyses the first committed step of the 2C-methyl-D-erythritol-4-phosphate (MEP) pathway, which is an alternative isoprenoids biosynthetic route that has been recently discovered.">
            <entity id="DS.d170.s0.e0" origId="O25121,O67036,O83796,O84335,P0A554,P0A555,P26242,P45205,P54523,P57536,P57848,P73067,P77488,Q0S1H1,Q0SS05,Q0TKM1,Q0TPD8,Q0VMI4,Q11KE0,Q11NY7,Q12CQ9,Q13RX1,Q18B68,Q1BLY7,Q1C4I9,Q1CL87,Q1CUF6,Q1D3G4,Q1GCG4,Q1GQK9,Q1GZD7,Q1IZP0,Q1LK34,Q1LTI9,Q1MKN4,Q1MRB3,Q1QE74,Q1QQ40,Q1R1E5,Q1RFC0,Q21A74,Q21F93,Q21UG7,Q24V05,Q253R7,Q2A3D3,Q2GC13,Q2IPZ2,Q2IRL7,Q2JDD9,Q2JK64,Q2JTX2,Q2KBR2,Q2KZ15,Q2LUA7,Q2NV94,Q2P472,Q2RIB9,Q2SA08,Q2T7N5,Q2W367,Q2YCH7,Q2YMF0,Q30TC5,Q30Z99,Q31AZ2,Q325I1,Q32JH8,Q393P4,Q3A3Z6,Q3AAN0,Q3AJP8,Q3AXZ4,Q3B5P3,Q3BRW8,Q3II09,Q3JAD1,Q3JKA3,Q3K660,Q3KM28,Q3M4F6,Q3SKF1,Q3SUZ1,Q3Z4Y9,Q3Z8G9,Q3ZXC2,Q46L36,Q474C2,Q47BJ0,Q47NL9,Q487D3,Q48NX0,Q493G7,Q4FN07,Q4FV64,Q4JVB5,Q4K5A5,Q4QKG6,Q4UW29,Q4ZYU8,Q50000,Q57ET1,Q57SE2,Q5E6Z0,Q5FAI2,Q5FUB1,Q5H1A0,Q5HWF0,Q5L6H4,Q5LH44,Q5LX42,Q5NG39,Q5P228,Q5PFR6,Q5QVE8,Q5SMD7,Q5WF63,Q5YTA2,Q60AN1,Q62DU1,Q635A7,Q63JF4,Q64Y02,Q65HJ2,Q65TP4,Q66DV4,Q67NB6,Q6A8V3,Q6AFD5,Q6AJQ1,Q6D844,Q6F7N5,Q6G0D4,Q6G4D1,Q6HDY8,Q6LU07,Q6MDK6,Q6NB76,Q6NGV3,Q71ZV7,Q72CD3,Q72H81,Q72U01,Q731B7,Q73LF4,Q73W57,Q75TB7,Q7M7Z0,Q7MN49,Q7MSZ3,Q7N0J7,Q7NP63,Q7NUK5,Q7U6P6,Q7UWB7,Q7V1G6,Q7V7Q3,Q7VC14,Q7VIJ7,Q7VNP7,Q7VRH9,Q7VV87,Q7W7Q0,Q7WL37,Q818R9,Q81M54,Q823V1,Q82VD3,Q83G46,Q83I20,Q83SG2,Q87C03,Q87RU0,Q889Q1,Q88QG7,Q894H0,Q89RW1,Q8A0C2,Q8D357,Q8DFA3,Q8DL74,Q8EGR9,Q8EWX7,Q8F153,Q8FKB9,Q8FPI2,Q8G292,Q8GAA0,Q8K9A1,Q8KFI9,Q8NPB2,Q8P815,Q8PJG7,Q8R639,Q8RAC5,Q8UHD7,Q8XE76,Q8XJE1,Q8XX95,Q8Y7C1,Q8YFM2,Q8YZ80,Q8Z8X3,Q8ZC45,Q8ZRD1,Q92BZ0,Q92RJ1,Q97HD5,Q985Y3,Q9A6M5,Q9JW13,Q9JXV7,Q9K971,Q9KGU7,Q9KTL3,Q9PB95,Q9PIH8,Q9PK62,Q9R6S7,Q9RBN6,Q9RUB5,Q9X291,Q9Z6J9,Q9ZM94" charOffset="0-39" type="protein" text="1-Deoxy-D-xylulose-5-phosphate synthase"/>
            <entity id="DS.d170.s0.e1" origId="192838,3262721" charOffset="98-122" type="compound" text="D-erythritol-4-phosphate"/>
            <entity id="DS.d170.s0.e2" origId="7728" charOffset="124-127" type="compound" text="MEP"/>
            <pair e1="DS.d170.s0.e2" e2="DS.d170.s0.e0" id="DS.d170.s0.i0" interaction="True"/>
            <pair e1="DS.d170.s0.e1" e2="DS.d170.s0.e0" id="DS.d170.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d171" origId="18437557">
        <sentence id="DS.d171.s0" origId="18437557-896" text="To get insight into the underlying mechanisms, we compared the ability of recombinant wild type and variant (D327N) SHBG to influence estradiol effects in MCF-7 breast cancer cells.">
            <entity id="DS.d171.s0.e0" origId="P04278,P08689,P15196,P97497,Q62588" charOffset="116-120" type="protein" text="SHBG"/>
            <entity id="DS.d171.s0.e1" origId="5757" charOffset="134-143" type="compound" text="estradiol"/>
            <pair e1="DS.d171.s0.e1" e2="DS.d171.s0.e0" id="DS.d171.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d171.s1" origId="18437557-897" text="D327N SHBG was more effective than wild type protein in inhibiting estradiol-induced cell proliferation and anti-apoptosis.">
            <entity id="DS.d171.s1.e0" origId="P04278,P08689,P15196,P97497,Q62588" charOffset="6-10" type="protein" text="SHBG"/>
            <entity id="DS.d171.s1.e1" origId="5757" charOffset="67-76" type="compound" text="estradiol"/>
            <pair e1="DS.d171.s1.e1" e2="DS.d171.s1.e0" id="DS.d171.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d172" origId="18437699">
        <sentence id="DS.d172.s0" origId="18437699-978" text="Our results suggest that Ni(II)-induced changes in cytokine secretion by monocytes are diverse and may be influenced by Nrf2 but are not likely influenced by changes in whole-cell Trx1 levels.">
            <entity id="DS.d172.s0.e0" origId="934" charOffset="25-30" type="compound" text="Ni(II"/>
            <entity id="DS.d172.s0.e1" origId="O54968,Q60795" charOffset="120-124" type="protein" text="Nrf2"/>
            <entity id="DS.d172.s0.e2" origId="O14463,P29445,Q8KEA4" charOffset="180-184" type="protein" text="Trx1"/>
            <pair e1="DS.d172.s0.e0" e2="DS.d172.s0.e2" id="DS.d172.s0.i0" interaction="True"/>
            <pair e1="DS.d172.s0.e0" e2="DS.d172.s0.e1" id="DS.d172.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d173" origId="18439591">
        <sentence id="DS.d173.s0" origId="18439591-271" text="To test the hypothesis that increasing DHEAS levels is associated with improved insulin resistance in patients with polycystic ovary syndrome (PCOS).">
            <entity id="DS.d173.s0.e0" origId="12594" charOffset="39-44" type="compound" text="DHEAS"/>
            <entity id="DS.d173.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="80-87" type="protein" text="insulin"/>
            <pair e1="DS.d173.s0.e0" e2="DS.d173.s0.e1" id="DS.d173.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d174" origId="18440842">
        <sentence id="DS.d174.s0" origId="18440842-362" text="Packed cell volume, total protein, creatinine, blood urea nitrogen, and sorbitol dehydrogenase concentrations decreased while foals were on PN, while serum chloride concentration increased.">
            <entity id="DS.d174.s0.e0" origId="588" charOffset="35-45" type="compound" text="creatinine"/>
            <entity id="DS.d174.s0.e1" origId="1176,265993" charOffset="53-57" type="compound" text="urea"/>
            <entity id="DS.d174.s0.e2" origId="947,123329" charOffset="58-66" type="compound" text="nitrogen"/>
            <entity id="DS.d174.s0.e3" origId="P07846,P27867,Q00796,Q02912,Q06004,Q29318,Q4R639,Q58D31,Q59787,Q64442,Q9Z9U1" charOffset="72-94" type="protein" text="sorbitol dehydrogenase"/>
            <entity id="DS.d174.s0.e4" origId="312" charOffset="156-164" type="compound" text="chloride"/>
            <pair e1="DS.d174.s0.e1" e2="DS.d174.s0.e3" id="DS.d174.s0.i0" interaction="False"/>
            <pair e1="DS.d174.s0.e4" e2="DS.d174.s0.e3" id="DS.d174.s0.i1" interaction="False"/>
            <pair e1="DS.d174.s0.e2" e2="DS.d174.s0.e3" id="DS.d174.s0.i2" interaction="False"/>
            <pair e1="DS.d174.s0.e0" e2="DS.d174.s0.e3" id="DS.d174.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d175" origId="18442069">
        <sentence id="DS.d175.s0" origId="18442069-1161" text="The gene expressions of CYP1A1 and CYP2E1 in the placenta increased significantly in nicotine-treated groups on GD 15 and GD 18, but returned to the level similar to the corresponding control on GD 21.">
            <entity id="DS.d175.s0.e0" origId="O42231,O42430,O42457,P00185,P04798,P05176,P33616,P56590,P56591,P79716,P98181,Q00557,Q06367,Q3LFU0,Q5KQT7,Q6GUR1,Q6JZS3,Q92039,Q92095,Q92100,Q92109,Q92110,Q92116,Q92148,Q9W683,Q9YH64" charOffset="24-30" type="protein" text="CYP1A1"/>
            <entity id="DS.d175.s0.e1" origId="O18963,P05181,P08682,P33266,P51581,P79383,Q6GUQ4" charOffset="35-41" type="protein" text="CYP2E1"/>
            <entity id="DS.d175.s0.e2" origId="942,89594,157672" charOffset="85-93" type="compound" text="nicotine"/>
            <pair e1="DS.d175.s0.e2" e2="DS.d175.s0.e1" id="DS.d175.s0.i0" interaction="True"/>
            <pair e1="DS.d175.s0.e2" e2="DS.d175.s0.e0" id="DS.d175.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d175.s1" origId="18442069-1162" text="In nicotine group, there was a decrease of mdr1a expression on GD 15, GD 18, and GD 21, with the most significant decrease on GD 15.">
            <entity id="DS.d175.s1.e0" origId="942,89594,157672" charOffset="3-11" type="compound" text="nicotine"/>
            <entity id="DS.d175.s1.e1" origId="P21447" charOffset="43-48" type="protein" text="mdr1a"/>
            <pair e1="DS.d175.s1.e0" e2="DS.d175.s1.e1" id="DS.d175.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d176" origId="18442070">
        <sentence id="DS.d176.s0" origId="18442070-1163" text="The present study was designed to understand the effects of sublethal concentrations of dichlorvos (DIC) on hematological constituent (red blood corpuscles, white blood corpuscles (WBC), mean cell volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet counts, hemoglobin and hematocrite levels) and serum damage marker enzymes (aspartate aminotransferase, alanin aminotransferase, alkaline phosphatase, and lactate dehydrogenase) in rats at subacute period under laboratory conditions.">
            <entity id="DS.d176.s0.e0" origId="3039" charOffset="88-98" type="compound" text="dichlorvos"/>
            <entity id="DS.d176.s0.e1" origId="P15160,P17724,P73925,Q03459" charOffset="222-232" type="protein" text="hemoglobin"/>
            <entity id="DS.d176.s0.e2" origId="P15160,P17724,P73925,Q03459" charOffset="251-261" type="protein" text="hemoglobin"/>
            <entity id="DS.d176.s0.e3" origId="P15160,P17724,P73925,Q03459" charOffset="251-261" type="protein" text="hemoglobin"/>
            <entity id="DS.d176.s0.e4" origId="O33822,O58489,O67781,O86459,O93744,P00509,P14909,P23034,P44425,P53001,P58661,P72173,Q4J8X2,Q55128,Q56114,Q56232,Q59228,Q60013,Q92JE7,Q972A2,Q9V0L2,Q9X0Y2,Q9ZE56" charOffset="362-388" type="protein" text="aspartate aminotransferase"/>
            <entity id="DS.d176.s0.e5" origId="O60109,P81800,P83456" charOffset="415-435" type="protein" text="alkaline phosphatase"/>
            <pair e1="DS.d176.s0.e0" e2="DS.d176.s0.e4" id="DS.d176.s0.i0" interaction="False"/>
            <pair e1="DS.d176.s0.e0" e2="DS.d176.s0.e5" id="DS.d176.s0.i1" interaction="False"/>
            <pair e1="DS.d176.s0.e0" e2="DS.d176.s0.e1" id="DS.d176.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d177" origId="18442075">
        <sentence id="DS.d177.s0" origId="18442075-634" text="Melatonin altered PHZ-induced responses significantly to a greater degree than vitamin E as evidenced by LPO status, SOD activity, and ABTS radical cation scavenging activity of antioxidants.">
            <entity id="DS.d177.s0.e0" origId="896" charOffset="0-9" type="compound" text="Melatonin"/>
            <entity id="DS.d177.s0.e1" origId="7516" charOffset="18-21" type="compound" text="PHZ"/>
            <entity id="DS.d177.s0.e2" origId="2116,14985,1548900,1742129" charOffset="79-88" type="compound" text="vitamin E"/>
            <entity id="DS.d177.s0.e3" origId="P22079,P80025" charOffset="105-108" type="protein" text="LPO"/>
            <entity id="DS.d177.s0.e4" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="117-120" type="protein" text="SOD"/>
            <entity id="DS.d177.s0.e5" origId="5464076" charOffset="135-154" type="compound" text="ABTS radical cation"/>
            <pair e1="DS.d177.s0.e2" e2="DS.d177.s0.e4" id="DS.d177.s0.i0" interaction="False"/>
            <pair e1="DS.d177.s0.e0" e2="DS.d177.s0.e4" id="DS.d177.s0.i1" interaction="True"/>
            <pair e1="DS.d177.s0.e0" e2="DS.d177.s0.e3" id="DS.d177.s0.i2" interaction="True"/>
            <pair e1="DS.d177.s0.e1" e2="DS.d177.s0.e4" id="DS.d177.s0.i3" interaction="False"/>
            <pair e1="DS.d177.s0.e5" e2="DS.d177.s0.e3" id="DS.d177.s0.i4" interaction="False"/>
            <pair e1="DS.d177.s0.e5" e2="DS.d177.s0.e4" id="DS.d177.s0.i5" interaction="False"/>
            <pair e1="DS.d177.s0.e1" e2="DS.d177.s0.e3" id="DS.d177.s0.i6" interaction="False"/>
            <pair e1="DS.d177.s0.e2" e2="DS.d177.s0.e3" id="DS.d177.s0.i7" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d178" origId="18443829">
        <sentence id="DS.d178.s0" origId="18443829-973" text="The hydrolysis reaction of p-nitrophenyl butyrate catalyzed by lipases was followed with in situ UV/vis diode array spectrophotometry.">
            <entity id="DS.d178.s0.e0" origId="75834" charOffset="27-49" type="compound" text="p-nitrophenyl butyrate"/>
            <entity id="DS.d178.s0.e1" origId="Q7M4U7" charOffset="63-70" type="protein" text="lipases"/>
            <pair e1="DS.d178.s0.e0" e2="DS.d178.s0.e1" id="DS.d178.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d178.s1" origId="18443829-974" text="Five enzymes-Candida antarctica lipase B and Fusarium solani pisi cutinase wild-type and three single-mutation variants-were tested as catalysts in homogeneous conditions and immobilized on zeolite NaY, on a polyacrylate support and as cross-linked aggregates.">
            <entity id="DS.d178.s1.e0" origId="Q7M4U7" charOffset="32-38" type="protein" text="lipase"/>
            <entity id="DS.d178.s1.e1" origId="445523" charOffset="198-201" type="compound" text="NaY"/>
            <entity id="DS.d178.s1.e2" origId="6581" charOffset="208-220" type="compound" text="polyacrylate"/>
            <pair e1="DS.d178.s1.e2" e2="DS.d178.s1.e0" id="DS.d178.s1.i0" interaction="False"/>
            <pair e1="DS.d178.s1.e1" e2="DS.d178.s1.e0" id="DS.d178.s1.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d179" origId="18443843">
        <sentence id="DS.d179.s0" origId="18443843-1157" text="At term, the impact of their coexposure was assessed by evaluating lipid peroxidation (LPO), activities of superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), glutathione-S-transferase (GST), different ATPases and acetylcholinesterase (AChE) in erythrocytes, serum glucose, and levels of glutathione (GSH) and glycosylated hemoglobin (GHb) in blood.">
            <entity id="DS.d179.s0.e0" origId="P22079,P80025" charOffset="87-90" type="protein" text="LPO"/>
            <entity id="DS.d179.s0.e1" origId="O50258" charOffset="107-127" type="protein" text="superoxide dismutase"/>
            <entity id="DS.d179.s0.e2" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="129-132" type="protein" text="SOD"/>
            <entity id="DS.d179.s0.e3" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="135-143" type="protein" text="catalase"/>
            <entity id="DS.d179.s0.e4" origId="O32770,O59858,Q00277,Q9CFV1" charOffset="145-167" type="protein" text="glutathione peroxidase"/>
            <entity id="DS.d179.s0.e5" origId="O04437,O18598,P0A9D2,P0A9D3,P30116,P44521,P46088,P46419,P46423,P46426,P46428,P46437,P48438,P80894,P81065,P82996,P82997,P82998,P82999,P83000,P83001,P83246,Q04522,Q08392,Q08393,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52,Q96324" charOffset="175-200" type="protein" text="glutathione-S-transferase"/>
            <entity id="DS.d179.s0.e6" origId="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52" charOffset="202-205" type="protein" text="GST"/>
            <entity id="DS.d179.s0.e7" origId="Q867X2,Q867X3,Q86GC9,Q92081" charOffset="230-250" type="protein" text="acetylcholinesterase"/>
            <entity id="DS.d179.s0.e8" origId="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3" charOffset="252-256" type="protein" text="AChE"/>
            <entity id="DS.d179.s0.e9" origId="206,5793,64689,79025" charOffset="281-288" type="compound" text="glucose"/>
            <entity id="DS.d179.s0.e10" origId="124886" charOffset="145-156" type="compound" text="glutathione"/>
            <entity id="DS.d179.s0.e11" origId="124886" charOffset="317-320" type="compound" text="GSH"/>
            <entity id="DS.d179.s0.e12" origId="P15160,P17724,P73925,Q03459" charOffset="339-349" type="protein" text="hemoglobin"/>
            <pair e1="DS.d179.s0.e11" e2="DS.d179.s0.e6" id="DS.d179.s0.i0" interaction="False"/>
            <pair e1="DS.d179.s0.e10" e2="DS.d179.s0.e6" id="DS.d179.s0.i1" interaction="False"/>
            <pair e1="DS.d179.s0.e9" e2="DS.d179.s0.e3" id="DS.d179.s0.i2" interaction="False"/>
            <pair e1="DS.d179.s0.e11" e2="DS.d179.s0.e1" id="DS.d179.s0.i3" interaction="False"/>
            <pair e1="DS.d179.s0.e11" e2="DS.d179.s0.e12" id="DS.d179.s0.i4" interaction="False"/>
            <pair e1="DS.d179.s0.e11" e2="DS.d179.s0.e2" id="DS.d179.s0.i5" interaction="False"/>
            <pair e1="DS.d179.s0.e10" e2="DS.d179.s0.e8" id="DS.d179.s0.i6" interaction="False"/>
            <pair e1="DS.d179.s0.e11" e2="DS.d179.s0.e0" id="DS.d179.s0.i7" interaction="False"/>
            <pair e1="DS.d179.s0.e9" e2="DS.d179.s0.e5" id="DS.d179.s0.i8" interaction="False"/>
            <pair e1="DS.d179.s0.e9" e2="DS.d179.s0.e7" id="DS.d179.s0.i9" interaction="False"/>
            <pair e1="DS.d179.s0.e10" e2="DS.d179.s0.e2" id="DS.d179.s0.i10" interaction="False"/>
            <pair e1="DS.d179.s0.e9" e2="DS.d179.s0.e1" id="DS.d179.s0.i11" interaction="False"/>
            <pair e1="DS.d179.s0.e9" e2="DS.d179.s0.e4" id="DS.d179.s0.i12" interaction="False"/>
            <pair e1="DS.d179.s0.e10" e2="DS.d179.s0.e3" id="DS.d179.s0.i13" interaction="False"/>
            <pair e1="DS.d179.s0.e10" e2="DS.d179.s0.e7" id="DS.d179.s0.i14" interaction="False"/>
            <pair e1="DS.d179.s0.e9" e2="DS.d179.s0.e12" id="DS.d179.s0.i15" interaction="False"/>
            <pair e1="DS.d179.s0.e11" e2="DS.d179.s0.e4" id="DS.d179.s0.i16" interaction="False"/>
            <pair e1="DS.d179.s0.e10" e2="DS.d179.s0.e0" id="DS.d179.s0.i17" interaction="False"/>
            <pair e1="DS.d179.s0.e9" e2="DS.d179.s0.e8" id="DS.d179.s0.i18" interaction="False"/>
            <pair e1="DS.d179.s0.e11" e2="DS.d179.s0.e5" id="DS.d179.s0.i19" interaction="False"/>
            <pair e1="DS.d179.s0.e10" e2="DS.d179.s0.e1" id="DS.d179.s0.i20" interaction="False"/>
            <pair e1="DS.d179.s0.e10" e2="DS.d179.s0.e4" id="DS.d179.s0.i21" interaction="False"/>
            <pair e1="DS.d179.s0.e9" e2="DS.d179.s0.e2" id="DS.d179.s0.i22" interaction="False"/>
            <pair e1="DS.d179.s0.e9" e2="DS.d179.s0.e0" id="DS.d179.s0.i23" interaction="False"/>
            <pair e1="DS.d179.s0.e11" e2="DS.d179.s0.e7" id="DS.d179.s0.i24" interaction="False"/>
            <pair e1="DS.d179.s0.e11" e2="DS.d179.s0.e8" id="DS.d179.s0.i25" interaction="False"/>
            <pair e1="DS.d179.s0.e10" e2="DS.d179.s0.e5" id="DS.d179.s0.i26" interaction="False"/>
            <pair e1="DS.d179.s0.e10" e2="DS.d179.s0.e12" id="DS.d179.s0.i27" interaction="False"/>
            <pair e1="DS.d179.s0.e11" e2="DS.d179.s0.e3" id="DS.d179.s0.i28" interaction="False"/>
            <pair e1="DS.d179.s0.e9" e2="DS.d179.s0.e6" id="DS.d179.s0.i29" interaction="False"/>
        </sentence>
        <sentence id="DS.d179.s1" origId="18443843-1158" text="Catalase was decreased with endosulfan and the coexposure, but not with arsenic, whereas GSH was decreased with arsenic and endosulfan, but not with the coexposure.">
            <entity id="DS.d179.s1.e0" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="0-8" type="protein" text="Catalase"/>
            <entity id="DS.d179.s1.e1" origId="3224" charOffset="28-38" type="compound" text="endosulfan"/>
            <entity id="DS.d179.s1.e2" origId="124886" charOffset="89-92" type="compound" text="GSH"/>
            <entity id="DS.d179.s1.e3" origId="3224" charOffset="124-134" type="compound" text="endosulfan"/>
            <pair e1="DS.d179.s1.e1" e2="DS.d179.s1.e0" id="DS.d179.s1.i0" interaction="True"/>
            <pair e1="DS.d179.s1.e2" e2="DS.d179.s1.e0" id="DS.d179.s1.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d179.s2" origId="18443843-1159" text="Na+-K+-ATPase activity was decreased in the endosulfan-treated and the coexposed birds.">
            <entity id="DS.d179.s2.e0" origId="P13607,P17326,P28774,P35317" charOffset="0-13" type="protein" text="Na+-K+-ATPase"/>
            <entity id="DS.d179.s2.e1" origId="3224" charOffset="44-54" type="compound" text="endosulfan"/>
            <pair e1="DS.d179.s2.e1" e2="DS.d179.s2.e0" id="DS.d179.s2.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d180" origId="18443897">
        <sentence id="DS.d180.s0" origId="18443897-1003" text="mRNA and protein levels of TNF-alpha, Fas, and caspase-8, which are closely related to cell apoptosis by a death ligand/receptor-dependent apoptosis pathway, were increased by L-carnitine treatment.">
            <entity id="DS.d180.s0.e0" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="27-36" type="protein" text="TNF-alpha"/>
            <entity id="DS.d180.s0.e1" origId="P25446,Q63199" charOffset="38-41" type="protein" text="Fas"/>
            <entity id="DS.d180.s0.e2" origId="10918" charOffset="176-187" type="compound" text="L-carnitine"/>
            <pair e1="DS.d180.s0.e2" e2="DS.d180.s0.e0" id="DS.d180.s0.i0" interaction="True"/>
            <pair e1="DS.d180.s0.e2" e2="DS.d180.s0.e1" id="DS.d180.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d180.s1" origId="18443897-1004" text="In addition, L-carnitine treatment regulated mitochondria-dependent apoptosis pathways by inducing the up-regulation of caspase-9 and caspase-3 and the down-regulation of Bcl-2 in hepa1c1c 7 cells.">
            <entity id="DS.d180.s1.e0" origId="10918" charOffset="13-24" type="compound" text="L-carnitine"/>
            <entity id="DS.d180.s1.e1" origId="P10417,P49950" charOffset="171-176" type="protein" text="Bcl-2"/>
            <pair e1="DS.d180.s1.e0" e2="DS.d180.s1.e1" id="DS.d180.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d180.s2" origId="18443897-1005" text="Taken together, the findings of this study have demonstrated that L-carnitine could induce apoptosis in hepa1c1c7 cells by regulating Fas ligands and inhibiting the expression of Bcl-2.">
            <entity id="DS.d180.s2.e0" origId="10918" charOffset="66-77" type="compound" text="L-carnitine"/>
            <entity id="DS.d180.s2.e1" origId="P36940,P41047,P48023,P63306,P63307,P63308,Q861W5,Q9BDN1,Q9BEA8" charOffset="134-145" type="protein" text="Fas ligands"/>
            <entity id="DS.d180.s2.e2" origId="P10417,P49950" charOffset="179-184" type="protein" text="Bcl-2"/>
            <pair e1="DS.d180.s2.e0" e2="DS.d180.s2.e1" id="DS.d180.s2.i0" interaction="True"/>
            <pair e1="DS.d180.s2.e0" e2="DS.d180.s2.e2" id="DS.d180.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d181" origId="18445079">
        <sentence id="DS.d181.s0" origId="18445079-363" text="Merlin is known to bind paxillin, beta1 integrin and focal adhesion kinase, members of focal contacts, multi-protein complexes that mediate cell adhesion to the extracellular matrix.">
            <entity id="DS.d181.s0.e0" origId="84098" charOffset="0-6" type="compound" text="Merlin"/>
            <entity id="DS.d181.s0.e1" origId="P49023,P49024,Q5R7I1,Q66H76,Q8VI36" charOffset="24-32" type="protein" text="paxillin"/>
            <pair e1="DS.d181.s0.e0" e2="DS.d181.s0.e1" id="DS.d181.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d182" origId="18445307">
        <sentence id="DS.d182.s0" origId="18445307-585" text="Furthermore, free radical overproduction and oxidative stress were associated with a significant decrease in hepatic glutathione levels in septic mice, and with an excessive NO production attributed to the induction of the inducible isoform of NO synthase (iNOS).">
            <entity id="DS.d182.s0.e0" origId="124886" charOffset="117-128" type="compound" text="glutathione"/>
            <entity id="DS.d182.s0.e1" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="257-261" type="protein" text="iNOS"/>
            <pair e1="DS.d182.s0.e0" e2="DS.d182.s0.e1" id="DS.d182.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d182.s1" origId="18445307-586" text="In fact, hepatic glutathione levels were significantly increased in the group of mice receiving the probiotic, and the increased iNOS expression both in the colon and lungs was down-regulated in those mice treated with L. fermentum.">
            <entity id="DS.d182.s1.e0" origId="124886" charOffset="17-28" type="compound" text="glutathione"/>
            <entity id="DS.d182.s1.e1" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="129-133" type="protein" text="iNOS"/>
            <pair e1="DS.d182.s1.e0" e2="DS.d182.s1.e1" id="DS.d182.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d183" origId="18448193">
        <sentence id="DS.d183.s0" origId="18448193-1146" text="Furthermore, supplementation of specific inhibitors of PAL, C4H and 4CL in elicited cell cultures led to suppressed accumulation of p-hydroxybenzoic acid, which opens up interesting questions regarding the probable route of the biosynthesis of this phenolic acid in C. nucifera.">
            <entity id="DS.d183.s0.e0" origId="O03979,O04058,O93967,P10248,P10731,P11544,P14166,P14717,P14925,P19021,P26600,P35511,P35512,P45726,P45727,P45730,P45731,P45735,P52777,P83388,P91268,P97467,Q42609,Q43210,Q9P2V4,Q9PSN0" charOffset="55-58" type="protein" text="PAL"/>
            <entity id="DS.d183.s0.e1" origId="O24312,O81928,P37114,P37115,P48522,P92994,Q04468,Q42797,Q43033,Q43054,Q43067,Q43240,Q96423,Q9AR74" charOffset="60-63" type="protein" text="C4H"/>
            <entity id="DS.d183.s0.e2" origId="O11451,O11452,O11453,O24540,O54075,O69140,P17814,P41636,P42516,P68763,P68764,P68765,P69180,P69181,P69182,P69183,P69184" charOffset="68-71" type="protein" text="4CL"/>
            <entity id="DS.d183.s0.e3" origId="135" charOffset="132-153" type="compound" text="p-hydroxybenzoic acid"/>
            <pair e1="DS.d183.s0.e3" e2="DS.d183.s0.e0" id="DS.d183.s0.i0" interaction="True"/>
            <pair e1="DS.d183.s0.e3" e2="DS.d183.s0.e2" id="DS.d183.s0.i1" interaction="True"/>
            <pair e1="DS.d183.s0.e3" e2="DS.d183.s0.e1" id="DS.d183.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d184" origId="18449471">
        <sentence id="DS.d184.s0" origId="18449471-648" text="Imatinib is transported by P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), however, the exact impact of these transporters on absorption, distribution, metabolism and excretion (ADME) of imatinib is not fully understood due to incomplete data.">
            <entity id="DS.d184.s0.e0" origId="5291" charOffset="0-8" type="compound" text="Imatinib"/>
            <entity id="DS.d184.s0.e1" origId="P08163" charOffset="29-41" type="protein" text="glycoprotein"/>
            <entity id="DS.d184.s0.e2" origId="Q9UNQ0" charOffset="53-85" type="protein" text="Breast Cancer Resistance Protein"/>
            <entity id="DS.d184.s0.e3" origId="Q9UNQ0" charOffset="87-91" type="protein" text="BCRP"/>
            <entity id="DS.d184.s0.e4" origId="5291" charOffset="206-214" type="compound" text="imatinib"/>
            <pair e1="DS.d184.s0.e4" e2="DS.d184.s0.e3" id="DS.d184.s0.i0" interaction="True"/>
            <pair e1="DS.d184.s0.e4" e2="DS.d184.s0.e2" id="DS.d184.s0.i1" interaction="True"/>
            <pair e1="DS.d184.s0.e0" e2="DS.d184.s0.e1" id="DS.d184.s0.i2" interaction="True"/>
            <pair e1="DS.d184.s0.e0" e2="DS.d184.s0.e3" id="DS.d184.s0.i3" interaction="True"/>
            <pair e1="DS.d184.s0.e0" e2="DS.d184.s0.e2" id="DS.d184.s0.i4" interaction="True"/>
            <pair e1="DS.d184.s0.e4" e2="DS.d184.s0.e1" id="DS.d184.s0.i5" interaction="True"/>
        </sentence>
        <sentence id="DS.d184.s1" origId="18449471-650" text="In conclusion, P-gp and BCRP have only a modest effect on the ADME of imatinib in comparison to metabolic elimination.">
            <entity id="DS.d184.s1.e0" origId="Q9UNQ0" charOffset="24-28" type="protein" text="BCRP"/>
            <entity id="DS.d184.s1.e1" origId="5291" charOffset="70-78" type="compound" text="imatinib"/>
            <pair e1="DS.d184.s1.e1" e2="DS.d184.s1.e0" id="DS.d184.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d184.s2" origId="18449471-651" text="The considerable drug-drug interaction observed with elacridar or pantoprazole is only partly mediated by inhibition of P-gp and BCRP and far more by the inhibition of other elimination pathways.">
            <entity id="DS.d184.s2.e0" origId="119373" charOffset="53-62" type="compound" text="elacridar"/>
            <entity id="DS.d184.s2.e1" origId="4679" charOffset="66-78" type="compound" text="pantoprazole"/>
            <entity id="DS.d184.s2.e2" origId="Q9UNQ0" charOffset="129-133" type="protein" text="BCRP"/>
            <pair e1="DS.d184.s2.e1" e2="DS.d184.s2.e2" id="DS.d184.s2.i0" interaction="True"/>
            <pair e1="DS.d184.s2.e0" e2="DS.d184.s2.e2" id="DS.d184.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d185" origId="18449536">
        <sentence id="DS.d185.s0" origId="18449536-687" text="There is clear evidence for TREK-1 and TASK-1 in the heart and these channels are likely to regulate cardiac action potential duration through their regulation by stretch, polyunsaturated fatty acids, pH, and neurotransmitters.">
            <entity id="DS.d185.s0.e0" origId="O95069" charOffset="28-32" type="protein" text="TREK"/>
            <entity id="DS.d185.s0.e1" origId="O14649" charOffset="39-43" type="protein" text="TASK"/>
            <entity id="DS.d185.s0.e2" origId="56842239" charOffset="172-199" type="compound" text="polyunsaturated fatty acids"/>
            <pair e1="DS.d185.s0.e2" e2="DS.d185.s0.e1" id="DS.d185.s0.i0" interaction="True"/>
            <pair e1="DS.d185.s0.e2" e2="DS.d185.s0.e0" id="DS.d185.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d185.s1" origId="18449536-688" text="TREK-1 may also have a critical role in mediating the vasodilator response of resistance arteries to polyunsaturated fatty acids, thus contributing to their protective effect on the cardiovascular system.">
            <entity id="DS.d185.s1.e0" origId="O95069" charOffset="0-4" type="protein" text="TREK"/>
            <entity id="DS.d185.s1.e1" origId="56842239" charOffset="101-128" type="compound" text="polyunsaturated fatty acids"/>
            <pair e1="DS.d185.s1.e1" e2="DS.d185.s1.e0" id="DS.d185.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d186" origId="18449944">
        <sentence id="DS.d186.s0" origId="18449944-953" text="Alumina ceramic particles, in comparison with titanium particles, hardly affect the expression of RANK-, TNF-alpha-, and OPG-mRNA in the THP-1 human monocytic cell line.">
            <entity id="DS.d186.s0.e0" origId="23963" charOffset="46-54" type="compound" text="titanium"/>
            <entity id="DS.d186.s0.e1" origId="Q9Y6Q6" charOffset="98-102" type="protein" text="RANK"/>
            <entity id="DS.d186.s0.e2" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="105-114" type="protein" text="TNF-alpha"/>
            <entity id="DS.d186.s0.e3" origId="O00300" charOffset="121-124" type="protein" text="OPG"/>
            <pair e1="DS.d186.s0.e0" e2="DS.d186.s0.e2" id="DS.d186.s0.i0" interaction="False"/>
            <pair e1="DS.d186.s0.e0" e2="DS.d186.s0.e1" id="DS.d186.s0.i1" interaction="False"/>
            <pair e1="DS.d186.s0.e0" e2="DS.d186.s0.e3" id="DS.d186.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d187" origId="18450412">
        <sentence id="DS.d187.s0" origId="18450412-1248" text="Indirubin-3-oxime-induced growth inhibition was associated with induction of Cdk inhibitor p21, inhibition of cyclin D1 and activation of caspase-3.">
            <entity id="DS.d187.s0.e0" origId="5326739" charOffset="0-17" type="compound" text="Indirubin-3-oxime"/>
            <entity id="DS.d187.s0.e1" origId="O01377,O16852,P04961,P12004,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P61074,Q00265,Q00268" charOffset="110-116" type="protein" text="cyclin"/>
            <pair e1="DS.d187.s0.e0" e2="DS.d187.s0.e1" id="DS.d187.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d188" origId="18452177">
        <sentence id="DS.d188.s0" origId="18452177-145" text="Three proteins, porcine somatotropin, bovine serum albumin, and immunoglobulin, as well as materials with a strong calorimetric glass transition (T(g)), that is, indomethacin and poly(vinypyrrolidone) (PVP), were studied by both TSC and differential scanning calorimetry (DSC).">
            <entity id="DS.d188.s0.e0" origId="P10766,P20391,P20392,P33092,P34005,P34006,P34747,P37885,P55755" charOffset="24-36" type="protein" text="somatotropin"/>
            <entity id="DS.d188.s0.e1" origId="P21847,P83517" charOffset="45-58" type="protein" text="serum albumin"/>
            <entity id="DS.d188.s0.e2" origId="3715" charOffset="162-174" type="compound" text="indomethacin"/>
            <pair e1="DS.d188.s0.e2" e2="DS.d188.s0.e1" id="DS.d188.s0.i0" interaction="False"/>
            <pair e1="DS.d188.s0.e2" e2="DS.d188.s0.e0" id="DS.d188.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d189" origId="18454352">
        <sentence id="DS.d189.s0" origId="18454352-1155" text="The recombinant protein exhibited high PAL activity and could catalyze the conversion of L:-Phe to trans-cinnamic acid.">
            <entity id="DS.d189.s0.e0" origId="O03979,O04058,O93967,P10248,P10731,P11544,P14166,P14717,P14925,P19021,P26600,P35511,P35512,P45726,P45727,P45730,P45731,P45735,P52777,P83388,P91268,P97467,Q42609,Q43210,Q9P2V4,Q9PSN0" charOffset="39-42" type="protein" text="PAL"/>
            <entity id="DS.d189.s0.e1" origId="444539" charOffset="99-118" type="compound" text="trans-cinnamic acid"/>
            <pair e1="DS.d189.s0.e1" e2="DS.d189.s0.e0" id="DS.d189.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d190" origId="18456422">
        <sentence id="DS.d190.s0" origId="18456422-1170" text="Only the beta-lactamases of pI 5.4 and superior to 7.6 hydrolyze the cefotaxime.">
            <entity id="DS.d190.s0.e0" origId="P80298,P80545,P81173" charOffset="9-24" type="protein" text="beta-lactamases"/>
            <entity id="DS.d190.s0.e1" origId="5479527,5742673,6540461" charOffset="69-79" type="compound" text="cefotaxime"/>
            <pair e1="DS.d190.s0.e1" e2="DS.d190.s0.e0" id="DS.d190.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d191" origId="18457934">
        <sentence id="DS.d191.s0" origId="18457934-815" text="To investigate this relationship, we used actively growing young Sprague-Dawley rats and CKD-732, one of the angiogenesis inhibitor (AI) to reveal the relationship of angiogenesis in the effect of PTH.">
            <entity id="DS.d191.s0.e0" origId="6918502" charOffset="89-96" type="compound" text="CKD-732"/>
            <entity id="DS.d191.s0.e1" origId="O27732,O28185,O66677,O74017,O74806,O83975,O84806,O85235,P01268,P01269,P01270,P04089,P0A281,P0A282,P0A7D1,P0A7D2,P0A7D3,P15743,P37470,P38876,P44682,P47329,P47714,P49607,P52212,P56077,P57287,P57820,P59490,P61234,P61235,P61414,P65863,P65864,P65865,P65866,P65867,P65868,P65869,P78034,Q27IM2,Q57NM8,Q59989,Q5F9L4,Q5FFA3,Q5FMA9,Q5FRT7,Q5GTI9,Q5GWR6,Q5HC85,Q5HIH3,Q5HRQ3,Q5HWF9,Q5JDB8,Q5L3U7,Q5LV91,Q5M222,Q5M6L4,Q5N2J4,Q5NGZ6,Q5NL75,Q5P722,Q5P9A6,Q5PCR7,Q5QV03,Q5SHZ2,Q5V1D3,Q5WAD6,Q5WTE7,Q5X1N7,Q5XEM3,Q5YPZ6,Q5ZS66,Q601M5,Q60363,Q60A14,Q62FC1,Q63HI2,Q63XM0,Q64X30,Q65PG8,Q65V47,Q65ZY7,Q66AY1,Q67JD0,Q68WD4,Q6AAC7,Q6ADQ8,Q6AJL9,Q6D557,Q6F240,Q6F8I7,Q6G0F9,Q6G2L1,Q6GBY6,Q6GJG9,Q6HPW6,Q6KHA3,Q6LNA9,Q6MJR3,Q6MS28,Q6N1P9,Q6NI78,Q6YP15,Q6YR64,Q724K0,Q72BR1,Q72IA8,Q72RZ0,Q73FF7,Q73II8,Q73Q01,Q741V9,Q74FE6,Q74LA8,Q7M7U8,Q7MMZ2,Q7MXK9,Q7N5A1,Q7NN75,Q7NQT1,Q7U9I5,Q7UKV0,Q7V342,Q7V4V4,Q7VDT7,Q7VG29,Q7VMI1,Q7VUH3,Q7W179,Q7WNY2,Q81J96,Q81VY9,Q821W6,Q82HE5,Q82TQ6,Q839C0,Q83AP0,Q83FR1,Q83HD8,Q83LE1,Q86Y79,Q877G5,Q87A24,Q87RN9,Q888C8,Q88PX8,Q88Z39,Q899I4,Q89DJ9,Q89YZ2,Q8BW00,Q8CQU9,Q8CXP8,Q8D2K4,Q8DFF4,Q8DJ45,Q8DRQ2,Q8DWN5,Q8E2I1,Q8E7Y8,Q8EHN5,Q8EWQ8,Q8F3Q2,Q8FQV6,Q8G5I6,Q8K8Z7,Q8K9V3,Q8KD05,Q8P327,Q8PC61,Q8PNT8,Q8Q0M4,Q8R757,Q8RIJ5,Q8RLD7,Q8TKX4,Q8TV04,Q8U0N0,Q8UD97,Q8XHJ8,Q8Y2E3,Q8YAD1,Q8YYK4,Q8ZEY4,Q8ZYM4,Q92F62,Q92H41,Q92N67,Q976I0,Q97CB4,Q97E97,Q97TD1,Q980V1,Q98HV6,Q98PE2,Q9A206,Q9AAV9,Q9AEQ5,Q9CD49,Q9CJI1,Q9F8Q3,Q9GL67,Q9HLW6,Q9HVC3,Q9J5H2,Q9JV42,Q9K029,Q9K3T8,Q9KGJ3,Q9KQ21,Q9PA78,Q9PII7,Q9PR67,Q9RRW3,Q9V108,Q9X1W1,Q9XT35,Q9YBD6,Q9Z6V6,Q9ZCV4,Q9ZJC3" charOffset="197-200" type="protein" text="PTH"/>
            <pair e1="DS.d191.s0.e0" e2="DS.d191.s0.e1" id="DS.d191.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d192" origId="18458677">
        <sentence id="DS.d192.s0" origId="18458677-190" text="Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment.">
            <entity id="DS.d192.s0.e0" origId="P41693" charOffset="32-45" type="protein" text="interleukin-6"/>
            <entity id="DS.d192.s0.e1" origId="37542" charOffset="138-147" type="compound" text="ribavirin"/>
            <pair e1="DS.d192.s0.e1" e2="DS.d192.s0.e0" id="DS.d192.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d193" origId="18458952">
        <sentence id="DS.d193.s0" origId="18458952-1204" text="An alpha-numeric code for representing N-linked glycan structures in secreted glycoproteins.">
            <entity id="DS.d193.s0.e0" origId="871" charOffset="48-54" type="compound" text="glycan"/>
            <entity id="DS.d193.s0.e1" origId="P08163" charOffset="78-91" type="protein" text="glycoproteins"/>
            <pair e1="DS.d193.s0.e0" e2="DS.d193.s0.e1" id="DS.d193.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d193.s1" origId="18458952-1205" text="Towards this end, we propose a fixed-length alpha-numeric code for representing N-linked glycan structures commonly found in secreted glycoproteins from mammalian cell cultures.">
            <entity id="DS.d193.s1.e0" origId="871" charOffset="89-95" type="compound" text="glycan"/>
            <entity id="DS.d193.s1.e1" origId="P08163" charOffset="134-147" type="protein" text="glycoproteins"/>
            <pair e1="DS.d193.s1.e0" e2="DS.d193.s1.e1" id="DS.d193.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d194" origId="18458994">
        <sentence id="DS.d194.s0" origId="18458994-119" text="There was a significant increase in cytochrome-c oxidase activity at 2.5 mg/L, which might indicate irgarol's disruption of the mitochondrial membrane and subsequently ATP synthesis.">
            <entity id="DS.d194.s0.e0" origId="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3" charOffset="36-48" type="protein" text="cytochrome-c"/>
            <entity id="DS.d194.s0.e1" origId="91590" charOffset="100-107" type="compound" text="irgarol"/>
            <entity id="DS.d194.s0.e2" origId="5957" charOffset="168-171" type="compound" text="ATP"/>
            <pair e1="DS.d194.s0.e1" e2="DS.d194.s0.e0" id="DS.d194.s0.i0" interaction="True"/>
            <pair e1="DS.d194.s0.e2" e2="DS.d194.s0.e0" id="DS.d194.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d195" origId="18459128">
        <sentence id="DS.d195.s0" origId="18459128-282" text="Treatment of A549, which express wild-type p53, and H1299, which are p53-deficient, human lung cancer cells with berberine resulted in inhibition of cell proliferation and an increase in apoptotic cell death ; however, A549 cells were more sensitive to the berberine-induced cytotoxic effects than H1299 cells.">
            <entity id="DS.d195.s0.e0" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="43-46" type="protein" text="p53"/>
            <entity id="DS.d195.s0.e1" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="69-72" type="protein" text="p53"/>
            <entity id="DS.d195.s0.e2" origId="2353" charOffset="113-122" type="compound" text="berberine"/>
            <entity id="DS.d195.s0.e3" origId="2353" charOffset="257-266" type="compound" text="berberine"/>
            <pair e1="DS.d195.s0.e2" e2="DS.d195.s0.e0" id="DS.d195.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d196" origId="18459941">
        <sentence id="DS.d196.s0" origId="18459941-785" text="Furthermore atorvastatin treatment markedly decreased the levels of TNF-alpha, IL-6 and MCP-1, reduced myocardial infiltration of macrophages and significantly increased myocardial and serum levels of the anti-inflammatory cytokine IL-10.">
            <entity id="DS.d196.s0.e0" origId="60823" charOffset="12-24" type="compound" text="atorvastatin"/>
            <entity id="DS.d196.s0.e1" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="68-77" type="protein" text="TNF-alpha"/>
            <entity id="DS.d196.s0.e2" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="79-83" type="protein" text="IL-6"/>
            <entity id="DS.d196.s0.e3" origId="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3" charOffset="88-93" type="protein" text="MCP-1"/>
            <entity id="DS.d196.s0.e4" origId="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5" charOffset="232-237" type="protein" text="IL-10"/>
            <pair e1="DS.d196.s0.e0" e2="DS.d196.s0.e4" id="DS.d196.s0.i0" interaction="True"/>
            <pair e1="DS.d196.s0.e0" e2="DS.d196.s0.e3" id="DS.d196.s0.i1" interaction="True"/>
            <pair e1="DS.d196.s0.e0" e2="DS.d196.s0.e2" id="DS.d196.s0.i2" interaction="True"/>
            <pair e1="DS.d196.s0.e0" e2="DS.d196.s0.e1" id="DS.d196.s0.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d196.s1" origId="18459941-787" text="Our study suggests that the modulation of the balance between pro- and anti-inflammatory cytokines towards the anti-inflammatory cytokine IL-10 is one salutary mechanism underlying how atorvastatin influences post-MI remodelling and thus improves LV function.">
            <entity id="DS.d196.s1.e0" origId="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5" charOffset="138-143" type="protein" text="IL-10"/>
            <entity id="DS.d196.s1.e1" origId="60823" charOffset="185-197" type="compound" text="atorvastatin"/>
            <pair e1="DS.d196.s1.e1" e2="DS.d196.s1.e0" id="DS.d196.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d197" origId="18459944">
        <sentence id="DS.d197.s0" origId="18459944-788" text="In addition, AUDA treatment attenuated macrophage infiltration and inhibited urinary excretion of MCP-1 (monocyte chemoattractant protein-1) and kidney cortex MCP-1 gene expression.">
            <entity id="DS.d197.s0.e0" origId="10069117" charOffset="13-17" type="compound" text="AUDA"/>
            <entity id="DS.d197.s0.e1" origId="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3" charOffset="98-103" type="protein" text="MCP-1"/>
            <entity id="DS.d197.s0.e2" origId="P10148,P13500,P14844,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3" charOffset="105-139" type="protein" text="monocyte chemoattractant protein-1"/>
            <entity id="DS.d197.s0.e3" origId="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3" charOffset="159-164" type="protein" text="MCP-1"/>
            <pair e1="DS.d197.s0.e0" e2="DS.d197.s0.e1" id="DS.d197.s0.i0" interaction="True"/>
            <pair e1="DS.d197.s0.e0" e2="DS.d197.s0.e2" id="DS.d197.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d198" origId="18462831">
        <sentence id="DS.d198.s0" origId="18462831-74" text="Exogenous spermidine, arsenic and beta-aminobutyric acid modulate tobacco resistance to tobacco mosaic virus, and affect local and systemic glucosylsalicylic acid levels and arginine decarboxylase gene expression in tobacco leaves.">
            <entity id="DS.d198.s0.e0" origId="1102" charOffset="10-20" type="compound" text="spermidine"/>
            <entity id="DS.d198.s0.e1" origId="10932" charOffset="34-56" type="compound" text="beta-aminobutyric acid"/>
            <entity id="DS.d198.s0.e2" origId="O81160,O82475,P21885,P22220,P49726,Q39827,Q43075,Q819L4,Q81MS2,Q96412,Q96A70,Q9K9K5,Q9SNN0" charOffset="174-196" type="protein" text="arginine decarboxylase"/>
            <pair e1="DS.d198.s0.e1" e2="DS.d198.s0.e2" id="DS.d198.s0.i0" interaction="True"/>
            <pair e1="DS.d198.s0.e0" e2="DS.d198.s0.e2" id="DS.d198.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d198.s1" origId="18462831-75" text="Moreover, this phenotypic response was correlated with changes in the endogenous concentration of the SAR-related molecule salicylic acid and in transcript levels of some pathogenesis/stress-related genes (pathogenesis-related proteins PR-1a and PR-2 and arginine decarboxylase (ADC)).">
            <entity id="DS.d198.s1.e0" origId="338" charOffset="123-137" type="compound" text="salicylic acid"/>
            <entity id="DS.d198.s1.e1" origId="P83834" charOffset="206-235" type="protein" text="pathogenesis-related proteins"/>
            <entity id="DS.d198.s1.e2" origId="P33157,P51525" charOffset="246-250" type="protein" text="PR-2"/>
            <entity id="DS.d198.s1.e3" origId="O81160,O82475,P21885,P22220,P49726,Q39827,Q43075,Q819L4,Q81MS2,Q96412,Q96A70,Q9K9K5,Q9SNN0" charOffset="255-277" type="protein" text="arginine decarboxylase"/>
            <entity id="DS.d198.s1.e4" origId="O81160,O82475,P21170,P22220,P23670,P28629,P49726,P60658,P60659,P81336,Q39827,Q43075,Q7MK24,Q7N121,Q7NE10,Q7NSA6,Q7NU27,Q7TUJ9,Q7U3S0,Q7UTS2,Q7V3M9,Q7VEG4,Q83Q93,Q87F25,Q87JS8,Q87VU3,Q88QC7,Q8A2B1,Q8BVM4,Q8DA54,Q8DHY6,Q8EFU5,Q8FE34,Q8P448,Q8PFQ5,Q8XCX9,Q8XR10,Q8YRP3,Q8ZHG8,Q96412,Q96A70,Q9CL60,Q9EYI7,Q9HUX1,Q9JT25,Q9K0U3,Q9KLD1,Q9PH02,Q9RPK1,Q9RXR4,Q9SNN0" charOffset="279-282" type="protein" text="ADC"/>
            <pair e1="DS.d198.s1.e0" e2="DS.d198.s1.e3" id="DS.d198.s1.i0" interaction="True"/>
            <pair e1="DS.d198.s1.e0" e2="DS.d198.s1.e1" id="DS.d198.s1.i1" interaction="True"/>
            <pair e1="DS.d198.s1.e0" e2="DS.d198.s1.e4" id="DS.d198.s1.i2" interaction="True"/>
            <pair e1="DS.d198.s1.e0" e2="DS.d198.s1.e2" id="DS.d198.s1.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d199" origId="18462962">
        <sentence id="DS.d199.s0" origId="18462962-149" text="She had a mutation in PANK2 gene consisting of an aminoacid change of Alanine to Valine in exon 5 (A382V).">
            <entity id="DS.d199.s0.e0" origId="Q9BZ23" charOffset="22-27" type="protein" text="PANK2"/>
            <entity id="DS.d199.s0.e1" origId="602,4580,5950,71080" charOffset="70-77" type="compound" text="Alanine"/>
            <entity id="DS.d199.s0.e2" origId="6287" charOffset="81-87" type="compound" text="Valine"/>
            <pair e1="DS.d199.s0.e2" e2="DS.d199.s0.e0" id="DS.d199.s0.i0" interaction="True"/>
            <pair e1="DS.d199.s0.e1" e2="DS.d199.s0.e0" id="DS.d199.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d200" origId="18466349">
        <sentence id="DS.d200.s0" origId="18466349-969" text="Decreased hepatic RBP4 secretion is correlated with reduced hepatic glucose production but is not associated with insulin resistance in patients with liver cirrhosis.">
            <entity id="DS.d200.s0.e0" origId="P02753,P06912,P18902,P27485,P41263,P61641,Q28369" charOffset="18-22" type="protein" text="RBP4"/>
            <entity id="DS.d200.s0.e1" origId="206,5793,64689,79025" charOffset="68-75" type="compound" text="glucose"/>
            <entity id="DS.d200.s0.e2" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="114-121" type="protein" text="insulin"/>
            <pair e1="DS.d200.s0.e1" e2="DS.d200.s0.e0" id="DS.d200.s0.i0" interaction="True"/>
            <pair e1="DS.d200.s0.e1" e2="DS.d200.s0.e2" id="DS.d200.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d201" origId="18466352">
        <sentence id="DS.d201.s0" origId="18466352-971" text="RAD001-induced growth suppression was associated with inactivation of downstream targets of mTOR, reduction in VEGF expression and microvessel density, inhibition of cell proliferation, up-regulation of p27 (Kip1) and down-regulation of p21 (Cip1/Waf1), Cdk-6, Cdk-2, Cdk-4, cdc-25C, cyclin B1 and c-Myc.">
            <entity id="DS.d201.s0.e0" origId="6442177" charOffset="0-6" type="compound" text="RAD001"/>
            <entity id="DS.d201.s0.e1" origId="P42345,P42346,Q9JLN9" charOffset="92-96" type="protein" text="mTOR"/>
            <entity id="DS.d201.s0.e2" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="111-115" type="protein" text="VEGF"/>
            <entity id="DS.d201.s0.e3" origId="O11451,O11452,O11453,O39927,O39928,O39929,O91936,O92529,O92530,O92531,O92532,P06934,P16342,P19751,P25880,P25881,P25882,P25884,P25989,P26660,P26661,P26662,P26663,P26664,P27958,P29833,P29846,P29996,P29997,P40305,P68763,P68764,P68765,P69180,P69181,P69182,P69183,P69184,P69618,P69619,Q00269,Q43735,Q5I2N3,Q66198,Q68749,Q68798,Q68801,Q81258,Q81487,Q81495,Q81754,Q81835,Q81842,Q8V439,Q8V6W7,Q913D4,Q91A29,Q91DH7,Q91DH8,Q91DH9,Q99IB8,Q9DHD6,Q9E925,Q9PYA3,Q9QAX1,Q9WMX2" charOffset="203-206" type="protein" text="p27"/>
            <entity id="DS.d201.s0.e4" origId="O19002,O39927,O39928,O39929,O91936,O92529,O92530,O92531,O92532,P26660,P26661,P26662,P26663,P26664,P27954,P27955,P27956,P27957,P27958,P27959,P27960,P27961,P29846,P38936,P39689,P61585,P63028,Q00269,Q01403,Q01404,Q07828,Q11118,Q42580,Q5EG65,Q5I2N3,Q62092,Q68749,Q68798,Q68801,Q81258,Q81487,Q81495,Q81754,Q913D4,Q99IB8,Q9DHD6,Q9QAX1,Q9WMX2" charOffset="237-240" type="protein" text="p21"/>
            <entity id="DS.d201.s0.e5" origId="O42923,P39689" charOffset="242-246" type="protein" text="Cip1"/>
            <entity id="DS.d201.s0.e6" origId="P39689" charOffset="247-251" type="protein" text="Waf1"/>
            <entity id="DS.d201.s0.e7" origId="O05982" charOffset="254-257" type="protein" text="Cdk"/>
            <entity id="DS.d201.s0.e8" origId="O05982" charOffset="261-264" type="protein" text="Cdk"/>
            <entity id="DS.d201.s0.e9" origId="O05982" charOffset="261-264" type="protein" text="Cdk"/>
            <entity id="DS.d201.s0.e10" origId="O01377,O16852,P04961,P12004,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P61074,Q00265,Q00268" charOffset="284-290" type="protein" text="cyclin"/>
            <entity id="DS.d201.s0.e11" origId="P01109,P06646,P49709,P52160,Q17103" charOffset="298-303" type="protein" text="c-Myc"/>
            <pair e1="DS.d201.s0.e0" e2="DS.d201.s0.e5" id="DS.d201.s0.i0" interaction="True"/>
            <pair e1="DS.d201.s0.e0" e2="DS.d201.s0.e3" id="DS.d201.s0.i1" interaction="True"/>
            <pair e1="DS.d201.s0.e0" e2="DS.d201.s0.e2" id="DS.d201.s0.i2" interaction="True"/>
            <pair e1="DS.d201.s0.e0" e2="DS.d201.s0.e7" id="DS.d201.s0.i3" interaction="True"/>
            <pair e1="DS.d201.s0.e0" e2="DS.d201.s0.e11" id="DS.d201.s0.i4" interaction="True"/>
            <pair e1="DS.d201.s0.e0" e2="DS.d201.s0.e6" id="DS.d201.s0.i5" interaction="True"/>
            <pair e1="DS.d201.s0.e0" e2="DS.d201.s0.e4" id="DS.d201.s0.i6" interaction="True"/>
            <pair e1="DS.d201.s0.e0" e2="DS.d201.s0.e10" id="DS.d201.s0.i7" interaction="True"/>
            <pair e1="DS.d201.s0.e0" e2="DS.d201.s0.e1" id="DS.d201.s0.i8" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d202" origId="18467006">
        <sentence id="DS.d202.s0" origId="18467006-128" text="A series of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles have been synthesized and evaluated for their ALK5 inhibitory activity in cell-based luciferase reporter assays.">
            <entity id="DS.d202.s0.e0" origId="7370" charOffset="12-30" type="compound" text="benzenesulfonamide"/>
            <entity id="DS.d202.s0.e1" origId="P36897" charOffset="143-147" type="protein" text="ALK5"/>
            <pair e1="DS.d202.s0.e0" e2="DS.d202.s0.e1" id="DS.d202.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d203" origId="18468607">
        <sentence id="DS.d203.s0" origId="18468607-1101" text="Genetic variation in CETP (cholesteryl ester transfer protein) has been clearly associated with HDL cholesterol levels but its association with cardiovascular disease and related phenotypes has been more controversial, possibly due to variability of polymorphisms and their frequencies across different ethnic populations.">
            <entity id="DS.d203.s0.e0" origId="P11597,P22687,P25914,P47896" charOffset="21-25" type="protein" text="CETP"/>
            <entity id="DS.d203.s0.e1" origId="P25914" charOffset="27-61" type="protein" text="cholesteryl ester transfer protein"/>
            <entity id="DS.d203.s0.e2" origId="304,5997,6432564,11025495" charOffset="100-111" type="compound" text="cholesterol"/>
            <pair e1="DS.d203.s0.e2" e2="DS.d203.s0.e0" id="DS.d203.s0.i0" interaction="True"/>
            <pair e1="DS.d203.s0.e2" e2="DS.d203.s0.e1" id="DS.d203.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d204" origId="18470629">
        <sentence id="DS.d204.s0" origId="18470629-1072" text="However, methomyl exhibited more potency in reducing AChE activity than methiocarb.">
            <entity id="DS.d204.s0.e0" origId="5353758" charOffset="9-17" type="compound" text="methomyl"/>
            <entity id="DS.d204.s0.e1" origId="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3" charOffset="53-57" type="protein" text="AChE"/>
            <entity id="DS.d204.s0.e2" origId="16248" charOffset="72-82" type="compound" text="methiocarb"/>
            <pair e1="DS.d204.s0.e0" e2="DS.d204.s0.e1" id="DS.d204.s0.i0" interaction="True"/>
            <pair e1="DS.d204.s0.e2" e2="DS.d204.s0.e1" id="DS.d204.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d205" origId="18470874">
        <sentence id="DS.d205.s0" origId="18470874-1230" text="Early and late 2-cell and late 4-cell stage embryos, prepared by in vitro fertilization (IVF), parthenogenetic activation (PG), and nuclear transfer of mouse embryonic fibroblast (MEF) and mouse HM1 embryonic stem cells (HM1), were processed for autoradiography following (3)H-uridine incubation (transcriptional activity), transmission electron microscopy (ultrastructure) and immunofluorescence (nucleolar proteins; upstream binding factor, UBF and nucleophosmin, B23).">
            <entity id="DS.d205.s0.e0" origId="6029" charOffset="277-284" type="compound" text="uridine"/>
            <entity id="DS.d205.s0.e1" origId="P17480" charOffset="443-446" type="protein" text="UBF"/>
            <entity id="DS.d205.s0.e2" origId="P06748,P07222,P13084,P16039,Q3T160,Q61937" charOffset="451-464" type="protein" text="nucleophosmin"/>
            <entity id="DS.d205.s0.e3" origId="P51472" charOffset="466-469" type="protein" text="B23"/>
            <pair e1="DS.d205.s0.e0" e2="DS.d205.s0.e2" id="DS.d205.s0.i0" interaction="False"/>
            <pair e1="DS.d205.s0.e0" e2="DS.d205.s0.e1" id="DS.d205.s0.i1" interaction="False"/>
            <pair e1="DS.d205.s0.e0" e2="DS.d205.s0.e3" id="DS.d205.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d206" origId="18471929">
        <sentence id="DS.d206.s0" origId="18471929-584" text="Furthermore, among the ROS scavenging antioxidant defense genes studied here, mRNA levels of salicylic acid-binding (SAbind) catalase (CAT) and lignin-forming peroxidase (POX) were found to be increased by proline and betaine under salt stress.">
            <entity id="DS.d206.s0.e0" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="125-133" type="protein" text="catalase"/>
            <entity id="DS.d206.s0.e1" origId="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7" charOffset="135-138" type="protein" text="CAT"/>
            <entity id="DS.d206.s0.e2" origId="P15984,P16147,P84714" charOffset="159-169" type="protein" text="peroxidase"/>
            <entity id="DS.d206.s0.e3" origId="P07003,P37063,P92983,Q54970" charOffset="171-174" type="protein" text="POX"/>
            <entity id="DS.d206.s0.e4" origId="614,8988,145742" charOffset="206-213" type="compound" text="proline"/>
            <entity id="DS.d206.s0.e5" origId="248" charOffset="218-225" type="compound" text="betaine"/>
            <pair e1="DS.d206.s0.e5" e2="DS.d206.s0.e2" id="DS.d206.s0.i0" interaction="True"/>
            <pair e1="DS.d206.s0.e4" e2="DS.d206.s0.e3" id="DS.d206.s0.i1" interaction="True"/>
            <pair e1="DS.d206.s0.e4" e2="DS.d206.s0.e2" id="DS.d206.s0.i2" interaction="True"/>
            <pair e1="DS.d206.s0.e4" e2="DS.d206.s0.e1" id="DS.d206.s0.i3" interaction="True"/>
            <pair e1="DS.d206.s0.e5" e2="DS.d206.s0.e1" id="DS.d206.s0.i4" interaction="True"/>
            <pair e1="DS.d206.s0.e4" e2="DS.d206.s0.e0" id="DS.d206.s0.i5" interaction="True"/>
            <pair e1="DS.d206.s0.e5" e2="DS.d206.s0.e0" id="DS.d206.s0.i6" interaction="True"/>
            <pair e1="DS.d206.s0.e5" e2="DS.d206.s0.e3" id="DS.d206.s0.i7" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d207" origId="18472163">
        <sentence id="DS.d207.s0" origId="18472163-737" text="Significant ALP activity changes, sensitivity of isozyme patterns (Mr of 60, 64, and 85kDa) and increased variation in ALP plasticity during acute exposure to cadmium point to its possible aplication as an exposure biomarker.">
            <entity id="DS.d207.s0.e0" origId="P03973,P12547,P22298,P28296,P29118,P35211,P83610,P97430,Q03420,Q53GG5,Q9H0A0,Q9PU47,Q9Z1X0" charOffset="12-15" type="protein" text="ALP"/>
            <entity id="DS.d207.s0.e1" origId="P03973,P12547,P22298,P28296,P29118,P35211,P83610,P97430,Q03420,Q53GG5,Q9H0A0,Q9PU47,Q9Z1X0" charOffset="119-122" type="protein" text="ALP"/>
            <entity id="DS.d207.s0.e2" origId="23973" charOffset="159-166" type="compound" text="cadmium"/>
            <pair e1="DS.d207.s0.e2" e2="DS.d207.s0.e0" id="DS.d207.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d208" origId="18472187">
        <sentence id="DS.d208.s0" origId="18472187-928" text="To decrease the level of androgen testosterone in the prostate, we are interested in developing inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (17beta-HSD5).">
            <entity id="DS.d208.s0.e0" origId="6013" charOffset="34-46" type="compound" text="testosterone"/>
            <entity id="DS.d208.s0.e1" origId="P42330,Q5R7C9" charOffset="110-152" type="protein" text="17beta-hydroxysteroid dehydrogenase type 5"/>
            <entity id="DS.d208.s0.e2" origId="P42330,P70694,Q5R7C9" charOffset="154-165" type="protein" text="17beta-HSD5"/>
            <pair e1="DS.d208.s0.e0" e2="DS.d208.s0.e2" id="DS.d208.s0.i0" interaction="False"/>
            <pair e1="DS.d208.s0.e0" e2="DS.d208.s0.e1" id="DS.d208.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d209" origId="18472342">
        <sentence id="DS.d209.s0" origId="18472342-221" text="A role for guanosine 3',5'-cyclic monophosphate (cGMP) and the protein kinase G (PKG) pathway in synaptic long-term depression (LTD) in the hippocampal CA1 region has been proposed, based on observations in vitro, where, for example, increases of (cGMP) result in short-term depression (STD) coupled with a reduction in presynaptic glutamate release.">
            <entity id="DS.d209.s0.e0" origId="24316" charOffset="11-47" type="compound" text="guanosine 3',5'-cyclic monophosphate"/>
            <entity id="DS.d209.s0.e1" origId="24316" charOffset="49-53" type="compound" text="cGMP"/>
            <entity id="DS.d209.s0.e2" origId="P00513,P25848" charOffset="63-77" type="protein" text="protein kinase"/>
            <entity id="DS.d209.s0.e3" origId="24316" charOffset="248-252" type="compound" text="cGMP"/>
            <entity id="DS.d209.s0.e4" origId="611,23327,33032" charOffset="332-341" type="compound" text="glutamate"/>
            <pair e1="DS.d209.s0.e4" e2="DS.d209.s0.e2" id="DS.d209.s0.i0" interaction="False"/>
            <pair e1="DS.d209.s0.e0" e2="DS.d209.s0.e2" id="DS.d209.s0.i1" interaction="False"/>
            <pair e1="DS.d209.s0.e1" e2="DS.d209.s0.e2" id="DS.d209.s0.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d209.s1" origId="18472342-222" text="Application of an inhibitor of soluble guanylate cyclase prevented LTD induced by low-frequency stimulation (LFS), and impaired LFS-STD elicited in the presence of Zaprinast.">
            <entity id="DS.d209.s1.e0" origId="O94303,P33734,Q9P4P9,Q9SZ30" charOffset="49-56" type="protein" text="cyclase"/>
            <entity id="DS.d209.s1.e3" origId="P50234,P52842,Q06520" charOffset="132-135" type="protein" text="STD"/>
            <entity id="DS.d209.s1.e4" origId="5722" charOffset="164-173" type="compound" text="Zaprinast"/>
            <pair e1="DS.d209.s1.e4" e2="DS.d209.s1.e0" id="DS.d209.s1.i0" interaction="False"/>
            <pair e1="DS.d209.s1.e4" e2="DS.d209.s1.e3" id="DS.d209.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d210" origId="18473163">
        <sentence id="DS.d210.s0" origId="18473163-133" text="beta-Hexosaminidases (EC 3.2.1.52) are lysosomal enzymes that remove terminal beta-glycosidically bound N-acetylglucosamine and N-acetylgalactosamine residues from a number of glycoconjugates.">
            <entity id="DS.d210.s0.e0" origId="O60502,P44955,P49010,P58067,P75949,P96155,P96157,Q04786,Q0TR53,Q2KXM7,Q2P4L0,Q2Y863,Q31G32,Q31ZG4,Q32EW7,Q3BVU6,Q3J953,Q3SKU2,Q3Z310,Q4QLU8,Q4USG7,Q57QE6,Q5FA94,Q5H1Q0,Q5P081,Q5PGT0,Q5QUZ5,Q606N2,Q65VK7,Q669N5,Q6D674,Q6LJ30,Q7N397,Q7NWB7,Q7UCW4,Q7VNI8,Q7VWV8,Q7W9J5,Q7WH65,Q82SJ8,Q87BR5,Q89ZI2,Q8EEW2,Q8FIN2,Q8PB42,Q8PMU1,Q8VIJ5,Q8XL08,Q8Z7I6,Q8ZFS3,Q8ZQ06,Q9CPH0,Q9EQQ9,Q9HZK0,Q9JVT3,Q9K0Q4,Q9KU37,Q9PAZ0" charOffset="0-20" type="protein" text="beta-Hexosaminidases"/>
            <entity id="DS.d210.s0.e1" origId="24139" charOffset="104-123" type="compound" text="N-acetylglucosamine"/>
            <entity id="DS.d210.s0.e2" origId="899,35717,84265,439174" charOffset="128-149" type="compound" text="N-acetylgalactosamine"/>
            <pair e1="DS.d210.s0.e2" e2="DS.d210.s0.e0" id="DS.d210.s0.i0" interaction="True"/>
            <pair e1="DS.d210.s0.e1" e2="DS.d210.s0.e0" id="DS.d210.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d211" origId="18473182">
        <sentence id="DS.d211.s0" origId="18473182-143" text="Overexpression of CYP2E1 induces HepG2 cells death by the AMP kinase activator 5'-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).">
            <entity id="DS.d211.s0.e0" origId="O18963,P05181,P08682,P33266,P51581,P79383,Q6GUQ4" charOffset="18-24" type="protein" text="CYP2E1"/>
            <entity id="DS.d211.s0.e1" origId="16078949" charOffset="79-134" type="compound" text="5'-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside"/>
            <pair e1="DS.d211.s0.e1" e2="DS.d211.s0.e0" id="DS.d211.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d212" origId="18474445">
        <sentence id="DS.d212.s0" origId="18474445-915" text="Distribution of the androgen receptor in the diencephalon and the pituitary gland in goats: Co-localisation with corticotrophin releasing hormone, arginine vasopressin and corticotrophs.">
            <entity id="DS.d212.s0.e0" origId="O97775,O97776,O97952,O97960,P10275,P15207,P19091,P49699,Q6QT55,Q7T1K4,Q8MIK0,Q9GKL7,Q9TT90" charOffset="20-37" type="protein" text="androgen receptor"/>
            <entity id="DS.d212.s0.e1" origId="8230,644077,44285245" charOffset="147-167" type="compound" text="arginine vasopressin"/>
            <pair e1="DS.d212.s0.e1" e2="DS.d212.s0.e0" id="DS.d212.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d213" origId="18475288">
        <sentence id="DS.d213.s0" origId="18475288-1020" text="Bicalutamide induced apoptosis in androgen-dependent PWR-1E cells via a caspase-dependent and calpain-independent mechanism.">
            <entity id="DS.d213.s0.e0" origId="2375" charOffset="0-12" type="compound" text="Bicalutamide"/>
            <entity id="DS.d213.s0.e1" origId="P27730" charOffset="94-101" type="protein" text="calpain"/>
            <pair e1="DS.d213.s0.e0" e2="DS.d213.s0.e1" id="DS.d213.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d213.s1" origId="18475288-1021" text="In androgen-independent PC-3 cells, bicalutamide also induced apoptosis by mechanisms that were partially inhibited by pan-caspase inhibition but were partially calpain dependent.">
            <entity id="DS.d213.s1.e0" origId="2375" charOffset="36-48" type="compound" text="bicalutamide"/>
            <entity id="DS.d213.s1.e1" origId="P27730" charOffset="161-168" type="protein" text="calpain"/>
            <pair e1="DS.d213.s1.e0" e2="DS.d213.s1.e1" id="DS.d213.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d214" origId="18477686">
        <sentence id="DS.d214.s0" origId="18477686-347" text="A differential regulation of the two GABA synthesizing enzymes (GAD65 and GAD67) parallels GABAergic neuron differentiation.">
            <entity id="DS.d214.s0.e0" origId="119" charOffset="37-41" type="compound" text="GABA"/>
            <entity id="DS.d214.s0.e1" origId="P48321,Q05329,Q4PRC2" charOffset="64-69" type="protein" text="GAD65"/>
            <entity id="DS.d214.s0.e2" origId="P14748,P48319,Q5IS68,Q99259" charOffset="74-79" type="protein" text="GAD67"/>
            <pair e1="DS.d214.s0.e0" e2="DS.d214.s0.e2" id="DS.d214.s0.i0" interaction="True"/>
            <pair e1="DS.d214.s0.e0" e2="DS.d214.s0.e1" id="DS.d214.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d215" origId="18479249">
        <sentence id="DS.d215.s0" origId="18479249-96" text="The results showed that portal pressure and IHR, hepatic levels of PIIINP, hepatic collagen deposition, mRNA expression of PIIIP-alpha1 and TGF-beta1, protein expression of iNOS and TXS, and production of TXA2 in liver perfusates were significantly decreased in UDCA-treated BDL rats.">
            <entity id="DS.d215.s0.e0" origId="Q08398" charOffset="129-135" type="protein" text="alpha1"/>
            <entity id="DS.d215.s0.e1" origId="O19011,O93449,P01137,P04202,P07200,P09531,P09533,P16176,P17246,P18341,P50414,P54831,Q38HS2,Q9PTQ2,Q9Z1Y6" charOffset="140-149" type="protein" text="TGF-beta1"/>
            <entity id="DS.d215.s0.e2" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="173-177" type="protein" text="iNOS"/>
            <entity id="DS.d215.s0.e3" origId="P24557,P36423,P47787,P49430,Q2KIG5" charOffset="182-185" type="protein" text="TXS"/>
            <entity id="DS.d215.s0.e4" origId="5280497" charOffset="205-209" type="compound" text="TXA2"/>
            <pair e1="DS.d215.s0.e4" e2="DS.d215.s0.e2" id="DS.d215.s0.i0" interaction="False"/>
            <pair e1="DS.d215.s0.e4" e2="DS.d215.s0.e0" id="DS.d215.s0.i1" interaction="False"/>
            <pair e1="DS.d215.s0.e4" e2="DS.d215.s0.e1" id="DS.d215.s0.i2" interaction="False"/>
            <pair e1="DS.d215.s0.e4" e2="DS.d215.s0.e3" id="DS.d215.s0.i3" interaction="False"/>
        </sentence>
        <sentence id="DS.d215.s1" origId="18479249-97" text="The increased levels of hepatic GSH and SOD activity and decreased levels of TBARS and nitrite were also observed in UDCA-treated BDL rats.">
            <entity id="DS.d215.s1.e0" origId="124886" charOffset="32-35" type="compound" text="GSH"/>
            <entity id="DS.d215.s1.e1" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="40-43" type="protein" text="SOD"/>
            <pair e1="DS.d215.s1.e0" e2="DS.d215.s1.e1" id="DS.d215.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d216" origId="18479251">
        <sentence id="DS.d216.s0" origId="18479251-501" text="The production of rhG-CSF was induced by switching from growth on glycerol to growth on methanol.">
            <entity id="DS.d216.s0.e0" origId="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481" charOffset="22-25" type="protein" text="CSF"/>
            <entity id="DS.d216.s0.e1" origId="753" charOffset="66-74" type="compound" text="glycerol"/>
            <entity id="DS.d216.s0.e2" origId="887,19314" charOffset="88-96" type="compound" text="methanol"/>
            <pair e1="DS.d216.s0.e1" e2="DS.d216.s0.e0" id="DS.d216.s0.i0" interaction="False"/>
            <pair e1="DS.d216.s0.e2" e2="DS.d216.s0.e0" id="DS.d216.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d216.s1" origId="18479251-502" text="In the induction phase, the methanol feed rate had a significant effect on the specific expression rate of rhG-CSF.">
            <entity id="DS.d216.s1.e0" origId="887,19314" charOffset="28-36" type="compound" text="methanol"/>
            <entity id="DS.d216.s1.e1" origId="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481" charOffset="111-114" type="protein" text="CSF"/>
            <pair e1="DS.d216.s1.e0" e2="DS.d216.s1.e1" id="DS.d216.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d216.s2" origId="18479251-503" text="Under this condition, a maximum concentration of 300 mg/l of rhG-CSF and the expression yield of 0.6 mg of rhG-CSF/g of methanol were attained.">
            <entity id="DS.d216.s2.e0" origId="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481" charOffset="65-68" type="protein" text="CSF"/>
            <entity id="DS.d216.s2.e1" origId="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481" charOffset="111-114" type="protein" text="CSF"/>
            <entity id="DS.d216.s2.e2" origId="887,19314" charOffset="120-128" type="compound" text="methanol"/>
            <pair e1="DS.d216.s2.e2" e2="DS.d216.s2.e0" id="DS.d216.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d216.s3" origId="18479251-504" text="Among seven additives tested, Tween 20, Tween 80 and betaine exhibited the best results in respect of preventing the formation of rhG-CSF protein aggregates.">
            <entity id="DS.d216.s3.e0" origId="443314" charOffset="30-38" type="compound" text="Tween 20"/>
            <entity id="DS.d216.s3.e1" origId="248" charOffset="53-60" type="compound" text="betaine"/>
            <entity id="DS.d216.s3.e2" origId="O62757,P01587,P04141,P11052,P28773,P48749,P48750,P51748,Q0MUT8,Q29118,Q60481" charOffset="134-137" type="protein" text="CSF"/>
            <pair e1="DS.d216.s3.e0" e2="DS.d216.s3.e2" id="DS.d216.s3.i0" interaction="True"/>
            <pair e1="DS.d216.s3.e1" e2="DS.d216.s3.e2" id="DS.d216.s3.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d217" origId="18479686">
        <sentence id="DS.d217.s0" origId="18479686-323" text="Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice.">
            <entity id="DS.d217.s0.e0" origId="150311" charOffset="0-9" type="compound" text="Ezetimibe"/>
            <entity id="DS.d217.s0.e1" origId="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600" charOffset="73-77" type="protein" text="eNOS"/>
            <pair e1="DS.d217.s0.e0" e2="DS.d217.s0.e1" id="DS.d217.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d217.s1" origId="18479686-324" text="Hypercholesterolemia is associated with decreased vascular nitric oxide bioavailability and deletion of endothelial nitric oxide synthase (eNOS) markedly accelerates atherosclerosis development in apolipoprotein E knockout (apoE ko) mice.">
            <entity id="DS.d217.s1.e0" origId="145068" charOffset="59-71" type="compound" text="nitric oxide"/>
            <entity id="DS.d217.s1.e1" origId="O61309,O61608,Q27571,Q9I9M2" charOffset="116-137" type="protein" text="nitric oxide synthase"/>
            <entity id="DS.d217.s1.e2" origId="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600" charOffset="139-143" type="protein" text="eNOS"/>
            <pair e1="DS.d217.s1.e0" e2="DS.d217.s1.e2" id="DS.d217.s1.i0" interaction="False"/>
            <pair e1="DS.d217.s1.e0" e2="DS.d217.s1.e1" id="DS.d217.s1.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d218" origId="18479896">
        <sentence id="DS.d218.s0" origId="18479896-454" text="Docosahexaenoic acid induces apoptosis in colorectal carcinoma cells by modulating the PI3 kinase and p38 MAPK pathways.">
            <entity id="DS.d218.s0.e0" origId="445580" charOffset="0-20" type="compound" text="Docosahexaenoic acid"/>
            <entity id="DS.d218.s0.e1" origId="P42347,P42348,P54673,P54674,P54675,P54676" charOffset="87-97" type="protein" text="PI3 kinase"/>
            <entity id="DS.d218.s0.e2" origId="O62618" charOffset="102-110" type="protein" text="p38 MAPK"/>
            <pair e1="DS.d218.s0.e0" e2="DS.d218.s0.e1" id="DS.d218.s0.i0" interaction="True"/>
            <pair e1="DS.d218.s0.e0" e2="DS.d218.s0.e2" id="DS.d218.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d218.s1" origId="18479896-455" text="The protein inhibitors wortmannin (phosphoinositide 3 kinase inhibitor), PD 98059 (MEK inhibitor) and SB 203580 (p38 inhibitor) as well as silencing RNA (small interfering RNA (siRNA)) of the p38 MAPK protein, were used to investigate cross-talk between signalling pathways.">
            <entity id="DS.d218.s1.e0" origId="312145" charOffset="23-33" type="compound" text="wortmannin"/>
            <entity id="DS.d218.s1.e1" origId="16738692" charOffset="35-51" type="compound" text="phosphoinositide"/>
            <entity id="DS.d218.s1.e2" origId="4713" charOffset="73-81" type="compound" text="PD 98059"/>
            <entity id="DS.d218.s1.e3" origId="176155" charOffset="102-111" type="compound" text="SB 203580"/>
            <entity id="DS.d218.s1.e4" origId="O62618" charOffset="192-200" type="protein" text="p38 MAPK"/>
            <pair e1="DS.d218.s1.e3" e2="DS.d218.s1.e4" id="DS.d218.s1.i0" interaction="False"/>
            <pair e1="DS.d218.s1.e1" e2="DS.d218.s1.e4" id="DS.d218.s1.i1" interaction="False"/>
            <pair e1="DS.d218.s1.e0" e2="DS.d218.s1.e4" id="DS.d218.s1.i2" interaction="False"/>
            <pair e1="DS.d218.s1.e2" e2="DS.d218.s1.e4" id="DS.d218.s1.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d219" origId="18479897">
        <sentence id="DS.d219.s0" origId="18479897-371" text="Feeding long-chain n-3 polyunsaturated fatty acids during gestation increases intestinal glucose absorption potentially via the acute activation of AMPK.">
            <entity id="DS.d219.s0.e0" origId="56842239" charOffset="23-50" type="compound" text="polyunsaturated fatty acids"/>
            <entity id="DS.d219.s0.e1" origId="206,5793,64689,79025" charOffset="89-96" type="compound" text="glucose"/>
            <entity id="DS.d219.s0.e2" origId="P54646,Q09136,Q9Y478" charOffset="148-152" type="protein" text="AMPK"/>
            <pair e1="DS.d219.s0.e1" e2="DS.d219.s0.e2" id="DS.d219.s0.i0" interaction="False"/>
            <pair e1="DS.d219.s0.e0" e2="DS.d219.s0.e2" id="DS.d219.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d219.s1" origId="18479897-373" text="Furthermore, adding docosahexaenoic acid (DHA) or an AMP-activated protein kinase (AMPK.05) in intestinal preparations obtained from the offspring fed the control diet, devoid of the PFO product and containing minimal concentrations of n-3 PUFA.">
            <entity id="DS.d219.s1.e0" origId="445580" charOffset="20-40" type="compound" text="docosahexaenoic acid"/>
            <entity id="DS.d219.s1.e1" origId="O24006" charOffset="53-56" type="protein" text="AMP"/>
            <entity id="DS.d219.s1.e2" origId="P00513,P25848" charOffset="67-81" type="protein" text="protein kinase"/>
            <entity id="DS.d219.s1.e3" origId="P54646,Q09136,Q9Y478" charOffset="83-87" type="protein" text="AMPK"/>
            <pair e1="DS.d219.s1.e0" e2="DS.d219.s1.e3" id="DS.d219.s1.i0" interaction="False"/>
            <pair e1="DS.d219.s1.e0" e2="DS.d219.s1.e2" id="DS.d219.s1.i1" interaction="False"/>
            <pair e1="DS.d219.s1.e0" e2="DS.d219.s1.e1" id="DS.d219.s1.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d220" origId="18479950">
        <sentence id="DS.d220.s0" origId="18479950-485" text="Prior to vitamin E supplementation, exercise induced a significant decrease in PON1 activity, EMF, vitamin E concentration and a significant increase in MDA concentration at t+1d.">
            <entity id="DS.d220.s0.e0" origId="2116,14985,1548900,1742129" charOffset="9-18" type="compound" text="vitamin E"/>
            <entity id="DS.d220.s0.e1" origId="P27169,P27170" charOffset="79-83" type="protein" text="PON1"/>
            <entity id="DS.d220.s0.e2" origId="23644574" charOffset="94-97" type="compound" text="EMF"/>
            <entity id="DS.d220.s0.e3" origId="2116,14985,1548900,1742129" charOffset="99-108" type="compound" text="vitamin E"/>
            <pair e1="DS.d220.s0.e0" e2="DS.d220.s0.e1" id="DS.d220.s0.i0" interaction="False"/>
            <pair e1="DS.d220.s0.e2" e2="DS.d220.s0.e1" id="DS.d220.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d220.s1" origId="18479950-486" text="After a 10 week vitamin E supplementation period, these exercise-induced changes in PON1 activity, EMF and MDA concentration were still significant in the control group, but not in the supplemented group.">
            <entity id="DS.d220.s1.e0" origId="2116,14985,1548900,1742129" charOffset="16-25" type="compound" text="vitamin E"/>
            <entity id="DS.d220.s1.e1" origId="P27169,P27170" charOffset="84-88" type="protein" text="PON1"/>
            <entity id="DS.d220.s1.e2" origId="23644574" charOffset="99-102" type="compound" text="EMF"/>
            <pair e1="DS.d220.s1.e2" e2="DS.d220.s1.e1" id="DS.d220.s1.i0" interaction="False"/>
            <pair e1="DS.d220.s1.e0" e2="DS.d220.s1.e1" id="DS.d220.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d221" origId="18481266">
        <sentence id="DS.d221.s0" origId="18481266-77" text="In adulthood, testosterone secreted by the testes is converted into estrogens by the preoptic aromatase.">
            <entity id="DS.d221.s0.e0" origId="6013" charOffset="14-26" type="compound" text="testosterone"/>
            <entity id="DS.d221.s0.e1" origId="O42145,O46512,P11511,P19098,P22443,P28649,P46194,P70091,P79304,P79430,P79699,Q29605,Q29624,Q5QQX7,Q69FB6,Q6QHT9,Q6YI21,Q92087,Q92111,Q92112,Q95M61,Q9XS28" charOffset="94-103" type="protein" text="aromatase"/>
            <pair e1="DS.d221.s0.e0" e2="DS.d221.s0.e1" id="DS.d221.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d222" origId="18481276">
        <sentence id="DS.d222.s0" origId="18481276-83" text="The model was used to investigate how on-treatment CRP related to baseline CRP and estimated treatment effects with rosuvastatin.">
            <entity id="DS.d222.s0.e0" origId="O19062,P02741,P02742,P08462,P18151,P21291,P41964,P47875,P49254,P49262,P52753,P67966,P67967,P97315,Q07203" charOffset="51-54" type="protein" text="CRP"/>
            <entity id="DS.d222.s0.e1" origId="O19062,P02741,P02742,P08462,P18151,P21291,P41964,P47875,P49254,P49262,P52753,P67966,P67967,P97315,Q07203" charOffset="75-78" type="protein" text="CRP"/>
            <entity id="DS.d222.s0.e2" origId="446157" charOffset="116-128" type="compound" text="rosuvastatin"/>
            <pair e1="DS.d222.s0.e2" e2="DS.d222.s0.e0" id="DS.d222.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d223" origId="18481313">
        <sentence id="DS.d223.s0" origId="18481313-107" text="Hepatocyte growth factor, keratinocyte growth factor or insulin prevented the effect of ethanol on cell permeability, but not on PGE (2) release.">
            <entity id="DS.d223.s0.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="56-63" type="protein" text="insulin"/>
            <entity id="DS.d223.s0.e1" origId="702" charOffset="88-95" type="compound" text="ethanol"/>
            <entity id="DS.d223.s0.e2" origId="Q29458" charOffset="129-132" type="protein" text="PGE"/>
            <pair e1="DS.d223.s0.e1" e2="DS.d223.s0.e0" id="DS.d223.s0.i0" interaction="True"/>
            <pair e1="DS.d223.s0.e1" e2="DS.d223.s0.e2" id="DS.d223.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d223.s1" origId="18481313-108" text="Cyclooxygenase-2 stimulated PGE (2) release mediated the reversible effect of ethanol on tight junctions and, meanwhile, contributed to cell survival.">
            <entity id="DS.d223.s1.e0" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="0-16" type="protein" text="Cyclooxygenase-2"/>
            <entity id="DS.d223.s1.e1" origId="Q29458" charOffset="28-31" type="protein" text="PGE"/>
            <entity id="DS.d223.s1.e2" origId="702" charOffset="78-85" type="compound" text="ethanol"/>
            <pair e1="DS.d223.s1.e2" e2="DS.d223.s1.e0" id="DS.d223.s1.i0" interaction="True"/>
            <pair e1="DS.d223.s1.e2" e2="DS.d223.s1.e1" id="DS.d223.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d224" origId="18482727">
        <sentence id="DS.d224.s0" origId="18482727-966" text="Interestingly, atorvastatin inhibited the expression of ICAM and MCP-1, followed by the suppression of macrophage recruitment into the aortic wall at 1 week after operation.">
            <entity id="DS.d224.s0.e0" origId="60823" charOffset="15-27" type="compound" text="atorvastatin"/>
            <entity id="DS.d224.s0.e1" origId="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3" charOffset="65-70" type="protein" text="MCP-1"/>
            <pair e1="DS.d224.s0.e0" e2="DS.d224.s0.e1" id="DS.d224.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d224.s1" origId="18482727-967" text="In addition, synthesis of collagen and elastin in the vascular wall were significantly increased by atorvastatin.">
            <entity id="DS.d224.s1.e0" origId="P11547" charOffset="39-46" type="protein" text="elastin"/>
            <entity id="DS.d224.s1.e1" origId="60823" charOffset="100-112" type="compound" text="atorvastatin"/>
            <pair e1="DS.d224.s1.e1" e2="DS.d224.s1.e0" id="DS.d224.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d225" origId="18484100">
        <sentence id="DS.d225.s0" origId="18484100-516" text="Organic cations (OCs) are primarily excreted via vectorial transport by various renal organic cation transporters (OCTs).">
            <entity id="DS.d225.s0.e0" origId="72886" charOffset="17-20" type="compound" text="OCs"/>
            <entity id="DS.d225.s0.e1" origId="O75051" charOffset="115-119" type="protein" text="OCTs"/>
            <pair e1="DS.d225.s0.e0" e2="DS.d225.s0.e1" id="DS.d225.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d225.s1" origId="18484100-517" text="In a rat ARF model, induction of ARF by uranyl nitrate (UN) treatment significantly decreased the levels of Oct2 (slc22a2) mRNA and protein in the kidney medulla.">
            <entity id="DS.d225.s1.e0" origId="24933" charOffset="40-54" type="compound" text="uranyl nitrate"/>
            <entity id="DS.d225.s1.e1" origId="Q00196" charOffset="108-112" type="protein" text="Oct2"/>
            <pair e1="DS.d225.s1.e0" e2="DS.d225.s1.e1" id="DS.d225.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d226" origId="18484622">
        <sentence id="DS.d226.s0" origId="18484622-1118" text="In all final products, dimethylsulfoxide used to prepare the insulin/lipid mixture was below 20 ppm.">
            <entity id="DS.d226.s0.e0" origId="679" charOffset="23-40" type="compound" text="dimethylsulfoxide"/>
            <entity id="DS.d226.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="61-68" type="protein" text="insulin"/>
            <pair e1="DS.d226.s0.e0" e2="DS.d226.s0.e1" id="DS.d226.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d227" origId="18485500">
        <sentence id="DS.d227.s0" origId="18485500-951" text="Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene.">
            <entity id="DS.d227.s0.e0" origId="2806,60606" charOffset="24-35" type="compound" text="clopidogrel"/>
            <entity id="DS.d227.s0.e1" origId="Q95KC3,Q9CPV9,Q9EPX4,Q9H244" charOffset="91-96" type="protein" text="P2Y12"/>
            <entity id="DS.d227.s0.e2" origId="P02783" charOffset="97-100" type="protein" text="ADP"/>
            <pair e1="DS.d227.s0.e0" e2="DS.d227.s0.e2" id="DS.d227.s0.i0" interaction="True"/>
            <pair e1="DS.d227.s0.e0" e2="DS.d227.s0.e1" id="DS.d227.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d228" origId="18486150">
        <sentence id="DS.d228.s0" origId="18486150-336" text="Cyclosporin A up-regulates and activates protein kinase C-zeta in EBV-infected and EBV-transformed human B-cells.">
            <entity id="DS.d228.s0.e0" origId="2909,5280754,5284373,5458585,5497195,6435893,24883466,49867938" charOffset="0-13" type="compound" text="Cyclosporin A"/>
            <entity id="DS.d228.s0.e1" origId="P13678,Q25378" charOffset="41-57" type="protein" text="protein kinase C"/>
            <pair e1="DS.d228.s0.e0" e2="DS.d228.s0.e1" id="DS.d228.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d228.s1" origId="18486150-337" text="We have proposed that cyclosporin A (CsA), despite being a calcineurin inhibitor, will activate PKC in B cells, thus promoting Epstein-Barr virus (EBV)-induced transformation.">
            <entity id="DS.d228.s1.e0" origId="2909,5280754,5284373,5458585,5497195,6435893,24883466,49867938" charOffset="22-35" type="compound" text="cyclosporin A"/>
            <entity id="DS.d228.s1.e1" origId="O88480,Q9Y6J0" charOffset="59-80" type="protein" text="calcineurin inhibitor"/>
            <entity id="DS.d228.s1.e2" origId="P05130,P13677,P13678,P34722" charOffset="96-99" type="protein" text="PKC"/>
            <pair e1="DS.d228.s1.e0" e2="DS.d228.s1.e1" id="DS.d228.s1.i0" interaction="True"/>
            <pair e1="DS.d228.s1.e0" e2="DS.d228.s1.e2" id="DS.d228.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d229" origId="18486994">
        <sentence id="DS.d229.s0" origId="18486994-189" text="Our results showed 2a, 2d and 2g as the most active compounds that inhibited the HIV-1 reverse transcriptase catalytic activity with cytotoxicity lower than AZT and SI higher than DDC and DDI.">
            <entity id="DS.d229.s0.e0" origId="O55528,O89344,P03523,P06447,P06829,P11205,P11213,P12576,P12577,P13179,P13615,P16289,P16379,P20894,P24658,P26676,P28887,P30929,P31332,P31352,P35262,P35341,P35946,P35975,P41357,Q03396,Q05318,Q06996,Q5XX01,Q66802,Q6V1Q2,Q88434,Q8JPX5,Q91DD4,Q997F0,Q9DUD8" charOffset="95-108" type="protein" text="transcriptase"/>
            <entity id="DS.d229.s0.e1" origId="35370" charOffset="157-160" type="compound" text="AZT"/>
            <pair e1="DS.d229.s0.e1" e2="DS.d229.s0.e0" id="DS.d229.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d230" origId="18487053">
        <sentence id="DS.d230.s0" origId="18487053-332" text="Resveratrol (4,3',5'-trihydroxystilbene) is a naturally occurring antioxidant that inhibits cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2) and the transcription factor NF-kappaB.">
            <entity id="DS.d230.s0.e0" origId="445154" charOffset="0-11" type="compound" text="Resveratrol"/>
            <entity id="DS.d230.s0.e1" origId="O62664,O97554,P05979,P22437,P23219,Q63921" charOffset="92-108" type="protein" text="cyclooxygenase-1"/>
            <entity id="DS.d230.s0.e2" origId="O62664,O97554,P05979,P22437,P23219,Q63921,Q9T0N8" charOffset="110-115" type="protein" text="COX-1"/>
            <entity id="DS.d230.s0.e3" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="118-134" type="protein" text="cyclooxygenase-2"/>
            <entity id="DS.d230.s0.e4" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="136-141" type="protein" text="COX-2"/>
            <pair e1="DS.d230.s0.e0" e2="DS.d230.s0.e3" id="DS.d230.s0.i0" interaction="True"/>
            <pair e1="DS.d230.s0.e0" e2="DS.d230.s0.e1" id="DS.d230.s0.i1" interaction="True"/>
            <pair e1="DS.d230.s0.e0" e2="DS.d230.s0.e2" id="DS.d230.s0.i2" interaction="True"/>
            <pair e1="DS.d230.s0.e0" e2="DS.d230.s0.e4" id="DS.d230.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d231" origId="18489490">
        <sentence id="DS.d231.s0" origId="18489490-99" text="After NMDA stimulation of SV-FHAS and neoplastic astrocytes, real-time polymerase chain reaction showed an increase of the CPE, containing EGR-1 splice variant only in astrocytoma cells.">
            <entity id="DS.d231.s0.e0" origId="22880" charOffset="6-10" type="compound" text="NMDA"/>
            <entity id="DS.d231.s0.e1" origId="O73691,O73692,O73693,O73694,P08046,P08154,P18146,P26632,Q29W20" charOffset="139-144" type="protein" text="EGR-1"/>
            <pair e1="DS.d231.s0.e0" e2="DS.d231.s0.e1" id="DS.d231.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d232" origId="18489909">
        <sentence id="DS.d232.s0" origId="18489909-317" text="Using both physiologically achievable (2 microM) and supraphysiological (10 microM) concentrations, we investigated the ability of quercetin and its predominant human metabolites to attenuate the expression of vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and monocyte chemoattractant protein-1 (MCP-1) in human umbilical artery smooth muscle cells (HUASMC) activated by tumor necrosis factor-alpha (TNFalpha).">
            <entity id="DS.d232.s0.e0" origId="5280343" charOffset="131-140" type="compound" text="quercetin"/>
            <entity id="DS.d232.s0.e1" origId="P19320,P29533,P29534,Q28260" charOffset="245-251" type="protein" text="VCAM-1"/>
            <entity id="DS.d232.s0.e2" origId="P05362,P13597,P33729,Q00238,Q28806,Q5NKV4,Q5NKV6,Q5NKV9,Q95132" charOffset="289-295" type="protein" text="ICAM-1"/>
            <entity id="DS.d232.s0.e3" origId="P10148,P13500,P14844,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3" charOffset="301-335" type="protein" text="monocyte chemoattractant protein-1"/>
            <entity id="DS.d232.s0.e4" origId="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3" charOffset="337-342" type="protein" text="MCP-1"/>
            <entity id="DS.d232.s0.e5" origId="Q8JFG3" charOffset="412-433" type="protein" text="tumor necrosis factor"/>
            <entity id="DS.d232.s0.e6" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="441-449" type="protein" text="TNFalpha"/>
            <pair e1="DS.d232.s0.e0" e2="DS.d232.s0.e6" id="DS.d232.s0.i0" interaction="False"/>
            <pair e1="DS.d232.s0.e0" e2="DS.d232.s0.e3" id="DS.d232.s0.i1" interaction="False"/>
            <pair e1="DS.d232.s0.e0" e2="DS.d232.s0.e5" id="DS.d232.s0.i2" interaction="False"/>
            <pair e1="DS.d232.s0.e0" e2="DS.d232.s0.e2" id="DS.d232.s0.i3" interaction="False"/>
            <pair e1="DS.d232.s0.e0" e2="DS.d232.s0.e4" id="DS.d232.s0.i4" interaction="False"/>
            <pair e1="DS.d232.s0.e0" e2="DS.d232.s0.e1" id="DS.d232.s0.i5" interaction="False"/>
        </sentence>
        <sentence id="DS.d232.s1" origId="18489909-318" text="Quercetin was able to reduce TNFalpha-induced upregulation of VCAM-1, ICAM-1 and MCP-1 at both the protein and transcript (mRNA) level in HUASMC.">
            <entity id="DS.d232.s1.e0" origId="5280343" charOffset="0-9" type="compound" text="Quercetin"/>
            <entity id="DS.d232.s1.e1" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="29-37" type="protein" text="TNFalpha"/>
            <entity id="DS.d232.s1.e2" origId="P19320,P29533,P29534,Q28260" charOffset="62-68" type="protein" text="VCAM-1"/>
            <entity id="DS.d232.s1.e3" origId="P05362,P13597,P33729,Q00238,Q28806,Q5NKV4,Q5NKV6,Q5NKV9,Q95132" charOffset="70-76" type="protein" text="ICAM-1"/>
            <entity id="DS.d232.s1.e4" origId="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3" charOffset="81-86" type="protein" text="MCP-1"/>
            <pair e1="DS.d232.s1.e0" e2="DS.d232.s1.e1" id="DS.d232.s1.i0" interaction="True"/>
            <pair e1="DS.d232.s1.e0" e2="DS.d232.s1.e3" id="DS.d232.s1.i1" interaction="True"/>
            <pair e1="DS.d232.s1.e0" e2="DS.d232.s1.e4" id="DS.d232.s1.i2" interaction="True"/>
            <pair e1="DS.d232.s1.e0" e2="DS.d232.s1.e2" id="DS.d232.s1.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d232.s2" origId="18489909-319" text="However the quercetin metabolites, quercetin 3'-sulfate, quercetin 3-glucuronide and 3'-methylquercetin 3-glucuronide, had no effect on TNFalpha-induced up regulation of adhesion molecule or chemokine expression, at either concentration tested.">
            <entity id="DS.d232.s2.e0" origId="5280362" charOffset="35-55" type="compound" text="quercetin 3'-sulfate"/>
            <entity id="DS.d232.s2.e1" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="136-144" type="protein" text="TNFalpha"/>
            <pair e1="DS.d232.s2.e0" e2="DS.d232.s2.e1" id="DS.d232.s2.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d233" origId="18490188">
        <sentence id="DS.d233.s0" origId="18490188-482" text="In its active form, thiamin pyrophosphate (TPP), it is a co-enzyme for several enzymes, including transketolase.">
            <entity id="DS.d233.s0.e0" origId="1132" charOffset="20-41" type="compound" text="thiamin pyrophosphate"/>
            <entity id="DS.d233.s0.e1" origId="O06811,O67642,O83571,P29277,P29401,P34736,P40142,P43757,P45694,P46708,P47312,P50137,P51010,P56900,P57195,P58333,P59956,P66962,P66963,P75611,P84540,P99161,Q12630,Q52723,Q5HG77,Q5HPJ9,Q5R1W6,Q5R4C1,Q60HC7,Q6B855,Q6G9L6,Q6GH64,Q89AY2,Q8CPC7,Q8KA26,Q9KAD7" charOffset="98-111" type="protein" text="transketolase"/>
            <pair e1="DS.d233.s0.e0" e2="DS.d233.s0.e1" id="DS.d233.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d234" origId="18492032">
        <sentence id="DS.d234.s0" origId="18492032-354" text="Coexpression pattern with VDR provides an indication that calcitriol could be the modulator of these adaptive responses to involution and dietary P restriction.">
            <entity id="DS.d234.s0.e0" origId="O13124,O42392,P11473,P13053,P48281,P49701,Q28037,Q95MH5" charOffset="26-29" type="protein" text="VDR"/>
            <entity id="DS.d234.s0.e1" origId="5280453" charOffset="58-68" type="compound" text="calcitriol"/>
            <pair e1="DS.d234.s0.e1" e2="DS.d234.s0.e0" id="DS.d234.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d235" origId="18492301">
        <sentence id="DS.d235.s0" origId="18492301-527" text="Dietary chia seed (Salvia hispanica L.) rich in alpha-linolenic acid improves adiposity and normalises hypertriacylglycerolaemia and insulin resistance in dyslipaemic rats.">
            <entity id="DS.d235.s0.e0" origId="5280934" charOffset="48-68" type="compound" text="alpha-linolenic acid"/>
            <entity id="DS.d235.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="133-140" type="protein" text="insulin"/>
            <pair e1="DS.d235.s0.e0" e2="DS.d235.s0.e1" id="DS.d235.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d235.s1" origId="18492301-528" text="The present study investigates the benefits of the dietary intake of chia seed (Salvia hispanica L.) rich in alpha-linolenic acid and fibre upon dyslipidaemia and insulin resistance (IR), induced by intake of a sucrose-rich (62.5 %) diet (SRD).">
            <entity id="DS.d235.s1.e0" origId="5280934" charOffset="109-129" type="compound" text="alpha-linolenic acid"/>
            <entity id="DS.d235.s1.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="163-170" type="protein" text="insulin"/>
            <entity id="DS.d235.s1.e2" origId="5988" charOffset="211-218" type="compound" text="sucrose"/>
            <pair e1="DS.d235.s1.e0" e2="DS.d235.s1.e1" id="DS.d235.s1.i0" interaction="False"/>
            <pair e1="DS.d235.s1.e2" e2="DS.d235.s1.e1" id="DS.d235.s1.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d236" origId="18492302">
        <sentence id="DS.d236.s0" origId="18492302-529" text="Pigs fed the high-lysine diet moreover had an increased concentration of trimethyllysine (TML), a reduced mRNA abundance of TML dioxygenase and reduced concentrations of gamma-butyrobetaine (BB) in muscle, indicating that the conversion of TML into BB in muscle was impaired.">
            <entity id="DS.d236.s0.e0" origId="866,5962" charOffset="18-24" type="compound" text="lysine"/>
            <entity id="DS.d236.s0.e1" origId="440121" charOffset="73-88" type="compound" text="trimethyllysine"/>
            <entity id="DS.d236.s0.e2" origId="Q0VC74,Q5F4B3,Q91ZE0,Q91ZW6,Q96UB1,Q9NVH6" charOffset="124-139" type="protein" text="TML dioxygenase"/>
            <entity id="DS.d236.s0.e3" origId="134" charOffset="170-189" type="compound" text="gamma-butyrobetaine"/>
            <pair e1="DS.d236.s0.e0" e2="DS.d236.s0.e2" id="DS.d236.s0.i0" interaction="False"/>
            <pair e1="DS.d236.s0.e1" e2="DS.d236.s0.e2" id="DS.d236.s0.i1" interaction="False"/>
            <pair e1="DS.d236.s0.e3" e2="DS.d236.s0.e2" id="DS.d236.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d237" origId="18494609">
        <sentence id="DS.d237.s0" origId="18494609-496" text="The cells exposed to 10 microM (15S)-HPETE for 3 h or to 40 microM (15S)-HETE for 6 h showed increased expression of Fas ligand and FADD (Fas-associated death domain), caspase 8 activation, Bid (BH3-interacting domain death agonist) cleavage, decrease in mitochondrial membrane potential, cytochrome c release, caspase 3 activation, PARP-1 (poly(ADP-ribose) polymerase-1) cleavage and DNA fragmentation, suggesting the involvement of both extrinsic and intrinsic death pathways.">
            <entity id="DS.d237.s0.e0" origId="5280893" charOffset="32-42" type="compound" text="15S)-HPETE"/>
            <entity id="DS.d237.s0.e1" origId="5280724" charOffset="68-77" type="compound" text="15S)-HETE"/>
            <entity id="DS.d237.s0.e2" origId="P36940,P41047,P48023,P63306,P63307,P63308,Q861W5,Q9BDN1,Q9BEA8" charOffset="117-127" type="protein" text="Fas ligand"/>
            <entity id="DS.d237.s0.e3" origId="P46310,Q13158" charOffset="132-136" type="protein" text="FADD"/>
            <entity id="DS.d237.s0.e4" origId="P25446,Q63199" charOffset="117-120" type="protein" text="Fas"/>
            <entity id="DS.d237.s0.e5" origId="P55957,P70444,Q4JHS0,Q8JGM8,Q9JLT6" charOffset="195-231" type="protein" text="BH3-interacting domain death agonist"/>
            <entity id="DS.d237.s0.e6" origId="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3" charOffset="289-301" type="protein" text="cytochrome c"/>
            <entity id="DS.d237.s0.e7" origId="P09874,P11103,P18493,P26446,P27008,Q7EYV7,Q9R152,Q9ZP54,Q9ZSV1" charOffset="333-339" type="protein" text="PARP-1"/>
            <entity id="DS.d237.s0.e8" origId="P02783" charOffset="346-349" type="protein" text="ADP"/>
            <pair e1="DS.d237.s0.e0" e2="DS.d237.s0.e3" id="DS.d237.s0.i0" interaction="True"/>
            <pair e1="DS.d237.s0.e0" e2="DS.d237.s0.e4" id="DS.d237.s0.i1" interaction="True"/>
            <pair e1="DS.d237.s0.e1" e2="DS.d237.s0.e5" id="DS.d237.s0.i2" interaction="True"/>
            <pair e1="DS.d237.s0.e1" e2="DS.d237.s0.e4" id="DS.d237.s0.i3" interaction="True"/>
            <pair e1="DS.d237.s0.e1" e2="DS.d237.s0.e8" id="DS.d237.s0.i4" interaction="True"/>
            <pair e1="DS.d237.s0.e1" e2="DS.d237.s0.e6" id="DS.d237.s0.i5" interaction="True"/>
            <pair e1="DS.d237.s0.e1" e2="DS.d237.s0.e2" id="DS.d237.s0.i6" interaction="True"/>
            <pair e1="DS.d237.s0.e0" e2="DS.d237.s0.e2" id="DS.d237.s0.i7" interaction="True"/>
            <pair e1="DS.d237.s0.e1" e2="DS.d237.s0.e3" id="DS.d237.s0.i8" interaction="True"/>
            <pair e1="DS.d237.s0.e0" e2="DS.d237.s0.e8" id="DS.d237.s0.i9" interaction="True"/>
            <pair e1="DS.d237.s0.e1" e2="DS.d237.s0.e7" id="DS.d237.s0.i10" interaction="True"/>
            <pair e1="DS.d237.s0.e0" e2="DS.d237.s0.e6" id="DS.d237.s0.i11" interaction="True"/>
            <pair e1="DS.d237.s0.e0" e2="DS.d237.s0.e5" id="DS.d237.s0.i12" interaction="True"/>
            <pair e1="DS.d237.s0.e0" e2="DS.d237.s0.e7" id="DS.d237.s0.i13" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d238" origId="18495128">
        <sentence id="DS.d238.s0" origId="18495128-1028" text="3-Deazaadenosine inhibits vasa vasorum neovascularization in aortas of ApoE (-/-)/LDL(-/-) double knockout mice.">
            <entity id="DS.d238.s0.e0" origId="1651,23190" charOffset="0-16" type="compound" text="3-Deazaadenosine"/>
            <entity id="DS.d238.s0.e1" origId="P02649,P02650,P05770,P08226,P10517,P18287,P18649,P18650,P23529,Q03247,Q28502,Q28995,Q7M2U7,Q7M2U8,Q9GJU3,Q9GLC0,Q9GLM6,Q9GLM7,Q9GLM8" charOffset="71-75" type="protein" text="ApoE"/>
            <pair e1="DS.d238.s0.e0" e2="DS.d238.s0.e1" id="DS.d238.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d239" origId="18495129">
        <sentence id="DS.d239.s0" origId="18495129-1029" text="Anthocyanin attenuates CD40-mediated endothelial cell activation and apoptosis by inhibiting CD40-induced MAPK activation.">
            <entity id="DS.d239.s0.e0" origId="145858" charOffset="0-11" type="compound" text="Anthocyanin"/>
            <entity id="DS.d239.s0.e1" origId="P25942,Q28203,Q3LRP1,Q3ZTK5,Q7YRL5,Q8SQ34" charOffset="23-27" type="protein" text="CD40"/>
            <entity id="DS.d239.s0.e2" origId="P25942,Q28203,Q3LRP1,Q3ZTK5,Q7YRL5,Q8SQ34" charOffset="93-97" type="protein" text="CD40"/>
            <entity id="DS.d239.s0.e3" origId="O42781,P27638,Q00859" charOffset="106-110" type="protein" text="MAPK"/>
            <pair e1="DS.d239.s0.e0" e2="DS.d239.s0.e3" id="DS.d239.s0.i0" interaction="True"/>
            <pair e1="DS.d239.s0.e0" e2="DS.d239.s0.e1" id="DS.d239.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d239.s1" origId="18495129-1030" text="Treatment of ECs with anthocyanins cyanidin-3-O-beta-glucoside (Cy-3-g) and peonidin-3-O-beta-glucoside (Pn-3-g) prevents CD40-induced endothelial activation by inhibiting production of proinflammatory cytokines and matrix metalloproteinases (MMPs).">
            <entity id="DS.d239.s1.e0" origId="53398755" charOffset="76-103" type="compound" text="peonidin-3-O-beta-glucoside"/>
            <entity id="DS.d239.s1.e1" origId="P25942,Q28203,Q3LRP1,Q3ZTK5,Q7YRL5,Q8SQ34" charOffset="122-126" type="protein" text="CD40"/>
            <pair e1="DS.d239.s1.e0" e2="DS.d239.s1.e1" id="DS.d239.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d239.s2" origId="18495129-1031" text="Collectively, our findings suggested that the inhibition of JNK and p38 activation interrupts CD40 induced endothelial cell activation and apoptosis, which thereby may represent a mechanism that would explain the anti-inflammatory response of anthocyanin and its athero-protective function.">
            <entity id="DS.d239.s2.e0" origId="P92208,Q966Y3" charOffset="60-63" type="protein" text="JNK"/>
            <entity id="DS.d239.s2.e1" origId="O24473,O75791,O95433,O97628,P46108,P80350,P82869,Q01552,Q04929,Q63768,Q64010,Q9LDA4,Q9Y2S7" charOffset="68-71" type="protein" text="p38"/>
            <entity id="DS.d239.s2.e2" origId="P25942,Q28203,Q3LRP1,Q3ZTK5,Q7YRL5,Q8SQ34" charOffset="94-98" type="protein" text="CD40"/>
            <entity id="DS.d239.s2.e3" origId="145858" charOffset="243-254" type="compound" text="anthocyanin"/>
            <pair e1="DS.d239.s2.e3" e2="DS.d239.s2.e1" id="DS.d239.s2.i0" interaction="True"/>
            <pair e1="DS.d239.s2.e3" e2="DS.d239.s2.e0" id="DS.d239.s2.i1" interaction="True"/>
            <pair e1="DS.d239.s2.e3" e2="DS.d239.s2.e2" id="DS.d239.s2.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d240" origId="18495357">
        <sentence id="DS.d240.s0" origId="18495357-1187" text="Postsynaptic action of ATP is mediated through metabotropic P2Y and ionotropic P2X receptors abundantly expressed in neural cells.">
            <entity id="DS.d240.s0.e0" origId="5957" charOffset="23-26" type="compound" text="ATP"/>
            <entity id="DS.d240.s0.e1" origId="P13900,P16604" charOffset="79-82" type="protein" text="P2X"/>
            <pair e1="DS.d240.s0.e0" e2="DS.d240.s0.e1" id="DS.d240.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d241" origId="18495456">
        <sentence id="DS.d241.s0" origId="18495456-706" text="However, the MTHFR C677T genotype, alone or together with a diet, influenced betaine (P=.03) and phosphatidylcholine (P=.03).">
            <entity id="DS.d241.s0.e0" origId="P42898,Q5I598,Q60HE5" charOffset="13-18" type="protein" text="MTHFR"/>
            <entity id="DS.d241.s0.e1" origId="248" charOffset="77-84" type="compound" text="betaine"/>
            <pair e1="DS.d241.s0.e1" e2="DS.d241.s0.e0" id="DS.d241.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d241.s1" origId="18495456-707" text="In addition, the MTHFR C677T genotype appears to influence the direction and use of choline moieties in this group of women.">
            <entity id="DS.d241.s1.e0" origId="P42898,Q5I598,Q60HE5" charOffset="17-22" type="protein" text="MTHFR"/>
            <entity id="DS.d241.s1.e1" origId="305" charOffset="84-91" type="compound" text="choline"/>
            <pair e1="DS.d241.s1.e1" e2="DS.d241.s1.e0" id="DS.d241.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d242" origId="18495458">
        <sentence id="DS.d242.s0" origId="18495458-1236" text="Epicatechin-induced survival was a rapid event that was accompanied by early and sustained activation of major survival signaling proteins, such as AKT/phosphatidylinositol 3-kinase and extracellular-regulated kinase (activated from 5 min to 18 h), as well as protein kinase C (PKC)-alpha (30 min to 18 h), in concert with unaltered c-jun N-amino terminal kinase levels and early inactivation of key death-related signals like PKC-delta (5 min to 18 h).">
            <entity id="DS.d242.s0.e0" origId="1203,72276,182232" charOffset="0-11" type="compound" text="Epicatechin"/>
            <entity id="DS.d242.s0.e1" origId="P13678,Q25378" charOffset="260-276" type="protein" text="protein kinase C"/>
            <entity id="DS.d242.s0.e2" origId="P05130,P13677,P13678,P34722" charOffset="278-281" type="protein" text="PKC"/>
            <entity id="DS.d242.s0.e3" origId="P05627,P17325,P18289" charOffset="335-338" type="protein" text="jun"/>
            <entity id="DS.d242.s0.e4" origId="P10829" charOffset="427-436" type="protein" text="PKC-delta"/>
            <pair e1="DS.d242.s0.e0" e2="DS.d242.s0.e3" id="DS.d242.s0.i0" interaction="True"/>
            <pair e1="DS.d242.s0.e0" e2="DS.d242.s0.e2" id="DS.d242.s0.i1" interaction="True"/>
            <pair e1="DS.d242.s0.e0" e2="DS.d242.s0.e4" id="DS.d242.s0.i2" interaction="True"/>
            <pair e1="DS.d242.s0.e0" e2="DS.d242.s0.e1" id="DS.d242.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d243" origId="18495460">
        <sentence id="DS.d243.s0" origId="18495460-1238" text="Phospholipidosis and down-regulation of the PI3-K/PDK-1/Akt signalling pathway are vitamin E inhibitable events associated with 7-ketocholesterol-induced apoptosis.">
            <entity id="DS.d243.s0.e0" origId="P19957" charOffset="44-47" type="protein" text="PI3"/>
            <entity id="DS.d243.s0.e1" origId="P22221,Q42736" charOffset="50-53" type="protein" text="PDK"/>
            <entity id="DS.d243.s0.e2" origId="P31750,Q8INB9" charOffset="56-59" type="protein" text="Akt"/>
            <entity id="DS.d243.s0.e3" origId="2116,14985,1548900,1742129" charOffset="83-92" type="compound" text="vitamin E"/>
            <pair e1="DS.d243.s0.e3" e2="DS.d243.s0.e0" id="DS.d243.s0.i0" interaction="True"/>
            <pair e1="DS.d243.s0.e3" e2="DS.d243.s0.e2" id="DS.d243.s0.i1" interaction="True"/>
            <pair e1="DS.d243.s0.e3" e2="DS.d243.s0.e1" id="DS.d243.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d244" origId="18495461">
        <sentence id="DS.d244.s0" origId="18495461-1165" text="Lack of vitamin A significantly changed mucin (MUC) dynamics, as reflected by the enlarged goblet-cell &quot;cup&quot; area relative to controls; decreased MUC2 mRNA expression in the jejunum, ileum and colon of VAD rats and increased MUC3 mRNA expression in the ileum and colon of these rats.">
            <entity id="DS.d244.s0.e0" origId="445354" charOffset="8-17" type="compound" text="vitamin A"/>
            <entity id="DS.d244.s0.e1" origId="Q02817" charOffset="146-150" type="protein" text="MUC2"/>
            <entity id="DS.d244.s0.e2" origId="Q02505" charOffset="225-229" type="protein" text="MUC3"/>
            <pair e1="DS.d244.s0.e0" e2="DS.d244.s0.e1" id="DS.d244.s0.i0" interaction="True"/>
            <pair e1="DS.d244.s0.e0" e2="DS.d244.s0.e2" id="DS.d244.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d244.s1" origId="18495461-1166" text="In addition, vitamin A deficiency down-regulated defensin 6 mRNA expression while up-regulating toll-like receptors 2 and 5 mRNA expressions.">
            <entity id="DS.d244.s1.e0" origId="445354" charOffset="13-22" type="compound" text="vitamin A"/>
            <entity id="DS.d244.s1.e1" origId="P17722,P37364,P80154,P80407,P81462,Q10745" charOffset="49-57" type="protein" text="defensin"/>
            <pair e1="DS.d244.s1.e0" e2="DS.d244.s1.e1" id="DS.d244.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d245" origId="18495463">
        <sentence id="DS.d245.s0" origId="18495463-1243" text="Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA.">
            <entity id="DS.d245.s0.e0" origId="969516" charOffset="0-8" type="compound" text="Curcumin"/>
            <entity id="DS.d245.s0.e1" origId="5324476" charOffset="10-27" type="compound" text="demethoxycurcumin"/>
            <entity id="DS.d245.s0.e2" origId="5315472" charOffset="32-52" type="compound" text="bisdemethoxycurcumin"/>
            <entity id="DS.d245.s0.e3" origId="P00749,P04185,P06869,P15120,P16227,P29598,Q05589" charOffset="137-140" type="protein" text="uPA"/>
            <pair e1="DS.d245.s0.e0" e2="DS.d245.s0.e3" id="DS.d245.s0.i0" interaction="True"/>
            <pair e1="DS.d245.s0.e2" e2="DS.d245.s0.e3" id="DS.d245.s0.i1" interaction="True"/>
            <pair e1="DS.d245.s0.e1" e2="DS.d245.s0.e3" id="DS.d245.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d246" origId="18496518">
        <sentence id="DS.d246.s0" origId="18496518-35" text="Glucocorticoid receptor antagonism augments fluoxetine-induced downregulation of the 5-HT transporter.">
            <entity id="DS.d246.s0.e0" origId="O13186,O46567,O73673,P04150,P06536,P06537,P35547,P49115,P49843,P49844,P59667,P79269,P79686,Q5R9P5,Q6XLJ0,Q95267,Q9N1U3" charOffset="0-23" type="protein" text="Glucocorticoid receptor"/>
            <entity id="DS.d246.s0.e1" origId="3386" charOffset="44-54" type="compound" text="fluoxetine"/>
            <pair e1="DS.d246.s0.e1" e2="DS.d246.s0.e0" id="DS.d246.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d246.s1" origId="18496518-37" text="In contrast, chronic fluoxetine markedly decreased 5-HTT levels in all regions.">
            <entity id="DS.d246.s1.e0" origId="3386" charOffset="21-31" type="compound" text="fluoxetine"/>
            <entity id="DS.d246.s1.e1" origId="P31645" charOffset="53-56" type="protein" text="HTT"/>
            <pair e1="DS.d246.s1.e0" e2="DS.d246.s1.e1" id="DS.d246.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d246.s2" origId="18496518-38" text="This downregulation of 5-HTT by fluoxetine and its enhancement by Org 34850 can explain our recent observation that GR antagonists augment the SSRI-induced increase in extracellular 5-HT.">
            <entity id="DS.d246.s2.e0" origId="P31645" charOffset="25-28" type="protein" text="HTT"/>
            <entity id="DS.d246.s2.e1" origId="3386" charOffset="32-42" type="compound" text="fluoxetine"/>
            <entity id="DS.d246.s2.e2" origId="5202" charOffset="23-27" type="compound" text="5-HT"/>
            <pair e1="DS.d246.s2.e2" e2="DS.d246.s2.e0" id="DS.d246.s2.i0" interaction="False"/>
            <pair e1="DS.d246.s2.e1" e2="DS.d246.s2.e0" id="DS.d246.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d247" origId="18496650">
        <sentence id="DS.d247.s0" origId="18496650-691" text="Moreover, intestinal, colonic and caecal TBARS, LOOH, CD and also the antioxidants superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), glutathione peroxidase (GPx), glutathione reductase (GR) and reduced glutathione (GSH) were significantly diminished in DMH 0.05) elevated on simultaneous morin supplementation.">
            <entity id="DS.d247.s0.e0" origId="O50258" charOffset="83-103" type="protein" text="superoxide dismutase"/>
            <entity id="DS.d247.s0.e1" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="105-108" type="protein" text="SOD"/>
            <entity id="DS.d247.s0.e2" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="111-119" type="protein" text="catalase"/>
            <entity id="DS.d247.s0.e3" origId="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7" charOffset="121-124" type="protein" text="CAT"/>
            <entity id="DS.d247.s0.e4" origId="O04437,O18598,P0A9D2,P0A9D3,P30116,P44521,P46088,P46419,P46423,P46426,P46428,P46437,P48438,P80894,P81065,P82996,P82997,P82998,P82999,P83000,P83001,P83246,Q04522,Q08392,Q08393,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52,Q96324" charOffset="127-152" type="protein" text="glutathione S-transferase"/>
            <entity id="DS.d247.s0.e5" origId="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52" charOffset="154-157" type="protein" text="GST"/>
            <entity id="DS.d247.s0.e6" origId="O32770,O59858,Q00277,Q9CFV1" charOffset="160-182" type="protein" text="glutathione peroxidase"/>
            <entity id="DS.d247.s0.e7" origId="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655" charOffset="190-211" type="protein" text="glutathione reductase"/>
            <entity id="DS.d247.s0.e8" origId="124886" charOffset="221-240" type="compound" text="reduced glutathione"/>
            <entity id="DS.d247.s0.e9" origId="124886" charOffset="242-245" type="compound" text="GSH"/>
            <entity id="DS.d247.s0.e10" origId="5281670" charOffset="315-320" type="compound" text="morin"/>
            <pair e1="DS.d247.s0.e9" e2="DS.d247.s0.e5" id="DS.d247.s0.i0" interaction="False"/>
            <pair e1="DS.d247.s0.e10" e2="DS.d247.s0.e5" id="DS.d247.s0.i1" interaction="True"/>
            <pair e1="DS.d247.s0.e10" e2="DS.d247.s0.e3" id="DS.d247.s0.i2" interaction="True"/>
            <pair e1="DS.d247.s0.e9" e2="DS.d247.s0.e0" id="DS.d247.s0.i3" interaction="False"/>
            <pair e1="DS.d247.s0.e10" e2="DS.d247.s0.e7" id="DS.d247.s0.i4" interaction="True"/>
            <pair e1="DS.d247.s0.e9" e2="DS.d247.s0.e1" id="DS.d247.s0.i5" interaction="False"/>
            <pair e1="DS.d247.s0.e8" e2="DS.d247.s0.e3" id="DS.d247.s0.i6" interaction="False"/>
            <pair e1="DS.d247.s0.e9" e2="DS.d247.s0.e4" id="DS.d247.s0.i7" interaction="False"/>
            <pair e1="DS.d247.s0.e8" e2="DS.d247.s0.e2" id="DS.d247.s0.i8" interaction="False"/>
            <pair e1="DS.d247.s0.e8" e2="DS.d247.s0.e1" id="DS.d247.s0.i9" interaction="False"/>
            <pair e1="DS.d247.s0.e8" e2="DS.d247.s0.e5" id="DS.d247.s0.i10" interaction="False"/>
            <pair e1="DS.d247.s0.e9" e2="DS.d247.s0.e3" id="DS.d247.s0.i11" interaction="False"/>
            <pair e1="DS.d247.s0.e9" e2="DS.d247.s0.e7" id="DS.d247.s0.i12" interaction="False"/>
            <pair e1="DS.d247.s0.e10" e2="DS.d247.s0.e2" id="DS.d247.s0.i13" interaction="True"/>
            <pair e1="DS.d247.s0.e8" e2="DS.d247.s0.e4" id="DS.d247.s0.i14" interaction="False"/>
            <pair e1="DS.d247.s0.e10" e2="DS.d247.s0.e4" id="DS.d247.s0.i15" interaction="True"/>
            <pair e1="DS.d247.s0.e9" e2="DS.d247.s0.e6" id="DS.d247.s0.i16" interaction="False"/>
            <pair e1="DS.d247.s0.e8" e2="DS.d247.s0.e0" id="DS.d247.s0.i17" interaction="False"/>
            <pair e1="DS.d247.s0.e10" e2="DS.d247.s0.e0" id="DS.d247.s0.i18" interaction="True"/>
            <pair e1="DS.d247.s0.e8" e2="DS.d247.s0.e6" id="DS.d247.s0.i19" interaction="False"/>
            <pair e1="DS.d247.s0.e10" e2="DS.d247.s0.e6" id="DS.d247.s0.i20" interaction="True"/>
            <pair e1="DS.d247.s0.e8" e2="DS.d247.s0.e7" id="DS.d247.s0.i21" interaction="False"/>
            <pair e1="DS.d247.s0.e10" e2="DS.d247.s0.e1" id="DS.d247.s0.i22" interaction="True"/>
            <pair e1="DS.d247.s0.e9" e2="DS.d247.s0.e2" id="DS.d247.s0.i23" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d248" origId="18496767">
        <sentence id="DS.d248.s0" origId="18496767-753" text="Using in vitro binding assays we have demonstrated that transcription factors Sp3, ZBP-89 and NF-Y are capable of binding to the SOX18 promoter region spanning the sequence-200 to-162 relative to ATG and that formation of complexes could be efficiently reduced by mithramycin A.">
            <entity id="DS.d248.s0.e0" origId="O70494,Q02447,Q90WR8" charOffset="56-81" type="protein" text="transcription factors Sp3"/>
            <entity id="DS.d248.s0.e1" origId="P35713" charOffset="129-134" type="protein" text="SOX18"/>
            <entity id="DS.d248.s0.e2" origId="29051,163659,230076,6326719" charOffset="264-277" type="compound" text="mithramycin A"/>
            <pair e1="DS.d248.s0.e2" e2="DS.d248.s0.e1" id="DS.d248.s0.i0" interaction="True"/>
            <pair e1="DS.d248.s0.e2" e2="DS.d248.s0.e0" id="DS.d248.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d249" origId="18496861">
        <sentence id="DS.d249.s0" origId="18496861-830" text="Treatment with hyaluronidase indicates that the dimensions of the small fibrils may be dependent upon the presence of hyaluronan within the matrix.">
            <entity id="DS.d249.s0.e0" origId="P15316,P26831,P49370,P49371,Q08169,Q53591,Q54699,Q54873,Q59634,Q59801,Q9U6V9" charOffset="15-28" type="protein" text="hyaluronidase"/>
            <entity id="DS.d249.s0.e1" origId="24759" charOffset="118-128" type="compound" text="hyaluronan"/>
            <pair e1="DS.d249.s0.e1" e2="DS.d249.s0.e0" id="DS.d249.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d250" origId="18496865">
        <sentence id="DS.d250.s0" origId="18496865-833" text="Tetraglyme coatings reduce fibrinogen and von Willebrand factor adsorption and platelet adhesion under both static and flow conditions.">
            <entity id="DS.d250.s0.e0" origId="8925" charOffset="0-10" type="compound" text="Tetraglyme"/>
            <entity id="DS.d250.s0.e1" origId="P22775,P81070" charOffset="27-37" type="protein" text="fibrinogen"/>
            <entity id="DS.d250.s0.e2" origId="Q62935" charOffset="42-63" type="protein" text="von Willebrand factor"/>
            <pair e1="DS.d250.s0.e0" e2="DS.d250.s0.e1" id="DS.d250.s0.i0" interaction="True"/>
            <pair e1="DS.d250.s0.e0" e2="DS.d250.s0.e2" id="DS.d250.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d250.s1" origId="18496865-834" text="Previous studies have showed that radio-frequency plasma deposited tetraglyme coatings greatly reduced fibrinogen adsorption (Gamma(Fg)) from highly diluted plasmas (0.1 and 1%) and subsequent platelet adhesion under static conditions.">
            <entity id="DS.d250.s1.e0" origId="8925" charOffset="67-77" type="compound" text="tetraglyme"/>
            <entity id="DS.d250.s1.e1" origId="P22775,P81070" charOffset="103-113" type="protein" text="fibrinogen"/>
            <pair e1="DS.d250.s1.e0" e2="DS.d250.s1.e1" id="DS.d250.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d251" origId="18497703">
        <sentence id="DS.d251.s0" origId="18497703-873" text="Effects of inhibition of NOS, iNOS, and nNOS by N-nitro-L-arginine methyl ester (L-NAME), aminoguanidine, and 7-nitroindazole, respectively, were determined on the antigen-induced systemic hypotension and portal hypertension in conscious Sprague-Dawley rats sensitized with the ovalbumin antigen.">
            <entity id="DS.d251.s0.e0" origId="O54705,O61309,O61608,Q26240,Q28969,Q9I9M2" charOffset="25-28" type="protein" text="NOS"/>
            <entity id="DS.d251.s0.e1" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="30-34" type="protein" text="iNOS"/>
            <entity id="DS.d251.s0.e2" origId="O19132,O61309,P29475,P29476,Q9Z0J4" charOffset="40-44" type="protein" text="nNOS"/>
            <entity id="DS.d251.s0.e3" origId="92932,550788" charOffset="56-79" type="compound" text="L-arginine methyl ester"/>
            <entity id="DS.d251.s0.e4" origId="2146" charOffset="90-104" type="compound" text="aminoguanidine"/>
            <entity id="DS.d251.s0.e5" origId="1893" charOffset="110-125" type="compound" text="7-nitroindazole"/>
            <pair e1="DS.d251.s0.e5" e2="DS.d251.s0.e0" id="DS.d251.s0.i0" interaction="False"/>
            <pair e1="DS.d251.s0.e4" e2="DS.d251.s0.e1" id="DS.d251.s0.i1" interaction="False"/>
            <pair e1="DS.d251.s0.e3" e2="DS.d251.s0.e0" id="DS.d251.s0.i2" interaction="False"/>
            <pair e1="DS.d251.s0.e3" e2="DS.d251.s0.e2" id="DS.d251.s0.i3" interaction="False"/>
            <pair e1="DS.d251.s0.e4" e2="DS.d251.s0.e2" id="DS.d251.s0.i4" interaction="False"/>
            <pair e1="DS.d251.s0.e4" e2="DS.d251.s0.e0" id="DS.d251.s0.i5" interaction="False"/>
            <pair e1="DS.d251.s0.e3" e2="DS.d251.s0.e1" id="DS.d251.s0.i6" interaction="False"/>
            <pair e1="DS.d251.s0.e5" e2="DS.d251.s0.e2" id="DS.d251.s0.i7" interaction="False"/>
            <pair e1="DS.d251.s0.e5" e2="DS.d251.s0.e1" id="DS.d251.s0.i8" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d252" origId="18497707">
        <sentence id="DS.d252.s0" origId="18497707-589" text="Differential gene expression of interleukin-1 receptor associated kinase-1 and interleukin-1 receptor associated kinase-M in peripheral blood mononuclear cells of young and aged rats following preconditioning with endotoxin.">
            <entity id="DS.d252.s0.e0" origId="P51617,Q62406" charOffset="32-74" type="protein" text="interleukin-1 receptor associated kinase-1"/>
            <entity id="DS.d252.s0.e1" origId="44268108" charOffset="214-223" type="compound" text="endotoxin"/>
            <pair e1="DS.d252.s0.e1" e2="DS.d252.s0.e0" id="DS.d252.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d252.s1" origId="18497707-590" text="The IL-1 receptor-associated kinase 1 (IRAK-1) and IRAK-M are key signaling molecules in cellular responses to endotoxin initiated through the Toll-like receptors (TLRs).">
            <entity id="DS.d252.s1.e0" origId="P51617,Q62406" charOffset="39-45" type="protein" text="IRAK-1"/>
            <entity id="DS.d252.s1.e1" origId="Q8K4B2,Q9Y616" charOffset="51-57" type="protein" text="IRAK-M"/>
            <entity id="DS.d252.s1.e2" origId="44268108" charOffset="111-120" type="compound" text="endotoxin"/>
            <entity id="DS.d252.s1.e3" origId="P23799" charOffset="164-168" type="protein" text="TLRs"/>
            <pair e1="DS.d252.s1.e2" e2="DS.d252.s1.e1" id="DS.d252.s1.i0" interaction="True"/>
            <pair e1="DS.d252.s1.e2" e2="DS.d252.s1.e3" id="DS.d252.s1.i1" interaction="True"/>
            <pair e1="DS.d252.s1.e2" e2="DS.d252.s1.e0" id="DS.d252.s1.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d252.s2" origId="18497707-591" text="The aim of this study was to evaluate the effect of age on the modulation of TLRs and IRAK-1 and IRAK-M in peripheral blood mononuclear cells (PBMCs) exposed in vitro to endotoxin under conditions that could induce endotoxin tolerance.">
            <entity id="DS.d252.s2.e0" origId="P23799" charOffset="77-81" type="protein" text="TLRs"/>
            <entity id="DS.d252.s2.e1" origId="P51617,Q62406" charOffset="86-92" type="protein" text="IRAK-1"/>
            <entity id="DS.d252.s2.e2" origId="Q8K4B2,Q9Y616" charOffset="97-103" type="protein" text="IRAK-M"/>
            <entity id="DS.d252.s2.e3" origId="44268108" charOffset="170-179" type="compound" text="endotoxin"/>
            <entity id="DS.d252.s2.e4" origId="44268108" charOffset="215-224" type="compound" text="endotoxin"/>
            <pair e1="DS.d252.s2.e3" e2="DS.d252.s2.e2" id="DS.d252.s2.i0" interaction="False"/>
            <pair e1="DS.d252.s2.e3" e2="DS.d252.s2.e1" id="DS.d252.s2.i1" interaction="False"/>
            <pair e1="DS.d252.s2.e3" e2="DS.d252.s2.e0" id="DS.d252.s2.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d253" origId="18497709">
        <sentence id="DS.d253.s0" origId="18497709-959" text="We also previously demonstrated that glutamine (GLN) significantly induced HO-1 in the lower intestinal tract.">
            <entity id="DS.d253.s0.e0" origId="738,5961" charOffset="37-46" type="compound" text="glutamine"/>
            <entity id="DS.d253.s0.e1" origId="P06762,P09601,P14791,P14901,P32394,Q5E9F2" charOffset="75-79" type="protein" text="HO-1"/>
            <pair e1="DS.d253.s0.e0" e2="DS.d253.s0.e1" id="DS.d253.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d253.s1" origId="18497709-961" text="Glutamine treatment before HS (MAP of 30 mmHg for 60 min) significantly ameliorated HS-induced mucosal inflammation and apoptotic cell death in the ileum, as judged by significant decreases in gene expression of TNF-alpha, iNOS, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1, myeloperoxidase activity, the number of infiltrated neutrophils, DNA fragmentation by in situ oligo ligation assay, and activated caspase-3 expression, and by increases in gene expression of IL-10 and Bcl-2.">
            <entity id="DS.d253.s1.e0" origId="738,5961" charOffset="0-9" type="compound" text="Glutamine"/>
            <entity id="DS.d253.s1.e1" origId="5047209,46173182" charOffset="27-29" type="compound" text="HS"/>
            <entity id="DS.d253.s1.e2" origId="5047209,46173182" charOffset="84-86" type="compound" text="HS"/>
            <entity id="DS.d253.s1.e3" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="212-221" type="protein" text="TNF-alpha"/>
            <entity id="DS.d253.s1.e4" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="223-227" type="protein" text="iNOS"/>
            <entity id="DS.d253.s1.e5" origId="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5" charOffset="494-499" type="protein" text="IL-10"/>
            <entity id="DS.d253.s1.e6" origId="P10417,P49950" charOffset="504-509" type="protein" text="Bcl-2"/>
            <pair e1="DS.d253.s1.e0" e2="DS.d253.s1.e5" id="DS.d253.s1.i0" interaction="True"/>
            <pair e1="DS.d253.s1.e0" e2="DS.d253.s1.e3" id="DS.d253.s1.i1" interaction="True"/>
            <pair e1="DS.d253.s1.e1" e2="DS.d253.s1.e5" id="DS.d253.s1.i2" interaction="False"/>
            <pair e1="DS.d253.s1.e0" e2="DS.d253.s1.e4" id="DS.d253.s1.i3" interaction="True"/>
            <pair e1="DS.d253.s1.e1" e2="DS.d253.s1.e4" id="DS.d253.s1.i4" interaction="False"/>
            <pair e1="DS.d253.s1.e0" e2="DS.d253.s1.e6" id="DS.d253.s1.i5" interaction="True"/>
            <pair e1="DS.d253.s1.e1" e2="DS.d253.s1.e6" id="DS.d253.s1.i6" interaction="False"/>
            <pair e1="DS.d253.s1.e1" e2="DS.d253.s1.e3" id="DS.d253.s1.i7" interaction="False"/>
        </sentence>
        <sentence id="DS.d253.s2" origId="18497709-964" text="Glutamine treatment may thus protect mucosal cells from HS-induced oxidative damage via the anti-inflammatory and antiapoptotic properties of HO-1.">
            <entity id="DS.d253.s2.e0" origId="738,5961" charOffset="0-9" type="compound" text="Glutamine"/>
            <entity id="DS.d253.s2.e1" origId="P06762,P09601,P14791,P14901,P32394,Q5E9F2" charOffset="142-146" type="protein" text="HO-1"/>
            <pair e1="DS.d253.s2.e0" e2="DS.d253.s2.e1" id="DS.d253.s2.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d254" origId="18498083">
        <sentence id="DS.d254.s0" origId="18498083-305" text="In this work, we identified a high affinity and potency metallocene-containing triazole peptide conjugate that suppresses the interactions of HIV-1 envelope gp120 at both its CD4 and co-receptor binding sites.">
            <entity id="DS.d254.s0.e0" origId="67516" charOffset="79-87" type="compound" text="triazole"/>
            <entity id="DS.d254.s0.e1" origId="O12164,O41803,O70902,O89292,O91086,P03375,P03377,P03378,P04577,P04578,P04579,P04580,P04581,P04582,P04583,P04624,P05877,P05878,P05879,P05880,P05881,P05882,P05883,P05884,P05885,P05886,P08810,P11267,P12449,P12487,P12488,P12489,P12490,P12491,P12492,P15831,P17281,P17755,P18040,P18094,P18799,P19503,P19549,P19550,P19551,P20871,P20872,P20888,P22380,P24105,P27757,P27977,P31819,P31872,P32536,P35961,Q02837,Q1A243,Q1A261,Q70626,Q73372,Q74126,Q75008,Q76638,Q77377,Q79670,Q89607,Q8AIH5,Q9IDV2,Q9Q714,Q9QBY2,Q9QBZ0,Q9QBZ4,Q9QBZ8,Q9QSQ7,Q9WC60,Q9WC69" charOffset="157-162" type="protein" text="gp120"/>
            <entity id="DS.d254.s0.e2" origId="P01730,P05542,P16003,P16004,P33705,P46630,P79184,P79185,Q08336,Q08338,Q08339,Q08340,Q29037,Q9XS78" charOffset="175-178" type="protein" text="CD4"/>
            <pair e1="DS.d254.s0.e0" e2="DS.d254.s0.e2" id="DS.d254.s0.i0" interaction="True"/>
            <pair e1="DS.d254.s0.e0" e2="DS.d254.s0.e1" id="DS.d254.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d254.s1" origId="18498083-306" text="Surface plasmon resonance interaction analysis revealed that, compared to a previously reported phenyl-containing triazole conjugate HNG-105 (105), peptide 156 had a higher direct binding affinity for several subtypes of HIV-1 gp120 due mainly to the decreased dissociation rate of the conjugate-gp120 complex.">
            <entity id="DS.d254.s1.e0" origId="67516" charOffset="114-122" type="compound" text="triazole"/>
            <entity id="DS.d254.s1.e1" origId="25085904" charOffset="133-140" type="compound" text="HNG-105"/>
            <entity id="DS.d254.s1.e2" origId="O12164,O41803,O70902,O89292,O91086,P03375,P03377,P03378,P04577,P04578,P04579,P04580,P04581,P04582,P04583,P04624,P05877,P05878,P05879,P05880,P05881,P05882,P05883,P05884,P05885,P05886,P08810,P11267,P12449,P12487,P12488,P12489,P12490,P12491,P12492,P15831,P17281,P17755,P18040,P18094,P18799,P19503,P19549,P19550,P19551,P20871,P20872,P20888,P22380,P24105,P27757,P27977,P31819,P31872,P32536,P35961,Q02837,Q1A243,Q1A261,Q70626,Q73372,Q74126,Q75008,Q76638,Q77377,Q79670,Q89607,Q8AIH5,Q9IDV2,Q9Q714,Q9QBY2,Q9QBZ0,Q9QBZ4,Q9QBZ8,Q9QSQ7,Q9WC60,Q9WC69" charOffset="227-232" type="protein" text="gp120"/>
            <pair e1="DS.d254.s1.e1" e2="DS.d254.s1.e2" id="DS.d254.s1.i0" interaction="True"/>
            <pair e1="DS.d254.s1.e0" e2="DS.d254.s1.e2" id="DS.d254.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d254.s2" origId="18498083-307" text="The ferrocene triazole conjugate bound to gp120 of both clade A (92UG037-08) and clade B (YU-2 and SF162) virus subtypes with nanomolar KD in direct binding and inhibited the binding of gp120 to soluble CD4 and to antibodies that bind to HIV-1YU-2 gp120 at both the CD4 binding site and CD4-induced binding sites.">
            <entity id="DS.d254.s2.e0" origId="67516" charOffset="14-22" type="compound" text="triazole"/>
            <entity id="DS.d254.s2.e1" origId="O12164,O41803,O70902,O89292,O91086,P03375,P03377,P03378,P04577,P04578,P04579,P04580,P04581,P04582,P04583,P04624,P05877,P05878,P05879,P05880,P05881,P05882,P05883,P05884,P05885,P05886,P08810,P11267,P12449,P12487,P12488,P12489,P12490,P12491,P12492,P15831,P17281,P17755,P18040,P18094,P18799,P19503,P19549,P19550,P19551,P20871,P20872,P20888,P22380,P24105,P27757,P27977,P31819,P31872,P32536,P35961,Q02837,Q1A243,Q1A261,Q70626,Q73372,Q74126,Q75008,Q76638,Q77377,Q79670,Q89607,Q8AIH5,Q9IDV2,Q9Q714,Q9QBY2,Q9QBZ0,Q9QBZ4,Q9QBZ8,Q9QSQ7,Q9WC60,Q9WC69" charOffset="42-47" type="protein" text="gp120"/>
            <entity id="DS.d254.s2.e2" origId="O12164,O41803,O70902,O89292,O91086,P03375,P03377,P03378,P04577,P04578,P04579,P04580,P04581,P04582,P04583,P04624,P05877,P05878,P05879,P05880,P05881,P05882,P05883,P05884,P05885,P05886,P08810,P11267,P12449,P12487,P12488,P12489,P12490,P12491,P12492,P15831,P17281,P17755,P18040,P18094,P18799,P19503,P19549,P19550,P19551,P20871,P20872,P20888,P22380,P24105,P27757,P27977,P31819,P31872,P32536,P35961,Q02837,Q1A243,Q1A261,Q70626,Q73372,Q74126,Q75008,Q76638,Q77377,Q79670,Q89607,Q8AIH5,Q9IDV2,Q9Q714,Q9QBY2,Q9QBZ0,Q9QBZ4,Q9QBZ8,Q9QSQ7,Q9WC60,Q9WC69" charOffset="186-191" type="protein" text="gp120"/>
            <entity id="DS.d254.s2.e3" origId="P01730,P05542,P16003,P16004,P33705,P46630,P79184,P79185,Q08336,Q08338,Q08339,Q08340,Q29037,Q9XS78" charOffset="203-206" type="protein" text="CD4"/>
            <entity id="DS.d254.s2.e4" origId="P01730,P05542,P16003,P16004,P33705,P46630,P79184,P79185,Q08336,Q08338,Q08339,Q08340,Q29037,Q9XS78" charOffset="266-269" type="protein" text="CD4"/>
            <entity id="DS.d254.s2.e5" origId="P01730,P05542,P16003,P16004,P33705,P46630,P79184,P79185,Q08336,Q08338,Q08339,Q08340,Q29037,Q9XS78" charOffset="266-269" type="protein" text="CD4"/>
            <pair e1="DS.d254.s2.e0" e2="DS.d254.s2.e3" id="DS.d254.s2.i0" interaction="True"/>
            <pair e1="DS.d254.s2.e0" e2="DS.d254.s2.e1" id="DS.d254.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d255" origId="18498357">
        <sentence id="DS.d255.s0" origId="18498357-470" text="Screening of risk factors for thromboembolism revealed that all patients carried a methylenetetrahydrofolate reductase 677C--&amp;gt;T (MTHFR) mutation in a gene involved in folate metabolism, and either borderline or elevated homocysteine levels.">
            <entity id="DS.d255.s0.e0" origId="P42898,Q5I598,Q60HE5,Q9WU20" charOffset="83-118" type="protein" text="methylenetetrahydrofolate reductase"/>
            <entity id="DS.d255.s0.e1" origId="P42898,Q5I598,Q60HE5" charOffset="132-137" type="protein" text="MTHFR"/>
            <entity id="DS.d255.s0.e2" origId="778" charOffset="223-235" type="compound" text="homocysteine"/>
            <pair e1="DS.d255.s0.e2" e2="DS.d255.s0.e0" id="DS.d255.s0.i0" interaction="False"/>
            <pair e1="DS.d255.s0.e2" e2="DS.d255.s0.e1" id="DS.d255.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d256" origId="18498673">
        <sentence id="DS.d256.s0" origId="18498673-382" text="Circulating leptin was negatively correlated with mRNA expression of adiponectin, LEPR and LPL, whereas thyroxine was positively correlated with levels of PPARGC1A.">
            <entity id="DS.d256.s0.e0" origId="O02750,O93416,Q28603,Q95189,Q95234" charOffset="12-18" type="protein" text="leptin"/>
            <entity id="DS.d256.s0.e1" origId="O02671,O15243,P48357,Q9MYL0" charOffset="82-86" type="protein" text="LEPR"/>
            <entity id="DS.d256.s0.e2" origId="O46647,P06858,P11151,P11152,P11153,P11602,P49060,P49923,P55031,Q06000,Q29524" charOffset="91-94" type="protein" text="LPL"/>
            <entity id="DS.d256.s0.e3" origId="853,5819" charOffset="104-113" type="compound" text="thyroxine"/>
            <entity id="DS.d256.s0.e4" origId="Q865B6,Q865B7,Q9UBK2" charOffset="155-163" type="protein" text="PPARGC1A"/>
            <pair e1="DS.d256.s0.e3" e2="DS.d256.s0.e2" id="DS.d256.s0.i0" interaction="False"/>
            <pair e1="DS.d256.s0.e3" e2="DS.d256.s0.e0" id="DS.d256.s0.i1" interaction="False"/>
            <pair e1="DS.d256.s0.e3" e2="DS.d256.s0.e4" id="DS.d256.s0.i2" interaction="True"/>
            <pair e1="DS.d256.s0.e3" e2="DS.d256.s0.e1" id="DS.d256.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d257" origId="18500430">
        <sentence id="DS.d257.s0" origId="18500430-564" text="In the absence of exogenous Ca(2+) and Mg(2+) and in the presence of EGTA, which favours the release of endogenous Ca(2+), the polyamine spermine is able to stimulate the activity of pyruvate dehydrogenase complex (PDC) of energized rat liver mitochondria (RLM).">
            <entity id="DS.d257.s0.e0" origId="271" charOffset="28-32" type="compound" text="Ca(2"/>
            <entity id="DS.d257.s0.e1" origId="6207" charOffset="69-73" type="compound" text="EGTA"/>
            <entity id="DS.d257.s0.e2" origId="271" charOffset="115-119" type="compound" text="Ca(2"/>
            <entity id="DS.d257.s0.e3" origId="1103" charOffset="137-145" type="compound" text="spermine"/>
            <entity id="DS.d257.s0.e4" origId="O77560,P06672,P19632,P20941,P28516,P34734,P41686,P51845,P51846,P51847,P51848,P51849,P51850,P51851,Q05326,Q05327,Q6FJA3,Q9XS39" charOffset="215-218" type="protein" text="PDC"/>
            <pair e1="DS.d257.s0.e3" e2="DS.d257.s0.e4" id="DS.d257.s0.i0" interaction="True"/>
            <pair e1="DS.d257.s0.e0" e2="DS.d257.s0.e4" id="DS.d257.s0.i1" interaction="False"/>
            <pair e1="DS.d257.s0.e1" e2="DS.d257.s0.e4" id="DS.d257.s0.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d257.s1" origId="18500430-565" text="At concentrations higher than 0.5 mM, spermine still stimulates PDC, when compared with the control, but shows a slight dose-dependent decrease.">
            <entity id="DS.d257.s1.e0" origId="1103" charOffset="38-46" type="compound" text="spermine"/>
            <entity id="DS.d257.s1.e1" origId="O77560,P06672,P19632,P20941,P28516,P34734,P41686,P51845,P51846,P51847,P51848,P51849,P51850,P51851,Q05326,Q05327,Q6FJA3,Q9XS39" charOffset="64-67" type="protein" text="PDC"/>
            <pair e1="DS.d257.s1.e0" e2="DS.d257.s1.e1" id="DS.d257.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d257.s2" origId="18500430-566" text="Changes in PDC stimulation are very close to the phosphorylation level of the E(1alpha) subunit of PDC, which regulates the activity of the complex, but it is also the target of spermine.">
            <entity id="DS.d257.s2.e0" origId="O77560,P06672,P19632,P20941,P28516,P34734,P41686,P51845,P51846,P51847,P51848,P51849,P51850,P51851,Q05326,Q05327,Q6FJA3,Q9XS39" charOffset="11-14" type="protein" text="PDC"/>
            <entity id="DS.d257.s2.e1" origId="O77560,P06672,P19632,P20941,P28516,P34734,P41686,P51845,P51846,P51847,P51848,P51849,P51850,P51851,Q05326,Q05327,Q6FJA3,Q9XS39" charOffset="99-102" type="protein" text="PDC"/>
            <entity id="DS.d257.s2.e2" origId="1103" charOffset="178-186" type="compound" text="spermine"/>
            <pair e1="DS.d257.s2.e2" e2="DS.d257.s2.e0" id="DS.d257.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d257.s3" origId="18500430-567" text="These results provide the first evidence that, when transported in RLM, spermine can interact in various ways with PDC, showing dose-dependent behaviour.">
            <entity id="DS.d257.s3.e0" origId="1103" charOffset="72-80" type="compound" text="spermine"/>
            <entity id="DS.d257.s3.e1" origId="O77560,P06672,P19632,P20941,P28516,P34734,P41686,P51845,P51846,P51847,P51848,P51849,P51850,P51851,Q05326,Q05327,Q6FJA3,Q9XS39" charOffset="115-118" type="protein" text="PDC"/>
            <pair e1="DS.d257.s3.e0" e2="DS.d257.s3.e1" id="DS.d257.s3.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d258" origId="18500522">
        <sentence id="DS.d258.s0" origId="18500522-58" text="This study assessed relationships between hNT levels and fludarabine uptake and cytotoxicity in cultures of human renal proximal tubule cells (hRPTCs) that produce multiple transporter types.">
            <entity id="DS.d258.s0.e0" origId="Q9P121" charOffset="42-45" type="protein" text="hNT"/>
            <entity id="DS.d258.s0.e1" origId="657237" charOffset="57-68" type="compound" text="fludarabine"/>
            <pair e1="DS.d258.s0.e1" e2="DS.d258.s0.e0" id="DS.d258.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d259" origId="18502597">
        <sentence id="DS.d259.s0" origId="18502597-1034" text="Multiple metabolic and neuroendocrine mechanisms are responsible for the CR-mediated anti-inflammatory effects, including reduced adiposity and secretion of pro-inflammatory adipokines, enhanced glucocorticoid production, reduced plasma glucose and advanced glycation end-product concentrations, increased parasympathetic tone, and increased ghrelin production.">
            <entity id="DS.d259.s0.e0" origId="206,5793,64689,79025" charOffset="237-244" type="compound" text="glucose"/>
            <entity id="DS.d259.s0.e1" origId="Q6BEG6,Q6BEG7,Q9BDJ6,Q9BEF8,Q9EQX0,Q9GKY5,Q9QYH7,Q9UBU3" charOffset="342-349" type="protein" text="ghrelin"/>
            <pair e1="DS.d259.s0.e0" e2="DS.d259.s0.e1" id="DS.d259.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d260" origId="18503570">
        <sentence id="DS.d260.s0" origId="18503570-926" text="From the known regulatory mechanisms of Arc expression, HFD reduced N-methyl-D-aspartate receptor (NMDAR) activity, as seen by decreases in tyrosine phosphorylation of NMDAR2A and levels of NMDAR1.">
            <entity id="DS.d260.s0.e0" origId="P35439,Q9R1M7" charOffset="68-97" type="protein" text="N-methyl-D-aspartate receptor"/>
            <entity id="DS.d260.s0.e1" origId="1153,6057,5460803" charOffset="140-148" type="compound" text="tyrosine"/>
            <entity id="DS.d260.s0.e2" origId="P35436,Q00959,Q12879,Q5IS45" charOffset="168-175" type="protein" text="NMDAR2A"/>
            <entity id="DS.d260.s0.e3" origId="Q05586,Q5R1P0" charOffset="190-196" type="protein" text="NMDAR1"/>
            <pair e1="DS.d260.s0.e1" e2="DS.d260.s0.e2" id="DS.d260.s0.i0" interaction="True"/>
            <pair e1="DS.d260.s0.e1" e2="DS.d260.s0.e0" id="DS.d260.s0.i1" interaction="True"/>
            <pair e1="DS.d260.s0.e1" e2="DS.d260.s0.e3" id="DS.d260.s0.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d260.s1" origId="18503570-927" text="Additionally, we demonstrated that 27-hydroxycholesterol, a cholesterol metabolite that enters the brain from the blood, decreases Arc levels as well as NMDAR and Src kinase activities in rat primary hippocampal neurons.">
            <entity id="DS.d260.s1.e0" origId="99470,123976,50990021" charOffset="35-56" type="compound" text="27-hydroxycholesterol"/>
            <entity id="DS.d260.s1.e1" origId="304,5997,6432564,11025495" charOffset="45-56" type="compound" text="cholesterol"/>
            <entity id="DS.d260.s1.e2" origId="P05480,Q9WUD9" charOffset="163-166" type="protein" text="Src"/>
            <pair e1="DS.d260.s1.e1" e2="DS.d260.s1.e2" id="DS.d260.s1.i0" interaction="True"/>
            <pair e1="DS.d260.s1.e0" e2="DS.d260.s1.e2" id="DS.d260.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d261" origId="18505747">
        <sentence id="DS.d261.s0" origId="18505747-21" text="Cyclooxygenase-2, an inducible enzyme important in inflammation, catalyzes the production of prostanoids from arachidonic acid.">
            <entity id="DS.d261.s0.e0" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="0-16" type="protein" text="Cyclooxygenase-2"/>
            <entity id="DS.d261.s0.e1" origId="444899" charOffset="110-126" type="compound" text="arachidonic acid"/>
            <pair e1="DS.d261.s0.e1" e2="DS.d261.s0.e0" id="DS.d261.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d262" origId="18506596">
        <sentence id="DS.d262.s0" origId="18506596-495" text="cDNA probes have been developed for subsequent use in monitoring the cadmium exposure of the clam Ruditapes decussatus and the cockle Cerastoderma glaucum using metallothionein (MT) gene expression in different tissues of these species.">
            <entity id="DS.d262.s0.e0" origId="23973" charOffset="69-76" type="compound" text="cadmium"/>
            <entity id="DS.d262.s0.e1" origId="O02033,O13257,O18842,O42152,O93571,P02807,P04358,P07216,P08002,P23038,P25127,P25128,P30331,P30565,P51902,P52723,P52725,P52726,P52728,P55945,P55946,P55948,P55951,P55952,P55953,P68494,P68495,P68497,P68498,P68499,P80367,P80593,P84865,Q05890,Q6J1T3,Q6S4N8,Q6XUW5,Q708T3,Q7ZZP9,Q800D3,Q8UVY1,Q94550,Q9IB50,Q9U568" charOffset="161-176" type="protein" text="metallothionein"/>
            <pair e1="DS.d262.s0.e0" e2="DS.d262.s0.e1" id="DS.d262.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d263" origId="18506630">
        <sentence id="DS.d263.s0" origId="18506630-727" text="Purified lignin peroxidase was able to oxidize a variety of substrates including Mn2+, tryptophan, mimosine, L-Dopa, hydroquinone, xylidine, n-propanol, veratryl alcohol, and ten textile dyes of various groups indicating as a versatile peroxidase.">
            <entity id="DS.d263.s0.e0" origId="P06181,P11542,P11543,P20010,P20011,P20012,P20013,P21764,P31837,P31838,P49012,P50622" charOffset="9-26" type="protein" text="lignin peroxidase"/>
            <entity id="DS.d263.s0.e1" origId="27854" charOffset="81-84" type="compound" text="Mn2"/>
            <entity id="DS.d263.s0.e2" origId="1148,6305,9060,5460840" charOffset="87-97" type="compound" text="tryptophan"/>
            <entity id="DS.d263.s0.e3" origId="3862" charOffset="99-107" type="compound" text="mimosine"/>
            <entity id="DS.d263.s0.e4" origId="6047" charOffset="109-115" type="compound" text="L-Dopa"/>
            <entity id="DS.d263.s0.e5" origId="785" charOffset="117-129" type="compound" text="hydroquinone"/>
            <entity id="DS.d263.s0.e6" origId="1031" charOffset="141-151" type="compound" text="n-propanol"/>
            <entity id="DS.d263.s0.e7" origId="7118" charOffset="153-169" type="compound" text="veratryl alcohol"/>
            <pair e1="DS.d263.s0.e6" e2="DS.d263.s0.e0" id="DS.d263.s0.i0" interaction="True"/>
            <pair e1="DS.d263.s0.e5" e2="DS.d263.s0.e0" id="DS.d263.s0.i2" interaction="True"/>
            <pair e1="DS.d263.s0.e1" e2="DS.d263.s0.e0" id="DS.d263.s0.i3" interaction="True"/>
            <pair e1="DS.d263.s0.e3" e2="DS.d263.s0.e0" id="DS.d263.s0.i7" interaction="True"/>
            <pair e1="DS.d263.s0.e4" e2="DS.d263.s0.e0" id="DS.d263.s0.i9" interaction="True"/>
            <pair e1="DS.d263.s0.e7" e2="DS.d263.s0.e0" id="DS.d263.s0.i10" interaction="True"/>
            <pair e1="DS.d263.s0.e2" e2="DS.d263.s0.e0" id="DS.d263.s0.i13" interaction="True"/>
        </sentence>
        <sentence id="DS.d263.s1" origId="18506630-728" text="Tryptophan stabilizes the lignin peroxidase activity during decolorization of dyes.">
            <entity id="DS.d263.s1.e0" origId="1148,6305,9060,5460840" charOffset="0-10" type="compound" text="Tryptophan"/>
            <entity id="DS.d263.s1.e1" origId="P06181,P11542,P11543,P20010,P20011,P20012,P20013,P21764,P31837,P31838,P49012,P50622" charOffset="26-43" type="protein" text="lignin peroxidase"/>
            <pair e1="DS.d263.s1.e0" e2="DS.d263.s1.e1" id="DS.d263.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d264" origId="18506631">
        <sentence id="DS.d264.s0" origId="18506631-523" text="To achieve enzymatic production of calcium-stearate at unfavorable conditions, i.e., pH 10 and 60 degrees C, suitable lipase was selected and reaction conditions were optimized using calcium hydroxide and hydrogenated beef tallow as substrates.">
            <entity id="DS.d264.s0.e0" origId="5281" charOffset="35-51" type="compound" text="calcium-stearate"/>
            <entity id="DS.d264.s0.e1" origId="Q7M4U7" charOffset="118-124" type="protein" text="lipase"/>
            <entity id="DS.d264.s0.e2" origId="961" charOffset="191-200" type="compound" text="hydroxide"/>
            <pair e1="DS.d264.s0.e2" e2="DS.d264.s0.e1" id="DS.d264.s0.i0" interaction="True"/>
            <pair e1="DS.d264.s0.e0" e2="DS.d264.s0.e1" id="DS.d264.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d264.s1" origId="18506631-524" text="Under optimum conditions, 95% of beef tallow, in 2.5 h, was converted into calcium-stearate by using commercial lipase SDL 451.">
            <entity id="DS.d264.s1.e0" origId="5281" charOffset="75-91" type="compound" text="calcium-stearate"/>
            <entity id="DS.d264.s1.e1" origId="Q7M4U7" charOffset="112-118" type="protein" text="lipase"/>
            <pair e1="DS.d264.s1.e0" e2="DS.d264.s1.e1" id="DS.d264.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d265" origId="18506760">
        <sentence id="DS.d265.s0" origId="18506760-597" text="Celecoxib could selectively inhibited COX-2 expression and PGE2 production.">
            <entity id="DS.d265.s0.e0" origId="2662" charOffset="0-9" type="compound" text="Celecoxib"/>
            <entity id="DS.d265.s0.e1" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="38-43" type="protein" text="COX-2"/>
            <entity id="DS.d265.s0.e2" origId="5280360" charOffset="59-63" type="compound" text="PGE2"/>
            <pair e1="DS.d265.s0.e0" e2="DS.d265.s0.e1" id="DS.d265.s0.i0" interaction="True"/>
            <pair e1="DS.d265.s0.e2" e2="DS.d265.s0.e1" id="DS.d265.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d265.s1" origId="18506760-598" text="Celecoxib also inhibited p(473Ser) Akt, raf and p53 expression, and induced apoptosis by release of cytochrome c and activation of caspase 9, 3, and 6, which were more remarkably in HBx positive cells than in control cells.">
            <entity id="DS.d265.s1.e0" origId="2662" charOffset="0-9" type="compound" text="Celecoxib"/>
            <entity id="DS.d265.s1.e1" origId="P31750,Q8INB9" charOffset="35-38" type="protein" text="Akt"/>
            <entity id="DS.d265.s1.e2" origId="P09560,P11345,Q80VX4,Q8C0C0" charOffset="40-43" type="protein" text="raf"/>
            <entity id="DS.d265.s1.e3" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="48-51" type="protein" text="p53"/>
            <entity id="DS.d265.s1.e4" origId="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3" charOffset="100-112" type="protein" text="cytochrome c"/>
            <pair e1="DS.d265.s1.e0" e2="DS.d265.s1.e4" id="DS.d265.s1.i0" interaction="True"/>
            <pair e1="DS.d265.s1.e0" e2="DS.d265.s1.e1" id="DS.d265.s1.i1" interaction="True"/>
            <pair e1="DS.d265.s1.e0" e2="DS.d265.s1.e2" id="DS.d265.s1.i2" interaction="True"/>
            <pair e1="DS.d265.s1.e0" e2="DS.d265.s1.e3" id="DS.d265.s1.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d268" origId="18509327">
        <sentence id="DS.d268.s0" origId="18509327-948" text="However, the simultaneous presence of the CYP3A4 *1B and CYP3A5 *1A alleles was associated with a 64% increase in docetaxel clearance (P = 0.0015), independent of both sex and CYP3A activity (as determined using the erythromycin breath test).">
            <entity id="DS.d268.s0.e0" origId="P08684" charOffset="42-48" type="protein" text="CYP3A4"/>
            <entity id="DS.d268.s0.e1" origId="P20815" charOffset="57-63" type="protein" text="CYP3A5"/>
            <entity id="DS.d268.s0.e2" origId="148124" charOffset="114-123" type="compound" text="docetaxel"/>
            <pair e1="DS.d268.s0.e2" e2="DS.d268.s0.e0" id="DS.d268.s0.i0" interaction="True"/>
            <pair e1="DS.d268.s0.e2" e2="DS.d268.s0.e1" id="DS.d268.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d269" origId="18509591">
        <sentence id="DS.d269.s0" origId="18509591-45" text="It was found that taurine administration produced lower levels of aspartate aminotransferase and alkaline aminotransferase than that of the untreated group.">
            <entity id="DS.d269.s0.e0" origId="1123" charOffset="18-25" type="compound" text="taurine"/>
            <entity id="DS.d269.s0.e1" origId="O33822,O58489,O67781,O86459,O93744,P00509,P14909,P23034,P44425,P53001,P58661,P72173,Q4J8X2,Q55128,Q56114,Q56232,Q59228,Q60013,Q92JE7,Q972A2,Q9V0L2,Q9X0Y2,Q9ZE56" charOffset="66-92" type="protein" text="aspartate aminotransferase"/>
            <pair e1="DS.d269.s0.e0" e2="DS.d269.s0.e1" id="DS.d269.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d269.s1" origId="18509591-46" text="In addition, the levels of hepatic total protein, glutathione and superoxide dismutase were higher in the taurine treated groups than those in the untreated control or the taurine depleted groups, while hepatic malondialdehyde content exhibited the negative effect.">
            <entity id="DS.d269.s1.e0" origId="124886" charOffset="50-61" type="compound" text="glutathione"/>
            <entity id="DS.d269.s1.e1" origId="O50258" charOffset="66-86" type="protein" text="superoxide dismutase"/>
            <entity id="DS.d269.s1.e2" origId="1123" charOffset="106-113" type="compound" text="taurine"/>
            <entity id="DS.d269.s1.e3" origId="1123" charOffset="172-179" type="compound" text="taurine"/>
            <entity id="DS.d269.s1.e4" origId="10964" charOffset="211-226" type="compound" text="malondialdehyde"/>
            <pair e1="DS.d269.s1.e2" e2="DS.d269.s1.e1" id="DS.d269.s1.i0" interaction="True"/>
            <pair e1="DS.d269.s1.e4" e2="DS.d269.s1.e1" id="DS.d269.s1.i1" interaction="True"/>
            <pair e1="DS.d269.s1.e0" e2="DS.d269.s1.e1" id="DS.d269.s1.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d269.s2" origId="18509591-47" text="Moreover, the concentrations of hepatic hydroxyproline, serum hyaluronic acid, interleukin-2, interleukin-6, tumor necrosis factor-alpha and laminin were all decreased in the taurine treated groups.">
            <entity id="DS.d269.s2.e0" origId="825,5810,69248,440015" charOffset="40-54" type="compound" text="hydroxyproline"/>
            <entity id="DS.d269.s2.e1" origId="24759,453618,3084050,24728612" charOffset="62-77" type="compound" text="hyaluronic acid"/>
            <entity id="DS.d269.s2.e2" origId="P41693" charOffset="94-107" type="protein" text="interleukin-6"/>
            <entity id="DS.d269.s2.e3" origId="Q8JFG3" charOffset="109-130" type="protein" text="tumor necrosis factor"/>
            <entity id="DS.d269.s2.e4" origId="44342165" charOffset="141-148" type="compound" text="laminin"/>
            <entity id="DS.d269.s2.e5" origId="1123" charOffset="175-182" type="compound" text="taurine"/>
            <pair e1="DS.d269.s2.e4" e2="DS.d269.s2.e2" id="DS.d269.s2.i0" interaction="False"/>
            <pair e1="DS.d269.s2.e1" e2="DS.d269.s2.e2" id="DS.d269.s2.i1" interaction="False"/>
            <pair e1="DS.d269.s2.e5" e2="DS.d269.s2.e3" id="DS.d269.s2.i2" interaction="True"/>
            <pair e1="DS.d269.s2.e0" e2="DS.d269.s2.e2" id="DS.d269.s2.i3" interaction="False"/>
            <pair e1="DS.d269.s2.e5" e2="DS.d269.s2.e2" id="DS.d269.s2.i4" interaction="True"/>
            <pair e1="DS.d269.s2.e4" e2="DS.d269.s2.e3" id="DS.d269.s2.i5" interaction="False"/>
            <pair e1="DS.d269.s2.e0" e2="DS.d269.s2.e3" id="DS.d269.s2.i6" interaction="False"/>
            <pair e1="DS.d269.s2.e1" e2="DS.d269.s2.e3" id="DS.d269.s2.i7" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d270" origId="18509644">
        <sentence id="DS.d270.s0" origId="18509644-1152" text="Pharmacological (flavopiridol) and molecular (shRNA) transcription inhibitor were used to impede formation of MET transcripts.">
            <entity id="DS.d270.s0.e0" origId="5287969" charOffset="17-29" type="compound" text="flavopiridol"/>
            <entity id="DS.d270.s0.e1" origId="P08581,Q07DV8,Q07DY1,Q07DZ1,Q07E01,Q07E24,Q07E37,Q07E48,Q09YH7,Q09YI9,Q09YK0,Q09YL1,Q09YN5,Q108U6,Q2IBA6,Q2IBC0,Q2IBD8,Q2IBF2,Q2IBG7,Q2QL89,Q2QLA9,Q2QLC0,Q2QLE0,Q2QLF1,Q2QLG5,Q2QLH6,Q42662,Q75ZY9" charOffset="110-113" type="protein" text="MET"/>
            <pair e1="DS.d270.s0.e0" e2="DS.d270.s0.e1" id="DS.d270.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d271" origId="18509748">
        <sentence id="DS.d271.s0" origId="18509748-1206" text="Effect of small interference RNA targeting HIF-1alpha mediated by rAAV combined L:-ascorbate on pancreatic tumors in athymic mice.">
            <entity id="DS.d271.s0.e0" origId="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9" charOffset="43-53" type="protein" text="HIF-1alpha"/>
            <entity id="DS.d271.s0.e1" origId="54690394" charOffset="80-92" type="compound" text="L:-ascorbate"/>
            <pair e1="DS.d271.s0.e1" e2="DS.d271.s0.e0" id="DS.d271.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d272" origId="18511076">
        <sentence id="DS.d272.s0" origId="18511076-738" text="Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine.">
            <entity id="DS.d272.s0.e0" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="11-15" type="protein" text="BDNF"/>
            <entity id="DS.d272.s0.e1" origId="68617" charOffset="108-118" type="compound" text="sertraline"/>
            <entity id="DS.d272.s0.e2" origId="146570" charOffset="120-132" type="compound" text="escitalopram"/>
            <entity id="DS.d272.s0.e3" origId="5656" charOffset="137-148" type="compound" text="venlafaxine"/>
            <pair e1="DS.d272.s0.e3" e2="DS.d272.s0.e0" id="DS.d272.s0.i0" interaction="True"/>
            <pair e1="DS.d272.s0.e1" e2="DS.d272.s0.e0" id="DS.d272.s0.i1" interaction="True"/>
            <pair e1="DS.d272.s0.e2" e2="DS.d272.s0.e0" id="DS.d272.s0.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d272.s1" origId="18511076-739" text="We assessed serum BDNF levels in 21 patients with major depressive episode treated with sertraline, escitalopram, or venlafaxine and 20 healthy controls.">
            <entity id="DS.d272.s1.e0" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="18-22" type="protein" text="BDNF"/>
            <entity id="DS.d272.s1.e1" origId="68617" charOffset="88-98" type="compound" text="sertraline"/>
            <entity id="DS.d272.s1.e2" origId="146570" charOffset="100-112" type="compound" text="escitalopram"/>
            <entity id="DS.d272.s1.e3" origId="5656" charOffset="117-128" type="compound" text="venlafaxine"/>
            <pair e1="DS.d272.s1.e3" e2="DS.d272.s1.e0" id="DS.d272.s1.i0" interaction="True"/>
            <pair e1="DS.d272.s1.e1" e2="DS.d272.s1.e0" id="DS.d272.s1.i1" interaction="True"/>
            <pair e1="DS.d272.s1.e2" e2="DS.d272.s1.e0" id="DS.d272.s1.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d272.s2" origId="18511076-740" text="Sertraline increased BDNF levels after 5 weeks and 6 months of treatment.">
            <entity id="DS.d272.s2.e0" origId="68617" charOffset="0-10" type="compound" text="Sertraline"/>
            <entity id="DS.d272.s2.e1" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="21-25" type="protein" text="BDNF"/>
            <pair e1="DS.d272.s2.e0" e2="DS.d272.s2.e1" id="DS.d272.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d272.s3" origId="18511076-741" text="Venlafaxine increased BDNF levels only after 6 months.">
            <entity id="DS.d272.s3.e0" origId="5656" charOffset="0-11" type="compound" text="Venlafaxine"/>
            <entity id="DS.d272.s3.e1" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="22-26" type="protein" text="BDNF"/>
            <pair e1="DS.d272.s3.e0" e2="DS.d272.s3.e1" id="DS.d272.s3.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d272.s4" origId="18511076-742" text="Escitalopram did not affect BDNF levels at either time point.">
            <entity id="DS.d272.s4.e0" origId="146570" charOffset="0-12" type="compound" text="Escitalopram"/>
            <entity id="DS.d272.s4.e1" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="28-32" type="protein" text="BDNF"/>
            <pair e1="DS.d272.s4.e0" e2="DS.d272.s4.e1" id="DS.d272.s4.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d273" origId="18513727">
        <sentence id="DS.d273.s0" origId="18513727-1142" text="The increase of cholesterol was accompanied by a marked posttranslational down-regulation of liver SR-BI expression.">
            <entity id="DS.d273.s0.e0" origId="304,5997,6432564,11025495" charOffset="16-27" type="compound" text="cholesterol"/>
            <entity id="DS.d273.s0.e1" origId="O18824,P97943,Q60417,Q61009,Q8SQC1,Q8WTV0" charOffset="99-104" type="protein" text="SR-BI"/>
            <pair e1="DS.d273.s0.e0" e2="DS.d273.s0.e1" id="DS.d273.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d273.s1" origId="18513727-1143" text="Taken together, a diet-induced increase of plasma and hepatic cholesterol levels leads to a posttranscriptional down-regulation of SR-BI in mouse liver via a mechanism likely involving PDZK1.">
            <entity id="DS.d273.s1.e0" origId="304,5997,6432564,11025495" charOffset="62-73" type="compound" text="cholesterol"/>
            <entity id="DS.d273.s1.e1" origId="O18824,P97943,Q60417,Q61009,Q8SQC1,Q8WTV0" charOffset="131-136" type="protein" text="SR-BI"/>
            <entity id="DS.d273.s1.e2" origId="Q3T0X8,Q5RCF7,Q5T2W1,Q865P3" charOffset="185-190" type="protein" text="PDZK1"/>
            <pair e1="DS.d273.s1.e0" e2="DS.d273.s1.e2" id="DS.d273.s1.i0" interaction="False"/>
            <pair e1="DS.d273.s1.e0" e2="DS.d273.s1.e1" id="DS.d273.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d274" origId="18513857">
        <sentence id="DS.d274.s0" origId="18513857-1213" text="A 5.5 kilobase-pair (kbp) Pst1-Kpn1 fragment containing gene(s) encoding for zearalenone degradation was cloned.">
            <entity id="DS.d274.s0.e0" origId="Q09750" charOffset="26-30" type="protein" text="Pst1"/>
            <entity id="DS.d274.s0.e1" origId="5281576" charOffset="77-88" type="compound" text="zearalenone"/>
            <pair e1="DS.d274.s0.e1" e2="DS.d274.s0.e0" id="DS.d274.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d275" origId="18514659">
        <sentence id="DS.d275.s0" origId="18514659-430" text="However, TXA(2) formation remains elevated in patients with cardiovascular disease on doses of aspirin that fully suppress platelet COX-1, suggesting other tissue sources for TXA(2) formation.">
            <entity id="DS.d275.s0.e0" origId="5280497" charOffset="9-14" type="compound" text="TXA(2"/>
            <entity id="DS.d275.s0.e1" origId="2244" charOffset="95-102" type="compound" text="aspirin"/>
            <entity id="DS.d275.s0.e2" origId="O62664,O97554,P05979,P22437,P23219,Q63921,Q9T0N8" charOffset="132-137" type="protein" text="COX-1"/>
            <entity id="DS.d275.s0.e3" origId="5280497" charOffset="175-180" type="compound" text="TXA(2"/>
            <pair e1="DS.d275.s0.e1" e2="DS.d275.s0.e2" id="DS.d275.s0.i0" interaction="True"/>
            <pair e1="DS.d275.s0.e0" e2="DS.d275.s0.e2" id="DS.d275.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d276" origId="18514900">
        <sentence id="DS.d276.s0" origId="18514900-1098" text=") production increased; metallothionein (MT) and glutathione levels increased in most cases, and acetylcholinesterase (AChE) activity decreased in summer.">
            <entity id="DS.d276.s0.e0" origId="O02033,O13257,O18842,O42152,O93571,P02807,P04358,P07216,P08002,P23038,P25127,P25128,P30331,P30565,P51902,P52723,P52725,P52726,P52728,P55945,P55946,P55948,P55951,P55952,P55953,P68494,P68495,P68497,P68498,P68499,P80367,P80593,P84865,Q05890,Q6J1T3,Q6S4N8,Q6XUW5,Q708T3,Q7ZZP9,Q800D3,Q8UVY1,Q94550,Q9IB50,Q9U568" charOffset="24-39" type="protein" text="metallothionein"/>
            <entity id="DS.d276.s0.e1" origId="124886" charOffset="49-60" type="compound" text="glutathione"/>
            <entity id="DS.d276.s0.e2" origId="Q867X2,Q867X3,Q86GC9,Q92081" charOffset="97-117" type="protein" text="acetylcholinesterase"/>
            <entity id="DS.d276.s0.e3" origId="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3" charOffset="119-123" type="protein" text="AChE"/>
            <pair e1="DS.d276.s0.e1" e2="DS.d276.s0.e3" id="DS.d276.s0.i1" interaction="False"/>
            <pair e1="DS.d276.s0.e1" e2="DS.d276.s0.e2" id="DS.d276.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d277" origId="18515453">
        <sentence id="DS.d277.s0" origId="18515453-577" text="From these findings, it is suggested that distigmine bromide may produce centrally mediated behavioural signs by increasing the ACh levels in the brain, resulting from its AChE and BuChE inhibitions.">
            <entity id="DS.d277.s0.e0" origId="3116" charOffset="42-60" type="compound" text="distigmine bromide"/>
            <entity id="DS.d277.s0.e1" origId="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3" charOffset="172-176" type="protein" text="AChE"/>
            <pair e1="DS.d277.s0.e0" e2="DS.d277.s0.e1" id="DS.d277.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d278" origId="18515457">
        <sentence id="DS.d278.s0" origId="18515457-594" text="Using DBA/2OlaHsd mice, we investigated the effects of chronic social defeat and concomitant treatment with R121919/NBI 30775 on 1) the behavioural profile in the modified hole board test and 2) in-situ hybridization analysis-based expression of arginine vasopressin (AVP) and CRH mRNA in both the hypothalamic paraventricular nucleus and supraoptic nucleus.">
            <entity id="DS.d278.s0.e0" origId="9821250" charOffset="108-115" type="compound" text="R121919"/>
            <entity id="DS.d278.s0.e2" origId="P01180,P01181,P01182,P01183,P01184,P01185,P10769,P31414,P81768" charOffset="268-271" type="protein" text="AVP"/>
            <entity id="DS.d278.s0.e3" origId="P01142,P06296,P06850,P49926,Q95MI6,Q9PTS1" charOffset="277-280" type="protein" text="CRH"/>
            <pair e1="DS.d278.s0.e0" e2="DS.d278.s0.e3" id="DS.d278.s0.i2" interaction="False"/>
            <pair e1="DS.d278.s0.e0" e2="DS.d278.s0.e2" id="DS.d278.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d279" origId="18515973">
        <sentence id="DS.d279.s0" origId="18515973-10" text="7-Ketocholesterol also enhanced IL-6 release from VSMC.">
            <entity id="DS.d279.s0.e0" origId="91474" charOffset="0-17" type="compound" text="7-Ketocholesterol"/>
            <entity id="DS.d279.s0.e1" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="32-36" type="protein" text="IL-6"/>
            <pair e1="DS.d279.s0.e0" e2="DS.d279.s0.e1" id="DS.d279.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d279.s1" origId="18515973-11" text="IL-6 release by 7-ketocholesterol, although significant, was not as remarkable as that induced by TNF-alpha.">
            <entity id="DS.d279.s1.e0" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="0-4" type="protein" text="IL-6"/>
            <entity id="DS.d279.s1.e1" origId="91474" charOffset="16-33" type="compound" text="7-ketocholesterol"/>
            <entity id="DS.d279.s1.e2" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="98-107" type="protein" text="TNF-alpha"/>
            <pair e1="DS.d279.s1.e1" e2="DS.d279.s1.e0" id="DS.d279.s1.i0" interaction="True"/>
            <pair e1="DS.d279.s1.e1" e2="DS.d279.s1.e2" id="DS.d279.s1.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d279.s2" origId="18515973-12" text="These data suggest that 7-ketocholesterol upregulates IL-6 via mechanisms distinct from TNF-alpha and contributes to the intra- and extracellular IL-6 deposits within the vasculature.">
            <entity id="DS.d279.s2.e0" origId="91474" charOffset="24-41" type="compound" text="7-ketocholesterol"/>
            <entity id="DS.d279.s2.e1" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="54-58" type="protein" text="IL-6"/>
            <entity id="DS.d279.s2.e2" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="88-97" type="protein" text="TNF-alpha"/>
            <entity id="DS.d279.s2.e3" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="146-150" type="protein" text="IL-6"/>
            <pair e1="DS.d279.s2.e0" e2="DS.d279.s2.e1" id="DS.d279.s2.i0" interaction="True"/>
            <pair e1="DS.d279.s2.e0" e2="DS.d279.s2.e2" id="DS.d279.s2.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d279.s3" origId="18515973-3" text="7-Ketocholesterol upregulates interleukin-6 via mechanisms that are distinct from those of tumor necrosis factor-alpha, in vascular smooth muscle cells.">
            <entity id="DS.d279.s3.e0" origId="91474" charOffset="0-17" type="compound" text="7-Ketocholesterol"/>
            <entity id="DS.d279.s3.e1" origId="P41693" charOffset="30-43" type="protein" text="interleukin-6"/>
            <entity id="DS.d279.s3.e2" origId="Q8JFG3" charOffset="91-112" type="protein" text="tumor necrosis factor"/>
            <pair e1="DS.d279.s3.e0" e2="DS.d279.s3.e1" id="DS.d279.s3.i0" interaction="True"/>
            <pair e1="DS.d279.s3.e0" e2="DS.d279.s3.e2" id="DS.d279.s3.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d279.s4" origId="18515973-4" text="Among the 7 IL examined, only IL-6 transcript was increased by 7-ketocholesterol treatment in human aorta smooth muscle cells.">
            <entity id="DS.d279.s4.e0" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="30-34" type="protein" text="IL-6"/>
            <entity id="DS.d279.s4.e1" origId="91474" charOffset="63-80" type="compound" text="7-ketocholesterol"/>
            <pair e1="DS.d279.s4.e1" e2="DS.d279.s4.e0" id="DS.d279.s4.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d279.s5" origId="18515973-5" text="IL-6 transcripts increased up to 24 h after treatment with 7-ketocholesterol, and this effect was profoundly repressed by treatment with p38 MAPK inhibitors and to a lesser extent JNK inhibitors.">
            <entity id="DS.d279.s5.e0" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="0-4" type="protein" text="IL-6"/>
            <entity id="DS.d279.s5.e1" origId="91474" charOffset="59-76" type="compound" text="7-ketocholesterol"/>
            <pair e1="DS.d279.s5.e1" e2="DS.d279.s5.e0" id="DS.d279.s5.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d279.s6" origId="18515973-6" text="7alpha-Hydroxycholesterol, 27-hydroxycholesterol or cholesterol, however, did not induce IL-6 expression.">
            <entity id="DS.d279.s6.e0" origId="107722" charOffset="0-25" type="compound" text="7alpha-Hydroxycholesterol"/>
            <entity id="DS.d279.s6.e1" origId="99470,123976,50990021" charOffset="27-48" type="compound" text="27-hydroxycholesterol"/>
            <entity id="DS.d279.s6.e2" origId="304,5997,6432564,11025495" charOffset="14-25" type="compound" text="cholesterol"/>
            <entity id="DS.d279.s6.e3" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="89-93" type="protein" text="IL-6"/>
            <pair e1="DS.d279.s6.e0" e2="DS.d279.s6.e3" id="DS.d279.s6.i0" interaction="False"/>
            <pair e1="DS.d279.s6.e2" e2="DS.d279.s6.e3" id="DS.d279.s6.i1" interaction="False"/>
            <pair e1="DS.d279.s6.e1" e2="DS.d279.s6.e3" id="DS.d279.s6.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d279.s7" origId="18515973-7" text="Mechanisms of IL-6 induction by 7-ketocholesterol were investigated in comparison with tumor necrosis factor (TNF)-alpha.">
            <entity id="DS.d279.s7.e0" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="14-18" type="protein" text="IL-6"/>
            <entity id="DS.d279.s7.e1" origId="91474" charOffset="32-49" type="compound" text="7-ketocholesterol"/>
            <entity id="DS.d279.s7.e2" origId="Q8JFG3" charOffset="87-108" type="protein" text="tumor necrosis factor"/>
            <entity id="DS.d279.s7.e3" origId="O35734,O77510,O77764,P01375,P04924,P13296,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="110-113" type="protein" text="TNF"/>
            <pair e1="DS.d279.s7.e1" e2="DS.d279.s7.e0" id="DS.d279.s7.i0" interaction="True"/>
            <pair e1="DS.d279.s7.e1" e2="DS.d279.s7.e3" id="DS.d279.s7.i1" interaction="False"/>
            <pair e1="DS.d279.s7.e1" e2="DS.d279.s7.e2" id="DS.d279.s7.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d279.s8" origId="18515973-8" text="Whereas TNF-alpha activated IL-6 promoter, which was impaired by p38 MAPK inhibitors or by mutation in the NF-kappaB-binding site within the promoter region, 7-ketocholesterol did not affect IL-6 promoter activity.">
            <entity id="DS.d279.s8.e0" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="8-17" type="protein" text="TNF-alpha"/>
            <entity id="DS.d279.s8.e1" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="28-32" type="protein" text="IL-6"/>
            <entity id="DS.d279.s8.e2" origId="91474" charOffset="158-175" type="compound" text="7-ketocholesterol"/>
            <entity id="DS.d279.s8.e3" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="191-195" type="protein" text="IL-6"/>
            <pair e1="DS.d279.s8.e2" e2="DS.d279.s8.e0" id="DS.d279.s8.i0" interaction="False"/>
            <pair e1="DS.d279.s8.e2" e2="DS.d279.s8.e1" id="DS.d279.s8.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d279.s9" origId="18515973-9" text="7-ketocholesterol significantly increased the amount of intracellular IL-6 protein in the presence of brefeldin A.">
            <entity id="DS.d279.s9.e0" origId="91474" charOffset="0-17" type="compound" text="7-ketocholesterol"/>
            <entity id="DS.d279.s9.e1" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="70-74" type="protein" text="IL-6"/>
            <entity id="DS.d279.s9.e2" origId="5287620" charOffset="102-113" type="compound" text="brefeldin A"/>
            <pair e1="DS.d279.s9.e0" e2="DS.d279.s9.e1" id="DS.d279.s9.i0" interaction="True"/>
            <pair e1="DS.d279.s9.e2" e2="DS.d279.s9.e1" id="DS.d279.s9.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d280" origId="18521540">
        <sentence id="DS.d280.s0" origId="18521540-51" text="AGI-1067 is a novel, phenolic antioxidant, and vascular protectant which dose-dependently inhibits PEA biomarkers in vitro.">
            <entity id="DS.d280.s0.e0" origId="216325" charOffset="0-8" type="compound" text="AGI-1067"/>
            <entity id="DS.d280.s0.e1" origId="P0C1A8,P0C1A9" charOffset="99-102" type="protein" text="PEA"/>
            <pair e1="DS.d280.s0.e0" e2="DS.d280.s0.e1" id="DS.d280.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d281" origId="18521605">
        <sentence id="DS.d281.s0" origId="18521605-224" text="Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.">
            <entity id="DS.d281.s0.e0" origId="3637" charOffset="0-11" type="compound" text="Hydralazine"/>
            <entity id="DS.d281.s0.e1" origId="P25054" charOffset="84-87" type="protein" text="APC"/>
            <pair e1="DS.d281.s0.e0" e2="DS.d281.s0.e1" id="DS.d281.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d281.s1" origId="18521605-225" text="Clinically, it has been approved that DNA methylation inhibitors, such as 5-aza-2'-deoxycytidine (5-Aza-dC), can reverse APC promoter methylation, but widespread clinical use of these inhibitors is limited by their toxicity and instability in aqueous solution.">
            <entity id="DS.d281.s1.e0" origId="451668" charOffset="74-96" type="compound" text="5-aza-2'-deoxycytidine"/>
            <entity id="DS.d281.s1.e1" origId="451668" charOffset="98-106" type="compound" text="5-Aza-dC"/>
            <entity id="DS.d281.s1.e2" origId="P25054" charOffset="121-124" type="protein" text="APC"/>
            <pair e1="DS.d281.s1.e0" e2="DS.d281.s1.e2" id="DS.d281.s1.i0" interaction="True"/>
            <pair e1="DS.d281.s1.e1" e2="DS.d281.s1.e2" id="DS.d281.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d282" origId="18521740">
        <sentence id="DS.d282.s1" origId="18521740-1015" text="Lastly, we found that the downstream metabolite of 5alpha-dihydrotestosterone, 5alpha- androstane-3beta,17beta-diol (3betaAdiol), is estrogenic in breast cancer cells, and induces growth and ER-signaling via activation of ERalpha.">
            <entity id="DS.d282.s1.e0" origId="10635" charOffset="51-77" type="compound" text="5alpha-dihydrotestosterone"/>
            <entity id="DS.d282.s1.e2" origId="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7" charOffset="222-229" type="protein" text="ERalpha"/>
            <pair e1="DS.d282.s1.e0" e2="DS.d282.s1.e2" id="DS.d282.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d283" origId="18521741">
        <sentence id="DS.d283.s0" origId="18521741-219" text="Here we demonstrate that an AR ligand, 5-alpha-dihydrotestosterone (DHT), inhibits MCF-7 breast cancer cell growth induced by insulin like growth factor 1 (IGF-I).">
            <entity id="DS.d283.s0.e0" origId="15,10635" charOffset="39-66" type="compound" text="5-alpha-dihydrotestosterone"/>
            <entity id="DS.d283.s0.e1" origId="10635" charOffset="68-71" type="compound" text="DHT"/>
            <entity id="DS.d283.s0.e3" origId="P05017,P07455,P08025,P10763,P16545,P17085,P17647,P18254,P33712,P51457,P51458,P51462,Q02815,Q28933,Q68LC0,Q6GUL6,Q6IVA5,Q6JLX1,Q95222" charOffset="156-161" type="protein" text="IGF-I"/>
            <pair e1="DS.d283.s0.e0" e2="DS.d283.s0.e3" id="DS.d283.s0.i0" interaction="True"/>
            <pair e1="DS.d283.s0.e1" e2="DS.d283.s0.e3" id="DS.d283.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d284" origId="18521748">
        <sentence id="DS.d284.s0" origId="18521748-1184" text="Here, we constructed variants to test whether any of these motifs may explain why TRPM2-DeltaN does not respond to stimulation with either ADP ribose or hydrogen peroxide.">
            <entity id="DS.d284.s0.e0" origId="O94759" charOffset="82-87" type="protein" text="TRPM2"/>
            <entity id="DS.d284.s0.e1" origId="784" charOffset="153-170" type="compound" text="hydrogen peroxide"/>
            <pair e1="DS.d284.s0.e1" e2="DS.d284.s0.e0" id="DS.d284.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d285" origId="18521846">
        <sentence id="DS.d285.s0" origId="18521846-1089" text="We found that 2-methoxyestradiol induced the activation of JNK, ERK, and p38 MAPKs.">
            <entity id="DS.d285.s0.e0" origId="66414" charOffset="14-32" type="compound" text="2-methoxyestradiol"/>
            <entity id="DS.d285.s0.e1" origId="P92208,Q966Y3" charOffset="59-62" type="protein" text="JNK"/>
            <entity id="DS.d285.s0.e2" origId="P29323" charOffset="64-67" type="protein" text="ERK"/>
            <entity id="DS.d285.s0.e3" origId="O62618" charOffset="73-82" type="protein" text="p38 MAPKs"/>
            <pair e1="DS.d285.s0.e0" e2="DS.d285.s0.e2" id="DS.d285.s0.i0" interaction="True"/>
            <pair e1="DS.d285.s0.e0" e2="DS.d285.s0.e3" id="DS.d285.s0.i1" interaction="True"/>
            <pair e1="DS.d285.s0.e0" e2="DS.d285.s0.e1" id="DS.d285.s0.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d285.s1" origId="18521846-1090" text="2-methoxyestradiol-induced JNK activation was associated with the induction of apoptosis through the mitochondrial pathways as a result of increased phosphorylation (inactivation) of the anti-apoptotic Bcl-2 and Bcl-xL proteins.">
            <entity id="DS.d285.s1.e0" origId="66414" charOffset="0-18" type="compound" text="2-methoxyestradiol"/>
            <entity id="DS.d285.s1.e1" origId="P92208,Q966Y3" charOffset="27-30" type="protein" text="JNK"/>
            <entity id="DS.d285.s1.e2" origId="P10417,P49950" charOffset="202-207" type="protein" text="Bcl-2"/>
            <pair e1="DS.d285.s1.e0" e2="DS.d285.s1.e2" id="DS.d285.s1.i0" interaction="True"/>
            <pair e1="DS.d285.s1.e0" e2="DS.d285.s1.e1" id="DS.d285.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d285.s2" origId="18521846-1091" text="In comparison, 2-methoxyestradiol-induced activation of ERK and p38 in these cells was found to have a protective effect against 2-MeO-E(2)-induced apoptosis.">
            <entity id="DS.d285.s2.e0" origId="66414" charOffset="15-33" type="compound" text="2-methoxyestradiol"/>
            <entity id="DS.d285.s2.e1" origId="P29323" charOffset="56-59" type="protein" text="ERK"/>
            <entity id="DS.d285.s2.e2" origId="O24473,O75791,O95433,O97628,P46108,P80350,P82869,Q01552,Q04929,Q63768,Q64010,Q9LDA4,Q9Y2S7" charOffset="64-67" type="protein" text="p38"/>
            <pair e1="DS.d285.s2.e0" e2="DS.d285.s2.e1" id="DS.d285.s2.i0" interaction="True"/>
            <pair e1="DS.d285.s2.e0" e2="DS.d285.s2.e2" id="DS.d285.s2.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d285.s3" origId="18521846-1093" text="Mechanistically, inhibition of ERK and p38 activity was associated with activation of various caspases and PARP cleavage, and it also stabilized the pro-apoptotic proteins Bax and Bim, thereby preventing them from degradation during 2-methoxyestradiol treatment.">
            <entity id="DS.d285.s3.e0" origId="P29323" charOffset="31-34" type="protein" text="ERK"/>
            <entity id="DS.d285.s3.e1" origId="O24473,O75791,O95433,O97628,P46108,P80350,P82869,Q01552,Q04929,Q63768,Q64010,Q9LDA4,Q9Y2S7" charOffset="39-42" type="protein" text="p38"/>
            <entity id="DS.d285.s3.e2" origId="O50017,P08469,P14043,P31669,P35875,P55057,Q08824,Q11208" charOffset="107-111" type="protein" text="PARP"/>
            <entity id="DS.d285.s3.e3" origId="P27297" charOffset="163-175" type="protein" text="proteins Bax"/>
            <entity id="DS.d285.s3.e4" origId="O54918,O88498" charOffset="180-183" type="protein" text="Bim"/>
            <entity id="DS.d285.s3.e5" origId="66414" charOffset="233-251" type="compound" text="2-methoxyestradiol"/>
            <pair e1="DS.d285.s3.e5" e2="DS.d285.s3.e0" id="DS.d285.s3.i0" interaction="False"/>
            <pair e1="DS.d285.s3.e5" e2="DS.d285.s3.e3" id="DS.d285.s3.i1" interaction="False"/>
            <pair e1="DS.d285.s3.e5" e2="DS.d285.s3.e2" id="DS.d285.s3.i2" interaction="False"/>
            <pair e1="DS.d285.s3.e5" e2="DS.d285.s3.e4" id="DS.d285.s3.i3" interaction="False"/>
            <pair e1="DS.d285.s3.e5" e2="DS.d285.s3.e1" id="DS.d285.s3.i4" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d286" origId="18521859">
        <sentence id="DS.d286.s0" origId="18521859-1108" text="Accumulating evidence suggests that phosphatidylinositol (PI) pathways have been involved in the secretion of dopamine (DA) and the regulation of DA transporter, which is a target of methamphetamine (METH).">
            <entity id="DS.d286.s0.e0" origId="53477912" charOffset="36-56" type="compound" text="phosphatidylinositol"/>
            <entity id="DS.d286.s0.e1" origId="681" charOffset="110-118" type="compound" text="dopamine"/>
            <entity id="DS.d286.s0.e2" origId="P23977,P27922,Q01959,Q03614,Q61327,Q9GJT6" charOffset="146-160" type="protein" text="DA transporter"/>
            <entity id="DS.d286.s0.e3" origId="1206,10836,36604" charOffset="183-198" type="compound" text="methamphetamine"/>
            <pair e1="DS.d286.s0.e1" e2="DS.d286.s0.e2" id="DS.d286.s0.i0" interaction="False"/>
            <pair e1="DS.d286.s0.e3" e2="DS.d286.s0.e2" id="DS.d286.s0.i1" interaction="True"/>
            <pair e1="DS.d286.s0.e0" e2="DS.d286.s0.e2" id="DS.d286.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d287" origId="18522674">
        <sentence id="DS.d287.s0" origId="18522674-789" text="Celecoxib caused a 60% reduction in testicular interstitial fluid (IF) prostaglandin E(2) (PGE (2)) concentrations, accompanied by a compensatory increase in COX-2 mRNA expression.">
            <entity id="DS.d287.s0.e0" origId="2662" charOffset="0-9" type="compound" text="Celecoxib"/>
            <entity id="DS.d287.s0.e1" origId="Q29458" charOffset="91-94" type="protein" text="PGE"/>
            <entity id="DS.d287.s0.e2" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="158-163" type="protein" text="COX-2"/>
            <pair e1="DS.d287.s0.e0" e2="DS.d287.s0.e2" id="DS.d287.s0.i0" interaction="True"/>
            <pair e1="DS.d287.s0.e0" e2="DS.d287.s0.e1" id="DS.d287.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d287.s1" origId="18522674-790" text="However, celecoxib had no effect on COX-2 protein levels or LPS-induced expression of the inflammatory mediators interleukin-1beta, tumour necrosis factor-alpha or inducible nitric-oxide synthase.">
            <entity id="DS.d287.s1.e0" origId="2662" charOffset="9-18" type="compound" text="celecoxib"/>
            <entity id="DS.d287.s1.e1" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="36-41" type="protein" text="COX-2"/>
            <entity id="DS.d287.s1.e2" origId="O61309,O61608,Q27571,Q9I9M2" charOffset="174-195" type="protein" text="nitric-oxide synthase"/>
            <pair e1="DS.d287.s1.e0" e2="DS.d287.s1.e1" id="DS.d287.s1.i0" interaction="False"/>
            <pair e1="DS.d287.s1.e0" e2="DS.d287.s1.e2" id="DS.d287.s1.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d287.s2" origId="18522674-791" text="These data indicate that celecoxib reduces intratesticular activity of COX-2 (as indicated by PGE (2) levels) and inhibits IF formation in the testis, but has no appreciable effect on steroidogenesis or spermatogenesis, at least in the short term.">
            <entity id="DS.d287.s2.e0" origId="2662" charOffset="25-34" type="compound" text="celecoxib"/>
            <entity id="DS.d287.s2.e1" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="71-76" type="protein" text="COX-2"/>
            <entity id="DS.d287.s2.e2" origId="Q29458" charOffset="94-97" type="protein" text="PGE"/>
            <pair e1="DS.d287.s2.e0" e2="DS.d287.s2.e1" id="DS.d287.s2.i0" interaction="True"/>
            <pair e1="DS.d287.s2.e0" e2="DS.d287.s2.e2" id="DS.d287.s2.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d287.s3" origId="18522674-792" text="These results indicate significant roles for products of the COX-2 pathway in testicular vascular control and steroidogenesis, which may have implications for men with marginal fertility taking celecoxib for extended periods, but also highlight the potential of this drug to ameliorate testicular damage caused by systemic or local inflammation.">
            <entity id="DS.d287.s3.e0" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="61-66" type="protein" text="COX-2"/>
            <entity id="DS.d287.s3.e1" origId="2662" charOffset="194-203" type="compound" text="celecoxib"/>
            <pair e1="DS.d287.s3.e1" e2="DS.d287.s3.e0" id="DS.d287.s3.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d288" origId="18528683">
        <sentence id="DS.d288.s0" origId="18528683-286" text="At the end of the experiment (after 6 weeks), lung histological changes, collagen staining, the activity of glutathione reductase (GR) and contents of reduced glutathione (GSH) and hydroxyproline (Hpr) in the lung as well as serum level of tumor necrosis factor-alpha (TNF-alpha) were evaluated.">
            <entity id="DS.d288.s0.e0" origId="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655" charOffset="108-129" type="protein" text="glutathione reductase"/>
            <entity id="DS.d288.s0.e1" origId="124886" charOffset="151-170" type="compound" text="reduced glutathione"/>
            <entity id="DS.d288.s0.e2" origId="124886" charOffset="172-175" type="compound" text="GSH"/>
            <entity id="DS.d288.s0.e3" origId="825,5810,69248,440015" charOffset="181-195" type="compound" text="hydroxyproline"/>
            <entity id="DS.d288.s0.e4" origId="Q8JFG3" charOffset="240-261" type="protein" text="tumor necrosis factor"/>
            <entity id="DS.d288.s0.e5" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="269-278" type="protein" text="TNF-alpha"/>
            <pair e1="DS.d288.s0.e3" e2="DS.d288.s0.e5" id="DS.d288.s0.i0" interaction="False"/>
            <pair e1="DS.d288.s0.e1" e2="DS.d288.s0.e5" id="DS.d288.s0.i1" interaction="False"/>
            <pair e1="DS.d288.s0.e1" e2="DS.d288.s0.e0" id="DS.d288.s0.i2" interaction="False"/>
            <pair e1="DS.d288.s0.e2" e2="DS.d288.s0.e5" id="DS.d288.s0.i3" interaction="False"/>
            <pair e1="DS.d288.s0.e1" e2="DS.d288.s0.e4" id="DS.d288.s0.i4" interaction="False"/>
            <pair e1="DS.d288.s0.e2" e2="DS.d288.s0.e0" id="DS.d288.s0.i5" interaction="False"/>
            <pair e1="DS.d288.s0.e3" e2="DS.d288.s0.e4" id="DS.d288.s0.i6" interaction="False"/>
            <pair e1="DS.d288.s0.e3" e2="DS.d288.s0.e0" id="DS.d288.s0.i7" interaction="False"/>
            <pair e1="DS.d288.s0.e2" e2="DS.d288.s0.e4" id="DS.d288.s0.i8" interaction="False"/>
        </sentence>
        <sentence id="DS.d288.s1" origId="18528683-287" text="The obtained data revealed that BCNU induced pathological changes and markedly increased lung collagen and level of Hpr but decreased GSH content and GR activity and increased serum TNF-alpha compared to both control and MT-administered rats.">
            <entity id="DS.d288.s1.e0" origId="2578" charOffset="32-36" type="compound" text="BCNU"/>
            <entity id="DS.d288.s1.e1" origId="P0AA04,P0AA07,P11065,P77335" charOffset="116-119" type="protein" text="Hpr"/>
            <entity id="DS.d288.s1.e2" origId="124886" charOffset="134-137" type="compound" text="GSH"/>
            <entity id="DS.d288.s1.e3" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="182-191" type="protein" text="TNF-alpha"/>
            <pair e1="DS.d288.s1.e2" e2="DS.d288.s1.e1" id="DS.d288.s1.i0" interaction="False"/>
            <pair e1="DS.d288.s1.e0" e2="DS.d288.s1.e1" id="DS.d288.s1.i1" interaction="True"/>
            <pair e1="DS.d288.s1.e0" e2="DS.d288.s1.e3" id="DS.d288.s1.i2" interaction="True"/>
            <pair e1="DS.d288.s1.e2" e2="DS.d288.s1.e3" id="DS.d288.s1.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d289" origId="18528747">
        <sentence id="DS.d289.s0" origId="18528747-574" text="Collectively, HMB supplementation increased concentrations of short-chain fatty acids in intestinal lumen, expression of proglucagon, GLP-2R, and eNOS genes, and net portal absorption of AA.">
            <entity id="DS.d289.s0.e0" origId="P06116" charOffset="14-17" type="protein" text="HMB"/>
            <entity id="DS.d289.s0.e1" origId="176" charOffset="62-85" type="compound" text="short-chain fatty acids"/>
            <entity id="DS.d289.s0.e2" origId="O95838,Q9Z0W0" charOffset="134-140" type="protein" text="GLP-2R"/>
            <entity id="DS.d289.s0.e3" origId="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600" charOffset="146-150" type="protein" text="eNOS"/>
            <pair e1="DS.d289.s0.e1" e2="DS.d289.s0.e0" id="DS.d289.s0.i0" interaction="True"/>
            <pair e1="DS.d289.s0.e1" e2="DS.d289.s0.e2" id="DS.d289.s0.i1" interaction="False"/>
            <pair e1="DS.d289.s0.e1" e2="DS.d289.s0.e3" id="DS.d289.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d290" origId="18528783">
        <sentence id="DS.d290.s0" origId="18528783-293" text="In search for the pharmacophore and to analyze structure-activity relationships we synthesized a series of truncated derivatives and analogs of RB-2, including 1-amino-2-sulfo-4-ar(alk)ylaminoanthraquinones, 1-amino-2-methyl-4-arylaminoanthraquinones, 1-amino-4-bromoanthraquinone 2-sulfonic acid esters and sulfonamides, and bis-(1-amino-4-bromoanthraquinone) sulfonamides, and investigated them in preparations of rat NTPDase1, 2, and 3 using a capillary electrophoresis assay.">
            <entity id="DS.d290.s0.e0" origId="656725" charOffset="144-148" type="compound" text="RB-2"/>
            <entity id="DS.d290.s0.e1" origId="22628" charOffset="252-296" type="compound" text="1-amino-4-bromoanthraquinone 2-sulfonic acid"/>
            <entity id="DS.d290.s0.e2" origId="O18956,O93295,P49961,P55772,P97687,Q9MYU4" charOffset="420-428" type="protein" text="NTPDase1"/>
            <pair e1="DS.d290.s0.e1" e2="DS.d290.s0.e2" id="DS.d290.s0.i0" interaction="False"/>
            <pair e1="DS.d290.s0.e0" e2="DS.d290.s0.e2" id="DS.d290.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d291" origId="18533896">
        <sentence id="DS.d291.s0" origId="18533896-944" text="Plasma insulin 0.05) following ingestion of GluF than after Glu alone, without any differences between the effects of either intervention on plasma glucose concentrations.">
            <entity id="DS.d291.s0.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="7-14" type="protein" text="insulin"/>
            <entity id="DS.d291.s0.e1" origId="206,5793,64689,79025" charOffset="148-155" type="compound" text="glucose"/>
            <pair e1="DS.d291.s0.e1" e2="DS.d291.s0.e0" id="DS.d291.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d292" origId="18534791">
        <sentence id="DS.d292.s0" origId="18534791-223" text="No significant differences were observed in plasma concentrations of glucose, NEFA, and insulin-like growth factor or hepatic triglyceride content, but all supplements tended to decrease beta hydroxybutyrate postpartum compared to CTL cows.">
            <entity id="DS.d292.s0.e0" origId="206,5793,64689,79025" charOffset="69-76" type="compound" text="glucose"/>
            <entity id="DS.d292.s0.e1" origId="P80303" charOffset="78-82" type="protein" text="NEFA"/>
            <entity id="DS.d292.s0.e3" origId="441" charOffset="187-207" type="compound" text="beta hydroxybutyrate"/>
            <pair e1="DS.d292.s0.e0" e2="DS.d292.s0.e1" id="DS.d292.s0.i0" interaction="False"/>
            <pair e1="DS.d292.s0.e3" e2="DS.d292.s0.e1" id="DS.d292.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d293" origId="18534811">
        <sentence id="DS.d293.s0" origId="18534811-234" text="The results showed that colchicine augmented splenic-specific IgG1 and IL-4 as well as cell proliferation but suppressed specific IgG2a and IFN-gamma levels.">
            <entity id="DS.d293.s0.e0" origId="2833,6167,53278" charOffset="24-34" type="compound" text="colchicine"/>
            <entity id="DS.d293.s0.e1" origId="O77762,P05112,P07750,P20096,P30367,P30368,P42202,P46652,P47966,P51492,P51744,P55030,P79155,P79339,Q04745,Q2PE74,Q3S4V6,Q58M18,Q60440,Q7YS71,Q865X5,Q865Y0,Q8HYB1,Q9MZR8,Q9XS58" charOffset="71-75" type="protein" text="IL-4"/>
            <entity id="DS.d293.s0.e2" origId="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9" charOffset="140-149" type="protein" text="IFN-gamma"/>
            <pair e1="DS.d293.s0.e0" e2="DS.d293.s0.e2" id="DS.d293.s0.i0" interaction="True"/>
            <pair e1="DS.d293.s0.e0" e2="DS.d293.s0.e1" id="DS.d293.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d294" origId="18534874">
        <sentence id="DS.d294.s0" origId="18534874-957" text="Sunitinib malate (Pfizer, Inc.) is a multitargeted kinase inhibitor that inhibits vascular endothelial growth factor (VEGF) receptor (R)-1, 2 and 3, platelet-derived growth factor receptors (PDGFR)-alpha and beta, Flt3, RET, and Kit.">
            <entity id="DS.d294.s0.e0" origId="5329102" charOffset="0-16" type="compound" text="Sunitinib malate"/>
            <entity id="DS.d294.s0.e1" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="118-122" type="protein" text="VEGF"/>
            <entity id="DS.d294.s0.e2" origId="Q00342" charOffset="214-218" type="protein" text="Flt3"/>
            <entity id="DS.d294.s0.e3" origId="P07949" charOffset="220-223" type="protein" text="RET"/>
            <pair e1="DS.d294.s0.e0" e2="DS.d294.s0.e3" id="DS.d294.s0.i0" interaction="True"/>
            <pair e1="DS.d294.s0.e0" e2="DS.d294.s0.e2" id="DS.d294.s0.i1" interaction="True"/>
            <pair e1="DS.d294.s0.e0" e2="DS.d294.s0.e1" id="DS.d294.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d295" origId="18536700">
        <sentence id="DS.d295.s0" origId="18536700-664" text="Narp deletion blocks extinction of morphine place preference conditioning.">
            <entity id="DS.d295.s0.e0" origId="P97738" charOffset="0-4" type="protein" text="Narp"/>
            <entity id="DS.d295.s0.e1" origId="5288826,5479215" charOffset="35-43" type="compound" text="morphine"/>
            <pair e1="DS.d295.s0.e1" e2="DS.d295.s0.e0" id="DS.d295.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d295.s1" origId="18536700-665" text="Accordingly, to assess its potential role in the long-lasting behavioral effects of drugs of abuse, we have investigated the impact of Narp deletion on sustained behavioral responses elicited by repeated morphine administration.">
            <entity id="DS.d295.s1.e0" origId="P97738" charOffset="135-139" type="protein" text="Narp"/>
            <entity id="DS.d295.s1.e1" origId="5288826,5479215" charOffset="204-212" type="compound" text="morphine"/>
            <pair e1="DS.d295.s1.e1" e2="DS.d295.s1.e0" id="DS.d295.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d296" origId="18536704">
        <sentence id="DS.d296.s0" origId="18536704-162" text="Decreased dopamine D4 receptor expression increases extracellular glutamate and alters its regulation in mouse striatum.">
            <entity id="DS.d296.s0.e0" origId="P21917,P30729,P51436,Q6TLJ0" charOffset="10-30" type="protein" text="dopamine D4 receptor"/>
            <entity id="DS.d296.s0.e1" origId="611,23327,33032" charOffset="66-75" type="compound" text="glutamate"/>
            <pair e1="DS.d296.s0.e1" e2="DS.d296.s0.e0" id="DS.d296.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d297" origId="18536705">
        <sentence id="DS.d297.s0" origId="18536705-163" text="injection of PACAP provoked a significant increase in plasma glucose level.">
            <entity id="DS.d297.s0.e0" origId="O70176,P13589,P16613,P18509,P41535,P41585,P48144,P81039,Q29W19" charOffset="13-18" type="protein" text="PACAP"/>
            <entity id="DS.d297.s0.e1" origId="206,5793,64689,79025" charOffset="61-68" type="compound" text="glucose"/>
            <pair e1="DS.d297.s0.e1" e2="DS.d297.s0.e0" id="DS.d297.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d298" origId="18536954">
        <sentence id="DS.d298.s0" origId="18536954-285" text="In 17 adults on a fixed metabolic diet, an 11-day course of cinacalcet increased serum gastrin and basal gastric acid output, but not maximal gastric acid output, compared with a placebo.">
            <entity id="DS.d298.s0.e0" origId="156419" charOffset="60-70" type="compound" text="cinacalcet"/>
            <entity id="DS.d298.s0.e1" origId="O02686,P01350,P01351,P01352,P01353,P01354,P04563,P04564,P06885,P10034,P33713,P33714,P48757,P55885" charOffset="87-94" type="protein" text="gastrin"/>
            <pair e1="DS.d298.s0.e0" e2="DS.d298.s0.e1" id="DS.d298.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d299" origId="18537150">
        <sentence id="DS.d299.s0" origId="18537150-81" text="Since PSC-833 was found to be a weak inhibitor of CYP 3A4 and to have no inhibitory effects on esterases, phenol sulfotransferases, and glucuronyltransferases, it is suggested PSC-833 enhances intestinal mucosal permeation of these cyclic prodrugs by inhibiting their polarized efflux and not by inhibiting their metabolism.">
            <entity id="DS.d299.s0.e0" origId="5281884" charOffset="6-13" type="compound" text="PSC-833"/>
            <entity id="DS.d299.s0.e1" origId="P16397,P18773" charOffset="95-104" type="protein" text="esterases"/>
            <entity id="DS.d299.s0.e2" origId="P17988,P50227,P52840,P52846,P82609,Q29476,Q80VR3" charOffset="106-130" type="protein" text="phenol sulfotransferases"/>
            <entity id="DS.d299.s0.e3" origId="5281884" charOffset="176-183" type="compound" text="PSC-833"/>
            <pair e1="DS.d299.s0.e0" e2="DS.d299.s0.e2" id="DS.d299.s0.i0" interaction="False"/>
            <pair e1="DS.d299.s0.e0" e2="DS.d299.s0.e1" id="DS.d299.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d300" origId="18538372">
        <sentence id="DS.d300.s0" origId="18538372-777" text="We showed that after treatment of HCT116 cells with a low dose of doxorubicin most of them stopped proliferation as documented by SA-beta-galactosidase activity and the lack of Ki67 expression.">
            <entity id="DS.d300.s0.e0" origId="31703" charOffset="66-77" type="compound" text="doxorubicin"/>
            <entity id="DS.d300.s0.e1" origId="O33815,O52629,O52847,P00722,P00723,P06219,P0C1Y0,P14288,P22498,P23989,P24131,P26257,P30812,P50388,P70753,P77989,P81650,Q1G9Z4,Q47077,Q48727,Q56307,Q59140,Q59750,Q9K9C6" charOffset="133-151" type="protein" text="beta-galactosidase"/>
            <pair e1="DS.d300.s0.e0" e2="DS.d300.s0.e1" id="DS.d300.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d302" origId="18539357">
        <sentence id="DS.d302.s0" origId="18539357-492" text="Tumor MUC1 differs from normal MUC1 by modified glycan side chains.">
            <entity id="DS.d302.s0.e0" origId="P08640,P15941,Q29435,Q60528" charOffset="6-10" type="protein" text="MUC1"/>
            <entity id="DS.d302.s0.e1" origId="P08640,P15941,Q29435,Q60528" charOffset="31-35" type="protein" text="MUC1"/>
            <entity id="DS.d302.s0.e2" origId="871" charOffset="48-54" type="compound" text="glycan"/>
            <pair e1="DS.d302.s0.e2" e2="DS.d302.s0.e0" id="DS.d302.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d303" origId="18539387">
        <sentence id="DS.d303.s0" origId="18539387-509" text="Mineralization and dehalogenation of 2,4,6-TCP was evidenced by high COD removal efficiencies (approximately 95%), and by the stoichiometric release of chloride ions from the halogenated compound (approximately 80%).">
            <entity id="DS.d303.s0.e0" origId="6914" charOffset="37-46" type="compound" text="2,4,6-TCP"/>
            <entity id="DS.d303.s0.e1" origId="P14678" charOffset="69-72" type="protein" text="COD"/>
            <entity id="DS.d303.s0.e2" origId="312" charOffset="152-160" type="compound" text="chloride"/>
            <pair e1="DS.d303.s0.e0" e2="DS.d303.s0.e1" id="DS.d303.s0.i0" interaction="True"/>
            <pair e1="DS.d303.s0.e2" e2="DS.d303.s0.e1" id="DS.d303.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d305" origId="18541345">
        <sentence id="DS.d305.s0" origId="18541345-459" text="Gliclazide can change the conformation of the active sites and decrease obviously the affinities between gliclazide in the active site and enzymes when it is docked in the second active sites in CYP2C9 and CYP2C19.">
            <entity id="DS.d305.s0.e0" origId="3475" charOffset="0-10" type="compound" text="Gliclazide"/>
            <entity id="DS.d305.s0.e1" origId="3475" charOffset="105-115" type="compound" text="gliclazide"/>
            <entity id="DS.d305.s0.e2" origId="P11712" charOffset="195-201" type="protein" text="CYP2C9"/>
            <entity id="DS.d305.s0.e3" origId="P33261" charOffset="206-213" type="protein" text="CYP2C19"/>
            <pair e1="DS.d305.s0.e0" e2="DS.d305.s0.e3" id="DS.d305.s0.i0" interaction="True"/>
            <pair e1="DS.d305.s0.e1" e2="DS.d305.s0.e2" id="DS.d305.s0.i1" interaction="True"/>
            <pair e1="DS.d305.s0.e0" e2="DS.d305.s0.e2" id="DS.d305.s0.i2" interaction="True"/>
            <pair e1="DS.d305.s0.e1" e2="DS.d305.s0.e3" id="DS.d305.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d306" origId="18543297">
        <sentence id="DS.d306.s0" origId="18543297-399" text="Metabolism of dextrorphan by CYP2D6 in different recombinantly expressed systems and its implications for the in vitro assessment of dextromethorphan metabolism.">
            <entity id="DS.d306.s0.e0" origId="3918,5360697" charOffset="14-25" type="compound" text="dextrorphan"/>
            <entity id="DS.d306.s0.e1" origId="P10635,Q2XNC8,Q2XNC9" charOffset="29-35" type="protein" text="CYP2D6"/>
            <entity id="DS.d306.s0.e2" origId="3008,5360696,5362449,12305042" charOffset="133-149" type="compound" text="dextromethorphan"/>
            <pair e1="DS.d306.s0.e0" e2="DS.d306.s0.e1" id="DS.d306.s0.i0" interaction="True"/>
            <pair e1="DS.d306.s0.e2" e2="DS.d306.s0.e1" id="DS.d306.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d306.s1" origId="18543297-400" text="Cytochrome P450 2D6 (CYP2D6) mediated formation of dextrorphan (DOR) from dextromethorphan (DEX) is widely used as a marker to assess the activity of this enzyme both in vitro and in vivo.">
            <entity id="DS.d306.s1.e0" origId="P10635,Q2XNC8,Q2XNC9" charOffset="0-19" type="protein" text="Cytochrome P450 2D6"/>
            <entity id="DS.d306.s1.e1" origId="P10635,Q2XNC8,Q2XNC9" charOffset="21-27" type="protein" text="CYP2D6"/>
            <entity id="DS.d306.s1.e2" origId="3918,5360697" charOffset="51-62" type="compound" text="dextrorphan"/>
            <entity id="DS.d306.s1.e3" origId="439216" charOffset="64-67" type="compound" text="DOR"/>
            <entity id="DS.d306.s1.e4" origId="3008,5360696,5362449,12305042" charOffset="74-90" type="compound" text="dextromethorphan"/>
            <pair e1="DS.d306.s1.e4" e2="DS.d306.s1.e0" id="DS.d306.s1.i0" interaction="True"/>
            <pair e1="DS.d306.s1.e2" e2="DS.d306.s1.e0" id="DS.d306.s1.i1" interaction="True"/>
            <pair e1="DS.d306.s1.e2" e2="DS.d306.s1.e1" id="DS.d306.s1.i2" interaction="True"/>
            <pair e1="DS.d306.s1.e4" e2="DS.d306.s1.e1" id="DS.d306.s1.i3" interaction="True"/>
            <pair e1="DS.d306.s1.e3" e2="DS.d306.s1.e0" id="DS.d306.s1.i4" interaction="True"/>
            <pair e1="DS.d306.s1.e3" e2="DS.d306.s1.e1" id="DS.d306.s1.i5" interaction="True"/>
        </sentence>
        <sentence id="DS.d306.s2" origId="18543297-401" text="The sequential metabolism of DOR during in vitro studies, particularly using recombinant systems (rCYPs) expressing human CYP2D6, is assumed to be negligible.">
            <entity id="DS.d306.s2.e0" origId="439216" charOffset="29-32" type="compound" text="DOR"/>
            <entity id="DS.d306.s2.e1" origId="P10635,Q2XNC8,Q2XNC9" charOffset="122-128" type="protein" text="CYP2D6"/>
            <pair e1="DS.d306.s2.e0" e2="DS.d306.s2.e1" id="DS.d306.s2.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d306.s3" origId="18543297-402" text="The extent of metabolism was investigated for a range of DEX and DOR concentrations in microsomal preparations from three different rCYPs expressing human CYP2D6 (yeast, Supersomes and Bactosomes) containing 10 pmol of the enzyme.">
            <entity id="DS.d306.s3.e0" origId="439216" charOffset="65-68" type="compound" text="DOR"/>
            <entity id="DS.d306.s3.e1" origId="P10635,Q2XNC8,Q2XNC9" charOffset="155-161" type="protein" text="CYP2D6"/>
            <pair e1="DS.d306.s3.e0" e2="DS.d306.s3.e1" id="DS.d306.s3.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d306.s4" origId="18543297-403" text="Two novel CYP2D6 related metabolites were identified in Bactosomes, and assigned as single hydroxylations in the phenyl rings of DOR and HYM using ion-trap mass spectrometry.">
            <entity id="DS.d306.s4.e0" origId="P10635,Q2XNC8,Q2XNC9" charOffset="10-16" type="protein" text="CYP2D6"/>
            <entity id="DS.d306.s4.e1" origId="439216" charOffset="129-132" type="compound" text="DOR"/>
            <entity id="DS.d306.s4.e2" origId="11840954" charOffset="137-140" type="compound" text="HYM"/>
            <pair e1="DS.d306.s4.e1" e2="DS.d306.s4.e0" id="DS.d306.s4.i0" interaction="True"/>
            <pair e1="DS.d306.s4.e2" e2="DS.d306.s4.e0" id="DS.d306.s4.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d307" origId="18543330">
        <sentence id="DS.d307.s0" origId="18543330-427" text="The metal-coordinating residues in the active site of ILL2 include a conserved cysteine that clearly distinguishes this protein from previously structurally characterized members of the M20 peptidase family.">
            <entity id="DS.d307.s0.e0" origId="P54970" charOffset="54-58" type="protein" text="ILL2"/>
            <entity id="DS.d307.s0.e1" origId="594,5862,5360637" charOffset="79-87" type="compound" text="cysteine"/>
            <pair e1="DS.d307.s0.e1" e2="DS.d307.s0.e0" id="DS.d307.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d307.s1" origId="18543330-428" text="Finally, the active site of ILL2 harbors an absolutely conserved glutamate (Glu172), which is well positioned to act as a general acid-base residue.">
            <entity id="DS.d307.s1.e0" origId="P54970" charOffset="28-32" type="protein" text="ILL2"/>
            <entity id="DS.d307.s1.e1" origId="611,23327,33032" charOffset="65-74" type="compound" text="glutamate"/>
            <pair e1="DS.d307.s1.e1" e2="DS.d307.s1.e0" id="DS.d307.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d308" origId="18544044">
        <sentence id="DS.d308.s0" origId="18544044-880" text="In this study, we tested the hypothesis that the Angiopoietin 1 (Ang1)/Tie2 pathway mediates simvastatin-induced vascular integrity and migration of neuroblasts after stroke.">
            <entity id="DS.d308.s0.e0" origId="P21570" charOffset="65-69" type="protein" text="Ang1"/>
            <entity id="DS.d308.s0.e1" origId="O73791,Q02858" charOffset="71-75" type="protein" text="Tie2"/>
            <entity id="DS.d308.s0.e2" origId="54454,4677798" charOffset="93-104" type="compound" text="simvastatin"/>
            <pair e1="DS.d308.s0.e2" e2="DS.d308.s0.e1" id="DS.d308.s0.i0" interaction="False"/>
            <pair e1="DS.d308.s0.e2" e2="DS.d308.s0.e0" id="DS.d308.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d308.s1" origId="18544044-881" text="Simvastatin treatment significantly decreased blood-brain barrier (BBB) leakage and concomitantly, increased Ang1, Tie2 and Occludin expression in the ischaemic border (IBZ) compared to the MCAo control group.">
            <entity id="DS.d308.s1.e0" origId="54454,4677798" charOffset="0-11" type="compound" text="Simvastatin"/>
            <entity id="DS.d308.s1.e1" origId="P21570" charOffset="109-113" type="protein" text="Ang1"/>
            <entity id="DS.d308.s1.e2" origId="O73791,Q02858" charOffset="115-119" type="protein" text="Tie2"/>
            <entity id="DS.d308.s1.e3" origId="Q16625,Q28269,Q28793,Q5RFS5,Q61146,Q6P6T5,Q91049,Q9PUN1" charOffset="124-132" type="protein" text="Occludin"/>
            <pair e1="DS.d308.s1.e0" e2="DS.d308.s1.e2" id="DS.d308.s1.i0" interaction="True"/>
            <pair e1="DS.d308.s1.e0" e2="DS.d308.s1.e3" id="DS.d308.s1.i1" interaction="True"/>
            <pair e1="DS.d308.s1.e0" e2="DS.d308.s1.e1" id="DS.d308.s1.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d308.s2" origId="18544044-882" text="Simvastatin also significantly increased doublecortin (DCX, a marker of migrating neuroblasts) expression in the IBZ compared to control MCAo rats.">
            <entity id="DS.d308.s2.e0" origId="54454,4677798" charOffset="0-11" type="compound" text="Simvastatin"/>
            <entity id="DS.d308.s2.e1" origId="O43602" charOffset="55-58" type="protein" text="DCX"/>
            <pair e1="DS.d308.s2.e0" e2="DS.d308.s2.e1" id="DS.d308.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d308.s3" origId="18544044-883" text="The data show that simvastatin treatment of RBMEC increased Ang1 and Tie2 gene and protein expression and promoted phosphorylated-Tie2 activity.">
            <entity id="DS.d308.s3.e0" origId="54454,4677798" charOffset="19-30" type="compound" text="simvastatin"/>
            <entity id="DS.d308.s3.e1" origId="P21570" charOffset="60-64" type="protein" text="Ang1"/>
            <entity id="DS.d308.s3.e2" origId="O73791,Q02858" charOffset="69-73" type="protein" text="Tie2"/>
            <entity id="DS.d308.s3.e3" origId="O73791,Q02858" charOffset="130-134" type="protein" text="Tie2"/>
            <pair e1="DS.d308.s3.e0" e2="DS.d308.s3.e2" id="DS.d308.s3.i0" interaction="True"/>
            <pair e1="DS.d308.s3.e0" e2="DS.d308.s3.e1" id="DS.d308.s3.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d308.s4" origId="18544044-884" text="Simvastatin treatment of stroke increases Ang1/Tie2 expression and thereby reduces BBB leakage and promotes vascular stabilization.">
            <entity id="DS.d308.s4.e0" origId="54454,4677798" charOffset="0-11" type="compound" text="Simvastatin"/>
            <entity id="DS.d308.s4.e1" origId="P21570" charOffset="42-46" type="protein" text="Ang1"/>
            <entity id="DS.d308.s4.e2" origId="O73791,Q02858" charOffset="47-51" type="protein" text="Tie2"/>
            <pair e1="DS.d308.s4.e0" e2="DS.d308.s4.e2" id="DS.d308.s4.i0" interaction="True"/>
            <pair e1="DS.d308.s4.e0" e2="DS.d308.s4.e1" id="DS.d308.s4.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d308.s5" origId="18544044-885" text="Ang1/Tie2 expression induced by simvastatin treatment promotes neuroblast micro-vascular coupling after stroke.">
            <entity id="DS.d308.s5.e0" origId="P21570" charOffset="0-4" type="protein" text="Ang1"/>
            <entity id="DS.d308.s5.e1" origId="O73791,Q02858" charOffset="5-9" type="protein" text="Tie2"/>
            <entity id="DS.d308.s5.e2" origId="54454,4677798" charOffset="32-43" type="compound" text="simvastatin"/>
            <pair e1="DS.d308.s5.e2" e2="DS.d308.s5.e1" id="DS.d308.s5.i0" interaction="True"/>
            <pair e1="DS.d308.s5.e2" e2="DS.d308.s5.e0" id="DS.d308.s5.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d309" origId="18544047">
        <sentence id="DS.d309.s0" origId="18544047-888" text="Suppressing the activity of ERRalpha in 3T3-L1 adipocytes reduces mitochondrial biogenesis but enhances glycolysis and basal glucose uptake.">
            <entity id="DS.d309.s0.e0" origId="O08580,P11474" charOffset="28-36" type="protein" text="ERRalpha"/>
            <entity id="DS.d309.s0.e1" origId="206,5793,64689,79025" charOffset="125-132" type="compound" text="glucose"/>
            <pair e1="DS.d309.s0.e1" e2="DS.d309.s0.e0" id="DS.d309.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d309.s2" origId="18544047-891" text="Therefore, ERRalpha stands at the crossroad of glucose and fatty acid utilization and acts as a homeostatic switch to regulate the flux of TCA cycle, mitochondrial membrane potential and glycolysis to maintain a steady level of ATP production, particularly, when mitochondrial biogenesis is reduced.">
            <entity id="DS.d309.s2.e0" origId="O08580,P11474" charOffset="11-19" type="protein" text="ERRalpha"/>
            <entity id="DS.d309.s2.e1" origId="206,5793,64689,79025" charOffset="47-54" type="compound" text="glucose"/>
            <entity id="DS.d309.s2.e2" origId="5957" charOffset="228-231" type="compound" text="ATP"/>
            <pair e1="DS.d309.s2.e2" e2="DS.d309.s2.e0" id="DS.d309.s2.i0" interaction="True"/>
            <pair e1="DS.d309.s2.e1" e2="DS.d309.s2.e0" id="DS.d309.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d310" origId="18544592">
        <sentence id="DS.d310.s0" origId="18544592-1218" text="A significant decrease in mean total nitric oxide (NOx), nitrite, and nitrate levels was also found after G-CSF plus dexamethasone administration.">
            <entity id="DS.d310.s0.e0" origId="145068" charOffset="37-49" type="compound" text="nitric oxide"/>
            <entity id="DS.d310.s0.e1" origId="943" charOffset="70-77" type="compound" text="nitrate"/>
            <entity id="DS.d310.s0.e2" origId="O02708,O02837,P09919,P09920,P35833,P35834,Q28746" charOffset="106-111" type="protein" text="G-CSF"/>
            <entity id="DS.d310.s0.e3" origId="5743" charOffset="117-130" type="compound" text="dexamethasone"/>
            <pair e1="DS.d310.s0.e1" e2="DS.d310.s0.e2" id="DS.d310.s0.i0" interaction="True"/>
            <pair e1="DS.d310.s0.e3" e2="DS.d310.s0.e2" id="DS.d310.s0.i1" interaction="False"/>
            <pair e1="DS.d310.s0.e0" e2="DS.d310.s0.e2" id="DS.d310.s0.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d310.s1" origId="18544592-1219" text="Even if partially compensated with u-PA and protein C, increased FVIII and vWF activity, and decreased nitric oxide levels may still partially contribute to progress of thrombosis risk in rhG-CSF plus dexamethasone administered healthy granulocyte donors.">
            <entity id="DS.d310.s1.e0" origId="O55527,O55779,P02810,P03314,P03424,P04861,P04862,P06022,P06164,P06165,P06941,P07602,P08097,P10030,P14253,P14254,P14340,P26035,P26779,P27384,P28055,P29165,P32533,P32534,P32535,P35940,P35948,P35977,P69738,Q00794,Q03339,Q074N0,Q1X880,Q1X881,Q6DV88,Q6J3P1,Q89277,Q98803,Q997F1,Q9DUE0,Q9WS38,Q9YRV3" charOffset="44-53" type="protein" text="protein C"/>
            <entity id="DS.d310.s1.e1" origId="P04275,P80012,Q28295,Q28833,Q8CIZ8" charOffset="75-78" type="protein" text="vWF"/>
            <entity id="DS.d310.s1.e2" origId="145068" charOffset="103-115" type="compound" text="nitric oxide"/>
            <entity id="DS.d310.s1.e3" origId="5743" charOffset="201-214" type="compound" text="dexamethasone"/>
            <pair e1="DS.d310.s1.e3" e2="DS.d310.s1.e0" id="DS.d310.s1.i0" interaction="False"/>
            <pair e1="DS.d310.s1.e2" e2="DS.d310.s1.e1" id="DS.d310.s1.i1" interaction="False"/>
            <pair e1="DS.d310.s1.e3" e2="DS.d310.s1.e1" id="DS.d310.s1.i2" interaction="False"/>
            <pair e1="DS.d310.s1.e2" e2="DS.d310.s1.e0" id="DS.d310.s1.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d312" origId="18547170">
        <sentence id="DS.d312.s0" origId="18547170-484" text="Amyloglucosidase from Rhizopus mould and beta-glucosidase from sweet almond were employed for the preparation of phenolic and vitamin glycosides of vanillin, N-vanillylnonanamide, DL-dopa, dopamine, curcumin, alpha-tocopherol (vitamin E), pyridoxine (vitamin B(6)), ergocalciferol (vitamin D (2)), thiamin (vitamin B(1)) and riboflavin (vitamin B(2)).">
            <entity id="DS.d312.s0.e0" origId="P12614,P15885,P27034,P29091,P40740,Q03506,Q46684" charOffset="41-57" type="protein" text="beta-glucosidase"/>
            <entity id="DS.d312.s0.e1" origId="1183" charOffset="148-156" type="compound" text="vanillin"/>
            <entity id="DS.d312.s0.e2" origId="2998" charOffset="158-178" type="compound" text="N-vanillylnonanamide"/>
            <entity id="DS.d312.s0.e3" origId="836" charOffset="180-187" type="compound" text="DL-dopa"/>
            <entity id="DS.d312.s0.e4" origId="681" charOffset="189-197" type="compound" text="dopamine"/>
            <entity id="DS.d312.s0.e5" origId="969516" charOffset="199-207" type="compound" text="curcumin"/>
            <entity id="DS.d312.s0.e6" origId="2116,14985" charOffset="209-225" type="compound" text="alpha-tocopherol"/>
            <entity id="DS.d312.s0.e7" origId="2116,14985,1548900,1742129" charOffset="227-236" type="compound" text="vitamin E"/>
            <entity id="DS.d312.s0.e8" origId="1054" charOffset="239-249" type="compound" text="pyridoxine"/>
            <entity id="DS.d312.s0.e9" origId="3249" charOffset="266-291" type="compound" text="ergocalciferol (vitamin D"/>
            <entity id="DS.d312.s0.e10" origId="1130" charOffset="298-305" type="compound" text="thiamin"/>
            <entity id="DS.d312.s0.e11" origId="1072,6759,493570" charOffset="325-335" type="compound" text="riboflavin"/>
            <pair e1="DS.d312.s0.e10" e2="DS.d312.s0.e0" id="DS.d312.s0.i0" interaction="True"/>
            <pair e1="DS.d312.s0.e4" e2="DS.d312.s0.e0" id="DS.d312.s0.i1" interaction="True"/>
            <pair e1="DS.d312.s0.e6" e2="DS.d312.s0.e0" id="DS.d312.s0.i2" interaction="True"/>
            <pair e1="DS.d312.s0.e5" e2="DS.d312.s0.e0" id="DS.d312.s0.i3" interaction="True"/>
            <pair e1="DS.d312.s0.e3" e2="DS.d312.s0.e0" id="DS.d312.s0.i4" interaction="True"/>
            <pair e1="DS.d312.s0.e8" e2="DS.d312.s0.e0" id="DS.d312.s0.i5" interaction="True"/>
            <pair e1="DS.d312.s0.e7" e2="DS.d312.s0.e0" id="DS.d312.s0.i6" interaction="True"/>
            <pair e1="DS.d312.s0.e2" e2="DS.d312.s0.e0" id="DS.d312.s0.i7" interaction="True"/>
            <pair e1="DS.d312.s0.e1" e2="DS.d312.s0.e0" id="DS.d312.s0.i8" interaction="True"/>
            <pair e1="DS.d312.s0.e9" e2="DS.d312.s0.e0" id="DS.d312.s0.i9" interaction="True"/>
            <pair e1="DS.d312.s0.e11" e2="DS.d312.s0.e0" id="DS.d312.s0.i10" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d313" origId="18547363">
        <sentence id="DS.d313.s0" origId="18547363-1222" text="Ochratoxin A impairs Nrf2-dependent gene expression in porcine kidney tubulus cells.">
            <entity id="DS.d313.s0.e0" origId="442530" charOffset="0-12" type="compound" text="Ochratoxin A"/>
            <entity id="DS.d313.s0.e1" origId="O54968,Q60795" charOffset="21-25" type="protein" text="Nrf2"/>
            <pair e1="DS.d313.s0.e0" e2="DS.d313.s0.e1" id="DS.d313.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d313.s1" origId="18547363-1223" text="Therefore, in the present study, the effects of OTA on the nuclear translocation and transactivation of the transcription factor Nrf2 as well as mRNA levels of Nrf2 target genes including glutathione-S-transferase and gamma-glutamylcysteinyl synthetase have been studied in cultured porcine kidney tubulus cells (LLC-PK1).">
            <entity id="DS.d313.s1.e0" origId="444766" charOffset="48-51" type="compound" text="OTA"/>
            <entity id="DS.d313.s1.e1" origId="O54968,Q60795" charOffset="129-133" type="protein" text="Nrf2"/>
            <entity id="DS.d313.s1.e2" origId="O54968,Q60795" charOffset="160-164" type="protein" text="Nrf2"/>
            <entity id="DS.d313.s1.e3" origId="O04437,O18598,P0A9D2,P0A9D3,P30116,P44521,P46088,P46419,P46423,P46426,P46428,P46437,P48438,P80894,P81065,P82996,P82997,P82998,P82999,P83000,P83001,P83246,Q04522,Q08392,Q08393,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52,Q96324" charOffset="188-213" type="protein" text="glutathione-S-transferase"/>
            <pair e1="DS.d313.s1.e0" e2="DS.d313.s1.e1" id="DS.d313.s1.i0" interaction="False"/>
            <pair e1="DS.d313.s1.e0" e2="DS.d313.s1.e3" id="DS.d313.s1.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d313.s2" origId="18547363-1224" text="Nrf2 was induced by sulforaphane, a well-known activator of this transcription factor.">
            <entity id="DS.d313.s2.e0" origId="O54968,Q60795" charOffset="0-4" type="protein" text="Nrf2"/>
            <entity id="DS.d313.s2.e1" origId="5350" charOffset="20-32" type="compound" text="sulforaphane"/>
            <pair e1="DS.d313.s2.e1" e2="DS.d313.s2.e0" id="DS.d313.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d313.s3" origId="18547363-1225" text="Ochratoxin A significantly decreased gamma-glutamylcysteinyl synthetase and glutathione-S-transferase mRNA levels in LLC-PK1 cells.">
            <entity id="DS.d313.s3.e0" origId="442530" charOffset="0-12" type="compound" text="Ochratoxin A"/>
            <entity id="DS.d313.s3.e1" origId="O04437,O18598,P0A9D2,P0A9D3,P30116,P44521,P46088,P46419,P46423,P46426,P46428,P46437,P48438,P80894,P81065,P82996,P82997,P82998,P82999,P83000,P83001,P83246,Q04522,Q08392,Q08393,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52,Q96324" charOffset="76-101" type="protein" text="glutathione-S-transferase"/>
            <pair e1="DS.d313.s3.e0" e2="DS.d313.s3.e1" id="DS.d313.s3.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d313.s4" origId="18547363-1226" text="Furthermore, OTA also lowered Nrf2 mRNA levels.">
            <entity id="DS.d313.s4.e0" origId="444766" charOffset="13-16" type="compound" text="OTA"/>
            <entity id="DS.d313.s4.e1" origId="O54968,Q60795" charOffset="30-34" type="protein" text="Nrf2"/>
            <pair e1="DS.d313.s4.e0" e2="DS.d313.s4.e1" id="DS.d313.s4.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d313.s5" origId="18547363-1227" text="Current data indicate that OTA nephrotoxicity may be, at least partly, mediated by an Nrf2-dependent signal transduction pathway.">
            <entity id="DS.d313.s5.e0" origId="444766" charOffset="27-30" type="compound" text="OTA"/>
            <entity id="DS.d313.s5.e1" origId="O54968,Q60795" charOffset="86-90" type="protein" text="Nrf2"/>
            <pair e1="DS.d313.s5.e0" e2="DS.d313.s5.e1" id="DS.d313.s5.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d314" origId="18547754">
        <sentence id="DS.d314.s0" origId="18547754-637" text="Parthenogenetic porcine blastocysts were generated by the following methods: (1) electroporation followed by blocking the activity of specific protein kinases with butyrolactone I ; (2) electroporation followed by inhibition of protein synthesis using cycloheximide ; and (3) electroporation only (control).">
            <entity id="DS.d314.s0.e0" origId="P00513,P25848" charOffset="143-158" type="protein" text="protein kinases"/>
            <entity id="DS.d314.s0.e1" origId="123740,5235506,51340302" charOffset="164-179" type="compound" text="butyrolactone I"/>
            <entity id="DS.d314.s0.e2" origId="6197" charOffset="252-265" type="compound" text="cycloheximide"/>
            <pair e1="DS.d314.s0.e1" e2="DS.d314.s0.e0" id="DS.d314.s0.i0" interaction="True"/>
            <pair e1="DS.d314.s0.e2" e2="DS.d314.s0.e0" id="DS.d314.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d315" origId="18547755">
        <sentence id="DS.d315.s0" origId="18547755-125" text="The aim of the present study was to investigate differences in the expression of mRNAs for ERalpha, ERbeta and PR in the sow uterus at different stages of the estrous cycle as well as in inseminated sows at estrus and during early pregnancy by use of solution hybridization and in relation to plasma levels of estradiol and progesterone.">
            <entity id="DS.d315.s0.e0" origId="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7" charOffset="91-98" type="protein" text="ERalpha"/>
            <entity id="DS.d315.s0.e1" origId="O08537,O13012,O93511,P57781,P57782,Q62986,Q92731,Q95171,Q9IAK1,Q9PTU5,Q9PVE2,Q9TTE5,Q9TU15,Q9W6M2,Q9XSB5,Q9XSW2,Q9YH32" charOffset="100-106" type="protein" text="ERbeta"/>
            <entity id="DS.d315.s0.e2" origId="5757" charOffset="310-319" type="compound" text="estradiol"/>
            <entity id="DS.d315.s0.e3" origId="5994" charOffset="324-336" type="compound" text="progesterone"/>
            <pair e1="DS.d315.s0.e3" e2="DS.d315.s0.e0" id="DS.d315.s0.i0" interaction="False"/>
            <pair e1="DS.d315.s0.e2" e2="DS.d315.s0.e0" id="DS.d315.s0.i1" interaction="False"/>
            <pair e1="DS.d315.s0.e3" e2="DS.d315.s0.e1" id="DS.d315.s0.i2" interaction="False"/>
            <pair e1="DS.d315.s0.e2" e2="DS.d315.s0.e1" id="DS.d315.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d316" origId="18547796">
        <sentence id="DS.d316.s0" origId="18547796-661" text="Increased incorporation of dietary plant sterols and cholesterol correlates with decreased expression of hepatic and intestinal Abcg5 and Abcg8 in diabetic BB rats.">
            <entity id="DS.d316.s0.e0" origId="304,5997,6432564,11025495" charOffset="53-64" type="compound" text="cholesterol"/>
            <entity id="DS.d316.s0.e1" origId="Q99PE7,Q99PE8" charOffset="128-133" type="protein" text="Abcg5"/>
            <entity id="DS.d316.s0.e2" origId="P58428,Q9DBM0" charOffset="138-143" type="protein" text="Abcg8"/>
            <pair e1="DS.d316.s0.e0" e2="DS.d316.s0.e2" id="DS.d316.s0.i0" interaction="True"/>
            <pair e1="DS.d316.s0.e0" e2="DS.d316.s0.e1" id="DS.d316.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d316.s1" origId="18547796-662" text="This increase in cholesterol and plant sterols and stanols was associated with a marked decrease in hepatic and intestinal Abcg5 (ATP-binding cassette transporter G5) and Abcg8 (ATP-binding cassette transporter G8) expressions in diabetic rats, as well as decreased mRNA levels of several other genes involved in sterol regulation.">
            <entity id="DS.d316.s1.e0" origId="304,5997,6432564,11025495" charOffset="17-28" type="compound" text="cholesterol"/>
            <entity id="DS.d316.s1.e1" origId="Q99PE7,Q99PE8" charOffset="123-128" type="protein" text="Abcg5"/>
            <entity id="DS.d316.s1.e2" origId="P58428,Q9DBM0" charOffset="171-176" type="protein" text="Abcg8"/>
            <pair e1="DS.d316.s1.e0" e2="DS.d316.s1.e2" id="DS.d316.s1.i0" interaction="True"/>
            <pair e1="DS.d316.s1.e0" e2="DS.d316.s1.e1" id="DS.d316.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d316.s2" origId="18547796-663" text="Therefore, lower expression levels of Abcg5/Abcg8 in diabetic rats may account for the increased accumulation of plant sterols and cholesterol in these rats.">
            <entity id="DS.d316.s2.e0" origId="Q99PE7,Q99PE8" charOffset="38-43" type="protein" text="Abcg5"/>
            <entity id="DS.d316.s2.e1" origId="P58428,Q9DBM0" charOffset="44-49" type="protein" text="Abcg8"/>
            <entity id="DS.d316.s2.e2" origId="304,5997,6432564,11025495" charOffset="131-142" type="compound" text="cholesterol"/>
            <pair e1="DS.d316.s2.e2" e2="DS.d316.s2.e1" id="DS.d316.s2.i0" interaction="True"/>
            <pair e1="DS.d316.s2.e2" e2="DS.d316.s2.e0" id="DS.d316.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d317" origId="18547798">
        <sentence id="DS.d317.s0" origId="18547798-666" text="Gallic acid, ferulic acid and p-coumaric acid at a dosage of 100 mg kg(-1) body weight significantly increased the activities of cardiac superoxide dismutase, glutathione peroxidase (GPx) and catalase (CAT.05).">
            <entity id="DS.d317.s0.e0" origId="370" charOffset="0-11" type="compound" text="Gallic acid"/>
            <entity id="DS.d317.s0.e1" origId="445858" charOffset="13-25" type="compound" text="ferulic acid"/>
            <entity id="DS.d317.s0.e2" origId="637542" charOffset="30-45" type="compound" text="p-coumaric acid"/>
            <entity id="DS.d317.s0.e3" origId="O50258" charOffset="137-157" type="protein" text="superoxide dismutase"/>
            <entity id="DS.d317.s0.e4" origId="O32770,O59858,Q00277,Q9CFV1" charOffset="159-181" type="protein" text="glutathione peroxidase"/>
            <entity id="DS.d317.s0.e5" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="192-200" type="protein" text="catalase"/>
            <entity id="DS.d317.s0.e6" origId="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7" charOffset="202-205" type="protein" text="CAT"/>
            <pair e1="DS.d317.s0.e1" e2="DS.d317.s0.e4" id="DS.d317.s0.i0" interaction="True"/>
            <pair e1="DS.d317.s0.e0" e2="DS.d317.s0.e4" id="DS.d317.s0.i1" interaction="True"/>
            <pair e1="DS.d317.s0.e2" e2="DS.d317.s0.e3" id="DS.d317.s0.i2" interaction="True"/>
            <pair e1="DS.d317.s0.e2" e2="DS.d317.s0.e4" id="DS.d317.s0.i3" interaction="True"/>
            <pair e1="DS.d317.s0.e1" e2="DS.d317.s0.e6" id="DS.d317.s0.i4" interaction="True"/>
            <pair e1="DS.d317.s0.e0" e2="DS.d317.s0.e6" id="DS.d317.s0.i5" interaction="True"/>
            <pair e1="DS.d317.s0.e0" e2="DS.d317.s0.e5" id="DS.d317.s0.i6" interaction="True"/>
            <pair e1="DS.d317.s0.e0" e2="DS.d317.s0.e3" id="DS.d317.s0.i7" interaction="True"/>
            <pair e1="DS.d317.s0.e2" e2="DS.d317.s0.e6" id="DS.d317.s0.i8" interaction="True"/>
            <pair e1="DS.d317.s0.e2" e2="DS.d317.s0.e5" id="DS.d317.s0.i9" interaction="True"/>
            <pair e1="DS.d317.s0.e1" e2="DS.d317.s0.e5" id="DS.d317.s0.i10" interaction="True"/>
            <pair e1="DS.d317.s0.e1" e2="DS.d317.s0.e3" id="DS.d317.s0.i11" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d318" origId="18547799">
        <sentence id="DS.d318.s0" origId="18547799-292" text="These effects of genistein during the differentiation period were associated with down-regulation of ERalpha and ERbeta expression.">
            <entity id="DS.d318.s0.e0" origId="5280961" charOffset="17-26" type="compound" text="genistein"/>
            <entity id="DS.d318.s0.e1" origId="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7" charOffset="101-108" type="protein" text="ERalpha"/>
            <entity id="DS.d318.s0.e2" origId="O08537,O13012,O93511,P57781,P57782,Q62986,Q92731,Q95171,Q9IAK1,Q9PTU5,Q9PVE2,Q9TTE5,Q9TU15,Q9W6M2,Q9XSB5,Q9XSW2,Q9YH32" charOffset="113-119" type="protein" text="ERbeta"/>
            <pair e1="DS.d318.s0.e0" e2="DS.d318.s0.e1" id="DS.d318.s0.i0" interaction="True"/>
            <pair e1="DS.d318.s0.e0" e2="DS.d318.s0.e2" id="DS.d318.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d319" origId="18548182">
        <sentence id="DS.d319.s0" origId="18548182-922" text="Activities of microbial extracellular enzymes involved in carbon, nitrogen, and phosphorus cycling declined appreciably with depth, the only exception being peroxidase.">
            <entity id="DS.d319.s0.e0" origId="947,123329" charOffset="66-74" type="compound" text="nitrogen"/>
            <entity id="DS.d319.s0.e1" origId="24404,139579" charOffset="80-90" type="compound" text="phosphorus"/>
            <entity id="DS.d319.s0.e2" origId="P15984,P16147,P84714" charOffset="157-167" type="protein" text="peroxidase"/>
            <pair e1="DS.d319.s0.e0" e2="DS.d319.s0.e2" id="DS.d319.s0.i0" interaction="False"/>
            <pair e1="DS.d319.s0.e1" e2="DS.d319.s0.e2" id="DS.d319.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d320" origId="18548275">
        <sentence id="DS.d320.s0" origId="18548275-801" text="Sulfonylurea (SU) treatment restores insulin secretion in patients with KCNJ11 mutations.">
            <entity id="DS.d320.s0.e0" origId="104818" charOffset="0-12" type="compound" text="Sulfonylurea"/>
            <entity id="DS.d320.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="37-44" type="protein" text="insulin"/>
            <entity id="DS.d320.s0.e2" origId="O02822,Q14654,Q9JHJ9" charOffset="72-78" type="protein" text="KCNJ11"/>
            <pair e1="DS.d320.s0.e0" e2="DS.d320.s0.e2" id="DS.d320.s0.i0" interaction="False"/>
            <pair e1="DS.d320.s0.e0" e2="DS.d320.s0.e1" id="DS.d320.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d321" origId="18548615">
        <sentence id="DS.d321.s0" origId="18548615-1193" text="The purpose of this study was to investigate the effect of three zinc salts (i.e., zinc oxide, zinc carbonate, and zinc acetate) on insulin encapsulation efficiency (EE), stability, and in vitro release kinetics from poly(lactic-co-glycolic acid) (PLGA) microspheres.">
            <entity id="DS.d321.s0.e0" origId="14806" charOffset="83-93" type="compound" text="zinc oxide"/>
            <entity id="DS.d321.s0.e1" origId="767" charOffset="95-109" type="compound" text="zinc carbonate"/>
            <entity id="DS.d321.s0.e2" origId="176" charOffset="115-127" type="compound" text="zinc acetate"/>
            <entity id="DS.d321.s0.e3" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="132-139" type="protein" text="insulin"/>
            <entity id="DS.d321.s0.e5" origId="36797" charOffset="248-252" type="compound" text="PLGA"/>
            <pair e1="DS.d321.s0.e1" e2="DS.d321.s0.e3" id="DS.d321.s0.i0" interaction="False"/>
            <pair e1="DS.d321.s0.e2" e2="DS.d321.s0.e3" id="DS.d321.s0.i1" interaction="False"/>
            <pair e1="DS.d321.s0.e5" e2="DS.d321.s0.e3" id="DS.d321.s0.i2" interaction="False"/>
            <pair e1="DS.d321.s0.e0" e2="DS.d321.s0.e3" id="DS.d321.s0.i4" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d322" origId="18550063">
        <sentence id="DS.d322.s0" origId="18550063-794" text="Tumor necrosis factor-alpha inhibition protects against endotoxin-induced endothelial glycocalyx perturbation.">
            <entity id="DS.d322.s0.e0" origId="Q8JFG3" charOffset="0-21" type="protein" text="Tumor necrosis factor"/>
            <entity id="DS.d322.s0.e1" origId="44268108" charOffset="56-65" type="compound" text="endotoxin"/>
            <pair e1="DS.d322.s0.e1" e2="DS.d322.s0.e0" id="DS.d322.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d322.s1" origId="18550063-795" text="In the present study, we investigated whether endotoxin-induced inflammatory reactions lead to a decrease of endothelial glycocalyx thickness in humans and whether tumor necrosis factor-alpha (TNFalpha) plays a role in this process.">
            <entity id="DS.d322.s1.e0" origId="44268108" charOffset="46-55" type="compound" text="endotoxin"/>
            <entity id="DS.d322.s1.e1" origId="Q8JFG3" charOffset="164-185" type="protein" text="tumor necrosis factor"/>
            <entity id="DS.d322.s1.e2" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="193-201" type="protein" text="TNFalpha"/>
            <pair e1="DS.d322.s1.e0" e2="DS.d322.s1.e1" id="DS.d322.s1.i0" interaction="False"/>
            <pair e1="DS.d322.s1.e0" e2="DS.d322.s1.e2" id="DS.d322.s1.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d323" origId="18550164">
        <sentence id="DS.d323.s0" origId="18550164-868" text="The amino acid sequence deduced from the coding sequence encodes for a protein of 73 amino acids containing 21 cysteine residues.">
            <entity id="DS.d323.s0.e0" origId="P03161,P03610,P03631,P03632,P07394,P15966,P25243,P25244,P35823,P98005" charOffset="69-78" type="protein" text="a protein"/>
            <entity id="DS.d323.s0.e1" origId="594,5862,5360637" charOffset="111-119" type="compound" text="cysteine"/>
            <pair e1="DS.d323.s0.e1" e2="DS.d323.s0.e0" id="DS.d323.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d324" origId="18550594">
        <sentence id="DS.d324.s0" origId="18550594-1147" text="Ultrastructural analysis in the macaque mediodorsal nucleus revealed that thalamic interneurons are a main postsynaptic target of DAT-ir axons ; this suggests that the marked expansion of the dopamine innervation in the primate in comparison to the rodent thalamus may be related to the presence of a sizable interneuron population in primates.">
            <entity id="DS.d324.s0.e0" origId="P13483,P23977,P27922,Q01959,Q03614,Q61327,Q9GJT6" charOffset="130-133" type="protein" text="DAT"/>
            <entity id="DS.d324.s0.e1" origId="681" charOffset="192-200" type="compound" text="dopamine"/>
            <pair e1="DS.d324.s0.e1" e2="DS.d324.s0.e0" id="DS.d324.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d325" origId="18550596">
        <sentence id="DS.d325.s0" origId="18550596-1150" text="Synapsin-dependent facilitation in MF synapses of WT mice was attenuated by blocking F-actin polymerization with cytochalasin B in hippocampal slices.">
            <entity id="DS.d325.s0.e0" origId="Q24546" charOffset="0-8" type="protein" text="Synapsin"/>
            <entity id="DS.d325.s0.e1" origId="O00937,O13419,O16808,O17320,O65314,O65315,O65316,O74258,O81221,P02577,P10365,P10989,P11426,P13363,P14235,P17128,P20904,P24902,P26182,P26183,P30161,P45520,P45521,P48465,P50138,P51775,P53455,P53476,P53477,P53491,P53498,P53499,P53500,P53502,P53689,P60009,P60010,P60011,P68555,P78711,P80709,P81085,P90689,P91754,Q05214,Q11212,Q24733,Q2U7A3,Q39596,Q39758,Q6TCF2,Q75D00,Q8SWN8,Q8X119,Q92192,Q92193,Q99023,Q9P4D1,Q9UVF3,Q9UVX4,Q9UVZ8" charOffset="87-92" type="protein" text="actin"/>
            <entity id="DS.d325.s0.e2" origId="2919,5311281,5368686,5836499,6364615,6433621" charOffset="113-127" type="compound" text="cytochalasin B"/>
            <pair e1="DS.d325.s0.e2" e2="DS.d325.s0.e0" id="DS.d325.s0.i0" interaction="True"/>
            <pair e1="DS.d325.s0.e2" e2="DS.d325.s0.e1" id="DS.d325.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d326" origId="18551377">
        <sentence id="DS.d326.s0" origId="18551377-641" text="Transformation was achieved using a vector that targets genes to the rrn16/rps12 intergenic region of the sugar beet plastome, employing the aadA gene as a selectable marker against spectinomycin and the gfp gene for visual screening of plastid transformants.">
            <entity id="DS.d326.s0.e0" origId="O14062,P02368,P06368,P11524,P13576,P14149,P17293,P17294,P19461,P29161,P39573,P41196,P42344,P46296,P46308,P47333,P47840,P48856,P49168,P49500,P51289,P52762,P56354,P59168,P61941,P62127,P63196,P63199,P63200,P63323,P63324,P74230,Q2JMY0,Q2JUX7,Q318N2,Q3AMT3,Q3AW56,Q3MDM2,Q46IW1,Q5F1R7,Q68S28,Q6B8X8,Q6ENC0,Q6L3C7,Q6YXM6,Q70XU7,Q7NAV1,Q7NEF4,Q7U4D4,Q7UZY4,Q7V503,Q7VA02,Q85BW6,Q85FG4,Q85X49,Q8KTP6,Q8MA18,Q8RUK6,Q8VMU2,Q8YP60,Q9AIG9,Q9CL86,Q9MUP2,Q9PPW5,Q9TJR0,Q9TKZ7,Q9TLV6,Q9XQE1" charOffset="75-80" type="protein" text="rps12"/>
            <entity id="DS.d326.s0.e1" origId="P08881,P0AG05,P0AG06" charOffset="141-145" type="protein" text="aadA"/>
            <entity id="DS.d326.s0.e2" origId="15541" charOffset="182-195" type="compound" text="spectinomycin"/>
            <pair e1="DS.d326.s0.e2" e2="DS.d326.s0.e1" id="DS.d326.s0.i0" interaction="True"/>
            <pair e1="DS.d326.s0.e2" e2="DS.d326.s0.e0" id="DS.d326.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d327" origId="18552508">
        <sentence id="DS.d327.s0" origId="18552508-1057" text="Celecoxib inhibits serum amyloid a-induced matrix metalloproteinase-10 expression in human endothelial cells.">
            <entity id="DS.d327.s0.e0" origId="2662" charOffset="0-9" type="compound" text="Celecoxib"/>
            <entity id="DS.d327.s0.e1" origId="O55123,P07152,P09238" charOffset="43-70" type="protein" text="matrix metalloproteinase-10"/>
            <pair e1="DS.d327.s0.e0" e2="DS.d327.s0.e1" id="DS.d327.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d328" origId="18553142">
        <sentence id="DS.d328.s0" origId="18553142-185" text="This article investigated the effect of sulfite on total antioxidant capacity (TAC), total oxidant status, lipid hydroperoxide (LOOH), and total free sulfydryl groups (-SH) levels in normal and SOX-deficient male albino rat plasma.">
            <entity id="DS.d328.s0.e0" origId="784" charOffset="113-126" type="compound" text="hydroperoxide"/>
            <entity id="DS.d328.s0.e1" origId="P79371,Q8JGM4,Q9S850" charOffset="194-197" type="protein" text="SOX"/>
            <pair e1="DS.d328.s0.e0" e2="DS.d328.s0.e1" id="DS.d328.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d328.s1" origId="18553142-186" text="SOX deficiency was established by feeding rats a low molybdenum diet and adding to their drinking water 200 ppm tungsten.">
            <entity id="DS.d328.s1.e0" origId="P79371,Q8JGM4,Q9S850" charOffset="0-3" type="protein" text="SOX"/>
            <entity id="DS.d328.s1.e1" origId="6422,23932" charOffset="53-63" type="compound" text="molybdenum"/>
            <entity id="DS.d328.s1.e2" origId="23964" charOffset="112-120" type="compound" text="tungsten"/>
            <pair e1="DS.d328.s1.e2" e2="DS.d328.s1.e0" id="DS.d328.s1.i0" interaction="True"/>
            <pair e1="DS.d328.s1.e1" e2="DS.d328.s1.e0" id="DS.d328.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d330" origId="18554595">
        <sentence id="DS.d330.s0" origId="18554595-1071" text="To test the hypothesis that DHEAS production from DHEA occurs in hepatic cells and that this production is augmented by the presence of sex steroids or insulin.">
            <entity id="DS.d330.s0.e0" origId="12594" charOffset="28-33" type="compound" text="DHEAS"/>
            <entity id="DS.d330.s0.e1" origId="5881" charOffset="28-32" type="compound" text="DHEA"/>
            <entity id="DS.d330.s0.e2" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="152-159" type="protein" text="insulin"/>
            <pair e1="DS.d330.s0.e1" e2="DS.d330.s0.e2" id="DS.d330.s0.i0" interaction="False"/>
            <pair e1="DS.d330.s0.e0" e2="DS.d330.s0.e2" id="DS.d330.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d331" origId="18554598">
        <sentence id="DS.d331.s0" origId="18554598-1073" text="Changes in tumor necrosis factor (TNF) production by lipopolysaccharide-stimulated peripheral blood mononuclear cells significantly correlated with serum P levels in postmenopausal women subjected to estrogen/medroxyprogesterone therapy.">
            <entity id="DS.d331.s0.e0" origId="Q8JFG3" charOffset="11-32" type="protein" text="tumor necrosis factor"/>
            <entity id="DS.d331.s0.e1" origId="O35734,O77510,O77764,P01375,P04924,P13296,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="34-37" type="protein" text="TNF"/>
            <entity id="DS.d331.s0.e2" origId="11970143" charOffset="53-71" type="compound" text="lipopolysaccharide"/>
            <entity id="DS.d331.s0.e3" origId="10631" charOffset="209-228" type="compound" text="medroxyprogesterone"/>
            <pair e1="DS.d331.s0.e3" e2="DS.d331.s0.e0" id="DS.d331.s0.i0" interaction="False"/>
            <pair e1="DS.d331.s0.e2" e2="DS.d331.s0.e1" id="DS.d331.s0.i1" interaction="True"/>
            <pair e1="DS.d331.s0.e2" e2="DS.d331.s0.e0" id="DS.d331.s0.i2" interaction="True"/>
            <pair e1="DS.d331.s0.e3" e2="DS.d331.s0.e1" id="DS.d331.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d332" origId="18554690">
        <sentence id="DS.d332.s0" origId="18554690-393" text="The differences in tissue distribution and protein levels of EcR-B1 during the programmed cell death indicate that the receptor plays a major role in the modulation and function of ecdysone activity in Bombyx anterior silk glands.">
            <entity id="DS.d332.s0.e0" origId="O18473,O18531,P34021,P49880,P49881,P49882,P49883" charOffset="61-64" type="protein" text="EcR"/>
            <entity id="DS.d332.s0.e1" origId="19212,4233007,5316996" charOffset="181-189" type="compound" text="ecdysone"/>
            <pair e1="DS.d332.s0.e1" e2="DS.d332.s0.e0" id="DS.d332.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d333" origId="18555241">
        <sentence id="DS.d333.s0" origId="18555241-208" text="Curcumin, a nutritional supplement with antineoplastic activity, enhances leiomyoma cell apoptosis and decreases fibronectin expression.">
            <entity id="DS.d333.s0.e0" origId="969516" charOffset="0-8" type="compound" text="Curcumin"/>
            <entity id="DS.d333.s0.e1" origId="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400" charOffset="113-124" type="protein" text="fibronectin"/>
            <pair e1="DS.d333.s0.e0" e2="DS.d333.s0.e1" id="DS.d333.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d334" origId="18555557">
        <sentence id="DS.d334.s0" origId="18555557-379" text="Methylthioadenosine phosphorylase (MTAP) is involved in the metabolism of purines and converts methylthioadenosine (MTA) to adenine.">
            <entity id="DS.d334.s0.e0" origId="Q13126" charOffset="35-39" type="protein" text="MTAP"/>
            <entity id="DS.d334.s0.e1" origId="190" charOffset="124-131" type="compound" text="adenine"/>
            <pair e1="DS.d334.s0.e1" e2="DS.d334.s0.e0" id="DS.d334.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d334.s1" origId="18555557-380" text="Methylation-specific primers were used to analyze methylation of the MTAP promoter, using DNA treated with sodium bisulfite.">
            <entity id="DS.d334.s1.e0" origId="Q13126" charOffset="69-73" type="protein" text="MTAP"/>
            <entity id="DS.d334.s1.e1" origId="23665763" charOffset="107-123" type="compound" text="sodium bisulfite"/>
            <pair e1="DS.d334.s1.e1" e2="DS.d334.s1.e0" id="DS.d334.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d335" origId="18555679">
        <sentence id="DS.d335.s0" origId="18555679-458" text="Long-chain fatty alcohols also reduced tumor necrosis factor-alpha and prostaglandin E(2) production, although the potency of inhibition for the latter was lower.">
            <entity id="DS.d335.s0.e0" origId="62238" charOffset="11-25" type="compound" text="fatty alcohols"/>
            <entity id="DS.d335.s0.e1" origId="Q8JFG3" charOffset="39-60" type="protein" text="tumor necrosis factor"/>
            <pair e1="DS.d335.s0.e0" e2="DS.d335.s0.e1" id="DS.d335.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d336" origId="18556000">
        <sentence id="DS.d336.s0" origId="18556000-671" text="Neopterin is released from human monocyte-derived macrophages upon stimulation with interferon-gamma and is a sensitive indicator for cellular immune activation.">
            <entity id="DS.d336.s0.e0" origId="4455" charOffset="0-9" type="compound" text="Neopterin"/>
            <entity id="DS.d336.s0.e1" origId="Q9TTB0" charOffset="84-100" type="protein" text="interferon-gamma"/>
            <pair e1="DS.d336.s0.e0" e2="DS.d336.s0.e1" id="DS.d336.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d337" origId="18556087">
        <sentence id="DS.d337.s0" origId="18556087-712" text="Both activity and expression of sulfate transporters and APS reductase in plants are modulated by the sulfur status of the plant.">
            <entity id="DS.d337.s0.e0" origId="O70531,P50443,Q62273" charOffset="32-52" type="protein" text="sulfate transporters"/>
            <entity id="DS.d337.s0.e2" origId="402" charOffset="102-108" type="compound" text="sulfur"/>
            <pair e1="DS.d337.s0.e2" e2="DS.d337.s0.e0" id="DS.d337.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d338" origId="18560889">
        <sentence id="DS.d338.s0" origId="18560889-729" text="Complex I deficiency is a novel cause of secretory diarrhea and may act via disrupting the supply of adenosine triphosphate (ATP) needed for the maintenance of ion gradients across membranes.">
            <entity id="DS.d338.s0.e0" origId="Q07842" charOffset="0-9" type="protein" text="Complex I"/>
            <entity id="DS.d338.s0.e1" origId="5957" charOffset="101-123" type="compound" text="adenosine triphosphate"/>
            <entity id="DS.d338.s0.e2" origId="5957" charOffset="125-128" type="compound" text="ATP"/>
            <pair e1="DS.d338.s0.e1" e2="DS.d338.s0.e0" id="DS.d338.s0.i0" interaction="True"/>
            <pair e1="DS.d338.s0.e2" e2="DS.d338.s0.e0" id="DS.d338.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d339" origId="18561093">
        <sentence id="DS.d339.s0" origId="18561093-53" text="This prospective cross-sectional study was performed to investigate the influence of GH excess on leptin and ghrelin levels at baseline and after glucose load in a large group of acromegalic patients.">
            <entity id="DS.d339.s0.e0" origId="O02750,O93416,Q28603,Q95189,Q95234" charOffset="98-104" type="protein" text="leptin"/>
            <entity id="DS.d339.s0.e1" origId="Q6BEG6,Q6BEG7,Q9BDJ6,Q9BEF8,Q9EQX0,Q9GKY5,Q9QYH7,Q9UBU3" charOffset="109-116" type="protein" text="ghrelin"/>
            <entity id="DS.d339.s0.e2" origId="206,5793,64689,79025" charOffset="146-153" type="compound" text="glucose"/>
            <pair e1="DS.d339.s0.e2" e2="DS.d339.s0.e0" id="DS.d339.s0.i0" interaction="False"/>
            <pair e1="DS.d339.s0.e2" e2="DS.d339.s0.e1" id="DS.d339.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d340" origId="18561170">
        <sentence id="DS.d340.s0" origId="18561170-499" text="Trypsin digestion, fluorescence anisotropy, and NMR experiments presented here were designed to resolve the issue and show that in arm-dimerization domain, the arms are structured, although differently, in the presence and absence of arabinose.">
            <entity id="DS.d340.s0.e0" origId="P23916,P24664,P35050,P83348,Q59149" charOffset="0-7" type="protein" text="Trypsin"/>
            <entity id="DS.d340.s0.e1" origId="66308" charOffset="234-243" type="compound" text="arabinose"/>
            <pair e1="DS.d340.s0.e1" e2="DS.d340.s0.e0" id="DS.d340.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d341" origId="18561187">
        <sentence id="DS.d341.s0" origId="18561187-110" text="DNA array studies have revealed that YhaK is strongly up-regulated by nitroso-glutathione (GSNO) and also displays a 12-fold increase in expression during biofilm growth of E. coli 83972 and VR50 in human urine.">
            <entity id="DS.d341.s0.e0" origId="P42624,P58115" charOffset="37-41" type="protein" text="YhaK"/>
            <entity id="DS.d341.s0.e2" origId="3514,104858,10404739" charOffset="91-95" type="compound" text="GSNO"/>
            <pair e1="DS.d341.s0.e2" e2="DS.d341.s0.e0" id="DS.d341.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d341.s1" origId="18561187-111" text="We found that the third cysteine in YhaK, Cys122, is oxidized to a sulfenic acid.">
            <entity id="DS.d341.s1.e0" origId="594,5862,5360637" charOffset="24-32" type="compound" text="cysteine"/>
            <entity id="DS.d341.s1.e1" origId="P42624,P58115" charOffset="36-40" type="protein" text="YhaK"/>
            <entity id="DS.d341.s1.e2" origId="447587" charOffset="67-80" type="compound" text="sulfenic acid"/>
            <pair e1="DS.d341.s1.e0" e2="DS.d341.s1.e1" id="DS.d341.s1.i0" interaction="False"/>
            <pair e1="DS.d341.s1.e2" e2="DS.d341.s1.e1" id="DS.d341.s1.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d341.s2" origId="18561187-112" text="E. coli thioredoxin reductase and NADPH produced ROS and caused oxidation and oligomerization of reduced YhaK.">
            <entity id="DS.d341.s2.e0" origId="O14313,O22711,O30973,O32823,O43099,O66790,O69777,O83790,O84101,P0A9P4,P0A9P5,P0AE52,P0AE53,P0AE54,P0AE55,P14292,P14293,P21762,P26830,P30044,P34227,P39916,P40553,P43496,P43788,P44411,P44758,P46843,P47348,P49537,P50971,P51272,P51978,P52213,P52214,P52215,P55979,P56431,P56577,P56578,P56876,P57279,P57399,P61076,P65688,P65689,P66010,P66011,P73728,P75531,P80880,P80892,P81433,P94284,P99029,P99101,Q01116,Q05741,Q25861,Q53212,Q55624,Q5HHQ4,Q5HQW4,Q6BIS1,Q6C7L4,Q6FR39,Q6GB66,Q6GIM7,Q75CM8,Q7Z7S3,Q89AJ2,Q89AS1,Q8CPY8,Q8J0U0,Q8K9W0,Q8T6Z1,Q92375,Q928B5,Q92I02,Q98PK9,Q9BGI1,Q9GLW7,Q9GLW9,Q9KSS4,Q9M7T0,Q9PKT7,Q9PR71,Q9R063,Q9Z8M4,Q9ZD97,Q9ZHF0,Q9ZL18,Q9ZMU4" charOffset="8-29" type="protein" text="thioredoxin reductase"/>
            <entity id="DS.d341.s2.e1" origId="5884" charOffset="34-39" type="compound" text="NADPH"/>
            <entity id="DS.d341.s2.e2" origId="P42624,P58115" charOffset="105-109" type="protein" text="YhaK"/>
            <pair e1="DS.d341.s2.e1" e2="DS.d341.s2.e2" id="DS.d341.s2.i0" interaction="True"/>
            <pair e1="DS.d341.s2.e1" e2="DS.d341.s2.e0" id="DS.d341.s2.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d342" origId="18562331">
        <sentence id="DS.d342.s0" origId="18562331-1081" text="In this report, we investigated the possible role of LA and vmPFC NR2Bs in the consolidation of fear extinction using the NR2B-selective antagonist ifenprodil.">
            <entity id="DS.d342.s0.e0" origId="Q00960,Q01097,Q13224" charOffset="66-71" type="protein" text="NR2Bs"/>
            <entity id="DS.d342.s0.e1" origId="Q00960,Q01097,Q13224" charOffset="66-70" type="protein" text="NR2B"/>
            <entity id="DS.d342.s0.e2" origId="3689,6604117,11198145,11771731" charOffset="148-158" type="compound" text="ifenprodil"/>
            <pair e1="DS.d342.s0.e2" e2="DS.d342.s0.e1" id="DS.d342.s0.i0" interaction="False"/>
            <pair e1="DS.d342.s0.e2" e2="DS.d342.s0.e0" id="DS.d342.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d343" origId="18562423">
        <sentence id="DS.d343.s0" origId="18562423-1156" text="Patients under clozapine-risperidone therapy developed a rise of serum prolactin levels.">
            <entity id="DS.d343.s0.e0" origId="2818" charOffset="15-24" type="compound" text="clozapine"/>
            <entity id="DS.d343.s0.e1" origId="5073" charOffset="25-36" type="compound" text="risperidone"/>
            <entity id="DS.d343.s0.e2" origId="P10765,P22393,P33089,P33090,P33091,P43001" charOffset="71-80" type="protein" text="prolactin"/>
            <pair e1="DS.d343.s0.e1" e2="DS.d343.s0.e2" id="DS.d343.s0.i0" interaction="True"/>
            <pair e1="DS.d343.s0.e0" e2="DS.d343.s0.e2" id="DS.d343.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d344" origId="18562442">
        <sentence id="DS.d344.s0" origId="18562442-1178" text="In experiment 3, administration of E(2) or DPN to ovariectomised wildtype, but not betaERKO, mice decreased immobility compared with vehicle administration, these data suggest that ERbeta may be required for some of the anti-depressant-like effects of E(2).">
            <entity id="DS.d344.s0.e0" origId="926,5893,447862" charOffset="43-46" type="compound" text="DPN"/>
            <entity id="DS.d344.s0.e1" origId="O08537,O13012,O93511,P57781,P57782,Q62986,Q92731,Q95171,Q9IAK1,Q9PTU5,Q9PVE2,Q9TTE5,Q9TU15,Q9W6M2,Q9XSB5,Q9XSW2,Q9YH32" charOffset="181-187" type="protein" text="ERbeta"/>
            <pair e1="DS.d344.s0.e0" e2="DS.d344.s0.e1" id="DS.d344.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d345" origId="18563306">
        <sentence id="DS.d345.s0" origId="18563306-164" text="Simvastatin treatment significantly increased the number of peripheral blood CD34+ CD133+ cells, and serum concentration of vascular endothelial growth factor (VEGF) and AKT was markedly increased in vivo.">
            <entity id="DS.d345.s0.e0" origId="54454,4677798" charOffset="0-11" type="compound" text="Simvastatin"/>
            <entity id="DS.d345.s0.e1" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="160-164" type="protein" text="VEGF"/>
            <pair e1="DS.d345.s0.e0" e2="DS.d345.s0.e1" id="DS.d345.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d345.s1" origId="18563306-165" text="In cultured EPC, simvastatin increased the concentrations of VEGF, AKT and eNOS.">
            <entity id="DS.d345.s1.e0" origId="54454,4677798" charOffset="17-28" type="compound" text="simvastatin"/>
            <entity id="DS.d345.s1.e1" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="61-65" type="protein" text="VEGF"/>
            <entity id="DS.d345.s1.e2" origId="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600" charOffset="75-79" type="protein" text="eNOS"/>
            <pair e1="DS.d345.s1.e0" e2="DS.d345.s1.e1" id="DS.d345.s1.i0" interaction="True"/>
            <pair e1="DS.d345.s1.e0" e2="DS.d345.s1.e2" id="DS.d345.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d345.s2" origId="18563306-166" text="Western blots analysis showed that simvastatin increased the phosphorylation of eNOS and FKHRL1, which can be blocked by the PI3K/AKT pathway blocker LY294002.">
            <entity id="DS.d345.s2.e0" origId="54454,4677798" charOffset="35-46" type="compound" text="simvastatin"/>
            <entity id="DS.d345.s2.e1" origId="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600" charOffset="80-84" type="protein" text="eNOS"/>
            <entity id="DS.d345.s2.e2" origId="O43524" charOffset="89-95" type="protein" text="FKHRL1"/>
            <entity id="DS.d345.s2.e3" origId="3973" charOffset="150-158" type="compound" text="LY294002"/>
            <pair e1="DS.d345.s2.e3" e2="DS.d345.s2.e1" id="DS.d345.s2.i0" interaction="True"/>
            <pair e1="DS.d345.s2.e3" e2="DS.d345.s2.e2" id="DS.d345.s2.i1" interaction="True"/>
            <pair e1="DS.d345.s2.e0" e2="DS.d345.s2.e1" id="DS.d345.s2.i2" interaction="True"/>
            <pair e1="DS.d345.s2.e0" e2="DS.d345.s2.e2" id="DS.d345.s2.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d345.s3" origId="18563306-167" text="In in vitro study, simvastatin increases the phosphorylation of eNOS and of FKHRL1 through the PI3K/AKT signaling pathway.">
            <entity id="DS.d345.s3.e0" origId="54454,4677798" charOffset="19-30" type="compound" text="simvastatin"/>
            <entity id="DS.d345.s3.e1" origId="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600" charOffset="64-68" type="protein" text="eNOS"/>
            <entity id="DS.d345.s3.e2" origId="O43524" charOffset="76-82" type="protein" text="FKHRL1"/>
            <entity id="DS.d345.s3.e3" origId="O00329,O02697,O35904,P23727,P26450,P27986,P32871,P42336,P42337,P42338,P42347,P42348,P48736,P54673,P54674,P54675,P54676,Q63787,Q8BTI9,Q8UUU2,Q9JHG7,Q9Z1L0" charOffset="95-99" type="protein" text="PI3K"/>
            <pair e1="DS.d345.s3.e0" e2="DS.d345.s3.e3" id="DS.d345.s3.i0" interaction="True"/>
            <pair e1="DS.d345.s3.e0" e2="DS.d345.s3.e1" id="DS.d345.s3.i1" interaction="True"/>
            <pair e1="DS.d345.s3.e0" e2="DS.d345.s3.e2" id="DS.d345.s3.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d346" origId="18563517">
        <sentence id="DS.d346.s0" origId="18563517-342" text="Only the intracellular IL-2 response in the lower tertile of IL-2 production was improved with glutamine indicating a small influence.">
            <entity id="DS.d346.s0.e0" origId="O62641,O77620,O97513,P04351,P05016,P17108,P19114,P26891,P36835,P37997,P46649,P51747,P60568,P60569,P68290,P68291,Q07885,Q08081,Q08867,Q1WM29,Q25BC3,Q29416,Q29615,Q2PE47,Q2PE78,Q4U313,Q5MBA8,Q5PXD0,Q7JFM2,Q7JFM3,Q7JFM4,Q7JFM5,Q865X2,Q865Y1,Q8MKH2,Q95KP3,Q9XS38,Q9XT83,Q9XT84" charOffset="23-27" type="protein" text="IL-2"/>
            <entity id="DS.d346.s0.e1" origId="O62641,O77620,O97513,P04351,P05016,P17108,P19114,P26891,P36835,P37997,P46649,P51747,P60568,P60569,P68290,P68291,Q07885,Q08081,Q08867,Q1WM29,Q25BC3,Q29416,Q29615,Q2PE47,Q2PE78,Q4U313,Q5MBA8,Q5PXD0,Q7JFM2,Q7JFM3,Q7JFM4,Q7JFM5,Q865X2,Q865Y1,Q8MKH2,Q95KP3,Q9XS38,Q9XT83,Q9XT84" charOffset="61-65" type="protein" text="IL-2"/>
            <entity id="DS.d346.s0.e2" origId="738,5961" charOffset="95-104" type="compound" text="glutamine"/>
            <pair e1="DS.d346.s0.e2" e2="DS.d346.s0.e0" id="DS.d346.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d346.s1" origId="18563517-343" text="The elevation of glutamine plasma levels by a perioperative intravenous infusion of L-alanyl-L-glutamine influenced the intracellular expression of IL-2 in the lower tertile only slightly.">
            <entity id="DS.d346.s1.e0" origId="738,5961" charOffset="17-26" type="compound" text="glutamine"/>
            <entity id="DS.d346.s1.e2" origId="O62641,O77620,O97513,P04351,P05016,P17108,P19114,P26891,P36835,P37997,P46649,P51747,P60568,P60569,P68290,P68291,Q07885,Q08081,Q08867,Q1WM29,Q25BC3,Q29416,Q29615,Q2PE47,Q2PE78,Q4U313,Q5MBA8,Q5PXD0,Q7JFM2,Q7JFM3,Q7JFM4,Q7JFM5,Q865X2,Q865Y1,Q8MKH2,Q95KP3,Q9XS38,Q9XT83,Q9XT84" charOffset="148-152" type="protein" text="IL-2"/>
            <pair e1="DS.d346.s1.e0" e2="DS.d346.s1.e2" id="DS.d346.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d347" origId="18563542">
        <sentence id="DS.d347.s0" origId="18563542-358" text="Determination of bioactive matter by affinity adsorption solid substrate-room temperature phosphorimetry based on lectin labeled with self-ordered ring of eosin Y.">
            <entity id="DS.d347.s0.e0" origId="P02871,P02873,P02874,P02875,P07386,P16108,P16349,P16351,P16352,P33888,P38662,P42088,P83410,P83511,P84987,Q41114" charOffset="114-120" type="protein" text="lectin"/>
            <entity id="DS.d347.s0.e1" origId="11049,27020" charOffset="155-162" type="compound" text="eosin Y"/>
            <pair e1="DS.d347.s0.e1" e2="DS.d347.s0.e0" id="DS.d347.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d347.s1" origId="18563542-359" text="Specific affinity adsorption (AA) reactions could be carried out between the products of concanavalin agglutinin (Con A), triticum vulgaris lectin (WGA) labeled with ESOR and alpha-fetoprotein variant (AFP-V), alkaline phosphatase (ALP), glucose (G), respectively.">
            <entity id="DS.d347.s1.e0" origId="P02872,P05046,P11218,P11219,P30617,P42088,P49329,P82859,P82953" charOffset="102-112" type="protein" text="agglutinin"/>
            <entity id="DS.d347.s1.e1" origId="P02866,P14894,P81460,P81461" charOffset="114-119" type="protein" text="Con A"/>
            <entity id="DS.d347.s1.e2" origId="P02871,P02873,P02874,P02875,P07386,P16108,P16349,P16351,P16352,P33888,P38662,P42088,P83410,P83511,P84987,Q41114" charOffset="140-146" type="protein" text="lectin"/>
            <entity id="DS.d347.s1.e3" origId="O80994,O80995,P02771,P05140,P07835,P09031,P23699,P28050,P49066,P83128,P84407,Q01758,Q08617,Q12899,Q28789,Q3SZ57,Q8MJU5" charOffset="202-205" type="protein" text="AFP"/>
            <entity id="DS.d347.s1.e4" origId="O60109,P81800,P83456" charOffset="210-230" type="protein" text="alkaline phosphatase"/>
            <entity id="DS.d347.s1.e5" origId="P03973,P12547,P22298,P28296,P29118,P35211,P83610,P97430,Q03420,Q53GG5,Q9H0A0,Q9PU47,Q9Z1X0" charOffset="232-235" type="protein" text="ALP"/>
            <entity id="DS.d347.s1.e6" origId="206,5793,64689,79025" charOffset="238-245" type="compound" text="glucose"/>
            <pair e1="DS.d347.s1.e6" e2="DS.d347.s1.e0" id="DS.d347.s1.i0" interaction="False"/>
            <pair e1="DS.d347.s1.e6" e2="DS.d347.s1.e5" id="DS.d347.s1.i1" interaction="False"/>
            <pair e1="DS.d347.s1.e6" e2="DS.d347.s1.e2" id="DS.d347.s1.i2" interaction="False"/>
            <pair e1="DS.d347.s1.e6" e2="DS.d347.s1.e3" id="DS.d347.s1.i3" interaction="False"/>
            <pair e1="DS.d347.s1.e6" e2="DS.d347.s1.e4" id="DS.d347.s1.i4" interaction="False"/>
            <pair e1="DS.d347.s1.e6" e2="DS.d347.s1.e1" id="DS.d347.s1.i5" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d348" origId="18563554">
        <sentence id="DS.d348.s0" origId="18563554-369" text="In this paper we demonstrate that hedgehog signaling antagonists, including cyclopamine, and a second compound, CUR0199691, can inhibit growth of estrogen receptor (ER)-positive and ER-negative tumorigenic breast cancer cells at elevated doses.">
            <entity id="DS.d348.s0.e0" origId="442972" charOffset="76-87" type="compound" text="cyclopamine"/>
            <entity id="DS.d348.s0.e1" origId="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7" charOffset="146-163" type="protein" text="estrogen receptor"/>
            <pair e1="DS.d348.s0.e0" e2="DS.d348.s0.e1" id="DS.d348.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d349" origId="18563559">
        <sentence id="DS.d349.s0" origId="18563559-375" text="The equality of K (D) of paroxetine binding to blood platelet membranes and to membranes from nerve endings appears to encourage the use of such membranes as a model for brain SERT.">
            <entity id="DS.d349.s0.e0" origId="43815" charOffset="25-35" type="compound" text="paroxetine"/>
            <entity id="DS.d349.s0.e1" origId="P31645,Q9XT49" charOffset="176-180" type="protein" text="SERT"/>
            <pair e1="DS.d349.s0.e0" e2="DS.d349.s0.e1" id="DS.d349.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d350" origId="18563560">
        <sentence id="DS.d350.s0" origId="18563560-376" text="With supplementation of taurine in diet, lower expression of GFAP and VEGF while higher expression of GLAST, GS and GAD in retina of diabetic rats were determinated by RT-PCR 0.05).">
            <entity id="DS.d350.s0.e0" origId="1123" charOffset="24-31" type="compound" text="taurine"/>
            <entity id="DS.d350.s0.e1" origId="P03995,P14136,P47819,Q28115" charOffset="61-65" type="protein" text="GFAP"/>
            <entity id="DS.d350.s0.e2" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="70-74" type="protein" text="VEGF"/>
            <entity id="DS.d350.s0.e3" origId="P24942,P56564" charOffset="102-107" type="protein" text="GLAST"/>
            <entity id="DS.d350.s0.e4" origId="P20228,P54767,Q04792,Q07346,Q42521,Q99259,Q9CG20" charOffset="116-119" type="protein" text="GAD"/>
            <pair e1="DS.d350.s0.e0" e2="DS.d350.s0.e2" id="DS.d350.s0.i0" interaction="True"/>
            <pair e1="DS.d350.s0.e0" e2="DS.d350.s0.e1" id="DS.d350.s0.i1" interaction="True"/>
            <pair e1="DS.d350.s0.e0" e2="DS.d350.s0.e4" id="DS.d350.s0.i2" interaction="True"/>
            <pair e1="DS.d350.s0.e0" e2="DS.d350.s0.e3" id="DS.d350.s0.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d350.s1" origId="18563560-377" text="GFAP, VEGF, GLAST, GS and GAD expressions in normal controls were not altered by taurine treatment.">
            <entity id="DS.d350.s1.e0" origId="P03995,P14136,P47819,Q28115" charOffset="0-4" type="protein" text="GFAP"/>
            <entity id="DS.d350.s1.e1" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="6-10" type="protein" text="VEGF"/>
            <entity id="DS.d350.s1.e2" origId="P24942,P56564" charOffset="12-17" type="protein" text="GLAST"/>
            <entity id="DS.d350.s1.e3" origId="P20228,P54767,Q04792,Q07346,Q42521,Q99259,Q9CG20" charOffset="26-29" type="protein" text="GAD"/>
            <entity id="DS.d350.s1.e4" origId="1123" charOffset="81-88" type="compound" text="taurine"/>
            <pair e1="DS.d350.s1.e4" e2="DS.d350.s1.e0" id="DS.d350.s1.i0" interaction="False"/>
            <pair e1="DS.d350.s1.e4" e2="DS.d350.s1.e2" id="DS.d350.s1.i1" interaction="False"/>
            <pair e1="DS.d350.s1.e4" e2="DS.d350.s1.e3" id="DS.d350.s1.i2" interaction="False"/>
            <pair e1="DS.d350.s1.e4" e2="DS.d350.s1.e1" id="DS.d350.s1.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d351" origId="18563561">
        <sentence id="DS.d351.s0" origId="18563561-378" text="Malondialdehyde (MDA), glutathione (GSH), nitric oxide (NO) levels and myeloperoxidase activity (MPO) were examined in plasma, liver and brain tissues.">
            <entity id="DS.d351.s0.e0" origId="10964" charOffset="0-15" type="compound" text="Malondialdehyde"/>
            <entity id="DS.d351.s0.e1" origId="124886" charOffset="23-34" type="compound" text="glutathione"/>
            <entity id="DS.d351.s0.e2" origId="124886" charOffset="36-39" type="compound" text="GSH"/>
            <entity id="DS.d351.s0.e3" origId="145068" charOffset="42-54" type="compound" text="nitric oxide"/>
            <entity id="DS.d351.s0.e4" origId="P05164,P11247" charOffset="97-100" type="protein" text="MPO"/>
            <pair e1="DS.d351.s0.e2" e2="DS.d351.s0.e4" id="DS.d351.s0.i0" interaction="False"/>
            <pair e1="DS.d351.s0.e0" e2="DS.d351.s0.e4" id="DS.d351.s0.i1" interaction="False"/>
            <pair e1="DS.d351.s0.e3" e2="DS.d351.s0.e4" id="DS.d351.s0.i2" interaction="False"/>
            <pair e1="DS.d351.s0.e1" e2="DS.d351.s0.e4" id="DS.d351.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d352" origId="18563616">
        <sentence id="DS.d352.s0" origId="18563616-418" text="Glutathione peroxidase 1 (GPX1) is a ubiquitously expressed selenium-dependent enzyme that protects cells against oxidative damage by reducing hydrogen peroxide and a wide range of organic peroxides.">
            <entity id="DS.d352.s0.e0" origId="O23970,P00435,P04041,P07203,P11352,P11909,P36014,Q4AEI1,Q4AEI2,Q4AEI3,Q865R2,Q8MJ14" charOffset="0-24" type="protein" text="Glutathione peroxidase 1"/>
            <entity id="DS.d352.s0.e1" origId="O48646,P00435,P07203,P11909,P36014,P52032,Q00277,Q4AEI1,Q4AEI2,Q4AEI3,Q865R2,Q8MJ14" charOffset="26-30" type="protein" text="GPX1"/>
            <entity id="DS.d352.s0.e2" origId="784" charOffset="143-160" type="compound" text="hydrogen peroxide"/>
            <pair e1="DS.d352.s0.e2" e2="DS.d352.s0.e0" id="DS.d352.s0.i0" interaction="True"/>
            <pair e1="DS.d352.s0.e2" e2="DS.d352.s0.e1" id="DS.d352.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d353" origId="18563708">
        <sentence id="DS.d353.s0" origId="18563708-512" text="Nitric oxide (NO), which is produced by nitric oxide synthase (NOS), may play a role in the development of ASD.">
            <entity id="DS.d353.s0.e0" origId="145068" charOffset="0-12" type="compound" text="Nitric oxide"/>
            <entity id="DS.d353.s0.e1" origId="O61309,O61608,Q27571,Q9I9M2" charOffset="40-61" type="protein" text="nitric oxide synthase"/>
            <entity id="DS.d353.s0.e2" origId="O54705,O61309,O61608,Q26240,Q28969,Q9I9M2" charOffset="63-66" type="protein" text="NOS"/>
            <pair e1="DS.d353.s0.e0" e2="DS.d353.s0.e2" id="DS.d353.s0.i0" interaction="True"/>
            <pair e1="DS.d353.s0.e0" e2="DS.d353.s0.e1" id="DS.d353.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d354" origId="18563803">
        <sentence id="DS.d354.s0" origId="18563803-210" text="In conclusion, TAD-A has sufficient bonding strength and comparatively low toxicity in clinical use of 0.3 mmol or less of TAD and 0.8 mL of 44 w/w % HSA solution.">
            <entity id="DS.d354.s0.e0" origId="124886,128225" charOffset="15-18" type="compound" text="TAD"/>
            <entity id="DS.d354.s0.e1" origId="124886,128225" charOffset="123-126" type="compound" text="TAD"/>
            <entity id="DS.d354.s0.e2" origId="P24807,Q07490" charOffset="150-153" type="protein" text="HSA"/>
            <pair e1="DS.d354.s0.e0" e2="DS.d354.s0.e2" id="DS.d354.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d355" origId="18563826">
        <sentence id="DS.d355.s0" origId="18563826-616" text="Long intercalated defects in canine ribs can be repaired successfully using porous beta-tricalcium phosphate (beta-TCP) cylinders, infused with a biodegradable polymer (poly D,L-lactic acid-polyethylene block copolymer) containing recombinant human bone morphogenetic protein-2 (rhBMP-2).">
            <entity id="DS.d355.s0.e0" origId="24456" charOffset="83-108" type="compound" text="beta-tricalcium phosphate"/>
            <entity id="DS.d355.s0.e1" origId="P07580" charOffset="254-275" type="protein" text="morphogenetic protein"/>
            <pair e1="DS.d355.s0.e0" e2="DS.d355.s0.e1" id="DS.d355.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d356" origId="18564056">
        <sentence id="DS.d356.s0" origId="18564056-810" text="In the present study we explored the possibility of using genetic engineering to increase the artemisinin content of A. annua by suppressing the expression of SQS (squalene synthase), a key enzyme of sterol pathway (a pathway competitive with that of artemisinin biosynthesis) by means of a hairpin-RNA-mediated RNAi (RNA interference) technique.">
            <entity id="DS.d356.s0.e0" origId="2240,68827,452191,641602,5458876,9838675,11836791,23757058,44266427,49796325" charOffset="94-105" type="compound" text="artemisinin"/>
            <entity id="DS.d356.s0.e1" origId="O74165,P29704,P36596,P37268,P53798,P53799,P53800,P78589,Q02769,Q752X9,Q7S4Z6,Q92459,Q9HGZ6,Q9Y753" charOffset="159-162" type="protein" text="SQS"/>
            <entity id="DS.d356.s0.e2" origId="2240,68827,452191,641602,5458876,9838675,11836791,23757058,44266427,49796325" charOffset="251-262" type="compound" text="artemisinin"/>
            <pair e1="DS.d356.s0.e0" e2="DS.d356.s0.e1" id="DS.d356.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d357" origId="18564176">
        <sentence id="DS.d357.s0" origId="18564176-915" text="Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-kappaB activation through a phosphoinoside 3-kinase-Akt-dependent pathway.">
            <entity id="DS.d357.s0.e0" origId="3476" charOffset="0-11" type="compound" text="Glimepiride"/>
            <entity id="DS.d357.s0.e1" origId="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600" charOffset="24-28" type="protein" text="eNOS"/>
            <pair e1="DS.d357.s0.e0" e2="DS.d357.s0.e1" id="DS.d357.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d358" origId="18564211">
        <sentence id="DS.d358.s0" origId="18564211-943" text="It has been reported that tamoxifen may affect hepatoma cell growth in vitro by suppressing transforming growth factor beta-1 (TGF-beta1) expression, suggesting that tamoxifen might also retard fibrogenesis.">
            <entity id="DS.d358.s0.e0" origId="2733526" charOffset="26-35" type="compound" text="tamoxifen"/>
            <entity id="DS.d358.s0.e1" origId="O19011,O93449,P01137,P04202,P07200,P09531,P09533,P16176,P17246,P18341,P50414,P54831,Q38HS2,Q9PTQ2,Q9Z1Y6" charOffset="127-136" type="protein" text="TGF-beta1"/>
            <entity id="DS.d358.s0.e2" origId="2733526" charOffset="166-175" type="compound" text="tamoxifen"/>
            <pair e1="DS.d358.s0.e0" e2="DS.d358.s0.e1" id="DS.d358.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d358.s1" origId="18564211-944" text="Thus, we examined whether tamoxifen might suppress TGF-beta1 expression and consequently inhibit the process of hepatic fibrosis in vivo.">
            <entity id="DS.d358.s1.e0" origId="2733526" charOffset="26-35" type="compound" text="tamoxifen"/>
            <entity id="DS.d358.s1.e1" origId="O19011,O93449,P01137,P04202,P07200,P09531,P09533,P16176,P17246,P18341,P50414,P54831,Q38HS2,Q9PTQ2,Q9Z1Y6" charOffset="51-60" type="protein" text="TGF-beta1"/>
            <pair e1="DS.d358.s1.e0" e2="DS.d358.s1.e1" id="DS.d358.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d359" origId="18564281">
        <sentence id="DS.d359.s0" origId="18564281-1010" text="We also explored the effect of substance P released by capsaicin because this neuropeptide is known to affect the microvasculature environment.">
            <entity id="DS.d359.s0.e0" origId="P01289,P06767,P19850,P20366,P28498,P28499,P41333,P41539,P41540,P67932,P67933,Q60541" charOffset="31-42" type="protein" text="substance P"/>
            <entity id="DS.d359.s0.e1" origId="1548943" charOffset="55-64" type="compound" text="capsaicin"/>
            <entity id="DS.d359.s0.e2" origId="P21259" charOffset="78-90" type="protein" text="neuropeptide"/>
            <pair e1="DS.d359.s0.e1" e2="DS.d359.s0.e0" id="DS.d359.s0.i0" interaction="False"/>
            <pair e1="DS.d359.s0.e1" e2="DS.d359.s0.e2" id="DS.d359.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d360" origId="18565553">
        <sentence id="DS.d360.s0" origId="18565553-422" text="Leukotriene C4 release and gene expressions of IL-8 and MCP-1 in porcine alveolar epithelial type II cells.">
            <entity id="DS.d360.s0.e0" origId="3907,5280493,5283121,5353716" charOffset="0-14" type="compound" text="Leukotriene C4"/>
            <entity id="DS.d360.s0.e1" origId="O62812,P08317,P10145,P19874,P26894,P36925,P41324,P46653,P49113,P67813,P67814,P79255,Q102R3,Q7YRB5,Q9XSX5" charOffset="47-51" type="protein" text="IL-8"/>
            <entity id="DS.d360.s0.e2" origId="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3" charOffset="56-61" type="protein" text="MCP-1"/>
            <pair e1="DS.d360.s0.e0" e2="DS.d360.s0.e1" id="DS.d360.s0.i0" interaction="False"/>
            <pair e1="DS.d360.s0.e0" e2="DS.d360.s0.e2" id="DS.d360.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d360.s1" origId="18565553-424" text="These findings suggest that AEC IIs play an important role in initial inflammatory reactions of the lung by releasing LTC4, and that they also modulate later inflammatory reactions, evidenced by consistent elevation of MCP-1 gene expression after and during exogenous challenge in pigs.">
            <entity id="DS.d360.s1.e0" origId="5280493" charOffset="118-122" type="compound" text="LTC4"/>
            <entity id="DS.d360.s1.e1" origId="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3" charOffset="219-224" type="protein" text="MCP-1"/>
            <pair e1="DS.d360.s1.e0" e2="DS.d360.s1.e1" id="DS.d360.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d361" origId="18565581">
        <sentence id="DS.d361.s0" origId="18565581-347" text="Whereas their toxicity is due to acetylcholinesterase inhibition, their secondary toxic effects have been related to free oxygen radicals.">
            <entity id="DS.d361.s0.e0" origId="Q867X2,Q867X3,Q86GC9,Q92081" charOffset="33-53" type="protein" text="acetylcholinesterase"/>
            <entity id="DS.d361.s0.e1" origId="977" charOffset="122-128" type="compound" text="oxygen"/>
            <pair e1="DS.d361.s0.e1" e2="DS.d361.s0.e0" id="DS.d361.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d361.s1" origId="18565581-348" text="Diazinon diminished the plasma acetylcholinesterase activity on day 1 post-treatment, although testosterone levels remained unaffected.">
            <entity id="DS.d361.s1.e0" origId="3017" charOffset="0-8" type="compound" text="Diazinon"/>
            <entity id="DS.d361.s1.e1" origId="Q867X2,Q867X3,Q86GC9,Q92081" charOffset="31-51" type="protein" text="acetylcholinesterase"/>
            <entity id="DS.d361.s1.e2" origId="6013" charOffset="95-107" type="compound" text="testosterone"/>
            <pair e1="DS.d361.s1.e0" e2="DS.d361.s1.e1" id="DS.d361.s1.i0" interaction="True"/>
            <pair e1="DS.d361.s1.e2" e2="DS.d361.s1.e1" id="DS.d361.s1.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d361.s2" origId="18565581-349" text="Melatonin pretreatment prevented every alteration induced by diazinon, except the diminution of acetylcholinesterase plasmatic activity.">
            <entity id="DS.d361.s2.e0" origId="896" charOffset="0-9" type="compound" text="Melatonin"/>
            <entity id="DS.d361.s2.e1" origId="3017" charOffset="61-69" type="compound" text="diazinon"/>
            <entity id="DS.d361.s2.e2" origId="Q867X2,Q867X3,Q86GC9,Q92081" charOffset="96-116" type="protein" text="acetylcholinesterase"/>
            <pair e1="DS.d361.s2.e1" e2="DS.d361.s2.e2" id="DS.d361.s2.i0" interaction="True"/>
            <pair e1="DS.d361.s2.e0" e2="DS.d361.s2.e2" id="DS.d361.s2.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d362" origId="18566887">
        <sentence id="DS.d362.s0" origId="18566887-1426" text="Sialic acid-specific O-acetyltransferases and O-acetylesterases are responsible for the metabolism of esterified sialic acids.">
            <entity id="DS.d362.s0.e0" origId="P16966" charOffset="23-41" type="protein" text="acetyltransferases"/>
            <entity id="DS.d362.s0.e1" origId="P23553,P23872,Q325C0,Q3Z4S3,Q57S73,Q5PFJ2,Q83M39,Q8FK82,Q8XD38,Q8Z8T1,Q8ZRA1" charOffset="48-63" type="protein" text="acetylesterases"/>
            <entity id="DS.d362.s0.e2" origId="349960" charOffset="113-125" type="compound" text="sialic acids"/>
            <pair e1="DS.d362.s0.e2" e2="DS.d362.s0.e0" id="DS.d362.s0.i0" interaction="True"/>
            <pair e1="DS.d362.s0.e2" e2="DS.d362.s0.e1" id="DS.d362.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d363" origId="18567517">
        <sentence id="DS.d363.s0" origId="18567517-267" text="Endomorphin-2 vector injection also reduced spontaneous pain-related behaviors in the delayed phase of the formalin test and in both CFA and formalin models suppressed spinal c-fos expression.">
            <entity id="DS.d363.s0.e0" origId="5311081" charOffset="0-13" type="compound" text="Endomorphin-2"/>
            <entity id="DS.d363.s0.e1" origId="O04350,O75347,P48427,P48428,P48606,P80584,P80585,Q9Y703" charOffset="133-136" type="protein" text="CFA"/>
            <entity id="DS.d363.s0.e2" origId="P01101,P12841,Q56415" charOffset="177-180" type="protein" text="fos"/>
            <pair e1="DS.d363.s0.e0" e2="DS.d363.s0.e2" id="DS.d363.s0.i0" interaction="True"/>
            <pair e1="DS.d363.s0.e0" e2="DS.d363.s0.e1" id="DS.d363.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d364" origId="18568363">
        <sentence id="DS.d364.s0" origId="18568363-1000" text="Furthermore, 8-bromo-cGMP and peroxynitrite failed to reproduce the inhibitory effect of NO, indicating that NO acts directly on TonEBP rather than through classical NO signaling pathways.">
            <entity id="DS.d364.s0.e0" origId="104767" charOffset="13-25" type="compound" text="8-bromo-cGMP"/>
            <entity id="DS.d364.s0.e1" origId="104806" charOffset="30-43" type="compound" text="peroxynitrite"/>
            <entity id="DS.d364.s0.e2" origId="O94916" charOffset="129-135" type="protein" text="TonEBP"/>
            <pair e1="DS.d364.s0.e1" e2="DS.d364.s0.e2" id="DS.d364.s0.i0" interaction="False"/>
            <pair e1="DS.d364.s0.e0" e2="DS.d364.s0.e2" id="DS.d364.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d364.s1" origId="18568363-998" text="Nitric oxide decreases expression of osmoprotective genes via direct inhibition of TonEBP transcriptional activity.">
            <entity id="DS.d364.s1.e0" origId="145068" charOffset="0-12" type="compound" text="Nitric oxide"/>
            <entity id="DS.d364.s1.e1" origId="O94916" charOffset="83-89" type="protein" text="TonEBP"/>
            <pair e1="DS.d364.s1.e0" e2="DS.d364.s1.e1" id="DS.d364.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d364.s2" origId="18568363-999" text="Because nitric oxide (NO) is abundantly produced in the renal medulla, the present studies addressed the effect of NO on expression of osmoprotective genes and TonEBP activation in MDCK cells.">
            <entity id="DS.d364.s2.e0" origId="145068" charOffset="8-20" type="compound" text="nitric oxide"/>
            <entity id="DS.d364.s2.e1" origId="O94916" charOffset="160-166" type="protein" text="TonEBP"/>
            <pair e1="DS.d364.s2.e0" e2="DS.d364.s2.e1" id="DS.d364.s2.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d365" origId="18568422">
        <sentence id="DS.d365.s0" origId="18568422-1042" text="Ran GTPase guanine nucleotide exchange factor RCC1 is phosphorylated on serine 11 by cdc2 kinase in vitro.">
            <entity id="DS.d365.s0.e0" origId="P18754,P23800,P52499" charOffset="46-50" type="protein" text="RCC1"/>
            <entity id="DS.d365.s0.e1" origId="5951" charOffset="72-78" type="compound" text="serine"/>
            <entity id="DS.d365.s0.e2" origId="P04551,P11440,P23572,P39951" charOffset="85-89" type="protein" text="cdc2"/>
            <pair e1="DS.d365.s0.e1" e2="DS.d365.s0.e0" id="DS.d365.s0.i0" interaction="False"/>
            <pair e1="DS.d365.s0.e1" e2="DS.d365.s0.e2" id="DS.d365.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d365.s1" origId="18568422-1043" text="An RCC1 mutant in which all N-terminal serine and threonine residues were substituted with glutamate residues to mimic phosphorylation at these residues showed decreased binding to the karyopherin, KPNA4, compared with wild type RCC1.">
            <entity id="DS.d365.s1.e0" origId="5951" charOffset="39-45" type="compound" text="serine"/>
            <entity id="DS.d365.s1.e1" origId="6288" charOffset="50-59" type="compound" text="threonine"/>
            <entity id="DS.d365.s1.e2" origId="611,23327,33032" charOffset="91-100" type="compound" text="glutamate"/>
            <entity id="DS.d365.s1.e3" origId="O00629" charOffset="198-203" type="protein" text="KPNA4"/>
            <pair e1="DS.d365.s1.e1" e2="DS.d365.s1.e3" id="DS.d365.s1.i0" interaction="False"/>
            <pair e1="DS.d365.s1.e0" e2="DS.d365.s1.e3" id="DS.d365.s1.i1" interaction="False"/>
            <pair e1="DS.d365.s1.e2" e2="DS.d365.s1.e3" id="DS.d365.s1.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d366" origId="18568426">
        <sentence id="DS.d366.s0" origId="18568426-1046" text="ATP, acting on P2X (7) receptors, stimulates changes in intracellular calcium concentrations, maturation, and release of interleukin-1beta (IL-1beta), and following prolonged agonist exposure, cell death.">
            <entity id="DS.d366.s0.e0" origId="5957" charOffset="0-3" type="compound" text="ATP"/>
            <entity id="DS.d366.s0.e1" origId="P13900,P16604" charOffset="15-18" type="protein" text="P2X"/>
            <entity id="DS.d366.s0.e2" origId="P01584,P09428,P10749,P14628,P21621,P26889,P41687,P46648,P48090,P51493,P51745,P79162,P79182,Q28292,Q28386,Q2HZH0,Q2MH07,Q63264,Q6PUD2,Q6R2X3,Q865X8,Q8WNR2,Q9WVG1,Q9XS77" charOffset="140-148" type="protein" text="IL-1beta"/>
            <pair e1="DS.d366.s0.e0" e2="DS.d366.s0.e2" id="DS.d366.s0.i0" interaction="True"/>
            <pair e1="DS.d366.s0.e0" e2="DS.d366.s0.e1" id="DS.d366.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d368" origId="18570315">
        <sentence id="DS.d368.s0" origId="18570315-909" text="While the total insulin released during a 1 h glucose stimulation period was the same from islets in each sample, increasing hydrogel crosslinking density contributed to delays in insulin release from hydrogel samples within the 1 h stimulation period.">
            <entity id="DS.d368.s0.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="16-23" type="protein" text="insulin"/>
            <entity id="DS.d368.s0.e1" origId="206,5793,64689,79025" charOffset="46-53" type="compound" text="glucose"/>
            <entity id="DS.d368.s0.e2" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="180-187" type="protein" text="insulin"/>
            <pair e1="DS.d368.s0.e1" e2="DS.d368.s0.e0" id="DS.d368.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d369" origId="18570630">
        <sentence id="DS.d369.s0" origId="18570630-1172" text="Ischaemia and insulin, but not ischaemia and contraction, act synergistically in stimulating muscle glucose uptake in vivo in humans.">
            <entity id="DS.d369.s0.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="14-21" type="protein" text="insulin"/>
            <entity id="DS.d369.s0.e1" origId="206,5793,64689,79025" charOffset="100-107" type="compound" text="glucose"/>
            <pair e1="DS.d369.s0.e1" e2="DS.d369.s0.e0" id="DS.d369.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d369.s1" origId="18570630-1173" text="In summary, ischaemia and insulin independently stimulate skeletal muscle glucose uptake in vivo in humans, whereas ischaemia and contraction do not.">
            <entity id="DS.d369.s1.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="26-33" type="protein" text="insulin"/>
            <entity id="DS.d369.s1.e1" origId="206,5793,64689,79025" charOffset="74-81" type="compound" text="glucose"/>
            <pair e1="DS.d369.s1.e1" e2="DS.d369.s1.e0" id="DS.d369.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d370" origId="18570631">
        <sentence id="DS.d370.s0" origId="18570631-224" text="A comparison of the inhibitory effect of paraoxon on soluble and immobilized AChE showed that immobilization increased the linearity of the inhibition plot particularly in the range 0.1 nM-0.1 microM.">
            <entity id="DS.d370.s0.e0" origId="9395" charOffset="41-49" type="compound" text="paraoxon"/>
            <entity id="DS.d370.s0.e1" origId="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3" charOffset="77-81" type="protein" text="AChE"/>
            <pair e1="DS.d370.s0.e0" e2="DS.d370.s0.e1" id="DS.d370.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d371" origId="18570695">
        <sentence id="DS.d371.s0" origId="18570695-1236" text="7,12-Dimethyl-benz(a) anthracene (DMBA) can induce expressions of CYP1A1 and CYP1B1 which are known to be responsive to PAH.">
            <entity id="DS.d371.s0.e1" origId="6001" charOffset="34-38" type="compound" text="DMBA"/>
            <entity id="DS.d371.s0.e2" origId="O42231,O42430,O42457,P00185,P04798,P05176,P33616,P56590,P56591,P79716,P98181,Q00557,Q06367,Q3LFU0,Q5KQT7,Q6GUR1,Q6JZS3,Q92039,Q92095,Q92100,Q92109,Q92110,Q92116,Q92148,Q9W683,Q9YH64" charOffset="66-72" type="protein" text="CYP1A1"/>
            <entity id="DS.d371.s0.e3" origId="Q16678" charOffset="77-83" type="protein" text="CYP1B1"/>
            <pair e1="DS.d371.s0.e1" e2="DS.d371.s0.e3" id="DS.d371.s0.i0" interaction="True"/>
            <pair e1="DS.d371.s0.e1" e2="DS.d371.s0.e2" id="DS.d371.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d372" origId="18571801">
        <sentence id="DS.d372.s0" origId="18571801-413" text="Extracellular lipase LIP prepared in our lab from the yeast Yarrowia lipolytica was used for the resolution of racemic ibuprofen.">
            <entity id="DS.d372.s0.e0" origId="Q7M4U7" charOffset="14-20" type="protein" text="lipase"/>
            <entity id="DS.d372.s0.e1" origId="O59952,P21764,P49081,Q06383,Q96Q15" charOffset="21-24" type="protein" text="LIP"/>
            <entity id="DS.d372.s0.e2" origId="3672,39912" charOffset="119-128" type="compound" text="ibuprofen"/>
            <pair e1="DS.d372.s0.e2" e2="DS.d372.s0.e1" id="DS.d372.s0.i0" interaction="True"/>
            <pair e1="DS.d372.s0.e2" e2="DS.d372.s0.e0" id="DS.d372.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d372.s1" origId="18571801-414" text="The high purity (S)-ibuprofen (ee = 0.98) was obtained using lipase LIP to catalyze hydrolysis of (S)-ester in 0.1 M phosphate buffer (pH = 8).">
            <entity id="DS.d372.s1.e0" origId="39912" charOffset="17-29" type="compound" text="S)-ibuprofen"/>
            <entity id="DS.d372.s1.e1" origId="Q7M4U7" charOffset="61-67" type="protein" text="lipase"/>
            <entity id="DS.d372.s1.e2" origId="O59952,P21764,P49081,Q06383,Q96Q15" charOffset="68-71" type="protein" text="LIP"/>
            <entity id="DS.d372.s1.e3" origId="1061,167704,644102" charOffset="117-126" type="compound" text="phosphate"/>
            <pair e1="DS.d372.s1.e0" e2="DS.d372.s1.e2" id="DS.d372.s1.i0" interaction="True"/>
            <pair e1="DS.d372.s1.e3" e2="DS.d372.s1.e2" id="DS.d372.s1.i1" interaction="False"/>
            <pair e1="DS.d372.s1.e0" e2="DS.d372.s1.e1" id="DS.d372.s1.i2" interaction="True"/>
            <pair e1="DS.d372.s1.e3" e2="DS.d372.s1.e1" id="DS.d372.s1.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d373" origId="18571950">
        <sentence id="DS.d373.s0" origId="18571950-552" text="The potential action of galactose as a &quot;chemical chaperone&quot;: increase of beta galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient.">
            <entity id="DS.d373.s0.e0" origId="6036,439353,439357" charOffset="24-33" type="compound" text="galactose"/>
            <entity id="DS.d373.s0.e1" origId="O33815,O52629,O52847,P00722,P00723,P06219,P0C1Y0,P14288,P22498,P23989,P24131,P26257,P30812,P50388,P70753,P77989,P81650,Q1G9Z4,Q47077,Q48727,Q56307,Q59140,Q59750,Q9K9C6" charOffset="73-91" type="protein" text="beta galactosidase"/>
            <pair e1="DS.d373.s0.e0" e2="DS.d373.s0.e1" id="DS.d373.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d374" origId="18571954">
        <sentence id="DS.d374.s0" origId="18571954-554" text="Citric acid perfusion marginally increased NGF levels to 7.3 fg/microg/ml on average in the upper arm and control axilla.">
            <entity id="DS.d374.s0.e0" origId="311" charOffset="0-11" type="compound" text="Citric acid"/>
            <entity id="DS.d374.s0.e1" origId="P21617,P34129,Q6YBR5,Q90W38" charOffset="43-46" type="protein" text="NGF"/>
            <pair e1="DS.d374.s0.e0" e2="DS.d374.s0.e1" id="DS.d374.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d374.s1" origId="18571954-555" text="In contrast, perfusion of the inflamed axilla with citric acid significantly enhanced the release of both NGF and BDNF.">
            <entity id="DS.d374.s1.e0" origId="311" charOffset="51-62" type="compound" text="citric acid"/>
            <entity id="DS.d374.s1.e1" origId="P21617,P34129,Q6YBR5,Q90W38" charOffset="106-109" type="protein" text="NGF"/>
            <entity id="DS.d374.s1.e2" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="114-118" type="protein" text="BDNF"/>
            <pair e1="DS.d374.s1.e0" e2="DS.d374.s1.e1" id="DS.d374.s1.i0" interaction="True"/>
            <pair e1="DS.d374.s1.e0" e2="DS.d374.s1.e2" id="DS.d374.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d375" origId="18572174">
        <sentence id="DS.d375.s0" origId="18572174-747" text="Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells.">
            <entity id="DS.d375.s0.e0" origId="5282452" charOffset="0-12" type="compound" text="Pitavastatin"/>
            <entity id="DS.d375.s0.e1" origId="P27169,P27170" charOffset="21-25" type="protein" text="PON1"/>
            <entity id="DS.d375.s0.e2" origId="P16342,P19751,Q66198,Q8TCB0,Q8V439,Q8V6W7,Q91A29,Q93V93,Q9PYA3" charOffset="45-48" type="protein" text="p44"/>
            <entity id="DS.d375.s0.e3" origId="P00513,P25848" charOffset="70-84" type="protein" text="protein kinase"/>
            <pair e1="DS.d375.s0.e0" e2="DS.d375.s0.e3" id="DS.d375.s0.i0" interaction="True"/>
            <pair e1="DS.d375.s0.e0" e2="DS.d375.s0.e2" id="DS.d375.s0.i1" interaction="True"/>
            <pair e1="DS.d375.s0.e0" e2="DS.d375.s0.e1" id="DS.d375.s0.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d375.s1" origId="18572174-748" text="Both PON1 gene promoter activity and PON1 protein expression were elevated by pitavastatin stimulation.">
            <entity id="DS.d375.s1.e0" origId="P27169,P27170" charOffset="5-9" type="protein" text="PON1"/>
            <entity id="DS.d375.s1.e1" origId="P27169,P27170" charOffset="37-41" type="protein" text="PON1"/>
            <entity id="DS.d375.s1.e2" origId="5282452" charOffset="78-90" type="compound" text="pitavastatin"/>
            <pair e1="DS.d375.s1.e2" e2="DS.d375.s1.e0" id="DS.d375.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d375.s2" origId="18572174-749" text="Pitavastatin phosphorylated p44/42 MAP kinase.">
            <entity id="DS.d375.s2.e0" origId="5282452" charOffset="0-12" type="compound" text="Pitavastatin"/>
            <entity id="DS.d375.s2.e1" origId="P16342,P19751,Q66198,Q8TCB0,Q8V439,Q8V6W7,Q91A29,Q93V93,Q9PYA3" charOffset="28-31" type="protein" text="p44"/>
            <pair e1="DS.d375.s2.e0" e2="DS.d375.s2.e1" id="DS.d375.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d375.s3" origId="18572174-751" text="Pitavastatin increased the Sp1-PON1 DNA complex and this effect was attenuated by PD98059.">
            <entity id="DS.d375.s3.e0" origId="5282452" charOffset="0-12" type="compound" text="Pitavastatin"/>
            <entity id="DS.d375.s3.e1" origId="O14300,O89090,P17379,Q01714,Q85439,Q85449,Q85451" charOffset="27-30" type="protein" text="Sp1"/>
            <entity id="DS.d375.s3.e2" origId="P27169,P27170" charOffset="31-35" type="protein" text="PON1"/>
            <entity id="DS.d375.s3.e3" origId="4713" charOffset="82-89" type="compound" text="PD98059"/>
            <pair e1="DS.d375.s3.e0" e2="DS.d375.s3.e1" id="DS.d375.s3.i0" interaction="True"/>
            <pair e1="DS.d375.s3.e3" e2="DS.d375.s3.e2" id="DS.d375.s3.i1" interaction="True"/>
            <pair e1="DS.d375.s3.e3" e2="DS.d375.s3.e1" id="DS.d375.s3.i2" interaction="True"/>
            <pair e1="DS.d375.s3.e0" e2="DS.d375.s3.e2" id="DS.d375.s3.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d375.s4" origId="18572174-752" text="These observations suggest that pitavastatin phosphorylates p44/42 MAP kinase and then activates the transcription of PON1 gene and increases the PON1 protein expression in Huh7 cells.">
            <entity id="DS.d375.s4.e0" origId="5282452" charOffset="32-44" type="compound" text="pitavastatin"/>
            <entity id="DS.d375.s4.e1" origId="P16342,P19751,Q66198,Q8TCB0,Q8V439,Q8V6W7,Q91A29,Q93V93,Q9PYA3" charOffset="60-63" type="protein" text="p44"/>
            <entity id="DS.d375.s4.e2" origId="P27169,P27170" charOffset="118-122" type="protein" text="PON1"/>
            <entity id="DS.d375.s4.e3" origId="P27169,P27170" charOffset="146-150" type="protein" text="PON1"/>
            <pair e1="DS.d375.s4.e0" e2="DS.d375.s4.e1" id="DS.d375.s4.i0" interaction="True"/>
            <pair e1="DS.d375.s4.e0" e2="DS.d375.s4.e2" id="DS.d375.s4.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d375.s5" origId="18572174-753" text="Furthermore, we speculate that pitavastatin affects both the phosphorylation of SREBP-2 and the Sp1 binding to PON1 DNA through the activation of p44/42 MAP kinase signaling cascade.">
            <entity id="DS.d375.s5.e0" origId="5282452" charOffset="31-43" type="compound" text="pitavastatin"/>
            <entity id="DS.d375.s5.e1" origId="Q12772,Q60429" charOffset="80-87" type="protein" text="SREBP-2"/>
            <entity id="DS.d375.s5.e2" origId="O14300,O89090,P17379,Q01714,Q85439,Q85449,Q85451" charOffset="96-99" type="protein" text="Sp1"/>
            <entity id="DS.d375.s5.e3" origId="P27169,P27170" charOffset="111-115" type="protein" text="PON1"/>
            <entity id="DS.d375.s5.e4" origId="P16342,P19751,Q66198,Q8TCB0,Q8V439,Q8V6W7,Q91A29,Q93V93,Q9PYA3" charOffset="146-149" type="protein" text="p44"/>
            <pair e1="DS.d375.s5.e0" e2="DS.d375.s5.e4" id="DS.d375.s5.i0" interaction="True"/>
            <pair e1="DS.d375.s5.e0" e2="DS.d375.s5.e1" id="DS.d375.s5.i1" interaction="False"/>
            <pair e1="DS.d375.s5.e0" e2="DS.d375.s5.e2" id="DS.d375.s5.i2" interaction="True"/>
            <pair e1="DS.d375.s5.e0" e2="DS.d375.s5.e3" id="DS.d375.s5.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d376" origId="18573668">
        <sentence id="DS.d376.s0" origId="18573668-277" text="Inhibition of cyclooxygenase 2 expression by diallyl sulfide on joint inflammation induced by urate crystal and IL-1beta.">
            <entity id="DS.d376.s0.e0" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="14-30" type="protein" text="cyclooxygenase 2"/>
            <entity id="DS.d376.s0.e1" origId="11617" charOffset="45-60" type="compound" text="diallyl sulfide"/>
            <entity id="DS.d376.s0.e2" origId="P01584,P09428,P10749,P14628,P21621,P26889,P41687,P46648,P48090,P51493,P51745,P79162,P79182,Q28292,Q28386,Q2HZH0,Q2MH07,Q63264,Q6PUD2,Q6R2X3,Q865X8,Q8WNR2,Q9WVG1,Q9XS77" charOffset="112-120" type="protein" text="IL-1beta"/>
            <pair e1="DS.d376.s0.e1" e2="DS.d376.s0.e2" id="DS.d376.s0.i0" interaction="False"/>
            <pair e1="DS.d376.s0.e1" e2="DS.d376.s0.e0" id="DS.d376.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d376.s1" origId="18573668-278" text="Investigation of the effects of diallyl sulfide (DAS), a garlic sulfur compound, on joint tissue inflammatory responses induced by monosodium urate (MSU) crystals and interleukin-1beta (IL-1beta).">
            <entity id="DS.d376.s1.e0" origId="11617" charOffset="32-47" type="compound" text="diallyl sulfide"/>
            <entity id="DS.d376.s1.e2" origId="1175" charOffset="131-147" type="compound" text="monosodium urate"/>
            <entity id="DS.d376.s1.e3" origId="P01584,P09428,P10749,P14628,P21621,P26889,P41687,P46648,P48090,P51493,P51745,P79162,P79182,Q28292,Q28386,Q2HZH0,Q2MH07,Q63264,Q6PUD2,Q6R2X3,Q865X8,Q8WNR2,Q9WVG1,Q9XS77" charOffset="186-194" type="protein" text="IL-1beta"/>
            <pair e1="DS.d376.s1.e0" e2="DS.d376.s1.e3" id="DS.d376.s1.i1" interaction="False"/>
            <pair e1="DS.d376.s1.e2" e2="DS.d376.s1.e3" id="DS.d376.s1.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d377" origId="18574025">
        <sentence id="DS.d377.s0" origId="18574025-577" text="Genetic variants of cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) are known to influence warfarin dose, but the effect of other genes has not been fully elucidated.">
            <entity id="DS.d377.s0.e0" origId="P11712" charOffset="20-39" type="protein" text="cytochrome P450 2C9"/>
            <entity id="DS.d377.s0.e1" origId="P11712" charOffset="41-47" type="protein" text="CYP2C9"/>
            <entity id="DS.d377.s0.e2" origId="Q6B4J2,Q9BQB6" charOffset="82-88" type="protein" text="VKORC1"/>
            <entity id="DS.d377.s0.e3" origId="54678486" charOffset="113-121" type="compound" text="warfarin"/>
            <pair e1="DS.d377.s0.e3" e2="DS.d377.s0.e0" id="DS.d377.s0.i0" interaction="True"/>
            <pair e1="DS.d377.s0.e3" e2="DS.d377.s0.e2" id="DS.d377.s0.i1" interaction="True"/>
            <pair e1="DS.d377.s0.e3" e2="DS.d377.s0.e1" id="DS.d377.s0.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d377.s1" origId="18574025-578" text="In conclusion, CYP2C9 and VKORC1 significantly influenced warfarin dose and predicted individuals predisposed to unstable anticoagulation.">
            <entity id="DS.d377.s1.e0" origId="P11712" charOffset="15-21" type="protein" text="CYP2C9"/>
            <entity id="DS.d377.s1.e1" origId="Q6B4J2,Q9BQB6" charOffset="26-32" type="protein" text="VKORC1"/>
            <entity id="DS.d377.s1.e2" origId="54678486" charOffset="58-66" type="compound" text="warfarin"/>
            <pair e1="DS.d377.s1.e2" e2="DS.d377.s1.e1" id="DS.d377.s1.i0" interaction="True"/>
            <pair e1="DS.d377.s1.e2" e2="DS.d377.s1.e0" id="DS.d377.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d378" origId="18574490">
        <sentence id="DS.d378.s0" origId="18574490-986" text="BMI and testosterone levels were evaluated for their ability to predict overall survival (OS) and prostate-specific antigen (PSA) declines in the TAX327 clinical trial, an international phase III randomized trial of one of the two schedules of docetaxel and prednisone compared with mitoxantrone and prednisone.">
            <entity id="DS.d378.s0.e0" origId="6013" charOffset="8-20" type="compound" text="testosterone"/>
            <entity id="DS.d378.s0.e1" origId="P07288,P10658,P33619,P55786,Q11011,Q6DT45,Q9Y617" charOffset="125-128" type="protein" text="PSA"/>
            <entity id="DS.d378.s0.e2" origId="148124" charOffset="244-253" type="compound" text="docetaxel"/>
            <entity id="DS.d378.s0.e3" origId="5865" charOffset="258-268" type="compound" text="prednisone"/>
            <entity id="DS.d378.s0.e4" origId="4212" charOffset="283-295" type="compound" text="mitoxantrone"/>
            <entity id="DS.d378.s0.e5" origId="5865" charOffset="300-310" type="compound" text="prednisone"/>
            <pair e1="DS.d378.s0.e2" e2="DS.d378.s0.e1" id="DS.d378.s0.i0" interaction="False"/>
            <pair e1="DS.d378.s0.e0" e2="DS.d378.s0.e1" id="DS.d378.s0.i1" interaction="False"/>
            <pair e1="DS.d378.s0.e4" e2="DS.d378.s0.e1" id="DS.d378.s0.i2" interaction="False"/>
            <pair e1="DS.d378.s0.e3" e2="DS.d378.s0.e1" id="DS.d378.s0.i3" interaction="False"/>
        </sentence>
        <sentence id="DS.d378.s1" origId="18574490-987" text="In multivariate analysis, neither BMI, presence of obesity, nor baseline testosterone was significantly associated with OS or PSA declines.">
            <entity id="DS.d378.s1.e0" origId="6013" charOffset="73-85" type="compound" text="testosterone"/>
            <entity id="DS.d378.s1.e1" origId="P07288,P10658,P33619,P55786,Q11011,Q6DT45,Q9Y617" charOffset="126-129" type="protein" text="PSA"/>
            <pair e1="DS.d378.s1.e0" e2="DS.d378.s1.e1" id="DS.d378.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d379" origId="18574670">
        <sentence id="DS.d379.s0" origId="18574670-1109" text="The interaction between PAF and the platelet agonists ADP, thrombin and convulxin was analyzed in vitro in whole blood with the use of flow cytometry and was further characterized with the use of receptor antagonists to PAF (ABT-491), P2Y1 (MRS-2179), and P2Y12 (cangrelor) as well as a monoclonal anti-PSGL-1 antibody (anti-CD162).">
            <entity id="DS.d379.s0.e0" origId="P84122" charOffset="59-67" type="protein" text="thrombin"/>
            <entity id="DS.d379.s0.e1" origId="5311303" charOffset="241-249" type="compound" text="MRS-2179"/>
            <entity id="DS.d379.s0.e2" origId="9854012" charOffset="263-272" type="compound" text="cangrelor"/>
            <pair e1="DS.d379.s0.e2" e2="DS.d379.s0.e0" id="DS.d379.s0.i0" interaction="False"/>
            <pair e1="DS.d379.s0.e1" e2="DS.d379.s0.e0" id="DS.d379.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d380" origId="18575957">
        <sentence id="DS.d380.s0" origId="18575957-472" text="Aim The present study sought insight into the effects of remifentanyl and fentanyl on LPS-induced release of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and IL-10 in human whole blood.">
            <entity id="DS.d380.s0.e0" origId="60815" charOffset="57-69" type="compound" text="remifentanyl"/>
            <entity id="DS.d380.s0.e2" origId="P41693" charOffset="109-122" type="protein" text="interleukin-6"/>
            <entity id="DS.d380.s0.e3" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="124-128" type="protein" text="IL-6"/>
            <entity id="DS.d380.s0.e4" origId="Q8JFG3" charOffset="131-152" type="protein" text="tumor necrosis factor"/>
            <entity id="DS.d380.s0.e5" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="160-169" type="protein" text="TNF-alpha"/>
            <entity id="DS.d380.s0.e6" origId="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5" charOffset="175-180" type="protein" text="IL-10"/>
            <pair e1="DS.d380.s0.e0" e2="DS.d380.s0.e5" id="DS.d380.s0.i0" interaction="False"/>
            <pair e1="DS.d380.s0.e0" e2="DS.d380.s0.e3" id="DS.d380.s0.i3" interaction="False"/>
            <pair e1="DS.d380.s0.e0" e2="DS.d380.s0.e4" id="DS.d380.s0.i4" interaction="False"/>
            <pair e1="DS.d380.s0.e0" e2="DS.d380.s0.e2" id="DS.d380.s0.i6" interaction="False"/>
            <pair e1="DS.d380.s0.e0" e2="DS.d380.s0.e6" id="DS.d380.s0.i9" interaction="False"/>
        </sentence>
        <sentence id="DS.d380.s1" origId="18575957-473" text="Effects of remifentanyl and fentanyl on spontaneous and endotoxin (lipopolysaccharide ; 100 ng ml(-1))-stimulated cytokine release were studied in whole blood from volunteers (n = 10) cultured for 6 h. Results IL-6, TNF-alpha and IL-10 0.01).">
            <entity id="DS.d380.s1.e0" origId="60815" charOffset="11-23" type="compound" text="remifentanyl"/>
            <entity id="DS.d380.s1.e2" origId="53481793" charOffset="56-85" type="compound" text="endotoxin (lipopolysaccharide"/>
            <entity id="DS.d380.s1.e3" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="210-214" type="protein" text="IL-6"/>
            <entity id="DS.d380.s1.e4" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="216-225" type="protein" text="TNF-alpha"/>
            <entity id="DS.d380.s1.e5" origId="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5" charOffset="230-235" type="protein" text="IL-10"/>
            <pair e1="DS.d380.s1.e0" e2="DS.d380.s1.e5" id="DS.d380.s1.i1" interaction="False"/>
            <pair e1="DS.d380.s1.e0" e2="DS.d380.s1.e4" id="DS.d380.s1.i3" interaction="False"/>
            <pair e1="DS.d380.s1.e2" e2="DS.d380.s1.e4" id="DS.d380.s1.i4" interaction="False"/>
            <pair e1="DS.d380.s1.e2" e2="DS.d380.s1.e3" id="DS.d380.s1.i5" interaction="False"/>
            <pair e1="DS.d380.s1.e2" e2="DS.d380.s1.e5" id="DS.d380.s1.i6" interaction="False"/>
            <pair e1="DS.d380.s1.e0" e2="DS.d380.s1.e3" id="DS.d380.s1.i8" interaction="False"/>
        </sentence>
        <sentence id="DS.d380.s2" origId="18575957-475" text="Remifentanyl and fentanyl could inhibit the expressions of IL-6, TNF-alpha and IL-10 induced by LPS.">
            <entity id="DS.d380.s2.e0" origId="60815" charOffset="0-12" type="compound" text="Remifentanyl"/>
            <entity id="DS.d380.s2.e2" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="59-63" type="protein" text="IL-6"/>
            <entity id="DS.d380.s2.e3" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="65-74" type="protein" text="TNF-alpha"/>
            <entity id="DS.d380.s2.e4" origId="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5" charOffset="79-84" type="protein" text="IL-10"/>
            <pair e1="DS.d380.s2.e0" e2="DS.d380.s2.e3" id="DS.d380.s2.i0" interaction="True"/>
            <pair e1="DS.d380.s2.e0" e2="DS.d380.s2.e2" id="DS.d380.s2.i2" interaction="True"/>
            <pair e1="DS.d380.s2.e0" e2="DS.d380.s2.e4" id="DS.d380.s2.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d381" origId="18577298">
        <sentence id="DS.d381.s0" origId="18577298-1601" text="This reduction was associated with the storage of decreased TAG and increased glycogen, which was a result of enhanced tyrosine phosphorylation of anti-insulin receptor substrate-2 and serine473 phosphporylation of protein kinase B (PKB, Akt).">
            <entity id="DS.d381.s0.e0" origId="439177" charOffset="78-86" type="compound" text="glycogen"/>
            <entity id="DS.d381.s0.e1" origId="1153,6057,5460803" charOffset="119-127" type="compound" text="tyrosine"/>
            <entity id="DS.d381.s0.e2" origId="P31749,P31750,P47196,Q01314,Q8INB9" charOffset="215-231" type="protein" text="protein kinase B"/>
            <entity id="DS.d381.s0.e3" origId="P31749,P31750,P47196,Q01314,Q8INB9" charOffset="233-236" type="protein" text="PKB"/>
            <entity id="DS.d381.s0.e4" origId="P31750,Q8INB9" charOffset="238-241" type="protein" text="Akt"/>
            <pair e1="DS.d381.s0.e1" e2="DS.d381.s0.e3" id="DS.d381.s0.i0" interaction="False"/>
            <pair e1="DS.d381.s0.e0" e2="DS.d381.s0.e4" id="DS.d381.s0.i1" interaction="False"/>
            <pair e1="DS.d381.s0.e0" e2="DS.d381.s0.e2" id="DS.d381.s0.i2" interaction="True"/>
            <pair e1="DS.d381.s0.e0" e2="DS.d381.s0.e3" id="DS.d381.s0.i3" interaction="True"/>
            <pair e1="DS.d381.s0.e1" e2="DS.d381.s0.e4" id="DS.d381.s0.i4" interaction="False"/>
            <pair e1="DS.d381.s0.e1" e2="DS.d381.s0.e2" id="DS.d381.s0.i5" interaction="False"/>
        </sentence>
        <sentence id="DS.d381.s1" origId="18577298-1602" text="Improved hepatic insulin signalling led to decreased phosphoenolpyruvate carboxykinase expression and reduced hepatic glucose output accordingly.">
            <entity id="DS.d381.s1.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="17-24" type="protein" text="insulin"/>
            <entity id="DS.d381.s1.e1" origId="206,5793,64689,79025" charOffset="118-125" type="compound" text="glucose"/>
            <pair e1="DS.d381.s1.e1" e2="DS.d381.s1.e0" id="DS.d381.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d382" origId="18577871">
        <sentence id="DS.d382.s0" origId="18577871-351" text="These data provide evidence that CMEC express CaSR, which is able to respond to physiological agonists by mobilizing Ca(2+) from intracellular InsP(3)-sensitive stores.">
            <entity id="DS.d382.s0.e0" origId="O62714,P35384,P41180,P48442,Q9QY96" charOffset="46-50" type="protein" text="CaSR"/>
            <entity id="DS.d382.s0.e1" origId="271" charOffset="117-121" type="compound" text="Ca(2"/>
            <pair e1="DS.d382.s0.e1" e2="DS.d382.s0.e0" id="DS.d382.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d383" origId="18579232">
        <sentence id="DS.d383.s0" origId="18579232-1493" text="Inhibition of these enzymes shows that chagasic autoantibodies up-regulation of COX-2/iNOS mRNA level is under the control of endogenous iNO/cGMP signaling system.">
            <entity id="DS.d383.s0.e0" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="80-85" type="protein" text="COX-2"/>
            <entity id="DS.d383.s0.e1" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="86-90" type="protein" text="iNOS"/>
            <entity id="DS.d383.s0.e3" origId="24316" charOffset="141-145" type="compound" text="cGMP"/>
            <pair e1="DS.d383.s0.e3" e2="DS.d383.s0.e0" id="DS.d383.s0.i1" interaction="True"/>
            <pair e1="DS.d383.s0.e3" e2="DS.d383.s0.e1" id="DS.d383.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d384" origId="18580872">
        <sentence id="DS.d384.s0" origId="18580872-1175" text="Pre-synaptic CB1Rs inhibit neurotransmitter release, suggesting that CB1R activation during extinction may decrease CCK peptide release as well as GABA release.">
            <entity id="DS.d384.s0.e0" origId="P52451" charOffset="13-18" type="protein" text="CB1Rs"/>
            <entity id="DS.d384.s0.e1" origId="P52451" charOffset="13-17" type="protein" text="CB1R"/>
            <entity id="DS.d384.s0.e2" origId="O57312,O93464,P01355,P01356,P06307,P09240,P0C229,P23362,P41520,P50144,P50145,P68125,P68126,P80344,P80345,Q9PU29,Q9PU41" charOffset="116-119" type="protein" text="CCK"/>
            <entity id="DS.d384.s0.e3" origId="119" charOffset="147-151" type="compound" text="GABA"/>
            <pair e1="DS.d384.s0.e3" e2="DS.d384.s0.e1" id="DS.d384.s0.i0" interaction="True"/>
            <pair e1="DS.d384.s0.e3" e2="DS.d384.s0.e2" id="DS.d384.s0.i1" interaction="False"/>
            <pair e1="DS.d384.s0.e3" e2="DS.d384.s0.e0" id="DS.d384.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d385" origId="18580876">
        <sentence id="DS.d385.s0" origId="18580876-1179" text="Acute cocaine, through D(2) dopamine receptors, induced a dose-response increase in FADD protein in the cortex, with opposite effects over pFADD (Ser191/194), and no induction of apoptotic cell death (poly-(ADP-ribose) polymerase cleavage).">
            <entity id="DS.d385.s0.e0" origId="2826,5760,439497,446220,644017,54613779" charOffset="6-13" type="compound" text="cocaine"/>
            <entity id="DS.d385.s0.e1" origId="O73810,P14416,P20288,P52702,P60026,P61168,P61169,Q6TLI9,Q9GJU1" charOffset="23-46" type="protein" text="D(2) dopamine receptors"/>
            <entity id="DS.d385.s0.e2" origId="Q13158,Q61160" charOffset="84-96" type="protein" text="FADD protein"/>
            <pair e1="DS.d385.s0.e0" e2="DS.d385.s0.e2" id="DS.d385.s0.i0" interaction="True"/>
            <pair e1="DS.d385.s0.e0" e2="DS.d385.s0.e1" id="DS.d385.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d385.s1" origId="18580876-1180" text="FADD was increased by cocaine in cytosol (approximately 142%), membranes (approximately 23%) and nucleus (approximately 54%).">
            <entity id="DS.d385.s1.e0" origId="P46310,Q13158" charOffset="0-4" type="protein" text="FADD"/>
            <entity id="DS.d385.s1.e1" origId="2826,5760,439497,446220,644017,54613779" charOffset="22-29" type="compound" text="cocaine"/>
            <pair e1="DS.d385.s1.e1" e2="DS.d385.s1.e0" id="DS.d385.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d385.s2" origId="18580876-1181" text="In a second experiment, possible FADD differences were investigated in rats selectively bred for differential responsiveness to novelty, propensity for drug-seeking and cocaine sensitization.">
            <entity id="DS.d385.s2.e0" origId="P46310,Q13158" charOffset="33-37" type="protein" text="FADD"/>
            <entity id="DS.d385.s2.e1" origId="2826,5760,439497,446220,644017,54613779" charOffset="169-176" type="compound" text="cocaine"/>
            <pair e1="DS.d385.s2.e1" e2="DS.d385.s2.e0" id="DS.d385.s2.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d386" origId="18581264">
        <sentence id="DS.d386.s0" origId="18581264-1465" text="Lignin peroxidases have the unique ability to catalyze oxidative cleavage of C-C bonds and ether (C-O-C) bonds in non-phenolic aromatic substrates of high redox potential.">
            <entity id="DS.d386.s0.e0" origId="P06181,P11542,P11543,P20010,P20011,P20012,P20013,P21764,P31837,P31838,P49012,P50622" charOffset="0-18" type="protein" text="Lignin peroxidases"/>
            <entity id="DS.d386.s0.e1" origId="3283,5382654" charOffset="91-96" type="compound" text="ether"/>
            <pair e1="DS.d386.s0.e1" e2="DS.d386.s0.e0" id="DS.d386.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d386.s1" origId="18581264-1466" text="Manganese peroxidases oxidize Mn(II) to Mn(III), which facilitates the degradation of phenolic compounds or, in turn, oxidizes a second mediator for the breakdown of non-phenolic compounds.">
            <entity id="DS.d386.s1.e0" origId="P15984,P16147,P84714" charOffset="10-21" type="protein" text="peroxidases"/>
            <entity id="DS.d386.s1.e1" origId="27854" charOffset="30-35" type="compound" text="Mn(II"/>
            <entity id="DS.d386.s1.e2" origId="105130" charOffset="40-46" type="compound" text="Mn(III"/>
            <pair e1="DS.d386.s1.e2" e2="DS.d386.s1.e0" id="DS.d386.s1.i0" interaction="True"/>
            <pair e1="DS.d386.s1.e1" e2="DS.d386.s1.e0" id="DS.d386.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d386.s2" origId="18581264-1467" text="Laccases are multi-copper-containing proteins that catalyze the oxidation of phenolic substrates with concomitant reduction of molecular oxygen to water.">
            <entity id="DS.d386.s2.e0" origId="Q12570" charOffset="0-8" type="protein" text="Laccases"/>
            <entity id="DS.d386.s2.e1" origId="23978" charOffset="19-25" type="compound" text="copper"/>
            <entity id="DS.d386.s2.e2" origId="977" charOffset="137-143" type="compound" text="oxygen"/>
            <pair e1="DS.d386.s2.e1" e2="DS.d386.s2.e0" id="DS.d386.s2.i0" interaction="True"/>
            <pair e1="DS.d386.s2.e2" e2="DS.d386.s2.e0" id="DS.d386.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d387" origId="18581270">
        <sentence id="DS.d387.s0" origId="18581270-1477" text="The co-expression of SERT with M6B results in a significant decrease in SERT-mediated serotonin uptake caused by a down-regulation of SERT surface expression.">
            <entity id="DS.d387.s0.e0" origId="P31645,Q9XT49" charOffset="21-25" type="protein" text="SERT"/>
            <entity id="DS.d387.s0.e1" origId="Q13491,Q5R603" charOffset="31-34" type="protein" text="M6B"/>
            <entity id="DS.d387.s0.e2" origId="P31645,Q9XT49" charOffset="72-76" type="protein" text="SERT"/>
            <entity id="DS.d387.s0.e3" origId="5202" charOffset="86-95" type="compound" text="serotonin"/>
            <entity id="DS.d387.s0.e4" origId="P31645,Q9XT49" charOffset="72-76" type="protein" text="SERT"/>
            <pair e1="DS.d387.s0.e3" e2="DS.d387.s0.e0" id="DS.d387.s0.i0" interaction="True"/>
            <pair e1="DS.d387.s0.e3" e2="DS.d387.s0.e1" id="DS.d387.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d388" origId="18582556">
        <sentence id="DS.d388.s0" origId="18582556-870" text="Hence, resistance to cancer in old Snell dwarf mice may be mediated by neuroendocrine factors that reduce glucose utilization besides elevated adiponectin, reduced IGF-I and a lack of GH, PRL and TSH, seen in both Snell and Ames dwarf mice.">
            <entity id="DS.d388.s0.e0" origId="206,5793,64689,79025" charOffset="106-113" type="compound" text="glucose"/>
            <entity id="DS.d388.s0.e1" origId="P05017,P07455,P08025,P10763,P16545,P17085,P17647,P18254,P33712,P51457,P51458,P51462,Q02815,Q28933,Q68LC0,Q6GUL6,Q6IVA5,Q6JLX1,Q95222" charOffset="164-169" type="protein" text="IGF-I"/>
            <entity id="DS.d388.s0.e2" origId="O62781,O62819,O93337,P01236,P01237,P01238,P01239,P01240,P06879,P09585,P10765,P12420,P14676,P17572,P21993,P22393,P29234,P29235,P33089,P33090,P33091,P33096,P34181,P35395,P37884,P40424,P43001,P43299,P46403,P48096,P48249,P51904,P55151,P87495,Q28318,Q28632,Q3Y4G6,Q6UC74,Q7ZZV3,Q8HXS1,Q9QZL1,Q9YGV6" charOffset="188-191" type="protein" text="PRL"/>
            <pair e1="DS.d388.s0.e0" e2="DS.d388.s0.e2" id="DS.d388.s0.i0" interaction="False"/>
            <pair e1="DS.d388.s0.e0" e2="DS.d388.s0.e1" id="DS.d388.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d389" origId="18582992">
        <sentence id="DS.d389.s0" origId="18582992-1242" text="Therefore, cinacalcet, which inhibit the production of parathormone by negative feedback, was considered a treatment option to control the evolution of calciphylaxis in a dialysed patient suffering from cholangiocarcinoma.">
            <entity id="DS.d389.s0.e0" origId="156419" charOffset="11-21" type="compound" text="cinacalcet"/>
            <entity id="DS.d389.s0.e1" origId="P01270" charOffset="55-67" type="protein" text="parathormone"/>
            <pair e1="DS.d389.s0.e0" e2="DS.d389.s0.e1" id="DS.d389.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d390" origId="18583434">
        <sentence id="DS.d390.s0" origId="18583434-1596" text="Glucose levels and hormones (Peptide YY(3-36), glucagon-like peptide-1 (GLP-1), leptin, ghrelin, insulin) that regulate EI were measured.">
            <entity id="DS.d390.s0.e0" origId="206,5793,64689,79025" charOffset="0-7" type="compound" text="Glucose"/>
            <entity id="DS.d390.s0.e1" origId="P10082,P68004,Q9TR93" charOffset="29-45" type="protein" text="Peptide YY(3-36)"/>
            <entity id="DS.d390.s0.e2" origId="O12956,P01272,P01273,P01274,P01275,P01278,P05110,P06883,P15438,P22890,P29794,P55095,P68259,Q8MJ25" charOffset="47-70" type="protein" text="glucagon-like peptide-1"/>
            <entity id="DS.d390.s0.e3" origId="O12956,P01272,P01273,P01274,P01275,P05110,P06883,P22890,P29794,P55095,P68259,Q06605,Q8MJ25" charOffset="72-77" type="protein" text="GLP-1"/>
            <entity id="DS.d390.s0.e4" origId="O02750,O93416,Q28603,Q95189,Q95234" charOffset="80-86" type="protein" text="leptin"/>
            <entity id="DS.d390.s0.e5" origId="Q6BEG6,Q6BEG7,Q9BDJ6,Q9BEF8,Q9EQX0,Q9GKY5,Q9QYH7,Q9UBU3" charOffset="88-95" type="protein" text="ghrelin"/>
            <entity id="DS.d390.s0.e6" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="97-104" type="protein" text="insulin"/>
            <pair e1="DS.d390.s0.e0" e2="DS.d390.s0.e2" id="DS.d390.s0.i0" interaction="False"/>
            <pair e1="DS.d390.s0.e0" e2="DS.d390.s0.e6" id="DS.d390.s0.i1" interaction="False"/>
            <pair e1="DS.d390.s0.e0" e2="DS.d390.s0.e5" id="DS.d390.s0.i2" interaction="False"/>
            <pair e1="DS.d390.s0.e0" e2="DS.d390.s0.e4" id="DS.d390.s0.i3" interaction="False"/>
            <pair e1="DS.d390.s0.e0" e2="DS.d390.s0.e3" id="DS.d390.s0.i4" interaction="False"/>
            <pair e1="DS.d390.s0.e0" e2="DS.d390.s0.e1" id="DS.d390.s0.i5" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d392" origId="18584285">
        <sentence id="DS.d392.s0" origId="18584285-592" text="Transglutaminases catalyze a calcium-dependent transamidation reaction that produces covalent cross-linking of available substrate glutamine residues and modifies the extracellular matrix.">
            <entity id="DS.d392.s0.e0" origId="P40746,P52183,P81453,Q819L3,Q81MS1,Q8GR90,Q9K5W7" charOffset="0-17" type="protein" text="Transglutaminases"/>
            <entity id="DS.d392.s0.e1" origId="738,5961" charOffset="131-140" type="compound" text="glutamine"/>
            <pair e1="DS.d392.s0.e1" e2="DS.d392.s0.e0" id="DS.d392.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d393" origId="18584286">
        <sentence id="DS.d393.s0" origId="18584286-593" text="We fed rats lysine or valine deficient diet for 4 weeks and examined the mRNA expressions of serine synthesising (3-phosphoglycerate dehydrogenase, PHGDH) and serine/threonine degrading enzymes (serine dehydratase, SDS) in the liver.">
            <entity id="DS.d393.s0.e0" origId="866,5962" charOffset="12-18" type="compound" text="lysine"/>
            <entity id="DS.d393.s0.e1" origId="6287" charOffset="22-28" type="compound" text="valine"/>
            <entity id="DS.d393.s0.e2" origId="O43175,Q5EAD2,Q5R7M2,Q60HD7" charOffset="148-153" type="protein" text="PHGDH"/>
            <entity id="DS.d393.s0.e3" origId="P20132" charOffset="215-218" type="protein" text="SDS"/>
            <pair e1="DS.d393.s0.e0" e2="DS.d393.s0.e2" id="DS.d393.s0.i0" interaction="False"/>
            <pair e1="DS.d393.s0.e1" e2="DS.d393.s0.e2" id="DS.d393.s0.i1" interaction="False"/>
            <pair e1="DS.d393.s0.e1" e2="DS.d393.s0.e3" id="DS.d393.s0.i2" interaction="False"/>
            <pair e1="DS.d393.s0.e0" e2="DS.d393.s0.e3" id="DS.d393.s0.i3" interaction="False"/>
        </sentence>
        <sentence id="DS.d393.s1" origId="18584286-594" text="Dietary deficiency induced marked elevation of hepatic serine and threonine levels associated with enhancement of PHGDH mRNA expression and repression of SDS mRNA expression.">
            <entity id="DS.d393.s1.e0" origId="5951" charOffset="55-61" type="compound" text="serine"/>
            <entity id="DS.d393.s1.e1" origId="6288" charOffset="66-75" type="compound" text="threonine"/>
            <entity id="DS.d393.s1.e2" origId="O43175,Q5EAD2,Q5R7M2,Q60HD7" charOffset="114-119" type="protein" text="PHGDH"/>
            <entity id="DS.d393.s1.e3" origId="P20132" charOffset="154-157" type="protein" text="SDS"/>
            <pair e1="DS.d393.s1.e1" e2="DS.d393.s1.e2" id="DS.d393.s1.i0" interaction="False"/>
            <pair e1="DS.d393.s1.e0" e2="DS.d393.s1.e2" id="DS.d393.s1.i1" interaction="False"/>
            <pair e1="DS.d393.s1.e1" e2="DS.d393.s1.e3" id="DS.d393.s1.i2" interaction="False"/>
            <pair e1="DS.d393.s1.e0" e2="DS.d393.s1.e3" id="DS.d393.s1.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d394" origId="18584306">
        <sentence id="DS.d394.s0" origId="18584306-333" text="Site-directed mutation test and mithramycin A treatment demonstrated that the ZNF230 promoter contained a functional Sp1 site.">
            <entity id="DS.d394.s0.e0" origId="29051,163659,230076,6326719" charOffset="32-45" type="compound" text="mithramycin A"/>
            <entity id="DS.d394.s0.e1" origId="Q8WVD5,Q9UIE0" charOffset="78-84" type="protein" text="ZNF230"/>
            <entity id="DS.d394.s0.e2" origId="O14300,O89090,P17379,Q01714,Q85439,Q85449,Q85451" charOffset="117-120" type="protein" text="Sp1"/>
            <pair e1="DS.d394.s0.e0" e2="DS.d394.s0.e2" id="DS.d394.s0.i0" interaction="True"/>
            <pair e1="DS.d394.s0.e0" e2="DS.d394.s0.e1" id="DS.d394.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d395" origId="18584320">
        <sentence id="DS.d395.s0" origId="18584320-630" text="Progesterone effects on neuronal ultrastructure and expression of microtubule-associated protein 2 (MAP2) in rats with acute spinal cord injury.">
            <entity id="DS.d395.s0.e0" origId="5994" charOffset="0-12" type="compound" text="Progesterone"/>
            <entity id="DS.d395.s0.e1" origId="P11137,P15146,P20357" charOffset="66-98" type="protein" text="microtubule-associated protein 2"/>
            <entity id="DS.d395.s0.e2" origId="P11137,P38174,Q5Z859,Q6XMH6,Q6XMH7,Q8SR45" charOffset="100-104" type="protein" text="MAP2"/>
            <pair e1="DS.d395.s0.e0" e2="DS.d395.s0.e1" id="DS.d395.s0.i0" interaction="True"/>
            <pair e1="DS.d395.s0.e0" e2="DS.d395.s0.e2" id="DS.d395.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d395.s1" origId="18584320-631" text="(4) Our data indicated that progesterone maintained in part neuronal ultrastructure, attenuated chromatolysis, and preclude the loss of MAP2, suggesting a protective effect during the early phases of spinal cord injury.">
            <entity id="DS.d395.s1.e0" origId="5994" charOffset="28-40" type="compound" text="progesterone"/>
            <entity id="DS.d395.s1.e1" origId="P11137,P38174,Q5Z859,Q6XMH6,Q6XMH7,Q8SR45" charOffset="136-140" type="protein" text="MAP2"/>
            <pair e1="DS.d395.s1.e0" e2="DS.d395.s1.e1" id="DS.d395.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d396" origId="18584336">
        <sentence id="DS.d396.s0" origId="18584336-637" text="In conclusion, our results indicate that chronic THC modulates the expression and subcellular localization of proteins implicated in Ras signaling, calcium-buffering potential, and trafficking.">
            <entity id="DS.d396.s0.e0" origId="16078,134740" charOffset="49-52" type="compound" text="THC"/>
            <entity id="DS.d396.s0.e1" origId="P03967,P22126,Q07152" charOffset="133-136" type="protein" text="Ras"/>
            <pair e1="DS.d396.s0.e0" e2="DS.d396.s0.e1" id="DS.d396.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d397" origId="18584896">
        <sentence id="DS.d397.s0" origId="18584896-1102" text="For this purpose, on day 0, male Wistar rats received NTG (120 microg/kg, iv) with or without pre-administration of PKC inhibitor chelerythrine (CHE), capsaicin (CAP) to deplete CGRP from sensory nerves or mK(ATP) channel blocker 5-hydroxydecaonic acid (5HD).">
            <entity id="DS.d397.s0.e0" origId="2703,411938" charOffset="130-143" type="compound" text="chelerythrine"/>
            <entity id="DS.d397.s0.e1" origId="1548943" charOffset="151-160" type="compound" text="capsaicin"/>
            <entity id="DS.d397.s0.e2" origId="P10286,P30880,P30881,P31888,P80511" charOffset="178-182" type="protein" text="CGRP"/>
            <entity id="DS.d397.s0.e3" origId="25058136" charOffset="254-257" type="compound" text="5HD"/>
            <pair e1="DS.d397.s0.e0" e2="DS.d397.s0.e2" id="DS.d397.s0.i0" interaction="False"/>
            <pair e1="DS.d397.s0.e3" e2="DS.d397.s0.e2" id="DS.d397.s0.i1" interaction="False"/>
            <pair e1="DS.d397.s0.e1" e2="DS.d397.s0.e2" id="DS.d397.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d398" origId="18585399">
        <sentence id="DS.d398.s0" origId="18585399-1508" text="The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator.">
            <entity id="DS.d398.s0.e0" origId="5311454" charOffset="20-31" type="compound" text="stiripentol"/>
            <entity id="DS.d398.s0.e1" origId="P26714,Q08832,Q9BLY8" charOffset="53-69" type="protein" text="GABA(A) receptor"/>
            <pair e1="DS.d398.s0.e0" e2="DS.d398.s0.e1" id="DS.d398.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d399" origId="18585720">
        <sentence id="DS.d399.s0" origId="18585720-96" text="Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies.">
            <entity id="DS.d399.s0.e0" origId="5885531" charOffset="3-9" type="compound" text="oleoyl"/>
            <entity id="DS.d399.s0.e1" origId="P27169,P27170" charOffset="66-70" type="protein" text="PON1"/>
            <pair e1="DS.d399.s0.e0" e2="DS.d399.s0.e1" id="DS.d399.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d400" origId="18585721">
        <sentence id="DS.d400.s0" origId="18585721-97" text="With the exception of specific genetic defects in purine metabolism, increased uric acid is generally associated with important risk factors for atherosclerosis like hypertension, abdominal obesity, insulin resistance, the metabolic syndrome and renal failure.">
            <entity id="DS.d400.s0.e0" origId="1044" charOffset="50-56" type="compound" text="purine"/>
            <entity id="DS.d400.s0.e1" origId="1175" charOffset="79-88" type="compound" text="uric acid"/>
            <entity id="DS.d400.s0.e2" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="199-206" type="protein" text="insulin"/>
            <pair e1="DS.d400.s0.e1" e2="DS.d400.s0.e2" id="DS.d400.s0.i0" interaction="True"/>
            <pair e1="DS.d400.s0.e0" e2="DS.d400.s0.e2" id="DS.d400.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d401" origId="18585744">
        <sentence id="DS.d401.s0" origId="18585744-108" text="The distribution of sugar moieties within the epididymal region of the Sudani duck was investigated using ten different fluorescein isothiocyanate (FITC) conjugated lectins.">
            <entity id="DS.d401.s0.e0" origId="18730" charOffset="120-146" type="compound" text="fluorescein isothiocyanate"/>
            <entity id="DS.d401.s0.e1" origId="18730" charOffset="148-152" type="compound" text="FITC"/>
            <entity id="DS.d401.s0.e2" origId="P02871,P02873,P02874,P02875,P07386,P16108,P16349,P16351,P16352,P33888,P38662,P42088,P83410,P83511,P84987,Q41114" charOffset="165-172" type="protein" text="lectins"/>
            <pair e1="DS.d401.s0.e0" e2="DS.d401.s0.e2" id="DS.d401.s0.i0" interaction="False"/>
            <pair e1="DS.d401.s0.e1" e2="DS.d401.s0.e2" id="DS.d401.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d402" origId="18586252">
        <sentence id="DS.d402.s0" origId="18586252-521" text="High glucose and interferon gamma synergistically stimulate MMP-1 expression in U937 macrophages by increasing transcription factor STAT1 activity.">
            <entity id="DS.d402.s0.e0" origId="206,5793,64689,79025" charOffset="5-12" type="compound" text="glucose"/>
            <entity id="DS.d402.s0.e1" origId="Q9TTB0" charOffset="17-33" type="protein" text="interferon gamma"/>
            <entity id="DS.d402.s0.e2" origId="P03956,P13943,P21692,P28053,P81563,Q11133,Q9XSZ5" charOffset="60-65" type="protein" text="MMP-1"/>
            <entity id="DS.d402.s0.e3" origId="P42224,Q764M5" charOffset="132-137" type="protein" text="STAT1"/>
            <pair e1="DS.d402.s0.e0" e2="DS.d402.s0.e1" id="DS.d402.s0.i0" interaction="False"/>
            <pair e1="DS.d402.s0.e0" e2="DS.d402.s0.e3" id="DS.d402.s0.i1" interaction="True"/>
            <pair e1="DS.d402.s0.e0" e2="DS.d402.s0.e2" id="DS.d402.s0.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d402.s1" origId="18586252-522" text="To test our hypothesis that hyperglycemia interplays with interferon gamma (IFN gamma), a key factor involved in atherosclerosis, to up-regulate the expression of genes such as matrix metalloproteinases (MMPs) and cytokines that are involved in plaque destabilization, U937 macrophages cultured in medium containing either normal or high glucose were challenged with IFN gamma and the expression of MMPs and cytokines were then quantified by real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA).">
            <entity id="DS.d402.s1.e0" origId="Q9TTB0" charOffset="58-74" type="protein" text="interferon gamma"/>
            <entity id="DS.d402.s1.e1" origId="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9" charOffset="76-85" type="protein" text="IFN gamma"/>
            <entity id="DS.d402.s1.e2" origId="206,5793,64689,79025" charOffset="338-345" type="compound" text="glucose"/>
            <entity id="DS.d402.s1.e3" origId="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9" charOffset="367-376" type="protein" text="IFN gamma"/>
            <pair e1="DS.d402.s1.e2" e2="DS.d402.s1.e0" id="DS.d402.s1.i0" interaction="False"/>
            <pair e1="DS.d402.s1.e2" e2="DS.d402.s1.e1" id="DS.d402.s1.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d402.s2" origId="18586252-523" text="Results showed that high glucose and IFN gamma had a synergistic effect on the expression of MMP-1, MMP-9 and IL-1 beta.">
            <entity id="DS.d402.s2.e0" origId="206,5793,64689,79025" charOffset="25-32" type="compound" text="glucose"/>
            <entity id="DS.d402.s2.e1" origId="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9" charOffset="37-46" type="protein" text="IFN gamma"/>
            <entity id="DS.d402.s2.e2" origId="P03956,P13943,P21692,P28053,P81563,Q11133,Q9XSZ5" charOffset="93-98" type="protein" text="MMP-1"/>
            <entity id="DS.d402.s2.e3" origId="O18733,P14780,P41245,P41246,P50282,P52176" charOffset="100-105" type="protein" text="MMP-9"/>
            <entity id="DS.d402.s2.e4" origId="P01584,P09428,P10749,P14628,P21621,P26889,P41687,P46648,P48090,P51493,P51745,P79162,P79182,Q28292,Q28386,Q2HZH0,Q2MH07,Q63264,Q6PUD2,Q6R2X3,Q865X8,Q8WNR2,Q9WVG1,Q9XS77" charOffset="110-119" type="protein" text="IL-1 beta"/>
            <pair e1="DS.d402.s2.e0" e2="DS.d402.s2.e4" id="DS.d402.s2.i0" interaction="True"/>
            <pair e1="DS.d402.s2.e0" e2="DS.d402.s2.e2" id="DS.d402.s2.i1" interaction="True"/>
            <pair e1="DS.d402.s2.e0" e2="DS.d402.s2.e1" id="DS.d402.s2.i2" interaction="False"/>
            <pair e1="DS.d402.s2.e0" e2="DS.d402.s2.e3" id="DS.d402.s2.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d402.s3" origId="18586252-525" text="Furthermore, high glucose and IFN gamma exert the synergistic effect on MMP-1 expression by enhancing STAT1 phosphorylation and STAT1 transcriptional activity.">
            <entity id="DS.d402.s3.e0" origId="206,5793,64689,79025" charOffset="18-25" type="compound" text="glucose"/>
            <entity id="DS.d402.s3.e1" origId="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9" charOffset="30-39" type="protein" text="IFN gamma"/>
            <entity id="DS.d402.s3.e2" origId="P03956,P13943,P21692,P28053,P81563,Q11133,Q9XSZ5" charOffset="72-77" type="protein" text="MMP-1"/>
            <entity id="DS.d402.s3.e3" origId="P42224,Q764M5" charOffset="102-107" type="protein" text="STAT1"/>
            <entity id="DS.d402.s3.e4" origId="P42224,Q764M5" charOffset="128-133" type="protein" text="STAT1"/>
            <pair e1="DS.d402.s3.e0" e2="DS.d402.s3.e3" id="DS.d402.s3.i0" interaction="True"/>
            <pair e1="DS.d402.s3.e0" e2="DS.d402.s3.e1" id="DS.d402.s3.i1" interaction="False"/>
            <pair e1="DS.d402.s3.e0" e2="DS.d402.s3.e2" id="DS.d402.s3.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d403" origId="18586420">
        <sentence id="DS.d403.s0" origId="18586420-663" text="In Experiment 2, lactoferrin (10 mg/mL) combined with cidofovir (62.5 microg/mL) inhibited up to 100,200 PFU/mL of virus in cell culture.">
            <entity id="DS.d403.s0.e0" origId="O77698,O77811,P02788,P08071,P14632,P24627,Q29477,Q9TUM0" charOffset="17-28" type="protein" text="lactoferrin"/>
            <entity id="DS.d403.s0.e1" origId="60613" charOffset="54-63" type="compound" text="cidofovir"/>
            <pair e1="DS.d403.s0.e1" e2="DS.d403.s0.e0" id="DS.d403.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d404" origId="18586549">
        <sentence id="DS.d404.s0" origId="18586549-790" text="We systematically investigated whether PD-related stresses including MG132 and epoxomicin (proteasomal impairment), tunicamycin (unfolded protein stress), and rotenone (mitochondrial dysfunction) resulted in expressional changes of parkin and other E3 ubiquitin ligases (dorfin, SIAH-1).">
            <entity id="DS.d404.s0.e0" origId="462382" charOffset="69-74" type="compound" text="MG132"/>
            <entity id="DS.d404.s0.e1" origId="6758" charOffset="159-167" type="compound" text="rotenone"/>
            <entity id="DS.d404.s0.e2" origId="O46543,P08565,P08618,P0C014,P0C072,P13117,P14624,P14792,P15174,P19848,P20685,P22589,P23324,P23398,P42739,P42740,P46574,P49634,P49635,P59263,P59669,P61862,P61863,P61864,P62972,P62973,P62974,P62975,P62976,P62977,P62988,P62989,P62990,P62991,P63049,P63051,P68195,P68196,P68197,P68198,P68199,P68201,P68204,P69308,P69309,P69310,P69311,P69312,P69313,P69314,P69315,P69316,P69317,P69318,P69319,P69320,P69321,P69322,P69323,P69324,P69325,P69326,P84589,Q05550,Q865C5,Q867C2,Q867C3,Q867C4,Q8MKD1,Q9Y848" charOffset="252-261" type="protein" text="ubiquitin"/>
            <entity id="DS.d404.s0.e3" origId="Q9NV58" charOffset="271-277" type="protein" text="dorfin"/>
            <pair e1="DS.d404.s0.e1" e2="DS.d404.s0.e2" id="DS.d404.s0.i0" interaction="False"/>
            <pair e1="DS.d404.s0.e1" e2="DS.d404.s0.e3" id="DS.d404.s0.i1" interaction="False"/>
            <pair e1="DS.d404.s0.e0" e2="DS.d404.s0.e3" id="DS.d404.s0.i2" interaction="False"/>
            <pair e1="DS.d404.s0.e0" e2="DS.d404.s0.e2" id="DS.d404.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d405" origId="18587580">
        <sentence id="DS.d405.s0" origId="18587580-1638" text="CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells.">
            <entity id="DS.d405.s0.e0" origId="400769" charOffset="0-7" type="compound" text="CDDO-Me"/>
            <entity id="DS.d405.s0.e1" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="58-62" type="protein" text="IL-6"/>
            <entity id="DS.d405.s0.e2" origId="P42227,P52631" charOffset="67-72" type="protein" text="Stat3"/>
            <pair e1="DS.d405.s0.e0" e2="DS.d405.s0.e2" id="DS.d405.s0.i0" interaction="True"/>
            <pair e1="DS.d405.s0.e0" e2="DS.d405.s0.e1" id="DS.d405.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d405.s1" origId="18587580-1639" text="To explore potential therapeutic strategies for interrupting signaling through this pathway, we assessed the ability of CDDO-Me, a synthetic triterpenoid, to inhibit IL-6 secretion, Stat3 phosphorylation, Stat3 nuclear translocation and paclitaxel sensitivity in several cell line model systems.">
            <entity id="DS.d405.s1.e0" origId="400769" charOffset="120-127" type="compound" text="CDDO-Me"/>
            <entity id="DS.d405.s1.e1" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="166-170" type="protein" text="IL-6"/>
            <entity id="DS.d405.s1.e2" origId="P42227,P52631" charOffset="182-187" type="protein" text="Stat3"/>
            <entity id="DS.d405.s1.e3" origId="P42227,P52631" charOffset="205-210" type="protein" text="Stat3"/>
            <entity id="DS.d405.s1.e4" origId="4666,36314,441276,5352019,6713921,6915727,44155032,53313247" charOffset="237-247" type="compound" text="paclitaxel"/>
            <pair e1="DS.d405.s1.e4" e2="DS.d405.s1.e2" id="DS.d405.s1.i0" interaction="False"/>
            <pair e1="DS.d405.s1.e0" e2="DS.d405.s1.e1" id="DS.d405.s1.i1" interaction="False"/>
            <pair e1="DS.d405.s1.e4" e2="DS.d405.s1.e1" id="DS.d405.s1.i2" interaction="False"/>
            <pair e1="DS.d405.s1.e0" e2="DS.d405.s1.e2" id="DS.d405.s1.i3" interaction="False"/>
        </sentence>
        <sentence id="DS.d405.s2" origId="18587580-1640" text="These studies demonstrated that CDDO-Me significantly inhibits IL-6 secretion in paclitaxel-resistant ovarian cancer cells and specifically suppresses IL-6-or oncostatin M-induced Stat3 nuclear translocation.">
            <entity id="DS.d405.s2.e0" origId="400769" charOffset="32-39" type="compound" text="CDDO-Me"/>
            <entity id="DS.d405.s2.e1" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="63-67" type="protein" text="IL-6"/>
            <entity id="DS.d405.s2.e2" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="151-155" type="protein" text="IL-6"/>
            <entity id="DS.d405.s2.e3" origId="P42227,P52631" charOffset="180-185" type="protein" text="Stat3"/>
            <pair e1="DS.d405.s2.e0" e2="DS.d405.s2.e3" id="DS.d405.s2.i0" interaction="True"/>
            <pair e1="DS.d405.s2.e0" e2="DS.d405.s2.e1" id="DS.d405.s2.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d405.s3" origId="18587580-1641" text="Treatment with CDDO-Me significantly decreases the levels of Stat3, Jak2, and Src phosphorylation in ovarian and breast cancer cell lines with constitutively activated Stat3.">
            <entity id="DS.d405.s3.e0" origId="400769" charOffset="15-22" type="compound" text="CDDO-Me"/>
            <entity id="DS.d405.s3.e1" origId="Q62120,Q62689" charOffset="68-72" type="protein" text="Jak2"/>
            <entity id="DS.d405.s3.e2" origId="P05480,Q9WUD9" charOffset="78-81" type="protein" text="Src"/>
            <pair e1="DS.d405.s3.e0" e2="DS.d405.s3.e1" id="DS.d405.s3.i0" interaction="True"/>
            <pair e1="DS.d405.s3.e0" e2="DS.d405.s3.e2" id="DS.d405.s3.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d405.s4" origId="18587580-1642" text="Our data confirm that CDDO-Me interrupts the signaling of multiple kinases involved in the IL-6-Stat3 and Src signaling pathways.">
            <entity id="DS.d405.s4.e0" origId="400769" charOffset="22-29" type="compound" text="CDDO-Me"/>
            <entity id="DS.d405.s4.e1" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="91-95" type="protein" text="IL-6"/>
            <entity id="DS.d405.s4.e2" origId="P42227,P52631" charOffset="96-101" type="protein" text="Stat3"/>
            <entity id="DS.d405.s4.e3" origId="P05480,Q9WUD9" charOffset="106-109" type="protein" text="Src"/>
            <pair e1="DS.d405.s4.e0" e2="DS.d405.s4.e2" id="DS.d405.s4.i0" interaction="True"/>
            <pair e1="DS.d405.s4.e0" e2="DS.d405.s4.e3" id="DS.d405.s4.i1" interaction="True"/>
            <pair e1="DS.d405.s4.e0" e2="DS.d405.s4.e1" id="DS.d405.s4.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d406" origId="18587601">
        <sentence id="DS.d406.s0" origId="18587601-1586" text="The anti-hyperlipemia effect of EPS and intracellular polysaccharide (IPS) extracted from mycelia were observed that both EPS and IPS can obviously reduce the serum triglyceride (TG), the blood cholesterol (TC) and serum low density lipoprotein (LDL) level, and increase the high density lipoprotein (HDL) level of the hyperlipemia mice.">
            <entity id="DS.d406.s0.e0" origId="304,5997,6432564,11025495" charOffset="194-205" type="compound" text="cholesterol"/>
            <entity id="DS.d406.s0.e1" origId="P81182" charOffset="275-299" type="protein" text="high density lipoprotein"/>
            <pair e1="DS.d406.s0.e0" e2="DS.d406.s0.e1" id="DS.d406.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d407" origId="18587610">
        <sentence id="DS.d407.s0" origId="18587610-1674" text="On a molar basis, streptomycin yields a signal that is approximately 0.67 times that of MurA.">
            <entity id="DS.d407.s0.e0" origId="5999,19649,6426892,6602485" charOffset="18-30" type="compound" text="streptomycin"/>
            <entity id="DS.d407.s0.e1" origId="O32849,O32857,O32858,O33159,O33160,O51428,O54312,O67315,O84461,P0A5L2,P0A5L3,P0A749,P0A750,P0A751,P19670,P33038,P33986,P45025,P45821,P56189,P57466,P57821,P65452,P65453,P65454,P65455,P65458,P65459,P70965,P84058,P84059,Q2RQ67,Q2YAN2,Q2YPB6,Q30T46,Q315P9,Q319I9,Q31GZ1,Q31W66,Q32BE4,Q39K93,Q39YP9,Q3A131,Q3A949,Q3AR32,Q3B5D7,Q3BQX2,Q3IG20,Q3J077,Q3J7G9,Q3JMZ4,Q3KHZ4,Q3KLP3,Q3MD78,Q3SHP2,Q3SW27,Q3YX52,Q46JH1,Q46WL0,Q47AK9,Q47KH3,Q47VJ4,Q48EC7,Q48UD0,Q493Y9,Q4FNE4,Q4FQF6,Q4JXA4,Q4KI75,Q4L7Y1,Q4QLK7,Q4UKX7,Q4UX36,Q4ZNV7,Q55673,Q57F97,Q57JG1,Q59561,Q5E7V0,Q5F5K6,Q5FME5,Q5FSM2,Q5GRP6,Q5H3C7,Q5HEA0,Q5HMC2,Q5HUT8,Q5L6U5,Q5L9P3,Q5LL90,Q5LZI4,Q5M439,Q5NLR2,Q5P787,Q5PBP4,Q5PLD1,Q5R0J5,Q5SM03,Q5WB82,Q5WY61,Q5X6Q6,Q5XCX7,Q5Z0X7,Q5ZX85,Q606Q0,Q62GD7,Q630W1,Q63Q84,Q64PY6,Q65RU6,Q661E8,Q665K4,Q68WF7,Q6AJM7,Q6DAF2,Q6FED0,Q6FYT1,Q6G226,Q6G7L0,Q6GEX5,Q6HAZ8,Q6LMC9,Q6MEP6,Q6MRK7,Q6N176,Q6NFK1,Q71WQ2,Q726D3,Q72GJ4,Q73FX6,Q73Q03,Q73X63,Q748B3,Q74LG1,Q7MAC1,Q7MPA3,Q7MUW1,Q7N068,Q7NGP3,Q7P0X5,Q7U5R6,Q7V0G1,Q7V8L0,Q7VAC5,Q7VAT0,Q7VIM8,Q7VP51,Q7VQS0,Q7VSZ3,Q7W2Y6,Q7WDY6,Q82TN2,Q83DI0,Q87DN8,Q87LF4,Q87WV2,Q88P88,Q89AE9,Q89W71,Q8A681,Q8CRN6,Q8D2M5,Q8DEB6,Q8DKS7,Q8DNE8,Q8E5U6,Q8EAF7,Q8EM86,Q8FMR0,Q8K825,Q8K9G4,Q8KEX7,Q8NML5,Q8P719,Q8PID3,Q8RIQ1,Q8UHW9,Q8X9J9,Q8XID7,Q8XV78,Q8Y4C4,Q8Z0C4,Q8ZB56,Q927W7,Q92H88,Q92S27,Q931H5,Q97F79,Q97NQ4,Q9A5U7,Q9CI17,Q9HVW7,Q9JWS7,Q9K1Q9,Q9K6I0,Q9KP62,Q9PDG4,Q9PJT7,Q9PP65,Q9RVA6,Q9WXW3,Q9Z3Z6,Q9Z7Y2,Q9ZCX3,Q9ZH21,Q9ZLI6" charOffset="88-92" type="protein" text="MurA"/>
            <pair e1="DS.d407.s0.e0" e2="DS.d407.s0.e1" id="DS.d407.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d408" origId="18587665">
        <sentence id="DS.d408.s0" origId="18587665-16" text="Puerarin regulates expressions of VEGF and HIF-1alpha stimulated by STZ.">
            <entity id="DS.d408.s0.e0" origId="5281807,5385074,5486172,44257207,53384442" charOffset="0-8" type="compound" text="Puerarin"/>
            <entity id="DS.d408.s0.e1" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="34-38" type="protein" text="VEGF"/>
            <entity id="DS.d408.s0.e2" origId="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9" charOffset="43-53" type="protein" text="HIF-1alpha"/>
            <pair e1="DS.d408.s0.e0" e2="DS.d408.s0.e2" id="DS.d408.s0.i0" interaction="True"/>
            <pair e1="DS.d408.s0.e0" e2="DS.d408.s0.e1" id="DS.d408.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d409" origId="18588512">
        <sentence id="DS.d409.s0" origId="18588512-710" text="In patients with hypertension and diabetes, ARB, ACEi and diuretic treatment increased Ras activation only during the first week.">
            <entity id="DS.d409.s0.e0" origId="439764" charOffset="44-47" type="compound" text="ARB"/>
            <entity id="DS.d409.s0.e1" origId="P03967,P22126,Q07152" charOffset="87-90" type="protein" text="Ras"/>
            <pair e1="DS.d409.s0.e0" e2="DS.d409.s0.e1" id="DS.d409.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d410" origId="18590515">
        <sentence id="DS.d410.s0" origId="18590515-661" text="Although the co-expression of alpha2,3-ST and CMP-SAS did not further increase sialylation, an increase in the intracellular pool of CMP-sialic acid was noted.">
            <entity id="DS.d410.s0.e0" origId="P54751,P61130,P61131,P72074,P72097,Q02745,Q11200,Q11201,Q11204,Q11205,Q11206,Q16842,Q48211,Q6KB58,Q6KB59,Q91Y74,Q9CNC4,Q9JUV5" charOffset="30-41" type="protein" text="alpha2,3-ST"/>
            <entity id="DS.d410.s0.e1" origId="906,444885,445063" charOffset="137-148" type="compound" text="sialic acid"/>
            <pair e1="DS.d410.s0.e1" e2="DS.d410.s0.e0" id="DS.d410.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d411" origId="18590587">
        <sentence id="DS.d411.s0" origId="18590587-733" text="NOPE-EGCG treatment improved insulin 0.0001).">
            <entity id="DS.d411.s0.e0" origId="65064" charOffset="5-9" type="compound" text="EGCG"/>
            <entity id="DS.d411.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="29-36" type="protein" text="insulin"/>
            <pair e1="DS.d411.s0.e0" e2="DS.d411.s0.e1" id="DS.d411.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d412" origId="18590597">
        <sentence id="DS.d412.s0" origId="18590597-739" text="A 23.5-fold increase in 7-ethoxy-4-trifluoromethylcoumarin O-deethylation activity suggested that metabolic resistance through elevated levels of cytochrome P450 dependent monooxygenase-activity is a possible resistance mechanism.However, synergism studies with different metabolic inhibitors revealed some contrasting resistance mechanisms between the METI-acaricides.">
            <entity id="DS.d412.s0.e0" origId="130779" charOffset="24-58" type="compound" text="7-ethoxy-4-trifluoromethylcoumarin"/>
            <entity id="DS.d412.s0.e1" origId="O08469" charOffset="146-161" type="protein" text="cytochrome P450"/>
            <pair e1="DS.d412.s0.e0" e2="DS.d412.s0.e1" id="DS.d412.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d413" origId="18592271">
        <sentence id="DS.d413.s0" origId="18592271-409" text="The activities of Rho GTPases are predominantly controlled by guanine nucleotide exchange factors (GEFs), which activate GTPases by catalyzing the exchange of bound GDP for GTP.">
            <entity id="DS.d413.s0.e1" origId="Q9NR83" charOffset="99-103" type="protein" text="GEFs"/>
            <entity id="DS.d413.s0.e2" origId="8977" charOffset="165-168" type="compound" text="GDP"/>
            <pair e1="DS.d413.s0.e2" e2="DS.d413.s0.e1" id="DS.d413.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d414" origId="18592327">
        <sentence id="DS.d414.s0" origId="18592327-379" text="11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) enzyme catalyzes interconversion of inactive cortisone to active cortisol.">
            <entity id="DS.d414.s0.e0" origId="P16232,P28845,P50172,P51975,Q29608,Q6QLL4,Q6R0J2,Q7M3I4" charOffset="44-55" type="protein" text="11beta-HSD1"/>
            <entity id="DS.d414.s0.e1" origId="222786" charOffset="102-111" type="compound" text="cortisone"/>
            <entity id="DS.d414.s0.e2" origId="5754" charOffset="122-130" type="compound" text="cortisol"/>
            <pair e1="DS.d414.s0.e2" e2="DS.d414.s0.e0" id="DS.d414.s0.i0" interaction="True"/>
            <pair e1="DS.d414.s0.e1" e2="DS.d414.s0.e0" id="DS.d414.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d415" origId="18592344">
        <sentence id="DS.d415.s0" origId="18592344-477" text="Rebinding experiments with Lys-Gly-Asp, an analogue of Arg-Gly-Asp, and other different peptides, such as cholecystokinin C-terminal tri- and pentapeptide and gramicidin, further indicated the selectivity of methacrylic acid-trimethylpropane trimethacrylate copolymer for Arg-Gly-Asp giving specific selectivity factor values 1.27, 1.98, 1.31 and 1.67, respectively.">
            <entity id="DS.d415.s0.e2" origId="P0C229,P50144,P50145,P68125,P68126" charOffset="106-121" type="protein" text="cholecystokinin"/>
            <entity id="DS.d415.s0.e4" origId="16130140" charOffset="159-169" type="compound" text="gramicidin"/>
            <pair e1="DS.d415.s0.e4" e2="DS.d415.s0.e2" id="DS.d415.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d416" origId="18592367">
        <sentence id="DS.d416.s0" origId="18592367-499" text="Parents (N = 19) of children with autism spectrum disorders (ASD) and adult controls (N = 17) underwent positron emission tomography (PET) using ((18)F) setoperone to image cortical serotonin type-2 (5-HT2) receptors.">
            <entity id="DS.d416.s0.e0" origId="68604" charOffset="153-163" type="compound" text="setoperone"/>
            <entity id="DS.d416.s0.e1" origId="O46635,P14842,P18599,P28223,P35363,P35382,P50128,P50129,Q5R4Q6,Q75Z89" charOffset="200-205" type="protein" text="5-HT2"/>
            <pair e1="DS.d416.s0.e0" e2="DS.d416.s0.e1" id="DS.d416.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d417" origId="18592408">
        <sentence id="DS.d417.s0" origId="18592408-535" text="Natural anacardic acid was enzymatically polymerized using soybean peroxidase.">
            <entity id="DS.d417.s0.e0" origId="167551" charOffset="8-22" type="compound" text="anacardic acid"/>
            <entity id="DS.d417.s0.e1" origId="P15984,P16147,P84714" charOffset="67-77" type="protein" text="peroxidase"/>
            <pair e1="DS.d417.s0.e0" e2="DS.d417.s0.e1" id="DS.d417.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d418" origId="18592416">
        <sentence id="DS.d418.s0" origId="18592416-542" text="Vesicle mobilization requires Ca(2+)-induced Ca2+ release by presynaptic endoplasmic reticulum (ER) ryanodine receptors (RyRs) that in turn stimulates Ca2+/calmodulin-dependent kinase II (CamKII).">
            <entity id="DS.d418.s0.e0" origId="271" charOffset="30-34" type="compound" text="Ca(2"/>
            <entity id="DS.d418.s0.e1" origId="Q24498" charOffset="121-125" type="protein" text="RyRs"/>
            <pair e1="DS.d418.s0.e0" e2="DS.d418.s0.e1" id="DS.d418.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d419" origId="18593507">
        <sentence id="DS.d419.s0" origId="18593507-1421" text="These results highlight both the interactions between mGluR5 and NMDA receptors in the determination of schizophreniform behaviours and the potential for the effects of clozapine to be mediated by NMDA receptor regulation.">
            <entity id="DS.d419.s0.e0" origId="P31424,P41594" charOffset="54-60" type="protein" text="mGluR5"/>
            <entity id="DS.d419.s0.e1" origId="2818" charOffset="169-178" type="compound" text="clozapine"/>
            <pair e1="DS.d419.s0.e1" e2="DS.d419.s0.e0" id="DS.d419.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d420" origId="18594129">
        <sentence id="DS.d420.s0" origId="18594129-259" text="Expression of rhtC reduced the intracellular L-threonine concentration from 140 to 11 mM and resulted in maximal excretion rates of 11.2 nmol min(-1) mg(-1) as compared to 2.3 nmol min(-1) mg(-1) obtained without rhtC expression.">
            <entity id="DS.d420.s0.e0" origId="P0AG38,P0AG39,Q8Z3B3,Q9L6N7" charOffset="14-18" type="protein" text="rhtC"/>
            <entity id="DS.d420.s0.e1" origId="6288" charOffset="45-56" type="compound" text="L-threonine"/>
            <entity id="DS.d420.s0.e2" origId="P0AG38,P0AG39,Q8Z3B3,Q9L6N7" charOffset="213-217" type="protein" text="rhtC"/>
            <pair e1="DS.d420.s0.e1" e2="DS.d420.s0.e0" id="DS.d420.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d420.s1" origId="18594129-260" text="In combination with an ilvA mutation generated and introduced into the chromosome, an accumulation of up to 54 mM L-threonine was achieved as compared to 21 mM obtained with the ancestor strain.">
            <entity id="DS.d420.s1.e0" origId="P04968,P20506,P37946,P46493,P53607,P66897,P66898,Q02145,Q04513,Q2FF63,Q2YUE8,Q3V7T4,Q3V7T5,Q49Z16,Q4L7U4,Q5HEE0,Q5HMF5,Q7A4H2,Q8CNK9,Q8NVI8,Q99SJ1,Q9CKJ2,Q9KC63,Q9X7F1" charOffset="23-27" type="protein" text="ilvA"/>
            <entity id="DS.d420.s1.e1" origId="6288" charOffset="114-125" type="compound" text="L-threonine"/>
            <pair e1="DS.d420.s1.e1" e2="DS.d420.s1.e0" id="DS.d420.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d421" origId="18594817">
        <sentence id="DS.d421.s0" origId="18594817-847" text="This additive effect was not observed when glioma cells were pre-treated with temozolomide, which was unable to increase Fas expression in tumor.">
            <entity id="DS.d421.s0.e0" origId="5394" charOffset="78-90" type="compound" text="temozolomide"/>
            <entity id="DS.d421.s0.e1" origId="P25446,Q63199" charOffset="121-124" type="protein" text="Fas"/>
            <pair e1="DS.d421.s0.e0" e2="DS.d421.s0.e1" id="DS.d421.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d421.s1" origId="18594817-848" text="Furthermore, the CD3(+) T cells co-cultured with topotecan treated U-87 and autologous GBM tumor cells showed a significant increase in expression in IFN-gamma, a key cytokine produced by activated T cells, and accordingly enhanced tumor cytotoxicity.">
            <entity id="DS.d421.s1.e0" origId="60700" charOffset="49-58" type="compound" text="topotecan"/>
            <entity id="DS.d421.s1.e1" origId="O35497,O35735,O57571,O57603,O57608,O73915,O77763,P01579,P01580,P01581,P07353,P17773,P17803,P28333,P28341,P30123,P42160,P42161,P42162,P46402,P49708,P63309,P63310,P63311,P79154,Q1WM28,Q25BC0,Q2PE75,Q4ZH68,Q5CCK0,Q5I6S9,Q62574,Q647G2,Q7TSP4,Q865W6,Q865X1,Q865Y4,Q866Y6,Q8MKF5,Q8SPW9,Q9QXX2,Q9TTB0,Q9TV67,Q9YGB9" charOffset="150-159" type="protein" text="IFN-gamma"/>
            <pair e1="DS.d421.s1.e0" e2="DS.d421.s1.e1" id="DS.d421.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d422" origId="18594856">
        <sentence id="DS.d422.s0" origId="18594856-883" text="Hypergravity also induced a transient reorganization of actin fibers in 3 min, which was inhibited by Rho-kinase inhibitor (Y27632) and tyrosine kinase inhibitors (herbimycin A and tyrphostin 46).">
            <entity id="DS.d422.s0.e0" origId="O00937,O13419,O16808,O17320,O65314,O65315,O65316,O74258,O81221,P02577,P10365,P10989,P11426,P13363,P14235,P17128,P20904,P24902,P26182,P26183,P30161,P45520,P45521,P48465,P50138,P51775,P53455,P53476,P53477,P53491,P53498,P53499,P53500,P53502,P53689,P60009,P60010,P60011,P68555,P78711,P80709,P81085,P90689,P91754,Q05214,Q11212,Q24733,Q2U7A3,Q39596,Q39758,Q6TCF2,Q75D00,Q8SWN8,Q8X119,Q92192,Q92193,Q99023,Q9P4D1,Q9UVF3,Q9UVX4,Q9UVZ8" charOffset="56-61" type="protein" text="actin"/>
            <entity id="DS.d422.s0.e1" origId="448042" charOffset="124-130" type="compound" text="Y27632"/>
            <entity id="DS.d422.s0.e2" origId="3591,5311102,6436247" charOffset="164-176" type="compound" text="herbimycin A"/>
            <entity id="DS.d422.s0.e3" origId="5328768" charOffset="181-194" type="compound" text="tyrphostin 46"/>
            <pair e1="DS.d422.s0.e1" e2="DS.d422.s0.e0" id="DS.d422.s0.i0" interaction="True"/>
            <pair e1="DS.d422.s0.e2" e2="DS.d422.s0.e0" id="DS.d422.s0.i1" interaction="True"/>
            <pair e1="DS.d422.s0.e3" e2="DS.d422.s0.e0" id="DS.d422.s0.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d422.s1" origId="18594856-886" text="Collectively, these results indicate that hypergravity induces ATP release and actin reorganization via RhoA activation and FAK phosphorylation, thereby activating cell proliferation and migration in BAECs.">
            <entity id="DS.d422.s1.e0" origId="5957" charOffset="63-66" type="compound" text="ATP"/>
            <entity id="DS.d422.s1.e1" origId="O00937,O13419,O16808,O17320,O65314,O65315,O65316,O74258,O81221,P02577,P10365,P10989,P11426,P13363,P14235,P17128,P20904,P24902,P26182,P26183,P30161,P45520,P45521,P48465,P50138,P51775,P53455,P53476,P53477,P53491,P53498,P53499,P53500,P53502,P53689,P60009,P60010,P60011,P68555,P78711,P80709,P81085,P90689,P91754,Q05214,Q11212,Q24733,Q2U7A3,Q39596,Q39758,Q6TCF2,Q75D00,Q8SWN8,Q8X119,Q92192,Q92193,Q99023,Q9P4D1,Q9UVF3,Q9UVX4,Q9UVZ8" charOffset="79-84" type="protein" text="actin"/>
            <entity id="DS.d422.s1.e2" origId="Q9C3Y4" charOffset="104-108" type="protein" text="RhoA"/>
            <entity id="DS.d422.s1.e3" origId="Q00944,Q05397" charOffset="124-127" type="protein" text="FAK"/>
            <pair e1="DS.d422.s1.e0" e2="DS.d422.s1.e3" id="DS.d422.s1.i0" interaction="True"/>
            <pair e1="DS.d422.s1.e0" e2="DS.d422.s1.e2" id="DS.d422.s1.i1" interaction="True"/>
            <pair e1="DS.d422.s1.e0" e2="DS.d422.s1.e1" id="DS.d422.s1.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d423" origId="18594946">
        <sentence id="DS.d423.s0" origId="18594946-953" text="Cell exposure to 250 microM homocysteine was able to induce transglutaminase 2 up-regulation and increased in situ transglutaminase activity.">
            <entity id="DS.d423.s0.e0" origId="778" charOffset="28-40" type="compound" text="homocysteine"/>
            <entity id="DS.d423.s0.e1" origId="P08587,P21980,P21981,P51176,P52181,Q01841" charOffset="60-78" type="protein" text="transglutaminase 2"/>
            <entity id="DS.d423.s0.e2" origId="P40746,P52183,P81453,Q819L3,Q81MS1,Q8GR90,Q9K5W7" charOffset="60-76" type="protein" text="transglutaminase"/>
            <pair e1="DS.d423.s0.e0" e2="DS.d423.s0.e2" id="DS.d423.s0.i0" interaction="True"/>
            <pair e1="DS.d423.s0.e0" e2="DS.d423.s0.e1" id="DS.d423.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d423.s1" origId="18594946-954" text="Homocysteine also induced NF-kappaB activation that seemed associated with transglutaminase 2 up-regulation since the specific NF-kappaB inhibition by SN50 was able to reduce transglutaminase expression and activity levels.">
            <entity id="DS.d423.s1.e0" origId="778" charOffset="0-12" type="compound" text="Homocysteine"/>
            <entity id="DS.d423.s1.e1" origId="P08587,P21980,P21981,P51176,P52181,Q01841" charOffset="75-93" type="protein" text="transglutaminase 2"/>
            <entity id="DS.d423.s1.e2" origId="P40746,P52183,P81453,Q819L3,Q81MS1,Q8GR90,Q9K5W7" charOffset="75-91" type="protein" text="transglutaminase"/>
            <pair e1="DS.d423.s1.e0" e2="DS.d423.s1.e2" id="DS.d423.s1.i0" interaction="True"/>
            <pair e1="DS.d423.s1.e0" e2="DS.d423.s1.e1" id="DS.d423.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d424" origId="18594965">
        <sentence id="DS.d424.s0" origId="18594965-980" text="Lysophosphatidic acid can support the formation of membranous structures and an increase in MBP mRNA levels in differentiating oligodendrocytes.">
            <entity id="DS.d424.s0.e0" origId="3988,5311263,5497152" charOffset="0-21" type="compound" text="Lysophosphatidic acid"/>
            <entity id="DS.d424.s0.e1" origId="P02686,P02687,P04370,P06906,P13727,P15720,P20939,P25188,P25274,P25336,P81558,P83487,P87346,P98190,Q61878,Q63189,Q91325,Q91439,Q9SAV1" charOffset="92-95" type="protein" text="MBP"/>
            <pair e1="DS.d424.s0.e0" e2="DS.d424.s0.e1" id="DS.d424.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d425" origId="18594989">
        <sentence id="DS.d425.s0" origId="18594989-1002" text="There was no correlation between the presence of significant heart-valve regurgitation and cabergoline cumulative dose, duration of cabergoline treatment, prior use of bromocriptine, age, adenoma size, or prolactin levels.">
            <entity id="DS.d425.s0.e0" origId="54746" charOffset="91-102" type="compound" text="cabergoline"/>
            <entity id="DS.d425.s0.e1" origId="54746" charOffset="132-143" type="compound" text="cabergoline"/>
            <entity id="DS.d425.s0.e2" origId="31101" charOffset="168-181" type="compound" text="bromocriptine"/>
            <entity id="DS.d425.s0.e3" origId="P10765,P22393,P33089,P33090,P33091,P43001" charOffset="205-214" type="protein" text="prolactin"/>
            <pair e1="DS.d425.s0.e0" e2="DS.d425.s0.e3" id="DS.d425.s0.i0" interaction="False"/>
            <pair e1="DS.d425.s0.e2" e2="DS.d425.s0.e3" id="DS.d425.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d426" origId="18595002">
        <sentence id="DS.d426.s0" origId="18595002-930" text="CHH elevates glucose levels in the hemolymph by stimulating glycogenolysis in target tissues.">
            <entity id="DS.d426.s0.e0" origId="O77220,P14944,P30814,P55845,P56687,P59685,P81032,P83800,Q25588,Q25589,Q25683,Q26181" charOffset="0-3" type="protein" text="CHH"/>
            <entity id="DS.d426.s0.e1" origId="206,5793,64689,79025" charOffset="13-20" type="compound" text="glucose"/>
            <pair e1="DS.d426.s0.e1" e2="DS.d426.s0.e0" id="DS.d426.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d427" origId="18596195">
        <sentence id="DS.d427.s0" origId="18596195-276" text="Here, we assessed the regulation of pancreatic cytochrome c release by Ca(2+), mitochondrial membrane potential (Delta Psi m), and reactive oxygen species (ROS), the signals involved in acute pancreatitis.">
            <entity id="DS.d427.s0.e0" origId="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3" charOffset="47-59" type="protein" text="cytochrome c"/>
            <entity id="DS.d427.s0.e1" origId="271" charOffset="71-75" type="compound" text="Ca(2"/>
            <pair e1="DS.d427.s0.e1" e2="DS.d427.s0.e0" id="DS.d427.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d428" origId="18596687">
        <sentence id="DS.d428.s0" origId="18596687-690" text="Here, we report the efficacy of betaxolol in reducing increases in gene expression of amygdalar corticotropin-releasing factor (CRF), a peptide known to be involved in mediating 'anxiety-like' behaviors during initial phases of cocaine abstinence.">
            <entity id="DS.d428.s0.e0" origId="2369,60657" charOffset="32-41" type="compound" text="betaxolol"/>
            <entity id="DS.d428.s0.e1" origId="P01142,P01143,P06296,P06850,P49188,P49926,Q8CIT0,Q95MI6,Q9PTS1" charOffset="96-126" type="protein" text="corticotropin-releasing factor"/>
            <entity id="DS.d428.s0.e2" origId="O75973,P01142,P01143,P06296,P06850,P49188,P49926,Q8CIT0,Q95MI6,Q9PTS1" charOffset="128-131" type="protein" text="CRF"/>
            <entity id="DS.d428.s0.e3" origId="2826,5760,439497,446220,644017,54613779" charOffset="228-235" type="compound" text="cocaine"/>
            <pair e1="DS.d428.s0.e3" e2="DS.d428.s0.e2" id="DS.d428.s0.i0" interaction="True"/>
            <pair e1="DS.d428.s0.e0" e2="DS.d428.s0.e1" id="DS.d428.s0.i1" interaction="True"/>
            <pair e1="DS.d428.s0.e0" e2="DS.d428.s0.e2" id="DS.d428.s0.i2" interaction="True"/>
            <pair e1="DS.d428.s0.e3" e2="DS.d428.s0.e1" id="DS.d428.s0.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d428.s1" origId="18596687-691" text="Results showed that betaxolol treatment during early cocaine withdrawal attenuated increases in amygdalar CRF gene expression and cyclic adenosine monophosphate-dependent protein kinase regulatory and catalytic subunit (nuclear fraction) protein expression.">
            <entity id="DS.d428.s1.e0" origId="2369,60657" charOffset="20-29" type="compound" text="betaxolol"/>
            <entity id="DS.d428.s1.e1" origId="2826,5760,439497,446220,644017,54613779" charOffset="53-60" type="compound" text="cocaine"/>
            <entity id="DS.d428.s1.e2" origId="O75973,P01142,P01143,P06296,P06850,P49188,P49926,Q8CIT0,Q95MI6,Q9PTS1" charOffset="106-109" type="protein" text="CRF"/>
            <entity id="DS.d428.s1.e3" origId="P00513,P25848" charOffset="171-185" type="protein" text="protein kinase"/>
            <pair e1="DS.d428.s1.e0" e2="DS.d428.s1.e3" id="DS.d428.s1.i0" interaction="True"/>
            <pair e1="DS.d428.s1.e1" e2="DS.d428.s1.e2" id="DS.d428.s1.i1" interaction="False"/>
            <pair e1="DS.d428.s1.e0" e2="DS.d428.s1.e2" id="DS.d428.s1.i2" interaction="True"/>
            <pair e1="DS.d428.s1.e1" e2="DS.d428.s1.e3" id="DS.d428.s1.i3" interaction="False"/>
        </sentence>
        <sentence id="DS.d428.s2" origId="18596687-692" text="The present findings suggest that the efficacy of betaxolol treatment on cocaine withdrawal-induced anxiety may be related, in part, to its effect on amygdalar beta(1)-adrenergic receptor, modulation of its downstream cell-signaling elements and CRF gene expression.">
            <entity id="DS.d428.s2.e0" origId="2369,60657" charOffset="50-59" type="compound" text="betaxolol"/>
            <entity id="DS.d428.s2.e1" origId="2826,5760,439497,446220,644017,54613779" charOffset="73-80" type="compound" text="cocaine"/>
            <entity id="DS.d428.s2.e2" origId="O75973,P01142,P01143,P06296,P06850,P49188,P49926,Q8CIT0,Q95MI6,Q9PTS1" charOffset="246-249" type="protein" text="CRF"/>
            <pair e1="DS.d428.s2.e1" e2="DS.d428.s2.e2" id="DS.d428.s2.i0" interaction="False"/>
            <pair e1="DS.d428.s2.e0" e2="DS.d428.s2.e2" id="DS.d428.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d429" origId="18597051">
        <sentence id="DS.d429.s0" origId="18597051-1012" text="Furthermore, it is demonstrated that this strain has xylanase activity, and the activity can be optimized under suitable growing conditions where wheat bran and urea are the primary sources of carbon and nitrogen.">
            <entity id="DS.d429.s0.e0" origId="O43097,O59859,O60206,P07529,P09850,P17137,P23360,P23557,P29417,P40943,P45703,P48793,P56588,P81536,Q53317" charOffset="53-61" type="protein" text="xylanase"/>
            <entity id="DS.d429.s0.e1" origId="1176,265993" charOffset="161-165" type="compound" text="urea"/>
            <entity id="DS.d429.s0.e2" origId="947,123329" charOffset="204-212" type="compound" text="nitrogen"/>
            <pair e1="DS.d429.s0.e1" e2="DS.d429.s0.e0" id="DS.d429.s0.i0" interaction="False"/>
            <pair e1="DS.d429.s0.e2" e2="DS.d429.s0.e0" id="DS.d429.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d430" origId="18597073">
        <sentence id="DS.d430.s0" origId="18597073-1033" text="Glutathione S-transferase (GST) isozymes catalyze nucleophilic attack by reduced Glutathione (GSH) on a variety of electrophilic compounds and play a central role in biotransformation of xenobiotics (Hayes et al., Annu Rev Pharmacol Toxicol 45:51-88, 2005).">
            <entity id="DS.d430.s0.e0" origId="O04437,O18598,P0A9D2,P0A9D3,P30116,P44521,P46088,P46419,P46423,P46426,P46428,P46437,P48438,P80894,P81065,P82996,P82997,P82998,P82999,P83000,P83001,P83246,Q04522,Q08392,Q08393,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52,Q96324" charOffset="0-25" type="protein" text="Glutathione S-transferase"/>
            <entity id="DS.d430.s0.e1" origId="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52" charOffset="27-30" type="protein" text="GST"/>
            <entity id="DS.d430.s0.e2" origId="124886" charOffset="73-92" type="compound" text="reduced Glutathione"/>
            <entity id="DS.d430.s0.e3" origId="124886" charOffset="94-97" type="compound" text="GSH"/>
            <pair e1="DS.d430.s0.e3" e2="DS.d430.s0.e1" id="DS.d430.s0.i0" interaction="True"/>
            <pair e1="DS.d430.s0.e2" e2="DS.d430.s0.e0" id="DS.d430.s0.i1" interaction="True"/>
            <pair e1="DS.d430.s0.e2" e2="DS.d430.s0.e1" id="DS.d430.s0.i2" interaction="True"/>
            <pair e1="DS.d430.s0.e3" e2="DS.d430.s0.e0" id="DS.d430.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d431" origId="18597869">
        <sentence id="DS.d431.s0" origId="18597869-1683" text="Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation.">
            <entity id="DS.d431.s0.e0" origId="4091" charOffset="0-9" type="compound" text="Metformin"/>
            <entity id="DS.d431.s0.e1" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="19-28" type="protein" text="TNF-alpha"/>
            <entity id="DS.d431.s0.e2" origId="O15111,Q60680" charOffset="37-51" type="protein" text="IkappaB kinase"/>
            <entity id="DS.d431.s0.e3" origId="P25963,Q08353,Q63746,Q91974,Q9Z1E3" charOffset="69-82" type="protein" text="IkappaB-alpha"/>
            <entity id="DS.d431.s0.e4" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="99-103" type="protein" text="IL-6"/>
            <entity id="DS.d431.s0.e5" origId="O00329,O02697,O35904,P23727,P26450,P27986,P32871,P42336,P42337,P42338,P42347,P42348,P48736,P54673,P54674,P54675,P54676,Q63787,Q8BTI9,Q8UUU2,Q9JHG7,Q9Z1L0" charOffset="144-148" type="protein" text="PI3K"/>
            <entity id="DS.d431.s0.e6" origId="P54646,Q09136,Q9Y478" charOffset="159-163" type="protein" text="AMPK"/>
            <pair e1="DS.d431.s0.e0" e2="DS.d431.s0.e6" id="DS.d431.s0.i0" interaction="True"/>
            <pair e1="DS.d431.s0.e0" e2="DS.d431.s0.e1" id="DS.d431.s0.i1" interaction="False"/>
            <pair e1="DS.d431.s0.e0" e2="DS.d431.s0.e5" id="DS.d431.s0.i2" interaction="True"/>
            <pair e1="DS.d431.s0.e0" e2="DS.d431.s0.e3" id="DS.d431.s0.i3" interaction="True"/>
            <pair e1="DS.d431.s0.e0" e2="DS.d431.s0.e4" id="DS.d431.s0.i4" interaction="True"/>
            <pair e1="DS.d431.s0.e0" e2="DS.d431.s0.e2" id="DS.d431.s0.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d432" origId="18599066">
        <sentence id="DS.d432.s0" origId="18599066-769" text="Palmitate phosphorylated p38 and JNK kinases, and blocking of these kinases with specific inhibitors diminished the palmitate-induced cytokine secretion.">
            <entity id="DS.d432.s0.e0" origId="985" charOffset="0-9" type="compound" text="Palmitate"/>
            <entity id="DS.d432.s0.e1" origId="O24473,O75791,O95433,O97628,P46108,P80350,P82869,Q01552,Q04929,Q63768,Q64010,Q9LDA4,Q9Y2S7" charOffset="25-28" type="protein" text="p38"/>
            <entity id="DS.d432.s0.e2" origId="P92208,Q966Y3" charOffset="33-36" type="protein" text="JNK"/>
            <entity id="DS.d432.s0.e3" origId="985" charOffset="116-125" type="compound" text="palmitate"/>
            <pair e1="DS.d432.s0.e0" e2="DS.d432.s0.e2" id="DS.d432.s0.i0" interaction="False"/>
            <pair e1="DS.d432.s0.e3" e2="DS.d432.s0.e1" id="DS.d432.s0.i1" interaction="False"/>
            <pair e1="DS.d432.s0.e0" e2="DS.d432.s0.e1" id="DS.d432.s0.i2" interaction="True"/>
            <pair e1="DS.d432.s0.e3" e2="DS.d432.s0.e2" id="DS.d432.s0.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d432.s1" origId="18599066-770" text="Palmitate also activated the AP-1 (c-Jun) transcription factor.">
            <entity id="DS.d432.s1.e0" origId="985" charOffset="0-9" type="compound" text="Palmitate"/>
            <entity id="DS.d432.s1.e1" origId="P21525" charOffset="29-33" type="protein" text="AP-1"/>
            <pair e1="DS.d432.s1.e0" e2="DS.d432.s1.e1" id="DS.d432.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d433" origId="18599093">
        <sentence id="DS.d433.s0" origId="18599093-1004" text="Characterisation of ATP analogues to cross-link and label P2X receptors.">
            <entity id="DS.d433.s0.e0" origId="5957" charOffset="20-23" type="compound" text="ATP"/>
            <entity id="DS.d433.s0.e1" origId="P13900,P16604" charOffset="58-61" type="protein" text="P2X"/>
            <pair e1="DS.d433.s0.e0" e2="DS.d433.s0.e1" id="DS.d433.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d433.s1" origId="18599093-1005" text="In this study we determined whether the UV light-reactive ATP analogues 2-azido ATP, ATP azidoanilide (ATP-AA) and 2', 3'-O-(4-benzoylbenzoyl)-ATP (BzATP) can be used to label the ATP binding site of P2X1 receptors.">
            <entity id="DS.d433.s1.e0" origId="5957" charOffset="58-61" type="compound" text="ATP"/>
            <entity id="DS.d433.s1.e1" origId="123645,189791" charOffset="72-83" type="compound" text="2-azido ATP"/>
            <entity id="DS.d433.s1.e2" origId="5957" charOffset="80-83" type="compound" text="ATP"/>
            <entity id="DS.d433.s1.e3" origId="5957" charOffset="80-83" type="compound" text="ATP"/>
            <entity id="DS.d433.s1.e4" origId="115205" charOffset="119-146" type="compound" text="3'-O-(4-benzoylbenzoyl)-ATP"/>
            <entity id="DS.d433.s1.e5" origId="115205" charOffset="148-153" type="compound" text="BzATP"/>
            <entity id="DS.d433.s1.e6" origId="P47824,P51575,P51576" charOffset="200-204" type="protein" text="P2X1"/>
            <pair e1="DS.d433.s1.e0" e2="DS.d433.s1.e6" id="DS.d433.s1.i0" interaction="True"/>
            <pair e1="DS.d433.s1.e1" e2="DS.d433.s1.e6" id="DS.d433.s1.i1" interaction="True"/>
            <pair e1="DS.d433.s1.e5" e2="DS.d433.s1.e6" id="DS.d433.s1.i2" interaction="True"/>
            <pair e1="DS.d433.s1.e4" e2="DS.d433.s1.e6" id="DS.d433.s1.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d433.s2" origId="18599093-1006" text="cross-linked to P2X1 receptors and this binding was reduced by co-incubation with ATP.">
            <entity id="DS.d433.s2.e0" origId="P47824,P51575,P51576" charOffset="16-20" type="protein" text="P2X1"/>
            <entity id="DS.d433.s2.e1" origId="5957" charOffset="82-85" type="compound" text="ATP"/>
            <pair e1="DS.d433.s2.e1" e2="DS.d433.s2.e0" id="DS.d433.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d433.s3" origId="18599093-1007" text="These studies demonstrate that photo-reactive ATP analogues can be used to label P2X receptor and may prove useful in elucidating the ATP binding site at this novel class of ATP binding proteins.">
            <entity id="DS.d433.s3.e0" origId="5957" charOffset="46-49" type="compound" text="ATP"/>
            <entity id="DS.d433.s3.e1" origId="P13900,P16604" charOffset="81-84" type="protein" text="P2X"/>
            <pair e1="DS.d433.s3.e0" e2="DS.d433.s3.e1" id="DS.d433.s3.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d434" origId="18599154">
        <sentence id="DS.d434.s0" origId="18599154-1053" text="TGF-beta1 treatment for 72 h also induced EMT in the A549 cells and this transition led to resistance to gefitinib.">
            <entity id="DS.d434.s0.e0" origId="O19011,O93449,P01137,P04202,P07200,P09531,P09533,P16176,P17246,P18341,P50414,P54831,Q38HS2,Q9PTQ2,Q9Z1Y6" charOffset="0-9" type="protein" text="TGF-beta1"/>
            <entity id="DS.d434.s0.e1" origId="123631" charOffset="105-114" type="compound" text="gefitinib"/>
            <pair e1="DS.d434.s0.e1" e2="DS.d434.s0.e0" id="DS.d434.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d435" origId="18599191">
        <sentence id="DS.d435.s0" origId="18599191-1078" text="Insulin-antagonistic effects of hormones, cytokines and excess metabolic substrates such as glucose and fatty acids may be exerted via common mechanisms involving for example reactive oxygen species (ROS) accumulation and associated inflammatory responses.">
            <entity id="DS.d435.s0.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="0-7" type="protein" text="Insulin"/>
            <entity id="DS.d435.s0.e1" origId="206,5793,64689,79025" charOffset="92-99" type="compound" text="glucose"/>
            <pair e1="DS.d435.s0.e1" e2="DS.d435.s0.e0" id="DS.d435.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d436" origId="18599210">
        <sentence id="DS.d436.s0" origId="18599210-1087" text="Optimization of decolorization of methylene blue (MB) dye by lignin peroxidase (LiP) enzyme produced by white-rot fungus Phanerochaete chrysosporium using sewage treatment plant (STP) sludge as a major substrate was carried out in the laboratory.">
            <entity id="DS.d436.s0.e0" origId="4139" charOffset="34-48" type="compound" text="methylene blue"/>
            <entity id="DS.d436.s0.e1" origId="P06181,P11542,P11543,P20010,P20011,P20012,P20013,P21764,P31837,P31838,P49012,P50622" charOffset="61-78" type="protein" text="lignin peroxidase"/>
            <pair e1="DS.d436.s0.e0" e2="DS.d436.s0.e1" id="DS.d436.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d437" origId="18600448">
        <sentence id="DS.d437.s0" origId="18600448-401" text="Glycine release was potentiated by the activation of protein kinase C and diminished by increasing cyclic guanosine monophosphate levels with a phosphodiesterase inhibitor, zaprinast.">
            <entity id="DS.d437.s0.e0" origId="750" charOffset="0-7" type="compound" text="Glycine"/>
            <entity id="DS.d437.s0.e1" origId="P13678,Q25378" charOffset="53-69" type="protein" text="protein kinase C"/>
            <entity id="DS.d437.s0.e2" origId="24316" charOffset="99-129" type="compound" text="cyclic guanosine monophosphate"/>
            <entity id="DS.d437.s0.e3" origId="5722" charOffset="173-182" type="compound" text="zaprinast"/>
            <pair e1="DS.d437.s0.e3" e2="DS.d437.s0.e1" id="DS.d437.s0.i0" interaction="False"/>
            <pair e1="DS.d437.s0.e2" e2="DS.d437.s0.e1" id="DS.d437.s0.i1" interaction="False"/>
            <pair e1="DS.d437.s0.e0" e2="DS.d437.s0.e1" id="DS.d437.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d438" origId="18600455">
        <sentence id="DS.d438.s0" origId="18600455-406" text="Our study demonstrates that taurocholate causes evident damage to acinar cells, impairing both calcium homeostasis and secretory response to CCK.">
            <entity id="DS.d438.s0.e0" origId="6675" charOffset="28-40" type="compound" text="taurocholate"/>
            <entity id="DS.d438.s0.e1" origId="O57312,O93464,P01355,P01356,P06307,P09240,P0C229,P23362,P41520,P50144,P50145,P68125,P68126,P80344,P80345,Q9PU29,Q9PU41" charOffset="141-144" type="protein" text="CCK"/>
            <pair e1="DS.d438.s0.e0" e2="DS.d438.s0.e1" id="DS.d438.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d439" origId="18600456">
        <sentence id="DS.d439.s0" origId="18600456-407" text="Enteric neuronal dopamine (DA) inhibits acetylcholine release and gastric motility; this has been thought to be mediated via neuronal dopamine-2 receptor (D2R).">
            <entity id="DS.d439.s0.e0" origId="187" charOffset="40-53" type="compound" text="acetylcholine"/>
            <entity id="DS.d439.s0.e1" origId="Q8IS44" charOffset="155-158" type="protein" text="D2R"/>
            <pair e1="DS.d439.s0.e0" e2="DS.d439.s0.e1" id="DS.d439.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d440" origId="18600473">
        <sentence id="DS.d440.s0" origId="18600473-984" text="As compared with parental B16 cells, the inhibitory effects of TGF-beta1 and activin A on melanin content were relative smaller in B16 F10 cells, a subline of B16 cells that contain more pigment.">
            <entity id="DS.d440.s0.e0" origId="O19011,O93449,P01137,P04202,P07200,P09531,P09533,P16176,P17246,P18341,P50414,P54831,Q38HS2,Q9PTQ2,Q9Z1Y6" charOffset="63-72" type="protein" text="TGF-beta1"/>
            <entity id="DS.d440.s0.e1" origId="6325610" charOffset="90-97" type="compound" text="melanin"/>
            <pair e1="DS.d440.s0.e1" e2="DS.d440.s0.e0" id="DS.d440.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d441" origId="18601937">
        <sentence id="DS.d441.s0" origId="18601937-1660" text="ATP-gated P2X receptors on excitatory nerve terminals onto interneurons initiate a form of asynchronous glutamate release.">
            <entity id="DS.d441.s0.e0" origId="P13900,P16604" charOffset="10-13" type="protein" text="P2X"/>
            <entity id="DS.d441.s0.e1" origId="611,23327,33032" charOffset="104-113" type="compound" text="glutamate"/>
            <pair e1="DS.d441.s0.e1" e2="DS.d441.s0.e0" id="DS.d441.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d441.s1" origId="18601937-1662" text="However asynchronous EPSCs were increased following synaptic depression and a component of these appeared to be initiated by endogenously released ATP acting on presynaptic P2X receptors.">
            <entity id="DS.d441.s1.e0" origId="5957" charOffset="147-150" type="compound" text="ATP"/>
            <entity id="DS.d441.s1.e1" origId="P13900,P16604" charOffset="173-176" type="protein" text="P2X"/>
            <pair e1="DS.d441.s1.e0" e2="DS.d441.s1.e1" id="DS.d441.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d441.s2" origId="18601937-1663" text="Unexpectedly, the data suggest P2X receptor activation initiates a form of asynchronous glutamate release, rather than detectably affecting the vesicles underlying action potential evoked release.">
            <entity id="DS.d441.s2.e0" origId="P13900,P16604" charOffset="31-34" type="protein" text="P2X"/>
            <entity id="DS.d441.s2.e1" origId="611,23327,33032" charOffset="88-97" type="compound" text="glutamate"/>
            <pair e1="DS.d441.s2.e1" e2="DS.d441.s2.e0" id="DS.d441.s2.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d442" origId="18601945">
        <sentence id="DS.d442.s0" origId="18601945-1673" text="The second enzyme of GSH synthesis, GSH synthase (GS) is also regulated in a coordinated manner as GCL subunits and its up-regulation can further enhance the capacity of the cell to synthesize GSH.">
            <entity id="DS.d442.s0.e0" origId="124886" charOffset="21-24" type="compound" text="GSH"/>
            <entity id="DS.d442.s0.e1" origId="124886" charOffset="36-39" type="compound" text="GSH"/>
            <entity id="DS.d442.s0.e2" origId="P28676,Q8NEA9,Q96IK5" charOffset="99-102" type="protein" text="GCL"/>
            <entity id="DS.d442.s0.e3" origId="124886" charOffset="36-39" type="compound" text="GSH"/>
            <pair e1="DS.d442.s0.e0" e2="DS.d442.s0.e2" id="DS.d442.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d443" origId="18602447">
        <sentence id="DS.d443.s0" origId="18602447-1075" text="The rise in (Ca(2+))(i) elicited by hGH is associated with an enhanced insulin secretion, effects that are mediated mainly through the prolactin receptor.">
            <entity id="DS.d443.s0.e0" origId="271" charOffset="13-17" type="compound" text="Ca(2"/>
            <entity id="DS.d443.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="71-78" type="protein" text="insulin"/>
            <entity id="DS.d443.s0.e2" origId="P10765,P22393,P33089,P33090,P33091,P43001" charOffset="135-144" type="protein" text="prolactin"/>
            <pair e1="DS.d443.s0.e0" e2="DS.d443.s0.e2" id="DS.d443.s0.i0" interaction="True"/>
            <pair e1="DS.d443.s0.e0" e2="DS.d443.s0.e1" id="DS.d443.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d443.s1" origId="18602447-1076" text="These mechanisms indicate that a rise in (Ca(2+))(i) elicited by activation of PRLR is JAK2-dependent and is associated with enhanced insulin secretion.">
            <entity id="DS.d443.s1.e0" origId="271" charOffset="42-46" type="compound" text="Ca(2"/>
            <entity id="DS.d443.s1.e1" origId="O46561,P14787,P16471,Q04594,Q28172,Q28235,Q6JTA8,Q90374,Q91094,Q91513" charOffset="79-83" type="protein" text="PRLR"/>
            <entity id="DS.d443.s1.e2" origId="O60674" charOffset="87-91" type="protein" text="JAK2"/>
            <entity id="DS.d443.s1.e3" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="134-141" type="protein" text="insulin"/>
            <pair e1="DS.d443.s1.e0" e2="DS.d443.s1.e2" id="DS.d443.s1.i0" interaction="True"/>
            <pair e1="DS.d443.s1.e0" e2="DS.d443.s1.e3" id="DS.d443.s1.i1" interaction="True"/>
            <pair e1="DS.d443.s1.e0" e2="DS.d443.s1.e1" id="DS.d443.s1.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d443.s2" origId="18602447-1077" text="In contrast, GH receptor-mediated increase in (Ca(2+))(i) is JAK2-independent and is dissociated from insulin secretion.">
            <entity id="DS.d443.s2.e0" origId="O46600,P10912,P16310,P16882,P19756,P19941,P79108,P79194,Q02092,Q28575,Q90375,Q95JF2,Q95ML5,Q9JI97,Q9TU69,Q9XSZ1" charOffset="13-24" type="protein" text="GH receptor"/>
            <entity id="DS.d443.s2.e1" origId="271" charOffset="47-51" type="compound" text="Ca(2"/>
            <entity id="DS.d443.s2.e2" origId="O60674" charOffset="61-65" type="protein" text="JAK2"/>
            <entity id="DS.d443.s2.e3" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="102-109" type="protein" text="insulin"/>
            <pair e1="DS.d443.s2.e1" e2="DS.d443.s2.e2" id="DS.d443.s2.i0" interaction="True"/>
            <pair e1="DS.d443.s2.e1" e2="DS.d443.s2.e3" id="DS.d443.s2.i1" interaction="False"/>
            <pair e1="DS.d443.s2.e1" e2="DS.d443.s2.e0" id="DS.d443.s2.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d444" origId="18602691">
        <sentence id="DS.d444.s0" origId="18602691-569" text="SEMG I expression is upregulated by IL-4, IL-6 and 5-azacytidine.">
            <entity id="DS.d444.s0.e0" origId="P04279" charOffset="0-4" type="protein" text="SEMG"/>
            <entity id="DS.d444.s0.e1" origId="O77762,P05112,P07750,P20096,P30367,P30368,P42202,P46652,P47966,P51492,P51744,P55030,P79155,P79339,Q04745,Q2PE74,Q3S4V6,Q58M18,Q60440,Q7YS71,Q865X5,Q865Y0,Q8HYB1,Q9MZR8,Q9XS58" charOffset="36-40" type="protein" text="IL-4"/>
            <entity id="DS.d444.s0.e2" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="42-46" type="protein" text="IL-6"/>
            <entity id="DS.d444.s0.e3" origId="9444" charOffset="51-64" type="compound" text="5-azacytidine"/>
            <pair e1="DS.d444.s0.e3" e2="DS.d444.s0.e1" id="DS.d444.s0.i0" interaction="False"/>
            <pair e1="DS.d444.s0.e3" e2="DS.d444.s0.e0" id="DS.d444.s0.i1" interaction="True"/>
            <pair e1="DS.d444.s0.e3" e2="DS.d444.s0.e2" id="DS.d444.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d445" origId="18602794">
        <sentence id="DS.d445.s0" origId="18602794-652" text="Trichostatin A down-regulates CYP19 transcript and protein levels in MCF-7 breast cancer cells.">
            <entity id="DS.d445.s0.e0" origId="444732" charOffset="0-14" type="compound" text="Trichostatin A"/>
            <entity id="DS.d445.s0.e1" origId="O46512,P11511,P19098,P46194,P70091,P79690,P79699,Q29605,Q29624,Q5QQX7,Q69FB6,Q6QHT9,Q6YI21,Q92087,Q92111,Q92112,Q95M61,Q9XS28" charOffset="30-35" type="protein" text="CYP19"/>
            <pair e1="DS.d445.s0.e0" e2="DS.d445.s0.e1" id="DS.d445.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d446" origId="18602807">
        <sentence id="DS.d446.s0" origId="18602807-667" text="Consumption of the trichothecene mycotoxin deoxynivalenol (DON) induces interleukin-6 (IL-6)-dependent IgA nephropathy (IgAN) in mice.">
            <entity id="DS.d446.s0.e1" origId="40024,430147,442408,6321385,6432495,49868109" charOffset="43-57" type="compound" text="deoxynivalenol"/>
            <entity id="DS.d446.s0.e2" origId="P41693" charOffset="72-85" type="protein" text="interleukin-6"/>
            <entity id="DS.d446.s0.e3" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="87-91" type="protein" text="IL-6"/>
            <pair e1="DS.d446.s0.e1" e2="DS.d446.s0.e2" id="DS.d446.s0.i0" interaction="True"/>
            <pair e1="DS.d446.s0.e1" e2="DS.d446.s0.e3" id="DS.d446.s0.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d446.s1" origId="18602807-668" text="The purpose of this study was to identify the signal transduction pathways by which DON up-regulates IL-6 in the peritoneal macrophage and how consumption of fish oil enriched with the n-3 PUFA docosahexaenoic acid (DHA) suppresses these processes.">
            <entity id="DS.d446.s1.e0" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="101-105" type="protein" text="IL-6"/>
            <entity id="DS.d446.s1.e1" origId="445580" charOffset="194-214" type="compound" text="docosahexaenoic acid"/>
            <pair e1="DS.d446.s1.e1" e2="DS.d446.s1.e0" id="DS.d446.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d448" origId="18602814">
        <sentence id="DS.d448.s0" origId="18602814-672" text="The aim of the present study was to determine the effects of niacin and chromium on HDL formation by investigating the changes in ABCA1 and ApoA-1 transcription in the human hepatoblastoma cell line (HepG2 cells).">
            <entity id="DS.d448.s0.e0" origId="938" charOffset="61-67" type="compound" text="niacin"/>
            <entity id="DS.d448.s0.e1" origId="23976" charOffset="72-80" type="compound" text="chromium"/>
            <entity id="DS.d448.s0.e2" origId="O95477" charOffset="130-135" type="protein" text="ABCA1"/>
            <pair e1="DS.d448.s0.e1" e2="DS.d448.s0.e2" id="DS.d448.s0.i0" interaction="False"/>
            <pair e1="DS.d448.s0.e0" e2="DS.d448.s0.e2" id="DS.d448.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d448.s1" origId="18602814-674" text="Niacin and chromium cotreatment significantly induced the expression of peroxisome proliferator-activated receptor-alpha (PPARalpha) mRNA by approximately 1.3-1.8-fold.">
            <entity id="DS.d448.s1.e0" origId="938" charOffset="0-6" type="compound" text="Niacin"/>
            <entity id="DS.d448.s1.e1" origId="23976" charOffset="11-19" type="compound" text="chromium"/>
            <entity id="DS.d448.s1.e2" origId="O35507,P23204,P37230,P37232,Q07869,Q8HYL6,Q95N78" charOffset="72-120" type="protein" text="peroxisome proliferator-activated receptor-alpha"/>
            <entity id="DS.d448.s1.e3" origId="O35507,P23204,P37230,P37232,Q07869,Q8HYL6,Q95N78" charOffset="122-131" type="protein" text="PPARalpha"/>
            <pair e1="DS.d448.s1.e1" e2="DS.d448.s1.e2" id="DS.d448.s1.i0" interaction="True"/>
            <pair e1="DS.d448.s1.e1" e2="DS.d448.s1.e3" id="DS.d448.s1.i1" interaction="True"/>
            <pair e1="DS.d448.s1.e0" e2="DS.d448.s1.e2" id="DS.d448.s1.i2" interaction="True"/>
            <pair e1="DS.d448.s1.e0" e2="DS.d448.s1.e3" id="DS.d448.s1.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d448.s2" origId="18602814-675" text="A combination of niacin and chromium chloride did not significantly increase (3+1 mM) but instead reduced (1+3 mM) ABCA1 gene expression.">
            <entity id="DS.d448.s2.e0" origId="938" charOffset="17-23" type="compound" text="niacin"/>
            <entity id="DS.d448.s2.e1" origId="24808,24871" charOffset="28-45" type="compound" text="chromium chloride"/>
            <entity id="DS.d448.s2.e2" origId="O95477" charOffset="115-120" type="protein" text="ABCA1"/>
            <pair e1="DS.d448.s2.e0" e2="DS.d448.s2.e2" id="DS.d448.s2.i0" interaction="True"/>
            <pair e1="DS.d448.s2.e1" e2="DS.d448.s2.e2" id="DS.d448.s2.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d448.s3" origId="18602814-676" text="We hypothesize that the stimulation of ABCA1 gene expression causes an enhanced cholesterol efflux, perhaps mediated by PPARalpha pathway(s).">
            <entity id="DS.d448.s3.e0" origId="O95477" charOffset="39-44" type="protein" text="ABCA1"/>
            <entity id="DS.d448.s3.e1" origId="304,5997,6432564,11025495" charOffset="80-91" type="compound" text="cholesterol"/>
            <entity id="DS.d448.s3.e2" origId="O35507,P23204,P37230,P37232,Q07869,Q8HYL6,Q95N78" charOffset="120-129" type="protein" text="PPARalpha"/>
            <pair e1="DS.d448.s3.e1" e2="DS.d448.s3.e0" id="DS.d448.s3.i0" interaction="True"/>
            <pair e1="DS.d448.s3.e1" e2="DS.d448.s3.e2" id="DS.d448.s3.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d450" origId="18602823">
        <sentence id="DS.d450.s0" origId="18602823-684" text="Sulforaphane inhibited cell proliferation with IC(50) values at 24 and 48 h of 12.5 and 7.5 muM doses, respectively, and decreased ERalpha protein expression at concentrations between 2.5 and 30 muM.">
            <entity id="DS.d450.s0.e0" origId="5350" charOffset="0-12" type="compound" text="Sulforaphane"/>
            <entity id="DS.d450.s0.e1" origId="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7" charOffset="131-138" type="protein" text="ERalpha"/>
            <pair e1="DS.d450.s0.e0" e2="DS.d450.s0.e1" id="DS.d450.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d450.s1" origId="18602823-685" text="30 muM, the SUL-induced suppression of ERalpha protein was reversed by preincubation with the proteasome inhibitor MG132 and was accompanied by an increase in protein levels of the 20S catalytic core subunit PSMB5.">
            <entity id="DS.d450.s1.e0" origId="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7" charOffset="39-46" type="protein" text="ERalpha"/>
            <entity id="DS.d450.s1.e1" origId="462382" charOffset="115-120" type="compound" text="MG132"/>
            <entity id="DS.d450.s1.e2" origId="P28074,P34065" charOffset="208-213" type="protein" text="PSMB5"/>
            <pair e1="DS.d450.s1.e1" e2="DS.d450.s1.e0" id="DS.d450.s1.i0" interaction="True"/>
            <pair e1="DS.d450.s1.e1" e2="DS.d450.s1.e2" id="DS.d450.s1.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d452" origId="18603252">
        <sentence id="DS.d452.s0" origId="18603252-1055" text="Of importance, treatment with ezetimibe significantly improved endothelial dysfunction as assessed by the vasodilator response to acetylcholine, accompanied by inhibition of interleukin-6 mRNA and an increase in endothelial nitric oxide synthase (eNOS) mRNA in the aorta.">
            <entity id="DS.d452.s0.e0" origId="150311" charOffset="30-39" type="compound" text="ezetimibe"/>
            <entity id="DS.d452.s0.e1" origId="187" charOffset="130-143" type="compound" text="acetylcholine"/>
            <entity id="DS.d452.s0.e2" origId="P41693" charOffset="174-187" type="protein" text="interleukin-6"/>
            <entity id="DS.d452.s0.e3" origId="O61309,O61608,Q27571,Q9I9M2" charOffset="224-245" type="protein" text="nitric oxide synthase"/>
            <entity id="DS.d452.s0.e4" origId="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600" charOffset="247-251" type="protein" text="eNOS"/>
            <pair e1="DS.d452.s0.e0" e2="DS.d452.s0.e4" id="DS.d452.s0.i0" interaction="True"/>
            <pair e1="DS.d452.s0.e1" e2="DS.d452.s0.e2" id="DS.d452.s0.i1" interaction="False"/>
            <pair e1="DS.d452.s0.e1" e2="DS.d452.s0.e3" id="DS.d452.s0.i2" interaction="False"/>
            <pair e1="DS.d452.s0.e0" e2="DS.d452.s0.e2" id="DS.d452.s0.i3" interaction="True"/>
            <pair e1="DS.d452.s0.e1" e2="DS.d452.s0.e4" id="DS.d452.s0.i4" interaction="False"/>
            <pair e1="DS.d452.s0.e0" e2="DS.d452.s0.e3" id="DS.d452.s0.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d453" origId="18603333">
        <sentence id="DS.d453.s0" origId="18603333-1106" text="A series of adamantane derivatives of thiazolyl-N-substituted amides were synthesized in a three-step reaction and tested for anti-inflammatory activity as well as lipoxygenase and cycloxygenase inhibitory actions.">
            <entity id="DS.d453.s0.e0" origId="9238" charOffset="12-22" type="compound" text="adamantane"/>
            <entity id="DS.d453.s0.e1" origId="P27481,P38414" charOffset="164-176" type="protein" text="lipoxygenase"/>
            <pair e1="DS.d453.s0.e0" e2="DS.d453.s0.e1" id="DS.d453.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d454" origId="18604600">
        <sentence id="DS.d454.s0" origId="18604600-443" text="Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI.">
            <entity id="DS.d454.s0.e0" origId="P21917,P30729,P51436,Q6TLJ0" charOffset="0-20" type="protein" text="Dopamine D4 receptor"/>
            <entity id="DS.d454.s0.e1" origId="5761" charOffset="83-86" type="compound" text="LSD"/>
            <entity id="DS.d454.s0.e2" origId="1001,31016" charOffset="100-114" type="compound" text="phenethylamine"/>
            <entity id="DS.d454.s0.e4" origId="1229,6603801,9840090" charOffset="128-131" type="compound" text="DOI"/>
            <pair e1="DS.d454.s0.e2" e2="DS.d454.s0.e0" id="DS.d454.s0.i0" interaction="False"/>
            <pair e1="DS.d454.s0.e1" e2="DS.d454.s0.e0" id="DS.d454.s0.i1" interaction="True"/>
            <pair e1="DS.d454.s0.e4" e2="DS.d454.s0.e0" id="DS.d454.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d455" origId="18606045">
        <sentence id="DS.d455.s0" origId="18606045-1675" text="Plasma levels of magnesium, zinc and carotenoids did not vary across quintiles, but weak negative correlations were observed with serum ferritin and transferrin saturation.">
            <entity id="DS.d455.s0.e0" origId="5462224" charOffset="17-26" type="compound" text="magnesium"/>
            <entity id="DS.d455.s0.e1" origId="Q26061" charOffset="136-144" type="protein" text="ferritin"/>
            <entity id="DS.d455.s0.e2" origId="P02787,P09571,P12346,P19134,P27425,Q29443,Q921I1" charOffset="149-160" type="protein" text="transferrin"/>
            <pair e1="DS.d455.s0.e0" e2="DS.d455.s0.e2" id="DS.d455.s0.i0" interaction="True"/>
            <pair e1="DS.d455.s0.e0" e2="DS.d455.s0.e1" id="DS.d455.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d456" origId="18606396">
        <sentence id="DS.d456.s0" origId="18606396-239" text="Two major groups of ligand-activated nuclear receptors/xenosensors evolved: the Ah receptor (activated by aryl hydrocarbons and drugs such as omeprazole) and type 2 steroid receptors such as PXR and CAR, activated by drugs such as rifampicin, carbamazepin and phenytoin.">
            <entity id="DS.d456.s0.e0" origId="O02747,P30561,P35869,P41738,Q8R4S2,Q8R4S4,Q8R4S5,Q8R4S6,Q8R4S7,Q95LD9" charOffset="80-91" type="protein" text="Ah receptor"/>
            <entity id="DS.d456.s0.e1" origId="4594,9579578" charOffset="142-152" type="compound" text="omeprazole"/>
            <entity id="DS.d456.s0.e2" origId="O75469,Q8SQ01" charOffset="191-194" type="protein" text="PXR"/>
            <entity id="DS.d456.s0.e3" origId="5381226,5388984,5458213,6243627,6842115,6913622,16043998,17753751,25141428,45356263,56947149" charOffset="231-241" type="compound" text="rifampicin"/>
            <entity id="DS.d456.s0.e4" origId="1775" charOffset="260-269" type="compound" text="phenytoin"/>
            <pair e1="DS.d456.s0.e4" e2="DS.d456.s0.e2" id="DS.d456.s0.i0" interaction="True"/>
            <pair e1="DS.d456.s0.e3" e2="DS.d456.s0.e0" id="DS.d456.s0.i1" interaction="False"/>
            <pair e1="DS.d456.s0.e3" e2="DS.d456.s0.e2" id="DS.d456.s0.i2" interaction="True"/>
            <pair e1="DS.d456.s0.e1" e2="DS.d456.s0.e2" id="DS.d456.s0.i3" interaction="False"/>
            <pair e1="DS.d456.s0.e4" e2="DS.d456.s0.e0" id="DS.d456.s0.i4" interaction="False"/>
            <pair e1="DS.d456.s0.e1" e2="DS.d456.s0.e0" id="DS.d456.s0.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d457" origId="18607531">
        <sentence id="DS.d457.s0" origId="18607531-1203" text="The structure-activity relationship between oxycoumarin derivatives showing inhibitory effects on iNOS in mouse macrophage RAW264.7 cells.">
            <entity id="DS.d457.s0.e0" origId="5281426" charOffset="44-55" type="compound" text="oxycoumarin"/>
            <entity id="DS.d457.s0.e1" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="98-102" type="protein" text="iNOS"/>
            <pair e1="DS.d457.s0.e0" e2="DS.d457.s0.e1" id="DS.d457.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d457.s1" origId="18607531-1204" text="We have investigated the structure-activity relationship between 63 natural oxycoumarin derivatives and their effects on the expression of inducible-nitric oxide synthase (iNOS) induced by lipopolysaccharide.">
            <entity id="DS.d457.s1.e0" origId="5281426" charOffset="76-87" type="compound" text="oxycoumarin"/>
            <entity id="DS.d457.s1.e1" origId="O61309,O61608,Q27571,Q9I9M2" charOffset="149-170" type="protein" text="nitric oxide synthase"/>
            <entity id="DS.d457.s1.e2" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="172-176" type="protein" text="iNOS"/>
            <entity id="DS.d457.s1.e3" origId="11970143" charOffset="189-207" type="compound" text="lipopolysaccharide"/>
            <pair e1="DS.d457.s1.e0" e2="DS.d457.s1.e2" id="DS.d457.s1.i0" interaction="False"/>
            <pair e1="DS.d457.s1.e3" e2="DS.d457.s1.e2" id="DS.d457.s1.i1" interaction="True"/>
            <pair e1="DS.d457.s1.e3" e2="DS.d457.s1.e1" id="DS.d457.s1.i2" interaction="True"/>
            <pair e1="DS.d457.s1.e0" e2="DS.d457.s1.e1" id="DS.d457.s1.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d458" origId="18607542">
        <sentence id="DS.d458.s0" origId="18607542-1212" text="Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells.">
            <entity id="DS.d458.s0.e0" origId="68791" charOffset="35-41" type="compound" text="imexon"/>
            <entity id="DS.d458.s0.e1" origId="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9" charOffset="50-60" type="protein" text="HIF-1alpha"/>
            <pair e1="DS.d458.s0.e0" e2="DS.d458.s0.e1" id="DS.d458.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d458.s1" origId="18607542-1213" text="Western blot analyses of imexon-treated cells demonstrated that imexon reduces HIF-1alpha protein levels in both normoxic and hypoxic conditions in a time- and concentration-dependant fashion.">
            <entity id="DS.d458.s1.e0" origId="68791" charOffset="25-31" type="compound" text="imexon"/>
            <entity id="DS.d458.s1.e1" origId="68791" charOffset="64-70" type="compound" text="imexon"/>
            <entity id="DS.d458.s1.e2" origId="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9" charOffset="79-89" type="protein" text="HIF-1alpha"/>
            <pair e1="DS.d458.s1.e0" e2="DS.d458.s1.e2" id="DS.d458.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d458.s2" origId="18607542-1214" text="Gemcitabine did not similarly affect HIF-1alpha levels.">
            <entity id="DS.d458.s2.e0" origId="60750" charOffset="0-11" type="compound" text="Gemcitabine"/>
            <entity id="DS.d458.s2.e1" origId="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9" charOffset="37-47" type="protein" text="HIF-1alpha"/>
            <pair e1="DS.d458.s2.e0" e2="DS.d458.s2.e1" id="DS.d458.s2.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d458.s3" origId="18607542-1216" text="Concurrently, the half-life of existing HIF-1alpha protein was increased by imexon, in association with a marked inhibition of chymotryptic activity in the 20S proteasome.">
            <entity id="DS.d458.s3.e0" origId="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9" charOffset="40-50" type="protein" text="HIF-1alpha"/>
            <entity id="DS.d458.s3.e1" origId="68791" charOffset="76-82" type="compound" text="imexon"/>
            <pair e1="DS.d458.s3.e1" e2="DS.d458.s3.e0" id="DS.d458.s3.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d458.s4" origId="18607542-1217" text="The inhibition of HIF-1alpha translation was not specific, rather it was part of a general decrease in protein translation caused by imexon.">
            <entity id="DS.d458.s4.e0" origId="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9" charOffset="18-28" type="protein" text="HIF-1alpha"/>
            <entity id="DS.d458.s4.e1" origId="68791" charOffset="133-139" type="compound" text="imexon"/>
            <pair e1="DS.d458.s4.e1" e2="DS.d458.s4.e0" id="DS.d458.s4.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d459" origId="18607689">
        <sentence id="DS.d459.s0" origId="18607689-1312" text="To determine whether a regimen of aspirin pretreatment, bivalirudin during the procedure and clopidogrel (600 mg) immediately after percutaneous coronary intervention (PCI) was associated with platelet activation during and shortly after (1 and 2 h) PCI, we characterized platelet function in 10 patients with the use of flow cytometry in the absence of agonist and in response to thrombin (10 nM), ADP (1 microM), the collagen-mimetic convulxin (5 ng/ml), and platelet activating factor (10 nM).">
            <entity id="DS.d459.s0.e0" origId="2244" charOffset="34-41" type="compound" text="aspirin"/>
            <entity id="DS.d459.s0.e1" origId="16129704" charOffset="56-67" type="compound" text="bivalirudin"/>
            <entity id="DS.d459.s0.e2" origId="2806,60606" charOffset="93-104" type="compound" text="clopidogrel"/>
            <entity id="DS.d459.s0.e3" origId="P84122" charOffset="381-389" type="protein" text="thrombin"/>
            <entity id="DS.d459.s0.e4" origId="108157" charOffset="461-487" type="compound" text="platelet activating factor"/>
            <pair e1="DS.d459.s0.e0" e2="DS.d459.s0.e3" id="DS.d459.s0.i0" interaction="False"/>
            <pair e1="DS.d459.s0.e4" e2="DS.d459.s0.e3" id="DS.d459.s0.i1" interaction="False"/>
            <pair e1="DS.d459.s0.e2" e2="DS.d459.s0.e3" id="DS.d459.s0.i2" interaction="False"/>
            <pair e1="DS.d459.s0.e1" e2="DS.d459.s0.e3" id="DS.d459.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d460" origId="18607722">
        <sentence id="DS.d460.s0" origId="18607722-1326" text="Brainstem concentrations of cholesterol are not influenced by genetic ablation of the low-density lipoprotein receptor.">
            <entity id="DS.d460.s0.e0" origId="304,5997,6432564,11025495" charOffset="28-39" type="compound" text="cholesterol"/>
            <entity id="DS.d460.s0.e1" origId="P01131,P20063,Q28832" charOffset="86-118" type="protein" text="low-density lipoprotein receptor"/>
            <pair e1="DS.d460.s0.e0" e2="DS.d460.s0.e1" id="DS.d460.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d460.s1" origId="18607722-1327" text="The low-density lipoprotein receptor (LDLr) mediates the uptake of LDL particles enriched with cholesterol, into several tissues.">
            <entity id="DS.d460.s1.e0" origId="P01131,P20063,Q28832" charOffset="4-36" type="protein" text="low-density lipoprotein receptor"/>
            <entity id="DS.d460.s1.e1" origId="304,5997,6432564,11025495" charOffset="95-106" type="compound" text="cholesterol"/>
            <pair e1="DS.d460.s1.e1" e2="DS.d460.s1.e0" id="DS.d460.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d461" origId="18607918">
        <sentence id="DS.d461.s0" origId="18607918-1505" text="Under the condition of delayed intervention (30 days after deafening) following gentamicin+ furosemide deafening in rats, we conclude that chronic intracochlear electrical stimulation (ES) and continuous intracochlear administration of brain-derived neurotrophic factor (BDNF) enhance spiral ganglion cell (SGC) body and peripheral process survival and improve auditory sensitivity.">
            <entity id="DS.d461.s0.e0" origId="3467" charOffset="80-90" type="compound" text="gentamicin"/>
            <entity id="DS.d461.s0.e1" origId="3440" charOffset="92-102" type="compound" text="furosemide"/>
            <entity id="DS.d461.s0.e2" origId="P25430,P25431,P25432,Q06225" charOffset="236-269" type="protein" text="brain-derived neurotrophic factor"/>
            <entity id="DS.d461.s0.e3" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="271-275" type="protein" text="BDNF"/>
            <pair e1="DS.d461.s0.e0" e2="DS.d461.s0.e2" id="DS.d461.s0.i0" interaction="False"/>
            <pair e1="DS.d461.s0.e0" e2="DS.d461.s0.e3" id="DS.d461.s0.i1" interaction="False"/>
            <pair e1="DS.d461.s0.e1" e2="DS.d461.s0.e2" id="DS.d461.s0.i2" interaction="False"/>
            <pair e1="DS.d461.s0.e1" e2="DS.d461.s0.e3" id="DS.d461.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d463" origId="18608753">
        <sentence id="DS.d463.s0" origId="18608753-1365" text="For this purpose, human erythrocyte glutathione reductase was initially purified 2139-fold in a yield of 29% by using 2', 5'-ADP Sepharose 4B affinity gel and Sephadex G-200 gel filtration chromatography.">
            <entity id="DS.d463.s0.e0" origId="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655" charOffset="36-57" type="protein" text="glutathione reductase"/>
            <entity id="DS.d463.s0.e1" origId="11966311" charOffset="129-138" type="compound" text="Sepharose"/>
            <pair e1="DS.d463.s0.e1" e2="DS.d463.s0.e0" id="DS.d463.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d464" origId="18608754">
        <sentence id="DS.d464.s0" origId="18608754-503" text="The enzyme deoxyuridine 5'-triphosphate nucleotidohydrolase (dUTPase) catalyses the hydrolysis of dUTP to dUMP and PPi thus controlling the incorporation of uracil into DNA genomes.">
            <entity id="DS.d464.s0.e0" origId="O25536,O30931,O41033,O48500,O52597,O54134,O66592,O68992,O83855,O84294,P03195,P03370,P06968,P09254,P0A552,P0A553,P10234,P14597,P16088,P16824,P16901,P17374,P19028,P23426,P23427,P28892,P28893,P30007,P31625,P31822,P32208,P32518,P33317,P33826,P35956,P43058,P43792,P52341,P52541,P57623,P57914,P59408,P61906,P61907,P61908,P61909,P61910,P61911,P61912,P61913,P64004,P64005,P64006,P64007,P64008,P64009,P68634,P68635,P70583,P87630,Q00030,Q01034,Q06095,Q07275,Q2Y742,Q2YRG4,Q31EC7,Q31UY6,Q329L7,Q39DM5,Q39V99,Q3A499,Q3AQ75,Q3B304,Q3BNA6,Q3J0B2,Q3J6W1,Q3JV72,Q3K4M6,Q3KM70,Q3SFR7,Q3SWM9,Q3YRU2,Q3YW02,Q45920,Q47BB1,Q47NK1,Q48Q06,Q491W8,Q49992,Q4FU67,Q4JVB1,Q4K3S2,Q4QLV3,Q4ULV2,Q4UPP2,Q4ZZX9,Q57BK5,Q57IA2,Q58502,Q5F9E0,Q5FN20,Q5GST1,Q5H5L9,Q5L6D8,Q5LIH9,Q5LWD3,Q5NHX4,Q5P7Z9,Q5PAE6,Q5PC28,Q5QZB6,Q5WTW6,Q5X242,Q5YT90,Q5ZSN0,Q603M1,Q62HL1,Q63WI6,Q64ZK3,Q65R66,Q66GD8,Q68WX8,Q69151,Q6A8W1,Q6AFE0,Q6AJZ0,Q6BRN7,Q6C141,Q6CQN7,Q6DAV9,Q6E4Q0,Q6FDR0,Q6FKQ6,Q6FYR2,Q6G202,Q6MEK7,Q6MVL2,Q6RZR1,Q6TUZ4,Q74ZF0,Q76RE7,Q775Z7,Q7M9N1,Q7MAX3,Q7MBE8,Q7MVT6,Q7NKL2,Q7VJU0,Q7VN49,Q7VRK0,Q7VVR1,Q7W8Z8,Q7WKE3,Q823Q9,Q82KK4,Q82UM1,Q83G43,Q83I22,Q83PN3,Q87F19,Q88BD3,Q88C95,Q895R1,Q89662,Q8A245,Q8D2F3,Q8E9M0,Q8F729,Q8FPH9,Q8G4E8,Q8K921,Q8NPA9,Q8P458,Q8PFR5,Q8RA46,Q8RER7,Q8SRS0,Q8UII1,Q8V2Y0,Q8XWL1,Q8ZJP5,Q90030,Q92I74,Q92SM6,Q97J61,Q98C10,Q9A253,Q9CJ30,Q9F7S4,Q9HTN3,Q9J5G5,Q9JUW1,Q9JZU7,Q9PGZ6,Q9PKA2,Q9X3X5,Q9YYS0,Q9Z9C2,Q9ZDD2,Q9ZKY3" charOffset="11-59" type="protein" text="deoxyuridine 5'-triphosphate nucleotidohydrolase"/>
            <entity id="DS.d464.s0.e1" origId="O25536,O27642,O29157,O30931,O41033,O48500,O52597,O54134,O66592,O68992,O83855,O84294,P03195,P03370,P06968,P09254,P0A552,P0A553,P10234,P14597,P16088,P16824,P16901,P17374,P19028,P23426,P23427,P28892,P28893,P30007,P31625,P31822,P32208,P32518,P33316,P33317,P33826,P35956,P43058,P43792,P52341,P52541,P57623,P57914,P59408,P61906,P61907,P61908,P61909,P61910,P61911,P61912,P61913,P64004,P64005,P64006,P64007,P64008,P64009,P68634,P68635,P70583,P87630,Q00030,Q01034,Q06095,Q07275,Q2Y742,Q2YRG4,Q31EC7,Q31UY6,Q329L7,Q39DM5,Q39V99,Q3A499,Q3AQ75,Q3B304,Q3BNA6,Q3J0B2,Q3J6W1,Q3JV72,Q3K4M6,Q3KM70,Q3SFR7,Q3SWM9,Q3YRU2,Q3YW02,Q45920,Q47BB1,Q47NK1,Q48Q06,Q491W8,Q49992,Q4FU67,Q4JVB1,Q4K3S2,Q4QLV3,Q4ULV2,Q4UPP2,Q4ZZX9,Q57BK5,Q57IA2,Q58502,Q5F9E0,Q5FN20,Q5GST1,Q5H5L9,Q5L6D8,Q5LIH9,Q5LWD3,Q5NHX4,Q5P7Z9,Q5PAE6,Q5PC28,Q5QZB6,Q5WTW6,Q5X242,Q5YT90,Q5ZSN0,Q603M1,Q62HL1,Q63WI6,Q64ZK3,Q65R66,Q66GD8,Q68WX8,Q69151,Q6A8W1,Q6AFE0,Q6AJZ0,Q6BRN7,Q6C141,Q6CQN7,Q6DAV9,Q6E4Q0,Q6FDR0,Q6FKQ6,Q6FYR2,Q6G202,Q6MEK7,Q6MVL2,Q6RZR1,Q6TUZ4,Q74ZF0,Q76RE7,Q775Z7,Q7M9N1,Q7MAX3,Q7MBE8,Q7MVT6,Q7NKL2,Q7VJU0,Q7VN49,Q7VRK0,Q7VVR1,Q7W8Z8,Q7WKE3,Q823Q9,Q82KK4,Q82UM1,Q83G43,Q83I22,Q83PN3,Q87F19,Q88BD3,Q88C95,Q895R1,Q89662,Q8A245,Q8D2F3,Q8E9M0,Q8F729,Q8FPH9,Q8G4E8,Q8K921,Q8NPA9,Q8P458,Q8PFR5,Q8PWG1,Q8RA46,Q8RER7,Q8SRS0,Q8TGX9,Q8TV34,Q8UII1,Q8V2Y0,Q8XWL1,Q8ZJP5,Q90030,Q92I74,Q92SM6,Q97J61,Q98C10,Q9A253,Q9CJ30,Q9F7S4,Q9HMF3,Q9HTN3,Q9J5G5,Q9JUW1,Q9JZU7,Q9P6Q5,Q9PGZ6,Q9PKA2,Q9X3X5,Q9YG32,Q9YYS0,Q9Z9C2,Q9ZDD2,Q9ZKY3" charOffset="61-68" type="protein" text="dUTPase"/>
            <entity id="DS.d464.s0.e3" origId="1174" charOffset="157-163" type="compound" text="uracil"/>
            <pair e1="DS.d464.s0.e3" e2="DS.d464.s0.e1" id="DS.d464.s0.i0" interaction="True"/>
            <pair e1="DS.d464.s0.e3" e2="DS.d464.s0.e0" id="DS.d464.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d464.s1" origId="18608754-504" text="In the present study we perform a kinetic analysis of Campylobacter dUTPase using the continuous spectrophotometric method and show that the enzyme is highly specific for deoxyuridine nucleotides.">
            <entity id="DS.d464.s1.e0" origId="O25536,O27642,O29157,O30931,O41033,O48500,O52597,O54134,O66592,O68992,O83855,O84294,P03195,P03370,P06968,P09254,P0A552,P0A553,P10234,P14597,P16088,P16824,P16901,P17374,P19028,P23426,P23427,P28892,P28893,P30007,P31625,P31822,P32208,P32518,P33316,P33317,P33826,P35956,P43058,P43792,P52341,P52541,P57623,P57914,P59408,P61906,P61907,P61908,P61909,P61910,P61911,P61912,P61913,P64004,P64005,P64006,P64007,P64008,P64009,P68634,P68635,P70583,P87630,Q00030,Q01034,Q06095,Q07275,Q2Y742,Q2YRG4,Q31EC7,Q31UY6,Q329L7,Q39DM5,Q39V99,Q3A499,Q3AQ75,Q3B304,Q3BNA6,Q3J0B2,Q3J6W1,Q3JV72,Q3K4M6,Q3KM70,Q3SFR7,Q3SWM9,Q3YRU2,Q3YW02,Q45920,Q47BB1,Q47NK1,Q48Q06,Q491W8,Q49992,Q4FU67,Q4JVB1,Q4K3S2,Q4QLV3,Q4ULV2,Q4UPP2,Q4ZZX9,Q57BK5,Q57IA2,Q58502,Q5F9E0,Q5FN20,Q5GST1,Q5H5L9,Q5L6D8,Q5LIH9,Q5LWD3,Q5NHX4,Q5P7Z9,Q5PAE6,Q5PC28,Q5QZB6,Q5WTW6,Q5X242,Q5YT90,Q5ZSN0,Q603M1,Q62HL1,Q63WI6,Q64ZK3,Q65R66,Q66GD8,Q68WX8,Q69151,Q6A8W1,Q6AFE0,Q6AJZ0,Q6BRN7,Q6C141,Q6CQN7,Q6DAV9,Q6E4Q0,Q6FDR0,Q6FKQ6,Q6FYR2,Q6G202,Q6MEK7,Q6MVL2,Q6RZR1,Q6TUZ4,Q74ZF0,Q76RE7,Q775Z7,Q7M9N1,Q7MAX3,Q7MBE8,Q7MVT6,Q7NKL2,Q7VJU0,Q7VN49,Q7VRK0,Q7VVR1,Q7W8Z8,Q7WKE3,Q823Q9,Q82KK4,Q82UM1,Q83G43,Q83I22,Q83PN3,Q87F19,Q88BD3,Q88C95,Q895R1,Q89662,Q8A245,Q8D2F3,Q8E9M0,Q8F729,Q8FPH9,Q8G4E8,Q8K921,Q8NPA9,Q8P458,Q8PFR5,Q8PWG1,Q8RA46,Q8RER7,Q8SRS0,Q8TGX9,Q8TV34,Q8UII1,Q8V2Y0,Q8XWL1,Q8ZJP5,Q90030,Q92I74,Q92SM6,Q97J61,Q98C10,Q9A253,Q9CJ30,Q9F7S4,Q9HMF3,Q9HTN3,Q9J5G5,Q9JUW1,Q9JZU7,Q9P6Q5,Q9PGZ6,Q9PKA2,Q9X3X5,Q9YG32,Q9YYS0,Q9Z9C2,Q9ZDD2,Q9ZKY3" charOffset="68-75" type="protein" text="dUTPase"/>
            <entity id="DS.d464.s1.e1" origId="13712" charOffset="171-183" type="compound" text="deoxyuridine"/>
            <pair e1="DS.d464.s1.e1" e2="DS.d464.s1.e0" id="DS.d464.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d465" origId="18608755">
        <sentence id="DS.d465.s0" origId="18608755-505" text="Tryptophanase (tryptophan indole-lyase, Tnase, EC 4.1.99.1), a bacterial enzyme with no counterpart in eukaryotic cells, produces from L-tryptophan pyruvate, ammonia and indole.">
            <entity id="DS.d465.s0.e0" origId="O07674,O30971,P0A853,P0A854,P21643,P28796,P48775,P48776,Q09474,Q2KIQ5,Q59342,Q5EBG2,Q5U4U6,Q7MCR1,Q7N8C9,Q7NYV9,Q7SY53,Q87JQ6,Q894M8,Q8D5Q4,Q8FBV2,Q8R9K5,Q8XB34,Q9CL27,Q9KN05,Q9ZNA8" charOffset="0-13" type="protein" text="Tryptophanase"/>
            <entity id="DS.d465.s0.e1" origId="4802,6305,5460850" charOffset="135-147" type="compound" text="L-tryptophan"/>
            <entity id="DS.d465.s0.e2" origId="1060" charOffset="148-156" type="compound" text="pyruvate"/>
            <entity id="DS.d465.s0.e3" origId="222" charOffset="158-165" type="compound" text="ammonia"/>
            <pair e1="DS.d465.s0.e3" e2="DS.d465.s0.e0" id="DS.d465.s0.i0" interaction="True"/>
            <pair e1="DS.d465.s0.e1" e2="DS.d465.s0.e0" id="DS.d465.s0.i1" interaction="True"/>
            <pair e1="DS.d465.s0.e2" e2="DS.d465.s0.e0" id="DS.d465.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d468" origId="18608766">
        <sentence id="DS.d468.s0" origId="18608766-514" text="Urease allows soil microorganisms to use urea as a source of nitrogen and aid in the rapid break down of urea-based fertilizers resulting in phytopathicity.">
            <entity id="DS.d468.s0.e0" origId="O00084,O13465,P07374,P08298,Q5KCQ6,Q6A3P9" charOffset="0-6" type="protein" text="Urease"/>
            <entity id="DS.d468.s0.e1" origId="1176,265993" charOffset="41-45" type="compound" text="urea"/>
            <entity id="DS.d468.s0.e2" origId="947,123329" charOffset="61-69" type="compound" text="nitrogen"/>
            <entity id="DS.d468.s0.e3" origId="1176,265993" charOffset="105-109" type="compound" text="urea"/>
            <pair e1="DS.d468.s0.e1" e2="DS.d468.s0.e0" id="DS.d468.s0.i0" interaction="True"/>
            <pair e1="DS.d468.s0.e2" e2="DS.d468.s0.e0" id="DS.d468.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d469" origId="18608782">
        <sentence id="DS.d469.s0" origId="18608782-527" text="Adenosine deaminase (ADA), an enzyme involved in purine metabolism, catalyzes the hydrolytic breakdown of adenosine into inosine and free ammonia.">
            <entity id="DS.d469.s0.e0" origId="O83085,P00813,P03958,P22333,P53909,P53984,P56658,P63907,P63908,P63909,P63910,Q2TZN9,Q4IMJ1,Q4X1Q4,Q59ZB1,Q5ZKP6,Q63ZU0,Q6CM42,Q6DG22,Q6FP78,Q6GP70,Q7M9R5,Q7MDL6,Q7N4H5,Q7VNV1,Q7WBG5,Q7WMY6,Q839J4,Q83RC0,Q889J2,Q88QA3,Q8D6Q8,Q8DTN8,Q8E8D4,Q8FH99,Q8UJ05,Q8X1T6,Q8X661,Q8XHH8,Q8XXL5,Q8Z6R2,Q8ZPL9,Q920P6,Q92T48,Q97EV1,Q98GV2,Q9A3M3,Q9CCL9,Q9CIR9,Q9I6Y4,Q9KNI7,Q9P6I7" charOffset="0-19" type="protein" text="Adenosine deaminase"/>
            <entity id="DS.d469.s0.e1" origId="P00813,P56658,Q5ZKP6" charOffset="21-24" type="protein" text="ADA"/>
            <entity id="DS.d469.s0.e2" origId="60961" charOffset="106-115" type="compound" text="adenosine"/>
            <entity id="DS.d469.s0.e3" origId="6021" charOffset="121-128" type="compound" text="inosine"/>
            <entity id="DS.d469.s0.e4" origId="222" charOffset="138-145" type="compound" text="ammonia"/>
            <pair e1="DS.d469.s0.e2" e2="DS.d469.s0.e1" id="DS.d469.s0.i0" interaction="True"/>
            <pair e1="DS.d469.s0.e3" e2="DS.d469.s0.e1" id="DS.d469.s0.i1" interaction="True"/>
            <pair e1="DS.d469.s0.e4" e2="DS.d469.s0.e1" id="DS.d469.s0.i2" interaction="True"/>
            <pair e1="DS.d469.s0.e2" e2="DS.d469.s0.e0" id="DS.d469.s0.i3" interaction="True"/>
            <pair e1="DS.d469.s0.e4" e2="DS.d469.s0.e0" id="DS.d469.s0.i4" interaction="True"/>
            <pair e1="DS.d469.s0.e3" e2="DS.d469.s0.e0" id="DS.d469.s0.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d470" origId="18609042">
        <sentence id="DS.d470.s0" origId="18609042-761" text="Diastolic function and BNP changes during exercise predict oxygen consumption in chronic heart failure patients.">
            <entity id="DS.d470.s0.e0" origId="P40753,P83965,Q805D7,Q805E8,Q9GLK4" charOffset="23-26" type="protein" text="BNP"/>
            <entity id="DS.d470.s0.e1" origId="977" charOffset="59-65" type="compound" text="oxygen"/>
            <pair e1="DS.d470.s0.e1" e2="DS.d470.s0.e0" id="DS.d470.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d471" origId="18609294">
        <sentence id="DS.d471.s0" origId="18609294-966" text="Although incubation with prolactin (PRL) and/or adrenocorticotrophic hormone (ACTH) resulted in a dose-dependent increase of corticosterone and progesterone release by adrenal cells from both HAA and LAA male rats, the responses were markedly increased for adrenal cells from LAA rats as compared with HAA rats.">
            <entity id="DS.d471.s0.e0" origId="P10765,P22393,P33089,P33090,P33091,P43001" charOffset="25-34" type="protein" text="prolactin"/>
            <entity id="DS.d471.s0.e1" origId="O62781,O62819,O93337,P01236,P01237,P01238,P01239,P01240,P06879,P09585,P10765,P12420,P14676,P17572,P21993,P22393,P29234,P29235,P33089,P33090,P33091,P33096,P34181,P35395,P37884,P40424,P43001,P43299,P46403,P48096,P48249,P51904,P55151,P87495,Q28318,Q28632,Q3Y4G6,Q6UC74,Q7ZZV3,Q8HXS1,Q9QZL1,Q9YGV6" charOffset="36-39" type="protein" text="PRL"/>
            <entity id="DS.d471.s0.e2" origId="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5" charOffset="78-82" type="protein" text="ACTH"/>
            <entity id="DS.d471.s0.e3" origId="5753" charOffset="125-139" type="compound" text="corticosterone"/>
            <entity id="DS.d471.s0.e4" origId="5994" charOffset="144-156" type="compound" text="progesterone"/>
            <pair e1="DS.d471.s0.e3" e2="DS.d471.s0.e2" id="DS.d471.s0.i0" interaction="True"/>
            <pair e1="DS.d471.s0.e3" e2="DS.d471.s0.e0" id="DS.d471.s0.i1" interaction="True"/>
            <pair e1="DS.d471.s0.e4" e2="DS.d471.s0.e2" id="DS.d471.s0.i2" interaction="True"/>
            <pair e1="DS.d471.s0.e3" e2="DS.d471.s0.e1" id="DS.d471.s0.i3" interaction="True"/>
            <pair e1="DS.d471.s0.e4" e2="DS.d471.s0.e1" id="DS.d471.s0.i4" interaction="True"/>
            <pair e1="DS.d471.s0.e4" e2="DS.d471.s0.e0" id="DS.d471.s0.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d472" origId="18609433">
        <sentence id="DS.d472.s0" origId="18609433-1079" text="Fluvoxamine, a SSRI, is mainly metabolized by cytochrome P450 (CYP) 2D6 and 1A2.">
            <entity id="DS.d472.s0.e0" origId="5324346" charOffset="0-11" type="compound" text="Fluvoxamine"/>
            <entity id="DS.d472.s0.e1" origId="O08469" charOffset="46-61" type="protein" text="cytochrome P450"/>
            <entity id="DS.d472.s0.e2" origId="P21568,P21569,P24525,P34887,Q26551" charOffset="63-66" type="protein" text="CYP"/>
            <pair e1="DS.d472.s0.e0" e2="DS.d472.s0.e2" id="DS.d472.s0.i0" interaction="True"/>
            <pair e1="DS.d472.s0.e0" e2="DS.d472.s0.e1" id="DS.d472.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d474" origId="18612599">
        <sentence id="DS.d474.s0" origId="18612599-292" text="GCK is expressed in the rat DVC, where mRNA is localized to neurons that exhibit electrophysiological sensitivity to glucose imbalance.">
            <entity id="DS.d474.s0.e0" origId="P35557,Q12851,Q61161" charOffset="0-3" type="protein" text="GCK"/>
            <entity id="DS.d474.s0.e1" origId="206,5793,64689,79025" charOffset="117-124" type="compound" text="glucose"/>
            <pair e1="DS.d474.s0.e1" e2="DS.d474.s0.e0" id="DS.d474.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d476" origId="18612775">
        <sentence id="DS.d476.s0" origId="18612775-1047" text="Indoleamine 2,3-dioxygenase (IDO) catalyzes the first and rate-limiting step of Kynurenine pathway along the major route of Tryptophan catabolism.">
            <entity id="DS.d476.s0.e0" origId="P14902,P28776" charOffset="0-27" type="protein" text="Indoleamine 2,3-dioxygenase"/>
            <entity id="DS.d476.s0.e1" origId="P14902,P28776" charOffset="29-32" type="protein" text="IDO"/>
            <entity id="DS.d476.s0.e2" origId="846" charOffset="80-90" type="compound" text="Kynurenine"/>
            <pair e1="DS.d476.s0.e2" e2="DS.d476.s0.e1" id="DS.d476.s0.i0" interaction="True"/>
            <pair e1="DS.d476.s0.e2" e2="DS.d476.s0.e0" id="DS.d476.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d477" origId="18612777">
        <sentence id="DS.d477.s0" origId="18612777-425" text="Type I transglutaminase (TG1), an enzyme that catalyzes the formation of epsilon-(gamma-glutamyl) lysine bonds, is the key protein responsible for generation of the crosslinks.">
            <entity id="DS.d477.s0.e0" origId="P40746,P52183,P81453,Q819L3,Q81MS1,Q8GR90,Q9K5W7" charOffset="7-23" type="protein" text="transglutaminase"/>
            <entity id="DS.d477.s0.e1" origId="866,5962" charOffset="98-104" type="compound" text="lysine"/>
            <pair e1="DS.d477.s0.e1" e2="DS.d477.s0.e0" id="DS.d477.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d478" origId="18612811">
        <sentence id="DS.d478.s0" origId="18612811-461" text="Myc-oncogene inactivating effect by proline rich polypeptide (PRP-1) in chondrosarcoma JJ012 cells.">
            <entity id="DS.d478.s0.e0" origId="P01108,P09416,P52160" charOffset="0-3" type="protein" text="Myc"/>
            <entity id="DS.d478.s0.e1" origId="614,8988,145742" charOffset="36-43" type="compound" text="proline"/>
            <pair e1="DS.d478.s0.e1" e2="DS.d478.s0.e0" id="DS.d478.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d479" origId="18612819">
        <sentence id="DS.d479.s0" origId="18612819-471" text="Like PSC, DSL6A cells secrete less ET-1 when cultured with bosentan.">
            <entity id="DS.d479.s0.e0" origId="P05305,P09558,P13206,P17322,P22387,P22388,P29560,P97740,Q28469,Q5NRP9,Q5NRQ1,Q9BG76" charOffset="35-39" type="protein" text="ET-1"/>
            <entity id="DS.d479.s0.e1" origId="104865" charOffset="59-67" type="compound" text="bosentan"/>
            <pair e1="DS.d479.s0.e1" e2="DS.d479.s0.e0" id="DS.d479.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d480" origId="18612824">
        <sentence id="DS.d480.s0" origId="18612824-1284" text="Caspase inhibition with z-VAD was unable to prevent AIF localization to the nucleus and subsequently unable to prevent cell death.">
            <entity id="DS.d480.s0.e0" origId="5289545" charOffset="26-29" type="compound" text="VAD"/>
            <entity id="DS.d480.s0.e1" origId="O95831" charOffset="52-55" type="protein" text="AIF"/>
            <pair e1="DS.d480.s0.e0" e2="DS.d480.s0.e1" id="DS.d480.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d481" origId="18614168">
        <sentence id="DS.d481.s0" origId="18614168-1607" text="Purinergic receptor agonists ATP and UTP selectively activate certain Src family tyrosine kinases and stimulate Na,K-ATPase activity.">
            <entity id="DS.d481.s0.e0" origId="5957" charOffset="29-32" type="compound" text="ATP"/>
            <entity id="DS.d481.s0.e1" origId="6133" charOffset="37-40" type="compound" text="UTP"/>
            <entity id="DS.d481.s0.e2" origId="P05480,Q9WUD9" charOffset="70-73" type="protein" text="Src"/>
            <pair e1="DS.d481.s0.e0" e2="DS.d481.s0.e2" id="DS.d481.s0.i0" interaction="True"/>
            <pair e1="DS.d481.s0.e1" e2="DS.d481.s0.e2" id="DS.d481.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d482" origId="18615010">
        <sentence id="DS.d482.s0" origId="18615010-596" text="Early deprivation led to decreases in hippocampal growth-associated protein-43 (GAP-43) mRNA, serotonin 1A receptor (5-HT(1A)R) mRNA and binding ((3H)WAY100635), and to increased vesicular GABA transporter mRNA.">
            <entity id="DS.d482.s0.e0" origId="P06836,P06837,P07936,P17677,P17691,P35001,P55860,Q5IS67,Q5NVP7,Q6S9D9,Q95K78,Q98987" charOffset="50-78" type="protein" text="growth-associated protein-43"/>
            <entity id="DS.d482.s0.e1" origId="P09851,P20936,P50904,P74851,P74873,Q5PEA9,Q92211,Q92263" charOffset="80-83" type="protein" text="GAP"/>
            <entity id="DS.d482.s0.e2" origId="5684" charOffset="147-159" type="compound" text="3H)WAY100635"/>
            <entity id="DS.d482.s0.e3" origId="O35458,O35633,P34579,Q95KE2,Q9H598" charOffset="179-205" type="protein" text="vesicular GABA transporter"/>
            <pair e1="DS.d482.s0.e3" e2="DS.d482.s0.e1" id="DS.d482.s0.i0" interaction="False"/>
            <pair e1="DS.d482.s0.e3" e2="DS.d482.s0.e0" id="DS.d482.s0.i1" interaction="False"/>
            <pair e1="DS.d482.s0.e3" e2="DS.d482.s0.e3" id="DS.d482.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d483" origId="18615011">
        <sentence id="DS.d483.s0" origId="18615011-597" text="We measured the ability to increase GABA in eight healthy subjects by comparing the binding of ((11)C) flumazenil, a positron emission tomography (PET) radiotracer specific for the benzodiazepine (BDZ) site, at baseline and in the presence of an acute elevation in GABA levels through the blockade of the GABA membrane transporter (GAT1).">
            <entity id="DS.d483.s0.e0" origId="3373" charOffset="103-113" type="compound" text="flumazenil"/>
            <entity id="DS.d483.s0.e1" origId="P30531,P36148,P43574" charOffset="332-336" type="protein" text="GAT1"/>
            <pair e1="DS.d483.s0.e0" e2="DS.d483.s0.e1" id="DS.d483.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d483.s1" origId="18615011-598" text="GAT1 blockade resulted in significant increases in mean (+/-SD) ((11)C) flumazenil-binding potential (BP(ND)) over baseline in brain regions representing the major functional domains of the cerebral cortex: association cortex+15.2+/-20.2% (p=0.05), sensory cortex+13.5+/-15.5% (p=0.03) and limbic (medial temporal lobe, MTL)+16.4+/-20.2% (p=0.03).">
            <entity id="DS.d483.s1.e0" origId="P30531,P36148,P43574" charOffset="0-4" type="protein" text="GAT1"/>
            <entity id="DS.d483.s1.e1" origId="3373" charOffset="72-82" type="compound" text="flumazenil"/>
            <pair e1="DS.d483.s1.e1" e2="DS.d483.s1.e0" id="DS.d483.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d484" origId="18615280">
        <sentence id="DS.d484.s0" origId="18615280-830" text="alpha-Glucosidase inhibitory activity of cyanidin-3-galactoside and synergistic effect with acarbose.">
            <entity id="DS.d484.s0.e0" origId="O33830,O43451,O59645,P21517,P43473,Q02751" charOffset="0-17" type="protein" text="alpha-Glucosidase"/>
            <entity id="DS.d484.s0.e1" origId="44256700" charOffset="41-63" type="compound" text="cyanidin-3-galactoside"/>
            <entity id="DS.d484.s0.e2" origId="41774,441184,444254,445421,4432690" charOffset="92-100" type="compound" text="acarbose"/>
            <pair e1="DS.d484.s0.e1" e2="DS.d484.s0.e0" id="DS.d484.s0.i0" interaction="True"/>
            <pair e1="DS.d484.s0.e2" e2="DS.d484.s0.e0" id="DS.d484.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d484.s1" origId="18615280-831" text="Cyanidin-3-galactoside, a natural anthocyanin, was investigated for its alpha-glucosidase inhibitory activity.">
            <entity id="DS.d484.s1.e0" origId="44256700" charOffset="0-22" type="compound" text="Cyanidin-3-galactoside"/>
            <entity id="DS.d484.s1.e1" origId="145858" charOffset="34-45" type="compound" text="anthocyanin"/>
            <entity id="DS.d484.s1.e2" origId="O33830,O43451,O59645,P21517,P43473,Q02751" charOffset="72-89" type="protein" text="alpha-glucosidase"/>
            <pair e1="DS.d484.s1.e1" e2="DS.d484.s1.e2" id="DS.d484.s1.i0" interaction="False"/>
            <pair e1="DS.d484.s1.e0" e2="DS.d484.s1.e2" id="DS.d484.s1.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d486" origId="18615705">
        <sentence id="DS.d486.s0" origId="18615705-81" text="The susceptibilities to three organophosphate (OP) insecticides (malathion, chlorpyrifos, and phoxim), responses to three metabolic synergists (triphenyl phosphate (TPP), piperonyl butoxide (PBO), and diethyl maleate (DEM)), activities of major detoxification enzymes (general esterases (ESTs), glutathione S-transferases (GSTs), and cytochrome P450 monooxygenases (P450s)), and sensitivity of the target enzyme acetylcholinesterase (AChE) were compared between a laboratory-susceptible strain (LS) and a field-resistant population (FR) of the oriental migratory locust, Locusta migratoria manilensis (Meyen).">
            <entity id="DS.d486.s0.e0" origId="4004" charOffset="65-74" type="compound" text="malathion"/>
            <entity id="DS.d486.s0.e1" origId="2730" charOffset="76-88" type="compound" text="chlorpyrifos"/>
            <entity id="DS.d486.s0.e2" origId="9570290" charOffset="94-100" type="compound" text="phoxim"/>
            <entity id="DS.d486.s0.e3" origId="8289" charOffset="144-163" type="compound" text="triphenyl phosphate"/>
            <entity id="DS.d486.s0.e4" origId="5794" charOffset="171-189" type="compound" text="piperonyl butoxide"/>
            <entity id="DS.d486.s0.e5" origId="5271566" charOffset="201-216" type="compound" text="diethyl maleate"/>
            <entity id="DS.d486.s0.e6" origId="P16397,P18773" charOffset="277-286" type="protein" text="esterases"/>
            <entity id="DS.d486.s0.e7" origId="O04437,O18598,P0A9D2,P0A9D3,P30116,P44521,P46088,P46419,P46423,P46426,P46428,P46437,P48438,P80894,P81065,P82996,P82997,P82998,P82999,P83000,P83001,P83246,Q04522,Q08392,Q08393,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52,Q96324" charOffset="295-321" type="protein" text="glutathione S-transferases"/>
            <entity id="DS.d486.s0.e8" origId="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52" charOffset="323-327" type="protein" text="GSTs"/>
            <entity id="DS.d486.s0.e9" origId="O08469" charOffset="334-349" type="protein" text="cytochrome P450"/>
            <entity id="DS.d486.s0.e10" origId="Q867X2,Q867X3,Q86GC9,Q92081" charOffset="412-432" type="protein" text="acetylcholinesterase"/>
            <entity id="DS.d486.s0.e11" origId="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3" charOffset="434-438" type="protein" text="AChE"/>
            <pair e1="DS.d486.s0.e3" e2="DS.d486.s0.e10" id="DS.d486.s0.i0" interaction="False"/>
            <pair e1="DS.d486.s0.e2" e2="DS.d486.s0.e10" id="DS.d486.s0.i1" interaction="False"/>
            <pair e1="DS.d486.s0.e2" e2="DS.d486.s0.e11" id="DS.d486.s0.i2" interaction="False"/>
            <pair e1="DS.d486.s0.e3" e2="DS.d486.s0.e8" id="DS.d486.s0.i3" interaction="False"/>
            <pair e1="DS.d486.s0.e2" e2="DS.d486.s0.e6" id="DS.d486.s0.i4" interaction="False"/>
            <pair e1="DS.d486.s0.e4" e2="DS.d486.s0.e8" id="DS.d486.s0.i5" interaction="False"/>
            <pair e1="DS.d486.s0.e3" e2="DS.d486.s0.e7" id="DS.d486.s0.i6" interaction="False"/>
            <pair e1="DS.d486.s0.e2" e2="DS.d486.s0.e8" id="DS.d486.s0.i7" interaction="False"/>
            <pair e1="DS.d486.s0.e1" e2="DS.d486.s0.e8" id="DS.d486.s0.i8" interaction="False"/>
            <pair e1="DS.d486.s0.e4" e2="DS.d486.s0.e7" id="DS.d486.s0.i9" interaction="False"/>
            <pair e1="DS.d486.s0.e4" e2="DS.d486.s0.e6" id="DS.d486.s0.i10" interaction="False"/>
            <pair e1="DS.d486.s0.e5" e2="DS.d486.s0.e9" id="DS.d486.s0.i11" interaction="False"/>
            <pair e1="DS.d486.s0.e5" e2="DS.d486.s0.e10" id="DS.d486.s0.i12" interaction="False"/>
            <pair e1="DS.d486.s0.e0" e2="DS.d486.s0.e10" id="DS.d486.s0.i13" interaction="False"/>
            <pair e1="DS.d486.s0.e0" e2="DS.d486.s0.e8" id="DS.d486.s0.i14" interaction="False"/>
            <pair e1="DS.d486.s0.e1" e2="DS.d486.s0.e9" id="DS.d486.s0.i15" interaction="False"/>
            <pair e1="DS.d486.s0.e1" e2="DS.d486.s0.e6" id="DS.d486.s0.i16" interaction="False"/>
            <pair e1="DS.d486.s0.e0" e2="DS.d486.s0.e9" id="DS.d486.s0.i17" interaction="False"/>
            <pair e1="DS.d486.s0.e4" e2="DS.d486.s0.e10" id="DS.d486.s0.i18" interaction="False"/>
            <pair e1="DS.d486.s0.e3" e2="DS.d486.s0.e6" id="DS.d486.s0.i19" interaction="False"/>
            <pair e1="DS.d486.s0.e4" e2="DS.d486.s0.e9" id="DS.d486.s0.i20" interaction="False"/>
            <pair e1="DS.d486.s0.e5" e2="DS.d486.s0.e11" id="DS.d486.s0.i21" interaction="False"/>
            <pair e1="DS.d486.s0.e5" e2="DS.d486.s0.e8" id="DS.d486.s0.i22" interaction="False"/>
            <pair e1="DS.d486.s0.e4" e2="DS.d486.s0.e11" id="DS.d486.s0.i23" interaction="False"/>
            <pair e1="DS.d486.s0.e1" e2="DS.d486.s0.e11" id="DS.d486.s0.i24" interaction="False"/>
            <pair e1="DS.d486.s0.e0" e2="DS.d486.s0.e6" id="DS.d486.s0.i25" interaction="False"/>
            <pair e1="DS.d486.s0.e3" e2="DS.d486.s0.e11" id="DS.d486.s0.i26" interaction="False"/>
            <pair e1="DS.d486.s0.e0" e2="DS.d486.s0.e11" id="DS.d486.s0.i27" interaction="False"/>
            <pair e1="DS.d486.s0.e2" e2="DS.d486.s0.e9" id="DS.d486.s0.i28" interaction="False"/>
            <pair e1="DS.d486.s0.e1" e2="DS.d486.s0.e10" id="DS.d486.s0.i29" interaction="False"/>
            <pair e1="DS.d486.s0.e5" e2="DS.d486.s0.e7" id="DS.d486.s0.i30" interaction="False"/>
            <pair e1="DS.d486.s0.e5" e2="DS.d486.s0.e6" id="DS.d486.s0.i31" interaction="False"/>
            <pair e1="DS.d486.s0.e2" e2="DS.d486.s0.e7" id="DS.d486.s0.i32" interaction="False"/>
            <pair e1="DS.d486.s0.e0" e2="DS.d486.s0.e7" id="DS.d486.s0.i33" interaction="False"/>
            <pair e1="DS.d486.s0.e1" e2="DS.d486.s0.e7" id="DS.d486.s0.i34" interaction="False"/>
            <pair e1="DS.d486.s0.e3" e2="DS.d486.s0.e9" id="DS.d486.s0.i35" interaction="False"/>
        </sentence>
        <sentence id="DS.d486.s1" origId="18615705-83" text="All these results clearly indicated that the observed malathion resistance in the FR was conferred by multiple mechanisms, including increased detoxification by ESTs and GSTs, and increased activity and reduced sensitivity of AChE to OP inhibition.">
            <entity id="DS.d486.s1.e0" origId="4004" charOffset="54-63" type="compound" text="malathion"/>
            <entity id="DS.d486.s1.e1" origId="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52" charOffset="170-174" type="protein" text="GSTs"/>
            <entity id="DS.d486.s1.e2" origId="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3" charOffset="226-230" type="protein" text="AChE"/>
            <pair e1="DS.d486.s1.e0" e2="DS.d486.s1.e1" id="DS.d486.s1.i0" interaction="True"/>
            <pair e1="DS.d486.s1.e0" e2="DS.d486.s1.e2" id="DS.d486.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d487" origId="18615707">
        <sentence id="DS.d487.s0" origId="18615707-1194" text="Lysozymes act as crucial bacteriolytic enzymes in insect immune system by hydrolyzing the beta (1--&amp;gt;4) bonds between N-acetylglucosamine and N-acetylmuramic acid in the peptidoglycan of prokaryotic cell walls.">
            <entity id="DS.d487.s0.e0" origId="O64362,O80288,O80292,P00720,P03706,P07540,P09963,P10439,P11187,P13656,P15057,P19385,P19386,P21270,P23472,P23473,P27359,P33486,P37715,P39046,P51771,P62692,P62693,P68920,P68921,P81241,P82174,P82175,P83673,Q27650,Q37875,Q37896,Q48603,Q7SID7,Q9CIT4,Q9T1X2,Q9ZXB7" charOffset="0-9" type="protein" text="Lysozymes"/>
            <entity id="DS.d487.s0.e1" origId="24139" charOffset="120-139" type="compound" text="N-acetylglucosamine"/>
            <entity id="DS.d487.s0.e2" origId="440822,542212,5462244,6323218" charOffset="144-164" type="compound" text="N-acetylmuramic acid"/>
            <entity id="DS.d487.s0.e3" origId="9816401" charOffset="172-185" type="compound" text="peptidoglycan"/>
            <pair e1="DS.d487.s0.e1" e2="DS.d487.s0.e0" id="DS.d487.s0.i0" interaction="True"/>
            <pair e1="DS.d487.s0.e2" e2="DS.d487.s0.e0" id="DS.d487.s0.i1" interaction="True"/>
            <pair e1="DS.d487.s0.e3" e2="DS.d487.s0.e0" id="DS.d487.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d488" origId="18615734">
        <sentence id="DS.d488.s0" origId="18615734-449" text="These mRNAs no longer encode the pleckstrin homology (PH) domain of collybistin, which we now show binds phosphatidylinositol-3-phosphate (PI3P/PtdIns-3-P), a phosphoinositide with an emerging role in membrane trafficking and signal transduction, rather than phosphatidylinositol 3,4,5-trisphosphate (PIP3/PtdIns-3,4,5-P) as previously suggested in the &quot; membrane activation model&quot; of gephyrin clustering.">
            <entity id="DS.d488.s0.e0" origId="P08567,Q4KM33,Q6Q308,Q9JHK5" charOffset="33-43" type="protein" text="pleckstrin"/>
            <entity id="DS.d488.s0.e1" origId="O43307,Q3UTH8,Q58DL7,Q5RDK0,Q9QX73" charOffset="68-79" type="protein" text="collybistin"/>
            <entity id="DS.d488.s0.e2" origId="6857403,9776841" charOffset="105-137" type="compound" text="phosphatidylinositol-3-phosphate"/>
            <entity id="DS.d488.s0.e3" origId="643964,24755494" charOffset="144-154" type="compound" text="PtdIns-3-P"/>
            <entity id="DS.d488.s0.e4" origId="16738692" charOffset="159-175" type="compound" text="phosphoinositide"/>
            <entity id="DS.d488.s0.e5" origId="643963" charOffset="259-299" type="compound" text="phosphatidylinositol 3,4,5-trisphosphate"/>
            <entity id="DS.d488.s0.e6" origId="643963" charOffset="306-320" type="compound" text="PtdIns-3,4,5-P"/>
            <entity id="DS.d488.s0.e7" origId="Q03555,Q9NQX3" charOffset="385-393" type="protein" text="gephyrin"/>
            <pair e1="DS.d488.s0.e2" e2="DS.d488.s0.e0" id="DS.d488.s0.i0" interaction="True"/>
            <pair e1="DS.d488.s0.e4" e2="DS.d488.s0.e1" id="DS.d488.s0.i1" interaction="True"/>
            <pair e1="DS.d488.s0.e3" e2="DS.d488.s0.e1" id="DS.d488.s0.i2" interaction="True"/>
            <pair e1="DS.d488.s0.e5" e2="DS.d488.s0.e1" id="DS.d488.s0.i3" interaction="True"/>
            <pair e1="DS.d488.s0.e5" e2="DS.d488.s0.e0" id="DS.d488.s0.i4" interaction="True"/>
            <pair e1="DS.d488.s0.e6" e2="DS.d488.s0.e1" id="DS.d488.s0.i5" interaction="True"/>
            <pair e1="DS.d488.s0.e3" e2="DS.d488.s0.e0" id="DS.d488.s0.i6" interaction="True"/>
            <pair e1="DS.d488.s0.e6" e2="DS.d488.s0.e0" id="DS.d488.s0.i7" interaction="True"/>
            <pair e1="DS.d488.s0.e6" e2="DS.d488.s0.e7" id="DS.d488.s0.i8" interaction="False"/>
            <pair e1="DS.d488.s0.e2" e2="DS.d488.s0.e1" id="DS.d488.s0.i9" interaction="True"/>
            <pair e1="DS.d488.s0.e4" e2="DS.d488.s0.e0" id="DS.d488.s0.i10" interaction="True"/>
            <pair e1="DS.d488.s0.e3" e2="DS.d488.s0.e7" id="DS.d488.s0.i11" interaction="False"/>
            <pair e1="DS.d488.s0.e2" e2="DS.d488.s0.e7" id="DS.d488.s0.i12" interaction="False"/>
            <pair e1="DS.d488.s0.e4" e2="DS.d488.s0.e7" id="DS.d488.s0.i13" interaction="False"/>
            <pair e1="DS.d488.s0.e5" e2="DS.d488.s0.e7" id="DS.d488.s0.i14" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d489" origId="18616717">
        <sentence id="DS.d489.s0" origId="18616717-310" text="We investigated whether several different inflammatory markers including C-reactive protein (CRP) and fibrinogen and white blood cells (WBCs) count, are associated with maximal oxygen consumption (VO(2 max)) in women with polycystic ovary syndrome (PCOS).">
            <entity id="DS.d489.s0.e0" origId="O19062,P02741,P02742,P08462,P18151,P21291,P41964,P47875,P49254,P49262,P52753,P67966,P67967,P97315,Q07203" charOffset="93-96" type="protein" text="CRP"/>
            <entity id="DS.d489.s0.e1" origId="P22775,P81070" charOffset="102-112" type="protein" text="fibrinogen"/>
            <entity id="DS.d489.s0.e2" origId="977" charOffset="177-183" type="compound" text="oxygen"/>
            <pair e1="DS.d489.s0.e2" e2="DS.d489.s0.e0" id="DS.d489.s0.i0" interaction="False"/>
            <pair e1="DS.d489.s0.e2" e2="DS.d489.s0.e1" id="DS.d489.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d491" origId="18617682">
        <sentence id="DS.d491.s0" origId="18617682-1119" text="CSE activated the MMP-1 promoter, and this induction was prevented by PD98059 blockade of ERK1/2 phosphorylation.">
            <entity id="DS.d491.s0.e0" origId="P03956,P13943,P21692,P28053,P81563,Q11133,Q9XSZ5" charOffset="18-23" type="protein" text="MMP-1"/>
            <entity id="DS.d491.s0.e1" origId="4713" charOffset="70-77" type="compound" text="PD98059"/>
            <entity id="DS.d491.s0.e2" origId="P27361,P28869,P42525,Q07176" charOffset="90-94" type="protein" text="ERK1"/>
            <pair e1="DS.d491.s0.e1" e2="DS.d491.s0.e2" id="DS.d491.s0.i0" interaction="True"/>
            <pair e1="DS.d491.s0.e1" e2="DS.d491.s0.e0" id="DS.d491.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d491.s1" origId="18617682-1120" text="Cotransfection, mithramycin, and electrophoretic mobility shift assay studies identified activating and repressive roles for Sp1 and PEA3 transcription factors, respectively.">
            <entity id="DS.d491.s1.e0" origId="29051,163659,230076,457831,6326719" charOffset="16-27" type="compound" text="mithramycin"/>
            <entity id="DS.d491.s1.e1" origId="O14300,O89090,P17379,Q01714,Q85439,Q85449,Q85451" charOffset="125-128" type="protein" text="Sp1"/>
            <pair e1="DS.d491.s1.e0" e2="DS.d491.s1.e1" id="DS.d491.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d492" origId="18617751">
        <sentence id="DS.d492.s0" origId="18617751-1188" text="We have previously demonstrated that iloprost, a stable prostacyclin (PGI (2)) analogue, induces angiogenesis in vivo, through a vascular endothelial growth factor (VEGF)-dependent mechanism.">
            <entity id="DS.d492.s0.e0" origId="5311181,6435378,6443959,53394043,53486260" charOffset="37-45" type="compound" text="iloprost"/>
            <entity id="DS.d492.s0.e1" origId="5280427,5282411,6434194" charOffset="56-68" type="compound" text="prostacyclin"/>
            <entity id="DS.d492.s0.e2" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="165-169" type="protein" text="VEGF"/>
            <pair e1="DS.d492.s0.e0" e2="DS.d492.s0.e2" id="DS.d492.s0.i0" interaction="True"/>
            <pair e1="DS.d492.s0.e1" e2="DS.d492.s0.e2" id="DS.d492.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d492.s1" origId="18617751-1189" text="In this study, we demonstrate that iloprost-induced angiogenesis and VEGF upregulation are modulated by peroxisome proliferator-activated receptor-alpha (PPARalpha), a ligand-inducible transcription factor that belongs to the nuclear hormone receptor superfamily and plays multiple biological activities in the vascular system.">
            <entity id="DS.d492.s1.e0" origId="5311181,6435378,6443959,53394043,53486260" charOffset="35-43" type="compound" text="iloprost"/>
            <entity id="DS.d492.s1.e1" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="69-73" type="protein" text="VEGF"/>
            <entity id="DS.d492.s1.e2" origId="O35507,P23204,P37230,P37232,Q07869,Q8HYL6,Q95N78" charOffset="104-152" type="protein" text="peroxisome proliferator-activated receptor-alpha"/>
            <entity id="DS.d492.s1.e3" origId="O35507,P23204,P37230,P37232,Q07869,Q8HYL6,Q95N78" charOffset="154-163" type="protein" text="PPARalpha"/>
            <pair e1="DS.d492.s1.e0" e2="DS.d492.s1.e1" id="DS.d492.s1.i0" interaction="True"/>
            <pair e1="DS.d492.s1.e0" e2="DS.d492.s1.e3" id="DS.d492.s1.i1" interaction="True"/>
            <pair e1="DS.d492.s1.e0" e2="DS.d492.s1.e2" id="DS.d492.s1.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d492.s2" origId="18617751-1191" text="In contrast, iloprost induces a robust angiogenic response in wild-type mice, along with local upregulation of VEGF.">
            <entity id="DS.d492.s2.e0" origId="5311181,6435378,6443959,53394043,53486260" charOffset="13-21" type="compound" text="iloprost"/>
            <entity id="DS.d492.s2.e1" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="111-115" type="protein" text="VEGF"/>
            <pair e1="DS.d492.s2.e0" e2="DS.d492.s2.e1" id="DS.d492.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d492.s3" origId="18617751-1192" text="Importantly, mice lacking the PPARalpha gene exhibit a normal angiogenic response to VEGF, indicating that the absence of PPARalpha does not result in a general impairment of angiogenesis, but specifically affects the ability of iloprost to induce angiogenesis.">
            <entity id="DS.d492.s3.e0" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="85-89" type="protein" text="VEGF"/>
            <entity id="DS.d492.s3.e1" origId="5311181,6435378,6443959,53394043,53486260" charOffset="229-237" type="compound" text="iloprost"/>
            <pair e1="DS.d492.s3.e1" e2="DS.d492.s3.e0" id="DS.d492.s3.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d493" origId="18618086">
        <sentence id="DS.d493.s1" origId="18618086-1425" text="The proportion of APP molecules that are directed to the novel cleavage pathway is regulated by the ratio of free cholesterol and cholesteryl esters in cells.">
            <entity id="DS.d493.s1.e0" origId="O73683,O93279,P05067,P08592,P0A3Z1,P0A3Z2,P0A3Z3,P0A3Z4,P12023,P29216,P47566,P53601,P75313,P79307,Q11207,Q28053,Q28280,Q28748,Q28757,Q29149,Q5IS80,Q60495,Q95241" charOffset="18-21" type="protein" text="APP"/>
            <entity id="DS.d493.s1.e1" origId="304,5997,6432564,11025495" charOffset="114-125" type="compound" text="cholesterol"/>
            <pair e1="DS.d493.s1.e1" e2="DS.d493.s1.e0" id="DS.d493.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d494" origId="18618240">
        <sentence id="DS.d494.s0" origId="18618240-1582" text="In the hormone receptor-positive breast cancer cell line T47-D expression of hCAR and its soluble isoforms was increased by treatment with estradiol and tamoxifen.">
            <entity id="DS.d494.s0.e0" origId="P78310" charOffset="77-81" type="protein" text="hCAR"/>
            <entity id="DS.d494.s0.e1" origId="5757" charOffset="139-148" type="compound" text="estradiol"/>
            <entity id="DS.d494.s0.e2" origId="2733526" charOffset="153-162" type="compound" text="tamoxifen"/>
            <pair e1="DS.d494.s0.e2" e2="DS.d494.s0.e0" id="DS.d494.s0.i0" interaction="True"/>
            <pair e1="DS.d494.s0.e1" e2="DS.d494.s0.e0" id="DS.d494.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d495" origId="18618241">
        <sentence id="DS.d495.s0" origId="18618241-1584" text="In contrast to the behavior in aqueous solution, lactose binding in DMSO resulted in an increase of the lectin's radius of gyration from 49+/-1 to 55.5+/-1 A.">
            <entity id="DS.d495.s0.e0" origId="679" charOffset="68-72" type="compound" text="DMSO"/>
            <entity id="DS.d495.s0.e1" origId="P02871,P02873,P02874,P02875,P07386,P16108,P16349,P16351,P16352,P33888,P38662,P42088,P83410,P83511,P84987,Q41114" charOffset="104-110" type="protein" text="lectin"/>
            <pair e1="DS.d495.s0.e0" e2="DS.d495.s0.e1" id="DS.d495.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d496" origId="18618243">
        <sentence id="DS.d496.s0" origId="18618243-1587" text="Tumor necrosis factor-alpha (TNF-alpha) levels were also investigated in rat serum, but there was no statistically significant difference between the TNF-alpha levels of the caffeine-treated rats groups and the control rats.">
            <entity id="DS.d496.s0.e0" origId="Q8JFG3" charOffset="0-21" type="protein" text="Tumor necrosis factor"/>
            <entity id="DS.d496.s0.e1" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="29-38" type="protein" text="TNF-alpha"/>
            <entity id="DS.d496.s0.e2" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="150-159" type="protein" text="TNF-alpha"/>
            <entity id="DS.d496.s0.e3" origId="2519" charOffset="174-182" type="compound" text="caffeine"/>
            <pair e1="DS.d496.s0.e3" e2="DS.d496.s0.e0" id="DS.d496.s0.i0" interaction="False"/>
            <pair e1="DS.d496.s0.e3" e2="DS.d496.s0.e1" id="DS.d496.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d496.s1" origId="18618243-1588" text="Our study indicates that brain arginase activity decreases after caffeine administration at doses of 30 mg/kg and 100 mg/kg.">
            <entity id="DS.d496.s1.e0" origId="O49046,P00812,P0A2X9,P0A2Y0,P0A2Y1,P14012,P33280,P37818,P39138,P40906,P46637,P53608,P60086,P60087,P60088,Q10066,Q12611,Q1E180,Q6G7E9,Q6GER3,Q74ZW4,Q7M0Z3,Q8NVE3" charOffset="31-39" type="protein" text="arginase"/>
            <entity id="DS.d496.s1.e1" origId="2519" charOffset="65-73" type="compound" text="caffeine"/>
            <pair e1="DS.d496.s1.e1" e2="DS.d496.s1.e0" id="DS.d496.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d497" origId="18618245">
        <sentence id="DS.d497.s0" origId="18618245-1590" text="Comparison of the PTM's of MBP's isolated from several vertebrate species reveals marked differences in their phosphate content.">
            <entity id="DS.d497.s0.e0" origId="P02686,P02687,P04370,P06906,P13727,P15720,P20939,P25188,P25274,P25336,P81558,P83487,P87346,P98190,Q61878,Q63189,Q91325,Q91439,Q9SAV1" charOffset="27-30" type="protein" text="MBP"/>
            <entity id="DS.d497.s0.e1" origId="1061,167704,644102" charOffset="110-119" type="compound" text="phosphate"/>
            <pair e1="DS.d497.s0.e1" e2="DS.d497.s0.e0" id="DS.d497.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d497.s1" origId="18618245-1591" text="Chicken MBP does not share any phosphorylated sites with dogfish MBP ; However, it does contain phosphorylated serine and threonine residues in common with mammalian MBP.">
            <entity id="DS.d497.s1.e0" origId="P02686,P02687,P04370,P06906,P13727,P15720,P20939,P25188,P25274,P25336,P81558,P83487,P87346,P98190,Q61878,Q63189,Q91325,Q91439,Q9SAV1" charOffset="8-11" type="protein" text="MBP"/>
            <entity id="DS.d497.s1.e1" origId="P02686,P02687,P04370,P06906,P13727,P15720,P20939,P25188,P25274,P25336,P81558,P83487,P87346,P98190,Q61878,Q63189,Q91325,Q91439,Q9SAV1" charOffset="65-68" type="protein" text="MBP"/>
            <entity id="DS.d497.s1.e2" origId="5951" charOffset="111-117" type="compound" text="serine"/>
            <entity id="DS.d497.s1.e3" origId="6288" charOffset="122-131" type="compound" text="threonine"/>
            <entity id="DS.d497.s1.e4" origId="P02686,P02687,P04370,P06906,P13727,P15720,P20939,P25188,P25274,P25336,P81558,P83487,P87346,P98190,Q61878,Q63189,Q91325,Q91439,Q9SAV1" charOffset="65-68" type="protein" text="MBP"/>
            <pair e1="DS.d497.s1.e3" e2="DS.d497.s1.e0" id="DS.d497.s1.i0" interaction="True"/>
            <pair e1="DS.d497.s1.e2" e2="DS.d497.s1.e0" id="DS.d497.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d498" origId="18618304">
        <sentence id="DS.d498.s0" origId="18618304-1646" text="Riluzole/NaPB administration increased acetylation at H4 and increased NF-kappaB p50 translocation to the nucleus in G93A mice, consistent with a therapeutic effect.">
            <entity id="DS.d498.s0.e0" origId="5070" charOffset="0-8" type="compound" text="Riluzole"/>
            <entity id="DS.d498.s0.e1" origId="4775" charOffset="9-13" type="compound" text="NaPB"/>
            <entity id="DS.d498.s0.e2" origId="P23061,P38644,P83939,Q05894,Q28618,Q43731" charOffset="81-84" type="protein" text="p50"/>
            <pair e1="DS.d498.s0.e0" e2="DS.d498.s0.e2" id="DS.d498.s0.i0" interaction="True"/>
            <pair e1="DS.d498.s0.e1" e2="DS.d498.s0.e2" id="DS.d498.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d499" origId="18618472">
        <sentence id="DS.d499.s0" origId="18618472-1060" text="Due to the absence of hydrophobic solute-material interactions, which limit the scope of microstructures fabricated from poly(dimethylsiloxane) for biocatalytic applications, the new microreactor was fully compatible with the alternate enzyme substrate 2-nitro-phenyl-beta-D-galactoside and the 2-nitro-phenol product resulting from its hydrolysis catalyzed by CelB.">
            <entity id="DS.d499.s0.e1" origId="6947" charOffset="295-309" type="compound" text="2-nitro-phenol"/>
            <entity id="DS.d499.s0.e2" origId="P04956,P06565,P06963,P10474,P17334,P18126,P22698,P23550,P23661,P26222,P37701,P38569,P46317,Q45400" charOffset="361-365" type="protein" text="CelB"/>
            <pair e1="DS.d499.s0.e1" e2="DS.d499.s0.e2" id="DS.d499.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d500" origId="18618621">
        <sentence id="DS.d500.s0" origId="18618621-1255" text="These findings suggest that multiple variations in the SLC6A4 gene are associated with remission in white non-Hispanic depressed adults treated with citalopram.">
            <entity id="DS.d500.s0.e0" origId="O35899,P31645,Q9MYX0,Q9XT49" charOffset="55-61" type="protein" text="SLC6A4"/>
            <entity id="DS.d500.s0.e1" origId="2771,146570" charOffset="149-159" type="compound" text="citalopram"/>
            <pair e1="DS.d500.s0.e1" e2="DS.d500.s0.e0" id="DS.d500.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d501" origId="18618694">
        <sentence id="DS.d501.s0" origId="18618694-248" text="The planar angle between the carbamoyl phosphate and aspartate domains of the catalytic chain is more open at pH 8.5 than in ATCase structures determined at lower pH values.">
            <entity id="DS.d501.s0.e0" origId="278" charOffset="29-48" type="compound" text="carbamoyl phosphate"/>
            <entity id="DS.d501.s0.e1" origId="5960" charOffset="53-62" type="compound" text="aspartate"/>
            <entity id="DS.d501.s0.e2" origId="O25716,O27464,O30130,O58451,O66726,P05654,P0A1Z4,P0A1Z5,P0A786,P0A787,P0A788,P0A789,P19910,P41008,P49077,P56585,P57450,P65611,P65612,P65613,P65614,P65615,P65616,P65617,P65618,P65619,P65620,P65621,P74163,P77883,P77918,P96079,P96111,P96174,Q04595,Q2W156,Q55338,Q58976,Q59653,Q59711,Q5E7U5,Q5FGW9,Q5FJB7,Q5FRG8,Q5H2Z0,Q5HBA3,Q5HGN2,Q5HPZ1,Q5HU06,Q5JHM9,Q5L0U6,Q5LX75,Q5M0X1,Q5M5F8,Q5N3S1,Q5NPE5,Q5P6I4,Q5PAN5,Q5PJB2,Q5SK66,Q5V2T3,Q5WFI9,Q5WYW3,Q5X7G7,Q5XCR9,Q5YTM0,Q5ZXZ2,Q60252,Q605F1,Q62I89,Q636D7,Q63RI2,Q64U74,Q65JV0,Q665I6,Q67Q01,Q6A917,Q6AF88,Q6AS40,Q6DA73,Q6FCR5,Q6FZS5,Q6G3F3,Q6GA13,Q6GHN5,Q6HES5,Q6L0F2,Q6LUX0,Q6LWQ0,Q6N565,Q6NH13,Q71YH8,Q727F4,Q72KU0,Q72NJ5,Q732I0,Q73GP1,Q741H5,Q74DP5,Q74J31,Q7M9Y9,Q7MHF1,Q7MX58,Q7MZ16,Q7NCV1,Q7P145,Q7U9G2,Q7UNR3,Q7V355,Q7V4X7,Q7VDV6,Q7VIT3,Q7W044,Q7W3U7,Q7WF77,Q819S0,Q81WE9,Q827R1,Q82U44,Q83A16,Q87C22,Q87LF8,Q87V99,Q88D30,Q89K19,Q8A9S3,Q8CPJ7,Q8D293,Q8DCF6,Q8DIM4,Q8DPH9,Q8DUP5,Q8DZQ5,Q8E5F3,Q8ER38,Q8EUX9,Q8F812,Q8FT39,Q8G655,Q8K9H9,Q8KBI7,Q8NQ38,Q8P1G1,Q8P767,Q8PII1,Q8PXK5,Q8R9R5,Q8RG89,Q8THL2,Q8TVB2,Q8U373,Q8UFT9,Q8XL59,Q8Y1L2,Q8Y662,Q8YWD2,Q8ZB39,Q8ZYH7,Q92AH0,Q92QL5,Q934T0,Q970X2,Q97B29,Q97FS3,Q97QE2,Q98M86,Q9A5K4,Q9CCR5,Q9CF79,Q9HHN4,Q9HKM2,Q9K9V6,Q9KP66,Q9KXR2,Q9L4N6,Q9L4T8,Q9PBB8,Q9PNJ6,Q9RVC0,Q9UX08,Q9YBD4,Q9ZM81" charOffset="125-131" type="protein" text="ATCase"/>
            <pair e1="DS.d501.s0.e1" e2="DS.d501.s0.e2" id="DS.d501.s0.i0" interaction="True"/>
            <pair e1="DS.d501.s0.e0" e2="DS.d501.s0.e2" id="DS.d501.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d502" origId="18618700">
        <sentence id="DS.d502.s0" origId="18618700-254" text="At 0.15 microM Ca(2+), ((35)S) CaM bound to RyR2 with decreased affinity and binding enthalpy compared with RyR1.">
            <entity id="DS.d502.s0.e0" origId="271" charOffset="15-19" type="compound" text="Ca(2"/>
            <entity id="DS.d502.s0.e1" origId="O02367,O16305,O60041,O82018,O94739,O96102,O97341,P02594,P02595,P02598,P02599,P04352,P04353,P04464,P05933,P05934,P05935,P06787,P07463,P11118,P11120,P11121,P15094,P17928,P18061,P21251,P23286,P24044,P27161,P27165,P27166,P41040,P41041,P48976,P60204,P60205,P60206,P61859,P61860,P61861,P62144,P62145,P62149,P62151,P62152,P62154,P62155,P62156,P62157,P62158,P62160,P62161,P62162,P62184,P62201,P62202,P62203,P62204,P69097,P69098,P84339,P93087,P93171,Q00168,Q05055,Q39752,Q40302,Q5EHV7,Q5RAD2,Q6IT78,Q6PI52,Q6R520,Q6YNX6,Q71UH5,Q71UH6,Q7T3T2,Q7Y052,Q8STF0,Q8X187,Q95NI4,Q95NR9,Q9GRJ1,Q9HFY6,Q9U6D3,Q9UWF0" charOffset="31-34" type="protein" text="CaM"/>
            <entity id="DS.d502.s0.e2" origId="P30957,Q92736" charOffset="44-48" type="protein" text="RyR2"/>
            <entity id="DS.d502.s0.e3" origId="P11716,P16960,P21817" charOffset="108-112" type="protein" text="RyR1"/>
            <pair e1="DS.d502.s0.e0" e2="DS.d502.s0.e2" id="DS.d502.s0.i0" interaction="False"/>
            <pair e1="DS.d502.s0.e0" e2="DS.d502.s0.e1" id="DS.d502.s0.i1" interaction="False"/>
            <pair e1="DS.d502.s0.e0" e2="DS.d502.s0.e3" id="DS.d502.s0.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d502.s1" origId="18618700-255" text="The rates of ((35)S) CaM dissociation from RyR1 increased as the temperature was raised, whereas at 0.15 microM Ca(2+) the rate from RyR2 was little affected.">
            <entity id="DS.d502.s1.e0" origId="O02367,O16305,O60041,O82018,O94739,O96102,O97341,P02594,P02595,P02598,P02599,P04352,P04353,P04464,P05933,P05934,P05935,P06787,P07463,P11118,P11120,P11121,P15094,P17928,P18061,P21251,P23286,P24044,P27161,P27165,P27166,P41040,P41041,P48976,P60204,P60205,P60206,P61859,P61860,P61861,P62144,P62145,P62149,P62151,P62152,P62154,P62155,P62156,P62157,P62158,P62160,P62161,P62162,P62184,P62201,P62202,P62203,P62204,P69097,P69098,P84339,P93087,P93171,Q00168,Q05055,Q39752,Q40302,Q5EHV7,Q5RAD2,Q6IT78,Q6PI52,Q6R520,Q6YNX6,Q71UH5,Q71UH6,Q7T3T2,Q7Y052,Q8STF0,Q8X187,Q95NI4,Q95NR9,Q9GRJ1,Q9HFY6,Q9U6D3,Q9UWF0" charOffset="21-24" type="protein" text="CaM"/>
            <entity id="DS.d502.s1.e1" origId="P11716,P16960,P21817" charOffset="43-47" type="protein" text="RyR1"/>
            <entity id="DS.d502.s1.e2" origId="271" charOffset="112-116" type="compound" text="Ca(2"/>
            <entity id="DS.d502.s1.e3" origId="P30957,Q92736" charOffset="133-137" type="protein" text="RyR2"/>
            <pair e1="DS.d502.s1.e2" e2="DS.d502.s1.e3" id="DS.d502.s1.i0" interaction="False"/>
            <pair e1="DS.d502.s1.e2" e2="DS.d502.s1.e1" id="DS.d502.s1.i1" interaction="False"/>
            <pair e1="DS.d502.s1.e2" e2="DS.d502.s1.e0" id="DS.d502.s1.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d503" origId="18619522">
        <sentence id="DS.d503.s0" origId="18619522-636" text="In rats, infusion of angiotensin II increases ferritin levels and arterial thickness which are reversed by treatment with the iron chelator deferoxamine.">
            <entity id="DS.d503.s0.e0" origId="Q26061" charOffset="46-54" type="protein" text="ferritin"/>
            <entity id="DS.d503.s0.e1" origId="2973" charOffset="140-152" type="compound" text="deferoxamine"/>
            <pair e1="DS.d503.s0.e1" e2="DS.d503.s0.e0" id="DS.d503.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d504" origId="18619705">
        <sentence id="DS.d504.s0" origId="18619705-1094" text="Furthermore, ellipticine regulated endogenous survival signaling by up-regulating phosphorylated Akt that returned to its basal level later.">
            <entity id="DS.d504.s0.e0" origId="3213" charOffset="13-24" type="compound" text="ellipticine"/>
            <entity id="DS.d504.s0.e1" origId="P31750,Q8INB9" charOffset="97-100" type="protein" text="Akt"/>
            <pair e1="DS.d504.s0.e0" e2="DS.d504.s0.e1" id="DS.d504.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d504.s1" origId="18619705-1095" text="Furthermore, ellipticine induced nucleus translocalization of p53 and Akt and recruitment of autophagosomes.">
            <entity id="DS.d504.s1.e0" origId="3213" charOffset="13-24" type="compound" text="ellipticine"/>
            <entity id="DS.d504.s1.e1" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="62-65" type="protein" text="p53"/>
            <entity id="DS.d504.s1.e2" origId="P31750,Q8INB9" charOffset="70-73" type="protein" text="Akt"/>
            <pair e1="DS.d504.s1.e0" e2="DS.d504.s1.e2" id="DS.d504.s1.i0" interaction="True"/>
            <pair e1="DS.d504.s1.e0" e2="DS.d504.s1.e1" id="DS.d504.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d505" origId="18619713">
        <sentence id="DS.d505.s0" origId="18619713-1104" text="The ubiquitous enzyme dUTP nucleotidohydrolase (dUTPase) catalyses the hydrolysis of dUTP to dUMP and can be considered as the first line of defence against incorporation of uracil into DNA.">
            <entity id="DS.d505.s0.e0" origId="O25536,O27642,O29157,O30931,O41033,O48500,O52597,O54134,O66592,O68992,O83855,O84294,P03195,P03370,P06968,P09254,P0A552,P0A553,P10234,P14597,P16088,P16824,P16901,P17374,P19028,P23426,P23427,P28892,P28893,P30007,P31625,P31822,P32208,P32518,P33316,P33317,P33826,P35956,P43058,P43792,P52341,P52541,P57623,P57914,P59408,P61906,P61907,P61908,P61909,P61910,P61911,P61912,P61913,P64004,P64005,P64006,P64007,P64008,P64009,P68634,P68635,P70583,P87630,Q00030,Q01034,Q06095,Q07275,Q2Y742,Q2YRG4,Q31EC7,Q31UY6,Q329L7,Q39DM5,Q39V99,Q3A499,Q3AQ75,Q3B304,Q3BNA6,Q3J0B2,Q3J6W1,Q3JV72,Q3K4M6,Q3KM70,Q3SFR7,Q3SWM9,Q3YRU2,Q3YW02,Q45920,Q47BB1,Q47NK1,Q48Q06,Q491W8,Q49992,Q4FU67,Q4JVB1,Q4K3S2,Q4QLV3,Q4ULV2,Q4UPP2,Q4ZZX9,Q57BK5,Q57IA2,Q58502,Q5F9E0,Q5FN20,Q5GST1,Q5H5L9,Q5L6D8,Q5LIH9,Q5LWD3,Q5NHX4,Q5P7Z9,Q5PAE6,Q5PC28,Q5QZB6,Q5WTW6,Q5X242,Q5YT90,Q5ZSN0,Q603M1,Q62HL1,Q63WI6,Q64ZK3,Q65R66,Q66GD8,Q68WX8,Q69151,Q6A8W1,Q6AFE0,Q6AJZ0,Q6BRN7,Q6C141,Q6CQN7,Q6DAV9,Q6E4Q0,Q6FDR0,Q6FKQ6,Q6FYR2,Q6G202,Q6MEK7,Q6MVL2,Q6RZR1,Q6TUZ4,Q74ZF0,Q76RE7,Q775Z7,Q7M9N1,Q7MAX3,Q7MBE8,Q7MVT6,Q7NKL2,Q7VJU0,Q7VN49,Q7VRK0,Q7VVR1,Q7W8Z8,Q7WKE3,Q823Q9,Q82KK4,Q82UM1,Q83G43,Q83I22,Q83PN3,Q87F19,Q88BD3,Q88C95,Q895R1,Q89662,Q8A245,Q8D2F3,Q8E9M0,Q8F729,Q8FPH9,Q8G4E8,Q8K921,Q8NPA9,Q8P458,Q8PFR5,Q8PWG1,Q8RA46,Q8RER7,Q8SRS0,Q8TGX9,Q8TV34,Q8UII1,Q8V2Y0,Q8XWL1,Q8ZJP5,Q90030,Q92I74,Q92SM6,Q97J61,Q98C10,Q9A253,Q9CJ30,Q9F7S4,Q9HMF3,Q9HTN3,Q9J5G5,Q9JUW1,Q9JZU7,Q9P6Q5,Q9PGZ6,Q9PKA2,Q9X3X5,Q9YG32,Q9YYS0,Q9Z9C2,Q9ZDD2,Q9ZKY3" charOffset="48-55" type="protein" text="dUTPase"/>
            <entity id="DS.d505.s0.e1" origId="1174" charOffset="174-180" type="compound" text="uracil"/>
            <pair e1="DS.d505.s0.e1" e2="DS.d505.s0.e0" id="DS.d505.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d506" origId="18621093">
        <sentence id="DS.d506.s0" origId="18621093-545" text="Recent findings indicate that the polypyrimidine tract-binding protein (PTB), also named hnRNP I, by binding to the 3'-UTR (untranslated region) of the preproinsulin mRNA molecule, stabilizes the messenger, thereby participating in the glucose-induced increase in preproinsulin mRNA.">
            <entity id="DS.d506.s0.e0" origId="P17225,P26599,Q00438,Q29099,Q8WN55,Q9MAC5,Q9UKA9" charOffset="72-75" type="protein" text="PTB"/>
            <entity id="DS.d506.s0.e1" origId="P17225,P26599,Q00438,Q29099" charOffset="89-96" type="protein" text="hnRNP I"/>
            <entity id="DS.d506.s0.e2" origId="206,5793,64689,79025" charOffset="236-243" type="compound" text="glucose"/>
            <pair e1="DS.d506.s0.e2" e2="DS.d506.s0.e0" id="DS.d506.s0.i0" interaction="True"/>
            <pair e1="DS.d506.s0.e2" e2="DS.d506.s0.e1" id="DS.d506.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d507" origId="18621373">
        <sentence id="DS.d507.s0" origId="18621373-794" text="Pretreatment with extracellular signal-regulated kinase (ERK) and Jun N-terminal kinase (JNK) inhibitors, but not p38 mitogen-activated protein kinase (p38MAPK) significantly decreased CRP-induced superoxide anion release from macrophages in vivo.">
            <entity id="DS.d507.s0.e0" origId="O62618" charOffset="152-159" type="protein" text="p38MAPK"/>
            <entity id="DS.d507.s0.e1" origId="O19062,P02741,P02742,P08462,P18151,P21291,P41964,P47875,P49254,P49262,P52753,P67966,P67967,P97315,Q07203" charOffset="185-188" type="protein" text="CRP"/>
            <entity id="DS.d507.s0.e2" origId="5359597" charOffset="197-207" type="compound" text="superoxide"/>
            <pair e1="DS.d507.s0.e2" e2="DS.d507.s0.e1" id="DS.d507.s0.i0" interaction="True"/>
            <pair e1="DS.d507.s0.e2" e2="DS.d507.s0.e0" id="DS.d507.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d508" origId="18621413">
        <sentence id="DS.d508.s0" origId="18621413-823" text="The free radicals produced are thought to be generated during the production of uric acid, a reaction catalyzed by xanthine oxidase.">
            <entity id="DS.d508.s0.e0" origId="1175" charOffset="80-89" type="compound" text="uric acid"/>
            <entity id="DS.d508.s0.e1" origId="P22985,P47989,P47990,P80457,Q00519,Q9MYW6" charOffset="115-131" type="protein" text="xanthine oxidase"/>
            <pair e1="DS.d508.s0.e0" e2="DS.d508.s0.e1" id="DS.d508.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d509" origId="18621448">
        <sentence id="DS.d509.s0" origId="18621448-855" text="In the diabetic group, a decrease in the pancreatic glutathione levels, glutathione peroxidase and superoxide dismutase activities and an increase in the pancreatic lipid peroxidation level and catalase activities were observed.">
            <entity id="DS.d509.s0.e0" origId="124886" charOffset="52-63" type="compound" text="glutathione"/>
            <entity id="DS.d509.s0.e1" origId="O32770,O59858,Q00277,Q9CFV1" charOffset="72-94" type="protein" text="glutathione peroxidase"/>
            <entity id="DS.d509.s0.e2" origId="O50258" charOffset="99-119" type="protein" text="superoxide dismutase"/>
            <entity id="DS.d509.s0.e3" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="194-202" type="protein" text="catalase"/>
            <pair e1="DS.d509.s0.e0" e2="DS.d509.s0.e3" id="DS.d509.s0.i0" interaction="False"/>
            <pair e1="DS.d509.s0.e0" e2="DS.d509.s0.e2" id="DS.d509.s0.i1" interaction="False"/>
            <pair e1="DS.d509.s0.e0" e2="DS.d509.s0.e1" id="DS.d509.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d510" origId="18621563">
        <sentence id="DS.d510.s0" origId="18621563-947" text="The immunomodulatory effects of thalidomide are at least partially mediated through its ability to down-regulate the pathogenic over-production of tumor necrosis factor-alpha (TNF-alpha).">
            <entity id="DS.d510.s0.e0" origId="5426,75792,92142" charOffset="32-43" type="compound" text="thalidomide"/>
            <entity id="DS.d510.s0.e1" origId="Q8JFG3" charOffset="147-168" type="protein" text="tumor necrosis factor"/>
            <entity id="DS.d510.s0.e2" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="176-185" type="protein" text="TNF-alpha"/>
            <pair e1="DS.d510.s0.e0" e2="DS.d510.s0.e2" id="DS.d510.s0.i0" interaction="True"/>
            <pair e1="DS.d510.s0.e0" e2="DS.d510.s0.e1" id="DS.d510.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d510.s1" origId="18621563-948" text="In the central nervous system, TNF-alpha is involved in induction of a fever response and triggers the release of other cytokines, and may also influence transport of compounds into the brain, leading to cerebrospinal fluid leukocytosis, increased protein influx, and lactate accumulation.">
            <entity id="DS.d510.s1.e0" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="31-40" type="protein" text="TNF-alpha"/>
            <entity id="DS.d510.s1.e1" origId="612" charOffset="268-275" type="compound" text="lactate"/>
            <pair e1="DS.d510.s1.e1" e2="DS.d510.s1.e0" id="DS.d510.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d510.s2" origId="18621563-949" text="Thalidomide has been shown to down-regulate the production of TNF-alpha.">
            <entity id="DS.d510.s2.e0" origId="5426,75792,92142" charOffset="0-11" type="compound" text="Thalidomide"/>
            <entity id="DS.d510.s2.e1" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="62-71" type="protein" text="TNF-alpha"/>
            <pair e1="DS.d510.s2.e0" e2="DS.d510.s2.e1" id="DS.d510.s2.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d511" origId="18622696">
        <sentence id="DS.d511.s0" origId="18622696-162" text="Both cell types expressed estrogen and progesterone receptors, although only the epithelial LM05-E cells were stimulated by estradiol and inhibited by tamoxifen.">
            <entity id="DS.d511.s0.e0" origId="P06186,P06401,P07812,P79373,Q00175,Q28590,Q63449,Q8AYI2,Q9GLW0" charOffset="39-61" type="protein" text="progesterone receptors"/>
            <entity id="DS.d511.s0.e1" origId="5757" charOffset="124-133" type="compound" text="estradiol"/>
            <entity id="DS.d511.s0.e2" origId="2733526" charOffset="151-160" type="compound" text="tamoxifen"/>
            <pair e1="DS.d511.s0.e1" e2="DS.d511.s0.e0" id="DS.d511.s0.i0" interaction="False"/>
            <pair e1="DS.d511.s0.e2" e2="DS.d511.s0.e0" id="DS.d511.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d512" origId="18622720">
        <sentence id="DS.d512.s0" origId="18622720-185" text="This study was performed to investigate the effect of combined treatment with niacin and chromium on vascular endothelial dysfunction, with the aim of gaining insight to the mechanisms by detecting the expression levels of ox-LDL and LOX-1.">
            <entity id="DS.d512.s0.e0" origId="938" charOffset="78-84" type="compound" text="niacin"/>
            <entity id="DS.d512.s0.e1" origId="23976" charOffset="89-97" type="compound" text="chromium"/>
            <entity id="DS.d512.s0.e2" origId="O70156,P78380,P79391,Q9EQ09,Q9TTK7,Q9XTA8" charOffset="234-239" type="protein" text="LOX-1"/>
            <pair e1="DS.d512.s0.e0" e2="DS.d512.s0.e2" id="DS.d512.s0.i0" interaction="False"/>
            <pair e1="DS.d512.s0.e1" e2="DS.d512.s0.e2" id="DS.d512.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d512.s1" origId="18622720-186" text="In HF group, the serum levels of total cholesterol (TC), low-density lipoprotein (LDL), oxidized low-density lipoprotein (ox-LDL) and endothelin (ET) were higher, whereas the levels of high-density lipoprotein (HDL), serum NO were lower than those in CG group.">
            <entity id="DS.d512.s1.e0" origId="304,5997,6432564,11025495" charOffset="39-50" type="compound" text="cholesterol"/>
            <entity id="DS.d512.s1.e1" origId="P81182" charOffset="185-209" type="protein" text="high-density lipoprotein"/>
            <pair e1="DS.d512.s1.e0" e2="DS.d512.s1.e1" id="DS.d512.s1.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d512.s2" origId="18622720-187" text="These findings indicated that combined treatment with niacin and chromium has potential therapeutic protection of endothelial function by down-regulating ox-LDL/LOX-1 signaling pathway.">
            <entity id="DS.d512.s2.e0" origId="938" charOffset="54-60" type="compound" text="niacin"/>
            <entity id="DS.d512.s2.e1" origId="23976" charOffset="65-73" type="compound" text="chromium"/>
            <entity id="DS.d512.s2.e2" origId="O70156,P78380,P79391,Q9EQ09,Q9TTK7,Q9XTA8" charOffset="161-166" type="protein" text="LOX-1"/>
            <pair e1="DS.d512.s2.e1" e2="DS.d512.s2.e2" id="DS.d512.s2.i0" interaction="True"/>
            <pair e1="DS.d512.s2.e0" e2="DS.d512.s2.e2" id="DS.d512.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d513" origId="18622759">
        <sentence id="DS.d513.s0" origId="18622759-218" text="The deduced amino acid sequence of Ai Lec was highly similar to those of the C-type lectins from other animals and contained a typical carbohydrate-recognition domain (CRD) of 131 residues, which has four conserved disulfide-bonded cysteine residues that define the CRD and two additional cysteine residues at the amino terminus.">
            <entity id="DS.d513.s0.e0" origId="P02871,P02873,P02874,P02875,P07386,P16108,P16349,P16351,P16352,P33888,P38662,P42088,P83410,P83511,P84987,Q41114" charOffset="84-91" type="protein" text="lectins"/>
            <entity id="DS.d513.s0.e1" origId="594,5862,5360637" charOffset="232-240" type="compound" text="cysteine"/>
            <entity id="DS.d513.s0.e2" origId="594,5862,5360637" charOffset="289-297" type="compound" text="cysteine"/>
            <pair e1="DS.d513.s0.e1" e2="DS.d513.s0.e0" id="DS.d513.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d514" origId="18623061">
        <sentence id="DS.d514.s0" origId="18623061-1275" text="Src kinases can be activated by trans-phosphorylation of a tyrosine located in the central activation loop of the catalytic domain.">
            <entity id="DS.d514.s0.e0" origId="P05480,Q9WUD9" charOffset="0-3" type="protein" text="Src"/>
            <entity id="DS.d514.s0.e1" origId="1153,6057,5460803" charOffset="59-67" type="compound" text="tyrosine"/>
            <pair e1="DS.d514.s0.e1" e2="DS.d514.s0.e0" id="DS.d514.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d514.s1" origId="18623061-1276" text="However, because the required exposure of this tyrosine is not observed in the down-regulated X-ray structures of Src kinases, transient partial opening of the activation loop appears to be necessary for such processes.">
            <entity id="DS.d514.s1.e0" origId="1153,6057,5460803" charOffset="47-55" type="compound" text="tyrosine"/>
            <entity id="DS.d514.s1.e1" origId="P05480,Q9WUD9" charOffset="114-117" type="protein" text="Src"/>
            <pair e1="DS.d514.s1.e0" e2="DS.d514.s1.e1" id="DS.d514.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d515" origId="18623078">
        <sentence id="DS.d515.s0" origId="18623078-486" text="The growth of L. minor (as fresh weight) and chlorophyll a content were significantly reduced and superoxide dismutase (SOD) activity was significantly decreased at microcystins concentration up to 0.5 mg/L.">
            <entity id="DS.d515.s0.e0" origId="5351507,5459387,6326752,6433193,6914133,9600410" charOffset="45-58" type="compound" text="chlorophyll a"/>
            <entity id="DS.d515.s0.e1" origId="O50258" charOffset="98-118" type="protein" text="superoxide dismutase"/>
            <entity id="DS.d515.s0.e2" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="120-123" type="protein" text="SOD"/>
            <pair e1="DS.d515.s0.e0" e2="DS.d515.s0.e1" id="DS.d515.s0.i0" interaction="False"/>
            <pair e1="DS.d515.s0.e0" e2="DS.d515.s0.e2" id="DS.d515.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d515.s1" origId="18623078-487" text="The experiment also indicated that catalase (CAT) activity was not significantly influenced by microcystin for both the two tested aquatic plants.">
            <entity id="DS.d515.s1.e0" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="35-43" type="protein" text="catalase"/>
            <entity id="DS.d515.s1.e1" origId="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7" charOffset="45-48" type="protein" text="CAT"/>
            <entity id="DS.d515.s1.e2" origId="56841897" charOffset="95-106" type="compound" text="microcystin"/>
            <pair e1="DS.d515.s1.e2" e2="DS.d515.s1.e1" id="DS.d515.s1.i0" interaction="False"/>
            <pair e1="DS.d515.s1.e2" e2="DS.d515.s1.e0" id="DS.d515.s1.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d516" origId="18623211">
        <sentence id="DS.d516.s0" origId="18623211-610" text="The purpose of this study was to investigate the solid-state properties of lyophilized formulations of protein (ribonuclease A) containing sucrose or trehalose across a wide range of compositions, both in the presence or absence of hydroxyethylstarch (HES).">
            <entity id="DS.d516.s0.e0" origId="P27043" charOffset="112-126" type="protein" text="ribonuclease A"/>
            <entity id="DS.d516.s0.e1" origId="5988" charOffset="139-146" type="compound" text="sucrose"/>
            <entity id="DS.d516.s0.e2" origId="7427" charOffset="150-159" type="compound" text="trehalose"/>
            <pair e1="DS.d516.s0.e1" e2="DS.d516.s0.e0" id="DS.d516.s0.i0" interaction="False"/>
            <pair e1="DS.d516.s0.e2" e2="DS.d516.s0.e0" id="DS.d516.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d517" origId="18624726">
        <sentence id="DS.d517.s0" origId="18624726-1067" text="The stimulatory effects of stearic, palmitic and palmitoleic acids on resistin secretion and the stimulatory effect of stearic acid on MCP-1 secretion are mediated via TLR-4.">
            <entity id="DS.d517.s0.e0" origId="5281" charOffset="119-131" type="compound" text="stearic acid"/>
            <entity id="DS.d517.s0.e1" origId="P10148,P13500,P14844,P28291,P28292,P42831,P52203,P61274,P61275,Q08782,Q9TTQ3" charOffset="135-140" type="protein" text="MCP-1"/>
            <entity id="DS.d517.s0.e2" origId="P23799" charOffset="168-171" type="protein" text="TLR"/>
            <pair e1="DS.d517.s0.e0" e2="DS.d517.s0.e1" id="DS.d517.s0.i0" interaction="True"/>
            <pair e1="DS.d517.s0.e0" e2="DS.d517.s0.e2" id="DS.d517.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d518" origId="18624760">
        <sentence id="DS.d518.s0" origId="18624760-178" text="Acitretin increased the levels of CD95 (Fas), CD95-ligand and Fas-associated death domain.">
            <entity id="DS.d518.s0.e0" origId="5284513" charOffset="0-9" type="compound" text="Acitretin"/>
            <entity id="DS.d518.s0.e1" origId="P25446,Q63199" charOffset="40-43" type="protein" text="Fas"/>
            <entity id="DS.d518.s0.e2" origId="P25446,Q63199" charOffset="62-65" type="protein" text="Fas"/>
            <pair e1="DS.d518.s0.e0" e2="DS.d518.s0.e1" id="DS.d518.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d519" origId="18624766">
        <sentence id="DS.d519.s0" origId="18624766-181" text="Since lithium and SB-415286-induced G(2)/M arrest we studied changes in the expression of proteins involved in this phase, specifically cyclin B, cdc2 and the phosphorylated form of this protein (tyr15-cdc2).">
            <entity id="DS.d519.s0.e0" origId="28486,3028194" charOffset="6-13" type="compound" text="lithium"/>
            <entity id="DS.d519.s0.e1" origId="4210951" charOffset="18-27" type="compound" text="SB-415286"/>
            <entity id="DS.d519.s0.e2" origId="O01377,O16852,P04961,P12004,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P61074,Q00265,Q00268" charOffset="136-142" type="protein" text="cyclin"/>
            <entity id="DS.d519.s0.e3" origId="P04551,P11440,P23572,P39951" charOffset="146-150" type="protein" text="cdc2"/>
            <entity id="DS.d519.s0.e4" origId="P04551,P11440,P23572,P39951" charOffset="202-206" type="protein" text="cdc2"/>
            <pair e1="DS.d519.s0.e1" e2="DS.d519.s0.e2" id="DS.d519.s0.i0" interaction="False"/>
            <pair e1="DS.d519.s0.e0" e2="DS.d519.s0.e3" id="DS.d519.s0.i1" interaction="False"/>
            <pair e1="DS.d519.s0.e1" e2="DS.d519.s0.e3" id="DS.d519.s0.i2" interaction="False"/>
            <pair e1="DS.d519.s0.e0" e2="DS.d519.s0.e2" id="DS.d519.s0.i3" interaction="False"/>
        </sentence>
        <sentence id="DS.d519.s1" origId="18624766-182" text="On the other hand, SB-415286 increased the expression of SIRT2, involved in the regulation of proliferation.">
            <entity id="DS.d519.s1.e0" origId="4210951" charOffset="19-28" type="compound" text="SB-415286"/>
            <entity id="DS.d519.s1.e1" origId="Q4R834,Q5RBF1,Q8IXJ6" charOffset="57-62" type="protein" text="SIRT2"/>
            <pair e1="DS.d519.s1.e0" e2="DS.d519.s1.e1" id="DS.d519.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d519.s2" origId="18624766-184" text="We conclude that inhibitors of GSK-3 induced cell-cycle arrest, mediated by the phosphorylation of cdc2 and, in the case of SB-415286, SIRT2 expression, which induced apoptosis in a caspase-independent manner.">
            <entity id="DS.d519.s2.e0" origId="P04551,P11440,P23572,P39951" charOffset="99-103" type="protein" text="cdc2"/>
            <entity id="DS.d519.s2.e1" origId="4210951" charOffset="124-133" type="compound" text="SB-415286"/>
            <entity id="DS.d519.s2.e2" origId="Q4R834,Q5RBF1,Q8IXJ6" charOffset="135-140" type="protein" text="SIRT2"/>
            <pair e1="DS.d519.s2.e1" e2="DS.d519.s2.e2" id="DS.d519.s2.i0" interaction="True"/>
            <pair e1="DS.d519.s2.e1" e2="DS.d519.s2.e0" id="DS.d519.s2.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d520" origId="18624772">
        <sentence id="DS.d520.s1" origId="18624772-192" text="Reduction of intracellular Ca(2+) levels abolished eNOS reduction by HOG-LDL, as did pharmacological or genetic through calcium channel blockers or calcium chelator BAPTA or inhibition of NAD(P)H oxidase (with apocynin) or inhibition of calpain (calpain 1-specific siRNA).">
            <entity id="DS.d520.s1.e0" origId="271" charOffset="27-31" type="compound" text="Ca(2"/>
            <entity id="DS.d520.s1.e1" origId="P29473,P29474,P70313,P79209,P97270,Q28969,Q62600" charOffset="51-55" type="protein" text="eNOS"/>
            <entity id="DS.d520.s1.e2" origId="104751" charOffset="165-170" type="compound" text="BAPTA"/>
            <entity id="DS.d520.s1.e3" origId="2214" charOffset="210-218" type="compound" text="apocynin"/>
            <pair e1="DS.d520.s1.e0" e2="DS.d520.s1.e1" id="DS.d520.s1.i0" interaction="True"/>
            <pair e1="DS.d520.s1.e2" e2="DS.d520.s1.e1" id="DS.d520.s1.i1" interaction="True"/>
            <pair e1="DS.d520.s1.e3" e2="DS.d520.s1.e1" id="DS.d520.s1.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d521" origId="18624794">
        <sentence id="DS.d521.s0" origId="18624794-206" text="In addition to transporting glutamate, EAAC1 plays other roles in regulating GABA synthesis, reducing oxidative stress in neurons, and is important in supporting neuron viability.">
            <entity id="DS.d521.s0.e0" origId="611,23327,33032" charOffset="28-37" type="compound" text="glutamate"/>
            <entity id="DS.d521.s0.e1" origId="P31597,P43005,Q95135" charOffset="39-44" type="protein" text="EAAC1"/>
            <entity id="DS.d521.s0.e2" origId="119" charOffset="77-81" type="compound" text="GABA"/>
            <pair e1="DS.d521.s0.e0" e2="DS.d521.s0.e1" id="DS.d521.s0.i0" interaction="True"/>
            <pair e1="DS.d521.s0.e2" e2="DS.d521.s0.e1" id="DS.d521.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d522" origId="18625283">
        <sentence id="DS.d522.s0" origId="18625283-633" text="Whereas both peptides lactoferricin (17-30) and lactoferrampin (265-284) did not have bactericidal activity, 40 microM of lactoferrin chimera (a fusion of the two peptides) inhibited the growth of all Vibrio tested to the same extent as the antibiotic gentamicin.">
            <entity id="DS.d522.s0.e0" origId="44567785" charOffset="22-35" type="compound" text="lactoferricin"/>
            <entity id="DS.d522.s0.e1" origId="O77698,O77811,P02788,P08071,P14632,P24627,Q29477,Q9TUM0" charOffset="122-133" type="protein" text="lactoferrin"/>
            <entity id="DS.d522.s0.e2" origId="3467" charOffset="252-262" type="compound" text="gentamicin"/>
            <pair e1="DS.d522.s0.e0" e2="DS.d522.s0.e1" id="DS.d522.s0.i0" interaction="False"/>
            <pair e1="DS.d522.s0.e2" e2="DS.d522.s0.e1" id="DS.d522.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d523" origId="18625298">
        <sentence id="DS.d523.s0" origId="18625298-638" text="We have recently shown that the antidepressant fluoxetine enhances T cell proliferation and T(H)1 cytokine production in vivo, without changes on CD4/CD8 subsets.">
            <entity id="DS.d523.s0.e0" origId="3386" charOffset="47-57" type="compound" text="fluoxetine"/>
            <entity id="DS.d523.s0.e1" origId="P01730,P05542,P16003,P16004,P33705,P46630,P79184,P79185,Q08336,Q08338,Q08339,Q08340,Q29037,Q9XS78" charOffset="146-149" type="protein" text="CD4"/>
            <pair e1="DS.d523.s0.e0" e2="DS.d523.s0.e1" id="DS.d523.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d523.s1" origId="18625298-639" text="We found that fluoxetine restored T cell proliferation and interleukin-2, interferon-gamma and tumor necrosis factor-alpha production by compensatory mechanisms.">
            <entity id="DS.d523.s1.e0" origId="3386" charOffset="14-24" type="compound" text="fluoxetine"/>
            <entity id="DS.d523.s1.e1" origId="Q9TTB0" charOffset="74-90" type="protein" text="interferon-gamma"/>
            <entity id="DS.d523.s1.e2" origId="Q8JFG3" charOffset="95-116" type="protein" text="tumor necrosis factor"/>
            <pair e1="DS.d523.s1.e0" e2="DS.d523.s1.e1" id="DS.d523.s1.i0" interaction="True"/>
            <pair e1="DS.d523.s1.e0" e2="DS.d523.s1.e2" id="DS.d523.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d524" origId="18625569">
        <sentence id="DS.d524.s0" origId="18625569-874" text="Here we report a case of intragenic EGFR microdeletion in renal cell carcinoma (RCC) associated with the effect of treatment by gefitinib.">
            <entity id="DS.d524.s0.e0" origId="P00533,P13387,P55245" charOffset="36-40" type="protein" text="EGFR"/>
            <entity id="DS.d524.s0.e1" origId="123631" charOffset="128-137" type="compound" text="gefitinib"/>
            <pair e1="DS.d524.s0.e1" e2="DS.d524.s0.e0" id="DS.d524.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d525" origId="18626508">
        <sentence id="DS.d525.s0" origId="18626508-1659" text="Taking advantage of this prostate cancer-specific property of PSMA (E/P), we successfully introduced bacterial UPRT into LNCaP cells where the tumoricidal effect of 5-fluorouracil (5-FU) was significantly increased when compared with the cells without the exogenous UPRT.">
            <entity id="DS.d525.s0.e0" origId="Q26998" charOffset="111-115" type="protein" text="UPRT"/>
            <entity id="DS.d525.s0.e1" origId="3385" charOffset="165-179" type="compound" text="5-fluorouracil"/>
            <entity id="DS.d525.s0.e2" origId="3385" charOffset="181-185" type="compound" text="5-FU"/>
            <entity id="DS.d525.s0.e3" origId="Q26998" charOffset="266-270" type="protein" text="UPRT"/>
            <pair e1="DS.d525.s0.e2" e2="DS.d525.s0.e0" id="DS.d525.s0.i0" interaction="True"/>
            <pair e1="DS.d525.s0.e1" e2="DS.d525.s0.e0" id="DS.d525.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d526" origId="18626658">
        <sentence id="DS.d526.s0" origId="18626658-281" text="UCP2 is expressed in pancreatic beta cells where its postulated uncoupling activity will modulate glucose-induced changes in ATP/ADP ratio and insulin secretion.">
            <entity id="DS.d526.s0.e0" origId="O97562,P55851,Q9N2J1,Q9W725" charOffset="0-4" type="protein" text="UCP2"/>
            <entity id="DS.d526.s0.e1" origId="206,5793,64689,79025" charOffset="98-105" type="compound" text="glucose"/>
            <entity id="DS.d526.s0.e2" origId="5957" charOffset="125-128" type="compound" text="ATP"/>
            <entity id="DS.d526.s0.e3" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="143-150" type="protein" text="insulin"/>
            <pair e1="DS.d526.s0.e1" e2="DS.d526.s0.e0" id="DS.d526.s0.i0" interaction="True"/>
            <pair e1="DS.d526.s0.e1" e2="DS.d526.s0.e3" id="DS.d526.s0.i1" interaction="True"/>
            <pair e1="DS.d526.s0.e2" e2="DS.d526.s0.e0" id="DS.d526.s0.i2" interaction="True"/>
            <pair e1="DS.d526.s0.e2" e2="DS.d526.s0.e3" id="DS.d526.s0.i3" interaction="False"/>
        </sentence>
        <sentence id="DS.d526.s2" origId="18626658-283" text="Neither UCP1 expression nor UCP2 overexpression modified basal or glucose-stimulated metabolic changes.">
            <entity id="DS.d526.s2.e0" origId="P04575,P10861,P14271,P25874,Q18P97,Q8K404,Q9ER18,Q9GMZ1" charOffset="8-12" type="protein" text="UCP1"/>
            <entity id="DS.d526.s2.e1" origId="O97562,P55851,Q9N2J1,Q9W725" charOffset="28-32" type="protein" text="UCP2"/>
            <entity id="DS.d526.s2.e2" origId="206,5793,64689,79025" charOffset="66-73" type="compound" text="glucose"/>
            <pair e1="DS.d526.s2.e2" e2="DS.d526.s2.e0" id="DS.d526.s2.i0" interaction="False"/>
            <pair e1="DS.d526.s2.e2" e2="DS.d526.s2.e1" id="DS.d526.s2.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d527" origId="18626709">
        <sentence id="DS.d527.s0" origId="18626709-112" text="The chitinase activity was increased by Mn(2+), Cu(2+), and Mg(2+), while strongly inhibited by Fe(2+) and Ba(2+).">
            <entity id="DS.d527.s0.e0" origId="P13656,P14529,P23472,P23473,P81241,P84754" charOffset="4-13" type="protein" text="chitinase"/>
            <entity id="DS.d527.s0.e1" origId="27854" charOffset="40-44" type="compound" text="Mn(2"/>
            <entity id="DS.d527.s0.e2" origId="27099" charOffset="48-52" type="compound" text="Cu(2"/>
            <entity id="DS.d527.s0.e3" origId="27284" charOffset="96-100" type="compound" text="Fe(2"/>
            <entity id="DS.d527.s0.e4" origId="104810" charOffset="107-111" type="compound" text="Ba(2"/>
            <pair e1="DS.d527.s0.e2" e2="DS.d527.s0.e0" id="DS.d527.s0.i0" interaction="True"/>
            <pair e1="DS.d527.s0.e1" e2="DS.d527.s0.e0" id="DS.d527.s0.i1" interaction="True"/>
            <pair e1="DS.d527.s0.e4" e2="DS.d527.s0.e0" id="DS.d527.s0.i2" interaction="True"/>
            <pair e1="DS.d527.s0.e3" e2="DS.d527.s0.e0" id="DS.d527.s0.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d527.s1" origId="18626709-113" text="Meanwhile, SDS, ethyleneglycoltetraacetic acid, urea, and ethylenediaminetetraacetic acid were found to have significantly inhibitory effect on chitinase activity.">
            <entity id="DS.d527.s1.e0" origId="1176,265993" charOffset="48-52" type="compound" text="urea"/>
            <entity id="DS.d527.s1.e1" origId="6049" charOffset="58-89" type="compound" text="ethylenediaminetetraacetic acid"/>
            <entity id="DS.d527.s1.e2" origId="P13656,P14529,P23472,P23473,P81241,P84754" charOffset="144-153" type="protein" text="chitinase"/>
            <pair e1="DS.d527.s1.e1" e2="DS.d527.s1.e2" id="DS.d527.s1.i0" interaction="True"/>
            <pair e1="DS.d527.s1.e0" e2="DS.d527.s1.e2" id="DS.d527.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d528" origId="18626726">
        <sentence id="DS.d528.s0" origId="18626726-122" text="In the present study, we screened the inhibitory effect of the extract from 50 Thai medicinal plants on an inducible-nitric oxide synthase (iNOS) expression induced by lipopolysaccharide (LPS) in mouse macrophages RAW 264.7.">
            <entity id="DS.d528.s0.e0" origId="O61309,O61608,Q27571,Q9I9M2" charOffset="117-138" type="protein" text="nitric oxide synthase"/>
            <entity id="DS.d528.s0.e1" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="140-144" type="protein" text="iNOS"/>
            <entity id="DS.d528.s0.e2" origId="11970143" charOffset="168-186" type="compound" text="lipopolysaccharide"/>
            <pair e1="DS.d528.s0.e2" e2="DS.d528.s0.e1" id="DS.d528.s0.i0" interaction="True"/>
            <pair e1="DS.d528.s0.e2" e2="DS.d528.s0.e0" id="DS.d528.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d529" origId="18626791">
        <sentence id="DS.d529.s0" origId="18626791-1140" text="Following thermal denaturation, rabbit reticulocyte lysate and ATP were added and luciferase activity measured.">
            <entity id="DS.d529.s0.e0" origId="5957" charOffset="63-66" type="compound" text="ATP"/>
            <entity id="DS.d529.s0.e1" origId="P08659,P13129,Q01158,Q26304,Q27757" charOffset="82-92" type="protein" text="luciferase"/>
            <pair e1="DS.d529.s0.e0" e2="DS.d529.s0.e1" id="DS.d529.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d530" origId="18626794">
        <sentence id="DS.d530.s0" origId="18626794-227" text="These results are in contrast to postmortem findings in schizophrenia and suggest that reduced synaptophysin protein levels in schizophrenia patients' postmortem brain do not result from perinatal oxygen deprivation.">
            <entity id="DS.d530.s0.e0" origId="P07825,P08247,P20488,Q5YJC1,Q62277" charOffset="95-108" type="protein" text="synaptophysin"/>
            <entity id="DS.d530.s0.e1" origId="977" charOffset="197-203" type="compound" text="oxygen"/>
            <pair e1="DS.d530.s0.e1" e2="DS.d530.s0.e0" id="DS.d530.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d531" origId="18627006">
        <sentence id="DS.d531.s0" origId="18627006-344" text="We found that the acetylated histone H3 at lysine 9 and lysine 14 (H3K9/K14ac) is reduced in both the myelin basic protein (MBP) and proteolipid protein (PLP) genes of maturing oligodendroglial OL-1 cells, and furthermore, this temporally correlates with increases in MBP, PLP, and histone deacetylase (HDAC) 11 expression.">
            <entity id="DS.d531.s0.e0" origId="P02299,P07041,P08437,P08898,P22843,P23753,P40285,P50564,P61830,P61831,P61832,P61833,P61834,P61835,P61836,P80553,P83864,P84235,P84236,P84237,P84238,P84239,P90543,Q06196,Q2UCQ0,Q5DWI3,Q757N1,Q7XYZ0,Q98RY4,Q9HDN1,Q9P427,Q9U7D1" charOffset="29-39" type="protein" text="histone H3"/>
            <entity id="DS.d531.s0.e1" origId="866,5962" charOffset="43-49" type="compound" text="lysine"/>
            <entity id="DS.d531.s0.e2" origId="866,5962" charOffset="56-62" type="compound" text="lysine"/>
            <entity id="DS.d531.s0.e3" origId="P02686,P02687,P04370,P06906,P15720,P20939,P25188,P25274,P81558,P83487,P87346,P98190,Q91325,Q91439" charOffset="102-122" type="protein" text="myelin basic protein"/>
            <entity id="DS.d531.s0.e4" origId="P02686,P02687,P04370,P06906,P13727,P15720,P20939,P25188,P25274,P25336,P81558,P83487,P87346,P98190,Q61878,Q63189,Q91325,Q91439,Q9SAV1" charOffset="124-127" type="protein" text="MBP"/>
            <entity id="DS.d531.s0.e5" origId="P04116,P13085,P22858,P23289,P23294,P30044,P47789,P47790,P60201,P60202,P60203,P79826,P80145,P99029,Q8HXW7,Q96GD0,Q9R063" charOffset="154-157" type="protein" text="PLP"/>
            <entity id="DS.d531.s0.e6" origId="P02686,P02687,P04370,P06906,P13727,P15720,P20939,P25188,P25274,P25336,P81558,P83487,P87346,P98190,Q61878,Q63189,Q91325,Q91439,Q9SAV1" charOffset="268-271" type="protein" text="MBP"/>
            <entity id="DS.d531.s0.e7" origId="P04116,P13085,P22858,P23289,P23294,P30044,P47789,P47790,P60201,P60202,P60203,P79826,P80145,P99029,Q8HXW7,Q96GD0,Q9R063" charOffset="273-276" type="protein" text="PLP"/>
            <entity id="DS.d531.s0.e8" origId="O22446" charOffset="282-301" type="protein" text="histone deacetylase"/>
            <pair e1="DS.d531.s0.e1" e2="DS.d531.s0.e0" id="DS.d531.s0.i0" interaction="True"/>
            <pair e1="DS.d531.s0.e1" e2="DS.d531.s0.e4" id="DS.d531.s0.i1" interaction="True"/>
            <pair e1="DS.d531.s0.e1" e2="DS.d531.s0.e8" id="DS.d531.s0.i2" interaction="False"/>
            <pair e1="DS.d531.s0.e1" e2="DS.d531.s0.e3" id="DS.d531.s0.i3" interaction="True"/>
            <pair e1="DS.d531.s0.e1" e2="DS.d531.s0.e5" id="DS.d531.s0.i4" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d532" origId="18627414">
        <sentence id="DS.d532.s0" origId="18627414-696" text="Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, HLA-B *1502, are at a higher risk for Stevens-Johnson syndrome when using carbamazepine, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy.">
            <entity id="DS.d532.s0.e0" origId="P01889,P03989,P10319,P18463,P18464,P18465,P30460,P30461,P30462,P30464,P30466,P30475,P30479,P30480,P30481,P30483,P30484,P30485,P30486,P30487,P30488,P30490,P30491,P30492,P30493,P30495,P30498,P30685,Q04826,Q29718,Q29836,Q29940,Q31610,Q31612,Q95365" charOffset="264-269" type="protein" text="HLA-B"/>
            <entity id="DS.d532.s0.e1" origId="2554" charOffset="338-351" type="compound" text="carbamazepine"/>
            <pair e1="DS.d532.s0.e1" e2="DS.d532.s0.e0" id="DS.d532.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d533" origId="18627421">
        <sentence id="DS.d533.s0" origId="18627421-707" text="However, OPN-(/-) mice showed increased serum levels of tumour necrosis factor (TNF)-alpha, which could be due to systemically present lipopolysaccharide translocated to the gut.">
            <entity id="DS.d533.s0.e0" origId="P10451,P14287,P31096,Q9XSY9" charOffset="9-12" type="protein" text="OPN"/>
            <entity id="DS.d533.s0.e1" origId="O35734,O77510,O77764,P01375,P04924,P13296,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="80-83" type="protein" text="TNF"/>
            <entity id="DS.d533.s0.e2" origId="11970143" charOffset="135-153" type="compound" text="lipopolysaccharide"/>
            <pair e1="DS.d533.s0.e2" e2="DS.d533.s0.e1" id="DS.d533.s0.i0" interaction="True"/>
            <pair e1="DS.d533.s0.e2" e2="DS.d533.s0.e0" id="DS.d533.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d534" origId="18627475">
        <sentence id="DS.d534.s0" origId="18627475-762" text="The expression of the ERG1, ERG3, ERG7, ERG9, ERG11 and ERG25 genes in response to incubation with fluconazole and biofilm formation was investigated using reverse-transcription PCR and real-time PCR in Candida albicans and Candida dubliniensis clinical isolates.">
            <entity id="DS.d534.s0.e0" origId="O08703,O08962,O13306,O35219,P32476,Q12809,Q14534,Q75F69,Q7GC09,Q86QT3,Q86QU1,Q86QU6,Q86QV0,Q86QV3,Q86QV6,Q8WNY2,Q92206,Q9PT84,Q9TSZ3,Q9TUI4" charOffset="22-26" type="protein" text="ERG1"/>
            <entity id="DS.d534.s0.e1" origId="O13597,O93875,P32353,P50860,P78575,Q754B9,Q7F9X0,Q86QT9,Q86QU4,Q86QU8,Q86QV1,Q86QV4,Q86QV9,Q8J207,Q8NJ57,Q9NS40" charOffset="28-32" type="protein" text="ERG3"/>
            <entity id="DS.d534.s0.e2" origId="P38604,Q04782,Q96WJ0" charOffset="34-38" type="protein" text="ERG7"/>
            <entity id="DS.d534.s0.e3" origId="O74165,P29704,P78589,Q752X9,Q92459,Q9HGZ6" charOffset="40-44" type="protein" text="ERG9"/>
            <entity id="DS.d534.s0.e4" origId="P10613,P10614,P14263,P49602,P50859,Q759W0" charOffset="46-51" type="protein" text="ERG11"/>
            <entity id="DS.d534.s0.e5" origId="O59933,P53045,Q15800" charOffset="56-61" type="protein" text="ERG25"/>
            <entity id="DS.d534.s0.e6" origId="3365" charOffset="99-110" type="compound" text="fluconazole"/>
            <pair e1="DS.d534.s0.e6" e2="DS.d534.s0.e3" id="DS.d534.s0.i0" interaction="True"/>
            <pair e1="DS.d534.s0.e6" e2="DS.d534.s0.e4" id="DS.d534.s0.i1" interaction="True"/>
            <pair e1="DS.d534.s0.e6" e2="DS.d534.s0.e5" id="DS.d534.s0.i2" interaction="True"/>
            <pair e1="DS.d534.s0.e6" e2="DS.d534.s0.e1" id="DS.d534.s0.i3" interaction="True"/>
            <pair e1="DS.d534.s0.e6" e2="DS.d534.s0.e0" id="DS.d534.s0.i4" interaction="True"/>
            <pair e1="DS.d534.s0.e6" e2="DS.d534.s0.e2" id="DS.d534.s0.i5" interaction="True"/>
        </sentence>
        <sentence id="DS.d534.s1" origId="18627475-763" text="Expression of the ERG11 gene was found to be low or moderate and it was regulated by fluconazole addition more so than by biofilm formation.">
            <entity id="DS.d534.s1.e0" origId="P10613,P10614,P14263,P49602,P50859,Q759W0" charOffset="18-23" type="protein" text="ERG11"/>
            <entity id="DS.d534.s1.e1" origId="3365" charOffset="85-96" type="compound" text="fluconazole"/>
            <pair e1="DS.d534.s1.e1" e2="DS.d534.s1.e0" id="DS.d534.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d534.s2" origId="18627475-764" text="The expression of the ERG9 increased in the presence of fluconazole in some isolates.">
            <entity id="DS.d534.s2.e0" origId="O74165,P29704,P78589,Q752X9,Q92459,Q9HGZ6" charOffset="22-26" type="protein" text="ERG9"/>
            <entity id="DS.d534.s2.e1" origId="3365" charOffset="56-67" type="compound" text="fluconazole"/>
            <pair e1="DS.d534.s2.e1" e2="DS.d534.s2.e0" id="DS.d534.s2.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d535" origId="18629545">
        <sentence id="DS.d535.s0" origId="18629545-780" text="Concentrations of polyethylene glycol 1000 and Na2SO4 were selected as independent variables to evaluate their impact on parameters of partitioning in aqueous two-phase system--the partition coefficient of pectinase, purification factor and pectinase yield.">
            <entity id="DS.d535.s0.e0" origId="174" charOffset="18-37" type="compound" text="polyethylene glycol"/>
            <entity id="DS.d535.s0.e1" origId="24436" charOffset="47-53" type="compound" text="Na2SO4"/>
            <entity id="DS.d535.s0.e2" origId="O42824,O59925,O93883,P05117,P20041,P24548,P26215,P26216,P27644,P35335,P35336,P35337,P35338,P35339,P41749,P41750,P43212,P47180,P48978,P48979,P49062,P49063,P49575,P58598,Q00446,Q02096,Q05967,Q07181,Q12708,Q39766,Q39786,Q40312,Q7M1E7,Q9FY19,Q9LW07,Q9Y718" charOffset="206-215" type="protein" text="pectinase"/>
            <entity id="DS.d535.s0.e3" origId="O42824,O59925,O93883,P05117,P20041,P24548,P26215,P26216,P27644,P35335,P35336,P35337,P35338,P35339,P41749,P41750,P43212,P47180,P48978,P48979,P49062,P49063,P49575,P58598,Q00446,Q02096,Q05967,Q07181,Q12708,Q39766,Q39786,Q40312,Q7M1E7,Q9FY19,Q9LW07,Q9Y718" charOffset="241-250" type="protein" text="pectinase"/>
            <pair e1="DS.d535.s0.e0" e2="DS.d535.s0.e2" id="DS.d535.s0.i0" interaction="False"/>
            <pair e1="DS.d535.s0.e1" e2="DS.d535.s0.e2" id="DS.d535.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d536" origId="18629605">
        <sentence id="DS.d536.s0" origId="18629605-1551" text="In aged animals, administration of L-carnitine for 21 days significantly decreased the levels of lipid peroxides and improved the activities of antioxidant enzymes like superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase.">
            <entity id="DS.d536.s0.e0" origId="10918" charOffset="35-46" type="compound" text="L-carnitine"/>
            <entity id="DS.d536.s0.e1" origId="O50258" charOffset="169-189" type="protein" text="superoxide dismutase"/>
            <entity id="DS.d536.s0.e2" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="191-199" type="protein" text="catalase"/>
            <entity id="DS.d536.s0.e3" origId="O32770,O59858,Q00277,Q9CFV1" charOffset="201-223" type="protein" text="glutathione peroxidase"/>
            <entity id="DS.d536.s0.e4" origId="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655" charOffset="228-249" type="protein" text="glutathione reductase"/>
            <pair e1="DS.d536.s0.e0" e2="DS.d536.s0.e2" id="DS.d536.s0.i0" interaction="True"/>
            <pair e1="DS.d536.s0.e0" e2="DS.d536.s0.e4" id="DS.d536.s0.i1" interaction="True"/>
            <pair e1="DS.d536.s0.e0" e2="DS.d536.s0.e3" id="DS.d536.s0.i2" interaction="True"/>
            <pair e1="DS.d536.s0.e0" e2="DS.d536.s0.e1" id="DS.d536.s0.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d536.s1" origId="18629605-1552" text="L-Carnitine enhanced T-cell proliferative responses as evaluated by T-cell proliferation assay using (3H) thymidine incorporation and also significantly reduced DNA damage, apoptosis and TNF-alpha level in lymphocytes of aged animals.">
            <entity id="DS.d536.s1.e0" origId="10918" charOffset="0-11" type="compound" text="L-Carnitine"/>
            <entity id="DS.d536.s1.e1" origId="5789" charOffset="106-115" type="compound" text="thymidine"/>
            <entity id="DS.d536.s1.e2" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="187-196" type="protein" text="TNF-alpha"/>
            <pair e1="DS.d536.s1.e1" e2="DS.d536.s1.e2" id="DS.d536.s1.i0" interaction="False"/>
            <pair e1="DS.d536.s1.e0" e2="DS.d536.s1.e2" id="DS.d536.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d537" origId="18629630">
        <sentence id="DS.d537.s0" origId="18629630-845" text="In our microarray analysis we observed that Seven-in-Absentia Homolog 2 (SIAH2) levels were low in estrogen receptor (ER) positive breast tumors of patients resistant to first-line tamoxifen therapy.">
            <entity id="DS.d537.s0.e0" origId="O43255,Q06986,Q8R4T2,Q9I8X5,Q9M2P4" charOffset="44-71" type="protein" text="Seven-in-Absentia Homolog 2"/>
            <entity id="DS.d537.s0.e1" origId="O43255" charOffset="73-78" type="protein" text="SIAH2"/>
            <entity id="DS.d537.s0.e2" origId="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7" charOffset="99-116" type="protein" text="estrogen receptor"/>
            <entity id="DS.d537.s0.e3" origId="2733526" charOffset="181-190" type="compound" text="tamoxifen"/>
            <pair e1="DS.d537.s0.e3" e2="DS.d537.s0.e2" id="DS.d537.s0.i0" interaction="True"/>
            <pair e1="DS.d537.s0.e3" e2="DS.d537.s0.e0" id="DS.d537.s0.i1" interaction="True"/>
            <pair e1="DS.d537.s0.e3" e2="DS.d537.s0.e1" id="DS.d537.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d538" origId="18629637">
        <sentence id="DS.d538.s0" origId="18629637-851" text="Fluorocitrate, an inhibitor of glial metabolism, inhibits the up-regulation of NOS expression, activity and NO production in the spinal cord induced by formalin test in rats.">
            <entity id="DS.d538.s0.e0" origId="107647" charOffset="0-13" type="compound" text="Fluorocitrate"/>
            <entity id="DS.d538.s0.e1" origId="O54705,O61309,O61608,Q26240,Q28969,Q9I9M2" charOffset="79-82" type="protein" text="NOS"/>
            <pair e1="DS.d538.s0.e0" e2="DS.d538.s0.e1" id="DS.d538.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d538.s1" origId="18629637-852" text="In order to explore the involvement of glia in the NO-mediated nociceptive transmission, the present study was undertaken to investigate the effect of fluorocitrate (FC), an inhibitor of glial metabolism, on NOS expression and activity and NO production in the spinal cord during the process of peripheral inflammatory pain and hyperalgesia induced by formalin test in rats.">
            <entity id="DS.d538.s1.e0" origId="107647" charOffset="151-164" type="compound" text="fluorocitrate"/>
            <entity id="DS.d538.s1.e1" origId="O54705,O61309,O61608,Q26240,Q28969,Q9I9M2" charOffset="208-211" type="protein" text="NOS"/>
            <pair e1="DS.d538.s1.e0" e2="DS.d538.s1.e1" id="DS.d538.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d539" origId="18629640">
        <sentence id="DS.d539.s0" origId="18629640-41" text="Oral administration of morin remarkably prevented weight loss in the body and liver from DMN and inhibited the elevation of serum alanine transaminase (ALT), aspartate transaminase (AST), and total bilirubin levels.">
            <entity id="DS.d539.s0.e0" origId="5281670" charOffset="23-28" type="compound" text="morin"/>
            <entity id="DS.d539.s0.e1" origId="P0AE37,P0AE38,P80357,P80358,Q0TH83,Q1C8B0,Q1RB46,Q321N9,Q32G89,Q3Z294,Q5PHB9,Q66B20,Q7N2G8,Q83L52,Q8FH00,Q8Z6G0,Q8ZPV1,Q9NRA2,Q9ZC67" charOffset="182-185" type="protein" text="AST"/>
            <entity id="DS.d539.s0.e2" origId="5280352" charOffset="198-207" type="compound" text="bilirubin"/>
            <pair e1="DS.d539.s0.e0" e2="DS.d539.s0.e1" id="DS.d539.s0.i0" interaction="True"/>
            <pair e1="DS.d539.s0.e2" e2="DS.d539.s0.e1" id="DS.d539.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d540" origId="18631247">
        <sentence id="DS.d540.s0" origId="18631247-468" text="Green tea extract reduces induction of p53 and apoptosis in UVB-irradiated human skin independent of transcriptional controls.">
            <entity id="DS.d540.s0.e0" origId="65064" charOffset="0-17" type="compound" text="Green tea extract"/>
            <entity id="DS.d540.s0.e1" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="39-42" type="protein" text="p53"/>
            <pair e1="DS.d540.s0.e0" e2="DS.d540.s0.e1" id="DS.d540.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d540.s1" origId="18631247-469" text="We found that while OM24 treatment did not significantly affect UV-induced erythema and thymidine dimer formation, OM24 treatment significantly reduced UV-induced p53 expression in keratinocytes.">
            <entity id="DS.d540.s1.e0" origId="5789" charOffset="88-97" type="compound" text="thymidine"/>
            <entity id="DS.d540.s1.e1" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="163-166" type="protein" text="p53"/>
            <pair e1="DS.d540.s1.e0" e2="DS.d540.s1.e1" id="DS.d540.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d542" origId="18632742">
        <sentence id="DS.d542.s0" origId="18632742-27" text="Here we show that NRG-1 selectively increases the power of kainate-induced, but not carbachol-induced, gamma oscillations in acute hippocampal slices.">
            <entity id="DS.d542.s0.e0" origId="Q99988,Q9JKM5" charOffset="18-23" type="protein" text="NRG-1"/>
            <entity id="DS.d542.s0.e1" origId="10255" charOffset="59-66" type="compound" text="kainate"/>
            <entity id="DS.d542.s0.e2" origId="2551" charOffset="84-93" type="compound" text="carbachol"/>
            <pair e1="DS.d542.s0.e1" e2="DS.d542.s0.e0" id="DS.d542.s0.i0" interaction="True"/>
            <pair e1="DS.d542.s0.e2" e2="DS.d542.s0.e0" id="DS.d542.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d542.s1" origId="18632742-28" text="These effects of NRG-1beta are blocked by PD158780, a pan-specific antagonist of ErbB receptors, and are mediated specifically via ErbB4 receptors, because mice harboring a targeted mutation of ErbB4 do not respond to NRG-1.">
            <entity id="DS.d542.s1.e0" origId="4707" charOffset="42-50" type="compound" text="PD158780"/>
            <entity id="DS.d542.s1.e1" origId="Q99988,Q9JKM5" charOffset="17-22" type="protein" text="NRG-1"/>
            <pair e1="DS.d542.s1.e0" e2="DS.d542.s1.e1" id="DS.d542.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d543" origId="18633436">
        <sentence id="DS.d543.s0" origId="18633436-86" text="Of various agents tested in HaCaT cell cultures, only retinoic acid (10(-6) M) and staurosporine (2.5 x 10(-8) M) upregulated MMP-21 mRNA and protein expression, whereas tumor promoters, hormones, or dexamethasone were without effect.">
            <entity id="DS.d543.s0.e0" origId="444795" charOffset="54-67" type="compound" text="retinoic acid"/>
            <entity id="DS.d543.s0.e1" origId="5279,44259,451705,5311103,5459111,6419748,6711321,9956178,44299148" charOffset="83-96" type="compound" text="staurosporine"/>
            <entity id="DS.d543.s0.e2" origId="O75900,O93470,Q8K3F2,Q8N119,Q90YC2,Q9R0S2" charOffset="126-132" type="protein" text="MMP-21"/>
            <entity id="DS.d543.s0.e3" origId="5743" charOffset="200-213" type="compound" text="dexamethasone"/>
            <pair e1="DS.d543.s0.e0" e2="DS.d543.s0.e2" id="DS.d543.s0.i0" interaction="True"/>
            <pair e1="DS.d543.s0.e1" e2="DS.d543.s0.e2" id="DS.d543.s0.i1" interaction="True"/>
            <pair e1="DS.d543.s0.e3" e2="DS.d543.s0.e2" id="DS.d543.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d544" origId="18633446">
        <sentence id="DS.d544.s0" origId="18633446-279" text="We have generated two novel chimeric VEGF-binding molecules, sFLT01 and sFLT02, which consist of the second immunoglobulin (IgG)-like domain of Flt-1 fused either to a human IgG1 Fc or solely to the CH3 domain of IgG1 Fc through a polyglycine linker 9Gly.">
            <entity id="DS.d544.s0.e0" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="37-41" type="protein" text="VEGF"/>
            <entity id="DS.d544.s0.e1" origId="P17948,P53767" charOffset="144-149" type="protein" text="Flt-1"/>
            <entity id="DS.d544.s0.e3" origId="750" charOffset="231-242" type="compound" text="polyglycine"/>
            <pair e1="DS.d544.s0.e3" e2="DS.d544.s0.e0" id="DS.d544.s0.i1" interaction="False"/>
            <pair e1="DS.d544.s0.e3" e2="DS.d544.s0.e1" id="DS.d544.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d545" origId="18633600">
        <sentence id="DS.d545.s0" origId="18633600-1063" text="By contrast, treatment of N2a cells with 1-10 microM DZO resulted in marked reductions in the expression of the axon growth-associated protein GAP-43.">
            <entity id="DS.d545.s0.e0" origId="6419789" charOffset="53-56" type="compound" text="DZO"/>
            <entity id="DS.d545.s0.e1" origId="P09851,P20936,P50904,P74851,P74873,Q5PEA9,Q92211,Q92263" charOffset="143-146" type="protein" text="GAP"/>
            <pair e1="DS.d545.s0.e0" e2="DS.d545.s0.e1" id="DS.d545.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d545.s1" origId="18633600-1064" text="DZO-treated cells also showed an increased expression of the heat shock protein HSP-70 compared to controls.">
            <entity id="DS.d545.s1.e0" origId="6419789" charOffset="0-3" type="compound" text="DZO"/>
            <entity id="DS.d545.s1.e1" origId="P27894" charOffset="80-86" type="protein" text="HSP-70"/>
            <pair e1="DS.d545.s1.e0" e2="DS.d545.s1.e1" id="DS.d545.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d547" origId="18633701">
        <sentence id="DS.d547.s0" origId="18633701-1577" text="We showed that in comparison to stage VI, stages I-V oocytes expressed higher levels of O-GlcNAc correlating changes in OGT expression, but not in UDP-GlcNAc pools.">
            <entity id="DS.d547.s0.e0" origId="O18158" charOffset="88-96" type="protein" text="O-GlcNAc"/>
            <entity id="DS.d547.s0.e1" origId="O15294,O18158,P81436" charOffset="120-123" type="protein" text="OGT"/>
            <entity id="DS.d547.s0.e2" origId="445675,643981,9547196" charOffset="147-157" type="compound" text="UDP-GlcNAc"/>
            <pair e1="DS.d547.s0.e2" e2="DS.d547.s0.e1" id="DS.d547.s0.i0" interaction="False"/>
            <pair e1="DS.d547.s0.e2" e2="DS.d547.s0.e0" id="DS.d547.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d547.s1" origId="18633701-1578" text="Upon progesterone stimulation, an O-GlcNAc level burst occurred during meiotic resumption long before MPF and Mos-Erk2 pathways activations.">
            <entity id="DS.d547.s1.e0" origId="5994" charOffset="5-17" type="compound" text="progesterone"/>
            <entity id="DS.d547.s1.e1" origId="O18158" charOffset="34-42" type="protein" text="O-GlcNAc"/>
            <entity id="DS.d547.s1.e2" origId="Q13421,Q61468,Q9ERA7" charOffset="102-105" type="protein" text="MPF"/>
            <entity id="DS.d547.s1.e3" origId="P00536,P00539,P12965" charOffset="110-113" type="protein" text="Mos"/>
            <entity id="DS.d547.s1.e4" origId="P63085,P63086" charOffset="114-118" type="protein" text="Erk2"/>
            <pair e1="DS.d547.s1.e0" e2="DS.d547.s1.e2" id="DS.d547.s1.i0" interaction="True"/>
            <pair e1="DS.d547.s1.e0" e2="DS.d547.s1.e3" id="DS.d547.s1.i1" interaction="True"/>
            <pair e1="DS.d547.s1.e0" e2="DS.d547.s1.e4" id="DS.d547.s1.i2" interaction="True"/>
            <pair e1="DS.d547.s1.e0" e2="DS.d547.s1.e1" id="DS.d547.s1.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d548" origId="18633707">
        <sentence id="DS.d548.s0" origId="18633707-828" text="Mean plasma levels of folic acid, homocysteine, and vitamin B12 did not change, but there was a significant decrease of CRP at T1, 0.36 mg dl(-1) on average (P = 0.01), which was maintained at T2.">
            <entity id="DS.d548.s0.e0" origId="6037" charOffset="22-32" type="compound" text="folic acid"/>
            <entity id="DS.d548.s0.e1" origId="778" charOffset="34-46" type="compound" text="homocysteine"/>
            <entity id="DS.d548.s0.e2" origId="O19062,P02741,P02742,P08462,P18151,P21291,P41964,P47875,P49254,P49262,P52753,P67966,P67967,P97315,Q07203" charOffset="120-123" type="protein" text="CRP"/>
            <pair e1="DS.d548.s0.e1" e2="DS.d548.s0.e2" id="DS.d548.s0.i0" interaction="False"/>
            <pair e1="DS.d548.s0.e0" e2="DS.d548.s0.e2" id="DS.d548.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d549" origId="18634065">
        <sentence id="DS.d549.s0" origId="18634065-1113" text="Chondrocytes grown in monolayer were treated with interleukin-1alpha (IL-1alpha), insulin-like growth factor-I (IGF-I), C3 Transferase, Y27632, or transfected with Rho wild type or two constitutively active mutants of Rho (Q63L and G14V).">
            <entity id="DS.d549.s0.e0" origId="O46612,O46613,P01582,P01583,P04822,P08831,P16598,P18430,P46647,P48089,P79161,P79340,Q28385,Q28579,Q3HWU1,Q60480,Q865X7" charOffset="70-79" type="protein" text="IL-1alpha"/>
            <entity id="DS.d549.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="82-89" type="protein" text="insulin"/>
            <entity id="DS.d549.s0.e2" origId="P05017,P07455,P08025,P10763,P16545,P17085,P17647,P18254,P33712,P51457,P51458,P51462,Q02815,Q28933,Q68LC0,Q6GUL6,Q6IVA5,Q6JLX1,Q95222" charOffset="112-117" type="protein" text="IGF-I"/>
            <entity id="DS.d549.s0.e3" origId="448042" charOffset="136-142" type="compound" text="Y27632"/>
            <pair e1="DS.d549.s0.e3" e2="DS.d549.s0.e0" id="DS.d549.s0.i0" interaction="False"/>
            <pair e1="DS.d549.s0.e3" e2="DS.d549.s0.e1" id="DS.d549.s0.i1" interaction="False"/>
            <pair e1="DS.d549.s0.e3" e2="DS.d549.s0.e2" id="DS.d549.s0.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d549.s1" origId="18634065-1115" text="Affinity assays were performed to measure endogenous GTP-bound Rho, and confocal microscopy was used to assess changes in organization of the actin cytoskeleton.">
            <entity id="DS.d549.s1.e0" origId="6830" charOffset="53-56" type="compound" text="GTP"/>
            <entity id="DS.d549.s1.e1" origId="O51891,O67031,O83281,P03304,P0A295,P0A296,P0AG30,P0AG31,P0AG32,P0AG33,P15409,P17593,P17594,P20350,P29403,P33561,P35359,P38527,P44619,P45835,P51489,P52152,P52153,P52154,P52155,P52156,P52157,P52158,P56466,P57652,P66028,P66029,Q03222,Q06447,Q89A22,Q9ZD24,Q9ZLS9" charOffset="63-66" type="protein" text="Rho"/>
            <entity id="DS.d549.s1.e2" origId="O00937,O13419,O16808,O17320,O65314,O65315,O65316,O74258,O81221,P02577,P10365,P10989,P11426,P13363,P14235,P17128,P20904,P24902,P26182,P26183,P30161,P45520,P45521,P48465,P50138,P51775,P53455,P53476,P53477,P53491,P53498,P53499,P53500,P53502,P53689,P60009,P60010,P60011,P68555,P78711,P80709,P81085,P90689,P91754,Q05214,Q11212,Q24733,Q2U7A3,Q39596,Q39758,Q6TCF2,Q75D00,Q8SWN8,Q8X119,Q92192,Q92193,Q99023,Q9P4D1,Q9UVF3,Q9UVX4,Q9UVZ8" charOffset="142-147" type="protein" text="actin"/>
            <pair e1="DS.d549.s1.e0" e2="DS.d549.s1.e1" id="DS.d549.s1.i0" interaction="True"/>
            <pair e1="DS.d549.s1.e0" e2="DS.d549.s1.e2" id="DS.d549.s1.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d549.s2" origId="18634065-1116" text="IL-1alpha and RhoG14V increased cytoplasmic actin stress fiber formation, which was blocked by C3 Transferase, and Y27632.">
            <entity id="DS.d549.s2.e0" origId="O46612,O46613,P01582,P01583,P04822,P08831,P16598,P18430,P46647,P48089,P79161,P79340,Q28385,Q28579,Q3HWU1,Q60480,Q865X7" charOffset="0-9" type="protein" text="IL-1alpha"/>
            <entity id="DS.d549.s2.e1" origId="O00937,O13419,O16808,O17320,O65314,O65315,O65316,O74258,O81221,P02577,P10365,P10989,P11426,P13363,P14235,P17128,P20904,P24902,P26182,P26183,P30161,P45520,P45521,P48465,P50138,P51775,P53455,P53476,P53477,P53491,P53498,P53499,P53500,P53502,P53689,P60009,P60010,P60011,P68555,P78711,P80709,P81085,P90689,P91754,Q05214,Q11212,Q24733,Q2U7A3,Q39596,Q39758,Q6TCF2,Q75D00,Q8SWN8,Q8X119,Q92192,Q92193,Q99023,Q9P4D1,Q9UVF3,Q9UVX4,Q9UVZ8" charOffset="44-49" type="protein" text="actin"/>
            <entity id="DS.d549.s2.e2" origId="448042" charOffset="115-121" type="compound" text="Y27632"/>
            <pair e1="DS.d549.s2.e2" e2="DS.d549.s2.e1" id="DS.d549.s2.i0" interaction="True"/>
            <pair e1="DS.d549.s2.e2" e2="DS.d549.s2.e0" id="DS.d549.s2.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d549.s3" origId="18634065-1118" text="Expression of RhoQ63L or RhoG14V resulted in increased MMP-13 expression; however, inhibition of Rho with Y27632 was unable to inhibit IL-1alpha-induced MMP-13 expression.">
            <entity id="DS.d549.s3.e0" origId="O18927,O62806,O77656,P23097,P33435,P45452,Q10835" charOffset="55-61" type="protein" text="MMP-13"/>
            <entity id="DS.d549.s3.e1" origId="O51891,O67031,O83281,P03304,P0A295,P0A296,P0AG30,P0AG31,P0AG32,P0AG33,P15409,P17593,P17594,P20350,P29403,P33561,P35359,P38527,P44619,P45835,P51489,P52152,P52153,P52154,P52155,P52156,P52157,P52158,P56466,P57652,P66028,P66029,Q03222,Q06447,Q89A22,Q9ZD24,Q9ZLS9" charOffset="14-17" type="protein" text="Rho"/>
            <entity id="DS.d549.s3.e2" origId="448042" charOffset="106-112" type="compound" text="Y27632"/>
            <entity id="DS.d549.s3.e3" origId="O46612,O46613,P01582,P01583,P04822,P08831,P16598,P18430,P46647,P48089,P79161,P79340,Q28385,Q28579,Q3HWU1,Q60480,Q865X7" charOffset="135-144" type="protein" text="IL-1alpha"/>
            <entity id="DS.d549.s3.e4" origId="O18927,O62806,O77656,P23097,P33435,P45452,Q10835" charOffset="153-159" type="protein" text="MMP-13"/>
            <pair e1="DS.d549.s3.e2" e2="DS.d549.s3.e3" id="DS.d549.s3.i0" interaction="False"/>
            <pair e1="DS.d549.s3.e2" e2="DS.d549.s3.e1" id="DS.d549.s3.i1" interaction="True"/>
            <pair e1="DS.d549.s3.e2" e2="DS.d549.s3.e0" id="DS.d549.s3.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d550" origId="18634706">
        <sentence id="DS.d550.s0" origId="18634706-392" text="Plasma total cholesterol, TAG, HDL, HDL2, HDL3, LDL, C-reactive protein, IL-6, IL-18, intercellular adhesion molecule-1, oxidised LDL, oxygen radical absorbance capacity using perchloric acid (ORACPCA), whole-blood fatty acids, bleeding time and blood pressure were measured at the beginning and end of each dietary period.">
            <entity id="DS.d550.s0.e0" origId="304,5997,6432564,11025495" charOffset="13-24" type="compound" text="cholesterol"/>
            <entity id="DS.d550.s0.e1" origId="P44321" charOffset="26-29" type="protein" text="TAG"/>
            <entity id="DS.d550.s0.e2" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="73-77" type="protein" text="IL-6"/>
            <entity id="DS.d550.s0.e3" origId="O19073,P70380,P97636,Q14116,Q3ZT29,Q5I931,Q8QFQ8,Q95M33,Q9TU73,Q9XSQ7,Q9XSR0" charOffset="79-84" type="protein" text="IL-18"/>
            <entity id="DS.d550.s0.e4" origId="977" charOffset="135-141" type="compound" text="oxygen"/>
            <entity id="DS.d550.s0.e5" origId="24247" charOffset="176-191" type="compound" text="perchloric acid"/>
            <pair e1="DS.d550.s0.e0" e2="DS.d550.s0.e2" id="DS.d550.s0.i0" interaction="False"/>
            <pair e1="DS.d550.s0.e0" e2="DS.d550.s0.e3" id="DS.d550.s0.i1" interaction="False"/>
            <pair e1="DS.d550.s0.e5" e2="DS.d550.s0.e1" id="DS.d550.s0.i2" interaction="False"/>
            <pair e1="DS.d550.s0.e4" e2="DS.d550.s0.e3" id="DS.d550.s0.i3" interaction="False"/>
            <pair e1="DS.d550.s0.e5" e2="DS.d550.s0.e3" id="DS.d550.s0.i4" interaction="False"/>
            <pair e1="DS.d550.s0.e0" e2="DS.d550.s0.e1" id="DS.d550.s0.i5" interaction="False"/>
            <pair e1="DS.d550.s0.e5" e2="DS.d550.s0.e2" id="DS.d550.s0.i6" interaction="False"/>
            <pair e1="DS.d550.s0.e4" e2="DS.d550.s0.e2" id="DS.d550.s0.i7" interaction="False"/>
            <pair e1="DS.d550.s0.e4" e2="DS.d550.s0.e1" id="DS.d550.s0.i8" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d551" origId="18634843">
        <sentence id="DS.d551.s0" origId="18634843-1147" text="The increase of mature IL-18 by macrophages was inhibited by caspase-1 inhibitor : caspase-1 is known to cleave the proform of IL-18 to produce active mature IL-18.">
            <entity id="DS.d551.s0.e0" origId="O19073,P70380,P97636,Q14116,Q3ZT29,Q5I931,Q8QFQ8,Q95M33,Q9TU73,Q9XSQ7,Q9XSR0" charOffset="23-28" type="protein" text="IL-18"/>
            <entity id="DS.d551.s0.e1" origId="44134608" charOffset="61-80" type="compound" text="caspase-1 inhibitor"/>
            <entity id="DS.d551.s0.e2" origId="O19073,P70380,P97636,Q14116,Q3ZT29,Q5I931,Q8QFQ8,Q95M33,Q9TU73,Q9XSQ7,Q9XSR0" charOffset="127-132" type="protein" text="IL-18"/>
            <entity id="DS.d551.s0.e3" origId="O19073,P70380,P97636,Q14116,Q3ZT29,Q5I931,Q8QFQ8,Q95M33,Q9TU73,Q9XSQ7,Q9XSR0" charOffset="127-132" type="protein" text="IL-18"/>
            <pair e1="DS.d551.s0.e1" e2="DS.d551.s0.e0" id="DS.d551.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d552" origId="18635261">
        <sentence id="DS.d552.s0" origId="18635261-398" text="In absence of stretch, we could activate Gns and deactivate GK1 by 1-oleoyl-2-acetyl-sn-glycerol (OAG) and other amphipaths.">
            <entity id="DS.d552.s0.e0" origId="P64267,P64268" charOffset="41-44" type="protein" text="Gns"/>
            <entity id="DS.d552.s0.e1" origId="Q9GTW9" charOffset="60-63" type="protein" text="GK1"/>
            <entity id="DS.d552.s0.e2" origId="1394,5353264,6437055" charOffset="67-96" type="compound" text="1-oleoyl-2-acetyl-sn-glycerol"/>
            <entity id="DS.d552.s0.e3" origId="5353264" charOffset="98-101" type="compound" text="OAG"/>
            <pair e1="DS.d552.s0.e3" e2="DS.d552.s0.e0" id="DS.d552.s0.i0" interaction="True"/>
            <pair e1="DS.d552.s0.e2" e2="DS.d552.s0.e0" id="DS.d552.s0.i1" interaction="True"/>
            <pair e1="DS.d552.s0.e2" e2="DS.d552.s0.e1" id="DS.d552.s0.i2" interaction="True"/>
            <pair e1="DS.d552.s0.e3" e2="DS.d552.s0.e1" id="DS.d552.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d553" origId="18635336">
        <sentence id="DS.d553.s0" origId="18635336-453" text="Using enzyme-linked immunosorbent assays, we showed DHMEQ to inhibit LPS-induced secretion of IL-6 and TNF-alpha.">
            <entity id="DS.d553.s0.e0" origId="9881652" charOffset="52-57" type="compound" text="DHMEQ"/>
            <entity id="DS.d553.s0.e1" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="94-98" type="protein" text="IL-6"/>
            <entity id="DS.d553.s0.e2" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="103-112" type="protein" text="TNF-alpha"/>
            <pair e1="DS.d553.s0.e0" e2="DS.d553.s0.e1" id="DS.d553.s0.i0" interaction="True"/>
            <pair e1="DS.d553.s0.e0" e2="DS.d553.s0.e2" id="DS.d553.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d554" origId="18635390">
        <sentence id="DS.d554.s0" origId="18635390-1443" text="The inhibition of DMBA-carcinogenesis by GLN application was associated with increased arterial GLN and GSH, elevated buccal mucosa GSH as well as induction of bax and PARP, and inhibition of bcl-2.">
            <entity id="DS.d554.s0.e0" origId="124886" charOffset="104-107" type="compound" text="GSH"/>
            <entity id="DS.d554.s0.e1" origId="124886" charOffset="132-135" type="compound" text="GSH"/>
            <entity id="DS.d554.s0.e2" origId="P27297,Q07813,Q63690" charOffset="160-163" type="protein" text="bax"/>
            <entity id="DS.d554.s0.e3" origId="O50017,P08469,P14043,P31669,P35875,P55057,Q08824,Q11208" charOffset="168-172" type="protein" text="PARP"/>
            <entity id="DS.d554.s0.e4" origId="P10417,P49950" charOffset="192-197" type="protein" text="bcl-2"/>
            <pair e1="DS.d554.s0.e0" e2="DS.d554.s0.e2" id="DS.d554.s0.i0" interaction="False"/>
            <pair e1="DS.d554.s0.e0" e2="DS.d554.s0.e4" id="DS.d554.s0.i1" interaction="False"/>
            <pair e1="DS.d554.s0.e0" e2="DS.d554.s0.e3" id="DS.d554.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d555" origId="18635693">
        <sentence id="DS.d555.s0" origId="18635693-781" text="Dopamine release and direct stimulation of dopamine D2 and serotonin 5-HT2A receptors also contributes to the overall action of MDMA.">
            <entity id="DS.d555.s0.e0" origId="P50129" charOffset="69-75" type="protein" text="5-HT2A"/>
            <entity id="DS.d555.s0.e1" origId="1615" charOffset="128-132" type="compound" text="MDMA"/>
            <pair e1="DS.d555.s0.e1" e2="DS.d555.s0.e0" id="DS.d555.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d555.s1" origId="18635693-783" text="Our findings suggest that MDMA differentially affects higher cognitive functions, but does not support the hypothesis from animal studies, that some of the MDMA effects are causally mediated through action at the 5-HT1A receptor system.">
            <entity id="DS.d555.s1.e0" origId="1615" charOffset="26-30" type="compound" text="MDMA"/>
            <entity id="DS.d555.s1.e1" origId="1615" charOffset="156-160" type="compound" text="MDMA"/>
            <entity id="DS.d555.s1.e2" origId="P08908,P19327,P28285,Q64264,Q6XXX9,Q6XXY0,Q98998,Q9N296,Q9N297,Q9N298" charOffset="213-219" type="protein" text="5-HT1A"/>
            <pair e1="DS.d555.s1.e0" e2="DS.d555.s1.e2" id="DS.d555.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d556" origId="18635704">
        <sentence id="DS.d556.s0" origId="18635704-791" text="These results suggest that AKT1 does not play a significant role in clinical and functional manifestations in patients with schizophrenia who receive risperidone treatment.">
            <entity id="DS.d556.s0.e0" origId="P31749,Q01314,Q38998,Q8VYX2" charOffset="27-31" type="protein" text="AKT1"/>
            <entity id="DS.d556.s0.e1" origId="5073" charOffset="150-161" type="compound" text="risperidone"/>
            <pair e1="DS.d556.s0.e1" e2="DS.d556.s0.e0" id="DS.d556.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d557" origId="18635814">
        <sentence id="DS.d557.s0" origId="18635814-879" text="Urethane is a chemical carcinogen found in tobacco smoke that causes activating mutations in Kras and induces lung tumors in mice.">
            <entity id="DS.d557.s0.e0" origId="5641" charOffset="0-8" type="compound" text="Urethane"/>
            <entity id="DS.d557.s0.e1" origId="P08644,P32883,Q05147" charOffset="93-97" type="protein" text="Kras"/>
            <pair e1="DS.d557.s0.e0" e2="DS.d557.s0.e1" id="DS.d557.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d558" origId="18636040">
        <sentence id="DS.d558.s0" origId="18636040-1068" text="In the present study, we measured plasma GSTA1-1 levels by enzyme-linked immunosorbent assay in seven healthy volunteers after repeated experimental endotoxemia induced by 2 ng kg Escherichia coli endotoxin per day (to investigate inflammation-induced hepatic injury) and in 21 patients within 12 h after the occurrence of severe sepsis/septic shock (to investigate its ability to predict an increase of transaminases on day 7).">
            <entity id="DS.d558.s0.e0" origId="P08263,Q08863" charOffset="41-48" type="protein" text="GSTA1-1"/>
            <entity id="DS.d558.s0.e1" origId="44268108" charOffset="197-206" type="compound" text="endotoxin"/>
            <pair e1="DS.d558.s0.e1" e2="DS.d558.s0.e0" id="DS.d558.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d558.s1" origId="18636040-1069" text="Furthermore, GSTA1-1 levels did not correlate with IL-6 levels but did with dobutamine infusion rate (Spearman r = 0.94; P = 0.02), suggesting that the extent of hemodynamic instability and not the degree of inflammation could be of importance for the occurrence of liver damage.">
            <entity id="DS.d558.s1.e0" origId="P08263,Q08863" charOffset="13-20" type="protein" text="GSTA1-1"/>
            <entity id="DS.d558.s1.e1" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="51-55" type="protein" text="IL-6"/>
            <entity id="DS.d558.s1.e2" origId="36811" charOffset="76-86" type="compound" text="dobutamine"/>
            <pair e1="DS.d558.s1.e2" e2="DS.d558.s1.e0" id="DS.d558.s1.i0" interaction="True"/>
            <pair e1="DS.d558.s1.e2" e2="DS.d558.s1.e1" id="DS.d558.s1.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d559" origId="18636042">
        <sentence id="DS.d559.s0" origId="18636042-1310" text="Heparin (H), argatroban (A), antithrombin III (ATIII), and recombinant human activated protein C (rhAPC) with and without thrombin were added to cells suspended in septic plasma and normal plasma.">
            <entity id="DS.d559.s0.e0" origId="2232,92722,152951,440542,445156" charOffset="13-23" type="compound" text="argatroban"/>
            <entity id="DS.d559.s0.e1" origId="P81050" charOffset="29-45" type="protein" text="antithrombin III"/>
            <entity id="DS.d559.s0.e2" origId="P01008,P32261,P32262,P41361,P81050,Q03352,Q5R5A3" charOffset="47-52" type="protein" text="ATIII"/>
            <entity id="DS.d559.s0.e3" origId="O55527,O55779,P02810,P03314,P03424,P04861,P04862,P06022,P06164,P06165,P06941,P07602,P08097,P10030,P14253,P14254,P14340,P26035,P26779,P27384,P28055,P29165,P32533,P32534,P32535,P35940,P35948,P35977,P69738,Q00794,Q03339,Q074N0,Q1X880,Q1X881,Q6DV88,Q6J3P1,Q89277,Q98803,Q997F1,Q9DUE0,Q9WS38,Q9YRV3" charOffset="87-96" type="protein" text="protein C"/>
            <entity id="DS.d559.s0.e4" origId="P84122" charOffset="33-41" type="protein" text="thrombin"/>
            <pair e1="DS.d559.s0.e0" e2="DS.d559.s0.e4" id="DS.d559.s0.i0" interaction="False"/>
            <pair e1="DS.d559.s0.e0" e2="DS.d559.s0.e3" id="DS.d559.s0.i1" interaction="False"/>
            <pair e1="DS.d559.s0.e0" e2="DS.d559.s0.e2" id="DS.d559.s0.i2" interaction="False"/>
            <pair e1="DS.d559.s0.e0" e2="DS.d559.s0.e1" id="DS.d559.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d560" origId="18636044">
        <sentence id="DS.d560.s0" origId="18636044-1070" text="Hydrogen sulfide (H2S) is a novel gaseous mediator produced by cystathionine-beta-synthase and cystathionine-gamma-lyase in the cardiovascular system, including the heart.">
            <entity id="DS.d560.s0.e0" origId="402,108196" charOffset="0-16" type="compound" text="Hydrogen sulfide"/>
            <entity id="DS.d560.s0.e1" origId="6857678" charOffset="18-21" type="compound" text="H2S"/>
            <entity id="DS.d560.s0.e2" origId="P32232,P32582,P35520,P46794,Q58H57,Q91WT9,Q9N0V7,Q9YBL2" charOffset="63-90" type="protein" text="cystathionine-beta-synthase"/>
            <entity id="DS.d560.s0.e3" origId="P18757,P31373,P32929,Q58DW2,Q60HG7,Q8VCN5" charOffset="95-120" type="protein" text="cystathionine-gamma-lyase"/>
            <pair e1="DS.d560.s0.e0" e2="DS.d560.s0.e2" id="DS.d560.s0.i0" interaction="True"/>
            <pair e1="DS.d560.s0.e1" e2="DS.d560.s0.e2" id="DS.d560.s0.i1" interaction="True"/>
            <pair e1="DS.d560.s0.e0" e2="DS.d560.s0.e3" id="DS.d560.s0.i2" interaction="True"/>
            <pair e1="DS.d560.s0.e1" e2="DS.d560.s0.e3" id="DS.d560.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d561" origId="18636221">
        <sentence id="DS.d561.s0" origId="18636221-1488" text="Chemotaxis, lysozyme release and superoxide anion production have been measured.">
            <entity id="DS.d561.s0.e0" origId="O64362,O80288,O80292,P00720,P03706,P07540,P09963,P10439,P11187,P13656,P15057,P19385,P19386,P21270,P23472,P23473,P27359,P33486,P37715,P39046,P51771,P62692,P62693,P68920,P68921,P81241,P82174,P82175,P83673,Q27650,Q37875,Q37896,Q48603,Q7SID7,Q9CIT4,Q9T1X2,Q9ZXB7" charOffset="12-20" type="protein" text="lysozyme"/>
            <entity id="DS.d561.s0.e1" origId="5359597" charOffset="33-43" type="compound" text="superoxide"/>
            <pair e1="DS.d561.s0.e1" e2="DS.d561.s0.e0" id="DS.d561.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d562" origId="18636241">
        <sentence id="DS.d562.s0" origId="18636241-1243" text="According to annexin V-binding, arsenic trioxide (7 microM) within 48 h significantly increased phosphatidylserine exposure of human erythrocytes without inducing hemolysis.">
            <entity id="DS.d562.s0.e0" origId="P08758,P14668,P17153,P48036,P70075,P81287,Q4R4H7,Q5R1W0" charOffset="13-22" type="protein" text="annexin V"/>
            <entity id="DS.d562.s0.e1" origId="445141,6323481,44147587" charOffset="96-114" type="compound" text="phosphatidylserine"/>
            <pair e1="DS.d562.s0.e1" e2="DS.d562.s0.e0" id="DS.d562.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d562.s1" origId="18636241-1244" text="Removal of extracellular Ca2+ or inhibition of the Ca2+-permeable cation channels with amiloride blunted the effects of arsenic on annexin V-binding and cell shrinkage.">
            <entity id="DS.d562.s1.e0" origId="16231" charOffset="87-96" type="compound" text="amiloride"/>
            <entity id="DS.d562.s1.e1" origId="P08758,P14668,P17153,P48036,P70075,P81287,Q4R4H7,Q5R1W0" charOffset="131-140" type="protein" text="annexin V"/>
            <pair e1="DS.d562.s1.e0" e2="DS.d562.s1.e1" id="DS.d562.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d563" origId="18636311">
        <sentence id="DS.d563.s0" origId="18636311-1287" text="In the present study, we investigated the inhibitory effect of the known oxycoumarins poncitrin (3), osthol (4), and xanthoxyletin (5), newly isolated from Clausena guillauminii (Rutaceae), together with the known carbazoles heptaphylline (1) and 7-methoxyheptaphylline (2) on inducible-nitric oxide synthase (iNOS) expression induced by lipopolysaccharide (LPS) and the NO generation in RAW 264.7 mouse macrophages.">
            <entity id="DS.d563.s0.e0" origId="10228" charOffset="101-107" type="compound" text="osthol"/>
            <entity id="DS.d563.s0.e1" origId="66548" charOffset="117-130" type="compound" text="xanthoxyletin"/>
            <entity id="DS.d563.s0.e2" origId="5318015" charOffset="225-238" type="compound" text="heptaphylline"/>
            <entity id="DS.d563.s0.e3" origId="O61309,O61608,Q27571,Q9I9M2" charOffset="287-308" type="protein" text="nitric oxide synthase"/>
            <entity id="DS.d563.s0.e4" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="310-314" type="protein" text="iNOS"/>
            <entity id="DS.d563.s0.e5" origId="11970143" charOffset="338-356" type="compound" text="lipopolysaccharide"/>
            <pair e1="DS.d563.s0.e0" e2="DS.d563.s0.e4" id="DS.d563.s0.i0" interaction="False"/>
            <pair e1="DS.d563.s0.e1" e2="DS.d563.s0.e4" id="DS.d563.s0.i1" interaction="False"/>
            <pair e1="DS.d563.s0.e2" e2="DS.d563.s0.e4" id="DS.d563.s0.i2" interaction="False"/>
            <pair e1="DS.d563.s0.e0" e2="DS.d563.s0.e3" id="DS.d563.s0.i3" interaction="False"/>
            <pair e1="DS.d563.s0.e5" e2="DS.d563.s0.e3" id="DS.d563.s0.i4" interaction="False"/>
            <pair e1="DS.d563.s0.e5" e2="DS.d563.s0.e4" id="DS.d563.s0.i5" interaction="False"/>
            <pair e1="DS.d563.s0.e2" e2="DS.d563.s0.e3" id="DS.d563.s0.i6" interaction="False"/>
            <pair e1="DS.d563.s0.e1" e2="DS.d563.s0.e3" id="DS.d563.s0.i7" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d564" origId="18636399">
        <sentence id="DS.d564.s0" origId="18636399-1328" text="Cell viability and reactive oxygen species concentration were determined, and the effects of pre-treatment with LA on these parameters were investigated together with the GST and GPx activity as well as the concentration of reduced glutathione.">
            <entity id="DS.d564.s0.e0" origId="977" charOffset="28-34" type="compound" text="oxygen"/>
            <entity id="DS.d564.s0.e1" origId="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52" charOffset="171-174" type="protein" text="GST"/>
            <entity id="DS.d564.s0.e2" origId="124886" charOffset="224-243" type="compound" text="reduced glutathione"/>
            <pair e1="DS.d564.s0.e2" e2="DS.d564.s0.e1" id="DS.d564.s0.i0" interaction="False"/>
            <pair e1="DS.d564.s0.e0" e2="DS.d564.s0.e1" id="DS.d564.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d565" origId="18636508">
        <sentence id="DS.d565.s0" origId="18636508-1410" text="Fibril growth was a second-order process with an enthalpy of activation (27+/-5 kcal mol(-1)), which is indistinguishable from that of tetramer formation by cystatins, which involves limited conformational changes including proline trans to cis isomerization.">
            <entity id="DS.d565.s0.e0" origId="P08935,P25973,P81061,P81714,Q06445" charOffset="157-166" type="protein" text="cystatins"/>
            <entity id="DS.d565.s0.e1" origId="614,8988,145742" charOffset="224-231" type="compound" text="proline"/>
            <pair e1="DS.d565.s0.e1" e2="DS.d565.s0.e0" id="DS.d565.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d566" origId="18636565">
        <sentence id="DS.d566.s0" origId="18636565-515" text="Mutations in MCT8 are associated with severe psychomotor retardation, high serum T3 and low 3,3',5'-triiodothyronine (rT3) levels.">
            <entity id="DS.d566.s0.e0" origId="P36021" charOffset="13-17" type="protein" text="MCT8"/>
            <entity id="DS.d566.s0.e1" origId="5920,644280" charOffset="92-116" type="compound" text="3,3',5'-triiodothyronine"/>
            <entity id="DS.d566.s0.e2" origId="644280" charOffset="118-121" type="compound" text="rT3"/>
            <pair e1="DS.d566.s0.e1" e2="DS.d566.s0.e0" id="DS.d566.s0.i0" interaction="True"/>
            <pair e1="DS.d566.s0.e2" e2="DS.d566.s0.e0" id="DS.d566.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d567" origId="18637152">
        <sentence id="DS.d567.s0" origId="18637152-268" text="Results showed that MENT treatments increased PSA secretion and proliferation rate with a potency ranged between T and DHT.">
            <entity id="DS.d567.s0.e0" origId="19582,9838899" charOffset="20-24" type="compound" text="MENT"/>
            <entity id="DS.d567.s0.e1" origId="P07288,P10658,P33619,P55786,Q11011,Q6DT45,Q9Y617" charOffset="46-49" type="protein" text="PSA"/>
            <entity id="DS.d567.s0.e2" origId="10635" charOffset="119-122" type="compound" text="DHT"/>
            <pair e1="DS.d567.s0.e2" e2="DS.d567.s0.e1" id="DS.d567.s0.i0" interaction="True"/>
            <pair e1="DS.d567.s0.e0" e2="DS.d567.s0.e1" id="DS.d567.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d567.s1" origId="18637152-269" text="The studies with finasteride showed that in BPH and CaP cells, the conversion of T into DHT significantly contributes to its effect on the proliferation and PSA secretion, and corroborated the resistance of MENT to the 5-AR.">
            <entity id="DS.d567.s1.e0" origId="57363" charOffset="17-28" type="compound" text="finasteride"/>
            <entity id="DS.d567.s1.e1" origId="10635" charOffset="88-91" type="compound" text="DHT"/>
            <entity id="DS.d567.s1.e2" origId="P07288,P10658,P33619,P55786,Q11011,Q6DT45,Q9Y617" charOffset="157-160" type="protein" text="PSA"/>
            <entity id="DS.d567.s1.e3" origId="19582,9838899" charOffset="207-211" type="compound" text="MENT"/>
            <pair e1="DS.d567.s1.e0" e2="DS.d567.s1.e2" id="DS.d567.s1.i0" interaction="False"/>
            <pair e1="DS.d567.s1.e3" e2="DS.d567.s1.e2" id="DS.d567.s1.i1" interaction="False"/>
            <pair e1="DS.d567.s1.e1" e2="DS.d567.s1.e2" id="DS.d567.s1.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d568" origId="18637154">
        <sentence id="DS.d568.s0" origId="18637154-273" text="Pregnant Sprague-Dawley female rats were treated once with TCDD (0, 0.3 or 1 microg/kg) by gavage on embryonic day (ED) 11 and the expression levels of androgen (AR) and estrogen receptors (ER), steroidogenic enzymes (P450scc and 3beta-HSD) and four regulatory factors (StAR, SF-1, GATA-4 and Insl-3) involved in foetal Leydig cell and adrenal function were analysed on ED 19.5.">
            <entity id="DS.d568.s0.e0" origId="15625" charOffset="59-63" type="compound" text="TCDD"/>
            <entity id="DS.d568.s0.e1" origId="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7" charOffset="170-188" type="protein" text="estrogen receptors"/>
            <entity id="DS.d568.s0.e2" origId="O46516,O57245,P14893,P21097,P26670,P27365,Q5IFP1,Q67477,Q9N119" charOffset="230-239" type="protein" text="3beta-HSD"/>
            <entity id="DS.d568.s0.e3" origId="O46689,P49675,P51557,P58864,P70114,P79245,P97826,Q28918,Q28996,Q9DE06,Q9DEB4,Q9DG08,Q9DG09,Q9DG10" charOffset="270-274" type="protein" text="StAR"/>
            <entity id="DS.d568.s0.e4" origId="P33242,P50569,P79387,Q04752,Q13285,Q95L87,Q9GKL2" charOffset="276-280" type="protein" text="SF-1"/>
            <entity id="DS.d568.s0.e5" origId="P49604" charOffset="282-286" type="protein" text="GATA"/>
            <pair e1="DS.d568.s0.e0" e2="DS.d568.s0.e1" id="DS.d568.s0.i0" interaction="False"/>
            <pair e1="DS.d568.s0.e0" e2="DS.d568.s0.e4" id="DS.d568.s0.i1" interaction="False"/>
            <pair e1="DS.d568.s0.e0" e2="DS.d568.s0.e2" id="DS.d568.s0.i2" interaction="False"/>
            <pair e1="DS.d568.s0.e0" e2="DS.d568.s0.e5" id="DS.d568.s0.i3" interaction="False"/>
            <pair e1="DS.d568.s0.e0" e2="DS.d568.s0.e3" id="DS.d568.s0.i4" interaction="False"/>
        </sentence>
        <sentence id="DS.d568.s1" origId="18637154-274" text="In utero exposure to TCDD reduced intratesticular T of foetal males (significant at 0.3 microg/kg TCDD) and tended to reduce the protein expression of ERalpha and AR of foetal male rat testis.">
            <entity id="DS.d568.s1.e0" origId="15625" charOffset="21-25" type="compound" text="TCDD"/>
            <entity id="DS.d568.s1.e1" origId="15625" charOffset="98-102" type="compound" text="TCDD"/>
            <entity id="DS.d568.s1.e2" origId="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7" charOffset="151-158" type="protein" text="ERalpha"/>
            <pair e1="DS.d568.s1.e0" e2="DS.d568.s1.e2" id="DS.d568.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d568.s2" origId="18637154-275" text="mRNA expression of developmental regulatory factors was not influenced by foetal TCDD exposure, except for significantly reduced adrenal SF-1.">
            <entity id="DS.d568.s2.e0" origId="15625" charOffset="81-85" type="compound" text="TCDD"/>
            <entity id="DS.d568.s2.e1" origId="P33242,P50569,P79387,Q04752,Q13285,Q95L87,Q9GKL2" charOffset="137-141" type="protein" text="SF-1"/>
            <pair e1="DS.d568.s2.e0" e2="DS.d568.s2.e1" id="DS.d568.s2.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d569" origId="18637708">
        <sentence id="DS.d569.s0" origId="18637708-746" text="Nitrogen-containing bisphosphonates were found to inhibit farnesyl diphosphate synthase-an essential enzyme in the cholesterol biosynthesis pathway, but their effect on cholesterol synthesis per se in the central nervous system (CNS) remains unknown.">
            <entity id="DS.d569.s0.e0" origId="947,123329" charOffset="0-8" type="compound" text="Nitrogen"/>
            <entity id="DS.d569.s0.e1" origId="O66126,O66952,P22939,P45204,P54383,P55539,P57537,Q08291,Q45220,Q8K9A0" charOffset="58-87" type="protein" text="farnesyl diphosphate synthase"/>
            <entity id="DS.d569.s0.e2" origId="304,5997,6432564,11025495" charOffset="115-126" type="compound" text="cholesterol"/>
            <pair e1="DS.d569.s0.e0" e2="DS.d569.s0.e1" id="DS.d569.s0.i0" interaction="False"/>
            <pair e1="DS.d569.s0.e2" e2="DS.d569.s0.e1" id="DS.d569.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d570" origId="18637712">
        <sentence id="DS.d570.s0" origId="18637712-756" text="hsBAFF-upregulated intracellular free Ca(2+) homeostasis regulates ERK1/2 activity and cell proliferation in B cells in vitro.">
            <entity id="DS.d570.s0.e0" origId="271" charOffset="38-42" type="compound" text="Ca(2"/>
            <entity id="DS.d570.s0.e1" origId="P27361,P28869,P42525,Q07176" charOffset="67-71" type="protein" text="ERK1"/>
            <pair e1="DS.d570.s0.e0" e2="DS.d570.s0.e1" id="DS.d570.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d570.s1" origId="18637712-757" text="Using immunocytochemistry and Western blot analysis, we found that the activation of ERK1/2 due to hsBAFF was triggered by a (Ca(2+))(i)-dependent pathway, leading to elevation of B cell proliferation.">
            <entity id="DS.d570.s1.e0" origId="P27361,P28869,P42525,Q07176" charOffset="85-89" type="protein" text="ERK1"/>
            <entity id="DS.d570.s1.e1" origId="271" charOffset="126-130" type="compound" text="Ca(2"/>
            <pair e1="DS.d570.s1.e1" e2="DS.d570.s1.e0" id="DS.d570.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d570.s2" origId="18637712-758" text="This is supported by the findings that intracellular Ca(2+) chelator BAPTA/AM attenuated phosphorylated ERK1/2 expression and cell proliferation in hsBAFF-stimulated B cells.">
            <entity id="DS.d570.s2.e0" origId="2293" charOffset="69-77" type="compound" text="BAPTA/AM"/>
            <entity id="DS.d570.s2.e1" origId="P27361,P28869,P42525,Q07176" charOffset="104-108" type="protein" text="ERK1"/>
            <pair e1="DS.d570.s2.e0" e2="DS.d570.s2.e1" id="DS.d570.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d570.s3" origId="18637712-759" text="Taken together, the main finding of this study is that hsBAFF elicits higher but homeostatic (Ca(2+))(i) levels, which regulates ERK1/2 activity and cell proliferation in in vitro B cells.">
            <entity id="DS.d570.s3.e0" origId="271" charOffset="94-98" type="compound" text="Ca(2"/>
            <entity id="DS.d570.s3.e1" origId="P27361,P28869,P42525,Q07176" charOffset="129-133" type="protein" text="ERK1"/>
            <pair e1="DS.d570.s3.e0" e2="DS.d570.s3.e1" id="DS.d570.s3.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d571" origId="18637714">
        <sentence id="DS.d571.s0" origId="18637714-1311" text="Surgical removal of pheochromocytoma significantly increased body weight, decreased both systolic and diastolic blood pressure, fasting blood glucose and glycated hemoglobin levels.">
            <entity id="DS.d571.s0.e0" origId="206,5793,64689,79025" charOffset="142-149" type="compound" text="glucose"/>
            <entity id="DS.d571.s0.e1" origId="P15160,P17724,P73925,Q03459" charOffset="163-173" type="protein" text="hemoglobin"/>
            <pair e1="DS.d571.s0.e0" e2="DS.d571.s0.e1" id="DS.d571.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d572" origId="18637715">
        <sentence id="DS.d572.s0" origId="18637715-1322" text="In this study we have investigated a long-term pattern of expression and production of spinal COX-1 and COX-2 in the model of osteoarthritis induced in rats by injection of monoiodoacetate (MIA) into the knee joint.">
            <entity id="DS.d572.s0.e0" origId="O62664,O97554,P05979,P22437,P23219,Q63921,Q9T0N8" charOffset="94-99" type="protein" text="COX-1"/>
            <entity id="DS.d572.s0.e1" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="104-109" type="protein" text="COX-2"/>
            <entity id="DS.d572.s0.e2" origId="5240" charOffset="173-188" type="compound" text="monoiodoacetate"/>
            <pair e1="DS.d572.s0.e2" e2="DS.d572.s0.e1" id="DS.d572.s0.i0" interaction="False"/>
            <pair e1="DS.d572.s0.e2" e2="DS.d572.s0.e0" id="DS.d572.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d573" origId="18639339">
        <sentence id="DS.d573.s0" origId="18639339-380" text="The enzyme indoleamine 2,3-dioxygenase (IDO) converts tryptophan to kynurenine, blocking T-cell activation and inducing immunosuppression.">
            <entity id="DS.d573.s0.e0" origId="P14902,P28776" charOffset="11-38" type="protein" text="indoleamine 2,3-dioxygenase"/>
            <entity id="DS.d573.s0.e1" origId="P14902,P28776" charOffset="40-43" type="protein" text="IDO"/>
            <entity id="DS.d573.s0.e2" origId="1148,6305,9060,5460840" charOffset="54-64" type="compound" text="tryptophan"/>
            <entity id="DS.d573.s0.e3" origId="846" charOffset="68-78" type="compound" text="kynurenine"/>
            <pair e1="DS.d573.s0.e2" e2="DS.d573.s0.e0" id="DS.d573.s0.i0" interaction="True"/>
            <pair e1="DS.d573.s0.e3" e2="DS.d573.s0.e1" id="DS.d573.s0.i1" interaction="True"/>
            <pair e1="DS.d573.s0.e2" e2="DS.d573.s0.e1" id="DS.d573.s0.i2" interaction="True"/>
            <pair e1="DS.d573.s0.e3" e2="DS.d573.s0.e0" id="DS.d573.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d574" origId="18639341">
        <sentence id="DS.d574.s0" origId="18639341-381" text="Serum l-kynurenine (l-KYN) concentrations, l-KYN/l-TRP ratio, and the level of IDO mRNA expression in ATLL cells were significantly increased in ATLL patients compared to those in healthy and HTLV-positive carrier subjects.">
            <entity id="DS.d574.s0.e0" origId="846" charOffset="8-18" type="compound" text="kynurenine"/>
            <entity id="DS.d574.s0.e1" origId="161166" charOffset="22-25" type="compound" text="KYN"/>
            <entity id="DS.d574.s0.e2" origId="161166" charOffset="45-48" type="compound" text="KYN"/>
            <entity id="DS.d574.s0.e3" origId="P07147,P17643" charOffset="51-54" type="protein" text="TRP"/>
            <entity id="DS.d574.s0.e4" origId="P14902,P28776" charOffset="79-82" type="protein" text="IDO"/>
            <pair e1="DS.d574.s0.e0" e2="DS.d574.s0.e3" id="DS.d574.s0.i0" interaction="False"/>
            <pair e1="DS.d574.s0.e1" e2="DS.d574.s0.e3" id="DS.d574.s0.i1" interaction="False"/>
            <pair e1="DS.d574.s0.e1" e2="DS.d574.s0.e4" id="DS.d574.s0.i2" interaction="False"/>
            <pair e1="DS.d574.s0.e0" e2="DS.d574.s0.e4" id="DS.d574.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d575" origId="18639629">
        <sentence id="DS.d575.s0" origId="18639629-311" text="Peripheral administration of the acetylcholinesterase inhibitor galantamine significantly reduced serum TNF levels through vagus nerve signaling, and protected against lethality during murine endotoxemia.">
            <entity id="DS.d575.s0.e0" origId="9651" charOffset="64-75" type="compound" text="galantamine"/>
            <entity id="DS.d575.s0.e1" origId="O35734,O77510,O77764,P01375,P04924,P13296,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="104-107" type="protein" text="TNF"/>
            <pair e1="DS.d575.s0.e0" e2="DS.d575.s0.e1" id="DS.d575.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d575.s1" origId="18639629-312" text="Administration of a centrally-acting muscarinic receptor antagonist abolished the suppression of TNF by galantamine, indicating that suppressing acetylcholinesterase activity, coupled with central muscarinic receptors, controls peripheral cytokine responses.">
            <entity id="DS.d575.s1.e0" origId="O35734,O77510,O77764,P01375,P04924,P13296,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="97-100" type="protein" text="TNF"/>
            <entity id="DS.d575.s1.e1" origId="9651" charOffset="104-115" type="compound" text="galantamine"/>
            <entity id="DS.d575.s1.e2" origId="Q867X2,Q867X3,Q86GC9,Q92081" charOffset="145-165" type="protein" text="acetylcholinesterase"/>
            <pair e1="DS.d575.s1.e1" e2="DS.d575.s1.e2" id="DS.d575.s1.i0" interaction="True"/>
            <pair e1="DS.d575.s1.e1" e2="DS.d575.s1.e0" id="DS.d575.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d575.s2" origId="18639629-313" text="Administration of galantamine to alpha7nAChR knockout mice failed to suppress TNF levels, indicating that the alpha7nAChR-mediated cholinergic anti-inflammatory pathway is required for the anti-inflammatory effect of galantamine.">
            <entity id="DS.d575.s2.e0" origId="9651" charOffset="18-29" type="compound" text="galantamine"/>
            <entity id="DS.d575.s2.e1" origId="O35734,O77510,O77764,P01375,P04924,P13296,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="78-81" type="protein" text="TNF"/>
            <entity id="DS.d575.s2.e2" origId="9651" charOffset="217-228" type="compound" text="galantamine"/>
            <pair e1="DS.d575.s2.e0" e2="DS.d575.s2.e1" id="DS.d575.s2.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d576" origId="18639930">
        <sentence id="DS.d576.s0" origId="18639930-897" text="The involvement of superoxide and nitric oxide was verified by the block of MSC using specific scavengers (tiron and PTIO, respectively).">
            <entity id="DS.d576.s0.e0" origId="5359597" charOffset="19-29" type="compound" text="superoxide"/>
            <entity id="DS.d576.s0.e1" origId="145068" charOffset="34-46" type="compound" text="nitric oxide"/>
            <entity id="DS.d576.s0.e2" origId="O60682" charOffset="76-79" type="protein" text="MSC"/>
            <entity id="DS.d576.s0.e3" origId="9002" charOffset="107-112" type="compound" text="tiron"/>
            <pair e1="DS.d576.s0.e0" e2="DS.d576.s0.e2" id="DS.d576.s0.i0" interaction="False"/>
            <pair e1="DS.d576.s0.e3" e2="DS.d576.s0.e2" id="DS.d576.s0.i1" interaction="True"/>
            <pair e1="DS.d576.s0.e1" e2="DS.d576.s0.e2" id="DS.d576.s0.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d576.s1" origId="18639930-898" text="Accordingly, MSC were blocked by the peroxynitrite scavenger uric acid and could be mimicked by application of exogenous peroxynitrite.">
            <entity id="DS.d576.s1.e0" origId="O60682" charOffset="13-16" type="protein" text="MSC"/>
            <entity id="DS.d576.s1.e2" origId="1175" charOffset="61-70" type="compound" text="uric acid"/>
            <pair e1="DS.d576.s1.e2" e2="DS.d576.s1.e0" id="DS.d576.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d576.s2" origId="18639930-899" text="This conclusion is supported by our findings that MSC were suppressed by inhibitors of phospholipases but could be mimicked by exogenous phospholipases or by amphipaths (oleic acid, Triton X-100).">
            <entity id="DS.d576.s2.e0" origId="O60682" charOffset="50-53" type="protein" text="MSC"/>
            <entity id="DS.d576.s2.e1" origId="445639" charOffset="170-180" type="compound" text="oleic acid"/>
            <entity id="DS.d576.s2.e2" origId="5590" charOffset="182-194" type="compound" text="Triton X-100"/>
            <pair e1="DS.d576.s2.e2" e2="DS.d576.s2.e0" id="DS.d576.s2.i0" interaction="True"/>
            <pair e1="DS.d576.s2.e1" e2="DS.d576.s2.e0" id="DS.d576.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d577" origId="18640003">
        <sentence id="DS.d577.s0" origId="18640003-956" text="In the present study, therefore, the effect of FA/AD in presence or absence of p38MAPK inhibitor SB203580 on the proliferation, apoptosis, p38MAPK, caspase-3, location of p38MAPK and caspase-3, and interaction between p38MAPK and caspase-3 in Bel-7402 cell was investigated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), annexin V-FITC/propidium iodide (PI) double staining, electron microscopy, immunoblot, immunofluorescence and immunoprecipitation/immunoblot assay, respectively.">
            <entity id="DS.d577.s0.e0" origId="64966" charOffset="277-338" type="compound" text="3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide"/>
            <entity id="DS.d577.s0.e1" origId="P08758,P14668,P17153,P48036,P70075,P81287,Q4R4H7,Q5R1W0" charOffset="346-355" type="protein" text="annexin V"/>
            <entity id="DS.d577.s0.e2" origId="18730" charOffset="356-360" type="compound" text="FITC"/>
            <entity id="DS.d577.s0.e3" origId="4939" charOffset="361-377" type="compound" text="propidium iodide"/>
            <pair e1="DS.d577.s0.e0" e2="DS.d577.s0.e1" id="DS.d577.s0.i0" interaction="False"/>
            <pair e1="DS.d577.s0.e3" e2="DS.d577.s0.e1" id="DS.d577.s0.i1" interaction="False"/>
            <pair e1="DS.d577.s0.e2" e2="DS.d577.s0.e1" id="DS.d577.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d578" origId="18640059">
        <sentence id="DS.d578.s0" origId="18640059-934" text="To investigate the role of adenosine analogs and electromagnetic field (EMF) stimulation on prostaglandin E(2) (PGE (2)) release and cyclooxygenase-2 (COX-2) expression in bovine synovial fibroblasts (SFs).">
            <entity id="DS.d578.s0.e0" origId="60961" charOffset="27-36" type="compound" text="adenosine"/>
            <entity id="DS.d578.s0.e1" origId="Q29458" charOffset="112-115" type="protein" text="PGE"/>
            <entity id="DS.d578.s0.e2" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="133-149" type="protein" text="cyclooxygenase-2"/>
            <entity id="DS.d578.s0.e3" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="151-156" type="protein" text="COX-2"/>
            <pair e1="DS.d578.s0.e0" e2="DS.d578.s0.e1" id="DS.d578.s0.i0" interaction="False"/>
            <pair e1="DS.d578.s0.e0" e2="DS.d578.s0.e3" id="DS.d578.s0.i1" interaction="False"/>
            <pair e1="DS.d578.s0.e0" e2="DS.d578.s0.e2" id="DS.d578.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d579" origId="18640663">
        <sentence id="DS.d579.s0" origId="18640663-1479" text="In this study, we compared the effects of insulin-like growth factor-I (IGF-I), basic fibroblast growth factor (bFGF), transforming growth factor beta1 (TGF-beta1), and glucosamine sulphate on porcine TMJ condylar cartilage and ankle cartilage cells in monolayer culture.">
            <entity id="DS.d579.s0.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="42-49" type="protein" text="insulin"/>
            <entity id="DS.d579.s0.e1" origId="P05017,P07455,P08025,P10763,P16545,P17085,P17647,P18254,P33712,P51457,P51458,P51462,Q02815,Q28933,Q68LC0,Q6GUL6,Q6IVA5,Q6JLX1,Q95222" charOffset="72-77" type="protein" text="IGF-I"/>
            <entity id="DS.d579.s0.e2" origId="P03969,P09038,P12226,P13109,P15655,P20003,P48798,P48799,P48800,Q60487" charOffset="80-110" type="protein" text="basic fibroblast growth factor"/>
            <entity id="DS.d579.s0.e3" origId="O19011,O93449,P01137,P04202,P07200,P09531,P09533,P16176,P17246,P18341,P50414,P54831,Q38HS2,Q9PTQ2,Q9Z1Y6" charOffset="153-162" type="protein" text="TGF-beta1"/>
            <entity id="DS.d579.s0.e4" origId="3034366" charOffset="169-189" type="compound" text="glucosamine sulphate"/>
            <pair e1="DS.d579.s0.e4" e2="DS.d579.s0.e0" id="DS.d579.s0.i0" interaction="False"/>
            <pair e1="DS.d579.s0.e4" e2="DS.d579.s0.e3" id="DS.d579.s0.i1" interaction="False"/>
            <pair e1="DS.d579.s0.e4" e2="DS.d579.s0.e1" id="DS.d579.s0.i2" interaction="False"/>
            <pair e1="DS.d579.s0.e4" e2="DS.d579.s0.e2" id="DS.d579.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d580" origId="18640679">
        <sentence id="DS.d580.s0" origId="18640679-288" text="Meanwhile, both the enhanced expression of VCAM-1 and increased activation of NF-kappaB induced by CRH in aortas of LDLr-/-mice were also largely suppressed by NBI27914, whereas these inhibitory effects were not observed in anti-Svg-30 group.">
            <entity id="DS.d580.s0.e0" origId="P19320,P29533,P29534,Q28260" charOffset="43-49" type="protein" text="VCAM-1"/>
            <entity id="DS.d580.s0.e1" origId="P01142,P06296,P06850,P49926,Q95MI6,Q9PTS1" charOffset="99-102" type="protein" text="CRH"/>
            <entity id="DS.d580.s0.e2" origId="176157" charOffset="160-168" type="compound" text="NBI27914"/>
            <pair e1="DS.d580.s0.e2" e2="DS.d580.s0.e0" id="DS.d580.s0.i0" interaction="True"/>
            <pair e1="DS.d580.s0.e2" e2="DS.d580.s0.e1" id="DS.d580.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d581" origId="18640717">
        <sentence id="DS.d581.s0" origId="18640717-1523" text="PI3K/Akt activity, analyzed by phosphatidylinositol trisphosphate production and phosphorylated Akt (p-Akt) expression, was higher in the resistant cell lines than in the sensitive one and inhibition with wortmannin or LY294002 improved apoptosis in the resistant cell lines.">
            <entity id="DS.d581.s0.e0" origId="O00329,O02697,O35904,P23727,P26450,P27986,P32871,P42336,P42337,P42338,P42347,P42348,P48736,P54673,P54674,P54675,P54676,Q63787,Q8BTI9,Q8UUU2,Q9JHG7,Q9Z1L0" charOffset="0-4" type="protein" text="PI3K"/>
            <entity id="DS.d581.s0.e1" origId="53477912" charOffset="31-51" type="compound" text="phosphatidylinositol"/>
            <entity id="DS.d581.s0.e2" origId="312145" charOffset="205-215" type="compound" text="wortmannin"/>
            <entity id="DS.d581.s0.e3" origId="3973" charOffset="219-227" type="compound" text="LY294002"/>
            <pair e1="DS.d581.s0.e2" e2="DS.d581.s0.e0" id="DS.d581.s0.i0" interaction="True"/>
            <pair e1="DS.d581.s0.e3" e2="DS.d581.s0.e0" id="DS.d581.s0.i1" interaction="True"/>
            <pair e1="DS.d581.s0.e1" e2="DS.d581.s0.e0" id="DS.d581.s0.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d581.s1" origId="18640717-1524" text="Vincristine but not doxorubicin increased p-Akt expression whereas co-treatment with PI3K inhibitors and vincristine increased apoptosis in the three cell lines.">
            <entity id="DS.d581.s1.e0" origId="5978" charOffset="0-11" type="compound" text="Vincristine"/>
            <entity id="DS.d581.s1.e1" origId="31703" charOffset="20-31" type="compound" text="doxorubicin"/>
            <entity id="DS.d581.s1.e2" origId="P31750,Q8INB9" charOffset="44-47" type="protein" text="Akt"/>
            <entity id="DS.d581.s1.e3" origId="5978" charOffset="105-116" type="compound" text="vincristine"/>
            <pair e1="DS.d581.s1.e1" e2="DS.d581.s1.e2" id="DS.d581.s1.i0" interaction="False"/>
            <pair e1="DS.d581.s1.e0" e2="DS.d581.s1.e2" id="DS.d581.s1.i1" interaction="True"/>
            <pair e1="DS.d581.s1.e3" e2="DS.d581.s1.e2" id="DS.d581.s1.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d581.s2" origId="18640717-1525" text="Wortmannin and LY294002 inhibited P-glycoprotein (Pgp) function and also increased NF-kappaB activity.">
            <entity id="DS.d581.s2.e0" origId="312145" charOffset="0-10" type="compound" text="Wortmannin"/>
            <entity id="DS.d581.s2.e1" origId="3973" charOffset="15-23" type="compound" text="LY294002"/>
            <entity id="DS.d581.s2.e2" origId="P08163" charOffset="36-48" type="protein" text="glycoprotein"/>
            <pair e1="DS.d581.s2.e1" e2="DS.d581.s2.e2" id="DS.d581.s2.i0" interaction="True"/>
            <pair e1="DS.d581.s2.e0" e2="DS.d581.s2.e2" id="DS.d581.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d582" origId="18640746">
        <sentence id="DS.d582.s0" origId="18640746-1557" text="Namely, the results obtained for the most active compounds, 5-(chloroacetylamino) uracil (2) and its acyclic sugar analogue 18, suggest that formation of a covalent bond between reactive substituent and several possible targets within the thymidylate synthase mechanism (sulphur of the cysteine residue, basic part of the enzyme, N,N-methylene tetrahydrofolate or its reactive iminium forms) is the most probable mode of action.">
            <entity id="DS.d582.s0.e1" origId="O02604,O26868,O33380,O66108,O76511,O81395,O96650,P00469,P00471,P04818,P06785,P06854,P07382,P07606,P07607,P09249,P0A0M5,P0A884,P0A885,P0A886,P0C0M4,P0C0M5,P12461,P12462,P13100,P13922,P16126,P19368,P20712,P44420,P45350,P45351,P45352,P46103,P47469,P48464,P51820,P57515,P57808,P59427,P67042,P67043,P67044,P67045,P67046,P67047,P67048,P67049,P67050,P67051,P67052,P78029,P80305,P90463,Q05762,Q05763,Q07422,Q23695,Q27713,Q27783,Q27793,Q27828,Q2QRX6,Q4QM04,Q57931,Q5D189,Q5E7P1,Q5FKL6,Q5GWB5,Q5HFZ6,Q5HMP6,Q5KZ25,Q5M0S7,Q5M5B3,Q5NFK5,Q5P233,Q5PEN6,Q5R064,Q5UQG3,Q5WDS1,Q5WSU5,Q5X119,Q5XCM3,Q5YPL7,Q5ZRL3,Q603S2,Q63BV5,Q64PV5,Q65J44,Q65VJ8,Q667F9,Q67JQ1,Q6A761,Q6AFI0,Q6D8I6,Q6F145,Q6FER7,Q6FZ91,Q6G2S8,Q6G9D4,Q6GGY0,Q6HJC7,Q6KIQ6,Q6LUM1,Q6MID2,Q6N447,Q6NIF2,Q6REU8,Q6YQT0,Q71YE1,Q738X7,Q73VZ2,Q74IU3,Q7MNN6,Q7MTB5,Q7N8U4,Q7NZ95,Q7UID0,Q7VMH2,Q7VUE3,Q7W1A9,Q7WP13,Q81E05,Q81R23,Q82WU3,Q834R3,Q83BG2,Q87BT4,Q87SA0,Q87UL4,Q88CN9,Q88W05,Q89940,Q89G35,Q8A639,Q8D2N4,Q8DER9,Q8DUI4,Q8DZ07,Q8E4L6,Q8EH94,Q8EQG0,Q8EV81,Q8FR47,Q8G3T9,Q8K9C3,Q8NS38,Q8P1D1,Q8PCE7,Q8PP46,Q8PXI1,Q8RGP6,Q8THH4,Q8TVL9,Q8UDS3,Q8Y0U6,Q8Y626,Q8Z412,Q8ZHV1,Q8ZMA9,Q92AD4,Q92NQ5,Q97EV3,Q98KH9,Q98Q31,Q9A6H0,Q9CBW0,Q9I6F1,Q9JT57,Q9JY72,Q9K7B5,Q9P4T7,Q9PB13,Q9RAM7,Q9XC19,Q9Z671" charOffset="239-259" type="protein" text="thymidylate synthase"/>
            <entity id="DS.d582.s0.e2" origId="594,5862,5360637" charOffset="286-294" type="compound" text="cysteine"/>
            <pair e1="DS.d582.s0.e2" e2="DS.d582.s0.e1" id="DS.d582.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d583" origId="18641920">
        <sentence id="DS.d583.s0" origId="18641920-846" text="PTK787/ZK222584, a potent orally active angiogenesis inhibitor capable of inhibiting all known isoforms of Vascular Endothelial Growth Factor (VEGF) receptor, belongs to the class of aminophthalazines.">
            <entity id="DS.d583.s0.e0" origId="151194" charOffset="0-15" type="compound" text="PTK787/ZK222584"/>
            <entity id="DS.d583.s0.e1" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="143-147" type="protein" text="VEGF"/>
            <pair e1="DS.d583.s0.e0" e2="DS.d583.s0.e1" id="DS.d583.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d584" origId="18642040">
        <sentence id="DS.d584.s0" origId="18642040-946" text="Recent evidence for toxic superoxide (O(2)(-)) production by marine microalgae is afforded particular attention given that release of O(2)(-) anions can be exacerbated by the binding of mannose-specific lectins to the microalgal cell wall ; a novel model for grazing-activated chemical defence is proposed.">
            <entity id="DS.d584.s0.e0" origId="5359597" charOffset="26-36" type="compound" text="superoxide"/>
            <entity id="DS.d584.s0.e1" origId="P82953" charOffset="186-210" type="protein" text="mannose-specific lectins"/>
            <pair e1="DS.d584.s0.e0" e2="DS.d584.s0.e1" id="DS.d584.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d585" origId="18642088">
        <sentence id="DS.d585.s0" origId="18642088-995" text="Activation of these receptors can inhibit ACTH-release in primary cultured corticotroph adenomas and compounds that target either sst (5) (pasireotide, or SOM230) or D(2) (cabergoline) have shown significant efficacy in subsets of patients in recent clinical studies.">
            <entity id="DS.d585.s0.e0" origId="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5" charOffset="42-46" type="protein" text="ACTH"/>
            <entity id="DS.d585.s0.e1" origId="56603683" charOffset="139-150" type="compound" text="pasireotide"/>
            <entity id="DS.d585.s0.e2" origId="56841596" charOffset="155-161" type="compound" text="SOM230"/>
            <entity id="DS.d585.s0.e3" origId="54746" charOffset="172-183" type="compound" text="cabergoline"/>
            <pair e1="DS.d585.s0.e1" e2="DS.d585.s0.e0" id="DS.d585.s0.i0" interaction="False"/>
            <pair e1="DS.d585.s0.e3" e2="DS.d585.s0.e0" id="DS.d585.s0.i1" interaction="False"/>
            <pair e1="DS.d585.s0.e2" e2="DS.d585.s0.e0" id="DS.d585.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d586" origId="18642106">
        <sentence id="DS.d586.s0" origId="18642106-1330" text="The glutamate induced chemotaxis was accompanied by polarization of the actin cytoskeleton, and by polymerization of F-actin.">
            <entity id="DS.d586.s0.e0" origId="611,23327,33032" charOffset="4-13" type="compound" text="glutamate"/>
            <entity id="DS.d586.s0.e1" origId="O00937,O13419,O16808,O17320,O65314,O65315,O65316,O74258,O81221,P02577,P10365,P10989,P11426,P13363,P14235,P17128,P20904,P24902,P26182,P26183,P30161,P45520,P45521,P48465,P50138,P51775,P53455,P53476,P53477,P53491,P53498,P53499,P53500,P53502,P53689,P60009,P60010,P60011,P68555,P78711,P80709,P81085,P90689,P91754,Q05214,Q11212,Q24733,Q2U7A3,Q39596,Q39758,Q6TCF2,Q75D00,Q8SWN8,Q8X119,Q92192,Q92193,Q99023,Q9P4D1,Q9UVF3,Q9UVX4,Q9UVZ8" charOffset="72-77" type="protein" text="actin"/>
            <entity id="DS.d586.s0.e2" origId="O00937,O13419,O16808,O17320,O65314,O65315,O65316,O74258,O81221,P02577,P10365,P10989,P11426,P13363,P14235,P17128,P20904,P24902,P26182,P26183,P30161,P45520,P45521,P48465,P50138,P51775,P53455,P53476,P53477,P53491,P53498,P53499,P53500,P53502,P53689,P60009,P60010,P60011,P68555,P78711,P80709,P81085,P90689,P91754,Q05214,Q11212,Q24733,Q2U7A3,Q39596,Q39758,Q6TCF2,Q75D00,Q8SWN8,Q8X119,Q92192,Q92193,Q99023,Q9P4D1,Q9UVF3,Q9UVX4,Q9UVZ8" charOffset="119-124" type="protein" text="actin"/>
            <pair e1="DS.d586.s0.e0" e2="DS.d586.s0.e1" id="DS.d586.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d587" origId="18642386">
        <sentence id="DS.d587.s0" origId="18642386-611" text="SD4 in anionic DSPG liposomes stimulated murine IL-6 production in RAW 264 cells at concentrations 25-to 30-fold lower than free drug.">
            <entity id="DS.d587.s0.e0" origId="97663" charOffset="0-3" type="compound" text="SD4"/>
            <entity id="DS.d587.s0.e1" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="48-52" type="protein" text="IL-6"/>
            <pair e1="DS.d587.s0.e0" e2="DS.d587.s0.e1" id="DS.d587.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d588" origId="18643838">
        <sentence id="DS.d588.s0" origId="18643838-993" text="To elucidate the mechanism by which rosiglitazone regulates adipose triglyceride lipase (ATGL).">
            <entity id="DS.d588.s0.e0" origId="77999" charOffset="36-49" type="compound" text="rosiglitazone"/>
            <entity id="DS.d588.s0.e1" origId="Q7M4U7" charOffset="81-87" type="protein" text="lipase"/>
            <pair e1="DS.d588.s0.e0" e2="DS.d588.s0.e1" id="DS.d588.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d589" origId="18643908">
        <sentence id="DS.d589.s0" origId="18643908-800" text="Rhodopsin is one of the members of the G protein-coupled receptor family that can catalyze a GDP-GTP exchange reaction on the retinal G protein transducin (Gt) upon photon absorption.">
            <entity id="DS.d589.s0.e0" origId="O16005,O16017,O16018,O16019,O16020,O18312,O18315,O18481,O18485,O18486,O18766,O42268,O42294,O42300,O42301,O42307,O42327,O42328,O42330,O42427,O42431,O42451,O42452,O42466,O42604,O62791,O62792,O62793,O62794,O62795,O62796,O62798,O93441,O93459,P02699,P02700,P08100,P09241,P15409,P22328,P22671,P24603,P28681,P29403,P31355,P31356,P32308,P32309,P35356,P35359,P35362,P35403,P41590,P41591,P49912,P51470,P51488,P51489,P52202,P56514,P56515,P56516,P79756,P79798,P79807,P79808,P79809,P79812,P79848,P79863,P79898,P79901,P79902,P79903,P79911,P79914,P87369,Q17094,Q17292,Q17296,Q28886,Q68J47,Q6W3E1,Q769E8,Q8HY69,Q90245,Q90305,Q90373,Q95KU1,Q98980,Q9DGG4,Q9YGY9,Q9YGZ0,Q9YGZ1,Q9YGZ2,Q9YGZ3,Q9YGZ4,Q9YGZ5,Q9YGZ6,Q9YGZ7,Q9YGZ8,Q9YGZ9,Q9YH00,Q9YH01,Q9YH02,Q9YH03,Q9YH04,Q9YH05" charOffset="0-9" type="protein" text="Rhodopsin"/>
            <entity id="DS.d589.s0.e1" origId="8977" charOffset="93-96" type="compound" text="GDP"/>
            <entity id="DS.d589.s0.e2" origId="6830" charOffset="97-100" type="compound" text="GTP"/>
            <entity id="DS.d589.s0.e3" origId="P49177" charOffset="144-154" type="protein" text="transducin"/>
            <pair e1="DS.d589.s0.e2" e2="DS.d589.s0.e0" id="DS.d589.s0.i0" interaction="True"/>
            <pair e1="DS.d589.s0.e1" e2="DS.d589.s0.e3" id="DS.d589.s0.i1" interaction="True"/>
            <pair e1="DS.d589.s0.e2" e2="DS.d589.s0.e3" id="DS.d589.s0.i2" interaction="True"/>
            <pair e1="DS.d589.s0.e1" e2="DS.d589.s0.e0" id="DS.d589.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d590" origId="18644606">
        <sentence id="DS.d590.s0" origId="18644606-1339" text="Olanzapine was associated with a lower frequency of extrapyramidal symptoms than other antipsychotics, fewer prolactin-related adverse events than risperidone and other atypical antipsychotics, but greater weight gain than typicals and risperidone.">
            <entity id="DS.d590.s0.e0" origId="4585" charOffset="0-10" type="compound" text="Olanzapine"/>
            <entity id="DS.d590.s0.e1" origId="P10765,P22393,P33089,P33090,P33091,P43001" charOffset="109-118" type="protein" text="prolactin"/>
            <pair e1="DS.d590.s0.e0" e2="DS.d590.s0.e1" id="DS.d590.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d591" origId="18646192">
        <sentence id="DS.d591.s0" origId="18646192-1003" text="In our earlier method, glutathione disulfide (GSSG) was measured by first reducing it to GSH with glutathione reductase (GR) in the presence of NADPH.">
            <entity id="DS.d591.s0.e0" origId="65359" charOffset="23-44" type="compound" text="glutathione disulfide"/>
            <entity id="DS.d591.s0.e1" origId="65359" charOffset="46-50" type="compound" text="GSSG"/>
            <entity id="DS.d591.s0.e2" origId="124886" charOffset="89-92" type="compound" text="GSH"/>
            <entity id="DS.d591.s0.e3" origId="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655" charOffset="98-119" type="protein" text="glutathione reductase"/>
            <entity id="DS.d591.s0.e4" origId="5884" charOffset="144-149" type="compound" text="NADPH"/>
            <pair e1="DS.d591.s0.e1" e2="DS.d591.s0.e3" id="DS.d591.s0.i0" interaction="True"/>
            <pair e1="DS.d591.s0.e0" e2="DS.d591.s0.e3" id="DS.d591.s0.i1" interaction="True"/>
            <pair e1="DS.d591.s0.e4" e2="DS.d591.s0.e3" id="DS.d591.s0.i2" interaction="True"/>
            <pair e1="DS.d591.s0.e2" e2="DS.d591.s0.e3" id="DS.d591.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d593" origId="18647135">
        <sentence id="DS.d593.s0" origId="18647135-78" text="The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension.">
            <entity id="DS.d593.s0.e0" origId="Q10751" charOffset="4-33" type="protein" text="angiotensin-converting enzyme"/>
            <entity id="DS.d593.s0.e1" origId="5359597" charOffset="120-130" type="compound" text="superoxide"/>
            <pair e1="DS.d593.s0.e1" e2="DS.d593.s0.e0" id="DS.d593.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d594" origId="18648748">
        <sentence id="DS.d594.s0" origId="18648748-1370" text="Administration of hesperetin to DMH treated rats significantly decreased the tumor incidence, the number of aberrant crypt foci with simultaneous enhancement of tissue lipid peroxidation, GST, GPx, SOD, and CAT activities.">
            <entity id="DS.d594.s0.e0" origId="72281" charOffset="18-28" type="compound" text="hesperetin"/>
            <entity id="DS.d594.s0.e1" origId="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52" charOffset="188-191" type="protein" text="GST"/>
            <entity id="DS.d594.s0.e2" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="198-201" type="protein" text="SOD"/>
            <entity id="DS.d594.s0.e3" origId="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7" charOffset="207-210" type="protein" text="CAT"/>
            <pair e1="DS.d594.s0.e0" e2="DS.d594.s0.e2" id="DS.d594.s0.i0" interaction="True"/>
            <pair e1="DS.d594.s0.e0" e2="DS.d594.s0.e1" id="DS.d594.s0.i1" interaction="True"/>
            <pair e1="DS.d594.s0.e0" e2="DS.d594.s0.e3" id="DS.d594.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d595" origId="18648826">
        <sentence id="DS.d595.s0" origId="18648826-1446" text="Culture of mid-segments of hair follicles in low calcium culture medium kept on agarose increased expression of filaggrin and Kdap, but downregulated expression of involucrin.">
            <entity id="DS.d595.s0.e0" origId="11966311" charOffset="80-87" type="compound" text="agarose"/>
            <entity id="DS.d595.s0.e1" origId="P11088,P20930" charOffset="112-121" type="protein" text="filaggrin"/>
            <entity id="DS.d595.s0.e2" origId="O09043" charOffset="126-130" type="protein" text="Kdap"/>
            <entity id="DS.d595.s0.e3" origId="P07476,P14590,P14591,P14708,P17941,P18174,P18175,P24708,P24709,P24710,P24711,P24712,P48997,P48998,Q95337" charOffset="164-174" type="protein" text="involucrin"/>
            <pair e1="DS.d595.s0.e0" e2="DS.d595.s0.e3" id="DS.d595.s0.i0" interaction="False"/>
            <pair e1="DS.d595.s0.e0" e2="DS.d595.s0.e1" id="DS.d595.s0.i1" interaction="False"/>
            <pair e1="DS.d595.s0.e0" e2="DS.d595.s0.e2" id="DS.d595.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d596" origId="18648877">
        <sentence id="DS.d596.s0" origId="18648877-1504" text="The p-hydroxyphenylpyruvate produced by the Escherichia coli host was converted to HGA through the oxidation reaction of introduced HPPD.">
            <entity id="DS.d596.s0.e0" origId="979" charOffset="4-27" type="compound" text="p-hydroxyphenylpyruvate"/>
            <entity id="DS.d596.s0.e1" origId="449178" charOffset="83-86" type="compound" text="HGA"/>
            <entity id="DS.d596.s0.e2" origId="O42764" charOffset="132-136" type="protein" text="HPPD"/>
            <pair e1="DS.d596.s0.e1" e2="DS.d596.s0.e2" id="DS.d596.s0.i0" interaction="True"/>
            <pair e1="DS.d596.s0.e0" e2="DS.d596.s0.e2" id="DS.d596.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d597" origId="18649000">
        <sentence id="DS.d597.s0" origId="18649000-1622" text="The results showed that the intakes of dry matter (DM), organic matter (OM), nitrogen (N), the N-balance, urinary purine derivatives (PD) excretion, the ratios of allantoin to creatinine (CR), PD to CR, the plasma urea-N (PUN) and insulin increased in the animals, but the intake of neutral detergent fiber (NDF), the coefficient of whole tract, apparent digestibility of NDF, the transit time (TT) and the mean retention time (TMRT) decreased, when the proportion of concentrate in the diet increased.">
            <entity id="DS.d597.s0.e0" origId="947,123329" charOffset="77-85" type="compound" text="nitrogen"/>
            <entity id="DS.d597.s0.e1" origId="1044" charOffset="114-120" type="compound" text="purine"/>
            <entity id="DS.d597.s0.e2" origId="204" charOffset="163-172" type="compound" text="allantoin"/>
            <entity id="DS.d597.s0.e3" origId="588" charOffset="176-186" type="compound" text="creatinine"/>
            <entity id="DS.d597.s0.e4" origId="23976" charOffset="188-190" type="compound" text="CR"/>
            <entity id="DS.d597.s0.e5" origId="23976" charOffset="199-201" type="compound" text="CR"/>
            <entity id="DS.d597.s0.e6" origId="1176,265993" charOffset="214-218" type="compound" text="urea"/>
            <entity id="DS.d597.s0.e7" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="231-238" type="protein" text="insulin"/>
            <pair e1="DS.d597.s0.e6" e2="DS.d597.s0.e7" id="DS.d597.s0.i0" interaction="False"/>
            <pair e1="DS.d597.s0.e0" e2="DS.d597.s0.e7" id="DS.d597.s0.i1" interaction="False"/>
            <pair e1="DS.d597.s0.e1" e2="DS.d597.s0.e7" id="DS.d597.s0.i2" interaction="False"/>
            <pair e1="DS.d597.s0.e4" e2="DS.d597.s0.e7" id="DS.d597.s0.i3" interaction="False"/>
            <pair e1="DS.d597.s0.e3" e2="DS.d597.s0.e7" id="DS.d597.s0.i4" interaction="False"/>
            <pair e1="DS.d597.s0.e2" e2="DS.d597.s0.e7" id="DS.d597.s0.i5" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d598" origId="18649135">
        <sentence id="DS.d598.s0" origId="18649135-39" text="Activation of interleukin-6/STAT3 in rat cholangiocyte proliferation induced by lipopolysaccharide.">
            <entity id="DS.d598.s0.e0" origId="P41693" charOffset="14-27" type="protein" text="interleukin-6"/>
            <entity id="DS.d598.s0.e1" origId="P40763,P61635" charOffset="28-33" type="protein" text="STAT3"/>
            <entity id="DS.d598.s0.e2" origId="11970143" charOffset="80-98" type="compound" text="lipopolysaccharide"/>
            <pair e1="DS.d598.s0.e2" e2="DS.d598.s0.e1" id="DS.d598.s0.i0" interaction="True"/>
            <pair e1="DS.d598.s0.e2" e2="DS.d598.s0.e0" id="DS.d598.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d599" origId="18650080">
        <sentence id="DS.d599.s1" origId="18650080-816" text="To investigate the activation pathways triggered by laccase, ESR spin-trapping techniques using N-tert-butyl-alpha-phenylnitrone (PBN) as spin trap followed by ethyl acetate extraction were employed to identify and quantify the free radical intermediates.">
            <entity id="DS.d599.s1.e0" origId="Q12570" charOffset="52-59" type="protein" text="laccase"/>
            <entity id="DS.d599.s1.e1" origId="8857" charOffset="160-173" type="compound" text="ethyl acetate"/>
            <pair e1="DS.d599.s1.e1" e2="DS.d599.s1.e0" id="DS.d599.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d600" origId="18650805">
        <sentence id="DS.d600.s0" origId="18650805-1377" text="Methylation of these CpG sites may lead to reduced OPRM1 expression in the lymphocytes of these former heroin addicts.">
            <entity id="DS.d600.s0.e0" origId="6804" charOffset="21-24" type="compound" text="CpG"/>
            <entity id="DS.d600.s0.e1" origId="P35372,P79350,P97266,Q5IS39,Q5IS84,Q95247,Q95M54,Q9MYW9" charOffset="51-56" type="protein" text="OPRM1"/>
            <pair e1="DS.d600.s0.e0" e2="DS.d600.s0.e1" id="DS.d600.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d601" origId="18651093">
        <sentence id="DS.d601.s0" origId="18651093-1447" text="Two infants with elevated serum gamma-GT had a decreased serum glutamine.">
            <entity id="DS.d601.s0.e0" origId="Q05902" charOffset="32-40" type="protein" text="gamma-GT"/>
            <entity id="DS.d601.s0.e1" origId="738,5961" charOffset="63-72" type="compound" text="glutamine"/>
            <pair e1="DS.d601.s0.e1" e2="DS.d601.s0.e0" id="DS.d601.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d602" origId="18651113">
        <sentence id="DS.d602.s0" origId="18651113-1681" text="Human bone marrow-derived mesenchymal stem cells and osteoblast differentiation on titanium with surface-grafted chitosan and immobilized bone morphogenetic protein-2.">
            <entity id="DS.d602.s0.e0" origId="23963" charOffset="83-91" type="compound" text="titanium"/>
            <entity id="DS.d602.s0.e1" origId="P07580" charOffset="143-164" type="protein" text="morphogenetic protein"/>
            <pair e1="DS.d602.s0.e0" e2="DS.d602.s0.e1" id="DS.d602.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d603" origId="18651133">
        <sentence id="DS.d603.s0" origId="18651133-1703" text="None of the compounds altered Cyp11b1 gene expression, indicating that 3-MeSO2-DDE inhibits CYP11B1 activity on the protein level.">
            <entity id="DS.d603.s0.e0" origId="P15393" charOffset="30-37" type="protein" text="Cyp11b1"/>
            <entity id="DS.d603.s0.e1" origId="119115" charOffset="73-82" type="compound" text="MeSO2-DDE"/>
            <entity id="DS.d603.s0.e2" origId="P15150,P15538,P51663,P97720,Q29527,Q29552,Q64408" charOffset="92-99" type="protein" text="CYP11B1"/>
            <pair e1="DS.d603.s0.e1" e2="DS.d603.s0.e0" id="DS.d603.s0.i0" interaction="False"/>
            <pair e1="DS.d603.s0.e1" e2="DS.d603.s0.e2" id="DS.d603.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d604" origId="18651191">
        <sentence id="DS.d604.s0" origId="18651191-669" text="Functional analysis demonstrated that elkj encoded a C20-elongase that mediated the elongation of EPA into docosapentaenoic acid (22:5n-3), confirming the two-step conversion from EPA to DHA in marine microalga.">
            <entity id="DS.d604.s0.e0" origId="Q9SDN0" charOffset="53-56" type="protein" text="C20"/>
            <entity id="DS.d604.s0.e1" origId="3145,5497182,6441454" charOffset="107-128" type="compound" text="docosapentaenoic acid"/>
            <pair e1="DS.d604.s0.e1" e2="DS.d604.s0.e0" id="DS.d604.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d605" origId="18651838">
        <sentence id="DS.d605.s0" origId="18651838-564" text="ANP (atrial natriuretic peptide) exerts its biological effects by binding to GC (guanylate cyclase)-A/NPR (natriuretic peptide receptor)-A, which generates the second messenger cGMP.">
            <entity id="DS.d605.s0.e0" origId="O46540,P01160,P01161,P05125,P07499,P07500,P07501,P09196,P18144,P18908,P18909,P24259,P27104,P27596,P83964,Q805D8,Q805E9,Q9GLD0" charOffset="0-3" type="protein" text="ANP"/>
            <entity id="DS.d605.s0.e1" origId="O46540,P01160,P01161,P05125,P07499,P07500,P07501,P09196,P18144,P18908,P18909,P24259,P27104,P27596,P83964,Q805D8,Q805E9,Q9GLD0" charOffset="5-31" type="protein" text="atrial natriuretic peptide"/>
            <entity id="DS.d605.s0.e2" origId="O94303,P33734,Q9P4P9,Q9SZ30" charOffset="91-98" type="protein" text="cyclase"/>
            <entity id="DS.d605.s0.e3" origId="P20910,Q41249" charOffset="102-105" type="protein" text="NPR"/>
            <entity id="DS.d605.s0.e4" origId="P28374" charOffset="12-31" type="protein" text="natriuretic peptide"/>
            <entity id="DS.d605.s0.e5" origId="24316" charOffset="177-181" type="compound" text="cGMP"/>
            <pair e1="DS.d605.s0.e5" e2="DS.d605.s0.e2" id="DS.d605.s0.i0" interaction="True"/>
            <pair e1="DS.d605.s0.e5" e2="DS.d605.s0.e0" id="DS.d605.s0.i1" interaction="True"/>
            <pair e1="DS.d605.s0.e5" e2="DS.d605.s0.e3" id="DS.d605.s0.i2" interaction="True"/>
            <pair e1="DS.d605.s0.e5" e2="DS.d605.s0.e4" id="DS.d605.s0.i3" interaction="True"/>
            <pair e1="DS.d605.s0.e5" e2="DS.d605.s0.e1" id="DS.d605.s0.i4" interaction="True"/>
        </sentence>
        <sentence id="DS.d605.s1" origId="18651838-565" text="Overexpression of Ets-1 enhanced significantly Npr1 mRNA levels, protein expression, GC activity and ANP-stimulated intracellular accumulation of cGMP in transfected cells.">
            <entity id="DS.d605.s1.e0" origId="P27577,P41156" charOffset="18-23" type="protein" text="Ets-1"/>
            <entity id="DS.d605.s1.e1" origId="P18293,P18910" charOffset="47-51" type="protein" text="Npr1"/>
            <entity id="DS.d605.s1.e2" origId="O46540,P01160,P01161,P05125,P07499,P07500,P07501,P09196,P18144,P18908,P18909,P24259,P27104,P27596,P83964,Q805D8,Q805E9,Q9GLD0" charOffset="101-104" type="protein" text="ANP"/>
            <entity id="DS.d605.s1.e3" origId="24316" charOffset="146-150" type="compound" text="cGMP"/>
            <pair e1="DS.d605.s1.e3" e2="DS.d605.s1.e1" id="DS.d605.s1.i0" interaction="False"/>
            <pair e1="DS.d605.s1.e3" e2="DS.d605.s1.e2" id="DS.d605.s1.i1" interaction="True"/>
            <pair e1="DS.d605.s1.e3" e2="DS.d605.s1.e0" id="DS.d605.s1.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d606" origId="18652538">
        <sentence id="DS.d606.s0" origId="18652538-1158" text="In the current study, these cells were cultured with three different media: &quot; BMP-plus&quot; medium containing dexamethasone and 100 ng/mL of rhBMP-2, &quot;odontogenic&quot; medium containing dexamethasone, and &quot;control&quot; medium without supplements.">
            <entity id="DS.d606.s0.e0" origId="P35855" charOffset="78-81" type="protein" text="BMP"/>
            <entity id="DS.d606.s0.e1" origId="5743" charOffset="106-119" type="compound" text="dexamethasone"/>
            <entity id="DS.d606.s0.e2" origId="5743" charOffset="178-191" type="compound" text="dexamethasone"/>
            <pair e1="DS.d606.s0.e1" e2="DS.d606.s0.e0" id="DS.d606.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d607" origId="18652864">
        <sentence id="DS.d607.s0" origId="18652864-1389" text="The allatostatins (ASTs), with a Tyr/Phe-Xaa-Phe-Gly-Leu/Ile-amide C-terminus, are neuropeptides that occur in many orders of insects, but are known to inhibit juvenile hormone (JH) synthesis by corpora allata (CA) only in cockroaches, crickets, and termites.">
            <entity id="DS.d607.s0.e0" origId="P42559" charOffset="4-17" type="protein" text="allatostatins"/>
            <entity id="DS.d607.s0.e1" origId="P0AE37,P0AE38,P80357,P80358,Q0TH83,Q1C8B0,Q1RB46,Q321N9,Q32G89,Q3Z294,Q5PHB9,Q66B20,Q7N2G8,Q83L52,Q8FH00,Q8Z6G0,Q8ZPV1,Q9NRA2,Q9ZC67" charOffset="19-23" type="protein" text="ASTs"/>
            <entity id="DS.d607.s0.e2" origId="P21259" charOffset="83-96" type="protein" text="neuropeptides"/>
            <entity id="DS.d607.s0.e3" origId="6439662" charOffset="160-176" type="compound" text="juvenile hormone"/>
            <pair e1="DS.d607.s0.e3" e2="DS.d607.s0.e1" id="DS.d607.s0.i0" interaction="True"/>
            <pair e1="DS.d607.s0.e3" e2="DS.d607.s0.e0" id="DS.d607.s0.i1" interaction="True"/>
            <pair e1="DS.d607.s0.e3" e2="DS.d607.s0.e2" id="DS.d607.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d608" origId="18652909">
        <sentence id="DS.d608.s0" origId="18652909-1018" text="Lecithin:retinol acyltransferase (LRAT) catalyzes the esterification of retinol (vitamin A).">
            <entity id="DS.d608.s0.e1" origId="O95237,Q9BGL2" charOffset="34-38" type="protein" text="LRAT"/>
            <entity id="DS.d608.s0.e2" origId="445354" charOffset="81-90" type="compound" text="vitamin A"/>
            <pair e1="DS.d608.s0.e2" e2="DS.d608.s0.e1" id="DS.d608.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d608.s1" origId="18652909-1019" text="Retinoic acid (RA) treatment increased this LRAT promoter-luciferase activity in PrEC cells, but not in PC-3 cells.">
            <entity id="DS.d608.s1.e0" origId="444795" charOffset="0-13" type="compound" text="Retinoic acid"/>
            <entity id="DS.d608.s1.e1" origId="O95237,Q9BGL2" charOffset="44-48" type="protein" text="LRAT"/>
            <entity id="DS.d608.s1.e2" origId="P08659,P13129,Q01158,Q26304,Q27757" charOffset="58-68" type="protein" text="luciferase"/>
            <pair e1="DS.d608.s1.e0" e2="DS.d608.s1.e1" id="DS.d608.s1.i0" interaction="True"/>
            <pair e1="DS.d608.s1.e0" e2="DS.d608.s1.e2" id="DS.d608.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d609" origId="18654608">
        <sentence id="DS.d609.s0" origId="18654608-1184" text="As multidrug resistance (MDR) is a major problem in the chemotherapy of progressive breast cancer, the in vitro effects of Ad-REIC treatment were investigated in terms of the sensitivity of multidrug-resistant MCF7/ADR cells to doxorubicin and of the P-glycoprotein expression.">
            <entity id="DS.d609.s0.e0" origId="Q9UBP4" charOffset="126-130" type="protein" text="REIC"/>
            <entity id="DS.d609.s0.e1" origId="31703" charOffset="228-239" type="compound" text="doxorubicin"/>
            <entity id="DS.d609.s0.e2" origId="P08163" charOffset="253-265" type="protein" text="glycoprotein"/>
            <pair e1="DS.d609.s0.e1" e2="DS.d609.s0.e2" id="DS.d609.s0.i0" interaction="False"/>
            <pair e1="DS.d609.s0.e1" e2="DS.d609.s0.e0" id="DS.d609.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d609.s1" origId="18654608-1185" text="Ad-REIC treatment in MCF7/ADR cells also downregulated P-glycoprotein expresssion through JNK activation, and sensitized its drug resistance against doxorubicin.">
            <entity id="DS.d609.s1.e0" origId="Q9UBP4" charOffset="3-7" type="protein" text="REIC"/>
            <entity id="DS.d609.s1.e1" origId="P08163" charOffset="57-69" type="protein" text="glycoprotein"/>
            <entity id="DS.d609.s1.e2" origId="P92208,Q966Y3" charOffset="90-93" type="protein" text="JNK"/>
            <entity id="DS.d609.s1.e3" origId="31703" charOffset="149-160" type="compound" text="doxorubicin"/>
            <pair e1="DS.d609.s1.e3" e2="DS.d609.s1.e2" id="DS.d609.s1.i0" interaction="False"/>
            <pair e1="DS.d609.s1.e3" e2="DS.d609.s1.e1" id="DS.d609.s1.i1" interaction="False"/>
            <pair e1="DS.d609.s1.e3" e2="DS.d609.s1.e0" id="DS.d609.s1.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d610" origId="18654747">
        <sentence id="DS.d610.s0" origId="18654747-1289" text="Diflomotecan, a homocamptothecin, targets DNA topoisomerase I.">
            <entity id="DS.d610.s0.e0" origId="219023" charOffset="0-12" type="compound" text="Diflomotecan"/>
            <entity id="DS.d610.s0.e1" origId="O27661,O28469,O34204,O51768,O58356,O66893,O69548,O73954,O83409,P04786,P06612,P07799,P0A2I1,P0A2I2,P0A620,P0A621,P11387,P16472,P30181,P30189,P32989,P34184,P34185,P39814,P40114,P41511,P41512,P43012,P46155,P46799,P47368,P55991,P57371,P68697,P68698,P73810,P78032,P93119,Q00313,Q04750,Q07050,Q59046,Q76ZS7,Q7YR26,Q87AQ6,Q8K9P7,Q92IH1,Q9CG80,Q9CN30,Q9HM08,Q9HZJ5,Q9JN65,Q9KA23,Q9KRB2,Q9PEV8,Q9PLZ2,Q9UYS8,Q9WUL0,Q9X3X7,Q9X909,Q9YB01,Q9ZDK2,Q9ZMV7" charOffset="42-61" type="protein" text="DNA topoisomerase I"/>
            <pair e1="DS.d610.s0.e0" e2="DS.d610.s0.e1" id="DS.d610.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d611" origId="18654835">
        <sentence id="DS.d611.s0" origId="18654835-1331" text="Both MudPIT and cDNA microarray analyses indicate that H2O2 treatment caused elevated levels of thioredoxin reductase 1.">
            <entity id="DS.d611.s0.e0" origId="784" charOffset="55-59" type="compound" text="H2O2"/>
            <entity id="DS.d611.s0.e1" origId="P29509,Q17745,Q39243" charOffset="96-119" type="protein" text="thioredoxin reductase 1"/>
            <pair e1="DS.d611.s0.e0" e2="DS.d611.s0.e1" id="DS.d611.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d612" origId="18655070">
        <sentence id="DS.d612.s0" origId="18655070-1550" text="Altogether these changes offer a straightforward explanation for how following the addition of Ca(2+), the coelenterazine could escape and become available for bioluminescence on Renilla luciferase.">
            <entity id="DS.d612.s0.e0" origId="271" charOffset="95-99" type="compound" text="Ca(2"/>
            <entity id="DS.d612.s0.e1" origId="2830" charOffset="107-121" type="compound" text="coelenterazine"/>
            <entity id="DS.d612.s0.e2" origId="P08659,P13129,Q01158,Q26304,Q27757" charOffset="187-197" type="protein" text="luciferase"/>
            <pair e1="DS.d612.s0.e1" e2="DS.d612.s0.e2" id="DS.d612.s0.i0" interaction="True"/>
            <pair e1="DS.d612.s0.e0" e2="DS.d612.s0.e2" id="DS.d612.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d613" origId="18655138">
        <sentence id="DS.d613.s0" origId="18655138-1615" text="The APTS functionalization was then used to immobilize bone morphogenetic protein on the bioactive glasses.">
            <entity id="DS.d613.s0.e0" origId="4346576" charOffset="4-8" type="compound" text="APTS"/>
            <entity id="DS.d613.s0.e1" origId="P07580" charOffset="60-81" type="protein" text="morphogenetic protein"/>
            <pair e1="DS.d613.s0.e0" e2="DS.d613.s0.e1" id="DS.d613.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d614" origId="18655158">
        <sentence id="DS.d614.s0" origId="18655158-1630" text="L-Kynurenine (KYN), a tryptophan metabolite, is metabolized to kynurenic acid (KYNA), which is an antagonist of N-methyl-D-aspartate and alpha7 nicotinic acetylcholine receptors, by kynurenine aminotransferase (KAT) I and KAT II.">
            <entity id="DS.d614.s0.e0" origId="846" charOffset="2-12" type="compound" text="Kynurenine"/>
            <entity id="DS.d614.s0.e1" origId="161166" charOffset="14-17" type="compound" text="KYN"/>
            <entity id="DS.d614.s0.e2" origId="1148,6305,9060,5460840" charOffset="22-32" type="compound" text="tryptophan"/>
            <entity id="DS.d614.s0.e3" origId="3845" charOffset="63-77" type="compound" text="kynurenic acid"/>
            <entity id="DS.d614.s0.e4" origId="3845" charOffset="79-83" type="compound" text="KYNA"/>
            <entity id="DS.d614.s0.e5" origId="846" charOffset="182-192" type="compound" text="kynurenine"/>
            <entity id="DS.d614.s0.e6" origId="Q8NFU3" charOffset="211-214" type="protein" text="KAT"/>
            <entity id="DS.d614.s0.e7" origId="Q8NFU3" charOffset="222-225" type="protein" text="KAT"/>
            <pair e1="DS.d614.s0.e4" e2="DS.d614.s0.e6" id="DS.d614.s0.i0" interaction="True"/>
            <pair e1="DS.d614.s0.e1" e2="DS.d614.s0.e6" id="DS.d614.s0.i1" interaction="True"/>
            <pair e1="DS.d614.s0.e0" e2="DS.d614.s0.e6" id="DS.d614.s0.i2" interaction="True"/>
            <pair e1="DS.d614.s0.e3" e2="DS.d614.s0.e6" id="DS.d614.s0.i3" interaction="True"/>
            <pair e1="DS.d614.s0.e2" e2="DS.d614.s0.e6" id="DS.d614.s0.i4" interaction="False"/>
            <pair e1="DS.d614.s0.e5" e2="DS.d614.s0.e6" id="DS.d614.s0.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d615" origId="18655176">
        <sentence id="DS.d615.s0" origId="18655176-1654" text="Exposure to benzo(a)pyrene (BaP) by intraperitoneal injection increased biliary BaP metabolites and liver CYP1A gene expression.">
            <entity id="DS.d615.s0.e0" origId="2336" charOffset="12-26" type="compound" text="benzo(a)pyrene"/>
            <entity id="DS.d615.s0.e1" origId="Q6JZS3,Q92039,Q9YH64" charOffset="106-111" type="protein" text="CYP1A"/>
            <pair e1="DS.d615.s0.e0" e2="DS.d615.s0.e1" id="DS.d615.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d616" origId="18655177">
        <sentence id="DS.d616.s0" origId="18655177-1378" text="We examined the effect of several different doses of malathion (25, 75, 200 microM), or malathion in combination with vitamin C (VC; 10 microM) or vitamin E (VE; 30 microM), on the levels of malondialdehyde (MDA), and superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activities in human erythrocytes in vitro.">
            <entity id="DS.d616.s0.e0" origId="4004" charOffset="53-62" type="compound" text="malathion"/>
            <entity id="DS.d616.s0.e1" origId="4004" charOffset="88-97" type="compound" text="malathion"/>
            <entity id="DS.d616.s0.e2" origId="54670067" charOffset="118-127" type="compound" text="vitamin C"/>
            <entity id="DS.d616.s0.e3" origId="2116,14985,1548900,1742129" charOffset="147-156" type="compound" text="vitamin E"/>
            <entity id="DS.d616.s0.e4" origId="10964" charOffset="191-206" type="compound" text="malondialdehyde"/>
            <entity id="DS.d616.s0.e5" origId="O50258" charOffset="218-238" type="protein" text="superoxide dismutase"/>
            <entity id="DS.d616.s0.e6" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="240-243" type="protein" text="SOD"/>
            <entity id="DS.d616.s0.e7" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="246-254" type="protein" text="catalase"/>
            <entity id="DS.d616.s0.e8" origId="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7" charOffset="256-259" type="protein" text="CAT"/>
            <entity id="DS.d616.s0.e9" origId="O32770,O59858,Q00277,Q9CFV1" charOffset="266-288" type="protein" text="glutathione peroxidase"/>
            <pair e1="DS.d616.s0.e3" e2="DS.d616.s0.e8" id="DS.d616.s0.i0" interaction="False"/>
            <pair e1="DS.d616.s0.e4" e2="DS.d616.s0.e7" id="DS.d616.s0.i1" interaction="False"/>
            <pair e1="DS.d616.s0.e2" e2="DS.d616.s0.e8" id="DS.d616.s0.i2" interaction="False"/>
            <pair e1="DS.d616.s0.e0" e2="DS.d616.s0.e9" id="DS.d616.s0.i3" interaction="False"/>
            <pair e1="DS.d616.s0.e3" e2="DS.d616.s0.e5" id="DS.d616.s0.i4" interaction="False"/>
            <pair e1="DS.d616.s0.e3" e2="DS.d616.s0.e7" id="DS.d616.s0.i5" interaction="False"/>
            <pair e1="DS.d616.s0.e2" e2="DS.d616.s0.e6" id="DS.d616.s0.i6" interaction="False"/>
            <pair e1="DS.d616.s0.e3" e2="DS.d616.s0.e6" id="DS.d616.s0.i7" interaction="False"/>
            <pair e1="DS.d616.s0.e0" e2="DS.d616.s0.e5" id="DS.d616.s0.i8" interaction="False"/>
            <pair e1="DS.d616.s0.e4" e2="DS.d616.s0.e6" id="DS.d616.s0.i9" interaction="False"/>
            <pair e1="DS.d616.s0.e4" e2="DS.d616.s0.e9" id="DS.d616.s0.i10" interaction="False"/>
            <pair e1="DS.d616.s0.e2" e2="DS.d616.s0.e7" id="DS.d616.s0.i11" interaction="False"/>
            <pair e1="DS.d616.s0.e0" e2="DS.d616.s0.e8" id="DS.d616.s0.i12" interaction="False"/>
            <pair e1="DS.d616.s0.e0" e2="DS.d616.s0.e6" id="DS.d616.s0.i13" interaction="False"/>
            <pair e1="DS.d616.s0.e4" e2="DS.d616.s0.e8" id="DS.d616.s0.i14" interaction="False"/>
            <pair e1="DS.d616.s0.e0" e2="DS.d616.s0.e7" id="DS.d616.s0.i15" interaction="False"/>
            <pair e1="DS.d616.s0.e4" e2="DS.d616.s0.e5" id="DS.d616.s0.i16" interaction="False"/>
            <pair e1="DS.d616.s0.e2" e2="DS.d616.s0.e9" id="DS.d616.s0.i17" interaction="False"/>
            <pair e1="DS.d616.s0.e3" e2="DS.d616.s0.e9" id="DS.d616.s0.i18" interaction="False"/>
            <pair e1="DS.d616.s0.e2" e2="DS.d616.s0.e5" id="DS.d616.s0.i19" interaction="False"/>
        </sentence>
        <sentence id="DS.d616.s1" origId="18655177-1379" text="Erythrocytes were incubated under various treatment conditions (malathion alone, vitamins alone, or malathion plus vitamin) at 37 degrees C for 60 min, and the levels of MDA, and SOD, CAT and GPx activities, were determined.">
            <entity id="DS.d616.s1.e0" origId="4004" charOffset="64-73" type="compound" text="malathion"/>
            <entity id="DS.d616.s1.e1" origId="4004" charOffset="100-109" type="compound" text="malathion"/>
            <entity id="DS.d616.s1.e2" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="179-182" type="protein" text="SOD"/>
            <entity id="DS.d616.s1.e3" origId="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7" charOffset="184-187" type="protein" text="CAT"/>
            <pair e1="DS.d616.s1.e0" e2="DS.d616.s1.e3" id="DS.d616.s1.i0" interaction="True"/>
            <pair e1="DS.d616.s1.e0" e2="DS.d616.s1.e2" id="DS.d616.s1.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d616.s2" origId="18655177-1380" text="Treatment with malathion alone increased the levels of MDA and decreased SOD, CAT 0.05).">
            <entity id="DS.d616.s2.e0" origId="4004" charOffset="15-24" type="compound" text="malathion"/>
            <entity id="DS.d616.s2.e1" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="73-76" type="protein" text="SOD"/>
            <entity id="DS.d616.s2.e2" origId="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7" charOffset="78-81" type="protein" text="CAT"/>
            <pair e1="DS.d616.s2.e0" e2="DS.d616.s2.e2" id="DS.d616.s2.i0" interaction="True"/>
            <pair e1="DS.d616.s2.e0" e2="DS.d616.s2.e1" id="DS.d616.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d617" origId="18655190">
        <sentence id="DS.d617.s0" origId="18655190-1668" text="Adrenomedullin reduces antioxidant defense system and enhances kidney tissue damage in cadmium and lead exposed rats.">
            <entity id="DS.d617.s0.e0" origId="O62827,O77559,P35318,P43145,P53366,P97297" charOffset="0-14" type="protein" text="Adrenomedullin"/>
            <entity id="DS.d617.s0.e1" origId="23973" charOffset="87-94" type="compound" text="cadmium"/>
            <pair e1="DS.d617.s0.e1" e2="DS.d617.s0.e0" id="DS.d617.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d617.s1" origId="18655190-1669" text="In the present study, we investigated the effect of AdM, Pb+ AdM, and Cd+ AdM treatments on superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) activities as well as the level of malondialdehyde (MDA) in the kidney.">
            <entity id="DS.d617.s1.e0" origId="O50258" charOffset="92-112" type="protein" text="superoxide dismutase"/>
            <entity id="DS.d617.s1.e1" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="114-117" type="protein" text="SOD"/>
            <entity id="DS.d617.s1.e2" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="120-128" type="protein" text="catalase"/>
            <entity id="DS.d617.s1.e3" origId="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7" charOffset="130-133" type="protein" text="CAT"/>
            <entity id="DS.d617.s1.e4" origId="O32770,O59858,Q00277,Q9CFV1" charOffset="140-162" type="protein" text="glutathione peroxidase"/>
            <entity id="DS.d617.s1.e5" origId="124886" charOffset="164-167" type="compound" text="GSH"/>
            <entity id="DS.d617.s1.e6" origId="10964" charOffset="207-222" type="compound" text="malondialdehyde"/>
            <pair e1="DS.d617.s1.e5" e2="DS.d617.s1.e1" id="DS.d617.s1.i0" interaction="False"/>
            <pair e1="DS.d617.s1.e5" e2="DS.d617.s1.e4" id="DS.d617.s1.i1" interaction="False"/>
            <pair e1="DS.d617.s1.e5" e2="DS.d617.s1.e0" id="DS.d617.s1.i2" interaction="False"/>
            <pair e1="DS.d617.s1.e6" e2="DS.d617.s1.e1" id="DS.d617.s1.i3" interaction="False"/>
            <pair e1="DS.d617.s1.e6" e2="DS.d617.s1.e4" id="DS.d617.s1.i4" interaction="False"/>
            <pair e1="DS.d617.s1.e5" e2="DS.d617.s1.e3" id="DS.d617.s1.i5" interaction="False"/>
            <pair e1="DS.d617.s1.e6" e2="DS.d617.s1.e3" id="DS.d617.s1.i6" interaction="False"/>
            <pair e1="DS.d617.s1.e5" e2="DS.d617.s1.e2" id="DS.d617.s1.i7" interaction="False"/>
            <pair e1="DS.d617.s1.e6" e2="DS.d617.s1.e0" id="DS.d617.s1.i8" interaction="False"/>
            <pair e1="DS.d617.s1.e6" e2="DS.d617.s1.e2" id="DS.d617.s1.i9" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d618" origId="18655797">
        <sentence id="DS.d618.s0" origId="18655797-440" text="We found that Fos expression in LH orexin neurons varied in proportion to preference for morphine, cocaine or food.">
            <entity id="DS.d618.s0.e0" origId="P01101,P12841,Q56415" charOffset="14-17" type="protein" text="Fos"/>
            <entity id="DS.d618.s0.e1" origId="5288826,5479215" charOffset="89-97" type="compound" text="morphine"/>
            <entity id="DS.d618.s0.e2" origId="2826,5760,439497,446220,644017,54613779" charOffset="99-106" type="compound" text="cocaine"/>
            <pair e1="DS.d618.s0.e2" e2="DS.d618.s0.e0" id="DS.d618.s0.i0" interaction="True"/>
            <pair e1="DS.d618.s0.e1" e2="DS.d618.s0.e0" id="DS.d618.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d618.s1" origId="18655797-441" text="Recent studies showed that LH orexin neurons that project to ventral tegmental area (VTA) have greater Fos induction in association with elevated morphine preference during protracted withdrawal than non-VTA-projecting orexin neurons, indicating that the VTA is an important site of action for orexin's role in reward processing.">
            <entity id="DS.d618.s1.e0" origId="P01101,P12841,Q56415" charOffset="103-106" type="protein" text="Fos"/>
            <entity id="DS.d618.s1.e1" origId="5288826,5479215" charOffset="146-154" type="compound" text="morphine"/>
            <pair e1="DS.d618.s1.e1" e2="DS.d618.s1.e0" id="DS.d618.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d619" origId="18655808">
        <sentence id="DS.d619.s0" origId="18655808-447" text="Cytochromes c are metalloproteins that function in electron transfer reactions and contain a heme moiety covalently attached via thioether linkages between the co-factor and a CXXCH motif in the protein.">
            <entity id="DS.d619.s0.e0" origId="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3" charOffset="0-13" type="protein" text="Cytochromes c"/>
            <entity id="DS.d619.s0.e1" origId="4971" charOffset="93-97" type="compound" text="heme"/>
            <pair e1="DS.d619.s0.e1" e2="DS.d619.s0.e0" id="DS.d619.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d620" origId="18655848">
        <sentence id="DS.d620.s0" origId="18655848-489" text="The antioxidant roles of selenium (Se) were evaluated in Brycon cephalus exposed to 2 mg L(-1) of Folisuper 600 BR (MP commercial formulation-MPc, 600 g L(-1)) for 96 h. Catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), glutathione S-transferase (GST), reduced glutathione (GSH) and lipid peroxidation (LPO) levels in the gills, white muscle and liver were evaluated in fish fed on diets containing 0 or 1.5 mg Se kg(-1) for 8 weeks.">
            <entity id="DS.d620.s0.e0" origId="6326970" charOffset="25-33" type="compound" text="selenium"/>
            <entity id="DS.d620.s0.e1" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="170-178" type="protein" text="Catalase"/>
            <entity id="DS.d620.s0.e2" origId="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7" charOffset="180-183" type="protein" text="CAT"/>
            <entity id="DS.d620.s0.e3" origId="O32770,O59858,Q00277,Q9CFV1" charOffset="186-208" type="protein" text="glutathione peroxidase"/>
            <entity id="DS.d620.s0.e4" origId="O50258" charOffset="216-236" type="protein" text="superoxide dismutase"/>
            <entity id="DS.d620.s0.e5" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="238-241" type="protein" text="SOD"/>
            <entity id="DS.d620.s0.e6" origId="O04437,O18598,P0A9D2,P0A9D3,P30116,P44521,P46088,P46419,P46423,P46426,P46428,P46437,P48438,P80894,P81065,P82996,P82997,P82998,P82999,P83000,P83001,P83246,Q04522,Q08392,Q08393,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52,Q96324" charOffset="244-269" type="protein" text="glutathione S-transferase"/>
            <entity id="DS.d620.s0.e7" origId="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52" charOffset="271-274" type="protein" text="GST"/>
            <entity id="DS.d620.s0.e8" origId="124886" charOffset="277-296" type="compound" text="reduced glutathione"/>
            <entity id="DS.d620.s0.e9" origId="124886" charOffset="298-301" type="compound" text="GSH"/>
            <pair e1="DS.d620.s0.e0" e2="DS.d620.s0.e6" id="DS.d620.s0.i0" interaction="False"/>
            <pair e1="DS.d620.s0.e9" e2="DS.d620.s0.e6" id="DS.d620.s0.i1" interaction="False"/>
            <pair e1="DS.d620.s0.e8" e2="DS.d620.s0.e1" id="DS.d620.s0.i2" interaction="False"/>
            <pair e1="DS.d620.s0.e9" e2="DS.d620.s0.e5" id="DS.d620.s0.i3" interaction="False"/>
            <pair e1="DS.d620.s0.e9" e2="DS.d620.s0.e3" id="DS.d620.s0.i4" interaction="False"/>
            <pair e1="DS.d620.s0.e0" e2="DS.d620.s0.e1" id="DS.d620.s0.i5" interaction="False"/>
            <pair e1="DS.d620.s0.e8" e2="DS.d620.s0.e3" id="DS.d620.s0.i6" interaction="False"/>
            <pair e1="DS.d620.s0.e8" e2="DS.d620.s0.e7" id="DS.d620.s0.i7" interaction="False"/>
            <pair e1="DS.d620.s0.e0" e2="DS.d620.s0.e2" id="DS.d620.s0.i8" interaction="False"/>
            <pair e1="DS.d620.s0.e9" e2="DS.d620.s0.e4" id="DS.d620.s0.i9" interaction="False"/>
            <pair e1="DS.d620.s0.e0" e2="DS.d620.s0.e7" id="DS.d620.s0.i10" interaction="False"/>
            <pair e1="DS.d620.s0.e8" e2="DS.d620.s0.e5" id="DS.d620.s0.i11" interaction="False"/>
            <pair e1="DS.d620.s0.e9" e2="DS.d620.s0.e2" id="DS.d620.s0.i12" interaction="False"/>
            <pair e1="DS.d620.s0.e0" e2="DS.d620.s0.e3" id="DS.d620.s0.i13" interaction="False"/>
            <pair e1="DS.d620.s0.e8" e2="DS.d620.s0.e2" id="DS.d620.s0.i14" interaction="False"/>
            <pair e1="DS.d620.s0.e9" e2="DS.d620.s0.e1" id="DS.d620.s0.i15" interaction="False"/>
            <pair e1="DS.d620.s0.e9" e2="DS.d620.s0.e7" id="DS.d620.s0.i16" interaction="False"/>
            <pair e1="DS.d620.s0.e0" e2="DS.d620.s0.e4" id="DS.d620.s0.i17" interaction="False"/>
            <pair e1="DS.d620.s0.e0" e2="DS.d620.s0.e5" id="DS.d620.s0.i18" interaction="False"/>
            <pair e1="DS.d620.s0.e8" e2="DS.d620.s0.e6" id="DS.d620.s0.i19" interaction="False"/>
            <pair e1="DS.d620.s0.e8" e2="DS.d620.s0.e4" id="DS.d620.s0.i20" interaction="False"/>
        </sentence>
        <sentence id="DS.d620.s1" origId="18655848-490" text="MPc also increased GST activity in all tissues with a concurrent decrease in GSH levels.">
            <entity id="DS.d620.s1.e0" origId="P20432,P30104,P30106,P30107,P30108,Q04522,Q0ZS46,Q7REH6,Q8ILQ7,Q8MU52" charOffset="19-22" type="protein" text="GST"/>
            <entity id="DS.d620.s1.e1" origId="124886" charOffset="77-80" type="compound" text="GSH"/>
            <pair e1="DS.d620.s1.e1" e2="DS.d620.s1.e0" id="DS.d620.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d621" origId="18656273">
        <sentence id="DS.d621.s0" origId="18656273-863" text="Resveratrol reverses ET-1-evoked mitogenic effects in human coronary arterial cells by activating the kinase-G to inhibit ERK-enzymes.">
            <entity id="DS.d621.s0.e0" origId="445154" charOffset="0-11" type="compound" text="Resveratrol"/>
            <entity id="DS.d621.s0.e1" origId="P05305,P09558,P13206,P17322,P22387,P22388,P29560,P97740,Q28469,Q5NRP9,Q5NRQ1,Q9BG76" charOffset="21-25" type="protein" text="ET-1"/>
            <entity id="DS.d621.s0.e2" origId="P29323" charOffset="122-125" type="protein" text="ERK"/>
            <pair e1="DS.d621.s0.e0" e2="DS.d621.s0.e2" id="DS.d621.s0.i0" interaction="True"/>
            <pair e1="DS.d621.s0.e0" e2="DS.d621.s0.e1" id="DS.d621.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d621.s1" origId="18656273-864" text="Pretreatment with the MEK-ERK inhibitor (PD98059) appreciably reversed the mitogenic effects of ET-1.">
            <entity id="DS.d621.s1.e0" origId="4713" charOffset="41-48" type="compound" text="PD98059"/>
            <entity id="DS.d621.s1.e1" origId="P05305,P09558,P13206,P17322,P22387,P22388,P29560,P97740,Q28469,Q5NRP9,Q5NRQ1,Q9BG76" charOffset="96-100" type="protein" text="ET-1"/>
            <pair e1="DS.d621.s1.e0" e2="DS.d621.s1.e1" id="DS.d621.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d621.s2" origId="18656273-865" text="On the other hand, pretreatment with the polyphenolic stilbene resveratrol (RSVL, 1-100 microM) triggered more prominent inhibition of ET-1-evoked cell proliferation and ERK1/2 activation.">
            <entity id="DS.d621.s2.e0" origId="638088" charOffset="54-62" type="compound" text="stilbene"/>
            <entity id="DS.d621.s2.e1" origId="445154" charOffset="63-74" type="compound" text="resveratrol"/>
            <entity id="DS.d621.s2.e2" origId="P27361,P28869,P42525,Q07176" charOffset="170-174" type="protein" text="ERK1"/>
            <pair e1="DS.d621.s2.e0" e2="DS.d621.s2.e2" id="DS.d621.s2.i0" interaction="False"/>
            <pair e1="DS.d621.s2.e1" e2="DS.d621.s2.e2" id="DS.d621.s2.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d621.s3" origId="18656273-866" text="Further, pretreatment with the specific cGMP-phosphodiesterase inhibitor, zaprinast (10 microM) appreciably augmented RSVL-evoked cGMP formation, ERK inhibition, and cytostatic response.">
            <entity id="DS.d621.s3.e0" origId="5722" charOffset="74-83" type="compound" text="zaprinast"/>
            <entity id="DS.d621.s3.e1" origId="P29323" charOffset="146-149" type="protein" text="ERK"/>
            <pair e1="DS.d621.s3.e0" e2="DS.d621.s3.e1" id="DS.d621.s3.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d621.s4" origId="18656273-867" text="Moreover, the RSVL-induced ERK-inhibitory effects were significantly reversed by the kinase-G inhibitor, KT-5823 (10 microM; 69%), but not by the kinase-A inhibitor (KT-5720).">
            <entity id="DS.d621.s4.e0" origId="P29323" charOffset="27-30" type="protein" text="ERK"/>
            <entity id="DS.d621.s4.e1" origId="108152" charOffset="105-112" type="compound" text="KT-5823"/>
            <entity id="DS.d621.s4.e2" origId="3844,454202,16219545" charOffset="166-173" type="compound" text="KT-5720"/>
            <pair e1="DS.d621.s4.e2" e2="DS.d621.s4.e0" id="DS.d621.s4.i0" interaction="False"/>
            <pair e1="DS.d621.s4.e1" e2="DS.d621.s4.e0" id="DS.d621.s4.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d622" origId="18656335">
        <sentence id="DS.d622.s0" origId="18656335-913" text="Adding beta-carotene to the diet of the mice during the period of irradiation suppressed the activity and expression of MMP-9 as well as the wrinkling and sagging formation.">
            <entity id="DS.d622.s0.e0" origId="5280489" charOffset="7-20" type="compound" text="beta-carotene"/>
            <entity id="DS.d622.s0.e1" origId="O18733,P14780,P41245,P41246,P50282,P52176" charOffset="120-125" type="protein" text="MMP-9"/>
            <pair e1="DS.d622.s0.e0" e2="DS.d622.s0.e1" id="DS.d622.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d622.s1" origId="18656335-914" text="Dietary beta-carotene prevents the expression of MMP-9, at least partly, by inhibiting photodynamic action involved in the formation of Chol-OOHs.">
            <entity id="DS.d622.s1.e0" origId="5280489" charOffset="8-21" type="compound" text="beta-carotene"/>
            <entity id="DS.d622.s1.e1" origId="O18733,P14780,P41245,P41246,P50282,P52176" charOffset="49-54" type="protein" text="MMP-9"/>
            <pair e1="DS.d622.s1.e0" e2="DS.d622.s1.e1" id="DS.d622.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d623" origId="18656337">
        <sentence id="DS.d623.s0" origId="18656337-916" text="Exposure to linoleic acid for 6 h induced expression of both caveolin-1 and cyclooxygenase (COX)-2.">
            <entity id="DS.d623.s0.e0" origId="5280450" charOffset="12-25" type="compound" text="linoleic acid"/>
            <entity id="DS.d623.s0.e1" origId="P33724,P35431,P41350,P49817,P79132,Q03135,Q07DV9,Q07DX1,Q07DY2,Q07DZ2,Q07E02,Q07E25,Q07E38,Q07E49,Q09YH8,Q09YK1,Q09YN6,Q108U7,Q2IBA5,Q2IBC1,Q2IBD7,Q2IBF0,Q2IBG8,Q2QL79,Q2QL90,Q2QLB0,Q2QLC1,Q2QLF2,Q2QLG6,Q2QLH7,Q6B3Y2,Q6RVA9,Q94051,Q9YGM8" charOffset="61-71" type="protein" text="caveolin-1"/>
            <entity id="DS.d623.s0.e2" origId="P11353,P36551,P36552,Q9UTE2,Q9V3D2" charOffset="92-95" type="protein" text="COX"/>
            <pair e1="DS.d623.s0.e0" e2="DS.d623.s0.e2" id="DS.d623.s0.i0" interaction="True"/>
            <pair e1="DS.d623.s0.e0" e2="DS.d623.s0.e1" id="DS.d623.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d623.s1" origId="18656337-917" text="Pretreatment with EGCG blocked fatty-acid-induced caveolin-1 and COX-2 expression in a time- and concentration-dependent manner.">
            <entity id="DS.d623.s1.e0" origId="65064" charOffset="18-22" type="compound" text="EGCG"/>
            <entity id="DS.d623.s1.e1" origId="P33724,P35431,P41350,P49817,P79132,Q03135,Q07DV9,Q07DX1,Q07DY2,Q07DZ2,Q07E02,Q07E25,Q07E38,Q07E49,Q09YH8,Q09YK1,Q09YN6,Q108U7,Q2IBA5,Q2IBC1,Q2IBD7,Q2IBF0,Q2IBG8,Q2QL79,Q2QL90,Q2QLB0,Q2QLC1,Q2QLF2,Q2QLG6,Q2QLH7,Q6B3Y2,Q6RVA9,Q94051,Q9YGM8" charOffset="50-60" type="protein" text="caveolin-1"/>
            <entity id="DS.d623.s1.e2" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="65-70" type="protein" text="COX-2"/>
            <pair e1="DS.d623.s1.e0" e2="DS.d623.s1.e1" id="DS.d623.s1.i0" interaction="True"/>
            <pair e1="DS.d623.s1.e0" e2="DS.d623.s1.e2" id="DS.d623.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d623.s2" origId="18656337-918" text="Exposure to linoleic acid rapidly increased phosphorylation of several kinases, including p38 MAPK, extracellular signal regulated kinase 1/2 (ERK1/2) and amino kinase terminal (Akt), with maximal induction at about 10 min.">
            <entity id="DS.d623.s2.e0" origId="5280450" charOffset="12-25" type="compound" text="linoleic acid"/>
            <entity id="DS.d623.s2.e1" origId="O62618" charOffset="90-98" type="protein" text="p38 MAPK"/>
            <entity id="DS.d623.s2.e2" origId="P21708,P27361,P28869,P42525,Q63844" charOffset="100-139" type="protein" text="extracellular signal regulated kinase 1"/>
            <entity id="DS.d623.s2.e3" origId="P27361,P28869,P42525,Q07176" charOffset="143-147" type="protein" text="ERK1"/>
            <entity id="DS.d623.s2.e4" origId="P31750,Q8INB9" charOffset="178-181" type="protein" text="Akt"/>
            <pair e1="DS.d623.s2.e0" e2="DS.d623.s2.e1" id="DS.d623.s2.i0" interaction="True"/>
            <pair e1="DS.d623.s2.e0" e2="DS.d623.s2.e4" id="DS.d623.s2.i1" interaction="True"/>
            <pair e1="DS.d623.s2.e0" e2="DS.d623.s2.e2" id="DS.d623.s2.i2" interaction="True"/>
            <pair e1="DS.d623.s2.e0" e2="DS.d623.s2.e3" id="DS.d623.s2.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d623.s3" origId="18656337-919" text="Inhibitors of ERK1/2 and Akt down-regulated the linoleic-acid-induced increase in COX-2 protein, which also occurred after pretreatment with EGCG.">
            <entity id="DS.d623.s3.e0" origId="5280450" charOffset="48-61" type="compound" text="linoleic-acid"/>
            <entity id="DS.d623.s3.e1" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="82-87" type="protein" text="COX-2"/>
            <entity id="DS.d623.s3.e2" origId="65064" charOffset="141-145" type="compound" text="EGCG"/>
            <pair e1="DS.d623.s3.e0" e2="DS.d623.s3.e1" id="DS.d623.s3.i0" interaction="True"/>
            <pair e1="DS.d623.s3.e2" e2="DS.d623.s3.e1" id="DS.d623.s3.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d623.s4" origId="18656337-920" text="Caveolin-1 silencing blocked linoleic-acid-induced phosphorylation of ERK1/2 and protein expression of COX-2, suggesting that specific MAPK signaling is caveolae dependent.">
            <entity id="DS.d623.s4.e0" origId="P33724,P35431,P41350,P49817,P79132,Q03135,Q07DV9,Q07DX1,Q07DY2,Q07DZ2,Q07E02,Q07E25,Q07E38,Q07E49,Q09YH8,Q09YK1,Q09YN6,Q108U7,Q2IBA5,Q2IBC1,Q2IBD7,Q2IBF0,Q2IBG8,Q2QL79,Q2QL90,Q2QLB0,Q2QLC1,Q2QLF2,Q2QLG6,Q2QLH7,Q6B3Y2,Q6RVA9,Q94051,Q9YGM8" charOffset="0-10" type="protein" text="Caveolin-1"/>
            <entity id="DS.d623.s4.e1" origId="5280450" charOffset="29-42" type="compound" text="linoleic-acid"/>
            <entity id="DS.d623.s4.e2" origId="P27361,P28869,P42525,Q07176" charOffset="70-74" type="protein" text="ERK1"/>
            <entity id="DS.d623.s4.e3" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="103-108" type="protein" text="COX-2"/>
            <entity id="DS.d623.s4.e4" origId="O42781,P27638,Q00859" charOffset="135-139" type="protein" text="MAPK"/>
            <pair e1="DS.d623.s4.e1" e2="DS.d623.s4.e2" id="DS.d623.s4.i0" interaction="True"/>
            <pair e1="DS.d623.s4.e1" e2="DS.d623.s4.e0" id="DS.d623.s4.i1" interaction="False"/>
            <pair e1="DS.d623.s4.e1" e2="DS.d623.s4.e4" id="DS.d623.s4.i2" interaction="True"/>
            <pair e1="DS.d623.s4.e1" e2="DS.d623.s4.e3" id="DS.d623.s4.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d624" origId="18656338">
        <sentence id="DS.d624.s0" origId="18656338-921" text="Apigenin causes G(2)/M arrest associated with the modulation of p21 (Cip1) and Cdc2 and activates p53-dependent apoptosis pathway in human breast cancer SK-BR-3 cells.">
            <entity id="DS.d624.s0.e0" origId="5280443" charOffset="0-8" type="compound" text="Apigenin"/>
            <entity id="DS.d624.s0.e1" origId="O19002,O39927,O39928,O39929,O91936,O92529,O92530,O92531,O92532,P26660,P26661,P26662,P26663,P26664,P27954,P27955,P27956,P27957,P27958,P27959,P27960,P27961,P29846,P38936,P39689,P61585,P63028,Q00269,Q01403,Q01404,Q07828,Q11118,Q42580,Q5EG65,Q5I2N3,Q62092,Q68749,Q68798,Q68801,Q81258,Q81487,Q81495,Q81754,Q913D4,Q99IB8,Q9DHD6,Q9QAX1,Q9WMX2" charOffset="64-67" type="protein" text="p21"/>
            <entity id="DS.d624.s0.e2" origId="O42923,P39689" charOffset="69-73" type="protein" text="Cip1"/>
            <entity id="DS.d624.s0.e3" origId="P04551,P11440,P23572,P39951" charOffset="79-83" type="protein" text="Cdc2"/>
            <entity id="DS.d624.s0.e4" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="98-101" type="protein" text="p53"/>
            <pair e1="DS.d624.s0.e0" e2="DS.d624.s0.e3" id="DS.d624.s0.i0" interaction="True"/>
            <pair e1="DS.d624.s0.e0" e2="DS.d624.s0.e4" id="DS.d624.s0.i1" interaction="True"/>
            <pair e1="DS.d624.s0.e0" e2="DS.d624.s0.e1" id="DS.d624.s0.i2" interaction="True"/>
            <pair e1="DS.d624.s0.e0" e2="DS.d624.s0.e2" id="DS.d624.s0.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d624.s1" origId="18656338-922" text="To investigate the regulatory proteins of cell cycle arrest affected by apigenin, we treated cells with 50 and 100 microM apigenin for 72 h. Apigenin caused a slight decrease in cyclin D and cyclin E expression, with no change in CDK2 and CDK4.">
            <entity id="DS.d624.s1.e0" origId="5280443" charOffset="72-80" type="compound" text="apigenin"/>
            <entity id="DS.d624.s1.e1" origId="5280443" charOffset="122-130" type="compound" text="apigenin"/>
            <entity id="DS.d624.s1.e2" origId="5280443" charOffset="141-149" type="compound" text="Apigenin"/>
            <entity id="DS.d624.s1.e3" origId="Q5SCB5" charOffset="178-186" type="protein" text="cyclin D"/>
            <entity id="DS.d624.s1.e5" origId="O55076,P24941,P43450,P48963,Q5E9Y0" charOffset="230-234" type="protein" text="CDK2"/>
            <entity id="DS.d624.s1.e6" origId="P11802,P79432" charOffset="239-243" type="protein" text="CDK4"/>
            <pair e1="DS.d624.s1.e0" e2="DS.d624.s1.e3" id="DS.d624.s1.i0" interaction="True"/>
            <pair e1="DS.d624.s1.e2" e2="DS.d624.s1.e5" id="DS.d624.s1.i2" interaction="False"/>
            <pair e1="DS.d624.s1.e0" e2="DS.d624.s1.e6" id="DS.d624.s1.i4" interaction="False"/>
            <pair e1="DS.d624.s1.e2" e2="DS.d624.s1.e3" id="DS.d624.s1.i5" interaction="True"/>
            <pair e1="DS.d624.s1.e0" e2="DS.d624.s1.e5" id="DS.d624.s1.i6" interaction="False"/>
            <pair e1="DS.d624.s1.e2" e2="DS.d624.s1.e6" id="DS.d624.s1.i7" interaction="False"/>
        </sentence>
        <sentence id="DS.d624.s2" origId="18656338-923" text="In addition, the apigenin-induced accumulation of the cell population in the G(2)/M phase resulted in a decrease in CDK1 together with cyclin A and cyclin B.">
            <entity id="DS.d624.s2.e0" origId="5280443" charOffset="17-25" type="compound" text="apigenin"/>
            <entity id="DS.d624.s2.e1" origId="P00546,P06493,P11440,P13863,P39951,P43063,P48734,P51958,Q5RCH1,Q9DG98,Q9DGA2,Q9DGA5,Q9DGD3" charOffset="116-120" type="protein" text="CDK1"/>
            <entity id="DS.d624.s2.e2" origId="P20248,P30274,P37881,P43449,P51943,Q92161" charOffset="135-143" type="protein" text="cyclin A"/>
            <entity id="DS.d624.s2.e3" origId="O01377,O16852,P04961,P12004,P17070,P17917,P17918,P18248,P22177,P24314,P31008,P53358,P61074,Q00265,Q00268" charOffset="135-141" type="protein" text="cyclin"/>
            <pair e1="DS.d624.s2.e0" e2="DS.d624.s2.e2" id="DS.d624.s2.i1" interaction="True"/>
            <pair e1="DS.d624.s2.e0" e2="DS.d624.s2.e1" id="DS.d624.s2.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d624.s3" origId="18656338-924" text="In an additional study, apigenin also increased the accumulation of p53 and further enhanced the level of p21 (Cip1), with no change in p27 (Kip1).">
            <entity id="DS.d624.s3.e0" origId="5280443" charOffset="24-32" type="compound" text="apigenin"/>
            <entity id="DS.d624.s3.e1" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="68-71" type="protein" text="p53"/>
            <entity id="DS.d624.s3.e2" origId="O19002,O39927,O39928,O39929,O91936,O92529,O92530,O92531,O92532,P26660,P26661,P26662,P26663,P26664,P27954,P27955,P27956,P27957,P27958,P27959,P27960,P27961,P29846,P38936,P39689,P61585,P63028,Q00269,Q01403,Q01404,Q07828,Q11118,Q42580,Q5EG65,Q5I2N3,Q62092,Q68749,Q68798,Q68801,Q81258,Q81487,Q81495,Q81754,Q913D4,Q99IB8,Q9DHD6,Q9QAX1,Q9WMX2" charOffset="106-109" type="protein" text="p21"/>
            <entity id="DS.d624.s3.e3" origId="O42923,P39689" charOffset="111-115" type="protein" text="Cip1"/>
            <entity id="DS.d624.s3.e4" origId="O11451,O11452,O11453,O39927,O39928,O39929,O91936,O92529,O92530,O92531,O92532,P06934,P16342,P19751,P25880,P25881,P25882,P25884,P25989,P26660,P26661,P26662,P26663,P26664,P27958,P29833,P29846,P29996,P29997,P40305,P68763,P68764,P68765,P69180,P69181,P69182,P69183,P69184,P69618,P69619,Q00269,Q43735,Q5I2N3,Q66198,Q68749,Q68798,Q68801,Q81258,Q81487,Q81495,Q81754,Q81835,Q81842,Q8V439,Q8V6W7,Q913D4,Q91A29,Q91DH7,Q91DH8,Q91DH9,Q99IB8,Q9DHD6,Q9E925,Q9PYA3,Q9QAX1,Q9WMX2" charOffset="136-139" type="protein" text="p27"/>
            <pair e1="DS.d624.s3.e0" e2="DS.d624.s3.e2" id="DS.d624.s3.i0" interaction="True"/>
            <pair e1="DS.d624.s3.e0" e2="DS.d624.s3.e3" id="DS.d624.s3.i1" interaction="True"/>
            <pair e1="DS.d624.s3.e0" e2="DS.d624.s3.e4" id="DS.d624.s3.i2" interaction="False"/>
            <pair e1="DS.d624.s3.e0" e2="DS.d624.s3.e1" id="DS.d624.s3.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d624.s4" origId="18656338-925" text="The expression of Bax and cytochrome c of p53 downstream target was increased markedly at high concentration treatment over 50 microM apigenin.">
            <entity id="DS.d624.s4.e0" origId="P27297,Q07813,Q63690" charOffset="18-21" type="protein" text="Bax"/>
            <entity id="DS.d624.s4.e1" origId="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3" charOffset="26-38" type="protein" text="cytochrome c"/>
            <entity id="DS.d624.s4.e2" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="42-45" type="protein" text="p53"/>
            <entity id="DS.d624.s4.e3" origId="5280443" charOffset="134-142" type="compound" text="apigenin"/>
            <pair e1="DS.d624.s4.e3" e2="DS.d624.s4.e1" id="DS.d624.s4.i0" interaction="True"/>
            <pair e1="DS.d624.s4.e3" e2="DS.d624.s4.e2" id="DS.d624.s4.i1" interaction="True"/>
            <pair e1="DS.d624.s4.e3" e2="DS.d624.s4.e0" id="DS.d624.s4.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d625" origId="18656400">
        <sentence id="DS.d625.s0" origId="18656400-711" text="Therefore, we next examined whether 5-HT2A and 5-HT2C receptors are involved, and from where 5-HT is released in the formalin test.">
            <entity id="DS.d625.s0.e0" origId="P50129" charOffset="36-42" type="protein" text="5-HT2A"/>
            <entity id="DS.d625.s0.e1" origId="P08909,P28335,P34968,Q5IS66,Q60F97" charOffset="47-53" type="protein" text="5-HT2C"/>
            <entity id="DS.d625.s0.e2" origId="5202" charOffset="36-40" type="compound" text="5-HT"/>
            <entity id="DS.d625.s0.e3" origId="712" charOffset="117-125" type="compound" text="formalin"/>
            <pair e1="DS.d625.s0.e3" e2="DS.d625.s0.e0" id="DS.d625.s0.i0" interaction="False"/>
            <pair e1="DS.d625.s0.e2" e2="DS.d625.s0.e1" id="DS.d625.s0.i1" interaction="False"/>
            <pair e1="DS.d625.s0.e2" e2="DS.d625.s0.e0" id="DS.d625.s0.i2" interaction="False"/>
            <pair e1="DS.d625.s0.e3" e2="DS.d625.s0.e1" id="DS.d625.s0.i3" interaction="False"/>
        </sentence>
        <sentence id="DS.d625.s1" origId="18656400-713" text="These results indicate that 5-HT released into peripheral tissue and its receptors, 5-HT2A as well as 5-HT2C, at the periphery have an important role in pain-related behaviors during acute peripheral inflammation.">
            <entity id="DS.d625.s1.e0" origId="5202" charOffset="28-32" type="compound" text="5-HT"/>
            <entity id="DS.d625.s1.e1" origId="P50129" charOffset="84-90" type="protein" text="5-HT2A"/>
            <entity id="DS.d625.s1.e2" origId="P08909,P28335,P34968,Q5IS66,Q60F97" charOffset="102-108" type="protein" text="5-HT2C"/>
            <pair e1="DS.d625.s1.e0" e2="DS.d625.s1.e1" id="DS.d625.s1.i0" interaction="True"/>
            <pair e1="DS.d625.s1.e0" e2="DS.d625.s1.e2" id="DS.d625.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d626" origId="18656896">
        <sentence id="DS.d626.s0" origId="18656896-1449" text="Haloperidol strongly decreased the expression of BDNF 0.01).">
            <entity id="DS.d626.s0.e0" origId="3559" charOffset="0-11" type="compound" text="Haloperidol"/>
            <entity id="DS.d626.s0.e1" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="49-53" type="protein" text="BDNF"/>
            <pair e1="DS.d626.s0.e0" e2="DS.d626.s0.e1" id="DS.d626.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d626.s1" origId="18656896-1450" text="In contrast, the administration of ziprasidone significantly attenuated the immobilization stress-induced decrease in BDNF 0.01).">
            <entity id="DS.d626.s1.e0" origId="60854" charOffset="35-46" type="compound" text="ziprasidone"/>
            <entity id="DS.d626.s1.e1" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="118-122" type="protein" text="BDNF"/>
            <pair e1="DS.d626.s1.e0" e2="DS.d626.s1.e1" id="DS.d626.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d626.s2" origId="18656896-1451" text="Ziprasidone exhibited differential effects on BDNF mRNA expression in the rat hippocampus and neocortex.">
            <entity id="DS.d626.s2.e0" origId="60854" charOffset="0-11" type="compound" text="Ziprasidone"/>
            <entity id="DS.d626.s2.e1" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="46-50" type="protein" text="BDNF"/>
            <pair e1="DS.d626.s2.e0" e2="DS.d626.s2.e1" id="DS.d626.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d626.s3" origId="18656896-1452" text="These results suggest that ziprasidone might have a neuroprotective effect by recovering stress-induced decreases in BDNF mRNA expression.">
            <entity id="DS.d626.s3.e0" origId="60854" charOffset="27-38" type="compound" text="ziprasidone"/>
            <entity id="DS.d626.s3.e1" origId="O18752,O18753,O18755,O70183,O97759,P14082,P21237,P23363,P23560,P25429,P25430,P25431,P25432,Q02193,Q06225,Q3SAT7,Q4L0Y3,Q5IS78,Q6LCI5,Q7YRB4,Q90322,Q95106,Q9TST3" charOffset="117-121" type="protein" text="BDNF"/>
            <pair e1="DS.d626.s3.e0" e2="DS.d626.s3.e1" id="DS.d626.s3.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d627" origId="18657000">
        <sentence id="DS.d627.s0" origId="18657000-1427" text="In conclusion, fructose overload in rats induced hypertriglyceridemia and insulin resistance associated with an enhanced oxidative stress.">
            <entity id="DS.d627.s0.e0" origId="5984" charOffset="15-23" type="compound" text="fructose"/>
            <entity id="DS.d627.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="74-81" type="protein" text="insulin"/>
            <pair e1="DS.d627.s0.e0" e2="DS.d627.s0.e1" id="DS.d627.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d628" origId="18657005">
        <sentence id="DS.d628.s0" origId="18657005-297" text="Clinical and biochemical parameters including fructosamine (FAM), glycated hemoglobin (HbA1c) and serum AGEs were investigated in children and adolescents with 1 type diabetes with (+DC) and without (-DC) complications.">
            <entity id="DS.d628.s0.e0" origId="20484" charOffset="46-58" type="compound" text="fructosamine"/>
            <entity id="DS.d628.s0.e1" origId="P15160,P17724,P73925,Q03459" charOffset="75-85" type="protein" text="hemoglobin"/>
            <entity id="DS.d628.s0.e2" origId="O18921,P17560,P51606,P51607,P82343" charOffset="104-108" type="protein" text="AGEs"/>
            <pair e1="DS.d628.s0.e0" e2="DS.d628.s0.e2" id="DS.d628.s0.i0" interaction="False"/>
            <pair e1="DS.d628.s0.e0" e2="DS.d628.s0.e1" id="DS.d628.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d629" origId="18657007">
        <sentence id="DS.d629.s0" origId="18657007-1437" text="Leptin and soluble leptin receptor changes after pulmonary endarterectomy: relations to cortisol and cytokine network.">
            <entity id="DS.d629.s0.e0" origId="O02750,O93416,Q28603,Q95189,Q95234" charOffset="0-6" type="protein" text="Leptin"/>
            <entity id="DS.d629.s0.e1" origId="O02750,O93416,Q28603,Q95189,Q95234" charOffset="19-25" type="protein" text="leptin"/>
            <entity id="DS.d629.s0.e2" origId="5754" charOffset="88-96" type="compound" text="cortisol"/>
            <pair e1="DS.d629.s0.e2" e2="DS.d629.s0.e1" id="DS.d629.s0.i0" interaction="True"/>
            <pair e1="DS.d629.s0.e2" e2="DS.d629.s0.e0" id="DS.d629.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d629.s1" origId="18657007-1438" text="Leptin and soluble leptin receptor (SLR) were compared with evolution of cortisol and inflammatory cytokines in twenty-two patients with chronic thromboembolic pulmonary hypertension treated with pulmonary endarterectomy using cardiopulmonary bypass (CBP) and deep hypothermic circulatory arrest (DHCA).">
            <entity id="DS.d629.s1.e0" origId="O02750,O93416,Q28603,Q95189,Q95234" charOffset="0-6" type="protein" text="Leptin"/>
            <entity id="DS.d629.s1.e1" origId="O02750,O93416,Q28603,Q95189,Q95234" charOffset="19-25" type="protein" text="leptin"/>
            <entity id="DS.d629.s1.e2" origId="5754" charOffset="73-81" type="compound" text="cortisol"/>
            <pair e1="DS.d629.s1.e2" e2="DS.d629.s1.e1" id="DS.d629.s1.i0" interaction="False"/>
            <pair e1="DS.d629.s1.e2" e2="DS.d629.s1.e0" id="DS.d629.s1.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d630" origId="18657009">
        <sentence id="DS.d630.s0" origId="18657009-1440" text="Using this method, we also determined whether streptozotocin-induced DM in rats (4-week duration) leads to changes in renal subcellular targeting of CAV-1, and evaluated the effects of tight metabolic control (insulin, 12 IU/day) and angiotensin receptor blocker, losartan (4 weeks, 20 mg/kg/day).">
            <entity id="DS.d630.s0.e0" origId="Q9YGM8" charOffset="149-154" type="protein" text="CAV-1"/>
            <entity id="DS.d630.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="210-217" type="protein" text="insulin"/>
            <entity id="DS.d630.s0.e2" origId="3961" charOffset="264-272" type="compound" text="losartan"/>
            <pair e1="DS.d630.s0.e2" e2="DS.d630.s0.e0" id="DS.d630.s0.i0" interaction="False"/>
            <pair e1="DS.d630.s0.e2" e2="DS.d630.s0.e1" id="DS.d630.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d631" origId="18657194">
        <sentence id="DS.d631.s0" origId="18657194-724" text="Androgenic action correlates inversely with a polymorphic CAG repeat region in the AR gene encoding for glutamine residues the length of which appears to influence high density lipoprotein (HDL) cholesterol levels.">
            <entity id="DS.d631.s0.e0" origId="738,5961" charOffset="104-113" type="compound" text="glutamine"/>
            <entity id="DS.d631.s0.e1" origId="P81182" charOffset="164-188" type="protein" text="high density lipoprotein"/>
            <entity id="DS.d631.s0.e2" origId="304,5997,6432564,11025495" charOffset="195-206" type="compound" text="cholesterol"/>
            <pair e1="DS.d631.s0.e2" e2="DS.d631.s0.e1" id="DS.d631.s0.i0" interaction="True"/>
            <pair e1="DS.d631.s0.e0" e2="DS.d631.s0.e1" id="DS.d631.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d632" origId="18657228">
        <sentence id="DS.d632.s0" origId="18657228-1396" text="These vessels are formed by proliferating cells that incorporate bromodeoxyuridine and express the endothelial cell markers vegfr2/kdr and fli1.">
            <entity id="DS.d632.s0.e0" origId="6035" charOffset="65-82" type="compound" text="bromodeoxyuridine"/>
            <entity id="DS.d632.s0.e1" origId="O08775,P35918,Q8AXB3" charOffset="131-134" type="protein" text="kdr"/>
            <entity id="DS.d632.s0.e2" origId="P26323,P41157,Q9JJ28" charOffset="139-143" type="protein" text="fli1"/>
            <pair e1="DS.d632.s0.e0" e2="DS.d632.s0.e1" id="DS.d632.s0.i0" interaction="False"/>
            <pair e1="DS.d632.s0.e0" e2="DS.d632.s0.e2" id="DS.d632.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d632.s1" origId="18657228-1398" text="Moreover, similar to rFGF2, injection of the zebrafish form of vascular endothelial growth factor-A (VEGF-A) induces a significant angiogenic response in the ZFYM assay that is suppressed by the VEGF receptor-2/KDR TK inhibitor SU5416.">
            <entity id="DS.d632.s1.e0" origId="P26617" charOffset="63-99" type="protein" text="vascular endothelial growth factor-A"/>
            <entity id="DS.d632.s1.e1" origId="P15691,P15692,P16612,P26617,P49151,P50412,P67860,P67964,P67965,P83906,Q00731,Q99PS1,Q9GKR0,Q9MYV3" charOffset="101-107" type="protein" text="VEGF-A"/>
            <entity id="DS.d632.s1.e2" origId="5329098" charOffset="228-234" type="compound" text="SU5416"/>
            <pair e1="DS.d632.s1.e2" e2="DS.d632.s1.e0" id="DS.d632.s1.i0" interaction="True"/>
            <pair e1="DS.d632.s1.e2" e2="DS.d632.s1.e1" id="DS.d632.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d633" origId="18657961">
        <sentence id="DS.d633.s0" origId="18657961-1695" text="In this study, we examined ferulate for its ability to suppress redox-sensitive, proinflammatory NF-kappaB activation via NF-kappaB-inducing kinase (NIK)/IkappaB kinase (IKK) and mitogen-activated protein kinases (MAPKs) by reducing oxidative stress in aged rats.">
            <entity id="DS.d633.s0.e0" origId="445858" charOffset="27-35" type="compound" text="ferulate"/>
            <entity id="DS.d633.s0.e1" origId="O95819,Q99558" charOffset="149-152" type="protein" text="NIK"/>
            <entity id="DS.d633.s0.e2" origId="O15111,Q60680" charOffset="154-168" type="protein" text="IkappaB kinase"/>
            <entity id="DS.d633.s0.e3" origId="Q00859" charOffset="179-212" type="protein" text="mitogen-activated protein kinases"/>
            <entity id="DS.d633.s0.e4" origId="O42781,P27638,Q00859" charOffset="214-219" type="protein" text="MAPKs"/>
            <pair e1="DS.d633.s0.e0" e2="DS.d633.s0.e2" id="DS.d633.s0.i0" interaction="True"/>
            <pair e1="DS.d633.s0.e0" e2="DS.d633.s0.e3" id="DS.d633.s0.i1" interaction="True"/>
            <pair e1="DS.d633.s0.e0" e2="DS.d633.s0.e4" id="DS.d633.s0.i2" interaction="True"/>
            <pair e1="DS.d633.s0.e0" e2="DS.d633.s0.e1" id="DS.d633.s0.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d633.s1" origId="18657961-1696" text="Data show that in aged kidney tissue, ferulate exhibited its antioxidative action by maintaining redox regulation, suppressing NF-kappaB activation and modulating the expression of NF-kappaB-induced, proinflammatory COX-2, iNOS, VCAM-1 and ICAM-1.">
            <entity id="DS.d633.s1.e0" origId="445858" charOffset="38-46" type="compound" text="ferulate"/>
            <entity id="DS.d633.s1.e1" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="216-221" type="protein" text="COX-2"/>
            <entity id="DS.d633.s1.e2" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="223-227" type="protein" text="iNOS"/>
            <entity id="DS.d633.s1.e3" origId="P19320,P29533,P29534,Q28260" charOffset="229-235" type="protein" text="VCAM-1"/>
            <entity id="DS.d633.s1.e4" origId="P05362,P13597,P33729,Q00238,Q28806,Q5NKV4,Q5NKV6,Q5NKV9,Q95132" charOffset="240-246" type="protein" text="ICAM-1"/>
            <pair e1="DS.d633.s1.e0" e2="DS.d633.s1.e1" id="DS.d633.s1.i0" interaction="True"/>
            <pair e1="DS.d633.s1.e0" e2="DS.d633.s1.e3" id="DS.d633.s1.i1" interaction="True"/>
            <pair e1="DS.d633.s1.e0" e2="DS.d633.s1.e2" id="DS.d633.s1.i2" interaction="True"/>
            <pair e1="DS.d633.s1.e0" e2="DS.d633.s1.e4" id="DS.d633.s1.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d633.s2" origId="18657961-1698" text="The molecular modulation of NF-kappaB by ferulate was further revealed in endothelial YPEN-1 cells through ferulate's ability to suppress the activation of NIK/IKK and MAPKs.">
            <entity id="DS.d633.s2.e0" origId="445858" charOffset="41-49" type="compound" text="ferulate"/>
            <entity id="DS.d633.s2.e1" origId="445858" charOffset="107-115" type="compound" text="ferulate"/>
            <entity id="DS.d633.s2.e2" origId="O95819,Q99558" charOffset="156-159" type="protein" text="NIK"/>
            <entity id="DS.d633.s2.e3" origId="O42781,P27638,Q00859" charOffset="168-173" type="protein" text="MAPKs"/>
            <pair e1="DS.d633.s2.e0" e2="DS.d633.s2.e2" id="DS.d633.s2.i0" interaction="True"/>
            <pair e1="DS.d633.s2.e0" e2="DS.d633.s2.e3" id="DS.d633.s2.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d633.s3" origId="18657961-1699" text="Based on these results, we conclude that ferulate's antioxidative capacity suppressed the age-related increase in NF-kappaB activity through inhibition of NIK/IKK and MAPKs in vivo.">
            <entity id="DS.d633.s3.e0" origId="445858" charOffset="41-49" type="compound" text="ferulate"/>
            <entity id="DS.d633.s3.e1" origId="O95819,Q99558" charOffset="155-158" type="protein" text="NIK"/>
            <entity id="DS.d633.s3.e2" origId="O42781,P27638,Q00859" charOffset="167-172" type="protein" text="MAPKs"/>
            <pair e1="DS.d633.s3.e0" e2="DS.d633.s3.e1" id="DS.d633.s3.i0" interaction="True"/>
            <pair e1="DS.d633.s3.e0" e2="DS.d633.s3.e2" id="DS.d633.s3.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d634" origId="18658095">
        <sentence id="DS.d634.s0" origId="18658095-656" text="Previous studies have shown that wounding of human corneal epithelial cells (HCECs) results in the release of G-protein-coupled receptor ligands such as ATP and lysophosphatidic acid (LPA), which in turn transactivate epidermal growth factor (EGF) receptor (EGFR) through ectodomain shedding of heparin-binding EGF-like growth factor (HB-EGF).">
            <entity id="DS.d634.s0.e0" origId="5957" charOffset="153-156" type="compound" text="ATP"/>
            <entity id="DS.d634.s0.e1" origId="3988,5311263,5497152" charOffset="161-182" type="compound" text="lysophosphatidic acid"/>
            <entity id="DS.d634.s0.e2" origId="P01132,P01133,P07522,Q00968,Q95ND4,Q9BEA0" charOffset="218-241" type="protein" text="epidermal growth factor"/>
            <entity id="DS.d634.s0.e3" origId="P01132,P01133,P07522,P26224,Q00968,Q95ND4,Q9BEA0" charOffset="243-246" type="protein" text="EGF"/>
            <entity id="DS.d634.s0.e4" origId="P00533,P13387,P55245" charOffset="258-262" type="protein" text="EGFR"/>
            <entity id="DS.d634.s0.e5" origId="P01132,P01133,P07522,P26224,Q00968,Q95ND4,Q9BEA0" charOffset="258-261" type="protein" text="EGF"/>
            <entity id="DS.d634.s0.e6" origId="Q01580,Q06175,Q06186,Q09118,Q99075" charOffset="335-341" type="protein" text="HB-EGF"/>
            <pair e1="DS.d634.s0.e0" e2="DS.d634.s0.e4" id="DS.d634.s0.i0" interaction="True"/>
            <pair e1="DS.d634.s0.e1" e2="DS.d634.s0.e6" id="DS.d634.s0.i1" interaction="True"/>
            <pair e1="DS.d634.s0.e0" e2="DS.d634.s0.e2" id="DS.d634.s0.i2" interaction="True"/>
            <pair e1="DS.d634.s0.e1" e2="DS.d634.s0.e4" id="DS.d634.s0.i3" interaction="True"/>
            <pair e1="DS.d634.s0.e1" e2="DS.d634.s0.e3" id="DS.d634.s0.i4" interaction="True"/>
            <pair e1="DS.d634.s0.e1" e2="DS.d634.s0.e2" id="DS.d634.s0.i5" interaction="True"/>
            <pair e1="DS.d634.s0.e0" e2="DS.d634.s0.e3" id="DS.d634.s0.i6" interaction="True"/>
            <pair e1="DS.d634.s0.e0" e2="DS.d634.s0.e6" id="DS.d634.s0.i7" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d635" origId="18660796">
        <sentence id="DS.d635.s0" origId="18660796-396" text="Nitric oxide is a free radical molecule synthesized from L-arginine by nitric oxide synthases that plays a critical role in various physiological and pathological processes, including tumor growth and angiogenesis.">
            <entity id="DS.d635.s0.e0" origId="145068" charOffset="0-12" type="compound" text="Nitric oxide"/>
            <entity id="DS.d635.s0.e1" origId="6322" charOffset="57-67" type="compound" text="L-arginine"/>
            <entity id="DS.d635.s0.e2" origId="O61309,O61608,Q27571,Q9I9M2" charOffset="71-93" type="protein" text="nitric oxide synthases"/>
            <pair e1="DS.d635.s0.e0" e2="DS.d635.s0.e2" id="DS.d635.s0.i0" interaction="True"/>
            <pair e1="DS.d635.s0.e1" e2="DS.d635.s0.e2" id="DS.d635.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d636" origId="18661133">
        <sentence id="DS.d636.s0" origId="18661133-1463" text="Furthermore, restoration of KSR1 expression in KSR (-/-) MEFs following stable transduction of cells with a KSR1 expression vector, enhanced sensitivity of cells to tunicamycin and cytochalasin H and decreased ERK1/2 activation following exposure to these drugs.">
            <entity id="DS.d636.s0.e0" origId="Q8IVT5" charOffset="28-32" type="protein" text="KSR1"/>
            <entity id="DS.d636.s0.e1" origId="Q8IVT5" charOffset="108-112" type="protein" text="KSR1"/>
            <entity id="DS.d636.s0.e2" origId="5351303,6434468,13892272,17751001" charOffset="181-195" type="compound" text="cytochalasin H"/>
            <entity id="DS.d636.s0.e3" origId="P27361,P28869,P42525,Q07176" charOffset="210-214" type="protein" text="ERK1"/>
            <pair e1="DS.d636.s0.e2" e2="DS.d636.s0.e3" id="DS.d636.s0.i0" interaction="False"/>
            <pair e1="DS.d636.s0.e2" e2="DS.d636.s0.e0" id="DS.d636.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d638" origId="18661233">
        <sentence id="DS.d638.s0" origId="18661233-1568" text="We demonstrated the increase in the levels of p53, Bax, and cytochrome c and decrease in the level of Bcl-2, which are associated with the induction of apoptotic cell death after 24 h treatment with baicalein in N18 cells.">
            <entity id="DS.d638.s0.e0" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="46-49" type="protein" text="p53"/>
            <entity id="DS.d638.s0.e1" origId="P27297,Q07813,Q63690" charOffset="51-54" type="protein" text="Bax"/>
            <entity id="DS.d638.s0.e2" origId="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3" charOffset="60-72" type="protein" text="cytochrome c"/>
            <entity id="DS.d638.s0.e3" origId="P10417,P49950" charOffset="102-107" type="protein" text="Bcl-2"/>
            <entity id="DS.d638.s0.e4" origId="5281605" charOffset="199-208" type="compound" text="baicalein"/>
            <pair e1="DS.d638.s0.e4" e2="DS.d638.s0.e2" id="DS.d638.s0.i0" interaction="True"/>
            <pair e1="DS.d638.s0.e4" e2="DS.d638.s0.e3" id="DS.d638.s0.i1" interaction="True"/>
            <pair e1="DS.d638.s0.e4" e2="DS.d638.s0.e1" id="DS.d638.s0.i2" interaction="True"/>
            <pair e1="DS.d638.s0.e4" e2="DS.d638.s0.e0" id="DS.d638.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d639" origId="18661547">
        <sentence id="DS.d639.s0" origId="18661547-124" text="GFP-fluorescent cells were slowly cycling, as shown by their long-term retention of BrdU, and less than 10% expressed the proliferative markers Ki67 and Mcm2.">
            <entity id="DS.d639.s0.e0" origId="6035" charOffset="84-88" type="compound" text="BrdU"/>
            <entity id="DS.d639.s0.e1" origId="P07759,P40377,P49735,P55861,P97310,Q6DIH3" charOffset="153-157" type="protein" text="Mcm2"/>
            <pair e1="DS.d639.s0.e0" e2="DS.d639.s0.e1" id="DS.d639.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d640" origId="18662278">
        <sentence id="DS.d640.s0" origId="18662278-741" text="MTHFR gene polymorphisms and high levels of homocysteine are associated with a high degree of steatosis and fibrosis, conditions associated with a low sustained virological response (SVR) rate.">
            <entity id="DS.d640.s0.e0" origId="P42898,Q5I598,Q60HE5" charOffset="0-5" type="protein" text="MTHFR"/>
            <entity id="DS.d640.s0.e1" origId="778" charOffset="44-56" type="compound" text="homocysteine"/>
            <pair e1="DS.d640.s0.e1" e2="DS.d640.s0.e0" id="DS.d640.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d641" origId="18662930">
        <sentence id="DS.d641.s0" origId="18662930-1285" text="Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes.">
            <entity id="DS.d641.s0.e0" origId="24759" charOffset="0-10" type="compound" text="Hyaluronan"/>
            <entity id="DS.d641.s0.e1" origId="O75173,Q5RFQ8,Q9TT93" charOffset="34-41" type="protein" text="ADAMTS4"/>
            <entity id="DS.d641.s0.e2" origId="O75173,Q5RFQ8,Q8BNJ2,Q9ESP7,Q9TT93" charOffset="43-56" type="protein" text="aggrecanase-1"/>
            <pair e1="DS.d641.s0.e0" e2="DS.d641.s0.e2" id="DS.d641.s0.i0" interaction="True"/>
            <pair e1="DS.d641.s0.e0" e2="DS.d641.s0.e1" id="DS.d641.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d642" origId="18663366">
        <sentence id="DS.d642.s0" origId="18663366-1650" text="The discovery that a common polymorphism (5-HTTLPR, short variant) in the human serotonin transporter gene (SLC6A4) can influence personality traits and increase the risk for depression in adulthood has led to the hypothesis that a relative increase in the extracellular levels of serotonin (5-HT) during development could be critical for the establishment of brain circuits.">
            <entity id="DS.d642.s0.e0" origId="O35899,P31645,Q9MYX0,Q9XT49" charOffset="108-114" type="protein" text="SLC6A4"/>
            <entity id="DS.d642.s0.e1" origId="5202" charOffset="42-46" type="compound" text="5-HT"/>
            <pair e1="DS.d642.s0.e1" e2="DS.d642.s0.e0" id="DS.d642.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d643" origId="18663367">
        <sentence id="DS.d643.s0" origId="18663367-1653" text="Besides the biogenesis of lysosome-related organelles complex 1 and dystrophin-associated protein complex, several molecules in the DTNBP1 network likely provide insight into the role of DTNBP1 in biological systems: retinoic acid, beta-estradiol, calmodulin and tumour necrosis factor.">
            <entity id="DS.d643.s0.e1" origId="Q96EV8" charOffset="132-138" type="protein" text="DTNBP1"/>
            <entity id="DS.d643.s0.e2" origId="Q96EV8" charOffset="187-193" type="protein" text="DTNBP1"/>
            <entity id="DS.d643.s0.e3" origId="444795" charOffset="217-230" type="compound" text="retinoic acid"/>
            <entity id="DS.d643.s0.e4" origId="5757" charOffset="232-246" type="compound" text="beta-estradiol"/>
            <entity id="DS.d643.s0.e5" origId="O02367,O16305,O60041,O82018,O94739,O96102,O97341,P02594,P02595,P02598,P02599,P04352,P04353,P04464,P05933,P05934,P05935,P06787,P07463,P11118,P11120,P11121,P15094,P17928,P18061,P21251,P23286,P24044,P27161,P27165,P27166,P41040,P41041,P48976,P60204,P60205,P60206,P61859,P61860,P61861,P62144,P62145,P62149,P62151,P62152,P62154,P62155,P62156,P62157,P62158,P62160,P62161,P62162,P62184,P62201,P62202,P62203,P62204,P69097,P69098,P84339,P93087,P93171,Q05055,Q39752,Q40302,Q5EHV7,Q5RAD2,Q6IT78,Q6PI52,Q6R520,Q6YNX6,Q71UH5,Q71UH6,Q7T3T2,Q7Y052,Q8STF0,Q8X187,Q95NI4,Q95NR9,Q9GRJ1,Q9HFY6,Q9U6D3,Q9UWF0" charOffset="248-258" type="protein" text="calmodulin"/>
            <pair e1="DS.d643.s0.e3" e2="DS.d643.s0.e5" id="DS.d643.s0.i1" interaction="False"/>
            <pair e1="DS.d643.s0.e3" e2="DS.d643.s0.e1" id="DS.d643.s0.i3" interaction="True"/>
            <pair e1="DS.d643.s0.e4" e2="DS.d643.s0.e5" id="DS.d643.s0.i4" interaction="False"/>
            <pair e1="DS.d643.s0.e4" e2="DS.d643.s0.e1" id="DS.d643.s0.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d644" origId="18663553">
        <sentence id="DS.d644.s0" origId="18663553-101" text="Prior to the first dose of leflunomide, serum concentrations of studied chemokines correlated with marker of RA activity such as the erythrocyte sedimentation rate and IL-8 level with DAS.">
            <entity id="DS.d644.s0.e0" origId="3899" charOffset="27-38" type="compound" text="leflunomide"/>
            <entity id="DS.d644.s0.e1" origId="O62812,P08317,P10145,P19874,P26894,P36925,P41324,P46653,P49113,P67813,P67814,P79255,Q102R3,Q7YRB5,Q9XSX5" charOffset="168-172" type="protein" text="IL-8"/>
            <pair e1="DS.d644.s0.e0" e2="DS.d644.s0.e1" id="DS.d644.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d645" origId="18663559">
        <sentence id="DS.d645.s0" origId="18663559-103" text="Hypothetically, cytochrome P450 2D6 influences the transport of taurine across the blood-brain barrier.">
            <entity id="DS.d645.s0.e0" origId="P10635,Q2XNC8,Q2XNC9" charOffset="16-35" type="protein" text="cytochrome P450 2D6"/>
            <entity id="DS.d645.s0.e1" origId="1123" charOffset="64-71" type="compound" text="taurine"/>
            <pair e1="DS.d645.s0.e1" e2="DS.d645.s0.e0" id="DS.d645.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d646" origId="18663659">
        <sentence id="DS.d646.s0" origId="18663659-168" text="Most genes involved in lipid metabolism and especially in ergosterol biosynthesis were up-regulated in response to itraconazole, including ERG6, ERG7, ERG11, ERG24, ERG25 and ERG26.">
            <entity id="DS.d646.s0.e0" origId="3793,55283,6917738,14179013" charOffset="115-127" type="compound" text="itraconazole"/>
            <entity id="DS.d646.s0.e1" origId="O74198,P25087,Q5EN22,Q6BRB7,Q6C2D9,Q6CYB3,Q6FRZ7,Q759S7,Q875K1" charOffset="139-143" type="protein" text="ERG6"/>
            <entity id="DS.d646.s0.e2" origId="P38604,Q04782,Q96WJ0" charOffset="145-149" type="protein" text="ERG7"/>
            <entity id="DS.d646.s0.e3" origId="P10613,P10614,P14263,P49602,P50859,Q759W0" charOffset="151-156" type="protein" text="ERG11"/>
            <entity id="DS.d646.s0.e4" origId="P32462" charOffset="158-163" type="protein" text="ERG24"/>
            <entity id="DS.d646.s0.e5" origId="O59933,P53045,Q15800" charOffset="165-170" type="protein" text="ERG25"/>
            <entity id="DS.d646.s0.e6" origId="P53199" charOffset="175-180" type="protein" text="ERG26"/>
            <pair e1="DS.d646.s0.e0" e2="DS.d646.s0.e2" id="DS.d646.s0.i0" interaction="True"/>
            <pair e1="DS.d646.s0.e0" e2="DS.d646.s0.e3" id="DS.d646.s0.i1" interaction="True"/>
            <pair e1="DS.d646.s0.e0" e2="DS.d646.s0.e1" id="DS.d646.s0.i2" interaction="True"/>
            <pair e1="DS.d646.s0.e0" e2="DS.d646.s0.e5" id="DS.d646.s0.i3" interaction="True"/>
            <pair e1="DS.d646.s0.e0" e2="DS.d646.s0.e6" id="DS.d646.s0.i4" interaction="True"/>
            <pair e1="DS.d646.s0.e0" e2="DS.d646.s0.e4" id="DS.d646.s0.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d647" origId="18665046">
        <sentence id="DS.d647.s0" origId="18665046-1318" text="In prolonged OJ with LPS administration, hepatocyte apoptosis depending on Fas ligand expression significantly increased in association with a decrease in ATP contents, thus resulting in liver necrapoptosis.">
            <entity id="DS.d647.s0.e0" origId="P36940,P41047,P48023,P63306,P63307,P63308,Q861W5,Q9BDN1,Q9BEA8" charOffset="75-85" type="protein" text="Fas ligand"/>
            <entity id="DS.d647.s0.e1" origId="5957" charOffset="155-158" type="compound" text="ATP"/>
            <pair e1="DS.d647.s0.e1" e2="DS.d647.s0.e0" id="DS.d647.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d648" origId="18665051">
        <sentence id="DS.d648.s0" origId="18665051-1321" text="Administration of ethyl pyruvate to inhibit HMGB1 or anti-RAGE antibody could significantly decrease expression levels of CTLA-4, Foxp3 on Tregs, and IL-10 production after burns.">
            <entity id="DS.d648.s0.e0" origId="12041" charOffset="18-32" type="compound" text="ethyl pyruvate"/>
            <entity id="DS.d648.s0.e1" origId="P09793,P16410,P42072,Q9MYX7,Q9XSI1" charOffset="122-128" type="protein" text="CTLA-4"/>
            <entity id="DS.d648.s0.e2" origId="Q99JB6" charOffset="130-135" type="protein" text="Foxp3"/>
            <entity id="DS.d648.s0.e3" origId="O46673,O97798,P18893,P22301,P29456,P43480,P46651,P47965,P48411,P51496,P51497,P51746,P55029,P79338,Q0Z972,Q25BC1,Q28374,Q29055,Q29408,Q2PE73,Q5Q0V6,Q865X4,Q8MKG9,Q9JHK7,Q9TSJ4,Q9Z1Y5" charOffset="150-155" type="protein" text="IL-10"/>
            <pair e1="DS.d648.s0.e0" e2="DS.d648.s0.e2" id="DS.d648.s0.i0" interaction="True"/>
            <pair e1="DS.d648.s0.e0" e2="DS.d648.s0.e3" id="DS.d648.s0.i1" interaction="True"/>
            <pair e1="DS.d648.s0.e0" e2="DS.d648.s0.e1" id="DS.d648.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d649" origId="18665052">
        <sentence id="DS.d649.s0" origId="18665052-290" text="In contrast, the degree of (1) spinal cord inflammation and tissue injury (histological score), (2) nitrotyrosine and poly(adenosine diphosphate (ADP) ribose) formation, (3) iNOS expression, (4) nuclear factor-kappaB activation, and (5) apoptosis (terminal deoxynucleotidyltransferase-mediated dUTP-biotin end labeling, Bax, and Bcl-2) was markedly reduced in spinal cord tissue obtained from mice treated with glycyrrhizin extract (10 mg/kg, i.p., 30 min before and 1 and 6 h after SCI).">
            <entity id="DS.d649.s0.e0" origId="6022" charOffset="123-144" type="compound" text="adenosine diphosphate"/>
            <entity id="DS.d649.s0.e1" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="174-178" type="protein" text="iNOS"/>
            <entity id="DS.d649.s0.e2" origId="O02789,O57486,P04053,P06526,P09838,P36195,P42118,Q92089" charOffset="248-284" type="protein" text="terminal deoxynucleotidyltransferase"/>
            <entity id="DS.d649.s0.e3" origId="P27297,Q07813,Q63690" charOffset="320-323" type="protein" text="Bax"/>
            <entity id="DS.d649.s0.e4" origId="P10417,P49950" charOffset="329-334" type="protein" text="Bcl-2"/>
            <entity id="DS.d649.s0.e5" origId="3495,14982,128229,44260118,45358130,46878350" charOffset="411-423" type="compound" text="glycyrrhizin"/>
            <pair e1="DS.d649.s0.e0" e2="DS.d649.s0.e1" id="DS.d649.s0.i0" interaction="False"/>
            <pair e1="DS.d649.s0.e5" e2="DS.d649.s0.e3" id="DS.d649.s0.i1" interaction="True"/>
            <pair e1="DS.d649.s0.e0" e2="DS.d649.s0.e4" id="DS.d649.s0.i2" interaction="False"/>
            <pair e1="DS.d649.s0.e5" e2="DS.d649.s0.e1" id="DS.d649.s0.i3" interaction="True"/>
            <pair e1="DS.d649.s0.e0" e2="DS.d649.s0.e3" id="DS.d649.s0.i4" interaction="False"/>
            <pair e1="DS.d649.s0.e0" e2="DS.d649.s0.e2" id="DS.d649.s0.i5" interaction="False"/>
            <pair e1="DS.d649.s0.e5" e2="DS.d649.s0.e2" id="DS.d649.s0.i6" interaction="True"/>
            <pair e1="DS.d649.s0.e5" e2="DS.d649.s0.e4" id="DS.d649.s0.i7" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d650" origId="18665326">
        <sentence id="DS.d650.s0" origId="18665326-1562" text="Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis.">
            <entity id="DS.d650.s0.e0" origId="5213,31553,1548994,3086637,24832061,44147684" charOffset="0-9" type="compound" text="Silymarin"/>
            <entity id="DS.d650.s0.e1" origId="P08253,P33434,P33436,P50757,Q90611,Q9GLE5" charOffset="80-107" type="protein" text="matrix metalloproteinases-2"/>
            <pair e1="DS.d650.s0.e0" e2="DS.d650.s0.e1" id="DS.d650.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d650.s1" origId="18665326-1563" text="NDEA administered rats showed increased MCD as revealed by toluidine blue staining along with upregulated expressions of MMP-2 and MMP-9.">
            <entity id="DS.d650.s1.e0" origId="5921" charOffset="0-4" type="compound" text="NDEA"/>
            <entity id="DS.d650.s1.e1" origId="P08253,P33434,P33436,P50757,Q90611,Q9GLE5" charOffset="121-126" type="protein" text="MMP-2"/>
            <entity id="DS.d650.s1.e2" origId="O18733,P14780,P41245,P41246,P50282,P52176" charOffset="131-136" type="protein" text="MMP-9"/>
            <pair e1="DS.d650.s1.e0" e2="DS.d650.s1.e2" id="DS.d650.s1.i0" interaction="True"/>
            <pair e1="DS.d650.s1.e0" e2="DS.d650.s1.e1" id="DS.d650.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d650.s2" origId="18665326-1564" text="Silymarin treatment inhibited this increase in MCD and downregulated the expressions of MMP-2 and MMP-9 as revealed by Western blotting and immunohistochemistry.">
            <entity id="DS.d650.s2.e0" origId="5213,31553,1548994,3086637,24832061,44147684" charOffset="0-9" type="compound" text="Silymarin"/>
            <entity id="DS.d650.s2.e1" origId="P08253,P33434,P33436,P50757,Q90611,Q9GLE5" charOffset="88-93" type="protein" text="MMP-2"/>
            <entity id="DS.d650.s2.e2" origId="O18733,P14780,P41245,P41246,P50282,P52176" charOffset="98-103" type="protein" text="MMP-9"/>
            <pair e1="DS.d650.s2.e0" e2="DS.d650.s2.e1" id="DS.d650.s2.i0" interaction="True"/>
            <pair e1="DS.d650.s2.e0" e2="DS.d650.s2.e2" id="DS.d650.s2.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d650.s3" origId="18665326-1565" text="In conclusion, silymarin exerted beneficial effects on liver carcinogenesis by attenuating the recruitment of mast cells and thereby decreased the expressions of MMP-2 and MMP-9.">
            <entity id="DS.d650.s3.e0" origId="5213,31553,1548994,3086637,24832061,44147684" charOffset="15-24" type="compound" text="silymarin"/>
            <entity id="DS.d650.s3.e1" origId="P08253,P33434,P33436,P50757,Q90611,Q9GLE5" charOffset="162-167" type="protein" text="MMP-2"/>
            <entity id="DS.d650.s3.e2" origId="O18733,P14780,P41245,P41246,P50282,P52176" charOffset="172-177" type="protein" text="MMP-9"/>
            <pair e1="DS.d650.s3.e0" e2="DS.d650.s3.e1" id="DS.d650.s3.i0" interaction="True"/>
            <pair e1="DS.d650.s3.e0" e2="DS.d650.s3.e2" id="DS.d650.s3.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d651" origId="18665390">
        <sentence id="DS.d651.s0" origId="18665390-1624" text="As a result, combined glucose and insulin infusion significantly decreased plasma K+ concentration despite a significant decrease of urinary K+ excretion in sgk1+/+ but not in sgk1-/-mice.">
            <entity id="DS.d651.s0.e0" origId="206,5793,64689,79025" charOffset="22-29" type="compound" text="glucose"/>
            <entity id="DS.d651.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="34-41" type="protein" text="insulin"/>
            <pair e1="DS.d651.s0.e0" e2="DS.d651.s0.e1" id="DS.d651.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d652" origId="18665391">
        <sentence id="DS.d652.s0" origId="18665391-1625" text="While it is clearly demonstrated that members of the TRPC3/6/7 subfamily are activated by diacylglycerol, the mechanism by which phospholipase C activates members of the TRPC1/4/5 subfamily remains a mystery.">
            <entity id="DS.d652.s0.e0" origId="Q13507" charOffset="53-58" type="protein" text="TRPC3"/>
            <entity id="DS.d652.s0.e1" origId="6026790" charOffset="90-104" type="compound" text="diacylglycerol"/>
            <entity id="DS.d652.s0.e2" origId="O18784,P48995,Q9TUN9" charOffset="170-175" type="protein" text="TRPC1"/>
            <pair e1="DS.d652.s0.e1" e2="DS.d652.s0.e0" id="DS.d652.s0.i0" interaction="True"/>
            <pair e1="DS.d652.s0.e1" e2="DS.d652.s0.e2" id="DS.d652.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d652.s1" origId="18665391-1626" text="Depletion of polyphosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate (PIP2) through inhibition of phosphatidylinositol 4-kinase activates calcium entry and membrane currents in TRPC5-expressing but not in TRPC3-or TRPC7-expressing cells.">
            <entity id="DS.d652.s1.e1" origId="5311358" charOffset="54-91" type="compound" text="phosphatidylinositol 4,5-bisphosphate"/>
            <entity id="DS.d652.s1.e2" origId="P54677" charOffset="121-150" type="protein" text="phosphatidylinositol 4-kinase"/>
            <entity id="DS.d652.s1.e3" origId="O62852,Q9MYV9,Q9UL62" charOffset="200-205" type="protein" text="TRPC5"/>
            <entity id="DS.d652.s1.e4" origId="Q13507" charOffset="228-233" type="protein" text="TRPC3"/>
            <entity id="DS.d652.s1.e5" origId="O94759,Q9HCX4" charOffset="237-242" type="protein" text="TRPC7"/>
            <pair e1="DS.d652.s1.e1" e2="DS.d652.s1.e2" id="DS.d652.s1.i0" interaction="True"/>
            <pair e1="DS.d652.s1.e1" e2="DS.d652.s1.e4" id="DS.d652.s1.i1" interaction="False"/>
            <pair e1="DS.d652.s1.e1" e2="DS.d652.s1.e5" id="DS.d652.s1.i2" interaction="False"/>
            <pair e1="DS.d652.s1.e1" e2="DS.d652.s1.e3" id="DS.d652.s1.i3" interaction="False"/>
        </sentence>
        <sentence id="DS.d652.s2" origId="18665391-1627" text="Inclusion of polyphosphatidylinositol 4-phosphate or PIP2, but not phosphatidylinositol 3,4,5-trisphosphate, in the patch pipette inhibited TRPC5 currents.">
            <entity id="DS.d652.s2.e1" origId="643963" charOffset="67-107" type="compound" text="phosphatidylinositol 3,4,5-trisphosphate"/>
            <entity id="DS.d652.s2.e2" origId="O62852,Q9MYV9,Q9UL62" charOffset="140-145" type="protein" text="TRPC5"/>
            <pair e1="DS.d652.s2.e1" e2="DS.d652.s2.e2" id="DS.d652.s2.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d653" origId="18665432">
        <sentence id="DS.d653.s0" origId="18665432-1672" text="Osteogenic differentiation was enhanced after treatment with alendronate as confirmed by Alizarin Red S staining, elevated alkaline phosphatase activity and osteocalcin mRNA expression, a greater calcium peak by energy-dispersive xray spectrophotometry, and by immunofluorescence staining against CD44 by flow cytometric analysis.">
            <entity id="DS.d653.s0.e0" origId="2088" charOffset="61-72" type="compound" text="alendronate"/>
            <entity id="DS.d653.s0.e1" origId="O60109,P81800,P83456" charOffset="123-143" type="protein" text="alkaline phosphatase"/>
            <entity id="DS.d653.s0.e2" origId="P02819,P02821,P02823,P0C225,P0C226,P15504,P28317,P39056,P81455,P83005,P83238,P83473,P83489,P84348,P84349,P84350,P84351,Q7LZI4,Q8HYY9" charOffset="157-168" type="protein" text="osteocalcin"/>
            <entity id="DS.d653.s0.e3" origId="P14745,P16070,P20944,Q05078,Q28284,Q29423,Q60522" charOffset="297-301" type="protein" text="CD44"/>
            <pair e1="DS.d653.s0.e0" e2="DS.d653.s0.e2" id="DS.d653.s0.i0" interaction="True"/>
            <pair e1="DS.d653.s0.e0" e2="DS.d653.s0.e1" id="DS.d653.s0.i1" interaction="True"/>
            <pair e1="DS.d653.s0.e0" e2="DS.d653.s0.e3" id="DS.d653.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d654" origId="18667202">
        <sentence id="DS.d654.s0" origId="18667202-1391" text="Ghrelin inhibits contraction and proliferation of human aortic smooth muscle cells by cAMP/PKA pathway activation.">
            <entity id="DS.d654.s0.e0" origId="Q6BEG6,Q6BEG7,Q9BDJ6,Q9BEF8,Q9EQX0,Q9GKY5,Q9QYH7,Q9UBU3" charOffset="0-7" type="protein" text="Ghrelin"/>
            <entity id="DS.d654.s0.e1" origId="6076" charOffset="86-90" type="compound" text="cAMP"/>
            <pair e1="DS.d654.s0.e1" e2="DS.d654.s0.e0" id="DS.d654.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d654.s1" origId="18667202-1393" text="Ghrelin was able to inhibit angiotensin II-induced proliferation and contraction in a dose-response fashion via the cAMP/PKA pathway.">
            <entity id="DS.d654.s1.e0" origId="Q6BEG6,Q6BEG7,Q9BDJ6,Q9BEF8,Q9EQX0,Q9GKY5,Q9QYH7,Q9UBU3" charOffset="0-7" type="protein" text="Ghrelin"/>
            <entity id="DS.d654.s1.e1" origId="6076" charOffset="116-120" type="compound" text="cAMP"/>
            <pair e1="DS.d654.s1.e1" e2="DS.d654.s1.e0" id="DS.d654.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d655" origId="18667302">
        <sentence id="DS.d655.s0" origId="18667302-1496" text="The results indicated that the backbone of POP was composed of (1--&amp;gt;6)-linked-alpha-D-galactopyranosyl and (1--&amp;gt;2,6)-linked-alpha-D-galactopyranosyl residues, which were terminated with a single terminal (1--&amp;gt;)-beta-D-glucose residue at the O-2 position of galactosyl along the main chain in the ratio of 1:1:1.">
            <entity id="DS.d655.s0.e0" origId="Q9XF19" charOffset="43-46" type="protein" text="POP"/>
            <entity id="DS.d655.s0.e1" origId="439271" charOffset="87-105" type="compound" text="D-galactopyranosyl"/>
            <entity id="DS.d655.s0.e2" origId="439271" charOffset="136-154" type="compound" text="D-galactopyranosyl"/>
            <entity id="DS.d655.s0.e3" origId="206,64689" charOffset="220-234" type="compound" text="beta-D-glucose"/>
            <pair e1="DS.d655.s0.e3" e2="DS.d655.s0.e0" id="DS.d655.s0.i0" interaction="True"/>
            <pair e1="DS.d655.s0.e1" e2="DS.d655.s0.e0" id="DS.d655.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d655.s1" origId="18667302-1497" text="Preliminary tests in vitro showed POP is capable of enhancing concanavalin A (ConA)-or lipopolysaccharide (LPS)-induced lymphocyte proliferation, which suggested that POP could be a potential immunostimulating agent for use in functional foods or medicine against both pathogens and cancer.">
            <entity id="DS.d655.s1.e0" origId="Q9XF19" charOffset="34-37" type="protein" text="POP"/>
            <entity id="DS.d655.s1.e1" origId="P81460,P81461" charOffset="62-76" type="protein" text="concanavalin A"/>
            <entity id="DS.d655.s1.e2" origId="P02866,P14894,P81460,P81461" charOffset="78-82" type="protein" text="ConA"/>
            <entity id="DS.d655.s1.e3" origId="11970143" charOffset="87-105" type="compound" text="lipopolysaccharide"/>
            <entity id="DS.d655.s1.e4" origId="Q9XF19" charOffset="167-170" type="protein" text="POP"/>
            <pair e1="DS.d655.s1.e3" e2="DS.d655.s1.e2" id="DS.d655.s1.i0" interaction="False"/>
            <pair e1="DS.d655.s1.e3" e2="DS.d655.s1.e0" id="DS.d655.s1.i1" interaction="True"/>
            <pair e1="DS.d655.s1.e3" e2="DS.d655.s1.e1" id="DS.d655.s1.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d656" origId="18668138">
        <sentence id="DS.d656.s0" origId="18668138-492" text="Inhibition of the phosphatidyl-inositol-3 kinase/Akt pathway by wortmannin and specific abrogation of Akt1 protein using small-interfering RNA revealed a regulatory function of Akt1 in insulin-mediated VEGF biosynthesis in keratinocytes.">
            <entity id="DS.d656.s0.e0" origId="312145" charOffset="64-74" type="compound" text="wortmannin"/>
            <entity id="DS.d656.s0.e1" origId="P31750,P47196,Q8INB9,Q98TY9" charOffset="102-106" type="protein" text="Akt1"/>
            <entity id="DS.d656.s0.e2" origId="P31750,P47196,Q8INB9,Q98TY9" charOffset="177-181" type="protein" text="Akt1"/>
            <entity id="DS.d656.s0.e3" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="185-192" type="protein" text="insulin"/>
            <entity id="DS.d656.s0.e4" origId="P15691,P15692,P26617,P49151,P50412,P67964,P67965,Q99PS1,Q9GKR0,Q9MYV3" charOffset="202-206" type="protein" text="VEGF"/>
            <pair e1="DS.d656.s0.e0" e2="DS.d656.s0.e3" id="DS.d656.s0.i0" interaction="False"/>
            <pair e1="DS.d656.s0.e0" e2="DS.d656.s0.e4" id="DS.d656.s0.i1" interaction="False"/>
            <pair e1="DS.d656.s0.e0" e2="DS.d656.s0.e1" id="DS.d656.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d657" origId="18668211">
        <sentence id="DS.d657.s0" origId="18668211-556" text="Cross-linked hydrogels showed increased resistance to digestion by testicular hyaluronidase and hyaluronidase SD with increasing hyaluronan concentration.">
            <entity id="DS.d657.s0.e0" origId="P15316,P26831,P49370,P49371,Q08169,Q53591,Q54699,Q54873,Q59634,Q59801,Q9U6V9" charOffset="78-91" type="protein" text="hyaluronidase"/>
            <entity id="DS.d657.s0.e1" origId="P15316,P26831,P49370,P49371,Q08169,Q53591,Q54699,Q54873,Q59634,Q59801,Q9U6V9" charOffset="96-109" type="protein" text="hyaluronidase"/>
            <entity id="DS.d657.s0.e2" origId="24759" charOffset="129-139" type="compound" text="hyaluronan"/>
            <pair e1="DS.d657.s0.e2" e2="DS.d657.s0.e0" id="DS.d657.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d658" origId="18668222">
        <sentence id="DS.d658.s0" origId="18668222-95" text="Chlorpyrifos (CPF), a commonly used organophosphorus insecticide, induces acetylcholinesterase inhibition and cholinergic toxicity.">
            <entity id="DS.d658.s0.e0" origId="2730" charOffset="0-12" type="compound" text="Chlorpyrifos"/>
            <entity id="DS.d658.s0.e1" origId="Q867X2,Q867X3,Q86GC9,Q92081" charOffset="74-94" type="protein" text="acetylcholinesterase"/>
            <pair e1="DS.d658.s0.e0" e2="DS.d658.s0.e1" id="DS.d658.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d659" origId="18668243">
        <sentence id="DS.d659.s0" origId="18668243-580" text="Role of RNase L in apoptosis induced by 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine.">
            <entity id="DS.d659.s0.e0" origId="Q05823,Q05921" charOffset="8-15" type="protein" text="RNase L"/>
            <entity id="DS.d659.s0.e1" origId="56841052" charOffset="40-90" type="compound" text="1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine"/>
            <pair e1="DS.d659.s0.e1" e2="DS.d659.s0.e0" id="DS.d659.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d660" origId="18668351">
        <sentence id="DS.d660.s0" origId="18668351-55" text="It was observed that administration of the PKC inhibitor chelerythrine chloride (5 mg/kg) suppressed the activation of three exercise-induced PKC isoforms (PKCalpha, PKCdelta, and PKCepsilon) and attenuated the exercise-mediated reduction of myocardial infarct size during ischemia-reperfusion injury.">
            <entity id="DS.d660.s0.e0" origId="2703" charOffset="57-79" type="compound" text="chelerythrine chloride"/>
            <entity id="DS.d660.s0.e1" origId="P04409,P05696,P10102,P17252,P20444" charOffset="156-164" type="protein" text="PKCalpha"/>
            <entity id="DS.d660.s0.e2" origId="P10829" charOffset="166-174" type="protein" text="PKCdelta"/>
            <pair e1="DS.d660.s0.e0" e2="DS.d660.s0.e2" id="DS.d660.s0.i0" interaction="True"/>
            <pair e1="DS.d660.s0.e0" e2="DS.d660.s0.e1" id="DS.d660.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d661" origId="18668366">
        <sentence id="DS.d661.s0" origId="18668366-689" text="Capsaicin is known to have regulatory effects on gastrointestinal functions via the vanilloid receptor (VR1).">
            <entity id="DS.d661.s0.e0" origId="1548943" charOffset="0-9" type="compound" text="Capsaicin"/>
            <entity id="DS.d661.s0.e1" origId="Q8NER1" charOffset="104-107" type="protein" text="VR1"/>
            <pair e1="DS.d661.s0.e0" e2="DS.d661.s0.e1" id="DS.d661.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d662" origId="18670196">
        <sentence id="DS.d662.s0" origId="18670196-1382" text="Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that facilitates the transfer of neutral lipids and phospholipids between lipoproteins and contributes to the regulation of the plasma concentration of high density lipoprotein cholesterol (HDL-C).">
            <entity id="DS.d662.s0.e0" origId="P25914" charOffset="0-34" type="protein" text="Cholesteryl ester transfer protein"/>
            <entity id="DS.d662.s0.e1" origId="P11597,P22687,P25914,P47896" charOffset="36-40" type="protein" text="CETP"/>
            <entity id="DS.d662.s0.e2" origId="P08163" charOffset="54-66" type="protein" text="glycoprotein"/>
            <entity id="DS.d662.s0.e3" origId="P81182" charOffset="219-243" type="protein" text="high density lipoprotein"/>
            <entity id="DS.d662.s0.e4" origId="304,5997,6432564,11025495" charOffset="244-255" type="compound" text="cholesterol"/>
            <pair e1="DS.d662.s0.e4" e2="DS.d662.s0.e1" id="DS.d662.s0.i0" interaction="True"/>
            <pair e1="DS.d662.s0.e4" e2="DS.d662.s0.e3" id="DS.d662.s0.i1" interaction="True"/>
            <pair e1="DS.d662.s0.e4" e2="DS.d662.s0.e2" id="DS.d662.s0.i2" interaction="True"/>
            <pair e1="DS.d662.s0.e4" e2="DS.d662.s0.e0" id="DS.d662.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d663" origId="18670732">
        <sentence id="DS.d663.s0" origId="18670732-960" text="These studies frequently showed that erythropoietic stimulating agents (ESA) with oral or IV iron often resulted in improvement in left ventricular systolic and diastolic function, dilation, and hypertrophy, stabilization or improvement in renal function, reduced hospitalizations, diuretic dose, mitral regurgitation, pulmonary artery pressure, plasma volume, heart rate, serum brain natriuretic peptide levels, and the inflammatory markers C reactive protein and Interleukin 6, and an improvement in New York Heart Association class, exercise capacity, oxygen utilization during exercise, sleep apnea, caloric intake, depression, and quality of life.">
            <entity id="DS.d663.s0.e0" origId="P40753" charOffset="379-404" type="protein" text="brain natriuretic peptide"/>
            <entity id="DS.d663.s0.e1" origId="P41693" charOffset="465-478" type="protein" text="Interleukin 6"/>
            <entity id="DS.d663.s0.e2" origId="977" charOffset="555-561" type="compound" text="oxygen"/>
            <pair e1="DS.d663.s0.e2" e2="DS.d663.s0.e1" id="DS.d663.s0.i0" interaction="False"/>
            <pair e1="DS.d663.s0.e2" e2="DS.d663.s0.e0" id="DS.d663.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d664" origId="18670809">
        <sentence id="DS.d664.s0" origId="18670809-1037" text="DNA sequences of a calmodulin (CaM)-encoding gene region containing three exons, two introns and a 411-bp mt intergenic spacer (IGS) spanning the cytochrome b (cytb) and NADH 2 genes, were obtained from 49 Acropora species.">
            <entity id="DS.d664.s0.e0" origId="O02367,O16305,O60041,O82018,O94739,O96102,O97341,P02594,P02595,P02598,P02599,P04352,P04353,P04464,P05933,P05934,P05935,P06787,P07463,P11118,P11120,P11121,P15094,P17928,P18061,P21251,P23286,P24044,P27161,P27165,P27166,P41040,P41041,P48976,P60204,P60205,P60206,P61859,P61860,P61861,P62144,P62145,P62149,P62151,P62152,P62154,P62155,P62156,P62157,P62158,P62160,P62161,P62162,P62184,P62201,P62202,P62203,P62204,P69097,P69098,P84339,P93087,P93171,Q05055,Q39752,Q40302,Q5EHV7,Q5RAD2,Q6IT78,Q6PI52,Q6R520,Q6YNX6,Q71UH5,Q71UH6,Q7T3T2,Q7Y052,Q8STF0,Q8X187,Q95NI4,Q95NR9,Q9GRJ1,Q9HFY6,Q9U6D3,Q9UWF0" charOffset="19-29" type="protein" text="calmodulin"/>
            <entity id="DS.d664.s0.e1" origId="O02367,O16305,O60041,O82018,O94739,O96102,O97341,P02594,P02595,P02598,P02599,P04352,P04353,P04464,P05933,P05934,P05935,P06787,P07463,P11118,P11120,P11121,P15094,P17928,P18061,P21251,P23286,P24044,P27161,P27165,P27166,P41040,P41041,P48976,P60204,P60205,P60206,P61859,P61860,P61861,P62144,P62145,P62149,P62151,P62152,P62154,P62155,P62156,P62157,P62158,P62160,P62161,P62162,P62184,P62201,P62202,P62203,P62204,P69097,P69098,P84339,P93087,P93171,Q00168,Q05055,Q39752,Q40302,Q5EHV7,Q5RAD2,Q6IT78,Q6PI52,Q6R520,Q6YNX6,Q71UH5,Q71UH6,Q7T3T2,Q7Y052,Q8STF0,Q8X187,Q95NI4,Q95NR9,Q9GRJ1,Q9HFY6,Q9U6D3,Q9UWF0" charOffset="31-34" type="protein" text="CaM"/>
            <entity id="DS.d664.s0.e2" origId="O03176,O03207,O03363,O03473,O03474,O03478,O03503,O03520,O03522,O03523,O03538,O03543,O03545,O03548,O03553,O03713,O03810,O03811,O03812,O20433,O20434,O20435,O20539,O20540,O20544,O20546,O20547,O20549,O20603,O20604,O20611,O20612,O20613,O20644,O20645,O20672,O20964,O20965,O20968,O20998,O21159,O21163,O21166,O21167,O21175,O21205,O21217,O21220,O21223,O21224,O21298,O21337,O21366,O21411,O21414,O21416,O21424,O21425,O21764,O21789,O21795,O21804,O21807,O21816,O31215,O47414,O47415,O47419,O47420,O47421,O47431,O47477,O47488,O47499,O47554,O47555,O47556,O47557,O47558,O47560,O47561,O47583,O47584,O47714,O47716,O47718,O47721,O47723,O47885,O47890,O47892,O47893,O47922,O47923,O47924,O47926,O47930,O47976,O47993,O48001,O48009,O48010,O48012,O48014,O48017,O48023,O48025,O48027,O48039,O48041,O48043,O48047,O48049,O48052,O48053,O48055,O48057,O48060,O48062,O48063,O48065,O48066,O48067,O48073,O48076,O48079,O48080,O48085,O48087,O48089,O48090,O48092,O48093,O48094,O48096,O48098,O48100,O48101,O48102,O48106,O48109,O48111,O48114,O48277,O48285,O48309,O48321,O48334,O48336,O48350,O48372,O54070,O63534,O63535,O63536,O63537,O63696,O63699,O63848,O78690,O78742,O78761,O78773,O78774,O78775,O78776,O78777,O78778,O78779,O78780,O78781,O78782,O78783,O78784,O78785,O78786,O78787,O78788,O78789,O78790,O78858,O78927,O78928,O78929,O78930,O78931,O78932,O78933,O78934,O78935,O78936,O78937,O79122,O79195,O79196,O79197,O79198,O79199,O79200,O79201,O79202,O79203,O79204,O79205,O79206,O79207,O79208,O79209,O79210,O79211,O79212,O79213,O79215,O79216,O79217,O79218,O79219,O79220,O79221,O79222,O79223,O79224,O79225,O79226,O79227,O79228,O79229,O79230,O79274,O79311,O79327,O79360,O79386,O79413,O79426,O79440,O79445,O79446,O79447,O79448,O79450,O79451,O79452,O79453,O79454,O79455,O79460,O79461,O79462,O79463,O79464,O79465,O79468,O79512,O79520,O79524,O79558,O79648,O79652,O79657,O79659,O79660,O79680,O79785,O79925,O79927,O79936,O79967,O79969,O79980,O79993,O79996,O79997,O80005,O80019,O99240,O99253,O99256,O99257,O99258,O99338,O99342,O99343,O99345,O99468,O99655,O99795,O99797,O99798,O99799,O99800,O99828,P00156,P00157,P00158,P00159,P00160,P00161,P00162,P00163,P00164,P04165,P05418,P05501,P05718,P07704,P07747,P08502,P09843,P11669,P12778,P14548,P14833,P15547,P15585,P16357,P16358,P16359,P16360,P16362,P16363,P16364,P16366,P16367,P16674,P18935,P18946,P21713,P21714,P21715,P21716,P21717,P21718,P21719,P21720,P21721,P21722,P21723,P23134,P23662,P23663,P24878,P24890,P24950,P24951,P24952,P24953,P24954,P24955,P24956,P24957,P24958,P24959,P24960,P24962,P24964,P24965,P24966,P24992,P26852,P29630,P29631,P29632,P29633,P29634,P29635,P29636,P29637,P29638,P29639,P29640,P29641,P29642,P29663,P29664,P29665,P29666,P29667,P29668,P29669,P29670,P29671,P29672,P29757,P33501,P34197,P34844,P34845,P34860,P34861,P34862,P34863,P34864,P34865,P34866,P34867,P34868,P34869,P34870,P34871,P34872,P34873,P34874,P34875,P34876,P35075,P38593,P38594,P39480,P41280,P41281,P41282,P41283,P41284,P41285,P41286,P41287,P41288,P41289,P41290,P41303,P42792,P48173,P48517,P48518,P48519,P48520,P48521,P48665,P48875,P48876,P48877,P48884,P48885,P48886,P49341,P49390,P50663,P51131,P51941,P56629,P56630,P56631,P56697,P56731,P62513,P68090,P68091,P68092,P68093,P68094,P68095,P68533,P68534,P69219,P69220,P69221,P81376,P81378,P81381,P82045,P82046,P82047,P82048,P82049,P87410,P87416,P87419,P87421,P92472,P92487,P92493,P92509,P92583,P92584,P92592,P92599,P92600,P92605,P92651,P92657,P92658,P92671,P92701,P92717,P92723,P92845,P92846,P92847,P92848,P92849,P92850,P92852,P92853,P92857,P92870,Q00228,Q00530,Q02655,Q02761,Q02768,Q04910,Q04911,Q104Y0,Q104Y1,Q104Y3,Q1EG05,Q1H8Y8,Q1HUU1,Q1HUV6,Q1KTB0,Q1MWH4,Q1MWK0,Q1PG50,Q1PG51,Q1PG54,Q1PG55,Q1PG56,Q1PG57,Q1PG58,Q1X6J6,Q1X6K1,Q1XA12,Q1XA32,Q1XII1,Q1XII7,Q1XII9,Q1XIJ0,Q1XIJ4,Q1XIK7,Q1XIK9,Q1XIL4,Q1XIM0,Q1XIM1,Q1XIM5,Q1XIM8,Q1XIN0,Q1XIN1,Q1XIN6,Q1XIP1,Q1XIP3,Q1XIP4,Q1XIP7,Q1XIP8,Q1XIQ2,Q1XIQ3,Q1XIQ4,Q1ZYR2,Q20FQ1,Q20FQ2,Q20FQ7,Q20FR3,Q20FR8,Q20FS0,Q20K40,Q20K43,Q25CF7,Q288H1,Q288H2,Q288H4,Q288H5,Q2N2B5,Q2N2B8,Q2N2J6,Q2N2J7,Q2Q1V7,Q2TVN0,Q2TVN1,Q2Y060,Q2Y067,Q31652,Q31684,Q33377,Q33401,Q33452,Q33487,Q33500,Q33537,Q33568,Q33607,Q33629,Q33645,Q33688,Q33695,Q33697,Q33706,Q33723,Q33754,Q33772,Q33782,Q33784,Q33798,Q33800,Q33818,Q33842,Q33865,Q33887,Q33941,Q33950,Q33954,Q33976,Q33987,Q33989,Q34028,Q34045,Q34070,Q34101,Q34106,Q34107,Q34108,Q34161,Q34169,Q34172,Q34179,Q34235,Q34253,Q34254,Q34260,Q34261,Q34279,Q34289,Q34300,Q34301,Q34302,Q34306,Q34321,Q34340,Q34341,Q34376,Q34382,Q34399,Q34409,Q34459,Q34462,Q34471,Q34473,Q34501,Q34534,Q34607,Q34653,Q34677,Q34683,Q34717,Q34724,Q34732,Q34760,Q34814,Q34876,Q34889,Q34890,Q34891,Q34893,Q34900,Q34902,Q34916,Q34945,Q34952,Q34957,Q34972,Q34973,Q35000,Q35019,Q35020,Q35038,Q35054,Q35065,Q35066,Q35075,Q35076,Q35078,Q35083,Q35111,Q35113,Q35117,Q35118,Q35130,Q35131,Q35157,Q35160,Q35172,Q35196,Q35273,Q35350,Q35377,Q35380,Q35409,Q35425,Q35438,Q35457,Q35459,Q35467,Q35468,Q35485,Q35505,Q35506,Q35516,Q35518,Q35522,Q35532,Q35533,Q35534,Q35553,Q35558,Q35614,Q35618,Q35621,Q35630,Q35653,Q35673,Q35675,Q35677,Q35695,Q35727,Q35805,Q35810,Q35819,Q35861,Q35873,Q35877,Q35886,Q35895,Q35925,Q35930,Q35942,Q35966,Q35968,Q35994,Q36012,Q36035,Q36055,Q36058,Q36082,Q36089,Q36096,Q36099,Q36118,Q36128,Q36192,Q36194,Q36201,Q36209,Q36222,Q36227,Q36229,Q36262,Q36266,Q36291,Q36294,Q36311,Q36319,Q36324,Q36368,Q36427,Q36445,Q36461,Q36507,Q36548,Q36549,Q36551,Q36572,Q36590,Q36644,Q36654,Q36659,Q36922,Q36976,Q37006,Q37064,Q37078,Q37080,Q37311,Q37378,Q37395,Q37713,Q3L2T5,Q3L6X7,Q3L701,Q3LTW2,Q3LZS3,Q3T4C8,Q3T4F1,Q3YLA8,Q3YLC2,Q3ZEC1,Q3ZEC3,Q3ZEC9,Q3ZED1,Q3ZEG3,Q4FBI3,Q4JQH5,Q4QXK3,Q4UJ67,Q4VGP8,Q4VKI6,Q4VKI7,Q4VUT8,Q4VUU0,Q4VUU2,Q4VUU4,Q4VUV4,Q4VUV8,Q4VUV9,Q4VUY0,Q4VUY6,Q4VUY8,Q4VUY9,Q4VWH4,Q4VWH9,Q508J0,Q508J1,Q508J2,Q508J3,Q508J4,Q508J5,Q508J7,Q508J9,Q508K1,Q508K2,Q508K4,Q508K5,Q508K6,Q508K7,Q508K8,Q508K9,Q508L0,Q508L1,Q508L2,Q508L3,Q508L4,Q508L6,Q508L8,Q508M1,Q508M2,Q508M3,Q508M4,Q508M6,Q508M8,Q508M9,Q508N0,Q508N1,Q508N2,Q508N3,Q508N6,Q508P2,Q50DL8,Q539B4,Q539Z1,Q53AJ7,Q53AK6,Q53AK8,Q53AL7,Q53AM3,Q564N6,Q564N8,Q564P1,Q564P2,Q58F56,Q58F69,Q58F82,Q597C5,Q597C7,Q597E2,Q597E3,Q597E4,Q597E6,Q597E7,Q597E8,Q597E9,Q597F0,Q597F1,Q597F2,Q598T9,Q598V2,Q599A4,Q5BQG8,Q5BQG9,Q5BU73,Q5C9H5,Q5DWG5,Q5DX17,Q5F4E4,Q5F4E8,Q5F4F1,Q5F4F4,Q5F4F5,Q5F4G0,Q5F4G2,Q5F4G3,Q5F4G7,Q5F4G9,Q5I191,Q5J1T0,Q5J1T3,Q5J1T4,Q5J1T5,Q5NUR5,Q5NUR7,Q5QD74,Q5QD76,Q5QFW4,Q5QFW5,Q5QFW6,Q5QS02,Q5QS15,Q5QS28,Q5QS41,Q5QS67,Q5S1V3,Q5UVI3,Q5UVI4,Q5UVI5,Q5UVI6,Q5UVI8,Q5UVJ0,Q5VJ36,Q5VJ37,Q5VJ39,Q5VJ41,Q5VJ42,Q5VJ44,Q5VJ45,Q5VJ46,Q5VJ49,Q5VJ50,Q5VJ52,Q5VJ55,Q5VJ57,Q5VJ58,Q5VJ59,Q5VJ60,Q5VJ61,Q5VJ65,Q5VJ67,Q5Y4Q0,Q5YBK0,Q5YJ58,Q5YJ78,Q5YJ93,Q5YKK4,Q5ZN98,Q64GI8,Q64GJ1,Q64J97,Q64JA0,Q678S1,Q678S2,Q678S3,Q678S5,Q678S8,Q678S9,Q692W3,Q698P7,Q6DUL2,Q6ED58,Q6ELU6,Q6ELU7,Q6ELU8,Q6ELU9,Q6ELV2,Q6ELV4,Q6ELV5,Q6ELV7,Q6ELV8,Q6ELV9,Q6ELW1,Q6ELW2,Q6ELW3,Q6ELW6,Q6IYG6,Q6JDN5,Q6JDP8,Q6JDQ6,Q6JDS2,Q6JDS4,Q6JDS5,Q6JDS6,Q6JDS8,Q6JDT0,Q6JDT3,Q6JDT4,Q6JDT8,Q6JDU0,Q6JDU8,Q6JWX5,Q6KF39,Q6KF53,Q6RSH5,Q6RSH6,Q6SQI7,Q6U1P6,Q6V8Y0,Q6V8Y1,Q6V9D6,Q6W6K7,Q6W6L7,Q6WRG2,Q6WRG3,Q6WRG4,Q6WRG7,Q6WRH2,Q6WRH4,Q6WRH5,Q6X2M0,Q6X9S4,Q6XBV1,Q6XBV6,Q6XBW1,Q6XBW4,Q6XBW5,Q6XBW7,Q6XBW8,Q6XZH2,Q6XZH3,Q6XZN8,Q6XZN9,Q6XZP4,Q6Y8J2,Q6Y8J6,Q6Y8J7,Q6YDK5,Q6YDK7,Q6YDL2,Q6YDL6,Q6YDL7,Q6YLN1,Q70RT7,Q70RV0,Q70RW3,Q70XG0,Q70XI6,Q710S3,Q711L6,Q71E87,Q71E89,Q71E95,Q71E97,Q71E99,Q71EA6,Q71EB0,Q71FH1,Q71FH2,Q71FI6,Q71FI8,Q71FI9,Q71FJ0,Q71FJ2,Q71MR3,Q71MR6,Q71RU1,Q75R30,Q76LN6,Q76MX5,Q7GEV4,Q7GGQ9,Q7GI23,Q7HEI2,Q7HFF9,Q7HFG0,Q7HKW1,Q7IY93,Q7IY99,Q7IYN8,Q7IYZ1,Q7J370,Q7J6I1,Q7JE02,Q7Y5X9,Q7Y778,Q7Y779,Q7Y7B2,Q7Y8F6,Q7Y8I2,Q7Y8J5,Q7Y8K8,Q7Y8L0,Q7Y8L4,Q7Y8L5,Q7Y8L6,Q7Y8L9,Q7Y8M0,Q7YA49,Q7YBY4,Q7YBY6,Q7YC63,Q7YC71,Q7YC73,Q7YC74,Q7YC75,Q7YC76,Q7YD12,Q7YD13,Q7YD16,Q7YD72,Q7YD73,Q7YD75,Q7YEV2,Q7YGD4,Q85AG5,Q85AV3,Q85C06,Q85C43,Q85DD9,Q85DE4,Q85DF2,Q85DF5,Q85DF8,Q85IN3,Q85IN4,Q85IN5,Q85IN6,Q85IN7,Q85IN8,Q85IN9,Q85PK7,Q85PM6,Q85PN0,Q85PN4,Q85PN6,Q85PN7,Q85PN8,Q85PP0,Q85PP1,Q85Q58,Q85QA4,Q85RV3,Q8HCJ4,Q8HD57,Q8HD60,Q8HEC2,Q8HEM1,Q8HF67,Q8HG55,Q8HL81,Q8HL93,Q8HLB9,Q8HLD2,Q8HLR2,Q8HMZ7,Q8HQ92,Q8HQE6,Q8HQE7,Q8HQE8,Q8HQE9,Q8HQF0,Q8HQF1,Q8HQF2,Q8LW83,Q8LWM2,Q8LWM4,Q8LWN0,Q8LWP6,Q8LWU4,Q8LX87,Q8LZ88,Q8LZ94,Q8LZ97,Q8M0A6,Q8M0E7,Q8M0K7,Q8M0K9,Q8M354,Q8M3J6,Q8M4C6,Q8M4C7,Q8M4D6,Q8M4E2,Q8M4E6,Q8M5M3,Q8M6Z3,Q8M700,Q8M703,Q8M706,Q8M708,Q8SE00,Q8SE72,Q8SE77,Q8SE89,Q8SEH7,Q8SEJ1,Q8SEL4,Q8SEP4,Q8SET9,Q8SFK5,Q8SFK7,Q8SG72,Q8SGA0,Q8SGQ9,Q8SJB6,Q8SJK5,Q8SJK6,Q8SJK7,Q8SJK8,Q8SJK9,Q8SJL1,Q8SJL2,Q8SJL3,Q8SJX4,Q8SJX5,Q8SJZ1,Q8SJZ2,Q8SJZ3,Q8SJZ4,Q8W7G4,Q8W822,Q8W8Q1,Q8W8W1,Q8W8Y1,Q8W926,Q8W9E4,Q8W9F5,Q8W9F9,Q8W9J6,Q8W9L2,Q8W9N7,Q8WA39,Q8WA47,Q8WB03,Q8WB05,Q8WBP9,Q8WBV2,Q8WCJ7,Q8WCK9,Q8WCL1,Q8WDK6,Q8WDU1,Q8WDV0,Q8WDV2,Q8WDV6,Q8WE97,Q8WEK2,Q8WEK7,Q8WEW8,Q8WFX3,Q8WGF6,Q8WGF7,Q8WGF8,Q8WGG5,Q8WGG8,Q8WGL0,Q94ND7,Q94NF7,Q94NM3,Q94P21,Q94PA3,Q94PB4,Q94Q38,Q94Q45,Q94Q84,Q94QD3,Q94QP2,Q94QQ7,Q94S37,Q94S78,Q94SA4,Q94SD0,Q94SJ5,Q94SK8,Q94SZ7,Q94T21,Q94T42,Q94T68,Q94TE4,Q94TI3,Q94UZ9,Q94V00,Q94V01,Q94V02,Q94VK4,Q94WP7,Q94WQ8,Q94WW5,Q94WW7,Q94WW9,Q94WX2,Q94WX4,Q94WX5,Q94WY6,Q94WY7,Q94Y46,Q94Y47,Q94Y50,Q94Y51,Q94Y56,Q94Y62,Q94Y64,Q94Y66,Q94Y71,Q94Y72,Q94YE5,Q94YL4,Q94YL5,Q94YL9,Q94ZD1,Q94ZJ2,Q94ZK8,Q950B9,Q950C2,Q950C6,Q950C7,Q950S3,Q951T4,Q951T6,Q953G9,Q953J5,Q953K8,Q955G5,Q955G6,Q956S6,Q956Y7,Q956Y9,Q956Z1,Q956Z2,Q956Z3,Q956Z5,Q956Z6,Q956Z7,Q956Z8,Q956Z9,Q95711,Q95718,Q95719,Q95723,Q95726,Q95727,Q95728,Q95729,Q95730,Q95731,Q95734,Q95735,Q95736,Q95737,Q95738,Q95739,Q95741,Q95744,Q95745,Q95750,Q95776,Q957A1,Q957A2,Q957A4,Q957A7,Q957A8,Q957A9,Q957B0,Q957B1,Q957B2,Q957B3,Q957B4,Q957B5,Q957B6,Q957B7,Q957B8,Q957B9,Q957C1,Q957C3,Q957C6,Q957C7,Q957C8,Q957D1,Q95920,Q959V6,Q96071,Q9B0S2,Q9B0Y1,Q9B106,Q9B161,Q9B167,Q9B1D2,Q9B1N0,Q9B1X4,Q9B1Z4,Q9B203,Q9B205,Q9B2C4,Q9B2F7,Q9B365,Q9B506,Q9B5Q1,Q9B5Q3,Q9B5Q4,Q9B5Q5,Q9B5Q6,Q9B5Q7,Q9B5Q8,Q9B5Q9,Q9B5R0,Q9B5R1,Q9B5R2,Q9B5R3,Q9B5R7,Q9B5R8,Q9B5S0,Q9B5S1,Q9B6D0,Q9B6F0,Q9B7V7,Q9B7W1,Q9B7W3,Q9B9E4,Q9B9E8,Q9B9F5,Q9B9F6,Q9B9F9,Q9B9G0,Q9B9Z1,Q9BA02,Q9G0M4,Q9G0S9,Q9G0W6,Q9G156,Q9G1B9,Q9G1C4,Q9G1F7,Q9G1R4,Q9G1Z0,Q9G210,Q9G215,Q9G250,Q9G273,Q9G2R8,Q9G2S5,Q9G2U4,Q9G2U7,Q9G2W6,Q9G396,Q9G3M2,Q9G3M7,Q9G3M9,Q9G3N1,Q9G3N2,Q9G3N4,Q9G3R1,Q9G3S4,Q9G3T7,Q9G4Q1,Q9G6G2,Q9G6G3,Q9G6M3,Q9G7T9,Q9G7U1,Q9G946,Q9G964,Q9G9J4,Q9G9J6,Q9G9J7,Q9GA18,Q9GAM6,Q9GAM7,Q9GAM9,Q9GAN2,Q9GAN4,Q9GAP0,Q9GAR5,Q9GAR6,Q9GAW0,Q9GAW3,Q9GAW6,Q9GBG9,Q9GBY1,Q9GBY4,Q9GBY5,Q9GBY6,Q9GBY8,Q9GBZ0,Q9GBZ1,Q9GBZ2,Q9GBZ4,Q9GBZ5,Q9GBZ6,Q9GBZ7,Q9MDF2,Q9MDZ9,Q9MED6,Q9MFN3,Q9MFN9,Q9MG84,Q9MGL5,Q9MGM4,Q9MI31,Q9MI32,Q9MI35,Q9MI36,Q9MI37,Q9MI38,Q9MI39,Q9MI64,Q9MI97,Q9MIX8,Q9MIZ2,Q9MJ99,Q9MJA1,Q9MJA2,Q9MJV1,Q9MLD6,Q9MLD7,Q9MLI3,Q9MLI6,Q9MLI7,Q9MLI8,Q9MLI9,Q9MLJ0,Q9MLJ1,Q9MLJ2,Q9MLJ3,Q9MLJ4,Q9MLJ5,Q9MLJ6,Q9MLJ7,Q9MLJ8,Q9MLJ9,Q9MLK0,Q9MLK1,Q9MLK2,Q9MLK3,Q9MLK4,Q9MLK5,Q9MLK6,Q9MLK7,Q9MLK8,Q9MLK9,Q9MLL0,Q9MLL3,Q9MLL4,Q9MLL5,Q9MLL6,Q9MMZ2,Q9MQX1,Q9MQX8,Q9MQY0,Q9MQY1,Q9MQY3,Q9MQY5,Q9MQY6,Q9MR49,Q9T3H9,Q9T3Q2,Q9T3R3,Q9T3S9,Q9T3Y0,Q9T3Y2,Q9T3Y3,Q9T443,Q9T469,Q9T475,Q9T4A7,Q9T4B2,Q9T4N0,Q9T4P2,Q9T4R0,Q9T4U3,Q9T5N4,Q9T6I4,Q9T6J0,Q9T6R2,Q9T6R3,Q9T6R5,Q9T6R8,Q9T6R9,Q9T7L5,Q9T7L6,Q9T7L7,Q9T7L8,Q9T7L9,Q9T7M0,Q9T7M3,Q9T7N2,Q9T7N5,Q9T7P0,Q9T7P1,Q9T7Q0,Q9T7Q5,Q9T7Q6,Q9T7Q8,Q9T7Q9,Q9T7S2,Q9T7T7,Q9T7T8,Q9T7T9,Q9T9A5,Q9T9A6,Q9T9A7,Q9T9A8,Q9T9B2,Q9T9B6,Q9T9B7,Q9T9B9,Q9T9C0,Q9T9C1,Q9T9C8,Q9T9I2,Q9T9I7,Q9T9J2,Q9T9J5,Q9T9V5,Q9T9W4,Q9T9Y3,Q9TA00,Q9TAB1,Q9TAD3,Q9TDJ6,Q9TDJ9,Q9TDK1,Q9TDK2,Q9TDK4,Q9TDK6,Q9TDK7,Q9TDK9,Q9TDL0,Q9TDL1,Q9TDL2,Q9TDL3,Q9TDL4,Q9TDL5,Q9TDL6,Q9TDL7,Q9TDL8,Q9TDL9,Q9TDM0,Q9TDM1,Q9TDM3,Q9TDM5,Q9TDM6,Q9TDM7,Q9TDN0,Q9TDN1,Q9TDN2,Q9TDQ5,Q9TDQ7,Q9TDT5,Q9TEB4,Q9TEB5,Q9TEC1,Q9TEU7,Q9TEX8,Q9TEY4,Q9TEY5,Q9TEY6,Q9TEY7,Q9TEY8,Q9TEZ5,Q9TF10,Q9TF12,Q9TF14,Q9TF17,Q9TF20,Q9TF27,Q9TF30,Q9TF31,Q9TF32,Q9TF34,Q9TF37,Q9TF45,Q9TF46,Q9TF47,Q9TF49,Q9TF50,Q9TF51,Q9TF52,Q9TF55,Q9TF57,Q9TF61,Q9TF73,Q9TF74,Q9TF80,Q9TF86,Q9TF89,Q9TF91,Q9TF93,Q9TF95,Q9TFA0,Q9TFX4,Q9TFX5,Q9TFX6,Q9TG16,Q9TGH6,Q9TGH8,Q9TGL9,Q9TH43,Q9TH45,Q9TH46,Q9TH47,Q9TH52,Q9TH56,Q9THD6,Q9XK52,Q9XK70,Q9XKC0,Q9XKK0,Q9XKK2,Q9XKK5,Q9XLE0,Q9XLE1,Q9XLE2,Q9XM10,Q9XMC1,Q9XMC2,Q9XNM0,Q9XNM1,Q9XNM5,Q9XNN0,Q9XNN1,Q9XNN3,Q9XNN4,Q9XNT9,Q9XNU0,Q9XNU2,Q9XNU4,Q9XNU5,Q9XNU6,Q9XNU9,Q9XNV3,Q9XNV4,Q9XNV7,Q9XNW3,Q9XNW4,Q9XNW5,Q9XNW7,Q9XNW8,Q9XNW9,Q9XNX0,Q9XNX1,Q9XNX3,Q9XNX4,Q9XNX6,Q9XNX7,Q9XNX8,Q9XP34,Q9XP68,Q9XP73,Q9XP76,Q9XP77,Q9XP78,Q9XP81,Q9XP82,Q9XP83,Q9XP84,Q9XP86,Q9XP87,Q9XP88,Q9XP89,Q9ZY14,Q9ZY15,Q9ZY46,Q9ZY49,Q9ZZ40,Q9ZZ42,Q9ZZD2,Q9ZZD4,Q9ZZD8,Q9ZZE3,Q9ZZE4,Q9ZZF6,Q9ZZR4,Q9ZZT5,Q9ZZT6,Q9ZZT7,Q9ZZT8,Q9ZZU1" charOffset="146-158" type="protein" text="cytochrome b"/>
            <entity id="DS.d664.s0.e3" origId="P00158,P00159,P00160,P00162,P05501,P07704,P18935,P24890,P51941,Q8HEC2,Q8HMZ7,Q8HQ92,Q8WA47,Q9MDZ9,Q9MGL5,Q9MGM4,Q9MIX8" charOffset="160-164" type="protein" text="cytb"/>
            <entity id="DS.d664.s0.e4" origId="439153" charOffset="170-174" type="compound" text="NADH"/>
            <pair e1="DS.d664.s0.e4" e2="DS.d664.s0.e1" id="DS.d664.s0.i0" interaction="False"/>
            <pair e1="DS.d664.s0.e4" e2="DS.d664.s0.e2" id="DS.d664.s0.i1" interaction="False"/>
            <pair e1="DS.d664.s0.e4" e2="DS.d664.s0.e3" id="DS.d664.s0.i2" interaction="False"/>
            <pair e1="DS.d664.s0.e4" e2="DS.d664.s0.e0" id="DS.d664.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d665" origId="18670810">
        <sentence id="DS.d665.s0" origId="18670810-1039" text="Both expression of tac and tac2 were induced by 2% sucrose.">
            <entity id="DS.d665.s0.e0" origId="P06767,P08435,P41539,P55099" charOffset="27-31" type="protein" text="tac2"/>
            <entity id="DS.d665.s0.e1" origId="5988" charOffset="51-58" type="compound" text="sucrose"/>
            <pair e1="DS.d665.s0.e1" e2="DS.d665.s0.e0" id="DS.d665.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d666" origId="18670880">
        <sentence id="DS.d666.s0" origId="18670880-1082" text="Contaminants of current high use in the LRGV, such as atrazine, and some of the highly persistent organochlorines, such as toxaphene and DDE, could be potentially associated with modulation of aromatase activity in avian tissues.">
            <entity id="DS.d666.s0.e0" origId="2256" charOffset="54-62" type="compound" text="atrazine"/>
            <entity id="DS.d666.s0.e1" origId="5284469" charOffset="123-132" type="compound" text="toxaphene"/>
            <entity id="DS.d666.s0.e2" origId="3035" charOffset="137-140" type="compound" text="DDE"/>
            <entity id="DS.d666.s0.e3" origId="O42145,O46512,P11511,P19098,P22443,P28649,P46194,P70091,P79304,P79430,P79699,Q29605,Q29624,Q5QQX7,Q69FB6,Q6QHT9,Q6YI21,Q92087,Q92111,Q92112,Q95M61,Q9XS28" charOffset="193-202" type="protein" text="aromatase"/>
            <pair e1="DS.d666.s0.e1" e2="DS.d666.s0.e3" id="DS.d666.s0.i0" interaction="True"/>
            <pair e1="DS.d666.s0.e0" e2="DS.d666.s0.e3" id="DS.d666.s0.i1" interaction="True"/>
            <pair e1="DS.d666.s0.e2" e2="DS.d666.s0.e3" id="DS.d666.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d667" origId="18670892">
        <sentence id="DS.d667.s0" origId="18670892-1460" text="In this view, this study aimed at the investigating the use of a crude peroxidase preparation from onion solid by-products for oxidising caffeic acid, a widespread o-diphenol, whose various derivatives may occur in food industry wastes, such as olive mill waste waters.">
            <entity id="DS.d667.s0.e0" origId="P15984,P16147,P84714" charOffset="71-81" type="protein" text="peroxidase"/>
            <entity id="DS.d667.s0.e1" origId="689043" charOffset="137-149" type="compound" text="caffeic acid"/>
            <pair e1="DS.d667.s0.e1" e2="DS.d667.s0.e0" id="DS.d667.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d668" origId="18670896">
        <sentence id="DS.d668.s0" origId="18670896-1090" text="Ziram exposures that caused a loss of binding function were examined for effects on expression of key NK cell-surface proteins needed for binding to targets.">
            <entity id="DS.d668.s0.e0" origId="6599" charOffset="0-5" type="compound" text="Ziram"/>
            <entity id="DS.d668.s0.e1" origId="O12164,O41803,O42043,O56861,O70902,O71037,O89292,O91086,P03374,P03375,P03377,P03378,P03379,P03380,P03381,P03383,P03385,P03386,P03387,P03388,P03390,P03391,P03392,P03395,P03396,P03397,P03399,P04027,P04502,P04577,P04578,P04579,P04580,P04581,P04582,P04583,P04624,P05877,P05878,P05879,P05880,P05881,P05882,P05883,P05884,P05885,P05886,P06445,P06751,P06752,P07575,P08359,P08360,P08810,P0C212,P10259,P10267,P10269,P11261,P11267,P11268,P11306,P12449,P12487,P12488,P12489,P12492,P14075,P14351,P15073,P15831,P16082,P16090,P16899,P17281,P17755,P18040,P18094,P18799,P19030,P19503,P19549,P19550,P19551,P19556,P19557,P20871,P20872,P20888,P21412,P21415,P21436,P21443,P21444,P21445,P22380,P22427,P22428,P22429,P22430,P23064,P23073,P23422,P23423,P24105,P25057,P25504,P25505,P25506,P25507,P26803,P26804,P27399,P27757,P27977,P31621,P31626,P31627,P31789,P31791,P31794,P31796,P31819,P31872,P32536,P32541,P33498,P35954,P35961,P51515,P51519,P51520,P60507,P60508,P60608,P61549,P61550,P61552,P61553,P61554,P61555,P61556,P61557,P61558,P61559,P61561,P61562,P61563,P61564,P61565,P61566,P61567,P61570,Q02076,Q02077,Q02282,Q02837,Q03804,Q03816,Q03817,Q04993,Q04995,Q05312,Q09SZ7,Q0R5Q9,Q14264,Q1A243,Q1A261,Q69384,Q70626,Q73372,Q74126,Q75008,Q76638,Q77377,Q79670,Q85646,Q89607,Q8AIH5,Q8MIB6,Q902F8,Q902F9,Q96L62,Q9IDV2,Q9N2J8,Q9N2J9,Q9N2K0,Q9NX77,Q9Q714,Q9QBY2,Q9QBZ0,Q9QBZ4,Q9QBZ8,Q9QSQ7,Q9TTC0,Q9UKH3,Q9UQF0,Q9WC60,Q9WC69" charOffset="110-126" type="protein" text="surface proteins"/>
            <pair e1="DS.d668.s0.e0" e2="DS.d668.s0.e1" id="DS.d668.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d669" origId="18670905">
        <sentence id="DS.d669.s0" origId="18670905-814" text="Here, we have investigated how the post-synthetic acetylation of HMGB1 affects its interaction with negatively supercoiled DNA by employing monoacetylated at Lys2 protein, isolated from butyrate-treated cells.">
            <entity id="DS.d669.s0.e0" origId="P07156,P09429,P10103,P12682,P36194,Q4R844,Q6YKA4" charOffset="65-70" type="protein" text="HMGB1"/>
            <entity id="DS.d669.s0.e1" origId="264" charOffset="186-194" type="compound" text="butyrate"/>
            <pair e1="DS.d669.s0.e1" e2="DS.d669.s0.e0" id="DS.d669.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d670" origId="18670906">
        <sentence id="DS.d670.s0" origId="18670906-1096" text="KAP8.1 protein contains high glycine and tyrosine, which concerns regulation and function of the matrix structure fiber.">
            <entity id="DS.d670.s0.e0" origId="Q8IUC2" charOffset="0-6" type="protein" text="KAP8.1"/>
            <entity id="DS.d670.s0.e1" origId="750" charOffset="29-36" type="compound" text="glycine"/>
            <entity id="DS.d670.s0.e2" origId="1153,6057,5460803" charOffset="41-49" type="compound" text="tyrosine"/>
            <pair e1="DS.d670.s0.e2" e2="DS.d670.s0.e0" id="DS.d670.s0.i0" interaction="True"/>
            <pair e1="DS.d670.s0.e1" e2="DS.d670.s0.e0" id="DS.d670.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d671" origId="18671273">
        <sentence id="DS.d671.s0" origId="18671273-1368" text="Cycloheximide inhibited MIH induced Mos expression and its phosphorylation, which in turn reduced Myt1 phosphorylation and GVBD.">
            <entity id="DS.d671.s0.e0" origId="6197" charOffset="0-13" type="compound" text="Cycloheximide"/>
            <entity id="DS.d671.s0.e1" origId="O61389,O96605,P19806,P55321,P55846,P55847,P55848,P83220,P83636,Q10987,Q27225" charOffset="24-27" type="protein" text="MIH"/>
            <entity id="DS.d671.s0.e2" origId="P00536,P00539,P12965" charOffset="36-39" type="protein" text="Mos"/>
            <entity id="DS.d671.s0.e3" origId="P70047,Q8CFC2,Q91618,Q9ESG9,Q9NI63" charOffset="98-102" type="protein" text="Myt1"/>
            <pair e1="DS.d671.s0.e0" e2="DS.d671.s0.e3" id="DS.d671.s0.i0" interaction="True"/>
            <pair e1="DS.d671.s0.e0" e2="DS.d671.s0.e2" id="DS.d671.s0.i1" interaction="True"/>
            <pair e1="DS.d671.s0.e0" e2="DS.d671.s0.e1" id="DS.d671.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d672" origId="18671672">
        <sentence id="DS.d672.s0" origId="18671672-48" text="CLNO2 levels were found to increase approximately 20-fold 24 h after macrophage activation with Escherichia coli lipopolysaccharide plus interferon-gamma ; this response was concurrent with an increase in the expression of NOS2 (inducible nitric oxide synthase) and was inhibited by the (*)NO (nitric oxide) inhibitor L-NAME (N(G)-nitro-L-arginine methyl ester).">
            <entity id="DS.d672.s0.e0" origId="11984615" charOffset="0-5" type="compound" text="CLNO2"/>
            <entity id="DS.d672.s0.e1" origId="11970143" charOffset="113-131" type="compound" text="lipopolysaccharide"/>
            <entity id="DS.d672.s0.e2" origId="Q9TTB0" charOffset="137-153" type="protein" text="interferon-gamma"/>
            <entity id="DS.d672.s0.e3" origId="O19114,O46660,O54705,O62699,P35228,P60321,P79290,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="223-227" type="protein" text="NOS2"/>
            <entity id="DS.d672.s0.e4" origId="O61309,O61608,Q27571,Q9I9M2" charOffset="239-260" type="protein" text="nitric oxide synthase"/>
            <entity id="DS.d672.s0.e6" origId="39836" charOffset="326-360" type="compound" text="N(G)-nitro-L-arginine methyl ester"/>
            <pair e1="DS.d672.s0.e0" e2="DS.d672.s0.e2" id="DS.d672.s0.i0" interaction="True"/>
            <pair e1="DS.d672.s0.e6" e2="DS.d672.s0.e2" id="DS.d672.s0.i1" interaction="False"/>
            <pair e1="DS.d672.s0.e0" e2="DS.d672.s0.e4" id="DS.d672.s0.i2" interaction="True"/>
            <pair e1="DS.d672.s0.e1" e2="DS.d672.s0.e3" id="DS.d672.s0.i4" interaction="True"/>
            <pair e1="DS.d672.s0.e6" e2="DS.d672.s0.e3" id="DS.d672.s0.i5" interaction="False"/>
            <pair e1="DS.d672.s0.e1" e2="DS.d672.s0.e4" id="DS.d672.s0.i6" interaction="False"/>
            <pair e1="DS.d672.s0.e0" e2="DS.d672.s0.e3" id="DS.d672.s0.i8" interaction="True"/>
            <pair e1="DS.d672.s0.e1" e2="DS.d672.s0.e2" id="DS.d672.s0.i10" interaction="False"/>
            <pair e1="DS.d672.s0.e6" e2="DS.d672.s0.e4" id="DS.d672.s0.i11" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d673" origId="18671761">
        <sentence id="DS.d673.s0" origId="18671761-109" text="Parkin-mediated ubiquitination regulates phospholipase C-gamma1.">
            <entity id="DS.d673.s0.e0" origId="3290" charOffset="0-6" type="compound" text="Parkin"/>
            <entity id="DS.d673.s0.e1" origId="P08487,P10686,P19174,Q62077" charOffset="41-63" type="protein" text="phospholipase C-gamma1"/>
            <pair e1="DS.d673.s0.e0" e2="DS.d673.s0.e1" id="DS.d673.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d674" origId="18671795">
        <sentence id="DS.d674.s0" origId="18671795-129" text="Short-acting insulin analogues, in comparison with regular human insulin (HRI), provide a greater control of postprandial glucose, while their superiority on haemoglobin A1c (HbA1c) is controversial.">
            <entity id="DS.d674.s0.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="13-20" type="protein" text="insulin"/>
            <entity id="DS.d674.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="65-72" type="protein" text="insulin"/>
            <entity id="DS.d674.s0.e2" origId="P33279,Q9BQI3" charOffset="74-77" type="protein" text="HRI"/>
            <entity id="DS.d674.s0.e3" origId="206,5793,64689,79025" charOffset="122-129" type="compound" text="glucose"/>
            <pair e1="DS.d674.s0.e3" e2="DS.d674.s0.e0" id="DS.d674.s0.i0" interaction="True"/>
            <pair e1="DS.d674.s0.e3" e2="DS.d674.s0.e2" id="DS.d674.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d675" origId="18671897">
        <sentence id="DS.d675.s0" origId="18671897-205" text="Western blotting showed that carbenoxolone down-regulated Cx43 protein expression in the BA, which in the SAH-only group was significantly higher than that of the normal group.">
            <entity id="DS.d675.s0.e0" origId="21913,636403,5311038" charOffset="29-42" type="compound" text="carbenoxolone"/>
            <entity id="DS.d675.s0.e1" origId="O57474,P08050,P14154,P16863,P17302,P18246,P23242,Q29101,Q6S9C0" charOffset="58-62" type="protein" text="Cx43"/>
            <pair e1="DS.d675.s0.e0" e2="DS.d675.s0.e1" id="DS.d675.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d676" origId="18672341">
        <sentence id="DS.d676.s0" origId="18672341-581" text="Hepatocytes exposed to resistin, but only in the presence of insulin, show a decrease in insulin-stimulated glycogen content.">
            <entity id="DS.d676.s0.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="61-68" type="protein" text="insulin"/>
            <entity id="DS.d676.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="89-96" type="protein" text="insulin"/>
            <entity id="DS.d676.s0.e2" origId="439177" charOffset="108-116" type="compound" text="glycogen"/>
            <pair e1="DS.d676.s0.e2" e2="DS.d676.s0.e0" id="DS.d676.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d678" origId="18673089">
        <sentence id="DS.d678.s0" origId="18673089-1229" text="Differentiated EBD cells in both monolayer and three-dimensional in vitro culture demonstrated fat granules by light microscopy, stained positive for lipids with oil red-O, and expressed adipocyte-specific genes (lipoprotein lipase (LPL), peroxisome proliferator activated receptor gamma2, and adipocyte-specific fatty acid binding protein (alphaP2)).">
            <entity id="DS.d678.s0.e0" origId="6046885,6821284" charOffset="162-171" type="compound" text="oil red-O"/>
            <entity id="DS.d678.s0.e1" origId="Q7M4U7" charOffset="225-231" type="protein" text="lipase"/>
            <entity id="DS.d678.s0.e2" origId="O46647,P06858,P11151,P11152,P11153,P11602,P49060,P49923,P55031,Q06000,Q29524" charOffset="233-236" type="protein" text="LPL"/>
            <entity id="DS.d678.s0.e3" origId="P02528" charOffset="282-288" type="protein" text="gamma2"/>
            <entity id="DS.d678.s0.e4" origId="O42494,O45035,O76821,P80547,Q17284,Q8MUC1,Q9U5P1" charOffset="313-339" type="protein" text="fatty acid binding protein"/>
            <pair e1="DS.d678.s0.e0" e2="DS.d678.s0.e1" id="DS.d678.s0.i0" interaction="False"/>
            <pair e1="DS.d678.s0.e0" e2="DS.d678.s0.e4" id="DS.d678.s0.i1" interaction="False"/>
            <pair e1="DS.d678.s0.e0" e2="DS.d678.s0.e2" id="DS.d678.s0.i2" interaction="False"/>
            <pair e1="DS.d678.s0.e0" e2="DS.d678.s0.e3" id="DS.d678.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d679" origId="18673303">
        <sentence id="DS.d679.s0" origId="18673303-1358" text="In addition, AIT induced a more favourable regulation of blood glucose and insulin compared with MTG.">
            <entity id="DS.d679.s0.e0" origId="206,5793,64689,79025" charOffset="63-70" type="compound" text="glucose"/>
            <entity id="DS.d679.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="75-82" type="protein" text="insulin"/>
            <pair e1="DS.d679.s0.e0" e2="DS.d679.s0.e1" id="DS.d679.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d680" origId="18673333">
        <sentence id="DS.d680.s0" origId="18673333-52" text="Beta1,4-galactosyltransferase-I (B4GALT1), one of seven beta1,4-galactosyltransferases, is an enzyme commonly found in the trans-Golgi complex that adds galactose to oligosaccharides.">
            <entity id="DS.d680.s0.e0" origId="P14769,P23336,P50127" charOffset="8-29" type="protein" text="galactosyltransferase"/>
            <entity id="DS.d680.s0.e1" origId="P08037,P15291" charOffset="33-40" type="protein" text="B4GALT1"/>
            <entity id="DS.d680.s0.e2" origId="P14769,P23336,P50127" charOffset="64-86" type="protein" text="galactosyltransferases"/>
            <entity id="DS.d680.s0.e3" origId="6036,439353,439357" charOffset="153-162" type="compound" text="galactose"/>
            <pair e1="DS.d680.s0.e3" e2="DS.d680.s0.e0" id="DS.d680.s0.i0" interaction="True"/>
            <pair e1="DS.d680.s0.e3" e2="DS.d680.s0.e1" id="DS.d680.s0.i1" interaction="True"/>
            <pair e1="DS.d680.s0.e3" e2="DS.d680.s0.e2" id="DS.d680.s0.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d680.s1" origId="18673333-53" text="When compared to the other mammalian B4GALT1 genes, the porcine coding sequence contained a single threonine codon inserted into the region encoding the cytoplasmic domain.">
            <entity id="DS.d680.s1.e0" origId="P08037,P15291" charOffset="37-44" type="protein" text="B4GALT1"/>
            <entity id="DS.d680.s1.e1" origId="6288" charOffset="99-108" type="compound" text="threonine"/>
            <pair e1="DS.d680.s1.e1" e2="DS.d680.s1.e0" id="DS.d680.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d681" origId="18674953">
        <sentence id="DS.d681.s0" origId="18674953-1307" text="Gyp inhibited the levels of the anti-apoptotic proteins Bcl-2 and Bcl-xl, but promoted the levels of the pro-apoptotic protein Bax.">
            <entity id="DS.d681.s0.e0" origId="64947" charOffset="0-3" type="compound" text="Gyp"/>
            <entity id="DS.d681.s0.e1" origId="P10417,P49950" charOffset="56-61" type="protein" text="Bcl-2"/>
            <entity id="DS.d681.s0.e2" origId="P27297" charOffset="119-130" type="protein" text="protein Bax"/>
            <pair e1="DS.d681.s0.e0" e2="DS.d681.s0.e1" id="DS.d681.s0.i0" interaction="True"/>
            <pair e1="DS.d681.s0.e0" e2="DS.d681.s0.e2" id="DS.d681.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d681.s1" origId="18674953-1308" text="In conclusion, Gyp induced ER stress and production of reactive oxygen species and Ca(2+), change the ratio of Bcl-2 and Bax, followed by the dysfunction of mitochondria, caused cytochrome c release, activation of caspase-3 before leading to apoptosis.">
            <entity id="DS.d681.s1.e0" origId="64947" charOffset="15-18" type="compound" text="Gyp"/>
            <entity id="DS.d681.s1.e1" origId="977" charOffset="64-70" type="compound" text="oxygen"/>
            <entity id="DS.d681.s1.e2" origId="271" charOffset="83-87" type="compound" text="Ca(2"/>
            <entity id="DS.d681.s1.e3" origId="P10417,P49950" charOffset="111-116" type="protein" text="Bcl-2"/>
            <entity id="DS.d681.s1.e4" origId="P27297,Q07813,Q63690" charOffset="121-124" type="protein" text="Bax"/>
            <entity id="DS.d681.s1.e5" origId="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3" charOffset="178-190" type="protein" text="cytochrome c"/>
            <pair e1="DS.d681.s1.e1" e2="DS.d681.s1.e3" id="DS.d681.s1.i0" interaction="False"/>
            <pair e1="DS.d681.s1.e2" e2="DS.d681.s1.e4" id="DS.d681.s1.i1" interaction="False"/>
            <pair e1="DS.d681.s1.e2" e2="DS.d681.s1.e3" id="DS.d681.s1.i2" interaction="False"/>
            <pair e1="DS.d681.s1.e1" e2="DS.d681.s1.e5" id="DS.d681.s1.i3" interaction="False"/>
            <pair e1="DS.d681.s1.e0" e2="DS.d681.s1.e3" id="DS.d681.s1.i4" interaction="True"/>
            <pair e1="DS.d681.s1.e2" e2="DS.d681.s1.e5" id="DS.d681.s1.i5" interaction="False"/>
            <pair e1="DS.d681.s1.e0" e2="DS.d681.s1.e5" id="DS.d681.s1.i6" interaction="True"/>
            <pair e1="DS.d681.s1.e1" e2="DS.d681.s1.e4" id="DS.d681.s1.i7" interaction="False"/>
            <pair e1="DS.d681.s1.e0" e2="DS.d681.s1.e4" id="DS.d681.s1.i8" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d682" origId="18675966">
        <sentence id="DS.d682.s0" origId="18675966-641" text="To compare expression of endometrial estrogen (ER) and progesterone (PR) receptors, beta(3)-integrin subunit, leukemia inhibitory factor (LIF), interleukin-6 (IL-6), and pinopodes in Indian women using ormeloxifene as a contraceptive with fertile and infertile subjects during the window of implantation.">
            <entity id="DS.d682.s0.e0" origId="O62728,P09056,P15018,P17777,Q27956" charOffset="138-141" type="protein" text="LIF"/>
            <entity id="DS.d682.s0.e1" origId="P41693" charOffset="144-157" type="protein" text="interleukin-6"/>
            <entity id="DS.d682.s0.e2" origId="O35736,P05231,P08505,P20607,P26892,P26893,P29455,P41323,P41683,P41693,P46650,P51494,P79341,Q25BC2,Q28319,Q28747,Q28819,Q2MH06,Q5I6E3,Q6V919,Q865W7,Q865X6,Q8MKH0,Q95181,Q9MZR1,Q9XT80" charOffset="159-163" type="protein" text="IL-6"/>
            <entity id="DS.d682.s0.e3" origId="35805,154413" charOffset="202-214" type="compound" text="ormeloxifene"/>
            <pair e1="DS.d682.s0.e3" e2="DS.d682.s0.e2" id="DS.d682.s0.i0" interaction="True"/>
            <pair e1="DS.d682.s0.e3" e2="DS.d682.s0.e1" id="DS.d682.s0.i1" interaction="True"/>
            <pair e1="DS.d682.s0.e3" e2="DS.d682.s0.e0" id="DS.d682.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d683" origId="18676014">
        <sentence id="DS.d683.s0" origId="18676014-229" text="We have also observed that the reduction of transition at 95+/-3 degrees C in thermal scans of nuclear preparations isolated from blood of B-CLL randomized patients who showed response to cladribine or fludarabine combined with cyclophosphamide, i.e., CC and FC, respectively, corresponded with the decrease or disappearance of anti-apoptotic proteins Bcl-2 and/or Mcl 1.">
            <entity id="DS.d683.s0.e0" origId="20279" charOffset="188-198" type="compound" text="cladribine"/>
            <entity id="DS.d683.s0.e1" origId="657237" charOffset="202-213" type="compound" text="fludarabine"/>
            <entity id="DS.d683.s0.e2" origId="2907,9554282" charOffset="228-244" type="compound" text="cyclophosphamide"/>
            <entity id="DS.d683.s0.e3" origId="P10417,P49950" charOffset="352-357" type="protein" text="Bcl-2"/>
            <entity id="DS.d683.s0.e4" origId="Q69FH1,Q9Z2H6" charOffset="365-368" type="protein" text="Mcl"/>
            <pair e1="DS.d683.s0.e0" e2="DS.d683.s0.e3" id="DS.d683.s0.i0" interaction="False"/>
            <pair e1="DS.d683.s0.e2" e2="DS.d683.s0.e3" id="DS.d683.s0.i1" interaction="False"/>
            <pair e1="DS.d683.s0.e1" e2="DS.d683.s0.e4" id="DS.d683.s0.i2" interaction="False"/>
            <pair e1="DS.d683.s0.e2" e2="DS.d683.s0.e4" id="DS.d683.s0.i3" interaction="False"/>
            <pair e1="DS.d683.s0.e1" e2="DS.d683.s0.e3" id="DS.d683.s0.i4" interaction="False"/>
            <pair e1="DS.d683.s0.e0" e2="DS.d683.s0.e4" id="DS.d683.s0.i5" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d684" origId="18676199">
        <sentence id="DS.d684.s0" origId="18676199-799" text="Exposure of erythrocytes to PGNs increased cytosolic Ca(2+) concentration, increased ceramide formation, enhanced the percentage of annexin V-binding erythrocytes, decreased erythrocyte forward scatter, and lowered the intracellular ATP concentration.">
            <entity id="DS.d684.s0.e0" origId="Q9UQ90" charOffset="28-32" type="protein" text="PGNs"/>
            <entity id="DS.d684.s0.e1" origId="271" charOffset="53-57" type="compound" text="Ca(2"/>
            <entity id="DS.d684.s0.e2" origId="P08758,P14668,P17153,P48036,P70075,P81287,Q4R4H7,Q5R1W0" charOffset="132-141" type="protein" text="annexin V"/>
            <entity id="DS.d684.s0.e3" origId="5957" charOffset="233-236" type="compound" text="ATP"/>
            <pair e1="DS.d684.s0.e3" e2="DS.d684.s0.e2" id="DS.d684.s0.i0" interaction="False"/>
            <pair e1="DS.d684.s0.e3" e2="DS.d684.s0.e0" id="DS.d684.s0.i1" interaction="True"/>
            <pair e1="DS.d684.s0.e1" e2="DS.d684.s0.e2" id="DS.d684.s0.i2" interaction="False"/>
            <pair e1="DS.d684.s0.e1" e2="DS.d684.s0.e0" id="DS.d684.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d685" origId="18676776">
        <sentence id="DS.d685.s0" origId="18676776-233" text="Inhibition of mitogen-activated protein kinase (MAPK) and Akt prevented the antiapoptotic effects of nicotine and decreased chemotherapy-induced apoptosis.">
            <entity id="DS.d685.s0.e0" origId="Q00859" charOffset="14-46" type="protein" text="mitogen-activated protein kinase"/>
            <entity id="DS.d685.s0.e1" origId="O42781,P27638,Q00859" charOffset="48-52" type="protein" text="MAPK"/>
            <entity id="DS.d685.s0.e2" origId="P31750,Q8INB9" charOffset="58-61" type="protein" text="Akt"/>
            <entity id="DS.d685.s0.e3" origId="942,89594,157672" charOffset="101-109" type="compound" text="nicotine"/>
            <pair e1="DS.d685.s0.e3" e2="DS.d685.s0.e2" id="DS.d685.s0.i0" interaction="True"/>
            <pair e1="DS.d685.s0.e3" e2="DS.d685.s0.e1" id="DS.d685.s0.i1" interaction="True"/>
            <pair e1="DS.d685.s0.e3" e2="DS.d685.s0.e0" id="DS.d685.s0.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d685.s1" origId="18676776-235" text="Nicotine up-regulated Akt-mediated antiapoptotic X-linked inhibitor of apoptosis protein and phosphorylated proapoptotic Bcl2-antagonist of cell death.">
            <entity id="DS.d685.s1.e0" origId="942,89594,157672" charOffset="0-8" type="compound" text="Nicotine"/>
            <entity id="DS.d685.s1.e3" origId="O35147,Q61337,Q92934" charOffset="121-150" type="protein" text="Bcl2-antagonist of cell death"/>
            <pair e1="DS.d685.s1.e0" e2="DS.d685.s1.e3" id="DS.d685.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d686" origId="18677478">
        <sentence id="DS.d686.s0" origId="18677478-391" text="Induction of NY-ESO-1 expression on tumor targets using the demethylating agent 5-aza-2'-deoxycytidine (alone or in combination with the histone deacetylase inhibitor depsipeptide) resulted in enhanced interferon-gamma secretion by the TCR-transduced PBL on culture with treated targets.">
            <entity id="DS.d686.s0.e0" origId="451668" charOffset="80-102" type="compound" text="5-aza-2'-deoxycytidine"/>
            <entity id="DS.d686.s0.e1" origId="5352062" charOffset="167-179" type="compound" text="depsipeptide"/>
            <entity id="DS.d686.s0.e2" origId="Q9TTB0" charOffset="202-218" type="protein" text="interferon-gamma"/>
            <pair e1="DS.d686.s0.e1" e2="DS.d686.s0.e2" id="DS.d686.s0.i0" interaction="True"/>
            <pair e1="DS.d686.s0.e0" e2="DS.d686.s0.e2" id="DS.d686.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d687" origId="18677521">
        <sentence id="DS.d687.s0" origId="18677521-1468" text="In the absence of OmcB, cells lost the ability to reduce soluble or insoluble Fe(III).">
            <entity id="DS.d687.s0.e0" origId="P18151,P21354,P23603,P23700,P23701,P26758,P94664,Q253E5,Q3KLQ7,Q548P6,Q933I7,Q9AIS7,Q9PJV0" charOffset="18-22" type="protein" text="OmcB"/>
            <entity id="DS.d687.s0.e1" origId="29936" charOffset="78-84" type="compound" text="Fe(III"/>
            <pair e1="DS.d687.s0.e1" e2="DS.d687.s0.e0" id="DS.d687.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d687.s1" origId="18677521-1470" text="DNA sequences of upstream regions of coregulated operons in the adapted mutant are divergent, suggesting the presence of recognition sites for different transcriptional regulators and indicating that adaptation of the omcB mutant to growth on soluble Fe(III) has shifted the relevant expression networks involved to a more diverse molecular basis.">
            <entity id="DS.d687.s1.e0" origId="Q9CJ45" charOffset="153-179" type="protein" text="transcriptional regulators"/>
            <entity id="DS.d687.s1.e1" origId="29936" charOffset="251-257" type="compound" text="Fe(III"/>
            <pair e1="DS.d687.s1.e1" e2="DS.d687.s1.e0" id="DS.d687.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d688" origId="18677561">
        <sentence id="DS.d688.s0" origId="18677561-697" text="Elevated beta1,4-galactosyltransferase-I induced by the intraspinal injection of lipopolysaccharide.">
            <entity id="DS.d688.s0.e0" origId="P14769,P23336,P50127" charOffset="17-38" type="protein" text="galactosyltransferase"/>
            <entity id="DS.d688.s0.e1" origId="11970143" charOffset="81-99" type="compound" text="lipopolysaccharide"/>
            <pair e1="DS.d688.s0.e1" e2="DS.d688.s0.e0" id="DS.d688.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d688.s1" origId="18677561-698" text="E-selectin, which ligand was modified by beta1,4-GalT-I, was correlated with galactose-containing glycans following injecting LPS into spinal cord.">
            <entity id="DS.d688.s1.e0" origId="O33836,O84904,P09148,P13212,P22714,P31764,P39575,P45981,P96994,Q00054,Q5LYY8,Q5M3K1,Q836N8,Q88SF0,Q8R8R6,Q8RHC9,Q8VS92,Q8XKP8,Q93MM1,Q97EZ4,Q9CE63,Q9KDV2,Q9RGR9,Q9S6S3,Q9ZB09" charOffset="49-53" type="protein" text="GalT"/>
            <entity id="DS.d688.s1.e1" origId="6036,439353,439357" charOffset="77-86" type="compound" text="galactose"/>
            <pair e1="DS.d688.s1.e1" e2="DS.d688.s1.e0" id="DS.d688.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d689" origId="18677571">
        <sentence id="DS.d689.s0" origId="18677571-1520" text="Effects of P85 on amino acid transporters were examined using their substrates: (3)H-phenylalanine, (3)H-lysine, and (3)H-methylaminoisobutyric acid, respectively.">
            <entity id="DS.d689.s0.e0" origId="O43439,P46655,P49846,Q14155" charOffset="11-14" type="protein" text="P85"/>
            <entity id="DS.d689.s0.e1" origId="994,6140,71567" charOffset="85-98" type="compound" text="phenylalanine"/>
            <entity id="DS.d689.s0.e2" origId="866,5962" charOffset="105-111" type="compound" text="lysine"/>
            <pair e1="DS.d689.s0.e1" e2="DS.d689.s0.e0" id="DS.d689.s0.i0" interaction="False"/>
            <pair e1="DS.d689.s0.e2" e2="DS.d689.s0.e0" id="DS.d689.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d690" origId="18677583">
        <sentence id="DS.d690.s0" origId="18677583-1526" text="Valproate, an anticonvulsant and mood stabilizer, up-regulates Bcl-2, a neurotrophic/neuroprotective protein.">
            <entity id="DS.d690.s0.e0" origId="3121" charOffset="0-9" type="compound" text="Valproate"/>
            <entity id="DS.d690.s0.e1" origId="P10417,P49950" charOffset="63-68" type="protein" text="Bcl-2"/>
            <pair e1="DS.d690.s0.e0" e2="DS.d690.s0.e1" id="DS.d690.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d690.s1" origId="18677583-1527" text="In this study, we investigated the molecular mechanism through which Bcl-2 is up-regulated by valproate using cultured human neuron-like cells.">
            <entity id="DS.d690.s1.e0" origId="P10417,P49950" charOffset="69-74" type="protein" text="Bcl-2"/>
            <entity id="DS.d690.s1.e1" origId="3121" charOffset="94-103" type="compound" text="valproate"/>
            <pair e1="DS.d690.s1.e1" e2="DS.d690.s1.e0" id="DS.d690.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d690.s2" origId="18677583-1528" text="Valproate, within therapeutically relevant ranges, induced time- and concentration-dependent up-regulations of both Bcl-2 messenger RNA and protein implicating an underlying gene transcriptional-mediated mechanism.">
            <entity id="DS.d690.s2.e0" origId="3121" charOffset="0-9" type="compound" text="Valproate"/>
            <entity id="DS.d690.s2.e1" origId="P10417,P49950" charOffset="116-121" type="protein" text="Bcl-2"/>
            <pair e1="DS.d690.s2.e0" e2="DS.d690.s2.e1" id="DS.d690.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d690.s3" origId="18677583-1529" text="Valproate increased transcriptional activity of a human bcl-2 promoter-reporter gene construct.">
            <entity id="DS.d690.s3.e0" origId="3121" charOffset="0-9" type="compound" text="Valproate"/>
            <entity id="DS.d690.s3.e1" origId="P10417,P49950" charOffset="56-61" type="protein" text="bcl-2"/>
            <pair e1="DS.d690.s3.e0" e2="DS.d690.s3.e1" id="DS.d690.s3.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d690.s4" origId="18677583-1530" text="ERK and/or PI3K pathway inhibitors and RSK1 small hairpin RNA knockdown reduced, but did not abolish, baseline and valproate-induced promoter activities and lowered Bcl-2 protein levels.">
            <entity id="DS.d690.s4.e0" origId="3121" charOffset="115-124" type="compound" text="valproate"/>
            <entity id="DS.d690.s4.e1" origId="P10417,P49950" charOffset="165-170" type="protein" text="Bcl-2"/>
            <pair e1="DS.d690.s4.e0" e2="DS.d690.s4.e1" id="DS.d690.s4.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d690.s5" origId="18677583-1531" text="These data collectively suggest that valproate induces Bcl-2 regulation partially through activations of the ERK and PI3K cascades and their convergent kinase, RSK, although other unknown mechanism(s) are likely involved.">
            <entity id="DS.d690.s5.e0" origId="3121" charOffset="37-46" type="compound" text="valproate"/>
            <entity id="DS.d690.s5.e1" origId="P10417,P49950" charOffset="55-60" type="protein" text="Bcl-2"/>
            <entity id="DS.d690.s5.e2" origId="P29323" charOffset="109-112" type="protein" text="ERK"/>
            <entity id="DS.d690.s5.e3" origId="O00329,O02697,O35904,P23727,P26450,P27986,P32871,P42336,P42337,P42338,P42347,P42348,P48736,P54673,P54674,P54675,P54676,Q63787,Q8BTI9,Q8UUU2,Q9JHG7,Q9Z1L0" charOffset="117-121" type="protein" text="PI3K"/>
            <entity id="DS.d690.s5.e4" origId="P18652" charOffset="160-163" type="protein" text="RSK"/>
            <pair e1="DS.d690.s5.e0" e2="DS.d690.s5.e3" id="DS.d690.s5.i0" interaction="True"/>
            <pair e1="DS.d690.s5.e0" e2="DS.d690.s5.e4" id="DS.d690.s5.i1" interaction="True"/>
            <pair e1="DS.d690.s5.e0" e2="DS.d690.s5.e1" id="DS.d690.s5.i2" interaction="True"/>
            <pair e1="DS.d690.s5.e0" e2="DS.d690.s5.e2" id="DS.d690.s5.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d690.s6" origId="18677583-1532" text="Given the known roles of Bcl-2 in the central nervous system, the current findings offer a partial yet complex molecular mechanistic explanation for the known neurobiological effects of valproate including neurite growth, neuronal survival, and neurogenesis.">
            <entity id="DS.d690.s6.e0" origId="P10417,P49950" charOffset="25-30" type="protein" text="Bcl-2"/>
            <entity id="DS.d690.s6.e1" origId="3121" charOffset="186-195" type="compound" text="valproate"/>
            <pair e1="DS.d690.s6.e1" e2="DS.d690.s6.e0" id="DS.d690.s6.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d691" origId="18679593">
        <sentence id="DS.d691.s0" origId="18679593-620" text="With covalent method, glutaraldehyde was introduced to immobilize cellobiase.">
            <entity id="DS.d691.s0.e0" origId="3485" charOffset="22-36" type="compound" text="glutaraldehyde"/>
            <entity id="DS.d691.s0.e1" origId="O33843,P06835,P07337,P10482,P12614,P14002,P15885,P16084,P22073,P22505,P22506,P22507,P26208,P27034,P29090,P29091,P33363,P38645,P40740,P42403,P48825,P49235,Q03506,Q08638,Q46684,Q56078" charOffset="66-76" type="protein" text="cellobiase"/>
            <pair e1="DS.d691.s0.e0" e2="DS.d691.s0.e1" id="DS.d691.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d692" origId="18679731">
        <sentence id="DS.d692.s0" origId="18679731-726" text="As metabolic flux for the operation of the flavonoid pathway is maintained through the activities of PAL and C4H, thus, catechins biosynthesis in tea is critically dependent on the products of these enzymes.">
            <entity id="DS.d692.s0.e0" origId="10251" charOffset="43-52" type="compound" text="flavonoid"/>
            <entity id="DS.d692.s0.e1" origId="O03979,O04058,O93967,P10248,P10731,P11544,P14166,P14717,P14925,P19021,P26600,P35511,P35512,P45726,P45727,P45730,P45731,P45735,P52777,P83388,P91268,P97467,Q42609,Q43210,Q9P2V4,Q9PSN0" charOffset="101-104" type="protein" text="PAL"/>
            <entity id="DS.d692.s0.e2" origId="O24312,O81928,P37114,P37115,P48522,P92994,Q04468,Q42797,Q43033,Q43054,Q43067,Q43240,Q96423,Q9AR74" charOffset="109-112" type="protein" text="C4H"/>
            <pair e1="DS.d692.s0.e0" e2="DS.d692.s0.e1" id="DS.d692.s0.i0" interaction="True"/>
            <pair e1="DS.d692.s0.e0" e2="DS.d692.s0.e2" id="DS.d692.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d693" origId="18679812">
        <sentence id="DS.d693.s0" origId="18679812-4" text="Activities of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glutatione-S-transferase, and reduced glutathione) in liver also decreased in carcinogen-administered rats, which were significantly elevated in bacoside A-pretreated rats.">
            <entity id="DS.d693.s0.e0" origId="O50258" charOffset="35-55" type="protein" text="superoxide dismutase"/>
            <entity id="DS.d693.s0.e1" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="57-65" type="protein" text="catalase"/>
            <entity id="DS.d693.s0.e2" origId="O32770,O59858,Q00277,Q9CFV1" charOffset="67-89" type="protein" text="glutathione peroxidase"/>
            <entity id="DS.d693.s0.e3" origId="O15770,P06715,P11804,P23189,P41921,P43783,P48638,P48639,P70619,P78965,Q60151,Q6BPI1,Q6C5H4,Q6FRV2,Q6HA23,Q74ZK4,Q873E8,Q94655" charOffset="91-112" type="protein" text="glutathione reductase"/>
            <entity id="DS.d693.s0.e4" origId="124886" charOffset="144-163" type="compound" text="reduced glutathione"/>
            <pair e1="DS.d693.s0.e4" e2="DS.d693.s0.e0" id="DS.d693.s0.i0" interaction="False"/>
            <pair e1="DS.d693.s0.e4" e2="DS.d693.s0.e2" id="DS.d693.s0.i1" interaction="False"/>
            <pair e1="DS.d693.s0.e4" e2="DS.d693.s0.e1" id="DS.d693.s0.i2" interaction="False"/>
            <pair e1="DS.d693.s0.e4" e2="DS.d693.s0.e3" id="DS.d693.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d694" origId="18679831">
        <sentence id="DS.d694.s0" origId="18679831-20" text="In this study, we report that AR-M1896, a non-GalR1 agonist, inhibited plasma extravasation induced by substance P and calcitonin gene-related peptide in a manner similar to galanin, confirming a non-GalR1-mediated effect.">
            <entity id="DS.d694.s0.e0" origId="77681" charOffset="33-38" type="compound" text="M1896"/>
            <entity id="DS.d694.s0.e1" origId="P01289,P06767,P19850,P20366,P28498,P28499,P41333,P41539,P41540,P67932,P67933,Q60541" charOffset="103-114" type="protein" text="substance P"/>
            <entity id="DS.d694.s0.e2" origId="P30880,P30881,P31888" charOffset="119-150" type="protein" text="calcitonin gene-related peptide"/>
            <entity id="DS.d694.s0.e3" origId="P07480,P10683,P11242,P22466,P30802,P31234,P33710,P47212,P47213,P47214,P47215,P47216,Q9W6M9" charOffset="174-181" type="protein" text="galanin"/>
            <pair e1="DS.d694.s0.e0" e2="DS.d694.s0.e2" id="DS.d694.s0.i0" interaction="False"/>
            <pair e1="DS.d694.s0.e0" e2="DS.d694.s0.e3" id="DS.d694.s0.i1" interaction="False"/>
            <pair e1="DS.d694.s0.e0" e2="DS.d694.s0.e1" id="DS.d694.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d695" origId="18680102">
        <sentence id="DS.d695.s0" origId="18680102-211" text="Inhibition of non-small cell lung cancer cell migration by grape seed proanthocyanidins is mediated through the inhibition of nitric oxide, guanylate cyclase, and ERK1/2.">
            <entity id="DS.d695.s0.e0" origId="108065" charOffset="70-87" type="compound" text="proanthocyanidins"/>
            <entity id="DS.d695.s0.e1" origId="O94303,P33734,Q9P4P9,Q9SZ30" charOffset="150-157" type="protein" text="cyclase"/>
            <entity id="DS.d695.s0.e2" origId="P27361,P28869,P42525,Q07176" charOffset="163-167" type="protein" text="ERK1"/>
            <pair e1="DS.d695.s0.e0" e2="DS.d695.s0.e2" id="DS.d695.s0.i0" interaction="True"/>
            <pair e1="DS.d695.s0.e0" e2="DS.d695.s0.e1" id="DS.d695.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d695.s1" origId="18680102-215" text="Additionally, UO126 and ODQ inhibited the migration restoring effects of L-arginine in L-NAME-treated cells, suggesting the involvement of cGMP and MAPK pathways in NO-mediated migration.">
            <entity id="DS.d695.s1.e0" origId="1456" charOffset="24-27" type="compound" text="ODQ"/>
            <entity id="DS.d695.s1.e1" origId="6322" charOffset="73-83" type="compound" text="L-arginine"/>
            <entity id="DS.d695.s1.e2" origId="24316" charOffset="139-143" type="compound" text="cGMP"/>
            <entity id="DS.d695.s1.e3" origId="O42781,P27638,Q00859" charOffset="148-152" type="protein" text="MAPK"/>
            <pair e1="DS.d695.s1.e0" e2="DS.d695.s1.e3" id="DS.d695.s1.i0" interaction="True"/>
            <pair e1="DS.d695.s1.e1" e2="DS.d695.s1.e3" id="DS.d695.s1.i1" interaction="True"/>
            <pair e1="DS.d695.s1.e2" e2="DS.d695.s1.e3" id="DS.d695.s1.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d695.s2" origId="18680102-216" text="GSPs inhibited L-arginine and 8-Br-cGMP-induced activation of ERK1/2 in A549 cells.">
            <entity id="DS.d695.s2.e0" origId="6322" charOffset="15-25" type="compound" text="L-arginine"/>
            <entity id="DS.d695.s2.e1" origId="104767" charOffset="30-39" type="compound" text="8-Br-cGMP"/>
            <entity id="DS.d695.s2.e2" origId="P27361,P28869,P42525,Q07176" charOffset="62-66" type="protein" text="ERK1"/>
            <pair e1="DS.d695.s2.e0" e2="DS.d695.s2.e2" id="DS.d695.s2.i0" interaction="True"/>
            <pair e1="DS.d695.s2.e1" e2="DS.d695.s2.e2" id="DS.d695.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d696" origId="18680106">
        <sentence id="DS.d696.s0" origId="18680106-970" text="Enhancement of p53 expression in keratinocytes by the bioflavonoid apigenin is associated with RNA-binding protein HuR.">
            <entity id="DS.d696.s0.e0" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="15-18" type="protein" text="p53"/>
            <entity id="DS.d696.s0.e1" origId="5280805" charOffset="54-66" type="compound" text="bioflavonoid"/>
            <entity id="DS.d696.s0.e2" origId="5280443" charOffset="67-75" type="compound" text="apigenin"/>
            <entity id="DS.d696.s0.e3" origId="P03526,P04487,P07940,P12002,P56958,P82866" charOffset="95-114" type="protein" text="RNA-binding protein"/>
            <entity id="DS.d696.s0.e4" origId="P70372,Q15717" charOffset="115-118" type="protein" text="HuR"/>
            <pair e1="DS.d696.s0.e1" e2="DS.d696.s0.e4" id="DS.d696.s0.i0" interaction="False"/>
            <pair e1="DS.d696.s0.e1" e2="DS.d696.s0.e0" id="DS.d696.s0.i1" interaction="False"/>
            <pair e1="DS.d696.s0.e2" e2="DS.d696.s0.e3" id="DS.d696.s0.i2" interaction="False"/>
            <pair e1="DS.d696.s0.e2" e2="DS.d696.s0.e4" id="DS.d696.s0.i3" interaction="True"/>
            <pair e1="DS.d696.s0.e2" e2="DS.d696.s0.e0" id="DS.d696.s0.i4" interaction="True"/>
            <pair e1="DS.d696.s0.e1" e2="DS.d696.s0.e3" id="DS.d696.s0.i5" interaction="False"/>
        </sentence>
        <sentence id="DS.d696.s1" origId="18680106-971" text="We have reported previously that apigenin, a naturally occurring nonmutagenic flavonoid, increased wild-type p53 protein expression in the mouse keratinocyte 308 cell line by a mechanism involving p53 protein stabilization.">
            <entity id="DS.d696.s1.e0" origId="5280443" charOffset="33-41" type="compound" text="apigenin"/>
            <entity id="DS.d696.s1.e1" origId="10251" charOffset="78-87" type="compound" text="flavonoid"/>
            <entity id="DS.d696.s1.e2" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="109-112" type="protein" text="p53"/>
            <entity id="DS.d696.s1.e3" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="197-200" type="protein" text="p53"/>
            <pair e1="DS.d696.s1.e0" e2="DS.d696.s1.e2" id="DS.d696.s1.i0" interaction="True"/>
            <pair e1="DS.d696.s1.e1" e2="DS.d696.s1.e2" id="DS.d696.s1.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d696.s2" origId="18680106-973" text="Instead, biosynthetic labeling showed that apigenin increased nascent p53 protein synthesis by enhancing p53 translation.">
            <entity id="DS.d696.s2.e0" origId="5280443" charOffset="43-51" type="compound" text="apigenin"/>
            <entity id="DS.d696.s2.e1" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="70-73" type="protein" text="p53"/>
            <entity id="DS.d696.s2.e2" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="105-108" type="protein" text="p53"/>
            <pair e1="DS.d696.s2.e0" e2="DS.d696.s2.e1" id="DS.d696.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d696.s3" origId="18680106-975" text="Furthermore, apigenin treatment increased the level of association of the RNA binding protein HuR with endogenous p53 mRNA.">
            <entity id="DS.d696.s3.e0" origId="5280443" charOffset="13-21" type="compound" text="apigenin"/>
            <entity id="DS.d696.s3.e1" origId="P03526,P04487,P07940,P12002,P56958,P82866" charOffset="74-93" type="protein" text="RNA binding protein"/>
            <entity id="DS.d696.s3.e2" origId="P70372,Q15717" charOffset="94-97" type="protein" text="HuR"/>
            <entity id="DS.d696.s3.e3" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="114-117" type="protein" text="p53"/>
            <pair e1="DS.d696.s3.e0" e2="DS.d696.s3.e3" id="DS.d696.s3.i0" interaction="True"/>
            <pair e1="DS.d696.s3.e0" e2="DS.d696.s3.e2" id="DS.d696.s3.i1" interaction="True"/>
            <pair e1="DS.d696.s3.e0" e2="DS.d696.s3.e1" id="DS.d696.s3.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d696.s4" origId="18680106-976" text="Apigenin treatment also augmented HuR translocation into the cytoplasm.">
            <entity id="DS.d696.s4.e0" origId="5280443" charOffset="0-8" type="compound" text="Apigenin"/>
            <entity id="DS.d696.s4.e1" origId="P70372,Q15717" charOffset="34-37" type="protein" text="HuR"/>
            <pair e1="DS.d696.s4.e0" e2="DS.d696.s4.e1" id="DS.d696.s4.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d696.s5" origId="18680106-979" text="Overall, these findings indicate that, in addition to modulating p53 protein stability, one of the mechanisms by which apigenin induces p53 protein expression is enhancement of translation through the RNA binding protein HuR.">
            <entity id="DS.d696.s5.e0" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="65-68" type="protein" text="p53"/>
            <entity id="DS.d696.s5.e1" origId="5280443" charOffset="119-127" type="compound" text="apigenin"/>
            <entity id="DS.d696.s5.e2" origId="O09185,O12946,O57538,O93379,P02340,P04637,P10361,P19558,P19559,P56423,P56424,P61260,P79820,P79892,Q29537,Q42578,Q8SPZ3,Q92143,Q9TTA1,Q9TUB2,Q9W678,Q9W679" charOffset="136-139" type="protein" text="p53"/>
            <entity id="DS.d696.s5.e3" origId="P03526,P04487,P07940,P12002,P56958,P82866" charOffset="201-220" type="protein" text="RNA binding protein"/>
            <entity id="DS.d696.s5.e4" origId="P70372,Q15717" charOffset="221-224" type="protein" text="HuR"/>
            <pair e1="DS.d696.s5.e1" e2="DS.d696.s5.e0" id="DS.d696.s5.i0" interaction="True"/>
            <pair e1="DS.d696.s5.e1" e2="DS.d696.s5.e4" id="DS.d696.s5.i1" interaction="True"/>
            <pair e1="DS.d696.s5.e1" e2="DS.d696.s5.e3" id="DS.d696.s5.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d697" origId="18680156">
        <sentence id="DS.d697.s0" origId="18680156-264" text="Immunoblot analysis of signaling molecules, including cyclic-AMP response element binding protein (CREB), mitogen-activated protein kinases (MAPKp44/42; ERK1/2), in area CA1 revealed that thyroxin treatment reversed hypothyroidism-induced reduction of signaling molecules essential for learning and memory, and L-LTP.">
            <entity id="DS.d697.s0.e0" origId="O24006" charOffset="61-64" type="protein" text="AMP"/>
            <entity id="DS.d697.s0.e1" origId="P15337,P16220,P27925,P51984,P51985,Q01147" charOffset="99-103" type="protein" text="CREB"/>
            <entity id="DS.d697.s0.e2" origId="Q00859" charOffset="106-139" type="protein" text="mitogen-activated protein kinases"/>
            <entity id="DS.d697.s0.e3" origId="P27361,P28869,P42525,Q07176" charOffset="153-157" type="protein" text="ERK1"/>
            <entity id="DS.d697.s0.e4" origId="5819" charOffset="188-196" type="compound" text="thyroxin"/>
            <pair e1="DS.d697.s0.e4" e2="DS.d697.s0.e1" id="DS.d697.s0.i0" interaction="True"/>
            <pair e1="DS.d697.s0.e4" e2="DS.d697.s0.e3" id="DS.d697.s0.i1" interaction="True"/>
            <pair e1="DS.d697.s0.e4" e2="DS.d697.s0.e2" id="DS.d697.s0.i2" interaction="True"/>
            <pair e1="DS.d697.s0.e4" e2="DS.d697.s0.e0" id="DS.d697.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d698" origId="18680550">
        <sentence id="DS.d698.s0" origId="18680550-1533" text="Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin.">
            <entity id="DS.d698.s0.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="0-7" type="protein" text="Insulin"/>
            <entity id="DS.d698.s0.e1" origId="37542" charOffset="157-166" type="compound" text="ribavirin"/>
            <pair e1="DS.d698.s0.e1" e2="DS.d698.s0.e0" id="DS.d698.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d698.s1" origId="18680550-1535" text="Aim To investigate retrospectively the impact of insulin resistance on treatment response in Chinese genotype 1 CHC patients receiving a 24-week course therapy with peginterferon alpha-2b/ribavirin.">
            <entity id="DS.d698.s1.e0" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="49-56" type="protein" text="insulin"/>
            <entity id="DS.d698.s1.e1" origId="37542" charOffset="188-197" type="compound" text="ribavirin"/>
            <pair e1="DS.d698.s1.e1" e2="DS.d698.s1.e0" id="DS.d698.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d699" origId="18680626">
        <sentence id="DS.d699.s0" origId="18680626-658" text="We hypothesised that OAT could be a limiting step in glutamine-arginine interconversion.">
            <entity id="DS.d699.s0.e0" origId="P04181,Q07805,Q4XWV5,Q6LFH8,Q7RT90" charOffset="21-24" type="protein" text="OAT"/>
            <entity id="DS.d699.s0.e1" origId="738,5961" charOffset="53-62" type="compound" text="glutamine"/>
            <entity id="DS.d699.s0.e2" origId="232,4367,6322" charOffset="63-71" type="compound" text="arginine"/>
            <pair e1="DS.d699.s0.e1" e2="DS.d699.s0.e0" id="DS.d699.s0.i0" interaction="True"/>
            <pair e1="DS.d699.s0.e2" e2="DS.d699.s0.e0" id="DS.d699.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d699.s1" origId="18680626-659" text="OAT overexpression decreased plasma and liver ornithine concentrations but did not affect glutamine or arginine homeostasis.">
            <entity id="DS.d699.s1.e0" origId="P04181,Q07805,Q4XWV5,Q6LFH8,Q7RT90" charOffset="0-3" type="protein" text="OAT"/>
            <entity id="DS.d699.s1.e1" origId="389,6262,71082" charOffset="46-55" type="compound" text="ornithine"/>
            <entity id="DS.d699.s1.e2" origId="738,5961" charOffset="90-99" type="compound" text="glutamine"/>
            <entity id="DS.d699.s1.e3" origId="232,4367,6322" charOffset="103-111" type="compound" text="arginine"/>
            <pair e1="DS.d699.s1.e1" e2="DS.d699.s1.e0" id="DS.d699.s1.i0" interaction="True"/>
            <pair e1="DS.d699.s1.e2" e2="DS.d699.s1.e0" id="DS.d699.s1.i1" interaction="False"/>
            <pair e1="DS.d699.s1.e3" e2="DS.d699.s1.e0" id="DS.d699.s1.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d699.s2" origId="18680626-660" text="There was an inverse relationship between ornithine levels and OAT activity.">
            <entity id="DS.d699.s2.e0" origId="389,6262,71082" charOffset="42-51" type="compound" text="ornithine"/>
            <entity id="DS.d699.s2.e1" origId="P04181,Q07805,Q4XWV5,Q6LFH8,Q7RT90" charOffset="63-66" type="protein" text="OAT"/>
            <pair e1="DS.d699.s2.e0" e2="DS.d699.s2.e1" id="DS.d699.s2.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d700" origId="18681858">
        <sentence id="DS.d700.s0" origId="18681858-1" text="In men there is a large interindividual variation of SHBG levels and consequently of testosterone (T) and E(2) levels.">
            <entity id="DS.d700.s0.e0" origId="P04278,P08689,P15196,P97497,Q62588" charOffset="53-57" type="protein" text="SHBG"/>
            <entity id="DS.d700.s0.e1" origId="6013" charOffset="85-97" type="compound" text="testosterone"/>
            <pair e1="DS.d700.s0.e1" e2="DS.d700.s0.e0" id="DS.d700.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d701" origId="18682334">
        <sentence id="DS.d701.s0" origId="18682334-364" text="Bone marrow cells were obtained from 5-day-old Muscovy ducks and cultured with (Group A) No added factors, (B) 30ng/mL soluble RANKL (sRANKL), (C) 30ng/mL sRANKL and 10ng/mL OPG, (D) 10ng/mL OPG, (E) 50ng/mL OPG, (F) 100ng/mL OPG and (G) 30ng/mL sRANKL, 6mmol/L Ca and 3mmol/L P. sRANKL promoted the survival of OCs on day 2, whereas the number of OCs decreased with addition of OPG in a dose-dependent manner.">
            <entity id="DS.d701.s0.e0" origId="O14788,O35235,Q9ESE2" charOffset="127-132" type="protein" text="RANKL"/>
            <entity id="DS.d701.s0.e1" origId="O00300" charOffset="174-177" type="protein" text="OPG"/>
            <entity id="DS.d701.s0.e2" origId="O00300" charOffset="191-194" type="protein" text="OPG"/>
            <entity id="DS.d701.s0.e3" origId="O00300" charOffset="191-194" type="protein" text="OPG"/>
            <entity id="DS.d701.s0.e4" origId="O00300" charOffset="191-194" type="protein" text="OPG"/>
            <entity id="DS.d701.s0.e5" origId="5281764" charOffset="260-264" type="compound" text="L Ca"/>
            <entity id="DS.d701.s0.e6" origId="O00300" charOffset="191-194" type="protein" text="OPG"/>
            <pair e1="DS.d701.s0.e5" e2="DS.d701.s0.e0" id="DS.d701.s0.i0" interaction="False"/>
            <pair e1="DS.d701.s0.e5" e2="DS.d701.s0.e1" id="DS.d701.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d702" origId="18682988">
        <sentence id="DS.d702.s0" origId="18682988-518" text="Over-expression of GDH decreased the yield of ethanol and 2,3-butanediol, meanwhile it increased the concentration of acetic acid.">
            <entity id="DS.d702.s0.e0" origId="O52310,O59650,O74024,O95479,P00366,P00367,P00368,P0AES2,P0AES3,P10860,P13443,P26443,P28270,P36234,P42174,P42206,P42238,P49448,P52596,P54385,P56201,P80319,P82264,P93541,P94598,P96110,Q09115,Q43260,Q47950,Q47951,Q53199,Q56304,Q59516,Q64HZ8,Q64HZ9,Q64I00,Q64I01,Q9HFR6,Q9HGU3,Q9HGU4,Q9RDE9,Q9URS1,Q9YC65" charOffset="19-22" type="protein" text="GDH"/>
            <entity id="DS.d702.s0.e1" origId="702" charOffset="46-53" type="compound" text="ethanol"/>
            <entity id="DS.d702.s0.e2" origId="262,225936" charOffset="58-72" type="compound" text="2,3-butanediol"/>
            <entity id="DS.d702.s0.e3" origId="176,286,291512" charOffset="118-129" type="compound" text="acetic acid"/>
            <pair e1="DS.d702.s0.e3" e2="DS.d702.s0.e0" id="DS.d702.s0.i0" interaction="True"/>
            <pair e1="DS.d702.s0.e1" e2="DS.d702.s0.e0" id="DS.d702.s0.i1" interaction="True"/>
            <pair e1="DS.d702.s0.e2" e2="DS.d702.s0.e0" id="DS.d702.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d703" origId="18683011">
        <sentence id="DS.d703.s0" origId="18683011-1547" text="Geranylgeranylacetone prevents acute liver damage after massive hepatectomy in rats through suppression of a CXC chemokine GRO1 and induction of heat shock proteins.">
            <entity id="DS.d703.s0.e0" origId="5282199" charOffset="0-21" type="compound" text="Geranylgeranylacetone"/>
            <entity id="DS.d703.s0.e1" origId="P09341" charOffset="123-127" type="protein" text="GRO1"/>
            <pair e1="DS.d703.s0.e0" e2="DS.d703.s0.e1" id="DS.d703.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d704" origId="18683188">
        <sentence id="DS.d704.s0" origId="18683188-1093" text="Furthermore, HA induced dose-dependent elevation of reactive oxygen species (ROS) level in SMCs, and antioxidant vitamin C and Trolox effectively suppressed HA-induced DNA damage and dysregulation of Bcl-2/Bax.">
            <entity id="DS.d704.s0.e0" origId="977" charOffset="61-67" type="compound" text="oxygen"/>
            <entity id="DS.d704.s0.e1" origId="54670067" charOffset="113-122" type="compound" text="vitamin C"/>
            <entity id="DS.d704.s0.e2" origId="40634" charOffset="127-133" type="compound" text="Trolox"/>
            <entity id="DS.d704.s0.e3" origId="P10417,P49950" charOffset="200-205" type="protein" text="Bcl-2"/>
            <entity id="DS.d704.s0.e4" origId="P27297,Q07813,Q63690" charOffset="206-209" type="protein" text="Bax"/>
            <pair e1="DS.d704.s0.e0" e2="DS.d704.s0.e3" id="DS.d704.s0.i0" interaction="False"/>
            <pair e1="DS.d704.s0.e2" e2="DS.d704.s0.e4" id="DS.d704.s0.i1" interaction="True"/>
            <pair e1="DS.d704.s0.e2" e2="DS.d704.s0.e3" id="DS.d704.s0.i2" interaction="True"/>
            <pair e1="DS.d704.s0.e1" e2="DS.d704.s0.e3" id="DS.d704.s0.i3" interaction="True"/>
            <pair e1="DS.d704.s0.e1" e2="DS.d704.s0.e4" id="DS.d704.s0.i4" interaction="True"/>
            <pair e1="DS.d704.s0.e0" e2="DS.d704.s0.e4" id="DS.d704.s0.i5" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d705" origId="18683221">
        <sentence id="DS.d705.s0" origId="18683221-1122" text="The adsorption of ovine fibrinogen onto PMA-modified surfaces was reduced relative to unmodified surfaces, and in vitro ovine blood contact through a rocking test revealed marked reductions in platelet deposition and bulk phase platelet activation relative to unmodified TiAl6V4 and polystyrene controls.">
            <entity id="DS.d705.s0.e0" origId="P22775,P81070" charOffset="24-34" type="protein" text="fibrinogen"/>
            <entity id="DS.d705.s0.e1" origId="27924,122634,22833501" charOffset="40-43" type="compound" text="PMA"/>
            <pair e1="DS.d705.s0.e1" e2="DS.d705.s0.e0" id="DS.d705.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d706" origId="18683225">
        <sentence id="DS.d706.s0" origId="18683225-1127" text="When the thrombin concentration was higher than 15 U/mL, the gelation could be finished within 1 min and yielded a composite with evenly suspended and distributed PLGA microspheres.">
            <entity id="DS.d706.s0.e0" origId="P84122" charOffset="9-17" type="protein" text="thrombin"/>
            <entity id="DS.d706.s0.e1" origId="36797" charOffset="163-167" type="compound" text="PLGA"/>
            <pair e1="DS.d706.s0.e1" e2="DS.d706.s0.e0" id="DS.d706.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d707" origId="18683233">
        <sentence id="DS.d707.s0" origId="18683233-58" text="The culture tests using MSCs show that the level of alkaline phosphatase (ALP) activity in the cells cultured on SPV-H increased during the 21-day culture in a medium without Dex and beta-GP.">
            <entity id="DS.d707.s0.e0" origId="O60109,P81800,P83456" charOffset="52-72" type="protein" text="alkaline phosphatase"/>
            <entity id="DS.d707.s0.e1" origId="P03973,P12547,P22298,P28296,P29118,P35211,P83610,P97430,Q03420,Q53GG5,Q9H0A0,Q9PU47,Q9Z1X0" charOffset="74-77" type="protein" text="ALP"/>
            <entity id="DS.d707.s0.e2" origId="2526" charOffset="183-190" type="compound" text="beta-GP"/>
            <pair e1="DS.d707.s0.e2" e2="DS.d707.s0.e1" id="DS.d707.s0.i0" interaction="True"/>
            <pair e1="DS.d707.s0.e2" e2="DS.d707.s0.e0" id="DS.d707.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d707.s1" origId="18683233-59" text="The level was unchanged in MSCs cultured on PV-H. In the case of supplementing Dex and beta-GP to the medium, the level of ALP activity in MSCs cultured on SPV-H was higher than that on PV-H at all time points during the 21-day culture.">
            <entity id="DS.d707.s1.e0" origId="2526" charOffset="87-94" type="compound" text="beta-GP"/>
            <entity id="DS.d707.s1.e1" origId="P03973,P12547,P22298,P28296,P29118,P35211,P83610,P97430,Q03420,Q53GG5,Q9H0A0,Q9PU47,Q9Z1X0" charOffset="123-126" type="protein" text="ALP"/>
            <pair e1="DS.d707.s1.e0" e2="DS.d707.s1.e1" id="DS.d707.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d708" origId="18683244">
        <sentence id="DS.d708.s0" origId="18683244-106" text="The combined treatment strategy not only decreased ubiquitin-positive aggregation in striatum, alleviated polyglutamine aggregation formation, and reduced striatal volume, but also extended life span in the R6/2 animal model.">
            <entity id="DS.d708.s0.e0" origId="O46543,P08565,P08618,P0C014,P0C072,P13117,P14624,P14792,P15174,P19848,P20685,P22589,P23324,P23398,P42739,P42740,P46574,P49634,P49635,P59263,P59669,P61862,P61863,P61864,P62972,P62973,P62974,P62975,P62976,P62977,P62988,P62989,P62990,P62991,P63049,P63051,P68195,P68196,P68197,P68198,P68199,P68201,P68204,P69308,P69309,P69310,P69311,P69312,P69313,P69314,P69315,P69316,P69317,P69318,P69319,P69320,P69321,P69322,P69323,P69324,P69325,P69326,P84589,Q05550,Q865C5,Q867C2,Q867C3,Q867C4,Q8MKD1,Q9Y848" charOffset="51-60" type="protein" text="ubiquitin"/>
            <entity id="DS.d708.s0.e1" origId="5961" charOffset="106-119" type="compound" text="polyglutamine"/>
            <pair e1="DS.d708.s0.e1" e2="DS.d708.s0.e0" id="DS.d708.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d709" origId="18683246">
        <sentence id="DS.d709.s0" origId="18683246-1143" text="Vasoactive intestinal peptide inhibits toll-like receptor 3-induced nitric oxide production in Schwann cells and subsequent sensory neuronal cell death in vitro.">
            <entity id="DS.d709.s0.e0" origId="P01282,P01283,P01284,P04566,P09684,P09685,P32648,P32649,P39089,P45644,P48142,P48143,P63289,P63290,P63291,P81016,P81401,P84488,P84771,P84772" charOffset="0-29" type="protein" text="Vasoactive intestinal peptide"/>
            <entity id="DS.d709.s0.e1" origId="145068" charOffset="68-80" type="compound" text="nitric oxide"/>
            <pair e1="DS.d709.s0.e1" e2="DS.d709.s0.e0" id="DS.d709.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d710" origId="18683252">
        <sentence id="DS.d710.s0" origId="18683252-1154" text="The GUS and LUC genes were chosen because they can be used as markers for the easy detection of transgenic plants, while histidine tail better enables the isolation of protein expressed in plant tissue.">
            <entity id="DS.d710.s0.e0" origId="P05804" charOffset="4-7" type="protein" text="GUS"/>
            <entity id="DS.d710.s0.e1" origId="773,6274" charOffset="121-130" type="compound" text="histidine"/>
            <pair e1="DS.d710.s0.e1" e2="DS.d710.s0.e0" id="DS.d710.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d711" origId="18683262">
        <sentence id="DS.d711.s0" origId="18683262-1162" text="Expression was performed in fusion to maltose binding protein using chemically defined minimal medium, followed by a single-step affinity capture and enzymatic cleavage using tobacco etch virus protease.">
            <entity id="DS.d711.s0.e0" origId="294,6255,439186,439341,10991489,45109807" charOffset="38-45" type="compound" text="maltose"/>
            <entity id="DS.d711.s0.e1" origId="O41798,O89290,O89940,O91080,O93215,P03311,P03353,P03355,P03356,P03362,P03363,P03366,P03367,P03369,P03370,P04023,P04024,P04323,P04584,P04585,P04587,P04588,P04589,P05959,P05960,P05961,P05962,P07570,P0C210,P0C211,P10210,P10265,P10270,P10271,P10272,P10273,P10274,P10394,P10978,P11227,P11365,P12451,P12497,P12498,P12499,P14074,P14078,P15833,P16046,P16423,P16901,P17757,P18042,P18096,P18802,P19028,P19199,P19560,P19561,P20825,P20875,P20876,P20892,P21407,P21414,P24107,P24740,P26808,P26809,P26810,P27502,P28936,P31822,P35956,P35963,P51518,P63119,P63120,P63121,P63122,P63123,P63124,P63125,P63127,P63128,P63129,P63131,P84454,Q09SZ9,Q0R5R2,Q0R5R3,Q1A249,Q1A267,Q4U0X6,Q73368,Q74120,Q75002,Q76634,Q77373,Q79666,Q89928,Q8AII1,Q8I7P9,Q9IDV9,Q9Q720,Q9QBY3,Q9QBZ1,Q9QBZ5,Q9QSR3,Q9WC54,Q9WC63,Q9Y6I0" charOffset="194-202" type="protein" text="protease"/>
            <pair e1="DS.d711.s0.e0" e2="DS.d711.s0.e1" id="DS.d711.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d712" origId="18683263">
        <sentence id="DS.d712.s0" origId="18683263-1164" text="The amplification of gltA gene encoding citrate synthase of TCA cycle was required for the efficient conversion of acetyl-CoA, generated during vanillin production from ferulic acid, to CoA, which is essential for vanillin production.">
            <entity id="DS.d712.s0.e0" origId="O33915,O34002,O68883,P09948,P0ABH7,P0ABH8,P14165,P18789,P20902,P20903,P21553,P26491,P39812,P42457,P51031,P51032,P51033,P51034,P51035,P51036,P51039,P51040,P51041,P51042,P51043,P51045,P56062,P80148,P94325,Q10530,Q53554,Q59136,Q59198,Q59258,Q59730,Q59732,Q59734,Q59741,Q59742,Q59748,Q59759,Q59768,Q59776,Q59778,Q59977,Q9RWB2,Q9ZN37" charOffset="21-25" type="protein" text="gltA"/>
            <entity id="DS.d712.s0.e1" origId="O33915,O34002,O68883,P09948,P0ABH7,P0ABH8,P14165,P18789,P20901,P20902,P20903,P21553,P26491,P27660,P42457,P51031,P51032,P51033,P51034,P51035,P51036,P51039,P51040,P51041,P51042,P51043,P51045,P56062,P80148,P84543,P94325,Q53554,Q59136,Q59198,Q59258,Q59730,Q59732,Q59734,Q59741,Q59742,Q59748,Q59759,Q59768,Q59776,Q59778,Q59939,Q59977,Q9RWB2,Q9ZN37" charOffset="40-56" type="protein" text="citrate synthase"/>
            <entity id="DS.d712.s0.e2" origId="1183" charOffset="144-152" type="compound" text="vanillin"/>
            <entity id="DS.d712.s0.e3" origId="445858" charOffset="169-181" type="compound" text="ferulic acid"/>
            <entity id="DS.d712.s0.e4" origId="1183" charOffset="214-222" type="compound" text="vanillin"/>
            <pair e1="DS.d712.s0.e3" e2="DS.d712.s0.e1" id="DS.d712.s0.i0" interaction="True"/>
            <pair e1="DS.d712.s0.e3" e2="DS.d712.s0.e0" id="DS.d712.s0.i1" interaction="True"/>
            <pair e1="DS.d712.s0.e2" e2="DS.d712.s0.e1" id="DS.d712.s0.i2" interaction="True"/>
            <pair e1="DS.d712.s0.e2" e2="DS.d712.s0.e0" id="DS.d712.s0.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d712.s1" origId="18683263-1167" text="The gltA amplification of the glyoxylate bypass in the icdA null mutant remarkably increased the production rate of vanillin with a little increase in the amount of vanillin production.">
            <entity id="DS.d712.s1.e0" origId="O33915,O34002,O68883,P09948,P0ABH7,P0ABH8,P14165,P18789,P20902,P20903,P21553,P26491,P39812,P42457,P51031,P51032,P51033,P51034,P51035,P51036,P51039,P51040,P51041,P51042,P51043,P51045,P56062,P80148,P94325,Q10530,Q53554,Q59136,Q59198,Q59258,Q59730,Q59732,Q59734,Q59741,Q59742,Q59748,Q59759,Q59768,Q59776,Q59778,Q59977,Q9RWB2,Q9ZN37" charOffset="4-8" type="protein" text="gltA"/>
            <entity id="DS.d712.s1.e1" origId="1183" charOffset="116-124" type="compound" text="vanillin"/>
            <entity id="DS.d712.s1.e2" origId="1183" charOffset="165-173" type="compound" text="vanillin"/>
            <pair e1="DS.d712.s1.e1" e2="DS.d712.s1.e0" id="DS.d712.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d712.s2" origId="18683263-1168" text="The real synergistic effect of gltA amplification and icdA deletion was observed with use of XAD-2 resin reducing the toxicity of vanillin produced during culture.">
            <entity id="DS.d712.s2.e0" origId="O33915,O34002,O68883,P09948,P0ABH7,P0ABH8,P14165,P18789,P20902,P20903,P21553,P26491,P39812,P42457,P51031,P51032,P51033,P51034,P51035,P51036,P51039,P51040,P51041,P51042,P51043,P51045,P56062,P80148,P94325,Q10530,Q53554,Q59136,Q59198,Q59258,Q59730,Q59732,Q59734,Q59741,Q59742,Q59748,Q59759,Q59768,Q59776,Q59778,Q59977,Q9RWB2,Q9ZN37" charOffset="31-35" type="protein" text="gltA"/>
            <entity id="DS.d712.s2.e1" origId="P08200,P79089" charOffset="54-58" type="protein" text="icdA"/>
            <entity id="DS.d712.s2.e2" origId="1183" charOffset="130-138" type="compound" text="vanillin"/>
            <pair e1="DS.d712.s2.e2" e2="DS.d712.s2.e0" id="DS.d712.s2.i0" interaction="True"/>
            <pair e1="DS.d712.s2.e2" e2="DS.d712.s2.e1" id="DS.d712.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d713" origId="18683889">
        <sentence id="DS.d713.s0" origId="18683889-1688" text="Treatment of dermal fibroblasts with vitamin D(3) induced expression of BMP-4 (1.2+/-0.2, 1.7+/-0.2, and 1.8+/-0.2 relative fold increase) and BMP-6 (9.1+/-0.3, 23.3+/-2.1, and 30.4+/-3.0 relative fold increase) at 3, 14, and 21 days, respectively.">
            <entity id="DS.d713.s0.e0" origId="5280795,5283711" charOffset="37-48" type="compound" text="vitamin D(3"/>
            <entity id="DS.d713.s0.e1" origId="O46576,P12644,P21275,P30885,Q06826,Q29607,Q2KJH1,Q8MJV5,Q90752" charOffset="72-77" type="protein" text="BMP-4"/>
            <entity id="DS.d713.s0.e2" origId="P20722,P22004,Q04906" charOffset="143-148" type="protein" text="BMP-6"/>
            <pair e1="DS.d713.s0.e0" e2="DS.d713.s0.e1" id="DS.d713.s0.i0" interaction="True"/>
            <pair e1="DS.d713.s0.e0" e2="DS.d713.s0.e2" id="DS.d713.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d713.s1" origId="18683889-1689" text="Vitamin D(3) was also shown to induce the expression of the osteoblast-specific markers, alkaline phosphatase and osteocalcin, in a dose-dependent manner in human dermal fibroblasts.">
            <entity id="DS.d713.s1.e0" origId="5280795,5283711" charOffset="0-11" type="compound" text="Vitamin D(3"/>
            <entity id="DS.d713.s1.e1" origId="O60109,P81800,P83456" charOffset="89-109" type="protein" text="alkaline phosphatase"/>
            <entity id="DS.d713.s1.e2" origId="P02819,P02821,P02823,P0C225,P0C226,P15504,P28317,P39056,P81455,P83005,P83238,P83473,P83489,P84348,P84349,P84350,P84351,Q7LZI4,Q8HYY9" charOffset="114-125" type="protein" text="osteocalcin"/>
            <pair e1="DS.d713.s1.e0" e2="DS.d713.s1.e1" id="DS.d713.s1.i0" interaction="True"/>
            <pair e1="DS.d713.s1.e0" e2="DS.d713.s1.e2" id="DS.d713.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d714" origId="18684212">
        <sentence id="DS.d714.s0" origId="18684212-1656" text="The aims of this study were: (i) to characterize the basal circadian rhythm of adrenocorticotropin hormone (ACTH) and cortisol in IBS vs healthy controls; (ii) to compare stimulated ACTH, cortisol and noradrenaline responses to a pelvic visceral stressor (sigmoidoscopy) in IBS and controls; and (iii) to correlate neuroendocrine responses with colonic mucosal cytokine expression and symptoms in IBS.">
            <entity id="DS.d714.s0.e0" origId="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5" charOffset="108-112" type="protein" text="ACTH"/>
            <entity id="DS.d714.s0.e1" origId="5754" charOffset="118-126" type="compound" text="cortisol"/>
            <entity id="DS.d714.s0.e2" origId="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5" charOffset="182-186" type="protein" text="ACTH"/>
            <entity id="DS.d714.s0.e3" origId="5754" charOffset="188-196" type="compound" text="cortisol"/>
            <entity id="DS.d714.s0.e4" origId="951,439260" charOffset="201-214" type="compound" text="noradrenaline"/>
            <pair e1="DS.d714.s0.e4" e2="DS.d714.s0.e0" id="DS.d714.s0.i0" interaction="False"/>
            <pair e1="DS.d714.s0.e1" e2="DS.d714.s0.e0" id="DS.d714.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d714.s1" origId="18684212-1657" text="In Study 1, basal cortisol levels were analysed in 41 IBS and 25 controls using 24-h collections of plasma ACTH and cortisol (q10 min sampling).">
            <entity id="DS.d714.s1.e0" origId="5754" charOffset="18-26" type="compound" text="cortisol"/>
            <entity id="DS.d714.s1.e1" origId="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5" charOffset="107-111" type="protein" text="ACTH"/>
            <entity id="DS.d714.s1.e2" origId="5754" charOffset="116-124" type="compound" text="cortisol"/>
            <pair e1="DS.d714.s1.e0" e2="DS.d714.s1.e1" id="DS.d714.s1.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d714.s2" origId="18684212-1658" text="Basal ACTH 0.05), while basal and stimulated plasma cortisol levels were higher in patients.">
            <entity id="DS.d714.s2.e0" origId="P01189,P01190,P01191,P01192,P01193,P01194,P01196,P01197,P01201,P06297,P06298,P06299,P10000,P11280,P11885,P19402,P21252,P22923,P68000,P68001,P87352,Q04617,Q04618,Q91082,Q9YGK2,Q9YGK4,Q9YGK5" charOffset="6-10" type="protein" text="ACTH"/>
            <entity id="DS.d714.s2.e1" origId="5754" charOffset="52-60" type="compound" text="cortisol"/>
            <pair e1="DS.d714.s2.e1" e2="DS.d714.s2.e0" id="DS.d714.s2.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d715" origId="18684339">
        <sentence id="DS.d715.s0" origId="18684339-438" text="A 3-fold increase in the expression of the MnSOD gene was associated with decreased CpG methylation of the analysed promoter region in the vegetarian group compared with the age-matched omnivores group.">
            <entity id="DS.d715.s0.e0" origId="P00448,P66828,P66829,Q8Z2V9,Q9RUV2" charOffset="43-48" type="protein" text="MnSOD"/>
            <entity id="DS.d715.s0.e1" origId="6804" charOffset="84-87" type="compound" text="CpG"/>
            <pair e1="DS.d715.s0.e1" e2="DS.d715.s0.e0" id="DS.d715.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d716" origId="18684712">
        <sentence id="DS.d716.s0" origId="18684712-650" text="ALK2 (R206H) with Smad1 or Smad5 induced osteoblastic differentiation that could be inhibited by Smad7 or dorsomorphin.">
            <entity id="DS.d716.s0.e0" origId="Q9Y758" charOffset="0-4" type="protein" text="ALK2"/>
            <entity id="DS.d716.s0.e1" origId="P70340,P97588,Q9I8V2" charOffset="18-23" type="protein" text="Smad1"/>
            <entity id="DS.d716.s0.e2" origId="P97454,Q99717,Q9R1V3,Q9W7E7" charOffset="27-32" type="protein" text="Smad5"/>
            <entity id="DS.d716.s0.e3" origId="O15105,O35253,O88406" charOffset="97-102" type="protein" text="Smad7"/>
            <entity id="DS.d716.s0.e4" origId="11524144" charOffset="106-118" type="compound" text="dorsomorphin"/>
            <pair e1="DS.d716.s0.e4" e2="DS.d716.s0.e1" id="DS.d716.s0.i0" interaction="True"/>
            <pair e1="DS.d716.s0.e4" e2="DS.d716.s0.e3" id="DS.d716.s0.i1" interaction="False"/>
            <pair e1="DS.d716.s0.e4" e2="DS.d716.s0.e2" id="DS.d716.s0.i2" interaction="True"/>
            <pair e1="DS.d716.s0.e4" e2="DS.d716.s0.e0" id="DS.d716.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d717" origId="18685817">
        <sentence id="DS.d717.s0" origId="18685817-1575" text="Combustion products of 1,3-butadiene inhibit catalase activity and induce expression of oxidative DNA damage repair enzymes in human bronchial epithelial cells.">
            <entity id="DS.d717.s0.e0" origId="7845" charOffset="23-36" type="compound" text="1,3-butadiene"/>
            <entity id="DS.d717.s0.e1" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="45-53" type="protein" text="catalase"/>
            <pair e1="DS.d717.s0.e0" e2="DS.d717.s0.e1" id="DS.d717.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d718" origId="18686014">
        <sentence id="DS.d718.s0" origId="18686014-49" text="The aim of the present study was to examine whether increased serum Hsp70 levels are related to clinical characteristics and standard laboratory parameters of preeclamptic patients, as well as to markers of inflammation (C-reactive protein), endothelial activation (von Willebrand factor antigen) or endothelial injury (fibronectin), trophoblast debris (cell-free fetal DNA) and oxidative stress (malondialdehyde).">
            <entity id="DS.d718.s0.e0" origId="P30722,P47547,P49463,P75344,Q7YQC6,Q8TQR2,Q9UXR0,Q9WYK6" charOffset="68-73" type="protein" text="Hsp70"/>
            <entity id="DS.d718.s0.e1" origId="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400" charOffset="320-331" type="protein" text="fibronectin"/>
            <entity id="DS.d718.s0.e2" origId="10964" charOffset="397-412" type="compound" text="malondialdehyde"/>
            <pair e1="DS.d718.s0.e2" e2="DS.d718.s0.e1" id="DS.d718.s0.i0" interaction="False"/>
            <pair e1="DS.d718.s0.e2" e2="DS.d718.s0.e0" id="DS.d718.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d718.s1" origId="18686014-50" text="Furthermore, serum levels of blood urea nitrogen, creatinine, bilirubin and CRP, serum alanine aminotransferase and lactate dehydrogenase (LDH) activities, as well as plasma levels of VWF :Ag, fibronectin, cell-free fetal DNA and malondialdehyde were also significantly higher in preeclamptic patients than in normotensive, healthy pregnant women.">
            <entity id="DS.d718.s1.e0" origId="1176,265993" charOffset="35-39" type="compound" text="urea"/>
            <entity id="DS.d718.s1.e1" origId="947,123329" charOffset="40-48" type="compound" text="nitrogen"/>
            <entity id="DS.d718.s1.e2" origId="588" charOffset="50-60" type="compound" text="creatinine"/>
            <entity id="DS.d718.s1.e3" origId="5280352" charOffset="62-71" type="compound" text="bilirubin"/>
            <entity id="DS.d718.s1.e4" origId="O19062,P02741,P02742,P08462,P18151,P21291,P41964,P47875,P49254,P49262,P52753,P67966,P67967,P97315,Q07203" charOffset="76-79" type="protein" text="CRP"/>
            <entity id="DS.d718.s1.e5" origId="P29038,P33571,P93052,Q27797,Q27888,Q95028,Q99289" charOffset="139-142" type="protein" text="LDH"/>
            <entity id="DS.d718.s1.e6" origId="P04275,P80012,Q28295,Q28833,Q8CIZ8" charOffset="184-187" type="protein" text="VWF"/>
            <entity id="DS.d718.s1.e7" origId="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400" charOffset="193-204" type="protein" text="fibronectin"/>
            <entity id="DS.d718.s1.e8" origId="10964" charOffset="230-245" type="compound" text="malondialdehyde"/>
            <pair e1="DS.d718.s1.e2" e2="DS.d718.s1.e7" id="DS.d718.s1.i0" interaction="False"/>
            <pair e1="DS.d718.s1.e8" e2="DS.d718.s1.e6" id="DS.d718.s1.i1" interaction="False"/>
            <pair e1="DS.d718.s1.e3" e2="DS.d718.s1.e6" id="DS.d718.s1.i2" interaction="False"/>
            <pair e1="DS.d718.s1.e1" e2="DS.d718.s1.e4" id="DS.d718.s1.i3" interaction="False"/>
            <pair e1="DS.d718.s1.e2" e2="DS.d718.s1.e4" id="DS.d718.s1.i4" interaction="False"/>
            <pair e1="DS.d718.s1.e1" e2="DS.d718.s1.e5" id="DS.d718.s1.i5" interaction="False"/>
            <pair e1="DS.d718.s1.e0" e2="DS.d718.s1.e7" id="DS.d718.s1.i6" interaction="False"/>
            <pair e1="DS.d718.s1.e0" e2="DS.d718.s1.e4" id="DS.d718.s1.i7" interaction="False"/>
            <pair e1="DS.d718.s1.e3" e2="DS.d718.s1.e5" id="DS.d718.s1.i8" interaction="False"/>
            <pair e1="DS.d718.s1.e8" e2="DS.d718.s1.e4" id="DS.d718.s1.i9" interaction="False"/>
            <pair e1="DS.d718.s1.e0" e2="DS.d718.s1.e6" id="DS.d718.s1.i10" interaction="False"/>
            <pair e1="DS.d718.s1.e2" e2="DS.d718.s1.e6" id="DS.d718.s1.i11" interaction="False"/>
            <pair e1="DS.d718.s1.e3" e2="DS.d718.s1.e7" id="DS.d718.s1.i12" interaction="False"/>
            <pair e1="DS.d718.s1.e1" e2="DS.d718.s1.e6" id="DS.d718.s1.i13" interaction="False"/>
            <pair e1="DS.d718.s1.e1" e2="DS.d718.s1.e7" id="DS.d718.s1.i14" interaction="False"/>
            <pair e1="DS.d718.s1.e3" e2="DS.d718.s1.e4" id="DS.d718.s1.i15" interaction="False"/>
            <pair e1="DS.d718.s1.e0" e2="DS.d718.s1.e5" id="DS.d718.s1.i16" interaction="False"/>
            <pair e1="DS.d718.s1.e8" e2="DS.d718.s1.e5" id="DS.d718.s1.i17" interaction="False"/>
            <pair e1="DS.d718.s1.e8" e2="DS.d718.s1.e7" id="DS.d718.s1.i18" interaction="False"/>
            <pair e1="DS.d718.s1.e2" e2="DS.d718.s1.e5" id="DS.d718.s1.i19" interaction="False"/>
        </sentence>
        <sentence id="DS.d718.s2" origId="18686014-51" text="In preeclamptic patients, serum Hsp70 levels showed significant correlations with serum CRP levels (Spearman R = 0.32, p = 0.010), serum aspartate aminotransferase (R = 0.32, p = 0.008) and LDH (0.001), as well as with plasma malondialdehyde levels (R = 0.25, p = 0.043).">
            <entity id="DS.d718.s2.e0" origId="P30722,P47547,P49463,P75344,Q7YQC6,Q8TQR2,Q9UXR0,Q9WYK6" charOffset="32-37" type="protein" text="Hsp70"/>
            <entity id="DS.d718.s2.e1" origId="O19062,P02741,P02742,P08462,P18151,P21291,P41964,P47875,P49254,P49262,P52753,P67966,P67967,P97315,Q07203" charOffset="88-91" type="protein" text="CRP"/>
            <entity id="DS.d718.s2.e2" origId="O33822,O58489,O67781,O86459,O93744,P00509,P14909,P23034,P44425,P53001,P58661,P72173,Q4J8X2,Q55128,Q56114,Q56232,Q59228,Q60013,Q92JE7,Q972A2,Q9V0L2,Q9X0Y2,Q9ZE56" charOffset="137-163" type="protein" text="aspartate aminotransferase"/>
            <entity id="DS.d718.s2.e3" origId="P29038,P33571,P93052,Q27797,Q27888,Q95028,Q99289" charOffset="190-193" type="protein" text="LDH"/>
            <entity id="DS.d718.s2.e4" origId="10964" charOffset="226-241" type="compound" text="malondialdehyde"/>
            <pair e1="DS.d718.s2.e4" e2="DS.d718.s2.e1" id="DS.d718.s2.i0" interaction="False"/>
            <pair e1="DS.d718.s2.e4" e2="DS.d718.s2.e0" id="DS.d718.s2.i1" interaction="True"/>
            <pair e1="DS.d718.s2.e4" e2="DS.d718.s2.e2" id="DS.d718.s2.i2" interaction="False"/>
            <pair e1="DS.d718.s2.e4" e2="DS.d718.s2.e3" id="DS.d718.s2.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d719" origId="18686047">
        <sentence id="DS.d719.s0" origId="18686047-887" text="In an effort to identify agents which enhance the activity of oligos and which possess less toxicity than traditionally employed chemotherapeutics, Rapamycin, an immunosuppressive agent known to regulate tumor growth and signal transduction mediated by the mTOR receptor, is compared to paclitaxel in combination therapy employing monospecific or bispecific oligos.">
            <entity id="DS.d719.s0.e0" origId="5040,478951,5284616,5358081,5374464,5460439,5497196,6436030,16760631,17753749,44295234,53627520,54600319" charOffset="148-157" type="compound" text="Rapamycin"/>
            <entity id="DS.d719.s0.e1" origId="P42345,P42346,Q9JLN9" charOffset="257-261" type="protein" text="mTOR"/>
            <entity id="DS.d719.s0.e2" origId="4666,36314,441276,5352019,6713921,6915727,44155032,53313247" charOffset="287-297" type="compound" text="paclitaxel"/>
            <pair e1="DS.d719.s0.e0" e2="DS.d719.s0.e1" id="DS.d719.s0.i0" interaction="True"/>
            <pair e1="DS.d719.s0.e2" e2="DS.d719.s0.e1" id="DS.d719.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d720" origId="18686136">
        <sentence id="DS.d720.s0" origId="18686136-131" text="In this study we investigated the superoxide radicals scavenging effect and xanthine oxidase inhibitory activity by magnesium lithospermate B, which was originally isolated from the roots of Salvia miltiorrhiza (also named Danshen or Dansham), an important herb in Oriental medicine.">
            <entity id="DS.d720.s0.e0" origId="5359597" charOffset="34-44" type="compound" text="superoxide"/>
            <entity id="DS.d720.s0.e1" origId="P22985,P47989,P47990,P80457,Q00519,Q9MYW6" charOffset="76-92" type="protein" text="xanthine oxidase"/>
            <entity id="DS.d720.s0.e2" origId="6451084" charOffset="116-141" type="compound" text="magnesium lithospermate B"/>
            <pair e1="DS.d720.s0.e2" e2="DS.d720.s0.e1" id="DS.d720.s0.i0" interaction="True"/>
            <pair e1="DS.d720.s0.e0" e2="DS.d720.s0.e1" id="DS.d720.s0.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d720.s1" origId="18686136-132" text="Superoxide radicals were generated both in beta-NADH/PMS system and xanthine/xanthine oxidase system.">
            <entity id="DS.d720.s1.e0" origId="5359597" charOffset="0-10" type="compound" text="Superoxide"/>
            <entity id="DS.d720.s1.e1" origId="928,439153,11250888" charOffset="43-52" type="compound" text="beta-NADH"/>
            <entity id="DS.d720.s1.e2" origId="9286" charOffset="53-56" type="compound" text="PMS"/>
            <entity id="DS.d720.s1.e3" origId="1188" charOffset="68-76" type="compound" text="xanthine"/>
            <entity id="DS.d720.s1.e4" origId="P22985,P47989,P47990,P80457,Q00519,Q9MYW6" charOffset="77-93" type="protein" text="xanthine oxidase"/>
            <pair e1="DS.d720.s1.e2" e2="DS.d720.s1.e4" id="DS.d720.s1.i0" interaction="False"/>
            <pair e1="DS.d720.s1.e1" e2="DS.d720.s1.e4" id="DS.d720.s1.i1" interaction="False"/>
            <pair e1="DS.d720.s1.e3" e2="DS.d720.s1.e4" id="DS.d720.s1.i2" interaction="True"/>
            <pair e1="DS.d720.s1.e0" e2="DS.d720.s1.e4" id="DS.d720.s1.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d720.s2" origId="18686136-133" text="Further study suggested that magnesium lithospermate B can directly inhibit xanthine oxidase and exhibits competitive inhibition.">
            <entity id="DS.d720.s2.e0" origId="6451084" charOffset="29-54" type="compound" text="magnesium lithospermate B"/>
            <entity id="DS.d720.s2.e1" origId="P22985,P47989,P47990,P80457,Q00519,Q9MYW6" charOffset="76-92" type="protein" text="xanthine oxidase"/>
            <pair e1="DS.d720.s2.e0" e2="DS.d720.s2.e1" id="DS.d720.s2.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d720.s3" origId="18686136-134" text="In addition, magnesium lithospermate B significantly protected HL-60 cells from superoxide radicals-induced apoptosis in the xanthine/xanthine oxidase reactions.">
            <entity id="DS.d720.s3.e0" origId="6451084" charOffset="13-38" type="compound" text="magnesium lithospermate B"/>
            <entity id="DS.d720.s3.e1" origId="1188" charOffset="125-133" type="compound" text="xanthine"/>
            <entity id="DS.d720.s3.e2" origId="P22985,P47989,P47990,P80457,Q00519,Q9MYW6" charOffset="134-150" type="protein" text="xanthine oxidase"/>
            <pair e1="DS.d720.s3.e0" e2="DS.d720.s3.e2" id="DS.d720.s3.i0" interaction="True"/>
            <pair e1="DS.d720.s3.e1" e2="DS.d720.s3.e2" id="DS.d720.s3.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d721" origId="18686165">
        <sentence id="DS.d721.s0" origId="18686165-403" text="Four different molecules contain galactofuranose in A. fumigatus: (i) the galactomannan present in the alkali soluble and insoluble fraction of the cell wall (ii) N- and O glycan moieties of secreted glycoproteins (iii) a GPI-anchored lipophosphogalactomannan and (iv) several sphingolipids also anchored to the membrane by an inositol phosphoceramide.">
            <entity id="DS.d721.s0.e0" origId="439336" charOffset="74-87" type="compound" text="galactomannan"/>
            <entity id="DS.d721.s0.e1" origId="871" charOffset="172-178" type="compound" text="glycan"/>
            <entity id="DS.d721.s0.e2" origId="P08163" charOffset="200-213" type="protein" text="glycoproteins"/>
            <entity id="DS.d721.s0.e3" origId="O25781,O51672,O59618,O66954,O82059,O83488,O84382,P06744,P06745,P08059,P0A0T0,P0A0T1,P0A6T1,P0A6T2,P12341,P12709,P13377,P18240,P28718,P29333,P34795,P34796,P34797,P42861,P44312,P46479,P47357,P49105,P50309,P52029,P52030,P52031,P52983,P54234,P54235,P54236,P54237,P54238,P54239,P54240,P54241,P54242,P54243,P57636,P64192,P64193,P64194,P64195,P64196,P77877,P78033,P78917,P80860,P81181,P83194,P83780,P84140,P99078,Q0TA36,Q0VR14,Q11MA0,Q13Z07,Q165T7,Q18FQ4,Q1ASN4,Q1BH79,Q1CSA0,Q1CX51,Q1GAY0,Q1GJQ5,Q1GTU1,Q1H1P4,Q1IYT4,Q1J8N2,Q1JDQ8,Q1JIS1,Q1JNM4,Q1LM68,Q1LU73,Q1MM06,Q1QEK1,Q1R3R3,Q1WUR2,Q21M11,Q21ZD5,Q24VW9,Q255I6,Q28QX4,Q2A2C5,Q2FIB3,Q2FZU0,Q2G7C4,Q2IE39,Q2JH03,Q2JHU0,Q2JX86,Q2KCY8,Q2KYE9,Q2LRD0,Q2NJ38,Q2NR04,Q2P380,Q2RQ51,Q2S8W1,Q2SS24,Q2SWP6,Q2VYV7,Q2YBU4,Q2YPF3,Q2YWS3,Q31AX5,Q31I19,Q31LL0,Q31TX1,Q328X7,Q38WF1,Q39FF4,Q39SU1,Q3A201,Q3AFH3,Q3AJU7,Q3ASZ0,Q3AXV8,Q3B3Q8,Q3BUL3,Q3IKH4,Q3IMS0,Q3J2U4,Q3JCN1,Q3JRE2,Q3K2Y2,Q3K6Q4,Q3KLX6,Q3M6S3,Q3YUW0,Q3ZBD7,Q44407,Q46L16,Q47IJ3,Q48N88,Q48VF9,Q491V0,Q49WA1,Q4A5S9,Q4A7J2,Q4A9F3,Q4FVH5,Q4JCA7,Q4JX51,Q4K5Y1,Q4L4X8,Q4QL07,Q4R591,Q4UTV8,Q4ZY88,Q57F73,Q57H06,Q59000,Q59088,Q5E847,Q5FL04,Q5H0A7,Q5HHC2,Q5HQJ9,Q5JE38,Q5KVS7,Q5L5E1,Q5L9E3,Q5LRS9,Q5M1N9,Q5N0B4,Q5NFC4,Q5P0T4,Q5PL07,Q5QWW0,Q5R4E3,Q5SLL6,Q5UXU0,Q5WDX0,Q5WYE0,Q5X6Y8,Q5XE09,Q5YPP1,Q5ZXH2,Q600A8,Q609I7,Q62JL8,Q632G4,Q63V31,Q64PM7,Q65FL6,Q65TC2,Q660E3,Q664W9,Q67QQ0,Q6A5X5,Q6AQ48,Q6D022,Q6F1L2,Q6FRW1,Q6G0T9,Q6GAW4,Q6GIC6,Q6HC08,Q6KH90,Q6LM51,Q6LXQ4,Q6MD44,Q6MTA3,Q6NIE5,Q6YQU0,Q711G1,Q71X61,Q72GY6,Q72MT7,Q72YI4,Q73K18,Q742E4,Q74DK5,Q74K31,Q758L0,Q7MH97,Q7MUV9,Q7MZB4,Q7NJY9,Q7S986,Q7U6T0,Q7V1I1,Q7V7M6,Q7VBZ6,Q7VNR9,Q7VRI4,Q7VUF4,Q7W197,Q7WP01,Q816G0,Q81K75,Q822E7,Q82SP4,Q835G1,Q83D91,Q83XM3,Q848I4,Q87EV7,Q87L81,Q888Q7,Q88UI4,Q891H2,Q89A35,Q8A5W2,Q8CT80,Q8D1V8,Q8DCK7,Q8DKY2,Q8DN74,Q8EBH1,Q8ENY8,Q8EVU1,Q8EZG6,Q8FB44,Q8FR39,Q8G2N3,Q8G7I6,Q8K8Q6,Q8K910,Q8KDQ7,Q8L1Z9,Q8NS31,Q8NXF1,Q8P2R3,Q8P9S7,Q8R924,Q8RHH5,Q8SRY1,Q8UI94,Q8VVB7,Q8XI54,Q8XYN9,Q8Y4R7,Q8YF86,Q8YY05,Q8Z1U7,Q8ZAS2,Q8ZKI4,Q8ZWV0,Q928R6,Q92SC4,Q96YC2,Q978F3,Q97FP8,Q97NG0,Q97WE5,Q98BV5,Q98R79,Q9A1L1,Q9ABK5,Q9CD75,Q9CNL2,Q9FXM4,Q9FXM5,Q9HGZ2,Q9HIC2,Q9HNQ6,Q9HV67,Q9K7L8,Q9KUY4,Q9KX58,Q9N1E2,Q9PGR6,Q9PK16,Q9PMD4,Q9RDY2,Q9RMC1,Q9RTL8,Q9UXW3,Q9X1A5,Q9X670,Q9YE01,Q9Z6N4,Q9ZK49" charOffset="222-225" type="protein" text="GPI"/>
            <entity id="DS.d721.s0.e4" origId="57339182" charOffset="327-351" type="compound" text="inositol phosphoceramide"/>
            <pair e1="DS.d721.s0.e0" e2="DS.d721.s0.e2" id="DS.d721.s0.i0" interaction="False"/>
            <pair e1="DS.d721.s0.e4" e2="DS.d721.s0.e2" id="DS.d721.s0.i1" interaction="False"/>
            <pair e1="DS.d721.s0.e0" e2="DS.d721.s0.e3" id="DS.d721.s0.i2" interaction="False"/>
            <pair e1="DS.d721.s0.e1" e2="DS.d721.s0.e2" id="DS.d721.s0.i3" interaction="True"/>
            <pair e1="DS.d721.s0.e4" e2="DS.d721.s0.e3" id="DS.d721.s0.i4" interaction="False"/>
            <pair e1="DS.d721.s0.e1" e2="DS.d721.s0.e3" id="DS.d721.s0.i5" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d722" origId="18687549">
        <sentence id="DS.d722.s0" origId="18687549-1315" text="The estimated CRP level and the IMCL content in these patients were correlated with body mass index, percentage of body fat, other measures of abdominal obesity, serum lipoproteins, fasting and post-oral glucose load serum insulin levels and other surrogate markers of insulin resistance.">
            <entity id="DS.d722.s0.e0" origId="O19062,P02741,P02742,P08462,P18151,P21291,P41964,P47875,P49254,P49262,P52753,P67966,P67967,P97315,Q07203" charOffset="14-17" type="protein" text="CRP"/>
            <entity id="DS.d722.s0.e1" origId="206,5793,64689,79025" charOffset="204-211" type="compound" text="glucose"/>
            <entity id="DS.d722.s0.e2" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="223-230" type="protein" text="insulin"/>
            <entity id="DS.d722.s0.e3" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="269-276" type="protein" text="insulin"/>
            <pair e1="DS.d722.s0.e1" e2="DS.d722.s0.e0" id="DS.d722.s0.i0" interaction="False"/>
            <pair e1="DS.d722.s0.e1" e2="DS.d722.s0.e2" id="DS.d722.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d723" origId="18687985">
        <sentence id="DS.d723.s0" origId="18687985-1621" text="Studies suggest that DKK1 activation in osteoblasts is the underlying cause of glucocorticoid- and estrogen deficiency-mediated osteoporosis, and at least partially underlies the teratogenic effects of thalidomide on limb development.">
            <entity id="DS.d723.s0.e0" origId="O94907" charOffset="21-25" type="protein" text="DKK1"/>
            <entity id="DS.d723.s0.e1" origId="5426,75792,92142" charOffset="202-213" type="compound" text="thalidomide"/>
            <pair e1="DS.d723.s0.e1" e2="DS.d723.s0.e0" id="DS.d723.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d724" origId="18688040">
        <sentence id="DS.d724.s0" origId="18688040-30" text="The IL-13-induced up-regulation of RhoA was inhibited by leflunomide, an inhibitor of signal transducer and activator of transcription 6 (STAT6).">
            <entity id="DS.d724.s0.e0" origId="P20109,P35225,P42203,P61126,Q5I6E4,Q864V6,Q865W5,Q865X3,Q95J68,Q9N0W9,Q9XSV9" charOffset="4-9" type="protein" text="IL-13"/>
            <entity id="DS.d724.s0.e1" origId="Q9C3Y4" charOffset="35-39" type="protein" text="RhoA"/>
            <entity id="DS.d724.s0.e2" origId="3899" charOffset="57-68" type="compound" text="leflunomide"/>
            <entity id="DS.d724.s0.e3" origId="P42226" charOffset="138-143" type="protein" text="STAT6"/>
            <pair e1="DS.d724.s0.e2" e2="DS.d724.s0.e0" id="DS.d724.s0.i0" interaction="False"/>
            <pair e1="DS.d724.s0.e2" e2="DS.d724.s0.e1" id="DS.d724.s0.i1" interaction="True"/>
            <pair e1="DS.d724.s0.e2" e2="DS.d724.s0.e3" id="DS.d724.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d725" origId="18688042">
        <sentence id="DS.d725.s0" origId="18688042-1313" text="The goal of this study was to determine the mechanisms by which 17beta-estradiol induces MUC5B gene expression in airway epithelial cells.">
            <entity id="DS.d725.s0.e0" origId="5757" charOffset="64-80" type="compound" text="17beta-estradiol"/>
            <entity id="DS.d725.s0.e1" origId="Q9HC84" charOffset="89-94" type="protein" text="MUC5B"/>
            <pair e1="DS.d725.s0.e0" e2="DS.d725.s0.e1" id="DS.d725.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d725.s1" origId="18688042-1314" text="Pretreatment with ER antagonist ICI 182,780 blocked both E2-induced ERK1/2-MAPK activation and MUC5B gene expression.">
            <entity id="DS.d725.s1.e0" origId="104741" charOffset="32-43" type="compound" text="ICI 182,780"/>
            <entity id="DS.d725.s1.e1" origId="P27361,P28869,P42525,Q07176" charOffset="68-72" type="protein" text="ERK1"/>
            <entity id="DS.d725.s1.e2" origId="O42781,P27638,Q00859" charOffset="75-79" type="protein" text="MAPK"/>
            <entity id="DS.d725.s1.e3" origId="Q9HC84" charOffset="95-100" type="protein" text="MUC5B"/>
            <pair e1="DS.d725.s1.e0" e2="DS.d725.s1.e1" id="DS.d725.s1.i0" interaction="True"/>
            <pair e1="DS.d725.s1.e0" e2="DS.d725.s1.e2" id="DS.d725.s1.i1" interaction="True"/>
            <pair e1="DS.d725.s1.e0" e2="DS.d725.s1.e3" id="DS.d725.s1.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d726" origId="18688696">
        <sentence id="DS.d726.s0" origId="18688696-558" text="We here show that calumenin in the presence of Ca(2+) binds to TSP1 with a dissociation constant K (d) around 0.4 muM.">
            <entity id="DS.d726.s0.e0" origId="271" charOffset="47-51" type="compound" text="Ca(2"/>
            <entity id="DS.d726.s0.e1" origId="P07996,P54000,Q28178" charOffset="63-67" type="protein" text="TSP1"/>
            <pair e1="DS.d726.s0.e0" e2="DS.d726.s0.e1" id="DS.d726.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d727" origId="18688816">
        <sentence id="DS.d727.s0" origId="18688816-657" text="It represents transition in sulfur-deprived conditions, known to lead to H2 production in Chlamydomonas reinhardtii, and the two main processes then induced which are an over-accumulation of intracellular starch and a progressive reduction of PSII activity for anoxia achievement.">
            <entity id="DS.d727.s0.e0" origId="402" charOffset="28-34" type="compound" text="sulfur"/>
            <entity id="DS.d727.s0.e1" origId="O47040,O78462,O96813,P12185,P12186,P12187,P13165,P17227,P17228,P28251,P30980,P48116,P49159,P49484,P51387,P52768,P56768,P58214,P69396,P69397,P69398,Q31909,Q5QA78,Q5SCW1,Q68RZ6,Q6B8K8,Q6ENG4,Q6ENV4,Q6EW69,Q6L390,Q6L603,Q6QBN9,Q70XZ3,Q7FNS8,Q7YJW3,Q85CI4,Q85FL2,Q85X26,Q8M9X5,Q8WI10,Q9BBS0,Q9GDV2,Q9MTL2,Q9MUQ4,Q9TL12,Q9TM24" charOffset="243-247" type="protein" text="PSII"/>
            <pair e1="DS.d727.s0.e0" e2="DS.d727.s0.e1" id="DS.d727.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d728" origId="18689429">
        <sentence id="DS.d728.s0" origId="18689429-1187" text="We examined whether aldosterone produced locally in the brain may contribute to the activation of mineralocorticoid receptors in the CNS.">
            <entity id="DS.d728.s0.e0" origId="5839" charOffset="20-31" type="compound" text="aldosterone"/>
            <entity id="DS.d728.s0.e1" origId="P08235,P22199,P79404,Q29131,Q3YC04,Q4JM28,Q8QHI2,Q8VII8,Q91573,Q9BDJ7,Q9IAC6,Q9N0W8" charOffset="98-125" type="protein" text="mineralocorticoid receptors"/>
            <pair e1="DS.d728.s0.e0" e2="DS.d728.s0.e1" id="DS.d728.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d729" origId="18690415">
        <sentence id="DS.d729.s0" origId="18690415-286" text="Macrophages isolated from iron deficient rats, or pregnant rats at day 21 of gestation, either supplemented with a single dose of iron dextran, 10 mg, at the commencement of pregnancy, or not, showed significant increases of macrophage ferroportin mRNA expression, which was paralleled by significant decreases in hepatic Hamp mRNA expression.">
            <entity id="DS.d729.s0.e0" origId="105075" charOffset="130-142" type="compound" text="iron dextran"/>
            <entity id="DS.d729.s0.e1" origId="Q7T273,Q99MH3,Q9EQ21" charOffset="322-326" type="protein" text="Hamp"/>
            <pair e1="DS.d729.s0.e0" e2="DS.d729.s0.e1" id="DS.d729.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d730" origId="18690549">
        <sentence id="DS.d730.s0" origId="18690549-796" text="Rat dicarboxylate transporter (SDCT1), expressed in renal tubular epithelial cells, plays a key role in regulating blood and urinary citrate level by reabsorbing citrate from the lumen.">
            <entity id="DS.d730.s0.e0" origId="Q13183,Q28615" charOffset="31-36" type="protein" text="SDCT1"/>
            <entity id="DS.d730.s0.e1" origId="311,2733526" charOffset="133-140" type="compound" text="citrate"/>
            <entity id="DS.d730.s0.e2" origId="311,2733526" charOffset="162-169" type="compound" text="citrate"/>
            <pair e1="DS.d730.s0.e1" e2="DS.d730.s0.e0" id="DS.d730.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d731" origId="18690792">
        <sentence id="DS.d731.s0" origId="18690792-145" text="However, as opposed to exogenous HS, the continuous use of FGF-2 during in vitro differentiation completely blocked rMSC mineralization.">
            <entity id="DS.d731.s0.e0" origId="5047209,46173182" charOffset="33-35" type="compound" text="HS"/>
            <entity id="DS.d731.s0.e1" origId="P03969,P20003,P48800,Q60487" charOffset="59-64" type="protein" text="FGF-2"/>
            <pair e1="DS.d731.s0.e0" e2="DS.d731.s0.e1" id="DS.d731.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d731.s1" origId="18690792-146" text="We show that the effects of both FGF-2 and HS are mediated through FGF receptor 1 (FGFR1) and that inhibition of signaling through this receptor arrests cell growth, resulting in the cells being unable to reach the critical density necessary to induce differentiation.">
            <entity id="DS.d731.s1.e0" origId="P03969,P20003,P48800,Q60487" charOffset="33-38" type="protein" text="FGF-2"/>
            <entity id="DS.d731.s1.e1" origId="5047209,46173182" charOffset="43-45" type="compound" text="HS"/>
            <entity id="DS.d731.s1.e2" origId="O10284,P41444" charOffset="33-36" type="protein" text="FGF"/>
            <entity id="DS.d731.s1.e3" origId="P11362,P21804,Q8MY86,Q91285" charOffset="83-88" type="protein" text="FGFR1"/>
            <pair e1="DS.d731.s1.e1" e2="DS.d731.s1.e2" id="DS.d731.s1.i0" interaction="False"/>
            <pair e1="DS.d731.s1.e1" e2="DS.d731.s1.e0" id="DS.d731.s1.i1" interaction="False"/>
            <pair e1="DS.d731.s1.e1" e2="DS.d731.s1.e3" id="DS.d731.s1.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d732" origId="18691156">
        <sentence id="DS.d732.s0" origId="18691156-926" text="Two related polytopic membrane proteins of the major facilitator family, NarK and NarU, catalyse nitrate uptake, nitrite export and nitrite uptake across the Escherichia coli cytoplasmic membrane by an unknown mechanism.">
            <entity id="DS.d732.s0.e0" origId="P16629,P24266,P28991,Q04565,Q07252" charOffset="22-39" type="protein" text="membrane proteins"/>
            <entity id="DS.d732.s0.e1" origId="P10903,P46907" charOffset="73-77" type="protein" text="NarK"/>
            <entity id="DS.d732.s0.e2" origId="P37593,P37758" charOffset="82-86" type="protein" text="NarU"/>
            <entity id="DS.d732.s0.e3" origId="943" charOffset="97-104" type="compound" text="nitrate"/>
            <pair e1="DS.d732.s0.e3" e2="DS.d732.s0.e0" id="DS.d732.s0.i0" interaction="False"/>
            <pair e1="DS.d732.s0.e3" e2="DS.d732.s0.e2" id="DS.d732.s0.i1" interaction="True"/>
            <pair e1="DS.d732.s0.e3" e2="DS.d732.s0.e1" id="DS.d732.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d733" origId="18691343">
        <sentence id="DS.d733.s0" origId="18691343-1073" text="Intracellular interleukin-4 (Th2 cytokine) and interferon-gamma (Th1 cytokine) production was assessed in CD4+ T lymphocytes activated by phorbol 12-myristate 13-acetate and ionomycin using flow cytometry.">
            <entity id="DS.d733.s0.e0" origId="Q9TTB0" charOffset="47-63" type="protein" text="interferon-gamma"/>
            <entity id="DS.d733.s0.e1" origId="Q64279,Q922L6" charOffset="65-68" type="protein" text="Th1"/>
            <entity id="DS.d733.s0.e2" origId="4792,27924,122634,22833501" charOffset="138-169" type="compound" text="phorbol 12-myristate 13-acetate"/>
            <entity id="DS.d733.s0.e3" origId="3733,6434517,6912226,25134244" charOffset="174-183" type="compound" text="ionomycin"/>
            <pair e1="DS.d733.s0.e3" e2="DS.d733.s0.e0" id="DS.d733.s0.i0" interaction="True"/>
            <pair e1="DS.d733.s0.e2" e2="DS.d733.s0.e1" id="DS.d733.s0.i1" interaction="True"/>
            <pair e1="DS.d733.s0.e2" e2="DS.d733.s0.e0" id="DS.d733.s0.i2" interaction="True"/>
            <pair e1="DS.d733.s0.e3" e2="DS.d733.s0.e1" id="DS.d733.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d734" origId="18691603">
        <sentence id="DS.d734.s0" origId="18691603-1685" text="This signaling system is engaged by the active component of cannabis, Delta9-tetrahydrocannabinol (Delta9-THC), which exerts its pharmacological effects by activation of G protein-coupled type-1 (CB1) and type-2 (CB2) cannabinoid receptors.">
            <entity id="DS.d734.s0.e0" origId="16078" charOffset="70-97" type="compound" text="Delta9-tetrahydrocannabinol"/>
            <entity id="DS.d734.s0.e1" origId="16078" charOffset="99-109" type="compound" text="Delta9-THC"/>
            <entity id="DS.d734.s0.e2" origId="O02777,P20272,P21554,P47746,P56971,Q333S9,Q5IS73,Q71SP5,Q801M1,Q9PUI7" charOffset="196-199" type="protein" text="CB1"/>
            <entity id="DS.d734.s0.e3" origId="P34972,P47936,Q9QZN9" charOffset="213-216" type="protein" text="CB2"/>
            <pair e1="DS.d734.s0.e1" e2="DS.d734.s0.e3" id="DS.d734.s0.i0" interaction="True"/>
            <pair e1="DS.d734.s0.e0" e2="DS.d734.s0.e3" id="DS.d734.s0.i1" interaction="True"/>
            <pair e1="DS.d734.s0.e0" e2="DS.d734.s0.e2" id="DS.d734.s0.i2" interaction="True"/>
            <pair e1="DS.d734.s0.e1" e2="DS.d734.s0.e2" id="DS.d734.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d735" origId="18691715">
        <sentence id="DS.d735.s0" origId="18691715-1342" text="Homocysteine stimulates antioxidant response element-mediated expression of glutamate-cysteine ligase in mouse macrophages.">
            <entity id="DS.d735.s0.e0" origId="778" charOffset="0-12" type="compound" text="Homocysteine"/>
            <entity id="DS.d735.s0.e1" origId="O68838,P0A6W9,P0A6X0,P32477,P57485,P58994,P61379,Q09768,Q20117,Q57KV3,Q5E7F8,Q5LYY5,Q5M3J8,Q5PF10,Q65RX0,Q66E64,Q6ANW2,Q6D1T4,Q6LMV1,Q71VZ1,Q72RD4,Q7MHS5,Q7N7A4,Q7W3F2,Q7WES2,Q82ZG8,Q87LS2,Q88AR1,Q88R90,Q88UW5,Q89AD8,Q8D2V5,Q8DC38,Q8DW15,Q8DXM9,Q8E399,Q8EBF9,Q8F4D5,Q8X0X0,Q8X900,Q8XK30,Q8Y3R3,Q8Z4D6,Q8ZBU2,Q926X7,Q97IV1,Q9CM00,Q9HF78,Q9HTY6,Q9KUG5,Q9NFN6,Q9W3K5" charOffset="76-101" type="protein" text="glutamate-cysteine ligase"/>
            <pair e1="DS.d735.s0.e0" e2="DS.d735.s0.e1" id="DS.d735.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d735.s1" origId="18691715-1343" text="The current study investigated whether homocysteine induces transcription of glutamate-cysteine ligase (Gcl), via ARE driven gene expression in mouse macrophages.">
            <entity id="DS.d735.s1.e0" origId="778" charOffset="39-51" type="compound" text="homocysteine"/>
            <entity id="DS.d735.s1.e1" origId="O68838,P0A6W9,P0A6X0,P32477,P57485,P58994,P61379,Q09768,Q20117,Q57KV3,Q5E7F8,Q5LYY5,Q5M3J8,Q5PF10,Q65RX0,Q66E64,Q6ANW2,Q6D1T4,Q6LMV1,Q71VZ1,Q72RD4,Q7MHS5,Q7N7A4,Q7W3F2,Q7WES2,Q82ZG8,Q87LS2,Q88AR1,Q88R90,Q88UW5,Q89AD8,Q8D2V5,Q8DC38,Q8DW15,Q8DXM9,Q8E399,Q8EBF9,Q8F4D5,Q8X0X0,Q8X900,Q8XK30,Q8Y3R3,Q8Z4D6,Q8ZBU2,Q926X7,Q97IV1,Q9CM00,Q9HF78,Q9HTY6,Q9KUG5,Q9NFN6,Q9W3K5" charOffset="77-102" type="protein" text="glutamate-cysteine ligase"/>
            <entity id="DS.d735.s1.e2" origId="P0AEP7,P0AEP8,Q01820,Q920G9" charOffset="104-107" type="protein" text="Gcl"/>
            <pair e1="DS.d735.s1.e0" e2="DS.d735.s1.e1" id="DS.d735.s1.i0" interaction="False"/>
            <pair e1="DS.d735.s1.e0" e2="DS.d735.s1.e2" id="DS.d735.s1.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d735.s2" origId="18691715-1344" text="Treatment of mouse macrophages with d-/l-homocysteine (50microM) induced depletion of intracellular glutathione and a compensatory increase in Gcl activity.">
            <entity id="DS.d735.s2.e0" origId="778" charOffset="41-53" type="compound" text="homocysteine"/>
            <entity id="DS.d735.s2.e1" origId="124886" charOffset="100-111" type="compound" text="glutathione"/>
            <entity id="DS.d735.s2.e2" origId="P0AEP7,P0AEP8,Q01820,Q920G9" charOffset="143-146" type="protein" text="Gcl"/>
            <pair e1="DS.d735.s2.e0" e2="DS.d735.s2.e2" id="DS.d735.s2.i0" interaction="True"/>
            <pair e1="DS.d735.s2.e1" e2="DS.d735.s2.e2" id="DS.d735.s2.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d735.s3" origId="18691715-1345" text="Real-time RT-PCR revealed increased mRNA-expression of the catalytic subunit of Gcl (Gclc) after treatment with homocysteine, and this occurred via increased transcription as demonstrated with luciferase promoter reporter constructs for Gclc.">
            <entity id="DS.d735.s3.e0" origId="778" charOffset="112-124" type="compound" text="homocysteine"/>
            <entity id="DS.d735.s3.e1" origId="P08659,P13129,Q01158,Q26304,Q27757" charOffset="193-203" type="protein" text="luciferase"/>
            <pair e1="DS.d735.s3.e0" e2="DS.d735.s3.e1" id="DS.d735.s3.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d736" origId="18691757">
        <sentence id="DS.d736.s0" origId="18691757-12" text="Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells.">
            <entity id="DS.d736.s0.e0" origId="Q00342" charOffset="15-19" type="protein" text="Flt3"/>
            <entity id="DS.d736.s0.e1" origId="42890" charOffset="109-119" type="compound" text="idarubicin"/>
            <pair e1="DS.d736.s0.e1" e2="DS.d736.s0.e0" id="DS.d736.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d737" origId="18692155">
        <sentence id="DS.d737.s0" origId="18692155-570" text="Only EGF activated ERK signaling and up-regulated early gene expression, while DHT triggered the expression of classical AR-responsive genes with the exception of the EGF-induced PSA transcript in A549 cells.">
            <entity id="DS.d737.s0.e0" origId="P01132,P01133,P07522,P26224,Q00968,Q95ND4,Q9BEA0" charOffset="5-8" type="protein" text="EGF"/>
            <entity id="DS.d737.s0.e1" origId="P29323" charOffset="19-22" type="protein" text="ERK"/>
            <entity id="DS.d737.s0.e2" origId="10635" charOffset="79-82" type="compound" text="DHT"/>
            <entity id="DS.d737.s0.e3" origId="P01132,P01133,P07522,P26224,Q00968,Q95ND4,Q9BEA0" charOffset="167-170" type="protein" text="EGF"/>
            <entity id="DS.d737.s0.e4" origId="P07288,P10658,P33619,P55786,Q11011,Q6DT45,Q9Y617" charOffset="179-182" type="protein" text="PSA"/>
            <pair e1="DS.d737.s0.e2" e2="DS.d737.s0.e1" id="DS.d737.s0.i0" interaction="False"/>
            <pair e1="DS.d737.s0.e2" e2="DS.d737.s0.e4" id="DS.d737.s0.i1" interaction="False"/>
            <pair e1="DS.d737.s0.e2" e2="DS.d737.s0.e0" id="DS.d737.s0.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d737.s1" origId="18692155-571" text="DHT and EGF up-regulated cyclinD1 (CD1) at both mRNA and protein levels in A549 cells, while in LNCaP cells each mitogen increased only CD1 protein expression.">
            <entity id="DS.d737.s1.e0" origId="10635" charOffset="0-3" type="compound" text="DHT"/>
            <entity id="DS.d737.s1.e1" origId="P01132,P01133,P07522,P26224,Q00968,Q95ND4,Q9BEA0" charOffset="8-11" type="protein" text="EGF"/>
            <entity id="DS.d737.s1.e2" origId="P23043" charOffset="35-38" type="protein" text="CD1"/>
            <entity id="DS.d737.s1.e3" origId="P23043" charOffset="136-139" type="protein" text="CD1"/>
            <pair e1="DS.d737.s1.e0" e2="DS.d737.s1.e1" id="DS.d737.s1.i0" interaction="False"/>
            <pair e1="DS.d737.s1.e0" e2="DS.d737.s1.e2" id="DS.d737.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d738" origId="18692592">
        <sentence id="DS.d738.s0" origId="18692592-835" text="High glucose induced endothelial cell growth inhibition is associated with an increase in TGFbeta1 secretion and inhibition of Ras prenylation via suppression of the mevalonate pathway.">
            <entity id="DS.d738.s0.e0" origId="206,5793,64689,79025" charOffset="5-12" type="compound" text="glucose"/>
            <entity id="DS.d738.s0.e1" origId="O19011,O93449,P01137,P04202,P07200,P09531,P09533,P16176,P17246,P18341,P50414,P54831,Q38HS2,Q9PTQ2,Q9Z1Y6" charOffset="90-98" type="protein" text="TGFbeta1"/>
            <entity id="DS.d738.s0.e2" origId="P03967,P22126,Q07152" charOffset="127-130" type="protein" text="Ras"/>
            <pair e1="DS.d738.s0.e0" e2="DS.d738.s0.e1" id="DS.d738.s0.i0" interaction="True"/>
            <pair e1="DS.d738.s0.e0" e2="DS.d738.s0.e2" id="DS.d738.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d738.s1" origId="18692592-836" text="The influence of the prenylation status of Ras on the observed changes in endothelial cell growth under high glucose conditions has not previously been examined.">
            <entity id="DS.d738.s1.e0" origId="P03967,P22126,Q07152" charOffset="43-46" type="protein" text="Ras"/>
            <entity id="DS.d738.s1.e1" origId="206,5793,64689,79025" charOffset="109-116" type="compound" text="glucose"/>
            <pair e1="DS.d738.s1.e1" e2="DS.d738.s1.e0" id="DS.d738.s1.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d739" origId="18692599">
        <sentence id="DS.d739.s0" origId="18692599-393" text="Calcineurin inhibitors (CsA, FK-506 and pimecrolimus) inhibited NO production and iNOS expression in a concentration-dependent manner, CsA being more potent than FK-506 and pimecrolimus.">
            <entity id="DS.d739.s0.e1" origId="6436007" charOffset="29-35" type="compound" text="FK-506"/>
            <entity id="DS.d739.s0.e2" origId="6447131,6509979,17753757,24847863,53394893,53486290" charOffset="40-52" type="compound" text="pimecrolimus"/>
            <entity id="DS.d739.s0.e3" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="82-86" type="protein" text="iNOS"/>
            <entity id="DS.d739.s0.e4" origId="6436007" charOffset="162-168" type="compound" text="FK-506"/>
            <entity id="DS.d739.s0.e5" origId="6447131,6509979,17753757,24847863,53394893,53486290" charOffset="173-185" type="compound" text="pimecrolimus"/>
            <pair e1="DS.d739.s0.e1" e2="DS.d739.s0.e3" id="DS.d739.s0.i1" interaction="True"/>
            <pair e1="DS.d739.s0.e2" e2="DS.d739.s0.e3" id="DS.d739.s0.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d739.s1" origId="18692599-395" text="In conclusion, the results suggest that calcineurin inhibitors cyclosporin A, tacrolimus (FK-506) and pimecrolimus inhibit iNOS expression and NO production in response to inflammatory stimuli by enhancing the decay of iNOS mRNA by a 3'UTR-dependent manner.">
            <entity id="DS.d739.s1.e1" origId="2909,5280754,5284373,5458585,5497195,6435893,24883466,49867938" charOffset="63-76" type="compound" text="cyclosporin A"/>
            <entity id="DS.d739.s1.e2" origId="5372,445643,445647,6426916,6436007,6473866,6536850,9940643,23581796,54611630" charOffset="78-88" type="compound" text="tacrolimus"/>
            <entity id="DS.d739.s1.e3" origId="6436007" charOffset="90-96" type="compound" text="FK-506"/>
            <entity id="DS.d739.s1.e4" origId="6447131,6509979,17753757,24847863,53394893,53486290" charOffset="102-114" type="compound" text="pimecrolimus"/>
            <entity id="DS.d739.s1.e5" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="123-127" type="protein" text="iNOS"/>
            <entity id="DS.d739.s1.e6" origId="O19114,O46660,O54705,O62699,P29477,P35228,P79290,Q06518,Q27995,Q28314,Q90703,Q92037,Q92091" charOffset="219-223" type="protein" text="iNOS"/>
            <pair e1="DS.d739.s1.e4" e2="DS.d739.s1.e5" id="DS.d739.s1.i1" interaction="True"/>
            <pair e1="DS.d739.s1.e1" e2="DS.d739.s1.e5" id="DS.d739.s1.i3" interaction="True"/>
            <pair e1="DS.d739.s1.e2" e2="DS.d739.s1.e5" id="DS.d739.s1.i5" interaction="True"/>
            <pair e1="DS.d739.s1.e3" e2="DS.d739.s1.e5" id="DS.d739.s1.i7" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d740" origId="18692849">
        <sentence id="DS.d740.s0" origId="18692849-615" text="An increased activity of ATP-binding cassette transporter A1 (ABCA1) and ABCG5/G8 heterodimer has been proposed as a mechanism underlying the hypocholesterolaemic effect of phytosterols.">
            <entity id="DS.d740.s0.e0" origId="O95477" charOffset="62-67" type="protein" text="ABCA1"/>
            <entity id="DS.d740.s0.e1" origId="Q9H222" charOffset="73-78" type="protein" text="ABCG5"/>
            <entity id="DS.d740.s0.e2" origId="12303662" charOffset="173-185" type="compound" text="phytosterols"/>
            <pair e1="DS.d740.s0.e2" e2="DS.d740.s0.e0" id="DS.d740.s0.i0" interaction="True"/>
            <pair e1="DS.d740.s0.e2" e2="DS.d740.s0.e1" id="DS.d740.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d741" origId="18692896">
        <sentence id="DS.d741.s0" origId="18692896-648" text="In sum, copper exposure lowered TOSC, a result that at least in part can be related to lowering of antioxidant enzymes like CAT.">
            <entity id="DS.d741.s0.e0" origId="23978" charOffset="8-14" type="compound" text="copper"/>
            <entity id="DS.d741.s0.e1" origId="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7" charOffset="124-127" type="protein" text="CAT"/>
            <pair e1="DS.d741.s0.e0" e2="DS.d741.s0.e1" id="DS.d741.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d742" origId="18693051">
        <sentence id="DS.d742.s0" origId="18693051-793" text="Accumulation of glucose in PA was increased by insulin at 10nM and by IGF-I at 1 nM and 10nM.">
            <entity id="DS.d742.s0.e0" origId="206,5793,64689,79025" charOffset="16-23" type="compound" text="glucose"/>
            <entity id="DS.d742.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="47-54" type="protein" text="insulin"/>
            <entity id="DS.d742.s0.e2" origId="P05017,P07455,P08025,P10763,P16545,P17085,P17647,P18254,P33712,P51457,P51458,P51462,Q02815,Q28933,Q68LC0,Q6GUL6,Q6IVA5,Q6JLX1,Q95222" charOffset="70-75" type="protein" text="IGF-I"/>
            <pair e1="DS.d742.s0.e0" e2="DS.d742.s0.e1" id="DS.d742.s0.i0" interaction="True"/>
            <pair e1="DS.d742.s0.e0" e2="DS.d742.s0.e2" id="DS.d742.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d743" origId="18693094">
        <sentence id="DS.d743.s0" origId="18693094-1555" text="Glucagon is important to this response because it increases glutamine uptake.">
            <entity id="DS.d743.s0.e0" origId="O12956,O42143,O42144,P01272,P01273,P01274,P01275,P04093,P05110,P06883,P07449,P09566,P09567,P09682,P09686,P0C235,P13189,P15438,P18108,P22890,P29794,P31297,P33528,P55095,P68259,P68260,P68273,P68274,P68275,P68952,P68953,P68954,P68955,P68956,P68957,P79695,P81880,Q8MJ25,Q9PRQ9" charOffset="0-8" type="protein" text="Glucagon"/>
            <entity id="DS.d743.s0.e1" origId="738,5961" charOffset="60-69" type="compound" text="glutamine"/>
            <pair e1="DS.d743.s0.e1" e2="DS.d743.s0.e0" id="DS.d743.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d744" origId="18693095">
        <sentence id="DS.d744.s0" origId="18693095-825" text="It was shown that PAR significantly increased serum ALT, AST, ALP, liver MDA levels and significantly decreased liver GSH-Px activity, when compared to the control group (Group 1).">
            <entity id="DS.d744.s0.e0" origId="P0AE37,P0AE38,P80357,P80358,Q0TH83,Q1C8B0,Q1RB46,Q321N9,Q32G89,Q3Z294,Q5PHB9,Q66B20,Q7N2G8,Q83L52,Q8FH00,Q8Z6G0,Q8ZPV1,Q9NRA2,Q9ZC67" charOffset="57-60" type="protein" text="AST"/>
            <entity id="DS.d744.s0.e1" origId="P03973,P12547,P22298,P28296,P29118,P35211,P83610,P97430,Q03420,Q53GG5,Q9H0A0,Q9PU47,Q9Z1X0" charOffset="62-65" type="protein" text="ALP"/>
            <entity id="DS.d744.s0.e2" origId="124886" charOffset="118-121" type="compound" text="GSH"/>
            <pair e1="DS.d744.s0.e2" e2="DS.d744.s0.e0" id="DS.d744.s0.i0" interaction="False"/>
            <pair e1="DS.d744.s0.e2" e2="DS.d744.s0.e1" id="DS.d744.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d745" origId="18693100">
        <sentence id="DS.d745.s0" origId="18693100-829" text="Biological testing of the compound demonstrated a significant antidiabetic activity by reducing the elevated blood glucose levels and restoring the insulin levels in streptozotocin-induced diabetic rats.">
            <entity id="DS.d745.s0.e0" origId="206,5793,64689,79025" charOffset="115-122" type="compound" text="glucose"/>
            <entity id="DS.d745.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="148-155" type="protein" text="insulin"/>
            <entity id="DS.d745.s0.e2" origId="5300,29327,6420074,6713972,7067772,45357367" charOffset="166-180" type="compound" text="streptozotocin"/>
            <pair e1="DS.d745.s0.e2" e2="DS.d745.s0.e1" id="DS.d745.s0.i0" interaction="False"/>
            <pair e1="DS.d745.s0.e0" e2="DS.d745.s0.e1" id="DS.d745.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d746" origId="18693294">
        <sentence id="DS.d746.s0" origId="18693294-868" text="The activity of guanylyl cyclase was determined by the amount of cGMP generated in responses to sodium nitroprusside (SNP) or ANP.">
            <entity id="DS.d746.s0.e0" origId="O94303,P33734,Q9P4P9,Q9SZ30" charOffset="25-32" type="protein" text="cyclase"/>
            <entity id="DS.d746.s0.e1" origId="24316" charOffset="65-69" type="compound" text="cGMP"/>
            <pair e1="DS.d746.s0.e1" e2="DS.d746.s0.e0" id="DS.d746.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d747" origId="18694296">
        <sentence id="DS.d747.s0" origId="18694296-116" text="Both SAHA and MS-275 induced an arrest in the cell cycle along with the induction of apoptotic pathways as evidenced by flow cytometry, annexin assay, detection of activated caspase 9, and molecular analysis of Bax/Bcl-2 expression.">
            <entity id="DS.d747.s0.e0" origId="5311" charOffset="5-9" type="compound" text="SAHA"/>
            <entity id="DS.d747.s0.e1" origId="4261" charOffset="14-20" type="compound" text="MS-275"/>
            <entity id="DS.d747.s0.e2" origId="P27297,Q07813,Q63690" charOffset="211-214" type="protein" text="Bax"/>
            <entity id="DS.d747.s0.e3" origId="P10417,P49950" charOffset="215-220" type="protein" text="Bcl-2"/>
            <pair e1="DS.d747.s0.e1" e2="DS.d747.s0.e2" id="DS.d747.s0.i0" interaction="True"/>
            <pair e1="DS.d747.s0.e0" e2="DS.d747.s0.e2" id="DS.d747.s0.i1" interaction="True"/>
            <pair e1="DS.d747.s0.e1" e2="DS.d747.s0.e3" id="DS.d747.s0.i2" interaction="True"/>
            <pair e1="DS.d747.s0.e0" e2="DS.d747.s0.e3" id="DS.d747.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d748" origId="18694429">
        <sentence id="DS.d748.s0" origId="18694429-208" text="Immunolocalization of androgen receptor in the boar epididymis: the effect of GnRH agonist deslorelin.">
            <entity id="DS.d748.s0.e0" origId="O97775,O97776,O97952,O97960,P10275,P15207,P19091,P49699,Q6QT55,Q7T1K4,Q8MIK0,Q9GKL7,Q9TT90" charOffset="22-39" type="protein" text="androgen receptor"/>
            <entity id="DS.d748.s0.e1" origId="25074999,25077495,25078016" charOffset="91-101" type="compound" text="deslorelin"/>
            <pair e1="DS.d748.s0.e1" e2="DS.d748.s0.e0" id="DS.d748.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d749" origId="18694845">
        <sentence id="DS.d749.s0" origId="18694845-560" text="E(2) increased the expression of caveolin-1 and caveolin-2 mRNA and proteins, but pre-treatment with ICI 182,780 (an estrogen receptor (ER) antagonist) inhibited E(2)-induced increase in caveolin-1 and caveolin-2 proteins expression.">
            <entity id="DS.d749.s0.e0" origId="P33724,P35431,P41350,P49817,P79132,Q03135,Q07DV9,Q07DX1,Q07DY2,Q07DZ2,Q07E02,Q07E25,Q07E38,Q07E49,Q09YH8,Q09YK1,Q09YN6,Q108U7,Q2IBA5,Q2IBC1,Q2IBD7,Q2IBF0,Q2IBG8,Q2QL79,Q2QL90,Q2QLB0,Q2QLC1,Q2QLF2,Q2QLG6,Q2QLH7,Q6B3Y2,Q6RVA9,Q94051,Q9YGM8" charOffset="33-43" type="protein" text="caveolin-1"/>
            <entity id="DS.d749.s0.e1" origId="O46550,P51636,Q07DW0,Q07DX2,Q07DZ3,Q07E26,Q07E39,Q07E50,Q09YH9,Q09YJ1,Q09YK2,Q09YL4,Q09YN7,Q108U8,Q18879,Q2IBA4,Q2IBC2,Q2IBD6,Q2IBF3,Q2IBG9,Q2QL80,Q2QL91,Q2QLB1,Q2QLC2,Q2QLD3,Q2QLE2,Q2QLF3,Q2QLG7,Q2QLH8,Q66WT7,Q9WVC3,Q9YGM9" charOffset="48-58" type="protein" text="caveolin-2"/>
            <entity id="DS.d749.s0.e2" origId="104741" charOffset="101-112" type="compound" text="ICI 182,780"/>
            <entity id="DS.d749.s0.e3" origId="P33724,P35431,P41350,P49817,P79132,Q03135,Q07DV9,Q07DX1,Q07DY2,Q07DZ2,Q07E02,Q07E25,Q07E38,Q07E49,Q09YH8,Q09YK1,Q09YN6,Q108U7,Q2IBA5,Q2IBC1,Q2IBD7,Q2IBF0,Q2IBG8,Q2QL79,Q2QL90,Q2QLB0,Q2QLC1,Q2QLF2,Q2QLG6,Q2QLH7,Q6B3Y2,Q6RVA9,Q94051,Q9YGM8" charOffset="187-197" type="protein" text="caveolin-1"/>
            <entity id="DS.d749.s0.e4" origId="O46550,P51636,Q07DW0,Q07DX2,Q07DZ3,Q07E26,Q07E39,Q07E50,Q09YH9,Q09YJ1,Q09YK2,Q09YL4,Q09YN7,Q108U8,Q18879,Q2IBA4,Q2IBC2,Q2IBD6,Q2IBF3,Q2IBG9,Q2QL80,Q2QL91,Q2QLB1,Q2QLC2,Q2QLD3,Q2QLE2,Q2QLF3,Q2QLG7,Q2QLH8,Q66WT7,Q9WVC3,Q9YGM9" charOffset="202-212" type="protein" text="caveolin-2"/>
            <pair e1="DS.d749.s0.e2" e2="DS.d749.s0.e0" id="DS.d749.s0.i0" interaction="True"/>
            <pair e1="DS.d749.s0.e2" e2="DS.d749.s0.e1" id="DS.d749.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d749.s1" origId="18694845-561" text="Phospho-caveolin-1 was significantly blocked by ICI 182,780 or pyrazolopyrimidine 2 (PP2 ; a Src-kinase inhibitor).">
            <entity id="DS.d749.s1.e0" origId="P33724,P35431,P41350,P49817,P79132,Q03135,Q07DV9,Q07DX1,Q07DY2,Q07DZ2,Q07E02,Q07E25,Q07E38,Q07E49,Q09YH8,Q09YK1,Q09YN6,Q108U7,Q2IBA5,Q2IBC1,Q2IBD7,Q2IBF0,Q2IBG8,Q2QL79,Q2QL90,Q2QLB0,Q2QLC1,Q2QLF2,Q2QLG6,Q2QLH7,Q6B3Y2,Q6RVA9,Q94051,Q9YGM8" charOffset="8-18" type="protein" text="caveolin-1"/>
            <entity id="DS.d749.s1.e1" origId="104741" charOffset="48-59" type="compound" text="ICI 182,780"/>
            <entity id="DS.d749.s1.e2" origId="15077741,21083976" charOffset="63-81" type="compound" text="pyrazolopyrimidine"/>
            <pair e1="DS.d749.s1.e1" e2="DS.d749.s1.e0" id="DS.d749.s1.i0" interaction="True"/>
            <pair e1="DS.d749.s1.e2" e2="DS.d749.s1.e0" id="DS.d749.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d749.s2" origId="18694845-562" text="LY 294002 (a PI3K inhibitor) or PD 98059 (an ERK1/2 inhibitor) prevented E(2)-induced increase in caveolin-1 expression and the accompanying ((3)H)-thymidine incorporation.">
            <entity id="DS.d749.s2.e0" origId="3973" charOffset="0-9" type="compound" text="LY 294002"/>
            <entity id="DS.d749.s2.e1" origId="4713" charOffset="32-40" type="compound" text="PD 98059"/>
            <entity id="DS.d749.s2.e2" origId="P33724,P35431,P41350,P49817,P79132,Q03135,Q07DV9,Q07DX1,Q07DY2,Q07DZ2,Q07E02,Q07E25,Q07E38,Q07E49,Q09YH8,Q09YK1,Q09YN6,Q108U7,Q2IBA5,Q2IBC1,Q2IBD7,Q2IBF0,Q2IBG8,Q2QL79,Q2QL90,Q2QLB0,Q2QLC1,Q2QLF2,Q2QLG6,Q2QLH7,Q6B3Y2,Q6RVA9,Q94051,Q9YGM8" charOffset="98-108" type="protein" text="caveolin-1"/>
            <entity id="DS.d749.s2.e3" origId="5789" charOffset="148-157" type="compound" text="thymidine"/>
            <pair e1="DS.d749.s2.e3" e2="DS.d749.s2.e2" id="DS.d749.s2.i0" interaction="True"/>
            <pair e1="DS.d749.s2.e1" e2="DS.d749.s2.e2" id="DS.d749.s2.i1" interaction="True"/>
            <pair e1="DS.d749.s2.e0" e2="DS.d749.s2.e2" id="DS.d749.s2.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d749.s3" origId="18694845-563" text="Furthermore, inhibition of caveolin-1 expression using a caveolin-1 siRNA significantly attenuated E(2)-induced up-regulation of proto-oncogenes, cell cycle regulatory proteins, ((3)H)-thymidine incorporation, overall cell number, and percent of the cell population in S phase, while mediating a concomitant increase in the G0/G1 population.">
            <entity id="DS.d749.s3.e0" origId="P18754,Q18211" charOffset="146-176" type="protein" text="cell cycle regulatory proteins"/>
            <entity id="DS.d749.s3.e1" origId="5789" charOffset="185-194" type="compound" text="thymidine"/>
            <pair e1="DS.d749.s3.e1" e2="DS.d749.s3.e0" id="DS.d749.s3.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d750" origId="18694847">
        <sentence id="DS.d750.s0" origId="18694847-1230" text="Almost all Akt kinase that translocates to the nucleus shows a marked phosphorylation on serine 473.">
            <entity id="DS.d750.s0.e0" origId="P31750,Q8INB9" charOffset="11-14" type="protein" text="Akt"/>
            <entity id="DS.d750.s0.e1" origId="5951" charOffset="89-95" type="compound" text="serine"/>
            <pair e1="DS.d750.s0.e1" e2="DS.d750.s0.e0" id="DS.d750.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d751" origId="18695846">
        <sentence id="DS.d751.s0" origId="18695846-1364" text="During the early response in AR, histamine has been found to be the most abundant mediator and it is associated with many symptoms of this disease mediated through the histamine H1 receptor.">
            <entity id="DS.d751.s0.e0" origId="774" charOffset="33-42" type="compound" text="histamine"/>
            <entity id="DS.d751.s0.e1" origId="P30546,P31389,P31390,P35367,P70174,Q9N2B0,Q9N2B1,Q9N2B2" charOffset="168-189" type="protein" text="histamine H1 receptor"/>
            <pair e1="DS.d751.s0.e0" e2="DS.d751.s0.e1" id="DS.d751.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d752" origId="18695937">
        <sentence id="DS.d752.s0" origId="18695937-929" text="During the incubation of L-phenylalanine with para-hydroquinones using laccase as biocatalyst, one or two main products were formed.">
            <entity id="DS.d752.s0.e0" origId="6140" charOffset="25-40" type="compound" text="L-phenylalanine"/>
            <entity id="DS.d752.s0.e1" origId="Q12570" charOffset="71-78" type="protein" text="laccase"/>
            <pair e1="DS.d752.s0.e0" e2="DS.d752.s0.e1" id="DS.d752.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d753" origId="18696104">
        <sentence id="DS.d753.s0" origId="18696104-1256" text="The effect on activation voltage but not that on amplitude was absent when expressing a cAMP-insensitive mutant (HCN2R/E), while a C-terminal truncated form of HCN2 (HCN2DeltaCx) exhibited only the voltage dependent but not the amplitude effect of erbstatin.">
            <entity id="DS.d753.s0.e0" origId="Q9UL51" charOffset="113-117" type="protein" text="HCN2"/>
            <entity id="DS.d753.s0.e1" origId="5328552" charOffset="248-257" type="compound" text="erbstatin"/>
            <pair e1="DS.d753.s0.e1" e2="DS.d753.s0.e0" id="DS.d753.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d753.s1" origId="18696104-1257" text="Thus, the action of erbstatin on the activation relation and current amplitude are distinct and separable in newborn myocytes, and the effect on activation voltage depends on the cAMP status of HCN2 channels.">
            <entity id="DS.d753.s1.e0" origId="5328552" charOffset="20-29" type="compound" text="erbstatin"/>
            <entity id="DS.d753.s1.e1" origId="6076" charOffset="179-183" type="compound" text="cAMP"/>
            <entity id="DS.d753.s1.e2" origId="Q9UL51" charOffset="194-198" type="protein" text="HCN2"/>
            <pair e1="DS.d753.s1.e1" e2="DS.d753.s1.e2" id="DS.d753.s1.i0" interaction="True"/>
            <pair e1="DS.d753.s1.e0" e2="DS.d753.s1.e2" id="DS.d753.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d753.s2" origId="18696104-1258" text="In contrast to newborn myocytes, erbstatin had no effect on HCN2 under control conditions in adult myocytes but induced a negative shift with no change in amplitude when saturated cAMP was added to the pipette solution.">
            <entity id="DS.d753.s2.e0" origId="5328552" charOffset="33-42" type="compound" text="erbstatin"/>
            <entity id="DS.d753.s2.e1" origId="Q9UL51" charOffset="60-64" type="protein" text="HCN2"/>
            <entity id="DS.d753.s2.e2" origId="6076" charOffset="180-184" type="compound" text="cAMP"/>
            <pair e1="DS.d753.s2.e0" e2="DS.d753.s2.e1" id="DS.d753.s2.i0" interaction="False"/>
            <pair e1="DS.d753.s2.e2" e2="DS.d753.s2.e1" id="DS.d753.s2.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d754" origId="18696216">
        <sentence id="DS.d754.s0" origId="18696216-140" text="Arginine-specific ADP-ribosyltransferase (Art) catalyzes the mono-ADP-ribosylation, in which it transfers a single ADP-ribose moiety of NAD to the arginine residue(s) of target proteins, and may regulate the function of the proteins or peptides in cellular processes.">
            <entity id="DS.d754.s0.e0" origId="232,4367,6322" charOffset="0-8" type="compound" text="Arginine"/>
            <entity id="DS.d754.s0.e1" origId="P14299" charOffset="18-40" type="protein" text="ADP-ribosyltransferase"/>
            <entity id="DS.d754.s0.e2" origId="5893" charOffset="136-139" type="compound" text="NAD"/>
            <entity id="DS.d754.s0.e3" origId="232,4367,6322" charOffset="147-155" type="compound" text="arginine"/>
            <pair e1="DS.d754.s0.e3" e2="DS.d754.s0.e1" id="DS.d754.s0.i0" interaction="True"/>
            <pair e1="DS.d754.s0.e0" e2="DS.d754.s0.e1" id="DS.d754.s0.i1" interaction="True"/>
            <pair e1="DS.d754.s0.e2" e2="DS.d754.s0.e1" id="DS.d754.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d756" origId="18696261">
        <sentence id="DS.d756.s0" origId="18696261-327" text="A D-amino acid oxidase gene (dao) was ligated with the P(Hase) and cloned into pGEMKT to constitutively express protein of DAAO without the use of any inducer such as isopropyl beta-D-1-thiogalactopyranoside which is poisonous to the cells and environment.">
            <entity id="DS.d756.s0.e0" origId="O35078,P18894" charOffset="29-32" type="protein" text="dao"/>
            <entity id="DS.d756.s0.e1" origId="O01739,O35078,P00371,P14920,P18894,P22942,P24552,P80324,Q19564,Q99042,Q9Z1M5,Q9Z302" charOffset="123-127" type="protein" text="DAAO"/>
            <entity id="DS.d756.s0.e2" origId="656894" charOffset="167-207" type="compound" text="isopropyl beta-D-1-thiogalactopyranoside"/>
            <pair e1="DS.d756.s0.e2" e2="DS.d756.s0.e1" id="DS.d756.s0.i0" interaction="True"/>
            <pair e1="DS.d756.s0.e2" e2="DS.d756.s0.e0" id="DS.d756.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d757" origId="18698091">
        <sentence id="DS.d757.s0" origId="18698091-1558" text="In response to a cholesterol-containing atherogenic diet, C57BL/6J mice significantly increased expression of UCP2 in the aorta, while mice lacking UCP2, in the absence of any other genetic modification, displayed significant endothelial dysfunction following the atherogenic diet.">
            <entity id="DS.d757.s0.e0" origId="304,5997,6432564,11025495" charOffset="17-28" type="compound" text="cholesterol"/>
            <entity id="DS.d757.s0.e1" origId="O97562,P55851,Q9N2J1,Q9W725" charOffset="110-114" type="protein" text="UCP2"/>
            <entity id="DS.d757.s0.e2" origId="O97562,P55851,Q9N2J1,Q9W725" charOffset="148-152" type="protein" text="UCP2"/>
            <pair e1="DS.d757.s0.e0" e2="DS.d757.s0.e1" id="DS.d757.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d757.s1" origId="18698091-1559" text="These data establish that in the vasculature UCP2 functions as an adaptive antioxidant defense to protect against the development of atherosclerosis in response to a fat and cholesterol diet.">
            <entity id="DS.d757.s1.e0" origId="O97562,P55851,Q9N2J1,Q9W725" charOffset="45-49" type="protein" text="UCP2"/>
            <entity id="DS.d757.s1.e1" origId="304,5997,6432564,11025495" charOffset="174-185" type="compound" text="cholesterol"/>
            <pair e1="DS.d757.s1.e1" e2="DS.d757.s1.e0" id="DS.d757.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d758" origId="18698130">
        <sentence id="DS.d758.s0" origId="18698130-1197" text="To confirm that mouse DMP1-PG possesses a single GAG chain attached to Ser (89), we substituted Ser (89) by Gly (89).">
            <entity id="DS.d758.s0.e0" origId="Q13316,Q95120" charOffset="22-26" type="protein" text="DMP1"/>
            <entity id="DS.d758.s0.e1" origId="750,5460845" charOffset="108-111" type="compound" text="Gly"/>
            <pair e1="DS.d758.s0.e1" e2="DS.d758.s0.e0" id="DS.d758.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d759" origId="18698132">
        <sentence id="DS.d759.s0" origId="18698132-1603" text="PC-1 is the primary generator of pyrophosphate in osteoblastic cells; therefore, regulated expression of PC-1 by FGFs may be a principal mechanism by which FGF signaling affects bone mineralization.">
            <entity id="DS.d759.s0.e0" origId="644102" charOffset="33-46" type="compound" text="pyrophosphate"/>
            <entity id="DS.d759.s0.e1" origId="O10284,P41444" charOffset="113-117" type="protein" text="FGFs"/>
            <entity id="DS.d759.s0.e2" origId="O10284,P41444" charOffset="113-116" type="protein" text="FGF"/>
            <pair e1="DS.d759.s0.e0" e2="DS.d759.s0.e2" id="DS.d759.s0.i0" interaction="True"/>
            <pair e1="DS.d759.s0.e0" e2="DS.d759.s0.e1" id="DS.d759.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d760" origId="18698333">
        <sentence id="DS.d760.s0" origId="18698333-75" text="In analogy to the reduction of Ca(2+) oscillation frequency, the blockers impaired HCEC contraction, NF-kappaB activation, and VCAM-1 expression.">
            <entity id="DS.d760.s0.e0" origId="271" charOffset="31-35" type="compound" text="Ca(2"/>
            <entity id="DS.d760.s0.e1" origId="P19320,P29533,P29534,Q28260" charOffset="127-133" type="protein" text="VCAM-1"/>
            <pair e1="DS.d760.s0.e0" e2="DS.d760.s0.e1" id="DS.d760.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d760.s1" origId="18698333-76" text="Cisternal SAH-CSF induces cytosolic Ca(2+) oscillations in HCEC that results in cellular constriction, NF-kappaB activation, and VCAM-1 expression.">
            <entity id="DS.d760.s1.e0" origId="271" charOffset="36-40" type="compound" text="Ca(2"/>
            <entity id="DS.d760.s1.e1" origId="P19320,P29533,P29534,Q28260" charOffset="129-135" type="protein" text="VCAM-1"/>
            <pair e1="DS.d760.s1.e0" e2="DS.d760.s1.e1" id="DS.d760.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d761" origId="18698636">
        <sentence id="DS.d761.s0" origId="18698636-309" text="For proof of principle, we use L-lactate and D-lactate as representative pair of enantiomers, L-lactate oxidase as stereospecific signal generator, and cascade blue hydrazide as reactive signal amplifier to capture the produced pyruvate.">
            <entity id="DS.d761.s0.e0" origId="107689" charOffset="31-40" type="compound" text="L-lactate"/>
            <entity id="DS.d761.s0.e1" origId="61503" charOffset="45-54" type="compound" text="D-lactate"/>
            <entity id="DS.d761.s0.e2" origId="P21795" charOffset="96-111" type="protein" text="lactate oxidase"/>
            <entity id="DS.d761.s0.e3" origId="1060" charOffset="228-236" type="compound" text="pyruvate"/>
            <pair e1="DS.d761.s0.e1" e2="DS.d761.s0.e2" id="DS.d761.s0.i0" interaction="False"/>
            <pair e1="DS.d761.s0.e0" e2="DS.d761.s0.e2" id="DS.d761.s0.i1" interaction="False"/>
            <pair e1="DS.d761.s0.e3" e2="DS.d761.s0.e2" id="DS.d761.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d762" origId="18698648">
        <sentence id="DS.d762.s0" origId="18698648-318" text="Escherichia coli strain PC09 (DeltaxylB, cAMP-independent CRP (crp *) mutant) expressing an NADPH-dependent xylose reductase from Candida boidinii (CbXR) was previously reported to produce xylitol from xylose while metabolizing glucose (Cirino et al.">
            <entity id="DS.d762.s0.e0" origId="P38715" charOffset="108-124" type="protein" text="xylose reductase"/>
            <entity id="DS.d762.s0.e1" origId="6912" charOffset="189-196" type="compound" text="xylitol"/>
            <entity id="DS.d762.s0.e2" origId="206,5793,64689,79025" charOffset="228-235" type="compound" text="glucose"/>
            <pair e1="DS.d762.s0.e1" e2="DS.d762.s0.e0" id="DS.d762.s0.i0" interaction="True"/>
            <pair e1="DS.d762.s0.e2" e2="DS.d762.s0.e0" id="DS.d762.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d762.s1" origId="18698648-319" text="Studies in which the expression of CbXR or a xylose transporter was increased suggest that enzyme activity and xylose transport are not limiting xylitol production in PC09.">
            <entity id="DS.d762.s1.e0" origId="P96792" charOffset="45-63" type="protein" text="xylose transporter"/>
            <entity id="DS.d762.s1.e1" origId="6912" charOffset="145-152" type="compound" text="xylitol"/>
            <pair e1="DS.d762.s1.e1" e2="DS.d762.s1.e0" id="DS.d762.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d762.s2" origId="18698648-321" text="For the case of xylose-proton symport, omitting the Zwf (glucose-6-phosphate dehydrogenase) or PntAB (membrane-bound transhydrogenase) reactions or TCA cycle activity from the model reduces the theoretical maximum yield from 9.2 to 8.8, 3.6, and 8.0 mol xylitol (mol glucose)(-1), respectively.">
            <entity id="DS.d762.s2.e0" origId="O51581,O54537,O68282,O83491,O84188,P0A584,P0A585,P0A586,P0A587,P0AC53,P0AC54,P11411,P21907,P29686,P37986,P44311,P48848,P48992,P54547,P56110,P57405,P73411,P77809,Q89AI7,Q8K9M2,Q8XCJ6,Q9PKK8,Q9X0N9,Q9Z3S2,Q9Z8U6,Q9ZKB2" charOffset="52-55" type="protein" text="Zwf"/>
            <entity id="DS.d762.s2.e1" origId="P0C187,P51995,Q2RSB3" charOffset="95-100" type="protein" text="PntAB"/>
            <entity id="DS.d762.s2.e2" origId="6912" charOffset="254-261" type="compound" text="xylitol"/>
            <pair e1="DS.d762.s2.e2" e2="DS.d762.s2.e0" id="DS.d762.s2.i0" interaction="True"/>
            <pair e1="DS.d762.s2.e2" e2="DS.d762.s2.e1" id="DS.d762.s2.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d762.s3" origId="18698648-322" text="Experimentally, deleting pgi (encoding phosphoglucose isomerase) from strain PC09 improves the yield from 3.4 to 4.0 mol xylitol (mol glucose)(-1), while deleting either or both E. coli transhydrogenases (sthA and pntA) has no significant effect on the measured yield.">
            <entity id="DS.d762.s3.e0" origId="O25781,O51672,O83488,O84382,O88015,P0A0T0,P0A0T1,P0A6T1,P0A6T2,P28718,P44312,P47357,P52029,P52030,P52031,P52983,P57636,P64192,P64193,P64194,P64195,P64196,P77877,P78033,P80860,P81181,P96803,P99078,Q0TA36,Q0VR14,Q11MA0,Q13Z07,Q165T7,Q18FQ4,Q1ASN4,Q1BH79,Q1CSA0,Q1CX51,Q1GAY0,Q1GJQ5,Q1GTU1,Q1H1P4,Q1IYT4,Q1J8N2,Q1JDQ8,Q1JIS1,Q1JNM4,Q1LM68,Q1LU73,Q1MM06,Q1QEK1,Q1R3R3,Q1WUR2,Q21M11,Q21ZD5,Q24VW9,Q255I6,Q28QX4,Q2A2C5,Q2FIB3,Q2FZU0,Q2G7C4,Q2IE39,Q2JH03,Q2JHU0,Q2JX86,Q2KCY8,Q2KYE9,Q2LRD0,Q2NJ38,Q2NR04,Q2P380,Q2RQ51,Q2S8W1,Q2SS24,Q2SWP6,Q2VYV7,Q2YBU4,Q2YPF3,Q2YWS3,Q31AX5,Q31I19,Q31LL0,Q31TX1,Q328X7,Q38WF1,Q39FF4,Q39SU1,Q3A201,Q3AFH3,Q3AJU7,Q3ASZ0,Q3AXV8,Q3B3Q8,Q3BUL3,Q3IKH4,Q3IMS0,Q3J2U4,Q3JCN1,Q3JRE2,Q3K2Y2,Q3K6Q4,Q3KLX6,Q3M6S3,Q3YUW0,Q46L16,Q47IJ3,Q48N88,Q48VF9,Q491V0,Q49WA1,Q4A5S9,Q4A7J2,Q4A9F3,Q4FVH5,Q4JX51,Q4K5Y1,Q4L4X8,Q4QL07,Q4UTV8,Q4ZY88,Q57F73,Q57H06,Q59000,Q59088,Q5E847,Q5FL04,Q5H0A7,Q5HHC2,Q5HQJ9,Q5KVS7,Q5L5E1,Q5L9E3,Q5LRS9,Q5M1N9,Q5N0B4,Q5NFC4,Q5P0T4,Q5PL07,Q5QWW0,Q5SLL6,Q5UXU0,Q5WDX0,Q5WYE0,Q5X6Y8,Q5XE09,Q5YPP1,Q5ZXH2,Q600A8,Q609I7,Q62JL8,Q632G4,Q63V31,Q64PM7,Q65FL6,Q65TC2,Q660E3,Q664W9,Q67QQ0,Q6A5X5,Q6AQ48,Q6D022,Q6F1L2,Q6G0T9,Q6GAW4,Q6GIC6,Q6HC08,Q6KH90,Q6LM51,Q6LXQ4,Q6MD44,Q6MTA3,Q6NIE5,Q6YQU0,Q71X61,Q72GY6,Q72MT7,Q72YI4,Q73K18,Q742E4,Q74DK5,Q74K31,Q7MH97,Q7MUV9,Q7MZB4,Q7NJY9,Q7U6T0,Q7V1I1,Q7V7M6,Q7VBZ6,Q7VNR9,Q7VRI4,Q7VUF4,Q7W197,Q7WP01,Q816G0,Q81K75,Q822E7,Q82SP4,Q835G1,Q83D91,Q83XM3,Q848I4,Q87EV7,Q87L81,Q888Q7,Q88UI4,Q891H2,Q89A35,Q8A5W2,Q8CT80,Q8D1V8,Q8DCK7,Q8DKY2,Q8DN74,Q8EBH1,Q8ENY8,Q8EVU1,Q8EZG6,Q8FB44,Q8FR39,Q8G2N3,Q8G7I6,Q8K8Q6,Q8K910,Q8KDQ7,Q8L1Z9,Q8NS31,Q8NXF1,Q8P2R3,Q8P9S7,Q8R924,Q8RHH5,Q8UI94,Q8VVB7,Q8XI54,Q8XYN9,Q8Y4R7,Q8YF86,Q8YY05,Q8Z1U7,Q8ZAS2,Q8ZKI4,Q928R6,Q92SC4,Q97FP8,Q97NG0,Q98BV5,Q98R79,Q9A1L1,Q9ABK5,Q9CD75,Q9CNL2,Q9HNQ6,Q9HV67,Q9K7L8,Q9KUY4,Q9KX58,Q9PGR6,Q9PK16,Q9PMD4,Q9RDY2,Q9RMC1,Q9RTL8,Q9X1A5,Q9X670,Q9Z6N4,Q9ZK49" charOffset="25-28" type="protein" text="pgi"/>
            <entity id="DS.d762.s3.e1" origId="O25781,O51672,O59618,O66954,O82059,O83488,O84382,P06744,P06745,P08059,P0A0T0,P0A0T1,P0A6T1,P0A6T2,P12341,P12709,P13377,P18240,P28718,P29333,P34795,P34796,P34797,P42861,P44312,P46479,P47357,P49105,P50309,P52029,P52030,P52031,P52983,P54234,P54235,P54236,P54237,P54238,P54239,P54240,P54241,P54242,P54243,P57636,P64192,P64193,P64194,P64195,P64196,P77877,P78033,P78917,P80860,P81181,P83194,P83780,P84140,P96803,P99078,Q0TA36,Q0VR14,Q11MA0,Q13Z07,Q165T7,Q18FQ4,Q1ASN4,Q1BH79,Q1CSA0,Q1CX51,Q1GAY0,Q1GJQ5,Q1GTU1,Q1H1P4,Q1IYT4,Q1J8N2,Q1JDQ8,Q1JIS1,Q1JNM4,Q1LM68,Q1LU73,Q1MM06,Q1QEK1,Q1R3R3,Q1WUR2,Q21M11,Q21ZD5,Q24VW9,Q255I6,Q28QX4,Q2A2C5,Q2FIB3,Q2FZU0,Q2G7C4,Q2IE39,Q2JH03,Q2JHU0,Q2JX86,Q2KCY8,Q2KYE9,Q2LRD0,Q2NJ38,Q2NR04,Q2P380,Q2RQ51,Q2S8W1,Q2SS24,Q2SWP6,Q2VYV7,Q2YBU4,Q2YPF3,Q2YWS3,Q31AX5,Q31I19,Q31LL0,Q31TX1,Q328X7,Q38WF1,Q39FF4,Q39SU1,Q3A201,Q3AFH3,Q3AJU7,Q3ASZ0,Q3AXV8,Q3B3Q8,Q3BUL3,Q3IKH4,Q3IMS0,Q3J2U4,Q3JCN1,Q3JRE2,Q3K2Y2,Q3K6Q4,Q3KLX6,Q3M6S3,Q3YUW0,Q3ZBD7,Q44407,Q46L16,Q47IJ3,Q48N88,Q48VF9,Q491V0,Q49WA1,Q4A5S9,Q4A7J2,Q4A9F3,Q4FVH5,Q4JCA7,Q4JX51,Q4K5Y1,Q4L4X8,Q4QL07,Q4R591,Q4UTV8,Q4ZY88,Q57F73,Q57H06,Q59000,Q59088,Q5E847,Q5FL04,Q5H0A7,Q5HHC2,Q5HQJ9,Q5JE38,Q5KVS7,Q5L5E1,Q5L9E3,Q5LRS9,Q5M1N9,Q5N0B4,Q5NFC4,Q5P0T4,Q5PL07,Q5QWW0,Q5R4E3,Q5SLL6,Q5UXU0,Q5WDX0,Q5WYE0,Q5X6Y8,Q5XE09,Q5YPP1,Q5ZXH2,Q600A8,Q609I7,Q62JL8,Q632G4,Q63V31,Q64PM7,Q65FL6,Q65TC2,Q660E3,Q664W9,Q67QQ0,Q6A5X5,Q6AQ48,Q6D022,Q6F1L2,Q6FRW1,Q6G0T9,Q6GAW4,Q6GIC6,Q6HC08,Q6KH90,Q6LM51,Q6LXQ4,Q6MD44,Q6MTA3,Q6NIE5,Q6YQU0,Q711G1,Q71X61,Q72GY6,Q72MT7,Q72YI4,Q73K18,Q742E4,Q74DK5,Q74K31,Q758L0,Q7MH97,Q7MUV9,Q7MZB4,Q7NJY9,Q7S986,Q7U6T0,Q7V1I1,Q7V7M6,Q7VBZ6,Q7VNR9,Q7VRI4,Q7VUF4,Q7W197,Q7WP01,Q816G0,Q81K75,Q822E7,Q82SP4,Q835G1,Q83D91,Q83XM3,Q848I4,Q87EV7,Q87L81,Q888Q7,Q88UI4,Q891H2,Q89A35,Q8A5W2,Q8CT80,Q8D1V8,Q8DCK7,Q8DKY2,Q8DN74,Q8EBH1,Q8ENY8,Q8EVU1,Q8EZG6,Q8FB44,Q8FR39,Q8G2N3,Q8G7I6,Q8K8Q6,Q8K910,Q8KDQ7,Q8L1Z9,Q8NS31,Q8NXF1,Q8P2R3,Q8P9S7,Q8R924,Q8RHH5,Q8SRY1,Q8UI94,Q8VVB7,Q8XI54,Q8XYN9,Q8Y4R7,Q8YF86,Q8YY05,Q8Z1U7,Q8ZAS2,Q8ZKI4,Q8ZWV0,Q928R6,Q92SC4,Q96YC2,Q978F3,Q97FP8,Q97NG0,Q97WE5,Q98BV5,Q98R79,Q9A1L1,Q9ABK5,Q9CD75,Q9CNL2,Q9FXM4,Q9FXM5,Q9HGZ2,Q9HIC2,Q9HNQ6,Q9HV67,Q9K7L8,Q9KUY4,Q9KX58,Q9N1E2,Q9PGR6,Q9PK16,Q9PMD4,Q9RDY2,Q9RMC1,Q9RTL8,Q9UXW3,Q9X1A5,Q9X670,Q9YE01,Q9Z6N4,Q9ZK49" charOffset="39-63" type="protein" text="phosphoglucose isomerase"/>
            <entity id="DS.d762.s3.e2" origId="6912" charOffset="121-128" type="compound" text="xylitol"/>
            <entity id="DS.d762.s3.e4" origId="O05139,P27306,P50529,P57112,P66006,P66007,P66008,P66009,P71317,Q0TA96,Q1CBU5,Q1CNP4,Q1QX78,Q1R3U7,Q2NQZ3,Q2SIP2,Q3K9F5,Q48A14,Q48KI8,Q4KFA6,Q4ZV77,Q57H91,Q5E212,Q5PK71,Q66G61,Q6CZB1,Q6LLT9,Q7MBG9,Q7MQ83,Q83MI1,Q87KN5,Q884I6,Q88KY8,Q8DD46,Q8FB93,Q8X727,Q8ZA97,Q9XBQ9" charOffset="205-209" type="protein" text="sthA"/>
            <entity id="DS.d762.s3.e5" origId="P07001,P43842" charOffset="214-218" type="protein" text="pntA"/>
            <pair e1="DS.d762.s3.e2" e2="DS.d762.s3.e1" id="DS.d762.s3.i1" interaction="True"/>
            <pair e1="DS.d762.s3.e2" e2="DS.d762.s3.e0" id="DS.d762.s3.i2" interaction="True"/>
            <pair e1="DS.d762.s3.e2" e2="DS.d762.s3.e4" id="DS.d762.s3.i3" interaction="False"/>
            <pair e1="DS.d762.s3.e2" e2="DS.d762.s3.e5" id="DS.d762.s3.i7" interaction="False"/>
        </sentence>
        <sentence id="DS.d762.s4" origId="18698648-323" text="Deleting either zwf or sucC (TCA cycle) significantly reduces the yield from 3.4 to 2.0 and 2.3 mol xylitol (mol glucose)(-1), respectively.">
            <entity id="DS.d762.s4.e0" origId="O51581,O54537,O68282,O83491,O84188,P0A584,P0A585,P0A586,P0A587,P0AC53,P0AC54,P11411,P21907,P29686,P37986,P44311,P48848,P48992,P54547,P56110,P57405,P73411,P77809,Q89AI7,Q8K9M2,Q8XCJ6,Q9PKK8,Q9X0N9,Q9Z3S2,Q9Z8U6,Q9ZKB2" charOffset="16-19" type="protein" text="zwf"/>
            <entity id="DS.d762.s4.e1" origId="O05966,O27115,O67546,O84828,O87840,P0A836,P0A837,P0A838,P0A839,P25126,P45101,P53592,P53593,P66867,P66868,P66869,P66870,P66871,P66872,P71559,P80886,P99071,Q49X32,Q4L5U8,Q4ULQ7,Q57663,Q57RL3,Q5HGI7,Q5HPU5,Q5PBI8,Q5PCM7,Q66DA0,Q68WU5,Q6F8L4,Q6G9W8,Q6GHJ0,Q72PA2,Q7MMN3,Q7U0Z1,Q7UKI3,Q822A1,Q87A98,Q87RE8,Q8CPH5,Q8DFQ1,Q8EFN8,Q8F746,Q8KFE7,Q8NMK7,Q8P676,Q8PHL5,Q8UC60,Q8Y1Y3,Q8ZH00,Q8ZVF3,Q92I21,Q98EC5,Q9AB94,Q9CNZ0,Q9EYG9,Q9HPP1,Q9JUT0,Q9JZP4,Q9KA20,Q9KQB5,Q9PAH1,Q9PHY1,Q9PL99,Q9RUY3,Q9Z5H8,Q9Z6T6" charOffset="23-27" type="protein" text="sucC"/>
            <entity id="DS.d762.s4.e2" origId="6912" charOffset="100-107" type="compound" text="xylitol"/>
            <entity id="DS.d762.s4.e3" origId="206,5793,64689,79025" charOffset="113-120" type="compound" text="glucose"/>
            <pair e1="DS.d762.s4.e3" e2="DS.d762.s4.e0" id="DS.d762.s4.i0" interaction="True"/>
            <pair e1="DS.d762.s4.e2" e2="DS.d762.s4.e1" id="DS.d762.s4.i1" interaction="True"/>
            <pair e1="DS.d762.s4.e3" e2="DS.d762.s4.e1" id="DS.d762.s4.i2" interaction="True"/>
            <pair e1="DS.d762.s4.e2" e2="DS.d762.s4.e0" id="DS.d762.s4.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d763" origId="18698649">
        <sentence id="DS.d763.s0" origId="18698649-324" text="In the process studied, the enzyme cellobiose dehydrogenase (CDH) oxidizes lactose at the C-1 position of the reducing sugar moiety to lactobionolactone, which spontaneously hydrolyzes to lactobionic acid.">
            <entity id="DS.d763.s0.e0" origId="P17444,P54223,P60336,P60337,Q01738,Q0TKW1,Q13NG7,Q1BQE2,Q1C932,Q1CFR7,Q1MJU4,Q1QXE1,Q1RFM3,Q2FDP9,Q2FV11,Q2KB43,Q2T6D0,Q2YWJ5,Q39A44,Q3BXK8,Q3JLL7,Q3K5H3,Q48CM7,Q4A0Q1,Q4K4K7,Q4L9D7,Q4UYN5,Q4ZM63,Q5HCU1,Q5HL11,Q62CH8,Q63KK7,Q66D54,Q6D6D9,Q6FDF9,Q6G664,Q6GDJ1,Q6LGH5,Q7MF12,Q88AE7,Q88CW6,Q8BJ64,Q8CMY2,Q8D3K2,Q8FKI9,Q8G1Z8,Q8NE62,Q8NUM0,Q8P5D7,Q8PPG8,Q8UH55,Q8X6C6,Q8YFY2,Q8ZGW0,Q985M5,Q9HTJ2,Q9L4K0,Q9RA05,Q9X2M2" charOffset="61-64" type="protein" text="CDH"/>
            <entity id="DS.d763.s0.e1" origId="294,6134,84571,440995" charOffset="75-82" type="compound" text="lactose"/>
            <entity id="DS.d763.s0.e2" origId="7314" charOffset="188-204" type="compound" text="lactobionic acid"/>
            <pair e1="DS.d763.s0.e2" e2="DS.d763.s0.e0" id="DS.d763.s0.i0" interaction="True"/>
            <pair e1="DS.d763.s0.e1" e2="DS.d763.s0.e0" id="DS.d763.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d763.s2" origId="18698649-326" text="Oxygen served as the terminal electron acceptor of the reaction and was fully reduced to water by laccase.">
            <entity id="DS.d763.s2.e0" origId="977" charOffset="0-6" type="compound" text="Oxygen"/>
            <entity id="DS.d763.s2.e1" origId="Q12570" charOffset="98-105" type="protein" text="laccase"/>
            <pair e1="DS.d763.s2.e0" e2="DS.d763.s2.e1" id="DS.d763.s2.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d764" origId="18699724">
        <sentence id="DS.d764.s0" origId="18699724-117" text="Immunocytochemical localization of cell surface markers like SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81, staining for alkaline phosphatase and reverse transcriptase polymerase chain reaction (RT-PCR) analysis of pluripotency state markers viz.">
            <entity id="DS.d764.s0.e0" origId="53262342" charOffset="61-67" type="compound" text="SSEA-3"/>
            <entity id="DS.d764.s0.e1" origId="444212" charOffset="77-80" type="compound" text="TRA"/>
            <entity id="DS.d764.s0.e2" origId="444212" charOffset="91-94" type="compound" text="TRA"/>
            <entity id="DS.d764.s0.e3" origId="O60109,P81800,P83456" charOffset="114-134" type="protein" text="alkaline phosphatase"/>
            <entity id="DS.d764.s0.e4" origId="P03358,P03554,P03555,P03556,P04323,P05400,P09523,P0A3U0,P0A3U1,P10394,P10399,P10400,P10401,P10978,P11283,P11369,P15629,P16423,P19199,P20825,P21325,P21328,P21329,P23070,P23071,P23072,P27502,Q00962,Q02964,Q03269,Q03270,Q03271,Q03272,Q03273,Q03274,Q03275,Q03276,Q03277,Q03278,Q03279,Q05118,Q8I7P9,Q95SX7,Q9NBX4,Q9QC07" charOffset="139-160" type="protein" text="reverse transcriptase"/>
            <entity id="DS.d764.s0.e5" origId="O66148,O80333,P15904,Q01289,Q39617,Q41249,Q59987,Q9SDT1" charOffset="191-194" type="protein" text="PCR"/>
            <pair e1="DS.d764.s0.e1" e2="DS.d764.s0.e4" id="DS.d764.s0.i0" interaction="False"/>
            <pair e1="DS.d764.s0.e0" e2="DS.d764.s0.e4" id="DS.d764.s0.i1" interaction="False"/>
            <pair e1="DS.d764.s0.e1" e2="DS.d764.s0.e3" id="DS.d764.s0.i2" interaction="False"/>
            <pair e1="DS.d764.s0.e1" e2="DS.d764.s0.e5" id="DS.d764.s0.i3" interaction="False"/>
            <pair e1="DS.d764.s0.e0" e2="DS.d764.s0.e5" id="DS.d764.s0.i4" interaction="False"/>
            <pair e1="DS.d764.s0.e0" e2="DS.d764.s0.e3" id="DS.d764.s0.i5" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d765" origId="18699774">
        <sentence id="DS.d765.s0" origId="18699774-1334" text="Solamargine induces apoptosis and enhances susceptibility to trastuzumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu.">
            <entity id="DS.d765.s0.e0" origId="73611" charOffset="0-11" type="compound" text="Solamargine"/>
            <entity id="DS.d765.s0.e1" origId="41867" charOffset="77-87" type="compound" text="epirubicin"/>
            <entity id="DS.d765.s0.e2" origId="P04626" charOffset="149-153" type="protein" text="HER2"/>
            <entity id="DS.d765.s0.e3" origId="O35657,P06494,P29503,P70424,Q24746" charOffset="154-157" type="protein" text="neu"/>
            <pair e1="DS.d765.s0.e1" e2="DS.d765.s0.e3" id="DS.d765.s0.i0" interaction="False"/>
            <pair e1="DS.d765.s0.e0" e2="DS.d765.s0.e2" id="DS.d765.s0.i1" interaction="False"/>
            <pair e1="DS.d765.s0.e1" e2="DS.d765.s0.e2" id="DS.d765.s0.i2" interaction="False"/>
            <pair e1="DS.d765.s0.e0" e2="DS.d765.s0.e3" id="DS.d765.s0.i3" interaction="False"/>
        </sentence>
        <sentence id="DS.d765.s1" origId="18699774-1335" text="SM (solamargine), a major steroidal alkaloid glycoside purified from Solanum incanum, triggered apoptosis of breast cancer cells (MCF-7 and SK-BR-3 cells) and non-cancerous breast epithelial cells (HBL-100 cells) within 3 h. To extend the application of trastuzumab in breast cancer patients, the regulation of HER2/neu expression by SM was investigated.">
            <entity id="DS.d765.s1.e0" origId="73611" charOffset="4-15" type="compound" text="solamargine"/>
            <entity id="DS.d765.s1.e1" origId="452975" charOffset="26-44" type="compound" text="steroidal alkaloid"/>
            <entity id="DS.d765.s1.e2" origId="P04626" charOffset="311-315" type="protein" text="HER2"/>
            <entity id="DS.d765.s1.e3" origId="O35657,P06494,P29503,P70424,Q24746" charOffset="316-319" type="protein" text="neu"/>
            <pair e1="DS.d765.s1.e0" e2="DS.d765.s1.e2" id="DS.d765.s1.i0" interaction="False"/>
            <pair e1="DS.d765.s1.e1" e2="DS.d765.s1.e3" id="DS.d765.s1.i1" interaction="False"/>
            <pair e1="DS.d765.s1.e0" e2="DS.d765.s1.e3" id="DS.d765.s1.i2" interaction="False"/>
            <pair e1="DS.d765.s1.e1" e2="DS.d765.s1.e2" id="DS.d765.s1.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d766" origId="18700056">
        <sentence id="DS.d766.s0" origId="18700056-1486" text="Since ondansetron completely reversed the effects of clorgyline on DA neuronal activity, the effects of MAOA inhibition appeared to be mediated by 5-HT3 receptors.">
            <entity id="DS.d766.s0.e0" origId="4595" charOffset="6-17" type="compound" text="ondansetron"/>
            <entity id="DS.d766.s0.e1" origId="4380" charOffset="53-63" type="compound" text="clorgyline"/>
            <entity id="DS.d766.s0.e2" origId="O18851,P21397,P21398,P58027,Q5NU32,Q5RE60,Q6Q2J0" charOffset="104-108" type="protein" text="MAOA"/>
            <entity id="DS.d766.s0.e3" origId="O70212,P23979,P35563,P46098" charOffset="147-152" type="protein" text="5-HT3"/>
            <pair e1="DS.d766.s0.e1" e2="DS.d766.s0.e3" id="DS.d766.s0.i0" interaction="False"/>
            <pair e1="DS.d766.s0.e1" e2="DS.d766.s0.e2" id="DS.d766.s0.i1" interaction="False"/>
            <pair e1="DS.d766.s0.e0" e2="DS.d766.s0.e3" id="DS.d766.s0.i2" interaction="False"/>
            <pair e1="DS.d766.s0.e0" e2="DS.d766.s0.e2" id="DS.d766.s0.i3" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d767" origId="18700057">
        <sentence id="DS.d767.s0" origId="18700057-534" text="The effects of Ipt were reversed by the mitochondrial KATP blocker, 5-hydroxydecanoate, indicating that mitochondrial KATP channels participate in the regulation of astrocyte activation.">
            <entity id="DS.d767.s0.e0" origId="P0A3L5,P0A3L6,P15653,P25018,P46376,Q04590,Q47851,Q80UN9" charOffset="15-18" type="protein" text="Ipt"/>
            <entity id="DS.d767.s0.e1" origId="1825" charOffset="68-86" type="compound" text="5-hydroxydecanoate"/>
            <pair e1="DS.d767.s0.e1" e2="DS.d767.s0.e0" id="DS.d767.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d768" origId="18700809">
        <sentence id="DS.d768.s0" origId="18700809-895" text="The cell proliferation, the up-regulation of pS2, and the down-regulation of ERalpha and ERbeta gene expressions induced by the racemate and enantiomers of o,p'-DDT were all reversed by cotreatment with 10(-6) mol/L ICI 182,780.">
            <entity id="DS.d768.s0.e0" origId="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7" charOffset="77-84" type="protein" text="ERalpha"/>
            <entity id="DS.d768.s0.e1" origId="O08537,O13012,O93511,P57781,P57782,Q62986,Q92731,Q95171,Q9IAK1,Q9PTU5,Q9PVE2,Q9TTE5,Q9TU15,Q9W6M2,Q9XSB5,Q9XSW2,Q9YH32" charOffset="89-95" type="protein" text="ERbeta"/>
            <entity id="DS.d768.s0.e2" origId="104741" charOffset="216-227" type="compound" text="ICI 182,780"/>
            <pair e1="DS.d768.s0.e2" e2="DS.d768.s0.e0" id="DS.d768.s0.i0" interaction="True"/>
            <pair e1="DS.d768.s0.e2" e2="DS.d768.s0.e1" id="DS.d768.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d769" origId="18700818">
        <sentence id="DS.d769.s0" origId="18700818-411" text="While bass in all diazinon treatment groups had significantly inhibited brain AChE activity, only the medium and high treatment groups showed a dose- and time-dependent increase in time to capture prey.">
            <entity id="DS.d769.s0.e0" origId="3017" charOffset="18-26" type="compound" text="diazinon"/>
            <entity id="DS.d769.s0.e1" origId="O42275,O62763,P04058,P07140,P07692,P21836,P22303,P23795,P36196,P37136,P56161,Q27677,Q29499,Q867X2,Q867X3,Q869C3,Q86GC8,Q86GC9,Q92035,Q92081,Q9DDE3" charOffset="78-82" type="protein" text="AChE"/>
            <pair e1="DS.d769.s0.e0" e2="DS.d769.s0.e1" id="DS.d769.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d770" origId="18701427">
        <sentence id="DS.d770.s0" origId="18701427-85" text="The aim of this phase 0 study was to investigate whether gemcitabine passes the blood-tumor barrier, and is phosphorylated in the tumor by deoxycytidine kinase (dCK) to gemcitabine nucleotides in order to enable radiosensitization, and whether it is deaminated by deoxycytidine deaminase (dCDA) to dFdU.">
            <entity id="DS.d770.s0.e0" origId="60750" charOffset="57-68" type="compound" text="gemcitabine"/>
            <entity id="DS.d770.s0.e1" origId="P27707,P43346,P48769" charOffset="139-159" type="protein" text="deoxycytidine kinase"/>
            <entity id="DS.d770.s0.e2" origId="P21974,P27707,P43346,P48769,Q9J579" charOffset="161-164" type="protein" text="dCK"/>
            <entity id="DS.d770.s0.e3" origId="60750" charOffset="169-180" type="compound" text="gemcitabine"/>
            <pair e1="DS.d770.s0.e0" e2="DS.d770.s0.e1" id="DS.d770.s0.i0" interaction="True"/>
            <pair e1="DS.d770.s0.e0" e2="DS.d770.s0.e2" id="DS.d770.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d771" origId="18701806">
        <sentence id="DS.d771.s0" origId="18701806-1254" text="The proline mutation at amino acid location 164 significantly reduced the initial hydrolysis of either the amelogenins in solution or the proteins bound on HAP, which was confirmed by amelogenin oligopeptide assays.">
            <entity id="DS.d771.s0.e0" origId="614,8988,145742" charOffset="4-11" type="compound" text="proline"/>
            <entity id="DS.d771.s0.e1" origId="O97646,O97647,Q28462" charOffset="107-118" type="protein" text="amelogenins"/>
            <pair e1="DS.d771.s0.e0" e2="DS.d771.s0.e1" id="DS.d771.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d772" origId="18701809">
        <sentence id="DS.d772.s0" origId="18701809-777" text="In conclusion, dentin mineralization in a corrected phosphate and vitamin D environment compensates the adverse effect of PHEX mutation.">
            <entity id="DS.d772.s0.e0" origId="1061,167704,644102" charOffset="52-61" type="compound" text="phosphate"/>
            <entity id="DS.d772.s0.e1" origId="5280795" charOffset="66-75" type="compound" text="vitamin D"/>
            <entity id="DS.d772.s0.e2" origId="P78562" charOffset="122-126" type="protein" text="PHEX"/>
            <pair e1="DS.d772.s0.e0" e2="DS.d772.s0.e2" id="DS.d772.s0.i0" interaction="False"/>
            <pair e1="DS.d772.s0.e1" e2="DS.d772.s0.e2" id="DS.d772.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d773" origId="18702173">
        <sentence id="DS.d773.s0" origId="18702173-1549" text="The considered biological model system consisted of a coating antibody (goat IgG), bovine serum albumin (BSA) as blocking agent, and a complementary antibody labelled with FITC (anti-goat IgG).">
            <entity id="DS.d773.s0.e0" origId="P21847,P83517" charOffset="90-103" type="protein" text="serum albumin"/>
            <entity id="DS.d773.s0.e1" origId="P02769" charOffset="105-108" type="protein" text="BSA"/>
            <entity id="DS.d773.s0.e2" origId="18730" charOffset="172-176" type="compound" text="FITC"/>
            <pair e1="DS.d773.s0.e2" e2="DS.d773.s0.e1" id="DS.d773.s0.i0" interaction="False"/>
            <pair e1="DS.d773.s0.e2" e2="DS.d773.s0.e0" id="DS.d773.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d774" origId="18702613">
        <sentence id="DS.d774.s0" origId="18702613-201" text="Prolonged L-alanine exposure induces changes in metabolism, Ca(2+) handling and desensitization of insulin secretion in clonal pancreatic beta-cells.">
            <entity id="DS.d774.s0.e0" origId="602,4580,5950,71080" charOffset="12-19" type="compound" text="alanine"/>
            <entity id="DS.d774.s0.e1" origId="271" charOffset="60-64" type="compound" text="Ca(2"/>
            <entity id="DS.d774.s0.e2" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="99-106" type="protein" text="insulin"/>
            <pair e1="DS.d774.s0.e1" e2="DS.d774.s0.e2" id="DS.d774.s0.i0" interaction="False"/>
            <pair e1="DS.d774.s0.e0" e2="DS.d774.s0.e2" id="DS.d774.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d774.s1" origId="18702613-203" text="Collectively, these results illustrate the phenomenon of beta-cell desensitization by amino acids, indicating that prolonged exposure to alanine can induce reversible alterations to metabolic flux, Ca(2+) handling and insulin secretion.">
            <entity id="DS.d774.s1.e0" origId="602,4580,5950,71080" charOffset="137-144" type="compound" text="alanine"/>
            <entity id="DS.d774.s1.e1" origId="271" charOffset="198-202" type="compound" text="Ca(2"/>
            <entity id="DS.d774.s1.e2" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="218-225" type="protein" text="insulin"/>
            <pair e1="DS.d774.s1.e1" e2="DS.d774.s1.e2" id="DS.d774.s1.i0" interaction="False"/>
            <pair e1="DS.d774.s1.e0" e2="DS.d774.s1.e2" id="DS.d774.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d775" origId="18702682">
        <sentence id="DS.d775.s0" origId="18702682-263" text="Acylation-stimulating protein (ASP) has been shown to positively stimulate fatty acid esterification and glucose uptake in adipocytes.">
            <entity id="DS.d775.s0.e0" origId="P32765,P42127,P45381,P79407,Q03288,Q16937,Q1XGU5,Q1XGU6,Q1XGU7,Q1XGU8,Q1XGU9,Q1XGV0,Q1XGV1,Q1XGV2,Q1XGV3,Q1XGV4,Q1XGV5,Q1XGV6,Q1XGV7,Q29414,Q5UK76,Q6ZYM3,Q865F0,Q95MP2,Q99JA2,Q9H1Y0,Q9NQ94" charOffset="31-34" type="protein" text="ASP"/>
            <entity id="DS.d775.s0.e1" origId="206,5793,64689,79025" charOffset="105-112" type="compound" text="glucose"/>
            <pair e1="DS.d775.s0.e1" e2="DS.d775.s0.e0" id="DS.d775.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d776" origId="18703100">
        <sentence id="DS.d776.s0" origId="18703100-623" text="Using a set of experiments aimed at manipulate a putative l-glutamate/NMDA/NO signal transduction pathway, we have demonstrated, by quantitative real-time PCR, that NMDA enhances the expression of GnRH mRNA in a dose-response manner.">
            <entity id="DS.d776.s0.e0" origId="33032" charOffset="58-69" type="compound" text="l-glutamate"/>
            <entity id="DS.d776.s0.e1" origId="22880" charOffset="70-74" type="compound" text="NMDA"/>
            <entity id="DS.d776.s0.e2" origId="22880" charOffset="165-169" type="compound" text="NMDA"/>
            <entity id="DS.d776.s0.e3" origId="P27429" charOffset="197-201" type="protein" text="GnRH"/>
            <pair e1="DS.d776.s0.e0" e2="DS.d776.s0.e3" id="DS.d776.s0.i0" interaction="True"/>
            <pair e1="DS.d776.s0.e1" e2="DS.d776.s0.e3" id="DS.d776.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d777" origId="18703333">
        <sentence id="DS.d777.s0" origId="18703333-1701" text="Reaction parameters for the production of XOS from corncob using endoxylanase from Aspergillus oryzae MTCC 5154 were optimized and an XOS yield of 10.2+/-0.14 mg ml(-1) corresponding to 81+/-3.9% with 73.5% xylobiose was obtained.">
            <entity id="DS.d777.s0.e0" origId="Q60042" charOffset="65-77" type="protein" text="endoxylanase"/>
            <entity id="DS.d777.s0.e1" origId="439538" charOffset="207-216" type="compound" text="xylobiose"/>
            <pair e1="DS.d777.s0.e1" e2="DS.d777.s0.e0" id="DS.d777.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d778" origId="18703532">
        <sentence id="DS.d778.s0" origId="18703532-1538" text="Cilostazol inhibits cytokine-induced nuclear factor-kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells.">
            <entity id="DS.d778.s0.e0" origId="2754" charOffset="0-10" type="compound" text="Cilostazol"/>
            <entity id="DS.d778.s0.e1" origId="P00513,P25848" charOffset="88-102" type="protein" text="protein kinase"/>
            <pair e1="DS.d778.s0.e0" e2="DS.d778.s0.e1" id="DS.d778.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d778.s1" origId="18703532-1539" text="Cilostazol is a selective inhibitor of phosphodiesterase 3 that increases intracellular cyclic AMP (cAMP) levels and activates protein kinase A, thereby inhibiting platelet aggregation and inducing peripheral vasodilation.">
            <entity id="DS.d778.s1.e0" origId="2754" charOffset="0-10" type="compound" text="Cilostazol"/>
            <entity id="DS.d778.s1.e1" origId="6076" charOffset="100-104" type="compound" text="cAMP"/>
            <entity id="DS.d778.s1.e2" origId="Q05608,Q9RI12" charOffset="127-143" type="protein" text="protein kinase A"/>
            <pair e1="DS.d778.s1.e1" e2="DS.d778.s1.e2" id="DS.d778.s1.i0" interaction="False"/>
            <pair e1="DS.d778.s1.e0" e2="DS.d778.s1.e2" id="DS.d778.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d778.s2" origId="18703532-1540" text="We hypothesized that cilostazol may prevent inflammatory cytokine induced-nuclear factor (NF)-kappaB activation by activating AMP-activated protein kinase (AMPK) in vascular endothelial cells.">
            <entity id="DS.d778.s2.e0" origId="2754" charOffset="21-31" type="compound" text="cilostazol"/>
            <entity id="DS.d778.s2.e1" origId="P00513,P25848" charOffset="140-154" type="protein" text="protein kinase"/>
            <entity id="DS.d778.s2.e2" origId="P54646,Q09136,Q9Y478" charOffset="156-160" type="protein" text="AMPK"/>
            <pair e1="DS.d778.s2.e0" e2="DS.d778.s2.e2" id="DS.d778.s2.i0" interaction="True"/>
            <pair e1="DS.d778.s2.e0" e2="DS.d778.s2.e1" id="DS.d778.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d779" origId="18703622">
        <sentence id="DS.d779.s0" origId="18703622-1294" text="Serum estradiol (E2) levels were not altered at any time point after IGF-I, demonstrating that the increased KiSS-1 expression observed was not caused by an elevation in E2.">
            <entity id="DS.d779.s0.e0" origId="5757" charOffset="6-15" type="compound" text="estradiol"/>
            <entity id="DS.d779.s0.e1" origId="P05017,P07455,P08025,P10763,P16545,P17085,P17647,P18254,P33712,P51457,P51458,P51462,Q02815,Q28933,Q68LC0,Q6GUL6,Q6IVA5,Q6JLX1,Q95222" charOffset="69-74" type="protein" text="IGF-I"/>
            <pair e1="DS.d779.s0.e0" e2="DS.d779.s0.e1" id="DS.d779.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d780" origId="18703794">
        <sentence id="DS.d780.s0" origId="18703794-1209" text="A2aR stimulation inhibits HA fragment-induced pro-fibrotic genes TNF-alpha, keratinocyte chemoattractant (KC), macrophage inflammatory protein (MIP)-2, and MIP-1alpha while simultaneously synergizing with hyaluronan fragments to up-regulate the TH1 cytokine IL-12.">
            <entity id="DS.d780.s0.e0" origId="O35734,O77510,O77764,P01375,P04924,P06804,P13296,P16599,P19101,P23383,P23563,P29553,P33620,P36939,P48094,P51435,P51742,P51743,P59684,P59693,P59694,P59695,P79337,P79374,Q06599,Q19LH4,Q1G1A2,Q1WM27,Q2MH05,Q539C2,Q75N23,Q8HZD9,Q8JFG3,Q8MKG8,Q8WNR1,Q9BEA1" charOffset="65-74" type="protein" text="TNF-alpha"/>
            <entity id="DS.d780.s0.e1" origId="P06624,P28238,P30301,P35999,P37932,Q01992,Q09734,Q10415,Q6J8I9,Q6RZ07,Q92973,Q99797" charOffset="144-147" type="protein" text="MIP"/>
            <entity id="DS.d780.s0.e2" origId="P10147,P10855,P50229,Q5I1Z0,Q8HYQ3,Q8SQA6" charOffset="156-166" type="protein" text="MIP-1alpha"/>
            <entity id="DS.d780.s0.e3" origId="24759" charOffset="205-215" type="compound" text="hyaluronan"/>
            <pair e1="DS.d780.s0.e3" e2="DS.d780.s0.e0" id="DS.d780.s0.i0" interaction="False"/>
            <pair e1="DS.d780.s0.e3" e2="DS.d780.s0.e1" id="DS.d780.s0.i1" interaction="False"/>
            <pair e1="DS.d780.s0.e3" e2="DS.d780.s0.e2" id="DS.d780.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d781" origId="18703795">
        <sentence id="DS.d781.s0" origId="18703795-1210" text="In addition, treatment of primary mouse lung fibroblasts with ADMA stimulated arginase activity and collagen formation in vitro.">
            <entity id="DS.d781.s0.e0" origId="123831" charOffset="62-66" type="compound" text="ADMA"/>
            <entity id="DS.d781.s0.e1" origId="O49046,P00812,P0A2X9,P0A2Y0,P0A2Y1,P14012,P33280,P37818,P39138,P40906,P46637,P53608,P60086,P60087,P60088,Q10066,Q12611,Q1E180,Q6G7E9,Q6GER3,Q74ZW4,Q7M0Z3,Q8NVE3" charOffset="78-86" type="protein" text="arginase"/>
            <pair e1="DS.d781.s0.e0" e2="DS.d781.s0.e1" id="DS.d781.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d781.s1" origId="18703795-1211" text="These data support the idea that ADMA may play a role in airway diseases, including asthma and pulmonary fibrosis, through NOS inhibition and enhancement of arginase activity.">
            <entity id="DS.d781.s1.e0" origId="123831" charOffset="33-37" type="compound" text="ADMA"/>
            <entity id="DS.d781.s1.e1" origId="O54705,O61309,O61608,Q26240,Q28969,Q9I9M2" charOffset="123-126" type="protein" text="NOS"/>
            <entity id="DS.d781.s1.e2" origId="O49046,P00812,P0A2X9,P0A2Y0,P0A2Y1,P14012,P33280,P37818,P39138,P40906,P46637,P53608,P60086,P60087,P60088,Q10066,Q12611,Q1E180,Q6G7E9,Q6GER3,Q74ZW4,Q7M0Z3,Q8NVE3" charOffset="157-165" type="protein" text="arginase"/>
            <pair e1="DS.d781.s1.e0" e2="DS.d781.s1.e2" id="DS.d781.s1.i0" interaction="True"/>
            <pair e1="DS.d781.s1.e0" e2="DS.d781.s1.e1" id="DS.d781.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d782" origId="18703867">
        <sentence id="DS.d782.s0" origId="18703867-1272" text="Osteopontin (OPN) inhibits the growth of calcium oxalate monohydrate (COM) and other crystal phases in a phosphorylation-dependent manner.">
            <entity id="DS.d782.s0.e0" origId="P10451,P14287,P31096,Q9XSY9" charOffset="13-16" type="protein" text="OPN"/>
            <entity id="DS.d782.s0.e1" origId="971" charOffset="41-68" type="compound" text="calcium oxalate monohydrate"/>
            <pair e1="DS.d782.s0.e1" e2="DS.d782.s0.e0" id="DS.d782.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d783" origId="18703992">
        <sentence id="DS.d783.s0" origId="18703992-1333" text="Prostaglandins D2, E2, and F2alpha were increased in the tissues from mouse pups exposed to &amp;gt;95% O2 at 7 d indicating a differential expression of cyclooxygenase-2 products.">
            <entity id="DS.d783.s0.e0" origId="977,5359597" charOffset="100-102" type="compound" text="O2"/>
            <entity id="DS.d783.s0.e1" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="150-166" type="protein" text="cyclooxygenase-2"/>
            <pair e1="DS.d783.s0.e0" e2="DS.d783.s0.e1" id="DS.d783.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d784" origId="18704001">
        <sentence id="DS.d784.s0" origId="18704001-1340" text="Glucose replacement to euglycemia causes hypoxia, acidosis, and decreased insulin secretion in fetal sheep with intrauterine growth restriction.">
            <entity id="DS.d784.s0.e0" origId="206,5793,64689,79025" charOffset="0-7" type="compound" text="Glucose"/>
            <entity id="DS.d784.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="74-81" type="protein" text="insulin"/>
            <pair e1="DS.d784.s0.e0" e2="DS.d784.s0.e1" id="DS.d784.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d784.s1" origId="18704001-1341" text="Glucose stimulated insulin secretion (GSIS) was lower in the Glu group.">
            <entity id="DS.d784.s1.e0" origId="206,5793,64689,79025" charOffset="0-7" type="compound" text="Glucose"/>
            <entity id="DS.d784.s1.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="19-26" type="protein" text="insulin"/>
            <pair e1="DS.d784.s1.e0" e2="DS.d784.s1.e1" id="DS.d784.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d785" origId="18704095">
        <sentence id="DS.d785.s0" origId="18704095-238" text="These data confirm that endogenous miR-34a regulates GRM7 levels and supports the notion that miR-34a contributes to the effects of lithium and VPA on GRM7.">
            <entity id="DS.d785.s0.e1" origId="Q14831,Q5RDQ8" charOffset="53-57" type="protein" text="GRM7"/>
            <entity id="DS.d785.s0.e3" origId="28486,3028194" charOffset="132-139" type="compound" text="lithium"/>
            <entity id="DS.d785.s0.e4" origId="Q14831,Q5RDQ8" charOffset="151-155" type="protein" text="GRM7"/>
            <pair e1="DS.d785.s0.e3" e2="DS.d785.s0.e1" id="DS.d785.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d786" origId="18704096">
        <sentence id="DS.d786.s0" origId="18704096-1413" text="These results confirm the therapeutic potential of mGluR5 blockade on motor symptoms induced by reduced striatal dopamine function.">
            <entity id="DS.d786.s0.e0" origId="P31424,P41594" charOffset="51-57" type="protein" text="mGluR5"/>
            <entity id="DS.d786.s0.e1" origId="681" charOffset="113-121" type="compound" text="dopamine"/>
            <pair e1="DS.d786.s0.e1" e2="DS.d786.s0.e0" id="DS.d786.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d786.s1" origId="18704096-1414" text="Further, they demonstrate that mGluR5 blockade may also have beneficial effects on cognitive deficits induced by dopamine depletion.">
            <entity id="DS.d786.s1.e0" origId="P31424,P41594" charOffset="31-37" type="protein" text="mGluR5"/>
            <entity id="DS.d786.s1.e1" origId="681" charOffset="113-121" type="compound" text="dopamine"/>
            <pair e1="DS.d786.s1.e1" e2="DS.d786.s1.e0" id="DS.d786.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d787" origId="18704103">
        <sentence id="DS.d787.s0" origId="18704103-600" text="Here, we found that the addition of glucocorticoids, such as dexamethasone and cortisol, to cultured human keratinocytes increased their TLR2 gene expression.">
            <entity id="DS.d787.s0.e0" origId="5743" charOffset="61-74" type="compound" text="dexamethasone"/>
            <entity id="DS.d787.s0.e1" origId="5754" charOffset="79-87" type="compound" text="cortisol"/>
            <entity id="DS.d787.s0.e2" origId="O60603,Q2V897,Q689D1,Q95LA9,Q95M53,Q9R1F8" charOffset="137-141" type="protein" text="TLR2"/>
            <pair e1="DS.d787.s0.e1" e2="DS.d787.s0.e2" id="DS.d787.s0.i0" interaction="True"/>
            <pair e1="DS.d787.s0.e0" e2="DS.d787.s0.e2" id="DS.d787.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d787.s1" origId="18704103-601" text="Gene expression of mitogen-activated protein kinase (MAPK) phosphatase-1 was also increased by the addition of dexamethasone.">
            <entity id="DS.d787.s1.e0" origId="O42781,P27638,Q00859" charOffset="53-57" type="protein" text="MAPK"/>
            <entity id="DS.d787.s1.e1" origId="5743" charOffset="111-124" type="compound" text="dexamethasone"/>
            <pair e1="DS.d787.s1.e1" e2="DS.d787.s1.e0" id="DS.d787.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d788" origId="18704264">
        <sentence id="DS.d788.s0" origId="18704264-1595" text="Administration of B(a)P (50 mg/kg body weight) to mice resulted in increased lipid peroxides (LPO), lung specific tumor marker carcinoembryonic antigen (CEA) and serum marker enzymes aryl hydrocarbon hydroxylase (AHH), gamma glutamyl transpeptidase (GGT), 5'nucleotidase (5'ND) and lactate dehydrogenase (LDH) with concomitant decrease in the levels of tissue antioxidants like superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), reduced glutathione (GSH), vitamin E and vitamin C.">
            <entity id="DS.d788.s0.e0" origId="P06731" charOffset="127-151" type="protein" text="carcinoembryonic antigen"/>
            <entity id="DS.d788.s0.e1" origId="P06731" charOffset="153-156" type="protein" text="CEA"/>
            <entity id="DS.d788.s0.e2" origId="P15557,P19440,P20735,Q05053" charOffset="250-253" type="protein" text="GGT"/>
            <entity id="DS.d788.s0.e3" origId="P07024,P52307,Q56878,Q9I767,Q9RN37,Q9XZ43" charOffset="256-270" type="protein" text="5'nucleotidase"/>
            <entity id="DS.d788.s0.e4" origId="P29038,P33571,P93052,Q27797,Q27888,Q95028,Q99289" charOffset="305-308" type="protein" text="LDH"/>
            <entity id="DS.d788.s0.e5" origId="O50258" charOffset="378-398" type="protein" text="superoxide dismutase"/>
            <entity id="DS.d788.s0.e6" origId="O12933,O22668,O75007,P24705,P51547,P93258,Q01137,Q27666,Q9SM64" charOffset="400-403" type="protein" text="SOD"/>
            <entity id="DS.d788.s0.e7" origId="O24339,O52762,O62839,O68146,O77229,O93662,O97492,P00432,P04040,P04762,P07145,P0A323,P0A324,P0A325,P0A326,P0A327,P11934,P17336,P24168,P24270,P25890,P29422,P30265,P30266,P32290,P42321,P44390,P45737,P45739,P55304,P55306,P55310,P55311,P55313,P77872,P81138,P90682,Q27710,Q49XC1,Q4L643,Q59296,Q59337,Q59602,Q59714,Q5HG86,Q5HPK8,Q5RF10,Q64405,Q6G9M4,Q6GH72,Q7A5T2,Q8CPD0,Q8FWU0,Q8NWV5,Q8X1P0,Q8Y3P9,Q926X0,Q99UE2,Q9AXH0,Q9KW19,Q9L4S1,Q9M5L6,Q9PT92,Q9PWF7,Q9Z598,Q9ZKX5,Q9ZN99" charOffset="406-414" type="protein" text="catalase"/>
            <entity id="DS.d788.s0.e8" origId="O62839,O97492,P00432,P00485,P00486,P00487,P04040,P06135,P07641,P11504,P20074,P22782,P25309,P25819,P26825,P26826,P32796,P36882,P36883,P43155,P47934,P49417,P52826,P58777,P62577,P62578,P62579,P62580,P90682,Q00614,Q02736,Q03058,Q5RF10,Q64405,Q704S8,Q9M5L6,Q9PWF7" charOffset="416-419" type="protein" text="CAT"/>
            <entity id="DS.d788.s0.e9" origId="O32770,O59858,Q00277,Q9CFV1" charOffset="422-444" type="protein" text="glutathione peroxidase"/>
            <entity id="DS.d788.s0.e10" origId="124886" charOffset="452-471" type="compound" text="reduced glutathione"/>
            <entity id="DS.d788.s0.e11" origId="124886" charOffset="473-476" type="compound" text="GSH"/>
            <entity id="DS.d788.s0.e12" origId="2116,14985,1548900,1742129" charOffset="479-488" type="compound" text="vitamin E"/>
            <entity id="DS.d788.s0.e13" origId="54670067" charOffset="493-502" type="compound" text="vitamin C"/>
            <pair e1="DS.d788.s0.e11" e2="DS.d788.s0.e6" id="DS.d788.s0.i0" interaction="False"/>
            <pair e1="DS.d788.s0.e10" e2="DS.d788.s0.e6" id="DS.d788.s0.i1" interaction="False"/>
            <pair e1="DS.d788.s0.e13" e2="DS.d788.s0.e1" id="DS.d788.s0.i2" interaction="False"/>
            <pair e1="DS.d788.s0.e13" e2="DS.d788.s0.e8" id="DS.d788.s0.i3" interaction="False"/>
            <pair e1="DS.d788.s0.e11" e2="DS.d788.s0.e2" id="DS.d788.s0.i4" interaction="False"/>
            <pair e1="DS.d788.s0.e10" e2="DS.d788.s0.e4" id="DS.d788.s0.i5" interaction="False"/>
            <pair e1="DS.d788.s0.e13" e2="DS.d788.s0.e7" id="DS.d788.s0.i6" interaction="False"/>
            <pair e1="DS.d788.s0.e10" e2="DS.d788.s0.e2" id="DS.d788.s0.i7" interaction="False"/>
            <pair e1="DS.d788.s0.e12" e2="DS.d788.s0.e1" id="DS.d788.s0.i8" interaction="False"/>
            <pair e1="DS.d788.s0.e12" e2="DS.d788.s0.e8" id="DS.d788.s0.i9" interaction="False"/>
            <pair e1="DS.d788.s0.e11" e2="DS.d788.s0.e1" id="DS.d788.s0.i10" interaction="False"/>
            <pair e1="DS.d788.s0.e12" e2="DS.d788.s0.e6" id="DS.d788.s0.i11" interaction="False"/>
            <pair e1="DS.d788.s0.e12" e2="DS.d788.s0.e7" id="DS.d788.s0.i12" interaction="False"/>
            <pair e1="DS.d788.s0.e11" e2="DS.d788.s0.e0" id="DS.d788.s0.i13" interaction="False"/>
            <pair e1="DS.d788.s0.e12" e2="DS.d788.s0.e2" id="DS.d788.s0.i14" interaction="False"/>
            <pair e1="DS.d788.s0.e11" e2="DS.d788.s0.e8" id="DS.d788.s0.i15" interaction="False"/>
            <pair e1="DS.d788.s0.e10" e2="DS.d788.s0.e8" id="DS.d788.s0.i16" interaction="False"/>
            <pair e1="DS.d788.s0.e12" e2="DS.d788.s0.e0" id="DS.d788.s0.i17" interaction="False"/>
            <pair e1="DS.d788.s0.e13" e2="DS.d788.s0.e0" id="DS.d788.s0.i18" interaction="False"/>
            <pair e1="DS.d788.s0.e12" e2="DS.d788.s0.e3" id="DS.d788.s0.i19" interaction="False"/>
            <pair e1="DS.d788.s0.e13" e2="DS.d788.s0.e2" id="DS.d788.s0.i20" interaction="False"/>
            <pair e1="DS.d788.s0.e11" e2="DS.d788.s0.e9" id="DS.d788.s0.i21" interaction="False"/>
            <pair e1="DS.d788.s0.e10" e2="DS.d788.s0.e3" id="DS.d788.s0.i22" interaction="False"/>
            <pair e1="DS.d788.s0.e10" e2="DS.d788.s0.e5" id="DS.d788.s0.i23" interaction="False"/>
            <pair e1="DS.d788.s0.e11" e2="DS.d788.s0.e5" id="DS.d788.s0.i24" interaction="False"/>
            <pair e1="DS.d788.s0.e12" e2="DS.d788.s0.e9" id="DS.d788.s0.i25" interaction="False"/>
            <pair e1="DS.d788.s0.e12" e2="DS.d788.s0.e5" id="DS.d788.s0.i26" interaction="False"/>
            <pair e1="DS.d788.s0.e11" e2="DS.d788.s0.e4" id="DS.d788.s0.i27" interaction="False"/>
            <pair e1="DS.d788.s0.e10" e2="DS.d788.s0.e1" id="DS.d788.s0.i28" interaction="False"/>
            <pair e1="DS.d788.s0.e10" e2="DS.d788.s0.e9" id="DS.d788.s0.i29" interaction="False"/>
            <pair e1="DS.d788.s0.e10" e2="DS.d788.s0.e7" id="DS.d788.s0.i30" interaction="False"/>
            <pair e1="DS.d788.s0.e11" e2="DS.d788.s0.e7" id="DS.d788.s0.i31" interaction="False"/>
            <pair e1="DS.d788.s0.e11" e2="DS.d788.s0.e3" id="DS.d788.s0.i32" interaction="False"/>
            <pair e1="DS.d788.s0.e13" e2="DS.d788.s0.e5" id="DS.d788.s0.i33" interaction="False"/>
            <pair e1="DS.d788.s0.e13" e2="DS.d788.s0.e9" id="DS.d788.s0.i34" interaction="False"/>
            <pair e1="DS.d788.s0.e13" e2="DS.d788.s0.e4" id="DS.d788.s0.i35" interaction="False"/>
            <pair e1="DS.d788.s0.e13" e2="DS.d788.s0.e3" id="DS.d788.s0.i36" interaction="False"/>
            <pair e1="DS.d788.s0.e13" e2="DS.d788.s0.e6" id="DS.d788.s0.i37" interaction="False"/>
            <pair e1="DS.d788.s0.e10" e2="DS.d788.s0.e0" id="DS.d788.s0.i38" interaction="False"/>
            <pair e1="DS.d788.s0.e12" e2="DS.d788.s0.e4" id="DS.d788.s0.i39" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d789" origId="18704417">
        <sentence id="DS.d789.s0" origId="18704417-141" text="Achieving CCgR within 12 months and maintaining it without an increase in BCR-ABL transcripts might indicate that low-dose imatinib therapy can produce acceptable outcomes without excess toxicity.">
            <entity id="DS.d789.s0.e0" origId="P11274" charOffset="74-77" type="protein" text="BCR"/>
            <entity id="DS.d789.s0.e1" origId="P00519,P00521,P10447,P11681,Q00022" charOffset="78-81" type="protein" text="ABL"/>
            <entity id="DS.d789.s0.e2" origId="5291" charOffset="123-131" type="compound" text="imatinib"/>
            <pair e1="DS.d789.s0.e2" e2="DS.d789.s0.e0" id="DS.d789.s0.i0" interaction="True"/>
            <pair e1="DS.d789.s0.e2" e2="DS.d789.s0.e1" id="DS.d789.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d790" origId="18704487">
        <sentence id="DS.d790.s0" origId="18704487-89" text="Rac1 (-/-) platelets displayed defective thrombus formation on collagen under flow conditions which could be fully restored by co-infusion of ADP and the TxA(2) analog U46619, indicating that impaired GPVI-, but not G-protein signaling, was responsible for the observed defect.">
            <entity id="DS.d790.s0.e0" origId="P40792,P63001,Q6RUV5" charOffset="0-4" type="protein" text="Rac1"/>
            <entity id="DS.d790.s0.e1" origId="5280497" charOffset="154-159" type="compound" text="TxA(2"/>
            <entity id="DS.d790.s0.e2" origId="P0C191,Q9HCN6" charOffset="201-205" type="protein" text="GPVI"/>
            <pair e1="DS.d790.s0.e1" e2="DS.d790.s0.e2" id="DS.d790.s0.i0" interaction="False"/>
            <pair e1="DS.d790.s0.e1" e2="DS.d790.s0.e0" id="DS.d790.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d791" origId="18704543">
        <sentence id="DS.d791.s0" origId="18704543-120" text="LCT 13910 CC genotype is associated with lactose intolerance, a condition often resulting in reduced milk intake.">
            <entity id="DS.d791.s0.e0" origId="P09848,P09849" charOffset="0-3" type="protein" text="LCT"/>
            <entity id="DS.d791.s0.e1" origId="294,6134,84571,440995" charOffset="41-48" type="compound" text="lactose"/>
            <pair e1="DS.d791.s0.e1" e2="DS.d791.s0.e0" id="DS.d791.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d792" origId="18704651">
        <sentence id="DS.d792.s0" origId="18704651-196" text="Osteointegration of titanium or its alloy with bone can be greatly improved by calcium phosphate coatings, and further enhanced by an extracellular matrix protein layer such as collagen.">
            <entity id="DS.d792.s0.e0" origId="23963" charOffset="20-28" type="compound" text="titanium"/>
            <entity id="DS.d792.s0.e1" origId="24441,24456,24632" charOffset="79-96" type="compound" text="calcium phosphate"/>
            <entity id="DS.d792.s0.e2" origId="O12705,O18559,O57299,O89341,P03314,P03344,P03419,P03426,P03519,P04876,P04888,P05769,P06157,P06166,P06446,P06502,P06503,P06935,P06942,P06943,P07564,P07720,P07873,P08325,P08671,P09732,P09866,P11206,P12446,P12823,P13616,P13844,P14335,P14336,P14340,P14403,P15200,P16287,P16628,P16629,P17748,P17763,P18356,P18611,P19110,P19692,P19718,P22046,P22338,P24266,P24615,P25058,P25182,P25223,P25224,P26034,P27019,P27020,P27287,P27395,P27663,P27910,P27912,P27913,P27915,P29165,P29837,P29838,P29983,P29984,P29990,P29991,P30026,P31035,P31620,P32886,P33478,P33482,P33515,P35947,P35976,P36355,P36356,P41358,P52637,P62683,P62684,P62685,P62689,P62690,P63117,P63126,P63128,P63130,P63145,P87577,P87889,Q01299,Q01427,Q04538,Q074N0,Q1X880,Q1X881,Q66112,Q6DV88,Q6J3P1,Q7LDI9,Q84131,Q88266,Q88428,Q89277,Q91B74,Q96PI4,Q98803,Q9HDB9,Q9IK90,Q9JAF2,Q9NRZ4,Q9UKH8,Q9YNA8,Q9YRV3" charOffset="148-162" type="protein" text="matrix protein"/>
            <pair e1="DS.d792.s0.e0" e2="DS.d792.s0.e2" id="DS.d792.s0.i0" interaction="True"/>
            <pair e1="DS.d792.s0.e1" e2="DS.d792.s0.e2" id="DS.d792.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d793" origId="18704653">
        <sentence id="DS.d793.s0" origId="18704653-197" text="Use of tissue transglutaminase and fibronectin to influence osteoblast responses to tricalcium phosphate scaffolds.">
            <entity id="DS.d793.s0.e0" origId="P08587,P21980,P21981,P51176,P52181,Q01841" charOffset="7-30" type="protein" text="tissue transglutaminase"/>
            <entity id="DS.d793.s0.e1" origId="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400" charOffset="35-46" type="protein" text="fibronectin"/>
            <entity id="DS.d793.s0.e2" origId="24456" charOffset="84-104" type="compound" text="tricalcium phosphate"/>
            <pair e1="DS.d793.s0.e2" e2="DS.d793.s0.e0" id="DS.d793.s0.i0" interaction="True"/>
            <pair e1="DS.d793.s0.e2" e2="DS.d793.s0.e1" id="DS.d793.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d793.s1" origId="18704653-198" text="To explore the possibility of controlling cell interaction with biomaterials, tricalcium phosphate scaffolds were modified using the enzyme tissue transglutaminase (tTgase) in conjunction with fibronectin.">
            <entity id="DS.d793.s1.e0" origId="24456" charOffset="78-98" type="compound" text="tricalcium phosphate"/>
            <entity id="DS.d793.s1.e1" origId="P08587,P21980,P21981,P51176,P52181,Q01841" charOffset="140-163" type="protein" text="tissue transglutaminase"/>
            <entity id="DS.d793.s1.e2" origId="P07589,P11722,Q28275,Q28377,Q28749,Q91289,Q91400" charOffset="193-204" type="protein" text="fibronectin"/>
            <pair e1="DS.d793.s1.e0" e2="DS.d793.s1.e1" id="DS.d793.s1.i0" interaction="True"/>
            <pair e1="DS.d793.s1.e0" e2="DS.d793.s1.e2" id="DS.d793.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d796" origId="18704766">
        <sentence id="DS.d796.s0" origId="18704766-300" text="Four MPTP monkeys received L-DOPA/Benserazide plus CI-1041 an NMDA antagonist selective for NR1/NR2B and four were treated with L-DOPA/Benserazide plus a small dose of cabergoline ; one monkey of each group developed mild dyskinesias at the end of treatment.">
            <entity id="DS.d796.s0.e0" origId="6047" charOffset="27-33" type="compound" text="L-DOPA"/>
            <entity id="DS.d796.s0.e1" origId="2327" charOffset="34-45" type="compound" text="Benserazide"/>
            <entity id="DS.d796.s0.e2" origId="P11605,P11832,P16081,P39865,Q9SML8" charOffset="92-95" type="protein" text="NR1"/>
            <entity id="DS.d796.s0.e3" origId="Q00960,Q01097,Q13224" charOffset="96-100" type="protein" text="NR2B"/>
            <entity id="DS.d796.s0.e4" origId="6047" charOffset="128-134" type="compound" text="L-DOPA"/>
            <entity id="DS.d796.s0.e5" origId="2327" charOffset="135-146" type="compound" text="Benserazide"/>
            <entity id="DS.d796.s0.e6" origId="54746" charOffset="168-179" type="compound" text="cabergoline"/>
            <pair e1="DS.d796.s0.e1" e2="DS.d796.s0.e2" id="DS.d796.s0.i0" interaction="False"/>
            <pair e1="DS.d796.s0.e6" e2="DS.d796.s0.e2" id="DS.d796.s0.i1" interaction="False"/>
            <pair e1="DS.d796.s0.e1" e2="DS.d796.s0.e3" id="DS.d796.s0.i2" interaction="False"/>
            <pair e1="DS.d796.s0.e0" e2="DS.d796.s0.e2" id="DS.d796.s0.i3" interaction="False"/>
            <pair e1="DS.d796.s0.e6" e2="DS.d796.s0.e3" id="DS.d796.s0.i4" interaction="False"/>
            <pair e1="DS.d796.s0.e0" e2="DS.d796.s0.e3" id="DS.d796.s0.i5" interaction="False"/>
        </sentence>
        <sentence id="DS.d796.s1" origId="18704766-304" text="Hence, MPTP lesion, L-DOPA treatment and prevention of LID with CI-1041 and cabergoline, or reduction with Ro 61-8048 were associated with modulation of NR2B/NMDA glutamate receptors.">
            <entity id="DS.d796.s1.e0" origId="6047" charOffset="20-26" type="compound" text="L-DOPA"/>
            <entity id="DS.d796.s1.e1" origId="54746" charOffset="76-87" type="compound" text="cabergoline"/>
            <entity id="DS.d796.s1.e2" origId="5282337" charOffset="107-117" type="compound" text="Ro 61-8048"/>
            <entity id="DS.d796.s1.e3" origId="Q00960,Q01097,Q13224" charOffset="153-157" type="protein" text="NR2B"/>
            <pair e1="DS.d796.s1.e2" e2="DS.d796.s1.e3" id="DS.d796.s1.i0" interaction="True"/>
            <pair e1="DS.d796.s1.e0" e2="DS.d796.s1.e3" id="DS.d796.s1.i1" interaction="True"/>
            <pair e1="DS.d796.s1.e1" e2="DS.d796.s1.e3" id="DS.d796.s1.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d797" origId="18704940">
        <sentence id="DS.d797.s0" origId="18704940-430" text="MurD (UDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase), a three-domain bacterial protein, catalyses a highly specific incorporation of D-glutamate to the cytoplasmic intermediate UDP-N-acetyl-muramoyl-L-alanine (UMA) utilizing ATP hydrolysis to ADP and P(i).">
            <entity id="DS.d797.s0.e0" origId="O06222,O07108,O07669,O25236,O51532,O67852,O83873,O84763,P0A089,P0A090,P0A091,P0C0D7,P0C0D8,P14900,P45063,P57313,P57995,P73668,Q03522,Q0SHR9,Q0SQ91,Q0TLQ1,Q0TMJ3,Q0VS04,Q11GS3,Q11RH3,Q12EL7,Q13TZ0,Q14J05,Q163I6,Q182Y7,Q1AVX1,Q1BZG5,Q1C212,Q1CMM9,Q1CU35,Q1D0S8,Q1GAT6,Q1GIV4,Q1GRX7,Q1GYZ9,Q1IKG8,Q1J147,Q1J5S5,Q1JAT4,Q1JG10,Q1JKY4,Q1LIM4,Q1LSW4,Q1ME31,Q1MPC1,Q1Q883,Q1QNU5,Q1QVG5,Q1RGA7,Q1RI52,Q1WT99,Q216E0,Q21MH1,Q21SW7,Q24TE4,Q255W7,Q28NN2,Q2A1Z9,Q2FHQ4,Q2FZ92,Q2G997,Q2IG29,Q2IYL0,Q2JD52,Q2JHP5,Q2JVR9,Q2K6B9,Q2KVF5,Q2LR50,Q2NVV3,Q2P5V2,Q2RK81,Q2RVU2,Q2S530,Q2S9Z0,Q2SZI5,Q2W0H5,Q2Y636,Q2YM69,Q2YXD9,Q313Q5,Q319C4,Q31I61,Q31MM2,Q326E7,Q32K04,Q38XM9,Q39JX2,Q39YM1,Q3A2G4,Q3AAE4,Q3AHP0,Q3ANV5,Q3AZI5,Q3B127,Q3BR29,Q3IG02,Q3J4M6,Q3J787,Q3JND6,Q3K2P4,Q3K742,Q3KKT4,Q3MF19,Q3SMH5,Q3STT0,Q3Z5S1,Q46JA8,Q46WZ2,Q47AA2,Q47QX1,Q47VQ7,Q48EF6,Q48SK8,Q493Q3,Q49WW5,Q4FQ21,Q4JW97,Q4K6J1,Q4L5N4,Q4QLG0,Q4ULT8,Q4UWX9,Q4ZNY8,Q52953,Q57C76,Q57TD2,Q5E2P8,Q5F6L6,Q5FKV3,Q5FUJ7,Q5GSC8,Q5H2Y1,Q5HGP8,Q5HQ09,Q5HW34,Q5L0X7,Q5L521,Q5LIJ5,Q5LU71,Q5M0D5,Q5M4Y2,Q5MZA8,Q5NHK3,Q5NPA7,Q5P6Z4,Q5PBH9,Q5PDC2,Q5R0M3,Q5SJD2,Q5WFG8,Q5WTI5,Q5X1S4,Q5XB04,Q5YYY1,Q5ZSA3,Q604V5,Q62GS5,Q636B4,Q63QJ5,Q64ZL9,Q65JY2,Q65RY4,Q66EK7,Q67QM7,Q68WW9,Q6A9Q4,Q6AE62,Q6AJ52,Q6D0I1,Q6FFC2,Q6G122,Q6G2Q3,Q6GA29,Q6GHQ2,Q6HEQ2,Q6LMF4,Q6MBS4,Q6MIF8,Q6N409,Q6NGC6,Q71XX7,Q728U6,Q72JQ1,Q72NP4,Q732F6,Q73GT3,Q73YQ6,Q748D4,Q74JY5,Q7MNV3,Q7MWM5,Q7N145,Q7NEZ5,Q7NPZ7,Q7U8T1,Q7V0A5,Q7V5V5,Q7VAM1,Q7VEP7,Q7VP56,Q7VQI9,Q7VUQ1,Q7W4B2,Q7WFS0,Q819Q2,Q81WC9,Q821S1,Q82AD8,Q82VS5,Q83F20,Q83GN2,Q83HK0,Q83MF9,Q879A1,Q87EA7,Q87SG6,Q87WY3,Q88N78,Q88V80,Q899G5,Q89AQ2,Q89FU5,Q8A256,Q8CSX6,Q8D2Z4,Q8DEK8,Q8DMN8,Q8DQM2,Q8DVE3,Q8E186,Q8E6P1,Q8E9P6,Q8ER50,Q8F7V4,Q8FL65,Q8FNT8,Q8FZP2,Q8G4Q6,Q8K9T2,Q8KGD2,Q8NX35,Q8P063,Q8P775,Q8PII9,Q8R9G4,Q8RDQ1,Q8UDM6,Q8X9Y9,Q8XHM4,Q8XVI5,Q8Y5M1,Q8YI68,Q8YPS9,Q8Z9H0,Q8ZIF1,Q8ZRU4,Q929Y1,Q92I60,Q97EB9,Q97RU8,Q98KB1,Q9A597,Q9CF91,Q9CPB0,Q9F1N2,Q9HVZ9,Q9JSZ5,Q9K0Y4,Q9K9S8,Q9KPG5,Q9PEB0,Q9PI73,Q9PLG5,Q9RRJ4,Q9S2W9,Q9WY76,Q9Z705,Q9ZDC2,Q9ZLY0" charOffset="0-4" type="protein" text="MurD"/>
            <entity id="DS.d797.s0.e1" origId="5496796" charOffset="214-217" type="compound" text="UMA"/>
            <pair e1="DS.d797.s0.e1" e2="DS.d797.s0.e0" id="DS.d797.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d797.s1" origId="18704940-431" text="On the basis of structural studies of MurD complexes, a stepwise catalytic mechanism was proposed that commences with a formation of the acyl-phosphate intermediate, followed by a nucleophilic attack of D-glutamate that, through the formation of a tetrahedral reaction intermediate and subsequent phosphate dissociation, affords the final product, UDP-N-acetyl-muramoyl-L-alanine-D-glutamate (UMAG).">
            <entity id="DS.d797.s1.e0" origId="O06222,O07108,O07669,O25236,O51532,O67852,O83873,O84763,P0A089,P0A090,P0A091,P0C0D7,P0C0D8,P14900,P45063,P57313,P57995,P73668,Q03522,Q0SHR9,Q0SQ91,Q0TLQ1,Q0TMJ3,Q0VS04,Q11GS3,Q11RH3,Q12EL7,Q13TZ0,Q14J05,Q163I6,Q182Y7,Q1AVX1,Q1BZG5,Q1C212,Q1CMM9,Q1CU35,Q1D0S8,Q1GAT6,Q1GIV4,Q1GRX7,Q1GYZ9,Q1IKG8,Q1J147,Q1J5S5,Q1JAT4,Q1JG10,Q1JKY4,Q1LIM4,Q1LSW4,Q1ME31,Q1MPC1,Q1Q883,Q1QNU5,Q1QVG5,Q1RGA7,Q1RI52,Q1WT99,Q216E0,Q21MH1,Q21SW7,Q24TE4,Q255W7,Q28NN2,Q2A1Z9,Q2FHQ4,Q2FZ92,Q2G997,Q2IG29,Q2IYL0,Q2JD52,Q2JHP5,Q2JVR9,Q2K6B9,Q2KVF5,Q2LR50,Q2NVV3,Q2P5V2,Q2RK81,Q2RVU2,Q2S530,Q2S9Z0,Q2SZI5,Q2W0H5,Q2Y636,Q2YM69,Q2YXD9,Q313Q5,Q319C4,Q31I61,Q31MM2,Q326E7,Q32K04,Q38XM9,Q39JX2,Q39YM1,Q3A2G4,Q3AAE4,Q3AHP0,Q3ANV5,Q3AZI5,Q3B127,Q3BR29,Q3IG02,Q3J4M6,Q3J787,Q3JND6,Q3K2P4,Q3K742,Q3KKT4,Q3MF19,Q3SMH5,Q3STT0,Q3Z5S1,Q46JA8,Q46WZ2,Q47AA2,Q47QX1,Q47VQ7,Q48EF6,Q48SK8,Q493Q3,Q49WW5,Q4FQ21,Q4JW97,Q4K6J1,Q4L5N4,Q4QLG0,Q4ULT8,Q4UWX9,Q4ZNY8,Q52953,Q57C76,Q57TD2,Q5E2P8,Q5F6L6,Q5FKV3,Q5FUJ7,Q5GSC8,Q5H2Y1,Q5HGP8,Q5HQ09,Q5HW34,Q5L0X7,Q5L521,Q5LIJ5,Q5LU71,Q5M0D5,Q5M4Y2,Q5MZA8,Q5NHK3,Q5NPA7,Q5P6Z4,Q5PBH9,Q5PDC2,Q5R0M3,Q5SJD2,Q5WFG8,Q5WTI5,Q5X1S4,Q5XB04,Q5YYY1,Q5ZSA3,Q604V5,Q62GS5,Q636B4,Q63QJ5,Q64ZL9,Q65JY2,Q65RY4,Q66EK7,Q67QM7,Q68WW9,Q6A9Q4,Q6AE62,Q6AJ52,Q6D0I1,Q6FFC2,Q6G122,Q6G2Q3,Q6GA29,Q6GHQ2,Q6HEQ2,Q6LMF4,Q6MBS4,Q6MIF8,Q6N409,Q6NGC6,Q71XX7,Q728U6,Q72JQ1,Q72NP4,Q732F6,Q73GT3,Q73YQ6,Q748D4,Q74JY5,Q7MNV3,Q7MWM5,Q7N145,Q7NEZ5,Q7NPZ7,Q7U8T1,Q7V0A5,Q7V5V5,Q7VAM1,Q7VEP7,Q7VP56,Q7VQI9,Q7VUQ1,Q7W4B2,Q7WFS0,Q819Q2,Q81WC9,Q821S1,Q82AD8,Q82VS5,Q83F20,Q83GN2,Q83HK0,Q83MF9,Q879A1,Q87EA7,Q87SG6,Q87WY3,Q88N78,Q88V80,Q899G5,Q89AQ2,Q89FU5,Q8A256,Q8CSX6,Q8D2Z4,Q8DEK8,Q8DMN8,Q8DQM2,Q8DVE3,Q8E186,Q8E6P1,Q8E9P6,Q8ER50,Q8F7V4,Q8FL65,Q8FNT8,Q8FZP2,Q8G4Q6,Q8K9T2,Q8KGD2,Q8NX35,Q8P063,Q8P775,Q8PII9,Q8R9G4,Q8RDQ1,Q8UDM6,Q8X9Y9,Q8XHM4,Q8XVI5,Q8Y5M1,Q8YI68,Q8YPS9,Q8Z9H0,Q8ZIF1,Q8ZRU4,Q929Y1,Q92I60,Q97EB9,Q97RU8,Q98KB1,Q9A597,Q9CF91,Q9CPB0,Q9F1N2,Q9HVZ9,Q9JSZ5,Q9K0Y4,Q9K9S8,Q9KPG5,Q9PEB0,Q9PI73,Q9PLG5,Q9RRJ4,Q9S2W9,Q9WY76,Q9Z705,Q9ZDC2,Q9ZLY0" charOffset="38-42" type="protein" text="MurD"/>
            <entity id="DS.d797.s1.e2" origId="23327" charOffset="203-214" type="compound" text="D-glutamate"/>
            <pair e1="DS.d797.s1.e2" e2="DS.d797.s1.e0" id="DS.d797.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d798" origId="18704946">
        <sentence id="DS.d798.s0" origId="18704946-1065" text="Although the overall amino acid identity between SERTs and the LeuT(Aa) is only 17%, it increases to above 50% in the first shell of the putative 5-HT binding site, allowing de novo computational docking of tryptamine derivatives in atomic detail.">
            <entity id="DS.d798.s0.e0" origId="P31645,Q9XT49" charOffset="49-54" type="protein" text="SERTs"/>
            <entity id="DS.d798.s0.e1" origId="1150" charOffset="207-217" type="compound" text="tryptamine"/>
            <pair e1="DS.d798.s0.e1" e2="DS.d798.s0.e0" id="DS.d798.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d799" origId="18704953">
        <sentence id="DS.d799.s0" origId="18704953-1278" text="Mal-sCT, prepared by conjugating sCT via thio-ether bonds with aqueous-soluble palmitic acid derivative at Cys 1 and Cys 7, was reacted with mPEG-succinimide (mPEG-Suc, 5 kDa).">
            <entity id="DS.d799.s0.e0" origId="P56862" charOffset="4-7" type="protein" text="sCT"/>
            <entity id="DS.d799.s0.e1" origId="P56862" charOffset="33-36" type="protein" text="sCT"/>
            <entity id="DS.d799.s0.e3" origId="985" charOffset="79-92" type="compound" text="palmitic acid"/>
            <entity id="DS.d799.s0.e4" origId="8019" charOffset="141-145" type="compound" text="mPEG"/>
            <entity id="DS.d799.s0.e5" origId="11439" charOffset="146-157" type="compound" text="succinimide"/>
            <entity id="DS.d799.s0.e6" origId="8019" charOffset="159-163" type="compound" text="mPEG"/>
            <pair e1="DS.d799.s0.e5" e2="DS.d799.s0.e0" id="DS.d799.s0.i0" interaction="True"/>
            <pair e1="DS.d799.s0.e3" e2="DS.d799.s0.e0" id="DS.d799.s0.i1" interaction="True"/>
            <pair e1="DS.d799.s0.e4" e2="DS.d799.s0.e0" id="DS.d799.s0.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d800" origId="18704955">
        <sentence id="DS.d800.s0" origId="18704955-1137" text="Our findings suggest that GLP-1 substituted with a PEG of an appropriate Mw at Lys (34) could be used as a promising type 2 anti-diabetic agent to timely control postprandial glucose levels.">
            <entity id="DS.d800.s0.e0" origId="O12956,P01272,P01273,P01274,P01275,P05110,P06883,P22890,P29794,P55095,P68259,Q06605,Q8MJ25" charOffset="26-31" type="protein" text="GLP-1"/>
            <entity id="DS.d800.s0.e1" origId="206,5793,64689,79025" charOffset="175-182" type="compound" text="glucose"/>
            <pair e1="DS.d800.s0.e1" e2="DS.d800.s0.e0" id="DS.d800.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d801" origId="18706130">
        <sentence id="DS.d801.s0" origId="18706130-1404" text="The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats.">
            <entity id="DS.d801.s0.e0" origId="82148" charOffset="19-30" type="compound" text="agomelatine"/>
            <entity id="DS.d801.s0.e1" origId="P13591,P13592,P31836" charOffset="158-162" type="protein" text="NCAM"/>
            <pair e1="DS.d801.s0.e0" e2="DS.d801.s0.e1" id="DS.d801.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d802" origId="18706695">
        <sentence id="DS.d802.s0" origId="18706695-1298" text="Phosphatase activity was also inhibited for all the soils treated with triclosan (from 0.1 to 50mg/kg dry soil), but a declining inhibition was observed after 2 days of incubation.">
            <entity id="DS.d802.s0.e0" origId="P06961,P45269,Q57JQ5,Q5E2K7,Q5F8K9,Q5P3T0,Q5PC82,Q5WT58,Q5X1E5,Q5ZRX9,Q60CQ4,Q62EU1,Q63YC3,Q65Q41,Q665U9,Q6D160,Q6FA38,Q6LV05,Q7M7K5,Q7MAZ9,Q7MBF4,Q821A6,Q82U82,Q87DS9,Q87SK9,Q88A53,Q88QU2,Q8CWL6,Q8CXX6,Q8P5D4,Q8PPG9,Q8XBL4,Q8Y395,Q8Z3M9,Q8ZI64,Q8ZLY4,Q9CP21,Q9I5V3,Q9JUB2,Q9JZ88,Q9KPC6,Q9L7A3,Q9PDL7" charOffset="0-11" type="protein" text="Phosphatase"/>
            <entity id="DS.d802.s0.e1" origId="5564" charOffset="71-80" type="compound" text="triclosan"/>
            <pair e1="DS.d802.s0.e1" e2="DS.d802.s0.e0" id="DS.d802.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d804" origId="18706940">
        <sentence id="DS.d804.s0" origId="18706940-826" text="The magnitude of autophagosome formation is tightly regulated by intracellular and extracellular amino acid concentrations and ATP levels via signaling pathways that include the nutrient sensing kinase TOR.">
            <entity id="DS.d804.s0.e0" origId="5957" charOffset="127-130" type="compound" text="ATP"/>
            <entity id="DS.d804.s0.e1" origId="P51450" charOffset="202-205" type="protein" text="TOR"/>
            <pair e1="DS.d804.s0.e0" e2="DS.d804.s0.e1" id="DS.d804.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d805" origId="18707755">
        <sentence id="DS.d805.s0" origId="18707755-1088" text="Normoglycemic (4.72 mmol/L), moderate (11.1 mmol/L) or high grade (16.7 mmol/L) glucose clamps were maintained for 6 hours by infusion of glucose, insulin and somatostatin.">
            <entity id="DS.d805.s0.e0" origId="2724488,10954115" charOffset="77-87" type="compound" text="L) glucose"/>
            <entity id="DS.d805.s0.e1" origId="206,5793,64689,79025" charOffset="80-87" type="compound" text="glucose"/>
            <entity id="DS.d805.s0.e2" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="147-154" type="protein" text="insulin"/>
            <entity id="DS.d805.s0.e3" origId="16129681,16129706" charOffset="159-171" type="compound" text="somatostatin"/>
            <pair e1="DS.d805.s0.e0" e2="DS.d805.s0.e2" id="DS.d805.s0.i0" interaction="False"/>
            <pair e1="DS.d805.s0.e1" e2="DS.d805.s0.e2" id="DS.d805.s0.i1" interaction="False"/>
            <pair e1="DS.d805.s0.e3" e2="DS.d805.s0.e2" id="DS.d805.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d806" origId="18708066">
        <sentence id="DS.d806.s0" origId="18708066-1324" text="or=6 ng/ml) was associated with increased expression of mrp-1 and pgp-1 and decreased glutathione, while higher level resistance (10 ng/ml) was primarily associated with the increased expression of P-glycoproteins.">
            <entity id="DS.d806.s0.e0" origId="O24999,O35379,O66946,P0AF08,P0AF09,P28667,P32653,P45135,P50863,P53381,P53382,P53383,P65441,P65442,Q92JA4,Q9RVM9,Q9ZE27,Q9ZMM5" charOffset="56-59" type="protein" text="mrp"/>
            <entity id="DS.d806.s0.e1" origId="P34712" charOffset="66-71" type="protein" text="pgp-1"/>
            <entity id="DS.d806.s0.e2" origId="124886" charOffset="86-97" type="compound" text="glutathione"/>
            <entity id="DS.d806.s0.e3" origId="P08163" charOffset="200-213" type="protein" text="glycoproteins"/>
            <pair e1="DS.d806.s0.e2" e2="DS.d806.s0.e1" id="DS.d806.s0.i0" interaction="False"/>
            <pair e1="DS.d806.s0.e2" e2="DS.d806.s0.e3" id="DS.d806.s0.i1" interaction="False"/>
            <pair e1="DS.d806.s0.e2" e2="DS.d806.s0.e0" id="DS.d806.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d807" origId="18708157">
        <sentence id="DS.d807.s0" origId="18708157-1383" text="Co(2+) also induces the release of the pro-apoptotic factors, cytochrome c and AIF.">
            <entity id="DS.d807.s0.e0" origId="104729" charOffset="0-4" type="compound" text="Co(2"/>
            <entity id="DS.d807.s0.e1" origId="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3" charOffset="62-74" type="protein" text="cytochrome c"/>
            <entity id="DS.d807.s0.e2" origId="O95831" charOffset="79-82" type="protein" text="AIF"/>
            <pair e1="DS.d807.s0.e0" e2="DS.d807.s0.e1" id="DS.d807.s0.i0" interaction="True"/>
            <pair e1="DS.d807.s0.e0" e2="DS.d807.s0.e2" id="DS.d807.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d807.s1" origId="18708157-1384" text="Incubation of rat hepatocyte primary cultures with Co(2+) results in apoptosis induction with caspase activation and increased level of expression of HIF-1alpha.">
            <entity id="DS.d807.s1.e0" origId="104729" charOffset="51-55" type="compound" text="Co(2"/>
            <entity id="DS.d807.s1.e1" origId="O35800,Q0PGG7,Q16665,Q309Z6,Q61221,Q98SW2,Q9I8A9,Q9XTA5,Q9YIB9" charOffset="150-160" type="protein" text="HIF-1alpha"/>
            <pair e1="DS.d807.s1.e0" e2="DS.d807.s1.e1" id="DS.d807.s1.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d808" origId="18708158">
        <sentence id="DS.d808.s0" origId="18708158-1385" text="Roscovitine reduced amounts of the caspase inhibitor XIAP, and API-2 increased amounts of the BH3-only protein Bim.">
            <entity id="DS.d808.s0.e0" origId="160355" charOffset="0-11" type="compound" text="Roscovitine"/>
            <entity id="DS.d808.s0.e1" origId="O54918,O88498" charOffset="111-114" type="protein" text="Bim"/>
            <pair e1="DS.d808.s0.e0" e2="DS.d808.s0.e1" id="DS.d808.s0.i0" interaction="False"/>
        </sentence>
        <sentence id="DS.d808.s1" origId="18708158-1386" text="Bax accumulated in mitochondria in response to API-2, whereas release of cytochrome c from mitochondria required both API-2 and roscovitine.">
            <entity id="DS.d808.s1.e0" origId="P27297,Q07813,Q63690" charOffset="0-3" type="protein" text="Bax"/>
            <entity id="DS.d808.s1.e1" origId="O07091,O13393,O22642,O93863,P00002,P00003,P00004,P00007,P00008,P00011,P00012,P00013,P00014,P00017,P00018,P00019,P00020,P00021,P00022,P00024,P00025,P00027,P00028,P00029,P00030,P00031,P00032,P00035,P00036,P00037,P00038,P00039,P00040,P00041,P00042,P00043,P00046,P00047,P00048,P00049,P00051,P00052,P00053,P00054,P00055,P00056,P00057,P00058,P00059,P00060,P00061,P00062,P00063,P00064,P00065,P00066,P00067,P00068,P00069,P00070,P00071,P00072,P00073,P00074,P00075,P00076,P00077,P00078,P00079,P12831,P15451,P18822,P19681,P19974,P21665,P22342,P25400,P29380,P32556,P38091,P53698,P56205,P59218,P62772,P62773,P62894,P62895,P62896,P67881,P67882,P68096,P68097,P68098,P68099,P68100,P68517,P68518,P68519,P81280,P81459,P99998,P99999,Q41346,Q4HVX7,Q52V08,Q52V09,Q52V10,Q5RFH4,Q640U4,Q6C9Q0,Q6IQM2,Q6Q4H8,Q6QLW4,Q6WUX8,Q753F4,Q7YR71,Q96VP3" charOffset="73-85" type="protein" text="cytochrome c"/>
            <entity id="DS.d808.s1.e2" origId="160355" charOffset="128-139" type="compound" text="roscovitine"/>
            <pair e1="DS.d808.s1.e2" e2="DS.d808.s1.e0" id="DS.d808.s1.i0" interaction="False"/>
            <pair e1="DS.d808.s1.e2" e2="DS.d808.s1.e1" id="DS.d808.s1.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d808.s2" origId="18708158-1387" text="We suggest that roscovitine elicits events that activate Bax once it translocates to mitochondria and that inactivation of cdk9 signals these events and the down-regulation of XIAP.">
            <entity id="DS.d808.s2.e0" origId="160355" charOffset="16-27" type="compound" text="roscovitine"/>
            <entity id="DS.d808.s2.e1" origId="P27297,Q07813,Q63690" charOffset="57-60" type="protein" text="Bax"/>
            <entity id="DS.d808.s2.e2" origId="Q641Z4,Q6GLD8,Q96WV9,Q99J95" charOffset="123-127" type="protein" text="cdk9"/>
            <pair e1="DS.d808.s2.e0" e2="DS.d808.s2.e2" id="DS.d808.s2.i0" interaction="True"/>
            <pair e1="DS.d808.s2.e0" e2="DS.d808.s2.e1" id="DS.d808.s2.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d809" origId="18708191">
        <sentence id="DS.d809.s0" origId="18708191-1226" text="Intravenous glutamine enhances COX-2 activity giving cardioprotection.">
            <entity id="DS.d809.s0.e0" origId="738,5961" charOffset="12-21" type="compound" text="glutamine"/>
            <entity id="DS.d809.s0.e1" origId="O02768,O19183,O62698,O62725,P27607,P35354,P35355,P70682,P79208,Q05769" charOffset="31-36" type="protein" text="COX-2"/>
            <pair e1="DS.d809.s0.e0" e2="DS.d809.s0.e1" id="DS.d809.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d809.s1" origId="18708191-1227" text="We investigated whether acute intravenous glutamine, through an effect on cyclooxygenase (COX)-2 and heat shock protein (HSP) 72, might induce preconditioning.">
            <entity id="DS.d809.s1.e0" origId="738,5961" charOffset="42-51" type="compound" text="glutamine"/>
            <entity id="DS.d809.s1.e1" origId="P11353,P36551,P36552,Q9UTE2,Q9V3D2" charOffset="90-93" type="protein" text="COX"/>
            <entity id="DS.d809.s1.e2" origId="P32590" charOffset="121-124" type="protein" text="HSP"/>
            <pair e1="DS.d809.s1.e0" e2="DS.d809.s1.e2" id="DS.d809.s1.i0" interaction="True"/>
            <pair e1="DS.d809.s1.e0" e2="DS.d809.s1.e1" id="DS.d809.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d810" origId="18708284">
        <sentence id="DS.d810.s0" origId="18708284-1027" text="Islets from taurine-supplemented mice had: (i) significantly higher insulin content, (ii) increased insulin secretion at stimulatory glucose concentrations, (iii) significantly displaced the dose-response curve for glucose-induced insulin release to the left, (iv) increased glucose metabolism at 5.6 and 11.1-mmol/L concentrations; (v) slowed cytosolic Ca2+ concentration ((Ca2+)i) oscillations in response to stimulatory glucose concentrations; (vi) increased insulin, sulfonylurea receptor-1, glucokinase, Glut-2, proconvertase and pancreas duodenum homeobox-1 (PDX-1) gene expression and (vii) increased PDX-1 expression in the nucleus.">
            <entity id="DS.d810.s0.e0" origId="1123" charOffset="12-19" type="compound" text="taurine"/>
            <entity id="DS.d810.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="68-75" type="protein" text="insulin"/>
            <entity id="DS.d810.s0.e2" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="100-107" type="protein" text="insulin"/>
            <entity id="DS.d810.s0.e3" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="100-107" type="protein" text="insulin"/>
            <entity id="DS.d810.s0.e4" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="100-107" type="protein" text="insulin"/>
            <entity id="DS.d810.s0.e5" origId="Q09427,Q09428,Q09429" charOffset="471-494" type="protein" text="sulfonylurea receptor-1"/>
            <entity id="DS.d810.s0.e6" origId="O25731,P0A4E1,P0A4E2,P0A6V8,P0A6V9,P17712,P21908,P35557,P52792,P54495,P58616,P58617,P58618,P58619,P64253,P64254,P82680,Q55855,Q56198,Q59171,Q668N7,Q6D7C4,Q7N6Y0,Q83K86,Q87EG6,Q8FFD4,Q8FV09,Q8P8U7,Q8PKU2,Q8UIV7,Q8YDC6,Q92407,Q92T27,Q93IM5,Q98DM2,Q9A6N3,Q9HZ46,Q9KCZ4,Q9PEG4,Q9ZKB0" charOffset="496-507" type="protein" text="glucokinase"/>
            <entity id="DS.d810.s0.e7" origId="P12336,P14246" charOffset="509-515" type="protein" text="Glut-2"/>
            <entity id="DS.d810.s0.e8" origId="P52945,P52946" charOffset="535-563" type="protein" text="pancreas duodenum homeobox-1"/>
            <entity id="DS.d810.s0.e9" origId="P52945" charOffset="565-570" type="protein" text="PDX-1"/>
            <entity id="DS.d810.s0.e10" origId="P52945" charOffset="608-613" type="protein" text="PDX-1"/>
            <pair e1="DS.d810.s0.e0" e2="DS.d810.s0.e1" id="DS.d810.s0.i0" interaction="True"/>
            <pair e1="DS.d810.s0.e0" e2="DS.d810.s0.e7" id="DS.d810.s0.i1" interaction="True"/>
            <pair e1="DS.d810.s0.e0" e2="DS.d810.s0.e8" id="DS.d810.s0.i2" interaction="True"/>
            <pair e1="DS.d810.s0.e0" e2="DS.d810.s0.e6" id="DS.d810.s0.i3" interaction="True"/>
            <pair e1="DS.d810.s0.e0" e2="DS.d810.s0.e9" id="DS.d810.s0.i4" interaction="True"/>
            <pair e1="DS.d810.s0.e0" e2="DS.d810.s0.e5" id="DS.d810.s0.i5" interaction="True"/>
        </sentence>
        <sentence id="DS.d810.s1" origId="18708284-1028" text="Moreover, taurine supplementation significantly increased both basal and insulin stimulated tyrosine phosphorylation of the insulin receptor in skeletal muscle and liver tissues.">
            <entity id="DS.d810.s1.e0" origId="1123" charOffset="10-17" type="compound" text="taurine"/>
            <entity id="DS.d810.s1.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="73-80" type="protein" text="insulin"/>
            <entity id="DS.d810.s1.e2" origId="1153,6057,5460803" charOffset="92-100" type="compound" text="tyrosine"/>
            <entity id="DS.d810.s1.e3" origId="Q28516" charOffset="124-140" type="protein" text="insulin receptor"/>
            <pair e1="DS.d810.s1.e0" e2="DS.d810.s1.e1" id="DS.d810.s1.i0" interaction="False"/>
            <pair e1="DS.d810.s1.e0" e2="DS.d810.s1.e3" id="DS.d810.s1.i1" interaction="True"/>
            <pair e1="DS.d810.s1.e2" e2="DS.d810.s1.e3" id="DS.d810.s1.i2" interaction="True"/>
            <pair e1="DS.d810.s1.e2" e2="DS.d810.s1.e1" id="DS.d810.s1.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d810.s2" origId="18708284-1029" text="These results indicate that taurine controls glucose homeostasis by regulating the expression of genes required for glucose-stimulated insulin secretion.">
            <entity id="DS.d810.s2.e0" origId="1123" charOffset="28-35" type="compound" text="taurine"/>
            <entity id="DS.d810.s2.e1" origId="206,5793,64689,79025" charOffset="45-52" type="compound" text="glucose"/>
            <entity id="DS.d810.s2.e2" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="135-142" type="protein" text="insulin"/>
            <pair e1="DS.d810.s2.e0" e2="DS.d810.s2.e2" id="DS.d810.s2.i0" interaction="True"/>
            <pair e1="DS.d810.s2.e1" e2="DS.d810.s2.e2" id="DS.d810.s2.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d810.s3" origId="18708284-1030" text="In addition, taurine enhances peripheral insulin sensitivity.">
            <entity id="DS.d810.s3.e0" origId="1123" charOffset="13-20" type="compound" text="taurine"/>
            <entity id="DS.d810.s3.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="41-48" type="protein" text="insulin"/>
            <pair e1="DS.d810.s3.e0" e2="DS.d810.s3.e1" id="DS.d810.s3.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d811" origId="18708285">
        <sentence id="DS.d811.s0" origId="18708285-1040" text="Furthermore, treatment of lycopene and EPA also synergistically blocked the activation of downstream mTOR molecule.">
            <entity id="DS.d811.s0.e0" origId="446925" charOffset="26-34" type="compound" text="lycopene"/>
            <entity id="DS.d811.s0.e1" origId="P42345,P42346,Q9JLN9" charOffset="101-105" type="protein" text="mTOR"/>
            <pair e1="DS.d811.s0.e0" e2="DS.d811.s0.e1" id="DS.d811.s0.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d811.s1" origId="18708285-1041" text="Immunocytochemical staining results revealed that lycopene and EPA could also up-regulate the expression of apoptotic proteins such as Bax and Fas ligand to suppress cell survival.">
            <entity id="DS.d811.s1.e0" origId="446925" charOffset="50-58" type="compound" text="lycopene"/>
            <entity id="DS.d811.s1.e1" origId="P27297,Q07813,Q63690" charOffset="135-138" type="protein" text="Bax"/>
            <entity id="DS.d811.s1.e2" origId="P36940,P41047,P48023,P63306,P63307,P63308,Q861W5,Q9BDN1,Q9BEA8" charOffset="143-153" type="protein" text="Fas ligand"/>
            <pair e1="DS.d811.s1.e0" e2="DS.d811.s1.e1" id="DS.d811.s1.i0" interaction="True"/>
            <pair e1="DS.d811.s1.e0" e2="DS.d811.s1.e2" id="DS.d811.s1.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d812" origId="18709446">
        <sentence id="DS.d812.s0" origId="18709446-802" text="Amino acids (alanine, aspartic acid, glutamic acid) and glucose oxidase (GOx) were adsorbed on CNF and the results were compared with those obtained when activated carbon (AC) was used as support.">
            <entity id="DS.d812.s0.e0" origId="602,4580,5950,71080" charOffset="13-20" type="compound" text="alanine"/>
            <entity id="DS.d812.s0.e1" origId="424,5960,83887" charOffset="22-35" type="compound" text="aspartic acid"/>
            <entity id="DS.d812.s0.e2" origId="P81156" charOffset="56-71" type="protein" text="glucose oxidase"/>
            <entity id="DS.d812.s0.e3" origId="297" charOffset="154-170" type="compound" text="activated carbon"/>
            <pair e1="DS.d812.s0.e0" e2="DS.d812.s0.e2" id="DS.d812.s0.i0" interaction="False"/>
            <pair e1="DS.d812.s0.e3" e2="DS.d812.s0.e2" id="DS.d812.s0.i1" interaction="False"/>
            <pair e1="DS.d812.s0.e1" e2="DS.d812.s0.e2" id="DS.d812.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d814" origId="18709646">
        <sentence id="DS.d814.s0" origId="18709646-694" text="The NSCs and neuroblasts had epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor alpha (PDGFRalpha) expressed on the ciliary apparatus and were the only cell types incorporating the proliferation marker BrdU.">
            <entity id="DS.d814.s0.e0" origId="P55245" charOffset="29-61" type="protein" text="epidermal growth factor receptor"/>
            <entity id="DS.d814.s0.e1" origId="P00533,P13387,P55245" charOffset="63-67" type="protein" text="EGFR"/>
            <entity id="DS.d814.s0.e2" origId="P16234,P20786,P26618,P26619,Q8AXC7,Q9DE49,Q9PUF6" charOffset="120-130" type="protein" text="PDGFRalpha"/>
            <entity id="DS.d814.s0.e3" origId="6035" charOffset="235-239" type="compound" text="BrdU"/>
            <pair e1="DS.d814.s0.e3" e2="DS.d814.s0.e2" id="DS.d814.s0.i0" interaction="False"/>
            <pair e1="DS.d814.s0.e3" e2="DS.d814.s0.e0" id="DS.d814.s0.i1" interaction="False"/>
            <pair e1="DS.d814.s0.e3" e2="DS.d814.s0.e1" id="DS.d814.s0.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d814.s1" origId="18709646-695" text="Ependymal and displaced ependymal cells also expressed EGFR and PDGFRalpha on their cilia but did not incorporate BrdU.">
            <entity id="DS.d814.s1.e0" origId="P00533,P13387,P55245" charOffset="55-59" type="protein" text="EGFR"/>
            <entity id="DS.d814.s1.e1" origId="P16234,P20786,P26618,P26619,Q8AXC7,Q9DE49,Q9PUF6" charOffset="64-74" type="protein" text="PDGFRalpha"/>
            <entity id="DS.d814.s1.e2" origId="6035" charOffset="114-118" type="compound" text="BrdU"/>
            <pair e1="DS.d814.s1.e2" e2="DS.d814.s1.e1" id="DS.d814.s1.i0" interaction="False"/>
            <pair e1="DS.d814.s1.e2" e2="DS.d814.s1.e0" id="DS.d814.s1.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d815" origId="18709647">
        <sentence id="DS.d815.s0" origId="18709647-968" text="Both 17alpha- and 17beta-estradiol elicited rapid phosphorylation of p42/44MAPK, Akt, and GSK-3beta within 8 min.">
            <entity id="DS.d815.s0.e0" origId="5757" charOffset="18-34" type="compound" text="17beta-estradiol"/>
            <entity id="DS.d815.s0.e1" origId="P46672,Q27272,Q8NFH3,Q9SB81" charOffset="69-72" type="protein" text="p42"/>
            <entity id="DS.d815.s0.e2" origId="P31750,Q8INB9" charOffset="81-84" type="protein" text="Akt"/>
            <entity id="DS.d815.s0.e3" origId="P18266,P49841,Q5YJC2,Q9WV60" charOffset="90-99" type="protein" text="GSK-3beta"/>
            <pair e1="DS.d815.s0.e0" e2="DS.d815.s0.e2" id="DS.d815.s0.i0" interaction="True"/>
            <pair e1="DS.d815.s0.e0" e2="DS.d815.s0.e3" id="DS.d815.s0.i1" interaction="True"/>
            <pair e1="DS.d815.s0.e0" e2="DS.d815.s0.e1" id="DS.d815.s0.i2" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d816" origId="18709649">
        <sentence id="DS.d816.s0" origId="18709649-718" text="Whereas Zn2+-dependent upregulation of metallothionein may help to counteract excessive astrocyte swelling and production of reactive oxygen and nitrogen oxide species, stimulation of PBR expression may augment HE development.">
            <entity id="DS.d816.s0.e0" origId="32051" charOffset="8-11" type="compound" text="Zn2"/>
            <entity id="DS.d816.s0.e1" origId="O02033,O13257,O18842,O42152,O93571,P02807,P04358,P07216,P08002,P23038,P25127,P25128,P30331,P30565,P51902,P52723,P52725,P52726,P52728,P55945,P55946,P55948,P55951,P55952,P55953,P68494,P68495,P68497,P68498,P68499,P80367,P80593,P84865,Q05890,Q6J1T3,Q6S4N8,Q6XUW5,Q708T3,Q7ZZP9,Q800D3,Q8UVY1,Q94550,Q9IB50,Q9U568" charOffset="39-54" type="protein" text="metallothionein"/>
            <entity id="DS.d816.s0.e2" origId="977" charOffset="134-140" type="compound" text="oxygen"/>
            <entity id="DS.d816.s0.e3" origId="945,948,25352,61526,160954,3609161" charOffset="145-159" type="compound" text="nitrogen oxide"/>
            <entity id="DS.d816.s0.e4" origId="P16257,P30535,P30536,P50637" charOffset="184-187" type="protein" text="PBR"/>
            <pair e1="DS.d816.s0.e3" e2="DS.d816.s0.e1" id="DS.d816.s0.i0" interaction="True"/>
            <pair e1="DS.d816.s0.e3" e2="DS.d816.s0.e4" id="DS.d816.s0.i1" interaction="False"/>
            <pair e1="DS.d816.s0.e0" e2="DS.d816.s0.e4" id="DS.d816.s0.i2" interaction="False"/>
            <pair e1="DS.d816.s0.e2" e2="DS.d816.s0.e1" id="DS.d816.s0.i3" interaction="True"/>
            <pair e1="DS.d816.s0.e2" e2="DS.d816.s0.e4" id="DS.d816.s0.i4" interaction="False"/>
            <pair e1="DS.d816.s0.e0" e2="DS.d816.s0.e1" id="DS.d816.s0.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d817" origId="18709661">
        <sentence id="DS.d817.s0" origId="18709661-989" text="Accordingly, the TLR3 agonist poly(I:C) (PIC) induced higher release of IFN-beta in primary and purified astroglia than in microglia.">
            <entity id="DS.d817.s0.e0" origId="32744,213546,274740" charOffset="30-38" type="compound" text="poly(I:C"/>
            <entity id="DS.d817.s0.e1" origId="1854" charOffset="41-44" type="compound" text="PIC"/>
            <entity id="DS.d817.s0.e2" origId="O77812,P01574,P01575,P05012,P70499,Q6XZW6,Q9N2J0" charOffset="72-80" type="protein" text="IFN-beta"/>
            <pair e1="DS.d817.s0.e0" e2="DS.d817.s0.e2" id="DS.d817.s0.i0" interaction="True"/>
            <pair e1="DS.d817.s0.e1" e2="DS.d817.s0.e2" id="DS.d817.s0.i1" interaction="True"/>
        </sentence>
        <sentence id="DS.d817.s1" origId="18709661-990" text="As siRNA, PIC induced IP-10, Stat1, VCAM-1, and Cox-2 and increased TLR3 mRNA expression.">
            <entity id="DS.d817.s1.e0" origId="1854" charOffset="10-13" type="compound" text="PIC"/>
            <entity id="DS.d817.s1.e1" origId="P02778,P17515,P48973" charOffset="22-27" type="protein" text="IP-10"/>
            <entity id="DS.d817.s1.e2" origId="P42225" charOffset="29-34" type="protein" text="Stat1"/>
            <entity id="DS.d817.s1.e3" origId="P19320,P29533,P29534,Q28260" charOffset="36-42" type="protein" text="VCAM-1"/>
            <entity id="DS.d817.s1.e4" origId="P00411,P24894,P35355,Q05769,Q8HEC3,Q8SEM9" charOffset="48-53" type="protein" text="Cox-2"/>
            <entity id="DS.d817.s1.e5" origId="O15455,Q0PV50,Q5TJ59" charOffset="68-72" type="protein" text="TLR3"/>
            <pair e1="DS.d817.s1.e0" e2="DS.d817.s1.e1" id="DS.d817.s1.i0" interaction="True"/>
            <pair e1="DS.d817.s1.e0" e2="DS.d817.s1.e3" id="DS.d817.s1.i1" interaction="True"/>
            <pair e1="DS.d817.s1.e0" e2="DS.d817.s1.e2" id="DS.d817.s1.i2" interaction="True"/>
            <pair e1="DS.d817.s1.e0" e2="DS.d817.s1.e5" id="DS.d817.s1.i3" interaction="True"/>
            <pair e1="DS.d817.s1.e0" e2="DS.d817.s1.e4" id="DS.d817.s1.i4" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d818" origId="18710402">
        <sentence id="DS.d818.s0" origId="18710402-1097" text="Intracellular concentrations of Ca(2+) modulate the strength of signal and alter the outcomes of cytotoxic T-lymphocyte antigen-4 (CD152)-CD80/CD86 interactions in CD4 (+) T lymphocytes.">
            <entity id="DS.d818.s0.e0" origId="271" charOffset="32-36" type="compound" text="Ca(2"/>
            <entity id="DS.d818.s0.e1" origId="P31522,Q26721,Q56982" charOffset="120-129" type="protein" text="antigen-4"/>
            <entity id="DS.d818.s0.e2" origId="P16410" charOffset="131-136" type="protein" text="CD152"/>
            <entity id="DS.d818.s0.e3" origId="P33681,P42070" charOffset="138-142" type="protein" text="CD80"/>
            <entity id="DS.d818.s0.e4" origId="P42071,P42081" charOffset="143-147" type="protein" text="CD86"/>
            <pair e1="DS.d818.s0.e0" e2="DS.d818.s0.e3" id="DS.d818.s0.i0" interaction="True"/>
            <pair e1="DS.d818.s0.e0" e2="DS.d818.s0.e4" id="DS.d818.s0.i1" interaction="True"/>
            <pair e1="DS.d818.s0.e0" e2="DS.d818.s0.e1" id="DS.d818.s0.i2" interaction="True"/>
            <pair e1="DS.d818.s0.e0" e2="DS.d818.s0.e2" id="DS.d818.s0.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d818.s1" origId="18710402-1099" text="During activation with PMA and low amounts of I, intracellular concentrations of calcium ((Ca(2+))(i)) were greatly reduced upon CTLA-4-CD80/CD86 blockade.">
            <entity id="DS.d818.s1.e0" origId="27924,122634,22833501" charOffset="23-26" type="compound" text="PMA"/>
            <entity id="DS.d818.s1.e1" origId="271" charOffset="91-95" type="compound" text="Ca(2"/>
            <entity id="DS.d818.s1.e2" origId="P09793,P16410,P42072,Q9MYX7,Q9XSI1" charOffset="129-135" type="protein" text="CTLA-4"/>
            <entity id="DS.d818.s1.e3" origId="P33681,P42070" charOffset="136-140" type="protein" text="CD80"/>
            <entity id="DS.d818.s1.e4" origId="P42071,P42081" charOffset="141-145" type="protein" text="CD86"/>
            <pair e1="DS.d818.s1.e0" e2="DS.d818.s1.e3" id="DS.d818.s1.i0" interaction="True"/>
            <pair e1="DS.d818.s1.e1" e2="DS.d818.s1.e4" id="DS.d818.s1.i1" interaction="True"/>
            <pair e1="DS.d818.s1.e0" e2="DS.d818.s1.e4" id="DS.d818.s1.i2" interaction="True"/>
            <pair e1="DS.d818.s1.e0" e2="DS.d818.s1.e2" id="DS.d818.s1.i3" interaction="True"/>
            <pair e1="DS.d818.s1.e1" e2="DS.d818.s1.e3" id="DS.d818.s1.i4" interaction="True"/>
            <pair e1="DS.d818.s1.e1" e2="DS.d818.s1.e2" id="DS.d818.s1.i5" interaction="True"/>
        </sentence>
        <sentence id="DS.d818.s2" origId="18710402-1100" text="Further experiments demonstrated that CTLA-4-CD80/CD86 interactions reduced cell cycling upon activation with PMA and high amounts of I or TG (high SOS) but the opposite occurred with PMA and low amounts of I or TG (low SOS).">
            <entity id="DS.d818.s2.e0" origId="P09793,P16410,P42072,Q9MYX7,Q9XSI1" charOffset="38-44" type="protein" text="CTLA-4"/>
            <entity id="DS.d818.s2.e1" origId="P33681,P42070" charOffset="45-49" type="protein" text="CD80"/>
            <entity id="DS.d818.s2.e2" origId="P42071,P42081" charOffset="50-54" type="protein" text="CD86"/>
            <entity id="DS.d818.s2.e3" origId="27924,122634,22833501" charOffset="110-113" type="compound" text="PMA"/>
            <entity id="DS.d818.s2.e4" origId="8885" charOffset="148-151" type="compound" text="SOS"/>
            <entity id="DS.d818.s2.e5" origId="27924,122634,22833501" charOffset="184-187" type="compound" text="PMA"/>
            <entity id="DS.d818.s2.e6" origId="8885" charOffset="220-223" type="compound" text="SOS"/>
            <pair e1="DS.d818.s2.e3" e2="DS.d818.s2.e1" id="DS.d818.s2.i0" interaction="True"/>
            <pair e1="DS.d818.s2.e4" e2="DS.d818.s2.e1" id="DS.d818.s2.i1" interaction="True"/>
            <pair e1="DS.d818.s2.e4" e2="DS.d818.s2.e0" id="DS.d818.s2.i2" interaction="True"/>
            <pair e1="DS.d818.s2.e3" e2="DS.d818.s2.e2" id="DS.d818.s2.i3" interaction="True"/>
            <pair e1="DS.d818.s2.e3" e2="DS.d818.s2.e0" id="DS.d818.s2.i4" interaction="True"/>
            <pair e1="DS.d818.s2.e4" e2="DS.d818.s2.e2" id="DS.d818.s2.i5" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d819" origId="18710604">
        <sentence id="DS.d819.s0" origId="18710604-62" text="FSO decreased fasting glucose by 20 % and liver weights by 37 % compared with those in the CLA group; it maintained circulating insulin, HOMA1-IR and HOMA1 for beta cell function at levels found in the control group.">
            <entity id="DS.d819.s0.e0" origId="5288258" charOffset="0-3" type="compound" text="FSO"/>
            <entity id="DS.d819.s0.e1" origId="206,5793,64689,79025" charOffset="22-29" type="compound" text="glucose"/>
            <entity id="DS.d819.s0.e2" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="128-135" type="protein" text="insulin"/>
            <pair e1="DS.d819.s0.e0" e2="DS.d819.s0.e2" id="DS.d819.s0.i0" interaction="True"/>
            <pair e1="DS.d819.s0.e1" e2="DS.d819.s0.e2" id="DS.d819.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d820" origId="18710606">
        <sentence id="DS.d820.s0" origId="18710606-240" text="Animal evidence indicates that green tea may modulate insulin sensitivity, with epigallocatechin-3-gallate (EGCG) proposed as a likely health-promoting component.">
            <entity id="DS.d820.s0.e0" origId="4630" charOffset="31-40" type="compound" text="green tea"/>
            <entity id="DS.d820.s0.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="54-61" type="protein" text="insulin"/>
            <entity id="DS.d820.s0.e2" origId="65064" charOffset="80-106" type="compound" text="epigallocatechin-3-gallate"/>
            <entity id="DS.d820.s0.e3" origId="65064" charOffset="108-112" type="compound" text="EGCG"/>
            <pair e1="DS.d820.s0.e3" e2="DS.d820.s0.e1" id="DS.d820.s0.i0" interaction="False"/>
            <pair e1="DS.d820.s0.e2" e2="DS.d820.s0.e1" id="DS.d820.s0.i1" interaction="False"/>
            <pair e1="DS.d820.s0.e0" e2="DS.d820.s0.e1" id="DS.d820.s0.i2" interaction="False"/>
        </sentence>
        <sentence id="DS.d820.s1" origId="18710606-241" text="The purpose of this study was to investigate the effect of dietary supplementation with EGCG on insulin resistance and associated metabolic risk factors in man.">
            <entity id="DS.d820.s1.e0" origId="65064" charOffset="88-92" type="compound" text="EGCG"/>
            <entity id="DS.d820.s1.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="96-103" type="protein" text="insulin"/>
            <pair e1="DS.d820.s1.e0" e2="DS.d820.s1.e1" id="DS.d820.s1.i0" interaction="True"/>
        </sentence>
        <sentence id="DS.d820.s2" origId="18710606-242" text="EGCG treatment had no effect on insulin sensitivity, insulin secretion or glucose tolerance but did reduce diastolic blood pressure (mean change: placebo-0.058 (se 0.75) mmHg; EGCG-2.68 (se 0.72) mmHg; P = 0.014).">
            <entity id="DS.d820.s2.e0" origId="65064" charOffset="0-4" type="compound" text="EGCG"/>
            <entity id="DS.d820.s2.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="32-39" type="protein" text="insulin"/>
            <entity id="DS.d820.s2.e2" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="53-60" type="protein" text="insulin"/>
            <entity id="DS.d820.s2.e3" origId="206,5793,64689,79025" charOffset="74-81" type="compound" text="glucose"/>
            <entity id="DS.d820.s2.e4" origId="65064" charOffset="176-180" type="compound" text="EGCG"/>
            <pair e1="DS.d820.s2.e0" e2="DS.d820.s2.e1" id="DS.d820.s2.i0" interaction="False"/>
            <pair e1="DS.d820.s2.e3" e2="DS.d820.s2.e1" id="DS.d820.s2.i1" interaction="False"/>
        </sentence>
        <sentence id="DS.d820.s3" origId="18710606-243" text="In conclusion, regular intake of EGCG had no effect on insulin resistance but did result in a modest reduction in diastolic blood pressure.">
            <entity id="DS.d820.s3.e0" origId="65064" charOffset="33-37" type="compound" text="EGCG"/>
            <entity id="DS.d820.s3.e1" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="55-62" type="protein" text="insulin"/>
            <pair e1="DS.d820.s3.e0" e2="DS.d820.s3.e1" id="DS.d820.s3.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d821" origId="18710702">
        <sentence id="DS.d821.s0" origId="18710702-125" text="We found that postovulatory administration of 1.5 mg of levonorgestrel to women with a subsequent or existing early pregnancy did not affect the immunohistochemical expressions of estrogen receptors (ER (alpha), ER (beta)), P receptors (PR(B), PR(A+B)), androgen receptor (AR), or proliferation index Ki67 in the first-trimester decidua and chorionic villi.">
            <entity id="DS.d821.s0.e0" origId="13109" charOffset="56-70" type="compound" text="levonorgestrel"/>
            <entity id="DS.d821.s0.e1" origId="O42132,P03372,P06211,P06212,P16058,P19785,P49884,P49885,P49886,P50240,P50241,P50242,P57717,P57753,P81559,Q29040,Q53AD2,Q91250,Q91424,Q9PVZ9,Q9QZJ5,Q9TV98,Q9YH33,Q9YHT3,Q9YHZ7" charOffset="180-198" type="protein" text="estrogen receptors"/>
            <entity id="DS.d821.s0.e2" origId="O97775,O97776,O97952,O97960,P10275,P15207,P19091,P49699,Q6QT55,Q7T1K4,Q8MIK0,Q9GKL7,Q9TT90" charOffset="254-271" type="protein" text="androgen receptor"/>
            <pair e1="DS.d821.s0.e0" e2="DS.d821.s0.e1" id="DS.d821.s0.i0" interaction="False"/>
            <pair e1="DS.d821.s0.e0" e2="DS.d821.s0.e2" id="DS.d821.s0.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d822" origId="18710819">
        <sentence id="DS.d822.s0" origId="18710819-1300" text="5-FU effect on HS cell viability was markedly reduced in hypoxic condition without an induction of chemoresistant related protein, P-glycoprotein.">
            <entity id="DS.d822.s0.e0" origId="3385" charOffset="0-4" type="compound" text="5-FU"/>
            <entity id="DS.d822.s0.e1" origId="P08163" charOffset="133-145" type="protein" text="glycoprotein"/>
            <pair e1="DS.d822.s0.e0" e2="DS.d822.s0.e1" id="DS.d822.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d823" origId="18710908">
        <sentence id="DS.d823.s0" origId="18710908-298" text="High-level toxin production occurred after detectable spore germination in all experiments except those with C. difficile PCR ribotype 027 and moxifloxacin, in which marked cytotoxin production preceded detectable germination, which coincided with isolate recovery on fluoroquinolone-containing medium.">
            <entity id="DS.d823.s0.e0" origId="152946" charOffset="143-155" type="compound" text="moxifloxacin"/>
            <entity id="DS.d823.s0.e1" origId="P07845,P81662" charOffset="173-182" type="protein" text="cytotoxin"/>
            <pair e1="DS.d823.s0.e0" e2="DS.d823.s0.e1" id="DS.d823.s0.i0" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d824" origId="18711728">
        <sentence id="DS.d824.s0" origId="18711728-143" text="Furthermore, Ngb overexpression reduced superoxide anion generation after H/R, whereas glutathione levels were significantly improved compared with WT controls.">
            <entity id="DS.d824.s0.e0" origId="Q90YJ2,Q99JA8,Q9ER97" charOffset="13-16" type="protein" text="Ngb"/>
            <entity id="DS.d824.s0.e1" origId="5359597" charOffset="40-50" type="compound" text="superoxide"/>
            <entity id="DS.d824.s0.e2" origId="124886" charOffset="87-98" type="compound" text="glutathione"/>
            <pair e1="DS.d824.s0.e1" e2="DS.d824.s0.e0" id="DS.d824.s0.i0" interaction="True"/>
            <pair e1="DS.d824.s0.e2" e2="DS.d824.s0.e0" id="DS.d824.s0.i1" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d825" origId="18711746">
        <sentence id="DS.d825.s0" origId="18711746-961" text="Our previous studies have shown that serotonin (5-HT) altered under diabetic condition was accompanied by alterations of protein kinase C-alpha (PKC-alpha) and CaMKII, and those alterations were reversed after insulin administration.">
            <entity id="DS.d825.s0.e0" origId="5202" charOffset="37-46" type="compound" text="serotonin"/>
            <entity id="DS.d825.s0.e1" origId="5202" charOffset="48-52" type="compound" text="5-HT"/>
            <entity id="DS.d825.s0.e2" origId="P13678,Q25378" charOffset="121-137" type="protein" text="protein kinase C"/>
            <entity id="DS.d825.s0.e3" origId="P04409,P05696,P10102,P17252,P20444" charOffset="145-154" type="protein" text="PKC-alpha"/>
            <entity id="DS.d825.s0.e4" origId="Q00168" charOffset="160-166" type="protein" text="CaMKII"/>
            <entity id="DS.d825.s0.e5" origId="P01314,P01316,P01319,P01320,P01324,P01328,P01330,P01331,P01334,P01336,P01340,P07453,P09476,P09477,P0C236,P12703,P12704,P12708,P13190,P18109,P29335,P42633,P67968,P67969,P67971,P67973,P67974,P68243,P68245,P68987,P68988,P68989,P68990,P68991,P68992,P69046,P69047,P69048,P81423,P81881,Q9TQY7" charOffset="210-217" type="protein" text="insulin"/>
            <pair e1="DS.d825.s0.e0" e2="DS.d825.s0.e3" id="DS.d825.s0.i0" interaction="True"/>
            <pair e1="DS.d825.s0.e0" e2="DS.d825.s0.e5" id="DS.d825.s0.i1" interaction="True"/>
            <pair e1="DS.d825.s0.e1" e2="DS.d825.s0.e3" id="DS.d825.s0.i2" interaction="True"/>
            <pair e1="DS.d825.s0.e1" e2="DS.d825.s0.e4" id="DS.d825.s0.i3" interaction="True"/>
            <pair e1="DS.d825.s0.e1" e2="DS.d825.s0.e2" id="DS.d825.s0.i4" interaction="True"/>
            <pair e1="DS.d825.s0.e1" e2="DS.d825.s0.e5" id="DS.d825.s0.i5" interaction="True"/>
            <pair e1="DS.d825.s0.e0" e2="DS.d825.s0.e2" id="DS.d825.s0.i6" interaction="True"/>
            <pair e1="DS.d825.s0.e0" e2="DS.d825.s0.e4" id="DS.d825.s0.i7" interaction="True"/>
        </sentence>
        <sentence id="DS.d825.s1" origId="18711746-962" text="The current study showed that alloxan-induced diabetic animals revealed hyperglycemia and was associated with an increase in the content of 5-HT, PKC-alpha expression and PKC 0.05) simultaneously in striatum (ST), midbrain (MB), pons medulla (PM), cerebellum (CB), and cerebral cortex (CCX) from 7 days to 60 days.">
            <entity id="DS.d825.s1.e0" origId="5781" charOffset="30-37" type="compound" text="alloxan"/>
            <entity id="DS.d825.s1.e1" origId="5202" charOffset="140-144" type="compound" text="5-HT"/>
            <entity id="DS.d825.s1.e2" origId="P04409,P05696,P10102,P17252,P20444" charOffset="146-155" type="protein" text="PKC-alpha"/>
            <entity id="DS.d825.s1.e3" origId="P05130,P13677,P13678,P34722" charOffset="146-149" type="protein" text="PKC"/>
            <entity id="DS.d825.s1.e4" origId="P52430,P55159" charOffset="229-233" type="protein" text="pons"/>
            <pair e1="DS.d825.s1.e1" e2="DS.d825.s1.e2" id="DS.d825.s1.i0" interaction="False"/>
            <pair e1="DS.d825.s1.e0" e2="DS.d825.s1.e4" id="DS.d825.s1.i1" interaction="False"/>
            <pair e1="DS.d825.s1.e1" e2="DS.d825.s1.e3" id="DS.d825.s1.i2" interaction="False"/>
            <pair e1="DS.d825.s1.e1" e2="DS.d825.s1.e4" id="DS.d825.s1.i3" interaction="False"/>
            <pair e1="DS.d825.s1.e0" e2="DS.d825.s1.e2" id="DS.d825.s1.i4" interaction="True"/>
            <pair e1="DS.d825.s1.e0" e2="DS.d825.s1.e3" id="DS.d825.s1.i5" interaction="True"/>
        </sentence>
        <sentence id="DS.d825.s2" origId="18711746-963" text="Although the 5-HT levels in hippocampus (HC) and hypothalamus (HT) were not altered, the PKC-alpha expression and PKC 0.05) in level in HC.">
            <entity id="DS.d825.s2.e0" origId="5202" charOffset="13-17" type="compound" text="5-HT"/>
            <entity id="DS.d825.s2.e1" origId="P04409,P05696,P10102,P17252,P20444" charOffset="89-98" type="protein" text="PKC-alpha"/>
            <entity id="DS.d825.s2.e2" origId="P05130,P13677,P13678,P34722" charOffset="89-92" type="protein" text="PKC"/>
            <pair e1="DS.d825.s2.e0" e2="DS.d825.s2.e1" id="DS.d825.s2.i0" interaction="False"/>
            <pair e1="DS.d825.s2.e0" e2="DS.d825.s2.e2" id="DS.d825.s2.i1" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d826" origId="18711749">
        <sentence id="DS.d826.s0" origId="18711749-1020" text="We tested the hypothesis that a nitric oxide donor, DETA-NONOate, up-regulates stromal cell-derived factor-1 (SDF1) and angiopoietin 1 (Ang1) in the ischemic brain and their respective receptors chemokine CXC motif receptor 4 (CXCR4) and Tie2 in the subventricular zone (SVZ) and thereby promote SVZ neuroblast cell migration after stroke.">
            <entity id="DS.d826.s0.e0" origId="145068" charOffset="32-44" type="compound" text="nitric oxide"/>
            <entity id="DS.d826.s0.e1" origId="1606" charOffset="52-64" type="compound" text="DETA-NONOate"/>
            <entity id="DS.d826.s0.e2" origId="O62657,P48061" charOffset="110-114" type="protein" text="SDF1"/>
            <entity id="DS.d826.s0.e3" origId="P21570" charOffset="136-140" type="protein" text="Ang1"/>
            <entity id="DS.d826.s0.e4" origId="O62747,P25930,P56491,P56498,P61072,P61073,P79394,Q28474,Q28553,Q3LSL6,Q764M9,Q7YS92,Q8HZU0,Q8HZU1,Q9TSQ8" charOffset="227-232" type="protein" text="CXCR4"/>
            <entity id="DS.d826.s0.e5" origId="O73791,Q02858" charOffset="238-242" type="protein" text="Tie2"/>
            <pair e1="DS.d826.s0.e1" e2="DS.d826.s0.e4" id="DS.d826.s0.i0" interaction="True"/>
            <pair e1="DS.d826.s0.e1" e2="DS.d826.s0.e2" id="DS.d826.s0.i1" interaction="True"/>
            <pair e1="DS.d826.s0.e0" e2="DS.d826.s0.e5" id="DS.d826.s0.i2" interaction="True"/>
            <pair e1="DS.d826.s0.e0" e2="DS.d826.s0.e2" id="DS.d826.s0.i3" interaction="True"/>
            <pair e1="DS.d826.s0.e0" e2="DS.d826.s0.e3" id="DS.d826.s0.i4" interaction="True"/>
            <pair e1="DS.d826.s0.e1" e2="DS.d826.s0.e5" id="DS.d826.s0.i5" interaction="True"/>
            <pair e1="DS.d826.s0.e1" e2="DS.d826.s0.e3" id="DS.d826.s0.i6" interaction="True"/>
            <pair e1="DS.d826.s0.e0" e2="DS.d826.s0.e4" id="DS.d826.s0.i7" interaction="True"/>
        </sentence>
        <sentence id="DS.d826.s1" origId="18711749-1021" text="To elucidate whether SDF1/CXCR4 and Ang1/Tie2 pathways mediate DETA-NONOate-induced SVZ migration after stroke, SDF1alpha, Ang1 peptide, a specific antagonist of CXCR4 (AMD3100), and a neutralizing antibody of Tie2 (anti-Tie2) were used in vitro.">
            <entity id="DS.d826.s1.e0" origId="O62657,P48061" charOffset="21-25" type="protein" text="SDF1"/>
            <entity id="DS.d826.s1.e1" origId="1606" charOffset="63-75" type="compound" text="DETA-NONOate"/>
            <entity id="DS.d826.s1.e2" origId="52944803" charOffset="128-138" type="compound" text="peptide, a"/>
            <entity id="DS.d826.s1.e3" origId="65015" charOffset="169-176" type="compound" text="AMD3100"/>
            <pair e1="DS.d826.s1.e3" e2="DS.d826.s1.e0" id="DS.d826.s1.i0" interaction="True"/>
            <pair e1="DS.d826.s1.e1" e2="DS.d826.s1.e0" id="DS.d826.s1.i1" interaction="True"/>
            <pair e1="DS.d826.s1.e2" e2="DS.d826.s1.e0" id="DS.d826.s1.i2" interaction="True"/>
        </sentence>
        <sentence id="DS.d826.s2" origId="18711749-1023" text="DETA-NONOate significantly increased the expression of SDF1 and Ang1 in the ischemic border and up-regulated CXCR4 and Tie2 in the SVZ compared with MCAo control.">
            <entity id="DS.d826.s2.e0" origId="1606" charOffset="0-12" type="compound" text="DETA-NONOate"/>
            <entity id="DS.d826.s2.e1" origId="O62657,P48061" charOffset="55-59" type="protein" text="SDF1"/>
            <entity id="DS.d826.s2.e2" origId="P21570" charOffset="64-68" type="protein" text="Ang1"/>
            <entity id="DS.d826.s2.e3" origId="O62747,P25930,P56491,P56498,P61072,P61073,P79394,Q28474,Q28553,Q3LSL6,Q764M9,Q7YS92,Q8HZU0,Q8HZU1,Q9TSQ8" charOffset="109-114" type="protein" text="CXCR4"/>
            <entity id="DS.d826.s2.e4" origId="O73791,Q02858" charOffset="119-123" type="protein" text="Tie2"/>
            <pair e1="DS.d826.s2.e0" e2="DS.d826.s2.e3" id="DS.d826.s2.i0" interaction="True"/>
            <pair e1="DS.d826.s2.e0" e2="DS.d826.s2.e4" id="DS.d826.s2.i1" interaction="True"/>
            <pair e1="DS.d826.s2.e0" e2="DS.d826.s2.e1" id="DS.d826.s2.i2" interaction="True"/>
            <pair e1="DS.d826.s2.e0" e2="DS.d826.s2.e2" id="DS.d826.s2.i3" interaction="True"/>
        </sentence>
        <sentence id="DS.d826.s3" origId="18711749-1025" text="Our data indicate that treatment of stroke with a nitric oxide donor up-regulates SDF1/CXCR4 and Ang1/Tie2 pathways and thereby likely increases SVZ neuroblast cell migration.">
            <entity id="DS.d826.s3.e0" origId="145068" charOffset="50-62" type="compound" text="nitric oxide"/>
            <entity id="DS.d826.s3.e1" origId="O62657,P48061" charOffset="82-86" type="protein" text="SDF1"/>
            <entity id="DS.d826.s3.e2" origId="O62747,P25930,P56491,P56498,P61072,P61073,P79394,Q28474,Q28553,Q3LSL6,Q764M9,Q7YS92,Q8HZU0,Q8HZU1,Q9TSQ8" charOffset="87-92" type="protein" text="CXCR4"/>
            <entity id="DS.d826.s3.e3" origId="P21570" charOffset="97-101" type="protein" text="Ang1"/>
            <entity id="DS.d826.s3.e4" origId="O73791,Q02858" charOffset="102-106" type="protein" text="Tie2"/>
            <pair e1="DS.d826.s3.e0" e2="DS.d826.s3.e4" id="DS.d826.s3.i0" interaction="True"/>
            <pair e1="DS.d826.s3.e0" e2="DS.d826.s3.e3" id="DS.d826.s3.i1" interaction="True"/>
            <pair e1="DS.d826.s3.e0" e2="DS.d826.s3.e1" id="DS.d826.s3.i2" interaction="True"/>
            <pair e1="DS.d826.s3.e0" e2="DS.d826.s3.e2" id="DS.d826.s3.i3" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d827" origId="18711750">
        <sentence id="DS.d827.s0" origId="18711750-1026" text="The MEK inhibitor PD98059 did not inhibit neurite outgrowth, and Y-27632 and staurosporine did not induce ERK phosphorylation, suggesting that the inhibitory effect of ODQ on neurite outgrowth is independent of the ERK signaling pathway.">
            <entity id="DS.d827.s0.e0" origId="4713" charOffset="18-25" type="compound" text="PD98059"/>
            <entity id="DS.d827.s0.e1" origId="5279,44259,451705,5311103,5459111,6419748,6711321,9956178,44299148" charOffset="77-90" type="compound" text="staurosporine"/>
            <entity id="DS.d827.s0.e2" origId="P29323" charOffset="106-109" type="protein" text="ERK"/>
            <entity id="DS.d827.s0.e3" origId="1456" charOffset="168-171" type="compound" text="ODQ"/>
            <entity id="DS.d827.s0.e4" origId="P29323" charOffset="215-218" type="protein" text="ERK"/>
            <pair e1="DS.d827.s0.e0" e2="DS.d827.s0.e2" id="DS.d827.s0.i0" interaction="False"/>
            <pair e1="DS.d827.s0.e3" e2="DS.d827.s0.e2" id="DS.d827.s0.i1" interaction="False"/>
            <pair e1="DS.d827.s0.e1" e2="DS.d827.s0.e2" id="DS.d827.s0.i2" interaction="False"/>
        </sentence>
    </document>
    <document id="DS.d828" origId="18712272">
        <sentence id="DS.d828.s0" origId="18712272-1403" text="We used this model to identify a potent competitive inhibitor, N1,N7-dihexyl-1,7-diamino-4-azaheptane, and to develop an affinity column, 1,16-diamino4,13-diazahexadecane-linked Sepharose, which was useful for the purification of PAO.">
            <entity id="DS.d828.s0.e0" origId="11966311" charOffset="178-187" type="compound" text="Sepharose"/>
            <entity id="DS.d828.s0.e1" origId="O64411,Q6QHF9,Q865R1,Q9FYC2" charOffset="230-233" type="protein" text="PAO"/>
            <pair e1="DS.d828.s0.e0" e2="DS.d828.s0.e1" id="DS.d828.s0.i0" interaction="True"/>
        </sentence>
    </document>
    <document id="DS.d829" origId="18712288">
        <sentence id="DS.d829.s0" origId="18712288-246" text="Rapid determination of L-glutamine using engineered Escherichia coli overexpressing glutamine synthetase.">
            <entity id="DS.d829.s0.e0" origId="5961,145815" charOffset="23-34" type="compound" text="L-glutamine"/>
            <entity id="DS.d829.s0.e1" origId="O00088,O04867,O08467,O27612,O29313,O58097,O59648,O66514,P00964,P04773,P07804,P09606,P0A039,P0A040,P0A1P6,P0A1P7,P0A9C5,P0A9C6,P0A9C7,P0A9C8,P10583,P10656,P11600,P12424,P12425,P13499,P15103,P15104,P15105,P15106,P15124,P15623,P16580,P19064,P19904,P20479,P21154,P22248,P23712,P23794,P25821,P28605,P28786,P32288,P33035,P36205,P43386,P43518,P43794,P45627,P46410,P51120,P51121,P60890,P77961,P94126,P94845,P99095,Q04831,Q05650,Q05907,Q06378,Q09179,Q12613,Q4R7U3,Q5HGC3,Q5HPN2,Q60182,Q6B4U7,Q6C3E0,Q6FMT6,Q6G9Q4,Q6GHC6,Q75BT9,Q86ZF9,Q86ZU6,Q874T6,Q8CSR8,Q8HZM5,Q8J1R3,Q8X169,Q96UG9,Q96UV5,Q96V52,Q9C2U9,Q9CDL9,Q9CLP2,Q9HH09,Q9HNI2,Q9HU65,Q9KNJ2,Q9QY94,Q9UUN6,Q9UY99,Q9ZLW5" charOffset="84-104" type="protein" text="glutamine synthetase"/>
            <pair e1="DS.d829.s0.e0" e2="DS.d829.s0.e1" id="DS.d829.s0.i0" interaction="True"/>
        </sentence>
    </document>
</corpus>
